article_title,journal_title,journal_abbre,article_date,abstract,article_type,pub_days,citation,abstract_clean,Breast Cancer,Lung Cancer,Leukemia,Prostate Cancer,Colorectal Cancer,Lymphoma,Bone Cancer,Melanoma,Liver Cancer,Kidney Cancer,Ovarian Cancer,Pancreatic Cancer,Brain Tumor,Head and Neck Cancer,Acute Myeloid Leukemia (AML),Multiple Myeloma,Sarcoma,Bladder Cancer,Skin Cancer,Gastric Cancer,Gastrointestinal Tumor,Endometrial Cancer,Acute Lymphoblastic Leukemia (ALL),Chronic Lymphocytic Leukemia (CLL),Cardiac Tumors,Cervical Cancer,Esophageal Cancer,Thyroid Cancer,Rectal Cancer,text_clean_seq,text_length,pmid,title_clean,bert_similarity_rank_vaginal_cancer,bert_similarity_rank_vaginal_cancer_percentile
Primary invasive vaginal cancer in the setting of the Mayer-Rokitansky-Kuster-Hauser syndrome.,Gynecologic oncology,Gynecol. Oncol.,2002-05-01,"The Mayer-Rokitansky-Kuster-Hauser syndrome occurs in 1 in 4000 to 5000 female births. Primary vaginal cancer constitutes less than 2% of all malignancies of the female genital tract. A report of the first case of the unlikely occurrence of both of these developments in the same patient is presented. A 34-year-old nulligravid Philippine woman with a history of Mayer-Rokitansky-Kuster-Hauser syndrome presented with a 5-month history of bleeding from a blind vaginal pouch. Vaginal biopsy identified a moderately differentiated endometrioid adenocarcinoma. Exploratory laparotomy, bilateral salpingo-oophorectomy, pelvic and iliac lymph node samplings, and excision of a mullerian remnant were performed with no evidence of disease. A FIGO Stage I vaginal cancer was assigned and pelvic irradiation was given. Disease recurred 4 months later and the patient underwent total pelvic exenteration. More than 1 year since the exenteration procedure, she is without evidence of disease. This is the first reported case of a primary vaginal cancer in a patient with Mayer-Rokitansky-Kuster-Hauser syndrome. It is a reminder that routine gynecologic examinations are still warranted as these patients are at risk for malignant changes in residual mullerian tissues.",Case Reports,6474.0,12.0,Mayer-Rokitansky-Kuster-Hauser syndrome occurs 1 4000 5000 female births Primary vaginal constitutes 2 malignancies female genital tract report case unlikely occurrence developments patient presented 34-year-old nulligravid Philippine woman history Mayer-Rokitansky-Kuster-Hauser syndrome presented 5-month history bleeding blind vaginal pouch Vaginal biopsy identified moderately differentiated endometrioid adenocarcinoma Exploratory laparotomy bilateral salpingo-oophorectomy pelvic iliac lymph node samplings excision mullerian remnant performed evidence disease FIGO Stage vaginal assigned pelvic irradiation given Disease recurred 4 months later patient underwent total pelvic exenteration 1 year exenteration procedure evidence disease reported case primary vaginal patient Mayer-Rokitansky-Kuster-Hauser syndrome reminder routine gynecologic examinations warranted patients risk malignant changes residual mullerian tissues,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 37143, 37144, 37145, 37146, 681, 1780, 4, 14, 4, 10660, 6, 10410, 1061, 9951, 86, 12, 6788, 299, 76, 18, 1, 62, 441, 1, 3, 1061, 8226, 1696, 8, 414, 1, 3, 157, 473, 1, 3, 3568, 2291, 1, 110, 1, 46, 3703, 4, 3, 827, 69, 16, 917, 8, 562, 111, 1095, 37147, 52847, 2854, 5, 8, 532, 1, 37143, 37144, 37145, 37146, 681, 917, 5, 8, 33, 811, 532, 1, 2294, 29, 8, 3142, 15832, 411, 108, 8, 3508, 1442, 3151, 449, 2386, 3274, 1607, 5690, 3470, 1110, 2, 6692, 263, 289, 33220, 2, 1366, 1, 8, 18773, 5644, 11, 173, 5, 77, 241, 1, 34, 8, 3837, 82, 70, 12, 10, 896, 2, 1110, 1104, 10, 447, 34, 3363, 39, 53, 1559, 2, 3, 69, 208, 181, 1110, 5668, 80, 76, 14, 111, 1192, 3, 5668, 1299, 3109, 16, 187, 241, 1, 34, 26, 16, 3, 157, 210, 473, 1, 8, 86, 12, 4, 8, 69, 5, 37143, 37144, 37145, 37146, 681, 192, 16, 8, 19448, 17, 1311, 1512, 4209, 32, 1234, 1197, 22, 46, 7, 32, 28, 43, 9, 393, 400, 4, 753, 18773, 742]",1204.0,11972406,Primary invasive vaginal setting Mayer-Rokitansky-Kuster-Hauser syndrome,0,0.0
Recurrent cervical cancer.,Current treatment options in oncology,Curr Treat Options Oncol,2002-04-01,"There are limited treatment options for patients with recurrent cervical carcinoma. Because of low response rates and a negligible impact on long-term survival, the use of chemotherapy in patients with unresectable recurrent disease should be considered palliative. Generally, radiation therapy in previously irradiated patients is considered palliative. For patients who develop recurrent disease after definitive surgery who have not received prior radiation therapy, salvage radiation therapy is the treatment of choice. Similarly, patients who have received definitive primary radiation therapy are candidates for surgical resection of their recurrence. However, there are specific criteria for surgical resection. Radical hysterectomy may be an option for the very rare patient with a small (<2 cm) centrally located recurrence in the cervix or vaginal fornices. However, for most patients, pelvic exenteration remains the only therapeutic option that offers the possibility of long-term survival. Patients who are candidates for exenteration are those with central local recurrences that have not extended to the pelvic sidewalls. The introduction of high-dose-rate intraoperative radiation therapy (HDR-IORT) combined with radical surgical resection has widened the scope of patients who may be offered surgery. Patients who in the past may not have been surgical candidates may benefit from radical surgical resection combined with HDR-IORT. All patients who are surgically fit and have undergone previous radiation therapy should be considered for surgical resection for centrally located recurrences. Patients whose recurrences extend close to the pelvic sidewalls should be referred to centers where HDR-IORT is available.",Journal Article,6504.0,40.0,limited treatment options patients recurrent cervical carcinoma low response rates negligible impact long-term survival use chemotherapy patients unresectable recurrent disease considered palliative Generally radiation therapy previously irradiated patients considered palliative patients develop recurrent disease definitive surgery received prior radiation therapy salvage radiation therapy treatment choice Similarly patients received definitive primary radiation therapy candidates surgical resection recurrence specific criteria surgical resection Radical hysterectomy option rare patient small 2 cm centrally located recurrence cervix vaginal fornices patients pelvic exenteration remains therapeutic option offers possibility long-term survival Patients candidates exenteration central local recurrences extended pelvic sidewalls introduction high-dose-rate intraoperative radiation therapy HDR-IORT combined radical surgical resection widened scope patients offered surgery Patients past surgical candidates benefit radical surgical resection combined HDR-IORT patients surgically fit undergone previous radiation therapy considered surgical resection centrally located recurrences Patients recurrences extend close pelvic sidewalls referred centers HDR-IORT available,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[125, 32, 383, 24, 838, 9, 7, 5, 387, 134, 408, 1, 154, 51, 151, 2, 8, 6821, 345, 23, 319, 337, 25, 3, 119, 1, 56, 4, 7, 5, 1468, 387, 34, 257, 40, 515, 994, 1228, 121, 36, 4, 373, 2398, 7, 16, 515, 994, 9, 7, 54, 690, 387, 34, 50, 1057, 152, 54, 47, 44, 103, 324, 121, 36, 992, 121, 36, 16, 3, 24, 1, 1866, 1813, 7, 54, 47, 103, 1057, 86, 121, 36, 32, 1931, 9, 221, 170, 1, 136, 146, 137, 125, 32, 112, 371, 9, 221, 170, 711, 2622, 68, 40, 35, 1501, 9, 3, 923, 622, 69, 5, 8, 302, 18, 494, 4604, 2308, 146, 4, 3, 3629, 15, 52960, 137, 9, 96, 7, 1110, 5668, 469, 3, 158, 189, 1501, 17, 2339, 3, 2526, 1, 319, 337, 25, 7, 54, 32, 1931, 9, 5668, 32, 135, 5, 854, 293, 1593, 17, 47, 44, 1747, 6, 3, 1110, 42959, 3, 2456, 1, 64, 61, 116, 1720, 121, 36, 5309, 4158, 397, 5, 711, 221, 170, 71, 21990, 3, 7924, 1, 7, 54, 68, 40, 2216, 152, 7, 54, 4, 3, 1219, 68, 44, 47, 85, 221, 1931, 68, 247, 29, 711, 221, 170, 397, 5, 5309, 4158, 62, 7, 54, 32, 2350, 2975, 2, 47, 1989, 698, 121, 36, 257, 40, 515, 9, 221, 170, 9, 4604, 2308, 1593, 7, 1310, 1593, 4087, 2336, 6, 3, 1110, 42959, 257, 40, 1995, 6, 1168, 1257, 5309, 4158, 16, 390]",1691.0,12057073,Recurrent cervical,154,0.7738693467336684
Photodynamic therapy of high-grade cervical intraepithelial neoplasia with 5-aminolevulinic acid.,Lasers in surgery and medicine,Lasers Surg Med,2002-01-01,"To determine the safety and efficacy of 5-aminolevulinic acid (ALA) as a topically applied photosensitizer for photodynamic therapy (PDT) of cervical intraepithelial neoplasia (CIN). Forty women, who were at least 18 years old with persistent biopsy-proven CIN 2 and CIN 3 within the previous 3 months of enrollment, underwent PDT in a phase I and II design. Five escalating radiant energies (increments of 25 J/cm(2), beginning at 50-150 J/cm(2)) using a Coherent Dye Model 920 argon pumped dye laser providing light at 630 nm (maximum output 0.8 W) were used to perform PDT with a fixed dose of ALA (200 mg/ml). ALA was placed in a cervical cap fitted to the cervix. After 90 minutes, the cap was removed and the ectocervix was illuminated for 5-16 minutes, depending on the irradiance. Success was defined as the absence of CIN on Pap smear or colposcopic examination at 12-months. Patients were monitored for toxicity. Thirty-two women (80%) completed the study with 1 year of follow-up. Sixty percent had CIN 3 and 40% CIN 2. Success rates at 4, 8, and 12 months were 51, 46, and 31%, respectively, and were not light-dose dependent. Three patients progressed from CIN 2 to CIN 3. Toxicity was tolerable and only consisted of spotting, vaginal discharge, mild cramping, and vaginal warmth. There was no apparent dose relationship to toxicity. PDT at this light and ALA dose is well tolerated but has minimal activity in the treatment of CIN 2 and CIN 3. Other doses and schedules of light and ALA or novel photosensitizers may improve efficacy.",Clinical Trial,6594.0,45.0,determine safety efficacy 5-aminolevulinic acid ALA topically applied photosensitizer photodynamic therapy PDT cervical intraepithelial neoplasia CIN women 18 years old persistent biopsy-proven CIN 2 CIN 3 previous 3 months enrollment underwent PDT phase II design escalating radiant energies increments 25 J/cm 2 beginning 50-150 J/cm 2 Coherent Dye Model 920 argon pumped dye laser providing light 630 nm maximum output 0.8 W perform PDT fixed dose ALA 200 mg/ml ALA placed cervical cap fitted cervix 90 minutes cap removed ectocervix illuminated 5-16 minutes depending irradiance Success defined absence CIN Pap smear colposcopic examination 12-months Patients monitored toxicity Thirty-two women 80 completed 1 year follow-up percent CIN 3 40 CIN 2 Success rates 4 8 12 months 51 46 31 respectively light-dose dependent patients progressed CIN 2 CIN 3 Toxicity tolerable consisted spotting vaginal discharge mild cramping vaginal warmth apparent dose relationship toxicity PDT light ALA dose tolerated minimal activity treatment CIN 2 CIN 3 doses schedules light ALA novel photosensitizers improve efficacy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 3, 367, 2, 209, 1, 33, 30218, 971, 8497, 22, 8, 21012, 1498, 10687, 9, 6910, 36, 3442, 1, 4153, 2298, 4652, 1213, 117, 54, 11, 28, 506, 203, 60, 1095, 5, 1882, 411, 1930, 4652, 18, 2, 4652, 27, 262, 3, 698, 27, 53, 1, 1798, 208, 3442, 4, 8, 124, 70, 2, 215, 771, 365, 2922, 11269, 24514, 8225, 1, 243, 3543, 494, 18, 2948, 28, 212, 1577, 3543, 494, 18, 75, 8, 22027, 3796, 202, 11533, 26069, 53141, 3796, 3555, 1736, 1691, 28, 10939, 2878, 689, 6911, 13, 66, 5444, 11, 95, 6, 2715, 3442, 5, 8, 1959, 61, 1, 8497, 1250, 81, 542, 8497, 10, 3295, 4, 8, 3204, 7315, 6, 3, 3629, 50, 424, 2511, 3, 3204, 10, 2264, 2, 3, 53142, 10, 22034, 9, 33, 245, 2511, 3221, 23, 3, 24515, 1825, 10, 395, 22, 3, 1127, 1, 4652, 23, 4290, 8379, 15, 14131, 1385, 28, 133, 53, 7, 11, 2909, 9, 155, 977, 100, 117, 493, 781, 3, 45, 5, 14, 111, 1, 166, 126, 1746, 714, 42, 4652, 27, 2, 327, 4652, 18, 1825, 151, 28, 39, 66, 2, 133, 53, 11, 725, 641, 2, 456, 106, 2, 11, 44, 1691, 61, 470, 169, 7, 1839, 29, 4652, 18, 6, 4652, 27, 155, 10, 2668, 2, 158, 1695, 1, 37278, 2993, 1980, 17149, 2, 27964, 125, 10, 77, 2235, 61, 858, 6, 155, 3442, 28, 26, 1691, 2, 8497, 61, 16, 149, 421, 84, 71, 1048, 128, 4, 3, 24, 1, 4652, 18, 2, 4652, 27, 127, 415, 2, 2314, 1, 1691, 2, 8497, 15, 229, 19499, 68, 401, 209]",1467.0,12355576,Photodynamic therapy high-grade cervical intraepithelial neoplasia 5-aminolevulinic acid,0,0.0
Sentinel node biopsy in vulvar and vaginal melanoma: presentation of six cases and a literature review.,Annals of surgical oncology,Ann. Surg. Oncol.,2002-11-01,"Urogenital melanoma is a rare neoplasm with poor prognosis. Its management in the past involved radical vulvectomy and complete bilateral inguinofemoral lymphadenectomy. Sentinel lymph node biopsy is an accurate low-morbidity procedure when used in the context of cutaneous melanoma. However, prophylactic lymphadenectomy has not been shown to improve survival of melanoma patients. We wanted to determine the feasibility of sentinel lymph node biopsy in patients with female urogenital melanoma as a staging procedure. Six patients with vulvar or vaginal melanomas underwent preoperative lymphatic mapping with (99m)Tc-labeled sulfur colloid followed by sentinel lymphadenectomy. In addition, we reviewed the literature on the application of sentinel lymph node biopsy in urogenital tract melanomas. One or more sentinel nodes were identified in all six patients by lymphoscintigraphy. All patients underwent sentinel lymphadenectomy, except for one patient with a deep vaginal melanoma that drained to pelvic nodes. The five successful cases had unilateral drainage patterns. None of the sentinel lymph nodes excised had tumor invasion. Combined with five other patients from the published literature, the success rate of localizing sentinel lymph nodes in the patients with urogenital melanoma approaches 100%. This experience, plus reports of a small number of patients from three similar studies, supports the impression that sentinel lymph node biopsy is feasible for vulvar and vaginal melanoma.",Journal Article,6290.0,59.0,Urogenital melanoma rare neoplasm poor prognosis management past involved radical vulvectomy complete bilateral inguinofemoral lymphadenectomy Sentinel lymph node biopsy accurate low-morbidity procedure context cutaneous melanoma prophylactic lymphadenectomy shown improve survival melanoma patients wanted determine feasibility sentinel lymph node biopsy patients female urogenital melanoma staging procedure patients vulvar vaginal melanomas underwent preoperative lymphatic mapping 99m Tc-labeled sulfur colloid followed sentinel lymphadenectomy addition reviewed literature application sentinel lymph node biopsy urogenital tract melanomas sentinel nodes identified patients lymphoscintigraphy patients underwent sentinel lymphadenectomy patient deep vaginal melanoma drained pelvic nodes successful cases unilateral drainage patterns sentinel lymph nodes excised invasion Combined patients published literature success rate localizing sentinel lymph nodes patients urogenital melanoma approaches 100 experience plus reports small number patients similar studies supports impression sentinel lymph node biopsy feasible vulvar vaginal melanoma,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[15162, 16, 8, 622, 2131, 5, 334, 356, 211, 284, 4, 3, 1219, 646, 711, 22043, 2, 236, 1607, 30333, 2048, 1323, 263, 289, 411, 16, 35, 1481, 154, 787, 1299, 198, 95, 4, 3, 1533, 1, 1486, 137, 1862, 2048, 71, 44, 85, 443, 6, 401, 25, 1, 7, 21, 7931, 6, 223, 3, 1437, 1, 1323, 263, 289, 411, 4, 7, 5, 1061, 15162, 22, 8, 632, 1299, 437, 7, 5, 15, 1965, 208, 498, 2936, 2568, 5, 6314, 3072, 2841, 10266, 7245, 370, 20, 1323, 2048, 4, 352, 21, 446, 3, 789, 23, 3, 1581, 1, 1323, 263, 289, 411, 4, 15162, 1696, 1965, 104, 15, 80, 1323, 502, 11, 108, 4, 62, 437, 7, 20, 6849, 62, 7, 208, 1323, 2048, 2187, 9, 104, 69, 5, 8, 2369, 17, 24458, 6, 1110, 502, 3, 365, 1401, 140, 42, 3208, 3528, 764, 1292, 1, 3, 1323, 263, 502, 5076, 42, 30, 578, 397, 5, 365, 127, 7, 29, 3, 983, 789, 3, 1825, 116, 1, 14384, 1323, 263, 502, 4, 3, 7, 5, 15162, 611, 394, 26, 730, 349, 1198, 1, 8, 302, 207, 1, 7, 29, 169, 288, 94, 2304, 3, 8925, 17, 1323, 263, 289, 411, 16, 1313, 9, 2]",1380.0,12417504,Sentinel node biopsy vulvar vaginal melanoma presentation cases literature review,0,0.0
Stage IIIC endometrioid corpus cancer includes distinct subgroups.,Gynecologic oncology,Gynecol. Oncol.,2002-10-01,"Because stage IIIC corpus cancer is a heterogeneous substage, the outcomes of patients with stage IIIC disease were assessed according to the extent of extrauterine disease. From 1984 through 1993, 51 patients with surgical stage IIIC corpus cancer were treated at our institution; 5 patients had tumors with nonendometrioid histologic features and were excluded from the analyses. Of the 46 patients with endometrioid carcinoma, 22 had lymph nodes as the only site of extrauterine disease (stage IIIC(0)) and 24 also had peritoneal cytologic, uterine serosal, adnexal, or vaginal involvement or a combination of these (stage IIIC(ab)). The mean number of lymph nodes removed was 18 pelvic and 8 aortic nodes. Median follow-up for surviving patients was 84 months. Patients with stage IIIC(0) cancer had a 5-year cause-specific survival (CSS) of 72% and a 5-year recurrence-free survival (RFS) of 68%, and those with stage IIIC(ab) had a CSS of 33% and an RFS of 25% (P < 0.01). Of the 22 patients with stage IIIC(0) endometrioid cancer, 21 had adjuvant radiotherapy (1 also received chemotherapy) and 1 was not treated. Relapse occurred in 7 (32%) patients, with only 1 having an initial failure component outside the node-bearing areas (lung). Of the 24 patients with stage IIIC(ab) cancer, 16 received adjuvant radiotherapy (1 had concomitant chemotherapy), 2 had chemotherapy, 4 had hormonal therapy, and 2 were not treated. We observed 16 recurrences (67%). Of the 14 patients with known initial sites of failure, 9 had an extranodal failure component. Assessment of CSS, RFS, and sites of relapse suggests that FIGO surgical stage IIIC endometrioid corpus cancer includes two distinct and readily separable subgroups: (1) stage IIIC(0), nodal involvement only, and (2) stage IIIC(ab), nodal plus cytologic, uterine serosal, adnexal, or vaginal involvement, or a combination of these. Our results also suggest that different treatment strategies are needed for these subgroups.",Journal Article,6321.0,62.0,stage IIIC corpus heterogeneous substage outcomes patients stage IIIC disease assessed according extent extrauterine disease 1984 1993 51 patients surgical stage IIIC corpus treated institution 5 patients nonendometrioid histologic features excluded 46 patients endometrioid carcinoma 22 lymph nodes site extrauterine disease stage IIIC 0 24 peritoneal cytologic uterine serosal adnexal vaginal involvement combination stage IIIC ab mean number lymph nodes removed 18 pelvic 8 aortic nodes Median follow-up surviving patients 84 months Patients stage IIIC 0 5-year cause-specific survival CSS 72 5-year recurrence-free survival RFS 68 stage IIIC ab CSS 33 RFS 25 P 0.01 22 patients stage IIIC 0 endometrioid 21 adjuvant radiotherapy 1 received chemotherapy 1 treated Relapse occurred 7 32 patients 1 initial failure component outside node-bearing areas lung 24 patients stage IIIC ab 16 received adjuvant radiotherapy 1 concomitant chemotherapy 2 chemotherapy 4 hormonal therapy 2 treated observed 16 recurrences 67 14 patients known initial sites failure 9 extranodal failure component Assessment CSS RFS sites relapse suggests FIGO surgical stage IIIC endometrioid corpus includes distinct readily separable subgroups 1 stage IIIC 0 nodal involvement 2 stage IIIC ab nodal plus cytologic uterine serosal adnexal vaginal involvement combination suggest different treatment strategies needed subgroups,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[408, 82, 3842, 7758, 12, 16, 8, 1564, 12758, 3, 123, 1, 7, 5, 82, 3842, 34, 11, 275, 768, 6, 3, 1039, 1, 12115, 34, 29, 6036, 298, 3343, 725, 7, 5, 221, 82, 3842, 7758, 12, 11, 73, 28, 114, 731, 33, 7, 42, 57, 5, 24547, 884, 404, 2, 11, 1800, 29, 3, 318, 1, 3, 641, 7, 5, 3151, 134, 350, 42, 263, 502, 22, 3, 158, 606, 1, 12115, 34, 82, 3842, 13, 2, 259, 120, 42, 1639, 4195, 17169, 6462, 15, 799, 15, 8, 150, 1, 46, 82, 3842, 5094, 3, 313, 207, 1, 263, 502, 2264, 10, 203, 1110, 2, 66, 3938, 502, 52, 166, 126, 9, 3050, 7, 10, 874, 53, 7, 5, 82, 3842, 13, 12, 42, 8, 33, 111, 708, 112, 25, 2687, 1, 720, 2, 8, 33, 111, 146, 115, 25, 1272, 1, 806, 2, 135, 5, 82, 3842, 5094, 42, 8, 2687, 1, 466, 2, 35, 1272, 1, 243, 19, 13, 355, 1, 3, 350, 7, 5, 82, 3842, 13, 3151, 12, 239, 42, 249, 310, 14, 120, 103, 56, 2, 14, 10, 44, 73, 429, 489, 4, 67, 531, 7, 5, 158, 14, 1041, 35, 388, 496, 1249, 2513, 3, 289, 1894, 1361, 1, 3, 259, 7, 5, 82, 3842, 5094, 12, 245, 103, 249, 310, 14, 42, 1781, 56, 18, 42, 56, 39, 42, 1761, 36, 2, 18, 11, 44, 73, 21, 164, 245, 1593, 598, 1, 3, 213, 7, 5, 440, 388, 633, 1, 496, 83, 42, 35, 4093, 496, 1249, 455, 1, 2687, 1272, 2, 633, 1, 429, 844, 17, 3837, 221, 82, 3842, 3151, 7758, 12, 1920, 100, 834, 2, 3860, 26095, 1453, 14, 82, 3842, 13, 779, 799, 158, 2, 18, 82, 3842, 5094, 779, 349, 4195, 17169, 6462, 15, 799, 15, 8, 150, 1, 46, 114, 99, 120, 309, 17, 338, 24, 422, 32, 575, 9, 46, 1453]",1867.0,12468351,Stage IIIC endometrioid corpus includes distinct subgroups,3,0.01507537688442211
Vaginal intraepithelial neoplasia: treatment by carbon dioxide laser and risk factors for failure.,"European journal of obstetrics, gynecology, and reproductive biology",Eur. J. Obstet. Gynecol. Reprod. Biol.,2003-01-01,"To evaluate the effectiveness of CO(2) laser ablation of vaginal intraepithelial neoplasia (VAIN) and to define prognostic factors. Medical records of 24 patients with VAIN II or III, treated by CO(2) laser ablation from 1990 to 1998 were reviewed. The grade, location, and focality of the lesions, the age, follow-up period and menopausal status of the patients, the power and duration of laser ablation, the presence of concurrent cervical or vulvar neoplasia or previous hysterectomy were evaluated as possible prognostic factors. Ablations of the VAIN were successfully accomplished in all of the patients with a mean period of 25.2+10.2 min, including additional simultaneous ablations of the cervix or vulva in eight (33.3%) patients. There was no early or late major complication. VAIN was completely eliminated in 17 (70.8%) patients after the first and in 19 (79.2%) patients after multiple episodes of ablation with a mean follow-up of 26.7+19.6 months. VAIN progressed to invasive vaginal carcinoma in one woman. None of the evaluated prognostic factors was found to be related to the persistence or recurrence. CO(2) laser ablation was a safe and effective method for the treatment of VAIN. However, since no prognostic factor was defined, all patients should be closely evaluated for persistence, recurrence or progression to invasion.",Clinical Trial,6229.0,36.0,evaluate effectiveness 2 laser ablation vaginal intraepithelial neoplasia VAIN define prognostic factors Medical records 24 patients VAIN II III treated 2 laser ablation 1990 1998 reviewed grade location focality lesions age follow-up period menopausal status patients power duration laser ablation presence concurrent cervical vulvar neoplasia previous hysterectomy evaluated possible prognostic factors Ablations VAIN successfully accomplished patients mean period 25.2+10.2 min including additional simultaneous ablations cervix vulva 33.3 patients early late major complication VAIN completely eliminated 17 70.8 patients 19 79.2 patients multiple episodes ablation mean follow-up 26.7+19.6 months VAIN progressed invasive vaginal carcinoma woman evaluated prognostic factors related persistence recurrence 2 laser ablation safe effective treatment VAIN prognostic factor defined patients closely evaluated persistence recurrence progression invasion,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 376, 3, 1236, 1, 1269, 18, 3555, 1650, 1, 4153, 2298, 14802, 2, 6, 1107, 177, 130, 484, 1064, 1, 259, 7, 5, 14802, 215, 15, 316, 73, 20, 1269, 18, 3555, 1650, 29, 2289, 6, 1850, 11, 446, 3, 88, 1147, 2, 24553, 1, 3, 406, 3, 89, 166, 126, 727, 2, 3565, 156, 1, 3, 7, 3, 2349, 2, 654, 1, 3555, 1650, 3, 463, 1, 750, 15, 2298, 15, 698, 2622, 11, 194, 22, 899, 177, 130, 15894, 1, 3, 14802, 11, 1878, 5741, 4, 62, 1, 3, 7, 5, 8, 313, 727, 1, 243, 18, 79, 18, 1538, 141, 402, 2824, 15894, 1, 3, 3629, 15, 9263, 4, 659, 466, 27, 7, 125, 10, 77, 191, 15, 807, 458, 1447, 14802, 10, 2500, 6173, 4, 269, 431, 66, 7, 50, 3, 157, 2, 4, 326, 842, 18, 7, 50, 232, 3750, 1, 1650, 5, 8, 313, 166, 126, 1, 432, 67, 326, 49, 53, 14802, 1839, 6, 416, 134, 4, 104, 2854, 1292, 1, 3, 194, 177, 130, 10, 204, 6, 40, 139, 6, 3, 4108, 15, 146, 1269, 18, 3555, 1650, 10, 8, 1165, 2, 323, 596, 9, 3, 24, 1, 14802, 137, 1192, 77, 177, 161, 10, 395, 62, 7, 257, 40, 3210, 194, 9, 4108, 146, 15, 91, 6, 578]",1281.0,12475584,Vaginal intraepithelial neoplasia treatment carbon dioxide laser risk factors failure,0,0.0
Vaginal cuff recurrence of endometrial cancer treated by laparoscopic-assisted vaginal hysterectomy.,Gynecologic oncology,Gynecol. Oncol.,2003-01-01,"Laparoscopic-assisted vaginal hysterectomy (LAVH) has been suggested as an alternative to total abdominal hysterectomy (TAH) for the treatment of early endometrial cancer. Although studies have reported good results with equivalent rates of recurrence and survival, the need for use of intrauterine manipulators during the LAVH raises the concern for operative dissemination of tumor cells. We report three patients with stage I, noninvasive or superficially invasive endometrial cancer with vaginal cuff recurrence within 9 months of treatment by LAVH. While LAVH may be a technically acceptable alternative to TAH for the management of early-stage endometrial cancer, its routine use should be undertaken with caution, as the long-term risks for recurrence and survival have yet to be defined in a randomized, controlled fashion.",Case Reports,6229.0,49.0,Laparoscopic-assisted vaginal hysterectomy LAVH suggested alternative total abdominal hysterectomy TAH treatment early endometrial studies reported good equivalent rates recurrence survival need use intrauterine manipulators LAVH raises concern operative dissemination report patients stage noninvasive superficially invasive endometrial vaginal cuff recurrence 9 months treatment LAVH LAVH technically acceptable alternative TAH management early-stage endometrial routine use undertaken caution long-term risks recurrence survival defined randomized controlled fashion,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[1964, 2927, 2622, 26101, 71, 85, 1148, 22, 35, 1091, 6, 181, 1467, 2622, 16704, 9, 3, 24, 1, 191, 12, 242, 94, 47, 210, 1178, 99, 5, 2017, 151, 1, 146, 2, 25, 3, 594, 9, 119, 1, 18242, 53317, 190, 3, 26101, 5789, 3, 2893, 9, 1208, 3430, 1, 30, 37, 21, 414, 169, 7, 5, 82, 70, 2957, 15, 24563, 416, 12, 5, 11445, 146, 262, 83, 53, 1, 24, 20, 26101, 369, 26101, 68, 40, 8, 6093, 1595, 1091, 6, 16704, 9, 3, 284, 1, 191, 82, 12, 211, 1311, 119, 257, 40, 2789, 5, 5526, 22, 3, 319, 337, 1098, 9, 146, 2, 25, 47, 1145, 6, 40, 395, 4, 8, 384, 1149, 3240]",766.0,12504629,Vaginal cuff recurrence endometrial treated laparoscopic-assisted vaginal hysterectomy,0,0.0
Primary small cell carcinoma of the vagina.,Gynecologic oncology,Gynecol. Oncol.,2003-03-01,"Primary vaginal small cell carcinoma is extremely rare, with a total number reported in English-language journals to date of 23. Most patients die of the disease within 2 years of diagnosis from metastatic disease. A 69-year-old woman presented with vaginal spotting while on Premarin. She was subsequently diagnosed with Stage I (T1N0M0) small cell carcinoma of the vagina. She underwent concurrent chemoradiation and then brachytherapy for persistent disease. Due to residual disease after the brachytherapy, surgical resection was planned but aborted because of metastatic disease. Of the three reported cases treated with concurrent chemoradiation, ours is the first case reported with persistent local disease after therapy. Extrapolating from the available clinical trials from lung carcinoma, concurrent chemoradiation as a primary treatment approach should still be considered.",Case Reports,6170.0,19.0,Primary vaginal small carcinoma extremely rare total number reported English-language journals date 23 patients die disease 2 years diagnosis metastatic disease 69-year-old woman presented vaginal spotting Premarin subsequently diagnosed Stage T1N0M0 small carcinoma vagina underwent concurrent chemoradiation brachytherapy persistent disease residual disease brachytherapy surgical resection planned aborted metastatic disease reported cases treated concurrent chemoradiation case reported persistent local disease therapy Extrapolating available clinical trials lung carcinoma concurrent chemoradiation primary treatment approach considered,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[86, 302, 31, 134, 16, 2938, 622, 5, 8, 181, 207, 210, 4, 4201, 4794, 6871, 6, 1244, 1, 382, 96, 7, 3384, 1, 3, 34, 262, 18, 60, 1, 147, 29, 113, 34, 8, 790, 111, 1095, 2854, 917, 5, 37278, 369, 23, 22085, 3109, 10, 1611, 265, 5, 82, 70, 17188, 302, 31, 134, 1, 3, 7553, 3109, 208, 750, 975, 2, 818, 1536, 9, 1882, 34, 520, 6, 753, 34, 50, 3, 1536, 221, 170, 10, 1465, 84, 17083, 408, 1, 113, 34, 1, 3, 169, 210, 140, 73, 5, 750, 975, 23206, 16, 3, 157, 473, 210, 5, 1882, 293, 34, 50, 36, 20278, 29, 3, 390, 38, 143, 29, 134, 750, 975, 22, 8, 86, 24, 353, 257, 1234, 40, 515]",850.0,12648603,Primary small carcinoma vagina,6,0.03015075376884422
Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy.,Gynecologic oncology,Gynecol. Oncol.,2003-05-01,"Women at risk for ovarian cancer may consider risk-reducing salpingo-oophorectomy (RRSO), and desire information regarding the health consequences of the procedure. We studied women who had undergone RRSO to assess quality of life after the procedure. Women (n = 59) undergoing RRSO between 1 January 1997 and 31 July 2000 completed a questionnaire composed of the Symptom Checklist (SCL), the Medical Outcomes Study SF-36 Health Survey, the Center for Epidemiological Studies Depression Scale, the Impact of Events Scale, and the Sexual Functioning Questionnaire-Female. At a mean of 23.8 months after RRSO, overall quality of life was similar to that reported for the general population and for breast cancer survivors. Estrogen deprivation symptoms, particularly vaginal dryness (35.2%) and dyspareunia (27.7%), were commonly bothersome. Genital symptoms resulting in sexual dysfunction were the most significant predictors of satisfaction with surgery. The prevalence of depression (20.4%) was similar to that of the general population, but a significant proportion of the group (20.7%) continued to report significant ovarian cancer-specific worries despite surgery. Vaginal symptoms are bothersome to women who have undergone RRSO, but overall health and psychological outcomes are not impaired. Although coital symptoms may not be a direct consequence of RRSO, they are the most important predictors of satisfaction. A proportion of women continue to report worries about ovarian cancer after surgery, and these women are at risk for psychological distress.",Journal Article,6109.0,102.0,Women risk ovarian consider risk-reducing salpingo-oophorectomy RRSO desire information health consequences procedure studied women undergone RRSO assess quality life procedure Women n 59 undergoing RRSO 1 January 1997 31 July 2000 completed questionnaire composed Symptom Checklist SCL Medical Outcomes SF-36 Health Survey Center Epidemiological Studies Depression Scale Impact Events Scale Sexual Functioning Questionnaire-Female mean 23.8 months RRSO overall quality life similar reported general population breast survivors Estrogen deprivation symptoms particularly vaginal dryness 35.2 dyspareunia 27.7 commonly bothersome Genital symptoms resulting sexual dysfunction significant predictors satisfaction surgery prevalence depression 20.4 similar general population significant proportion group 20.7 continued report significant ovarian cancer-specific worries despite surgery Vaginal symptoms bothersome women undergone RRSO overall health psychological outcomes impaired coital symptoms direct consequence RRSO important predictors satisfaction proportion women continue report worries ovarian surgery women risk psychological distress,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[117, 28, 43, 9, 12, 68, 2419, 43, 1818, 5690, 3470, 7376, 2, 5278, 487, 666, 3, 341, 3255, 1, 3, 1299, 21, 656, 117, 54, 42, 1989, 7376, 6, 423, 372, 1, 358, 50, 3, 1299, 117, 78, 728, 479, 7376, 59, 14, 1024, 2341, 2, 456, 2066, 1081, 781, 8, 1770, 3317, 1, 3, 934, 9787, 17194, 3, 484, 123, 45, 4086, 511, 341, 1407, 3, 574, 9, 4614, 94, 1774, 1124, 3, 345, 1, 281, 1124, 2, 3, 2232, 2702, 1770, 1061, 28, 8, 313, 1, 382, 66, 53, 50, 7376, 63, 372, 1, 358, 10, 288, 6, 17, 210, 9, 3, 1083, 266, 2, 9, 12, 332, 808, 1868, 507, 823, 15822, 465, 18, 2, 22098, 428, 67, 11, 841, 14768, 8226, 507, 1113, 4, 2232, 1527, 11, 3, 96, 93, 674, 1, 2885, 5, 152, 3, 1078, 1, 1774, 179, 39, 10, 288, 6, 17, 1, 3, 1083, 266, 84, 8, 93, 920, 1, 3, 87, 179, 67, 1351, 6, 414, 93, 12, 112, 10956, 550, 152, 507, 32, 14768, 6, 117, 54, 47, 1989, 7376, 84, 63, 341, 2, 2624, 123, 32, 44, 2364, 242, 53500, 507, 68, 44, 40, 8, 1196, 4177, 1, 7376, 491, 32, 3, 96, 305, 674, 1, 2885, 8, 920, 1, 117, 1906, 6, 414, 10956, 545, 12, 50, 152, 2, 46, 117, 32, 28, 43, 9, 2624, 1462]",1475.0,12713992,Quality life women risk ovarian undergone risk-reducing oophorectomy,4,0.020100502512562814
The use of MRI in the diagnosis and management of a bulky cervical carcinoma.,Gynecologic oncology,Gynecol. Oncol.,2003-06-01,"In the treatment of gynecologic cancer, surgical planning depends on the site and extent of disease. The evaluation of the origin of a large pelvic mass with combined pelvic examination and ultrasound is often adequate. However, the following case report illustrates the utility of magnetic resonance imaging (MRI) when sonographic findings are indeterminate and the origin of a pelvic mass is unclear. A 73-year-old woman presented for her first gynecologic exam in over 40 years. On speculum examination the cervix was not visible. A large, mobile pelvic mass was palpated during physical examination. Pelvic ultrasound revealed a large, cystic pelvic mass thought to be ovarian in origin. Surgery for presumed ovarian carcinoma was planned. Because a vaginal Pap smear revealed squamous-cell carcinoma, MRI was performed for further evaluation. MRI demonstrated a blood distended uterus with a large cervical tumor obstructing the endocervical os. After cervical dilatation under sonographic guidance, evacuation of the hematometrium was performed. Multiple biopsies of the cervix confirmed the diagnosis of a bulky Stage IIA squamous-cell carcinoma of the cervix. The patient was subsequently treated with concomitant chemotherapy and radiation therapy. Follow-up MRI demonstrated an excellent treatment response. Modified radical hysterectomy was performed demonstrating very small residual tumor. Magnetic resonance imaging, through multiplanar capabilities and high-contrast resolution, is a valuable tool that can assist the clinician in the evaluation, diagnosis, and management of challenging gynecologic malignancies.",Case Reports,6078.0,6.0,treatment gynecologic surgical planning depends site extent disease evaluation origin large pelvic mass combined pelvic examination ultrasound adequate following case report illustrates utility magnetic resonance imaging MRI sonographic findings indeterminate origin pelvic mass unclear 73-year-old woman presented gynecologic exam 40 years speculum examination cervix visible large mobile pelvic mass palpated physical examination Pelvic ultrasound revealed large cystic pelvic mass thought ovarian origin Surgery presumed ovarian carcinoma planned vaginal Pap smear revealed squamous-cell carcinoma MRI performed evaluation MRI demonstrated blood distended uterus large cervical obstructing endocervical os cervical dilatation sonographic guidance evacuation hematometrium performed Multiple biopsies cervix confirmed diagnosis bulky Stage IIA squamous-cell carcinoma cervix patient subsequently treated concomitant chemotherapy radiation therapy Follow-up MRI demonstrated excellent treatment response Modified radical hysterectomy performed demonstrating small residual Magnetic resonance imaging multiplanar capabilities high-contrast resolution valuable tool assist clinician evaluation diagnosis management challenging gynecologic malignancies,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[4, 3, 24, 1, 1512, 12, 221, 1349, 3828, 23, 3, 606, 2, 1039, 1, 34, 3, 451, 1, 3, 1938, 1, 8, 375, 1110, 782, 5, 397, 1110, 1385, 2, 1945, 16, 629, 1658, 137, 3, 366, 473, 414, 6342, 3, 1207, 1, 1484, 1535, 270, 704, 198, 9240, 272, 32, 5167, 2, 3, 1938, 1, 8, 1110, 782, 16, 1200, 8, 803, 111, 1095, 2854, 917, 9, 1084, 157, 1512, 6747, 4, 252, 327, 60, 23, 53572, 1385, 3, 3629, 10, 44, 4822, 8, 375, 7489, 1110, 782, 10, 28066, 190, 900, 1385, 1110, 1945, 553, 8, 375, 2965, 1110, 782, 2739, 6, 40, 4, 1938, 152, 9, 5472, 134, 10, 1465, 408, 8, 4290, 8379, 553, 691, 31, 134, 704, 10, 173, 9, 195, 451, 704, 264, 8, 315, 26178, 5, 8, 375, 30, 43269, 3, 10174, 118, 50, 12799, 669, 9240, 2753, 21156, 1, 3, 53573, 10, 173, 232, 1154, 1, 3, 3629, 557, 3, 147, 1, 8, 4112, 82, 4088, 691, 31, 134, 1, 3, 3629, 3, 69, 10, 1611, 73, 5, 1781, 56, 2, 121, 36, 166, 126, 704, 264, 35, 1503, 24, 51, 1230, 711, 2622, 10, 173, 2219, 923, 302, 753, 30, 1484, 1535, 270, 298, 17732, 8190, 2, 64, 748, 2125, 16, 8, 2926, 1515, 17, 122, 3425, 3, 3744, 4, 3, 451, 147, 2, 284, 1, 1950, 1512, 441]",1551.0,12798721,use MRI diagnosis management bulky cervical carcinoma,4,0.020100502512562814
Sarcomatoid carcinoma of the cervix.,Gynecologic oncology,Gynecol. Oncol.,2003-07-01,"To characterize clinical and pathologic characteristics of sarcomatoid carcinoma of the cervix. We retrospectively reviewed the charts of women with sarcomatoid carcinoma of the cervix identified by query of the Snomed pathologic diagnostic retrieval system and by direct physician query. Data were extracted from available charts, and pathology review was performed on all cases. SPSS was used for statistical analysis. Nine of 12 identified patients had complete clinical information and pathologic material available. The mean age at diagnosis was 48 (range, 29-76) years. Stage at diagnosis was I (4 patients), II (2 patients), and IV (3 patients). Patients younger than 40 years of age presented with stage I disease. All patients had visible tumor; 8 of 9 had vaginal bleeding or discharge at presentation. Microscopic evaluation revealed areas of spindle-cell sarcomatous tumor confluent with areas of poorly differentiated squamous cell carcinoma. Immunohistochemistry demonstrated coexpression of cytokeratin and vimentin in tumor cells. Tumors with a prominent spindle-cell component also expressed smooth muscle actin. Initial treatment varied, but all patients had a complete response to initial treatment. Five patients recurred with a median disease-free interval of 4.9 (range, 2-9.5) months, and none responded to second-line therapy. Four patients remained disease-free at 5, 18, 30, and 40 months, respectively, after completing initial therapy. Sarcomatoid carcinoma of the cervix is an aggressive neoplasm. Primary treatment offers the best chance for cure in women with early-stage disease. Patients with advanced disease at presentation or recurrence succumb to their disease.",Journal Article,6048.0,22.0,characterize clinical pathologic characteristics sarcomatoid carcinoma cervix retrospectively reviewed charts women sarcomatoid carcinoma cervix identified query Snomed pathologic diagnostic retrieval direct physician query extracted available charts pathology review performed cases SPSS statistical 12 identified patients complete clinical information pathologic material available mean age diagnosis 48 range 29-76 years Stage diagnosis 4 patients II 2 patients IV 3 patients Patients younger 40 years age presented stage disease patients visible 8 9 vaginal bleeding discharge presentation Microscopic evaluation revealed areas spindle-cell sarcomatous confluent areas poorly differentiated squamous carcinoma Immunohistochemistry demonstrated coexpression cytokeratin vimentin prominent spindle-cell component expressed smooth muscle actin Initial treatment varied patients complete response initial treatment patients recurred median disease-free interval 4.9 range 2-9.5 months responded second-line therapy patients remained disease-free 5 18 30 40 months respectively completing initial therapy Sarcomatoid carcinoma cervix aggressive neoplasm Primary treatment offers best chance cure women early-stage disease Patients advanced disease presentation recurrence succumb disease,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 1507, 38, 2, 510, 374, 1, 3912, 134, 1, 3, 3629, 21, 894, 446, 3, 4413, 1, 117, 5, 3912, 134, 1, 3, 3629, 108, 20, 12259, 1, 3, 53594, 510, 752, 8372, 398, 2, 20, 1196, 1473, 12259, 74, 11, 2484, 29, 390, 4413, 2, 1117, 206, 10, 173, 23, 62, 140, 11461, 10, 95, 9, 1050, 65, 762, 1, 133, 108, 7, 42, 236, 38, 487, 2, 510, 3692, 390, 3, 313, 89, 28, 147, 10, 576, 184, 462, 846, 60, 82, 28, 147, 10, 70, 39, 7, 215, 18, 7, 2, 478, 27, 7, 7, 773, 76, 327, 60, 1, 89, 917, 5, 82, 70, 34, 62, 7, 42, 4822, 30, 66, 1, 83, 42, 2294, 15, 2993, 28, 1031, 2984, 451, 553, 1361, 1, 4052, 31, 10445, 30, 18223, 5, 1361, 1, 1240, 1442, 691, 31, 134, 888, 264, 7588, 1, 4292, 2, 4840, 4, 30, 37, 57, 5, 8, 3689, 4052, 31, 1249, 120, 570, 5774, 1502, 5525, 388, 24, 2051, 84, 62, 7, 42, 8, 236, 51, 6, 388, 24, 365, 7, 3363, 5, 8, 52, 34, 115, 268, 1, 39, 83, 184, 18, 83, 33, 53, 2, 1292, 2211, 6, 419, 328, 36, 294, 7, 958, 34, 115, 28, 33, 203, 201, 2, 327, 53, 106, 50, 4144, 388, 36, 3912, 134, 1, 3, 3629, 16, 35, 571, 2131, 86, 24, 2339, 3, 824, 3477, 9, 1722, 4, 117, 5, 191, 82, 34, 7, 5, 131, 34, 28, 1031, 15, 146, 9025, 6, 136, 34]",1649.0,12821337,Sarcomatoid carcinoma cervix,24,0.12060301507537688
Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2003-08-01,"To determine the outcome of patients after radical radiotherapy (RT) for isolated vaginal recurrence of endometrial carcinoma and to determine the clinical and pathologic predictors of outcome. We reviewed the records of 91 patients treated at our institution between 1960 and 1997 with radical RT for vaginal recurrence after definitive surgery for endometrial carcinoma. Thirty-one percent of the patients received external beam RT (EBRT) alone, 12% received brachytherapy alone, and 57% received a combination. The median dose of radiation was 75 Gy (range 34-122). All end points were measured from the time of the first recurrence. The median duration of follow-up after recurrence was 58 months (range 1-289). The 2- and 5-year local control (LC) rate and overall survival rate was 82% and 75% and 69% and 43%, respectively. The median time from initial diagnosis of endometrial cancer to death from disease was 38 months. On univariate analysis, a dose to the relapse site of > or =80 Gy and EBRT plus brachytherapy vs. single-modality therapy were significant predictors of improved LC. On multivariate analysis, only the type of treatment correlated significantly with LC (p = 0.03). On univariate analysis, Grade 1 or 2 vs. Grade 3 tumor and EBRT plus brachytherapy vs. single-modality therapy were significant predictors of improved overall survival. RT provides excellent LC of isolated vaginal recurrences of endometrial carcinoma, particularly when high doses are given using a combination of EBRT and brachytherapy. However, distant metastases frequently develop despite local disease control, contributing to a 5-year overall survival rate of <50%. For patients who have an isolated vaginal recurrence, the time from initial diagnosis of endometrial cancer to death from disease is usually >3 years. For this reason, in studies of adjuvant RT, long-term follow-up is required to permit evaluation of the impact of treatment on survival.",Journal Article,6017.0,96.0,determine outcome patients radical radiotherapy RT isolated vaginal recurrence endometrial carcinoma determine clinical pathologic predictors outcome reviewed records 91 patients treated institution 1960 1997 radical RT vaginal recurrence definitive surgery endometrial carcinoma Thirty-one percent patients received external beam RT EBRT 12 received brachytherapy 57 received combination median dose radiation 75 Gy range 34-122 end points measured time recurrence median duration follow-up recurrence 58 months range 1-289 2- 5-year local control LC rate overall survival rate 82 75 69 43 respectively median time initial diagnosis endometrial death disease 38 months univariate dose relapse site =80 Gy EBRT plus brachytherapy vs. single-modality therapy significant predictors improved LC multivariate type treatment correlated significantly LC p 0.03 univariate Grade 1 2 vs. Grade 3 EBRT plus brachytherapy vs. single-modality therapy significant predictors improved overall survival RT provides excellent LC isolated vaginal recurrences endometrial carcinoma particularly high doses given combination EBRT brachytherapy distant metastases frequently develop despite local disease control contributing 5-year overall survival rate 50 patients isolated vaginal recurrence time initial diagnosis endometrial death disease usually 3 years reason studies adjuvant RT long-term follow-up required permit evaluation impact treatment survival,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[6, 223, 3, 228, 1, 7, 50, 711, 310, 240, 9, 1355, 146, 1, 134, 2, 6, 223, 3, 38, 2, 510, 674, 1, 228, 21, 446, 3, 1064, 1, 970, 7, 73, 28, 114, 731, 59, 10391, 2, 2341, 5, 711, 240, 9, 146, 50, 1057, 152, 9, 134, 977, 104, 714, 1, 3, 7, 103, 1455, 1345, 240, 1883, 279, 133, 103, 1536, 279, 2, 696, 103, 8, 150, 3, 52, 61, 1, 121, 10, 481, 381, 184, 562, 3285, 62, 396, 862, 11, 644, 29, 3, 98, 1, 3, 157, 146, 3, 52, 654, 1, 166, 126, 50, 146, 10, 717, 53, 184, 14, 9080, 3, 18, 2, 33, 111, 293, 182, 1837, 116, 2, 63, 25, 116, 10, 878, 2, 481, 2, 790, 2, 601, 106, 3, 52, 98, 29, 388, 147, 1, 12, 6, 273, 29, 34, 10, 519, 53, 23, 880, 65, 8, 61, 6, 3, 429, 606, 1, 15, 493, 381, 2, 1883, 349, 1536, 105, 226, 1396, 36, 11, 93, 674, 1, 231, 1837, 23, 331, 65, 158, 3, 267, 1, 24, 438, 97, 5, 1837, 19, 13, 680, 23, 880, 65, 88, 14, 15, 18, 105, 88, 27, 30, 2, 1883, 349, 1536, 105, 226, 1396, 36, 11, 93, 674, 1, 231, 63, 25, 240, 777, 1503, 1837, 1, 1355, 1593, 1, 134, 823, 198, 64, 415, 32, 447, 75, 8, 150, 1, 1883, 2, 1536, 137, 626, 196, 746, 690, 550, 293, 34, 182, 3156, 6, 8, 33, 111, 63, 25, 116, 1, 212, 9, 7, 54, 47, 35, 1355, 146, 3, 98, 29, 388, 147, 1, 12, 6, 273, 29, 34, 16, 2082, 27, 60, 9, 26, 3852, 4, 94, 1, 249, 240, 319, 337, 166, 126, 16, 616, 6, 5634, 451, 1, 3, 345, 1, 24, 23, 25]",1808.0,12873682,Definitive radiotherapy patients isolated vaginal recurrence endometrial carcinoma hysterectomy,2,0.010050251256281407
Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2003-09-01,"Uterine papillary serous carcinoma (UPSC) is an aggressive variant of endometrial carcinoma. The majority of patients with clinical Stage I UPSC are found to have extrauterine disease at the time of surgery. Most authors report survival rates of 35-50% for Stage I-II and 0-15% for Stage III and IV UPSC. Surgical treatment as the sole therapy for patients with Stage I-IV UPSC is unacceptable because of high recurrence rates. Chemotherapy, radiotherapy, or both have been added after surgery in an attempt to improve survival. However, the survival benefit to patients from such multimodality therapy remains uncertain. This study analyzes the patterns of failure in patients with FIGO Stages I-IV UPSC treated by multimodality therapy. Forty-two women with FIGO Stages I-IV UPSC who were treated by multimodality therapy were analyzed retrospectively between 1988 and 1998. Data were obtained from tumor registry, hospital, and radiotherapy chart reviews, operative notes, pathology, and chemotherapy flow sheets. All the patients underwent staging laparotomy, peritoneal cytology, total abdominal hysterectomy and salpingo oophorectomy, pelvic and para-aortic lymph node sampling, omentectomy, and cytoreductive surgery, when indicated followed by radiotherapy and/or chemotherapy. Therapy consisted of external beam radiation therapy in 11 patients (26%), systemic chemotherapy in 20 (48%), and both radiotherapy and chemotherapy in 11 (26%). The treatments were not assigned in a randomized fashion. The dose of external beam radiation therapy ranged from 45-50.40 Gy (median 45). Of the 31 patients (74%) who received chemotherapy, 18 received single-agent (58%), whereas 13 received multiagent chemotherapy (42%). Median follow-up for all patients was 19 months (range 4-72). Median follow-up for the surviving patients was 36 months (range 21-72). Their median age was 65 years. Six patients (14%) had Stage I, 8 patients (19%) had Stage II, 10 (24%) had Stage III, and 18 (43%) had Stage IV disease. Twenty-nine patients (69%) had suffered recurrence at the time of last follow-up. The actuarial failure rate at 2 and 5 years was 58% and 67%, respectively. The majority of the patients (19/29) recurred in the abdomen, vagina, or pelvis (66%). Metastases outside the abdomen were much less common as the first site of failure (17%). Twenty-five patients (60%) had died at the time of reporting; the observed survival rate at 2 years and 5 years was 52% and 43%, respectively. Our data suggest that, after multimodality therapy of FIGO Stage I-IV UPSC, most patients developed abdominopelvic (locoregional) failure, and the great majority of the failures occurred in the abdomen, vagina, and pelvis (66%). Abdominopelvic failure as a component of distant failure occurred in an additional 5 patients (17%). Distant failure alone occurred in 17% of the patients.We propose that future studies should combine whole abdominal radiotherapy (WART) with pelvic and vaginal boosts, in addition to chemotherapy for FIGO Stage I-IV UPSC, especially in patients with minimal residual disease, to attempt to improve the dismal prognosis of patients with UPSC.",Journal Article,5986.0,45.0,Uterine papillary serous carcinoma UPSC aggressive endometrial carcinoma majority patients clinical Stage UPSC extrauterine disease time surgery authors report survival rates 35-50 Stage I-II 0-15 Stage III IV UPSC Surgical treatment sole therapy patients Stage I-IV UPSC unacceptable high recurrence rates Chemotherapy radiotherapy added surgery attempt improve survival survival benefit patients multimodality therapy remains uncertain analyzes patterns failure patients FIGO Stages I-IV UPSC treated multimodality therapy Forty-two women FIGO Stages I-IV UPSC treated multimodality therapy retrospectively 1988 1998 obtained registry hospital radiotherapy chart reviews operative notes pathology chemotherapy flow sheets patients underwent staging laparotomy peritoneal cytology total abdominal hysterectomy salpingo oophorectomy pelvic para-aortic lymph node sampling omentectomy cytoreductive surgery indicated followed radiotherapy and/or chemotherapy Therapy consisted external beam radiation therapy 11 patients 26 systemic chemotherapy 20 48 radiotherapy chemotherapy 11 26 treatments assigned randomized fashion dose external beam radiation therapy ranged 45-50.40 Gy median 45 31 patients 74 received chemotherapy 18 received single-agent 58 13 received multiagent chemotherapy 42 Median follow-up patients 19 months range 4-72 Median follow-up surviving patients 36 months range 21-72 median age 65 years patients 14 Stage 8 patients 19 Stage II 10 24 Stage III 18 43 Stage IV disease Twenty-nine patients 69 suffered recurrence time follow-up actuarial failure rate 2 5 years 58 67 respectively majority patients 19/29 recurred abdomen vagina pelvis 66 Metastases outside abdomen common site failure 17 Twenty-five patients 60 died time reporting observed survival rate 2 years 5 years 52 43 respectively suggest multimodality therapy FIGO Stage I-IV UPSC patients developed abdominopelvic locoregional failure great majority failures occurred abdomen vagina pelvis 66 Abdominopelvic failure component distant failure occurred additional 5 patients 17 Distant failure occurred 17 patients.We propose future studies combine abdominal radiotherapy WART pelvic vaginal boosts addition chemotherapy FIGO Stage I-IV UPSC especially patients minimal residual disease attempt improve dismal prognosis patients UPSC,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[1796, 1744, 134, 5676, 16, 35, 571, 1142, 1, 134, 3, 686, 1, 7, 5, 38, 82, 70, 5676, 32, 204, 6, 47, 12115, 34, 28, 3, 98, 1, 152, 96, 738, 414, 25, 151, 1, 465, 212, 9, 82, 70, 215, 2, 13, 167, 9, 82, 316, 2, 478, 5676, 221, 24, 22, 3, 4991, 36, 9, 7, 5, 82, 70, 478, 5676, 16, 3215, 408, 1, 64, 146, 151, 56, 310, 15, 110, 47, 85, 1953, 50, 152, 4, 35, 3448, 6, 401, 25, 137, 3, 25, 247, 6, 7, 29, 225, 2425, 36, 469, 2717, 26, 45, 11113, 3, 764, 1, 496, 4, 7, 5, 3837, 1153, 70, 478, 5676, 73, 20, 2425, 36, 1213, 100, 117, 5, 3837, 1153, 70, 478, 5676, 54, 11, 73, 20, 2425, 36, 11, 311, 894, 59, 3314, 2, 1850, 74, 11, 683, 29, 30, 1608, 702, 2, 310, 2937, 2004, 1208, 8192, 1117, 2, 56, 1412, 13568, 62, 3, 7, 208, 632, 3274, 1639, 2045, 181, 1467, 2622, 2, 5690, 3470, 1110, 2, 4615, 3938, 263, 289, 2874, 20196, 2, 2604, 152, 198, 1103, 370, 20, 310, 2, 15, 56, 36, 1695, 1, 1455, 1345, 121, 36, 4, 175, 7, 432, 403, 56, 4, 179, 576, 2, 110, 310, 2, 56, 4, 175, 432, 3, 640, 11, 44, 896, 4, 8, 384, 3240, 3, 61, 1, 1455, 1345, 121, 36, 1869, 29, 512, 212, 327, 381, 52, 512, 1, 3, 456, 7, 794, 54, 103, 56, 203, 103, 226, 420, 717, 547, 233, 103, 7148, 56, 595, 52, 166, 126, 9, 62, 7, 10, 326, 53, 184, 39, 720, 52, 166, 126, 9, 3, 3050, 7, 10, 511, 53, 184, 239, 720, 136, 52, 89, 10, 556, 60, 437, 7, 213, 42, 82, 70, 66, 7, 326, 42, 82, 215, 79, 259, 42, 82, 316, 2, 203, 601, 42, 82, 478, 34, 737, 762, 7, 790, 42, 6388, 146, 28, 3, 98, 1, 1060, 166, 126, 3, 2361, 496, 116, 28, 18, 2, 33, 60, 10, 717, 2, 598, 106, 3, 686, 1, 3, 7, 326, 462, 3363, 4, 3, 4036, 7553, 15, 3270, 700, 196, 2513, 3, 4036, 11, 1802, 299, 186, 22, 3, 157, 606, 1, 496, 269, 737, 365, 7, 335, 42, 1016, 28, 3, 98, 1, 1760, 3, 164, 25, 116, 28, 18, 60, 2, 33, 60, 10, 653, 2, 601, 106, 114, 74, 309, 17, 50, 2425, 36, 1, 3837, 82, 70, 478, 5676, 96, 7, 276, 12147, 1325, 496, 2, 3, 2797, 686, 1, 3, 3368, 489, 4, 3, 4036, 7553, 2, 3270, 700, 12147, 496, 22, 8, 1249, 1, 626, 496, 489, 4, 35, 402, 33, 7, 269, 626, 496, 279, 489, 4, 269, 1, 3, 7, 21, 2548, 17, 508, 94, 257, 4680, 902, 1467, 310, 18296, 5, 1110, 2, 20239, 4, 352, 6, 56, 9, 3837, 82, 70, 478, 5676, 1093, 4, 7, 5, 1048, 753, 34, 6, 3448, 6, 401, 3, 3929, 356, 1, 7, 5, 5676]",3000.0,12909235,Patterns failure multimodality treatment uterine papillary serous carcinoma,16,0.08040201005025126
Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial.,JAMA,JAMA,2003-10-01,"The effects of continuous combined hormone therapy on gynecologic cancers have not been investigated previously in a randomized trial setting. To determine the possible associations of estrogen plus progestin on gynecologic cancers and related diagnostic procedures. Randomized, double-blind, placebo-controlled trial of 16 608 postmenopausal women, who had not had a hysterectomy at baseline and who had been recruited from 40 US clinical centers between September 1993 and October 1998 (average follow-up, 5.6 years). One tablet per day containing 0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate (n = 8506) or placebo (n = 8102). Incident invasive cancer of the ovary and endometrium. In 5.6 years of follow-up, there were 32 cases of invasive ovarian cancer, 58 cases of endometrial cancer, 1 case of nonendometrial uterine cancer, 13 cases of cervical cancer, and 7 cases of other gynecologic cancers. The hazard ratio (HR) for invasive ovarian cancer in women assigned to estrogen plus progestin compared with placebo was 1.58 (95% confidence interval [CI], 0.77-3.24). The HR for endometrial cancer was 0.81 (95% CI, 0.48-1.36). No appreciable differences were found in the distributions of tumor histology, stage, or grade for either cancer site. The incidence of other gynecologic cancers was low and did not differ by randomization assignment. More women taking estrogen plus progestin required endometrial biopsies (33% vs 6%; P<.001). This randomized trial suggests that continuous combined estrogen plus progestin therapy may increase the risk of ovarian cancer while producing endometrial cancer rates similar to placebo. The increased burden of endometrial biopsies required to assess vaginal bleeding further limits the acceptability of this regimen. These data provide additional support for caution in the use of continuous combined hormones.",Clinical Trial,5956.0,438.0,effects continuous combined hormone therapy gynecologic investigated previously randomized trial setting determine possible associations estrogen plus progestin gynecologic related diagnostic procedures Randomized double-blind placebo-controlled trial 16 608 postmenopausal women hysterectomy baseline recruited 40 clinical centers September 1993 October 1998 average follow-up 5.6 years tablet day containing 0.625 mg conjugated equine estrogens plus 2.5 mg medroxyprogesterone acetate n 8506 placebo n 8102 Incident invasive ovary endometrium 5.6 years follow-up 32 cases invasive ovarian 58 cases endometrial 1 case nonendometrial uterine 13 cases cervical 7 cases gynecologic hazard ratio HR invasive ovarian women assigned estrogen plus progestin compared placebo 1.58 95 confidence interval CI 0.77-3.24 HR endometrial 0.81 95 CI 0.48-1.36 appreciable differences distributions histology stage grade site incidence gynecologic low differ randomization assignment women taking estrogen plus progestin required endometrial biopsies 33 vs 6 P .001 randomized trial suggests continuous combined estrogen plus progestin therapy increase risk ovarian producing endometrial rates similar placebo increased burden endometrial biopsies required assess vaginal bleeding limits acceptability regimen provide additional support caution use continuous combined hormones,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 176, 1, 1314, 397, 785, 36, 23, 1512, 163, 47, 44, 85, 565, 373, 4, 8, 384, 160, 546, 6, 223, 3, 899, 685, 1, 808, 349, 9370, 23, 1512, 163, 2, 139, 752, 1369, 384, 1627, 3142, 619, 1149, 160, 1, 245, 11768, 1679, 117, 54, 42, 44, 42, 8, 2622, 28, 330, 2, 54, 42, 85, 2619, 29, 327, 843, 38, 1168, 59, 2636, 3343, 2, 2551, 1850, 1011, 166, 126, 33, 49, 60, 104, 6977, 379, 218, 1101, 13, 9629, 81, 1, 3868, 17759, 6293, 349, 18, 33, 81, 1, 18815, 3424, 78, 43374, 15, 619, 78, 43375, 2631, 416, 12, 1, 3, 3631, 2, 4, 33, 49, 60, 1, 166, 126, 125, 11, 531, 140, 1, 416, 12, 717, 140, 1, 12, 14, 473, 1, 53767, 12, 233, 140, 1, 12, 2, 67, 140, 1, 127, 1512, 163, 3, 360, 197, 168, 9, 416, 12, 4, 117, 896, 6, 808, 349, 9370, 72, 5, 619, 10, 14, 717, 48, 307, 268, 58, 13, 849, 27, 259, 3, 168, 9, 12, 10, 13, 865, 48, 58, 13, 576, 14, 511, 77, 9371, 362, 11, 204, 4, 3, 4477, 1, 30, 784, 82, 15, 88, 9, 361, 12, 606, 3, 287, 1, 127, 1512, 163, 10, 154, 2, 205, 44, 1505, 20, 3644, 4392, 80, 117, 2727, 808, 349, 9370, 616, 1154, 466, 105, 49, 19, 144, 26, 384, 160, 844, 17, 1314, 397, 808, 349, 9370, 36, 68, 344, 3, 43, 1, 12, 369, 3787, 12, 151, 288, 6, 619, 3, 101, 892, 1, 1154, 616, 6, 423, 2294, 195, 3526, 3, 8065, 1, 26, 477, 46, 74, 377, 402, 538, 9, 5526, 4, 3, 119, 1, 1314, 397, 4927]",1721.0,14519708,Effects estrogen plus progestin gynecologic associated diagnostic procedures Women 's Health Initiative randomized trial,0,0.0
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.,The New England journal of medicine,N. Engl. J. Med.,2003-10-09,"In hormone-dependent breast cancer, five years of postoperative tamoxifen therapy--but not tamoxifen therapy of longer duration--prolongs disease-free and overall survival. The aromatase inhibitor letrozole, by suppressing estrogen production, might improve the outcome after the discontinuation of tamoxifen therapy. We conducted a double-blind, placebo-controlled trial to test the effectiveness of five years of letrozole therapy in postmenopausal women with breast cancer who have completed five years of tamoxifen therapy. The primary end point was disease-free survival. A total of 5187 women were enrolled (median follow-up, 2.4 years). At the first interim analysis, there were 207 local or metastatic recurrences of breast cancer or new primary cancers in the contralateral breast--75 in the letrozole group and 132 in the placebo group--with estimated four-year disease-free survival rates of 93 percent and 87 percent, respectively, in the two groups (P< or =0.001 for the comparison of disease-free survival). A total of 42 women in the placebo group and 31 women in the letrozole group died (P=0.25 for the comparison of overall survival). Low-grade hot flashes, arthritis, arthralgia, and myalgia were more frequent in the letrozole group, but vaginal bleeding was less frequent. There were new diagnoses of osteoporosis in 5.8 percent of the women in the letrozole group and 4.5 percent of the women in the placebo group (P=0.07); the rates of fracture were similar. After the first interim analysis, the independent data and safety monitoring committee recommended termination of the trial and prompt communication of the results to the participants. As compared with placebo, letrozole therapy after the completion of standard tamoxifen treatment significantly improves disease-free survival.",Clinical Trial,5948.0,1555.0,hormone-dependent breast years postoperative tamoxifen therapy -- tamoxifen therapy longer duration -- prolongs disease-free overall survival aromatase inhibitor letrozole suppressing estrogen production improve outcome discontinuation tamoxifen therapy conducted double-blind placebo-controlled trial test effectiveness years letrozole therapy postmenopausal women breast completed years tamoxifen therapy primary end point disease-free survival total 5187 women enrolled median follow-up 2.4 years interim 207 local metastatic recurrences breast new primary contralateral breast -- 75 letrozole group 132 placebo group -- estimated four-year disease-free survival rates 93 percent 87 percent respectively groups P =0.001 comparison disease-free survival total 42 women placebo group 31 women letrozole group died P=0.25 comparison overall survival Low-grade hot flashes arthritis arthralgia myalgia frequent letrozole group vaginal bleeding frequent new diagnoses osteoporosis 5.8 percent women letrozole group 4.5 percent women placebo group P=0.07 rates fracture similar interim independent safety monitoring committee recommended termination trial prompt communication participants compared placebo letrozole therapy completion standard tamoxifen treatment significantly improves disease-free survival,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4, 785, 470, 12, 365, 60, 1, 573, 1105, 36, 84, 44, 1105, 36, 1, 589, 654, 5613, 34, 115, 2, 63, 25, 3, 2106, 230, 2800, 20, 4669, 808, 1529, 822, 401, 3, 228, 50, 3, 2007, 1, 1105, 36, 21, 426, 8, 1627, 3142, 619, 1149, 160, 6, 412, 3, 1236, 1, 365, 60, 1, 2800, 36, 4, 1679, 117, 5, 12, 54, 47, 781, 365, 60, 1, 1105, 36, 3, 86, 396, 741, 10, 34, 115, 25, 8, 181, 1, 37556, 117, 11, 346, 52, 166, 126, 18, 39, 60, 28, 3, 157, 2914, 65, 125, 11, 5292, 293, 15, 113, 1593, 1, 12, 15, 217, 86, 163, 4, 3, 2138, 481, 4, 3, 2800, 87, 2, 4255, 4, 3, 619, 87, 5, 661, 294, 111, 34, 115, 25, 151, 1, 966, 714, 2, 912, 714, 106, 4, 3, 100, 271, 19, 15, 13, 144, 9, 3, 1155, 1, 34, 115, 25, 8, 181, 1, 595, 117, 4, 3, 619, 87, 2, 456, 117, 4, 3, 2800, 87, 1016, 19, 13, 243, 9, 3, 1155, 1, 63, 25, 154, 88, 2859, 4193, 8646, 8451, 2, 8490, 11, 80, 908, 4, 3, 2800, 87, 84, 2294, 10, 299, 908, 125, 11, 217, 2403, 1, 4970, 4, 33, 66, 714, 1, 3, 117, 4, 3, 2800, 87, 2, 39, 33, 714, 1, 3, 117, 4, 3, 619, 87, 19, 13, 1615, 3, 151, 1, 3956, 11, 288, 50, 3, 157, 2914, 65, 3, 306, 74, 2, 367, 1315, 2002, 793, 7202, 1, 3, 160, 2, 4776, 2063, 1, 3, 99, 6, 3, 776, 22, 72, 5, 619, 2800, 36, 50, 3, 1438, 1, 260, 1105, 24, 97, 1804, 34, 115, 25]",1746.0,14551341,randomized trial letrozole postmenopausal women years tamoxifen therapy early-stage breast,0,0.0
Primary abdominal gestational choriocarcinoma.,Obstetrics and gynecology,Obstet Gynecol,2003-11-01,"Gestational choriocarcinoma associated with ectopic pregnancy is an extremely infrequent event. Primary abdominal gestational choriocarcinoma has not been previously described. A pregnant woman presented to the emergency room with 6 days of vaginal spotting. Her last menstrual period suggested a gestation at 6 4/7 weeks. Transvaginal sonogram showed a hemoperitoneum with no intrauterine pregnancy. The serum human chorionic gonadotropin level was noted to be 317,735 mIU/mL. A 20 x 20-mm friable, bleeding mass on the left anterior abdominal wall was laparoscopically resected. Gestational choriocarcinoma was identified on histopathologic review. International Federation of Gynecology and Obstetrics stage IV:4 was assigned, and the patient achieved clinical remission with combination chemotherapy. Primary abdominal gestational choriocarcinoma can present with findings similar to a ruptured ectopic pregnancy; it should be treated by surgical excision and chemotherapy.",Case Reports,5925.0,6.0,"Gestational choriocarcinoma associated ectopic pregnancy extremely infrequent event Primary abdominal gestational choriocarcinoma previously described pregnant woman presented emergency room 6 days vaginal spotting menstrual period suggested gestation 6 4/7 weeks Transvaginal sonogram showed hemoperitoneum intrauterine pregnancy serum human chorionic gonadotropin level noted 317,735 mIU/mL 20 x 20-mm friable bleeding mass left anterior abdominal wall laparoscopically resected Gestational choriocarcinoma identified histopathologic review International Federation Gynecology Obstetrics stage IV:4 assigned patient achieved clinical remission combination chemotherapy Primary abdominal gestational choriocarcinoma present findings similar ruptured ectopic pregnancy treated surgical excision chemotherapy",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[9383, 13081, 41, 5, 3647, 2290, 16, 35, 2938, 4475, 774, 86, 1467, 9383, 13081, 71, 44, 85, 373, 1027, 8, 6086, 2854, 917, 6, 3, 4605, 4698, 5, 49, 162, 1, 37278, 1084, 1060, 8518, 727, 1148, 8, 13250, 28, 49, 39, 67, 244, 9487, 33567, 224, 8, 30282, 5, 77, 18242, 2290, 3, 524, 171, 10420, 6501, 301, 10, 1051, 6, 40, 7869, 15232, 8356, 542, 8, 179, 1006, 179, 321, 37598, 2294, 782, 23, 3, 1712, 2882, 1467, 2397, 10, 11472, 1133, 9383, 13081, 10, 108, 23, 2630, 206, 944, 7303, 1, 6429, 2, 7407, 82, 478, 39, 10, 896, 2, 3, 69, 513, 38, 734, 5, 150, 56, 86, 1467, 9383, 13081, 122, 364, 5, 272, 288, 6, 8, 18937, 3647, 2290, 192, 257, 40, 73, 20, 221, 1366, 2, 56]",956.0,14672474,Primary abdominal gestational choriocarcinoma,0,0.0
Role of CT in the management of recurrent ovarian cancer.,AJR. American journal of roentgenology,AJR Am J Roentgenol,2004-02-01,"The purpose of this study was to evaluate the potential role of preoperative CT in patients with recurrent ovarian cancer who undergo secondary cytoreductive surgery. Preoperative CT examinations of 36 consecutive patients (age range, 30-75 years; mean age, 55 years) were reviewed retrospectively. Patients had recurrent ovarian cancer and secondary cytoreduction within a mean CT-surgery interval of 22 days (range, 2-69 days). The CT findings recorded were upper abdominal metastases (e.g., peritoneal carcinomatosis; perihepatic, perisplenic, gastrohepatic or gastrosplenic ligaments; gallbladder fossa; falciform ligament; lesser sac), lymphadenopathy (above or below the renal hilum), liver metastasis, large- and small-bowel obstruction, hydronephrosis, ascites, and the presence of a pelvic mass. CT findings and cancer antigen-125 (CA-125) levels were correlated with surgical resectability. At surgery, tumors in 27 patients were optimally debulked (residual disease of <or= 1 cm) and in nine patients were nonresectable. Using multivariate analysis, hydronephrosis (odds ratio = 19.4, p = 0.03) and invasion of pelvic sidewall (odds ratio = 35.6, p = 0.006) were found to be most indicative of tumor nonresectability. The presence of small-bowel obstruction; nodal or perihepatic liver metastasis; ascites; peritoneal carcinomatosis; bladder, rectum, sigmoid colon, or vaginal involvement; or infrarenal paraaortic adenopathy; and the level of CA-125 were not strong indicators of tumor nonresectability. In patients with recurrent ovarian carcinoma considered for secondary cytoreductive surgery, preoperative CT can be helpful in identifying the extent of the disease and can be used as an adjunct to treatment planning and management decisions.",Evaluation Study,5833.0,38.0,purpose evaluate potential role preoperative CT patients recurrent ovarian undergo secondary cytoreductive surgery Preoperative CT examinations 36 consecutive patients age range 30-75 years mean age 55 years reviewed retrospectively Patients recurrent ovarian secondary cytoreduction mean CT-surgery interval 22 days range 2-69 days CT findings recorded upper abdominal metastases e.g. peritoneal carcinomatosis perihepatic perisplenic gastrohepatic gastrosplenic ligaments gallbladder fossa falciform ligament lesser sac lymphadenopathy renal hilum liver metastasis large- small-bowel obstruction hydronephrosis ascites presence pelvic mass CT findings antigen-125 CA-125 levels correlated surgical resectability surgery 27 patients optimally debulked residual disease or= 1 cm patients nonresectable multivariate hydronephrosis odds ratio 19.4 p 0.03 invasion pelvic sidewall odds ratio 35.6 p 0.006 indicative nonresectability presence small-bowel obstruction nodal perihepatic liver metastasis ascites peritoneal carcinomatosis bladder rectum sigmoid colon vaginal involvement infrarenal paraaortic adenopathy level CA-125 strong indicators nonresectability patients recurrent ovarian carcinoma considered secondary cytoreductive surgery preoperative CT helpful identifying extent disease adjunct treatment planning management decisions,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[3, 743, 1, 26, 45, 10, 6, 376, 3, 174, 200, 1, 498, 425, 4, 7, 5, 387, 12, 54, 1251, 568, 2604, 152, 498, 425, 4209, 1, 511, 935, 7, 89, 184, 201, 481, 60, 313, 89, 614, 60, 11, 446, 894, 7, 42, 387, 12, 2, 568, 2844, 262, 8, 313, 425, 152, 268, 1, 350, 162, 184, 18, 790, 162, 3, 425, 272, 1872, 11, 1726, 1467, 196, 563, 499, 1639, 5622, 11976, 43487, 33405, 15, 53964, 43488, 5100, 37617, 15908, 5191, 7948, 4962, 2090, 15, 2736, 3, 17244, 278, 375, 2, 302, 1659, 3191, 11977, 3819, 2, 3, 463, 1, 8, 1110, 782, 425, 272, 2, 12, 448, 1731, 1568, 1731, 148, 11, 438, 5, 221, 5150, 28, 152, 57, 4, 428, 7, 11, 5074, 11118, 753, 34, 1, 15, 14, 494, 2, 4, 762, 7, 11, 24583, 75, 331, 65, 11977, 610, 197, 326, 39, 19, 13, 680, 2, 578, 1, 1110, 12599, 610, 197, 465, 49, 19, 13, 1861, 11, 204, 6, 40, 96, 5572, 1, 30, 43489, 3, 463, 1, 302, 1659, 3191, 779, 15, 11976, 278, 3819, 1639, 5622, 3660, 9356, 15, 799, 15, 30536, 7401, 7741, 2, 3, 301, 1, 1568, 1731, 11, 44, 1082, 3539, 1, 30, 43489, 4, 7, 5, 387, 134, 515, 9, 568, 2604, 152, 498, 425, 122, 40, 3951, 4, 1386, 3, 1039, 1, 3, 34, 2, 122, 40, 95, 22, 35, 5471, 6, 24, 1349, 2, 284, 1526]",1617.0,14736669,Role CT management recurrent ovarian,4,0.020100502512562814
Predictors of sexual functioning in ovarian cancer patients.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2004-03-01,"To characterize sexual functioning of ovarian cancer patients and identify factors predicting sexual activity, functioning or satisfaction, discomfort, and habit or frequency. Data were collected on 232 women with epithelial ovarian cancer, 47% of whom were receiving treatment. Fifty percent of the patients had engaged in sexual activity in the past month. Of those who were sexually active, 47% reported no or little desire, 80% reported problems with vaginal dryness, and 62% reported pain or discomfort during penetration. Of those who were sexually inactive, reasons included no partner (44.1%), lack of interest (38.7%), physical problems making sex difficult (23.4%), and fatigue (10.8%). Partner factors also were identified, including physical problems (16.2%), lack of interest (15.3%), and fatigue (5.4%). A multivariate model was used to predict sexual activity and included demographic, medical, and psychosocial factors as predictors. Women who were married (P <.001), were younger than 56 years (P <.001), were not receiving active treatment (P <.01), had a longer time since original diagnosis (P =.104), and liked the appearance of their bodies (P =.004) were more likely to be sexually active. Univariate analyses indicated that demographic, medical, and psychosocial factors are significantly associated with sexual functioning or satisfaction, sexual discomfort, and sexual frequency or habit. Sexual rehabilitation for ovarian cancer patients should address management of physical and psychologic symptoms and include the patient's partner when appropriate.",Comparative Study,5804.0,149.0,characterize sexual functioning ovarian patients identify factors predicting sexual activity functioning satisfaction discomfort habit frequency collected 232 women epithelial ovarian 47 receiving treatment percent patients engaged sexual activity past month sexually active 47 reported little desire 80 reported problems vaginal dryness 62 reported pain discomfort penetration sexually inactive reasons included partner 44.1 lack 38.7 physical problems making sex difficult 23.4 fatigue 10.8 Partner factors identified including physical problems 16.2 lack 15.3 fatigue 5.4 multivariate model predict sexual activity included demographic medical psychosocial factors predictors Women married P .001 younger 56 years P .001 receiving active treatment P .01 longer time original diagnosis P =.104 liked appearance bodies P =.004 likely sexually active Univariate indicated demographic medical psychosocial factors significantly associated sexual functioning satisfaction sexual discomfort sexual frequency habit Sexual rehabilitation ovarian patients address management physical psychologic symptoms include patient 's partner appropriate,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 1507, 2232, 2702, 1, 12, 7, 2, 255, 130, 1434, 2232, 128, 2702, 15, 2885, 7381, 2, 24477, 15, 675, 74, 11, 786, 23, 7186, 117, 5, 701, 12, 662, 1, 953, 11, 357, 24, 1461, 714, 1, 3, 7, 42, 9173, 4, 2232, 128, 4, 3, 1219, 811, 1, 135, 54, 11, 13588, 544, 662, 210, 77, 15, 1215, 5278, 493, 210, 2408, 5, 15822, 2, 744, 210, 559, 15, 7381, 190, 4618, 1, 135, 54, 11, 13588, 5002, 2325, 159, 77, 4852, 584, 14, 926, 1, 1333, 519, 67, 900, 2408, 1079, 1035, 1740, 382, 39, 2, 613, 79, 66, 4852, 130, 120, 11, 108, 141, 900, 2408, 245, 18, 926, 1, 1333, 167, 27, 2, 613, 33, 39, 8, 331, 202, 10, 95, 6, 678, 2232, 128, 2, 159, 1540, 484, 2, 2322, 130, 22, 674, 117, 54, 11, 5365, 19, 144, 11, 773, 76, 664, 60, 19, 144, 11, 44, 357, 544, 24, 19, 355, 42, 8, 589, 98, 1192, 2279, 147, 19, 3407, 2, 37642, 3, 3592, 1, 136, 7442, 19, 1520, 11, 80, 322, 6, 40, 13588, 544, 880, 318, 1103, 17, 1540, 484, 2, 2322, 130, 32, 97, 41, 5, 2232, 2702, 15, 2885, 2232, 7381, 2, 2232, 675, 15, 24477, 2232, 4182, 9, 12, 7, 257, 1539, 284, 1, 900, 2, 14388, 507, 2, 643, 3, 69, 292, 4852, 198, 870]",1476.0,14990644,Predictors sexual functioning ovarian patients,1,0.005025125628140704
Chemotherapy-induced dyspareunia: a case study of vaginal mucositis and pegylated liposomal doxorubicin injection in advanced stage ovarian carcinoma.,Gynecologic oncology,Gynecol. Oncol.,2004-05-01,"Chemotherapy can cause vaginal irritation and mucositis, although rarely reported. A 62-year-old patient with ovarian cancer reported vaginal burning associated with dyspareunia, which emerged 3-5 days after her initial chemotherapy and persisted throughout her treatment. Her discomfort persisted until she was evaluated by our sexual health service and interventions were implemented. On examination, her vaginal vault was erythematous, with mild signs of vaginal atrophy. Her management schema consisted of the following: avoidance of intercourse 3-5 days after chemotherapy, intravaginal vitamin E suppositories three times per week, intravaginal estrogen tablets (initial course of 14 days followed by twice weekly usage), use of lubricants (Astroglide) during coitus, and counseling. Once interventions were introduced, she subsequently resumed sexual intercourse during the remainder of her chemotherapy treatments. Patients with sexual complaints during or following cancer treatment can be treated by their community gynecologists or gynecology oncologists or can be treated through a comprehensive sexual health program with restoration of sexual function.",Case Reports,5743.0,14.0,Chemotherapy cause vaginal irritation mucositis rarely reported 62-year-old patient ovarian reported vaginal burning associated dyspareunia emerged 3-5 days initial chemotherapy persisted treatment discomfort persisted evaluated sexual health service interventions implemented examination vaginal vault erythematous mild signs vaginal atrophy management schema consisted following avoidance intercourse 3-5 days chemotherapy intravaginal vitamin E suppositories times week intravaginal estrogen tablets initial course 14 days followed twice weekly usage use lubricants Astroglide coitus counseling interventions introduced subsequently resumed sexual intercourse remainder chemotherapy treatments Patients sexual complaints following treatment treated community gynecologists gynecology oncologists treated comprehensive sexual health program restoration sexual function,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[56, 122, 708, 11765, 2, 2606, 242, 2416, 210, 8, 744, 111, 1095, 69, 5, 12, 210, 17792, 41, 5, 22098, 92, 2054, 27, 33, 162, 50, 1084, 388, 56, 2, 3760, 2432, 1084, 24, 1084, 7381, 3760, 1100, 3109, 10, 194, 20, 114, 2232, 341, 3086, 2, 1151, 11, 3426, 23, 1385, 1084, 28115, 10, 15973, 5, 1980, 3408, 1, 7637, 1084, 284, 8371, 1695, 1, 3, 366, 5863, 1, 12361, 27, 33, 162, 50, 56, 16720, 1610, 563, 43586, 169, 1072, 379, 647, 16720, 808, 6675, 388, 906, 1, 213, 162, 370, 20, 936, 709, 5015, 119, 1, 37673, 54126, 190, 54127, 2, 2011, 1059, 1151, 11, 3955, 3109, 1611, 11294, 2232, 12361, 190, 3, 7095, 1, 1084, 56, 640, 7, 5, 2232, 6938, 190, 15, 366, 12, 24, 122, 40, 73, 20, 136, 1714, 14854, 15, 6429, 1339, 15, 122, 40, 73, 298, 8, 949, 2232, 341, 1243, 5, 5194, 1, 2232, 343]",1105.0,15099982,Chemotherapy-induced dyspareunia case vaginal mucositis pegylated liposomal doxorubicin injection advanced stage ovarian carcinoma,23,0.11557788944723618
Radical hysterectomy followed by tailored postoperative therapy in the treatment of stage IB2 cervical cancer: feasibility and indications for adjuvant therapy.,Gynecologic oncology,Gynecol. Oncol.,2004-07-01,"To determine the outcome, complications and likelihood of requiring adjuvant therapy of patients with stage IB2 cervical cancer treated with primary radical hysterectomy and lymph node dissection. Clinical and pathologic data between 1985 and 1999 were reviewed. Associations between clinical and pathologic variables were tested using the Fisher's exact test. Survival was estimated using the Kaplan-Meier method with significance being calculated using the Log Rank test. Six hundred radical hysterectomies were performed during the study period. Fifty-eight of these women (9.6% of all radical hysterectomies) were diagnosed with FIGO stage IB2 cancers. Sixteen patients (28%) had positive pelvic lymph nodes. Forty-six patients (79%) had invasion involving the outer 1/3 of the cervical stroma, six had positive vaginal margins while five had occult parametrial extension. After retrospective review of the histopathologic data from this case series, criteria from two recently published prospective multicenter Gynecologic Oncology Group (GOG) trials were applied to this data set. According to criteria established by GOG protocol 92, 30 (52%) patients should have theoretically received adjuvant pelvic radiation while 21 (36%) would have qualified for adjuvant chemotherapy and radiation according to the results of GOG protocol 109. In actual fact, only 35 patients (60%) received adjuvant radiotherapy and one received adjuvant chemo-radiation. Severe toxicity was unusual with two developing urinary fistulae and one having a pulmonary embolism. Despite the lack of adjuvant therapy in most cases, only 21 women (38%) recurred of whom 11 failed on the pelvic wall, with an estimated 5-year survival of 62.1%. Radical hysterectomy and tailored adjuvant radiation therapy in stage IB2 cervical cancer is feasible. Even without the liberal use of adjuvant therapy, survival in this high-risk group compares favorably to primary chemotherapy and radiation. According to recently published randomized clinical trials, most patients should receive adjuvant postoperative therapy. The benefits of this multimodality approach require randomized study.",Journal Article,5682.0,64.0,determine outcome complications likelihood requiring adjuvant therapy patients stage IB2 cervical treated primary radical hysterectomy lymph node dissection Clinical pathologic 1985 1999 reviewed Associations clinical pathologic variables tested Fisher 's exact test Survival estimated Kaplan-Meier significance calculated Log Rank test radical hysterectomies performed period Fifty-eight women 9.6 radical hysterectomies diagnosed FIGO stage IB2 Sixteen patients 28 positive pelvic lymph nodes Forty-six patients 79 invasion involving outer 1/3 cervical stroma positive vaginal margins occult parametrial extension retrospective review histopathologic case series criteria recently published prospective multicenter Gynecologic Oncology Group GOG trials applied set According criteria established GOG protocol 92 30 52 patients theoretically received adjuvant pelvic radiation 21 36 qualified adjuvant chemotherapy radiation according GOG protocol 109 actual fact 35 patients 60 received adjuvant radiotherapy received adjuvant chemo-radiation Severe toxicity unusual developing urinary fistulae pulmonary embolism Despite lack adjuvant therapy cases 21 women 38 recurred 11 failed pelvic wall estimated 5-year survival 62.1 Radical hysterectomy tailored adjuvant radiation therapy stage IB2 cervical feasible liberal use adjuvant therapy survival high-risk group compares favorably primary chemotherapy radiation According recently published randomized clinical trials patients receive adjuvant postoperative therapy benefits multimodality approach require randomized,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 3, 228, 521, 2, 1420, 1, 1888, 249, 36, 1, 7, 5, 82, 9537, 12, 73, 5, 86, 711, 2622, 2, 263, 289, 1161, 38, 2, 510, 74, 59, 4675, 2, 2043, 11, 446, 685, 59, 38, 2, 510, 682, 11, 650, 75, 3, 3135, 292, 2472, 412, 25, 10, 661, 75, 3, 876, 882, 596, 5, 724, 486, 981, 75, 3, 1066, 1026, 412, 437, 1128, 711, 15266, 11, 173, 190, 3, 45, 727, 1461, 659, 1, 46, 117, 83, 49, 1, 62, 711, 15266, 11, 265, 5, 3837, 82, 9537, 163, 3228, 7, 339, 42, 109, 1110, 263, 502, 1213, 437, 7, 842, 42, 578, 1267, 3, 7808, 14, 27, 1, 3, 2477, 437, 42, 109, 1012, 369, 365, 42, 2879, 8726, 2401, 50, 459, 206, 1, 3, 2630, 74, 29, 26, 473, 988, 371, 29, 100, 761, 983, 482, 1570, 1512, 413, 87, 4760, 143, 11, 1498, 6, 26, 74, 916, 768, 6, 371, 635, 20, 4760, 1182, 937, 201, 653, 7, 257, 47, 9662, 103, 249, 1110, 121, 369, 239, 511, 688, 47, 9575, 9, 249, 56, 2, 121, 768, 6, 3, 99, 1, 4760, 1182, 3486, 4, 3480, 1991, 158, 465, 7, 335, 103, 249, 310, 2, 104, 103, 249, 3341, 121, 905, 155, 10, 4015, 5, 100, 931, 1660, 17809, 2, 104, 1041, 8, 1087, 5475, 550, 3, 926, 1, 249, 36, 4, 96, 140, 158, 239, 117, 519, 3363, 1, 953, 175, 1551, 23, 3, 1110, 2397, 5, 35, 661, 33, 111, 25, 1, 744, 14, 711, 2622, 2, 3632, 249, 121, 36, 4, 82, 9537, 12, 16, 1313, 871, 187, 3, 23341, 119, 1, 249, 36, 25, 4, 26, 64, 43, 87, 5815, 5001, 6, 86, 56, 2, 121, 768, 6, 761, 983, 384, 38, 143, 96, 7, 257, 560, 249, 573, 36, 3, 1141, 1, 26, 2425, 353, 1353, 384, 45]",2070.0,15262120,Radical hysterectomy followed tailored postoperative therapy treatment stage IB2 cervical feasibility indications adjuvant therapy,63,0.3165829145728643
Adenocarcinoma of the cervix and vagina in pediatric patients.,Pediatric blood & cancer,Pediatr Blood Cancer,2004-09-01,Here we report our combined analysis of vaginal mesonephric adenocarcinoma (MA) in a 13 years old treated at our institution and of reported vaginal or cervical MA and clear-cell adenocarcinoma in 37 patients 18 years old or younger. Tumors in 27 patients arose in the vagina; 8 (21%) had metastases at diagnosis. The predominant symptom was vaginal bleeding; 62% of patients were exposed to diethylstilbestrol in utero. The 3-year survival estimate was 71% +/- 11%. Surgical treatment and metastasis at diagnosis were significant predictors of survival. The association between tumor excision and excellent outcome suggests that radical hysterectomy or pelvic exenteration is unnecessary. Radiotherapy as an adjunct may have contributed to this outcome.,Journal Article,5620.0,17.0,report combined vaginal mesonephric adenocarcinoma 13 years old treated institution reported vaginal cervical clear-cell adenocarcinoma 37 patients 18 years old younger 27 patients arose vagina 8 21 metastases diagnosis predominant symptom vaginal bleeding 62 patients exposed diethylstilbestrol utero 3-year survival estimate 71 +/- 11 Surgical treatment metastasis diagnosis significant predictors survival association excision excellent outcome suggests radical hysterectomy pelvic exenteration unnecessary Radiotherapy adjunct contributed outcome,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[467, 21, 414, 114, 397, 65, 1, 28259, 449, 3687, 4, 8, 233, 60, 1095, 73, 28, 114, 731, 2, 1, 210, 15, 3687, 2, 885, 31, 449, 4, 567, 7, 203, 60, 1095, 15, 773, 57, 4, 428, 7, 7268, 4, 3, 7553, 66, 239, 42, 196, 28, 147, 3, 2750, 934, 10, 2294, 744, 1, 7, 11, 2234, 6, 15522, 4, 13767, 3, 27, 111, 25, 1191, 10, 792, 175, 221, 24, 2, 278, 28, 147, 11, 93, 674, 1, 25, 3, 248, 59, 30, 1366, 2, 1503, 228, 844, 17, 711, 2622, 15, 1110, 5668, 16, 4224, 310, 22, 35, 5471, 68, 47, 3447, 6, 26, 228]",704.0,15266416,Adenocarcinoma cervix vagina pediatric patients,2,0.010050251256281407
Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases.,Gynecologic oncology,Gynecol. Oncol.,2004-08-01,"Synchronous primary cancers of the endometrium and ovary are found in 10% of women with ovarian cancer and 5% of women with endometrial cancer. The purpose of this study was to characterize patients diagnosed with synchronous primary cancers of the endometrium and ovary with an emphasis on risk factors. Between 1989 and 2002, 84 patients with synchronous primary cancers of the endometrium and ovary were identified. Patients with uterine papillary serous carcinoma were excluded. Clinical and pathologic information was obtained from medical records. Parametric methods were used to compare clinical and pathologic features. Kaplan-Meier survival analyses were performed and compared using the log rank test. Median age at diagnosis was 50 years. Median body mass index (BMI) was 28 kg/m(2). Fifty-one percent (43/84) of the women were premenopausal and 33% (28/84) were nulliparous. The most common presenting symptom was abnormal vaginal bleeding; in those women with abnormal vaginal bleeding, 69% had stage I ovarian cancer. Ovarian cancer was an incidental finding in 48% of these patients. Sixty-eight percent of patients (57/84) had endometrioid histology of both their endometrial and ovarian cancers. Patients with early stage ovarian cancer tended to have a more favorable prognosis than those with advanced stage disease (median survival not reached in stage I and II versus 66 months in stage III and IV, P = 0.06). Patients with concordant endometrioid histology had a favorable prognosis (median survival 119 versus 48 months in all other groups, P = 0.02). In this large series of patients, women with synchronous primary cancers of the endometrium and ovary were young, obese, nulliparous, and premenopausal. Patients with concordant endometrioid tumors of the endometrium and ovary had a favorable prognosis, with median survival approaching 10 years.",Journal Article,5651.0,172.0,Synchronous primary endometrium ovary 10 women ovarian 5 women endometrial purpose characterize patients diagnosed synchronous primary endometrium ovary emphasis risk factors 1989 2002 84 patients synchronous primary endometrium ovary identified Patients uterine papillary serous carcinoma excluded Clinical pathologic information obtained medical records Parametric methods compare clinical pathologic features Kaplan-Meier survival performed compared log rank test Median age diagnosis 50 years Median body mass index BMI 28 kg/m 2 Fifty-one percent 43/84 women premenopausal 33 28/84 nulliparous common presenting symptom abnormal vaginal bleeding women abnormal vaginal bleeding 69 stage ovarian Ovarian incidental finding 48 patients Sixty-eight percent patients 57/84 endometrioid histology endometrial ovarian Patients early stage ovarian tended favorable prognosis advanced stage disease median survival reached stage II versus 66 months stage III IV P 0.06 Patients concordant endometrioid histology favorable prognosis median survival 119 versus 48 months groups P 0.02 large series patients women synchronous primary endometrium ovary young obese nulliparous premenopausal Patients concordant endometrioid endometrium ovary favorable prognosis median survival approaching 10 years,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[2734, 86, 163, 1, 3, 2, 3631, 32, 204, 4, 79, 1, 117, 5, 12, 2, 33, 1, 117, 5, 12, 3, 743, 1, 26, 45, 10, 6, 1507, 7, 265, 5, 2734, 86, 163, 1, 3, 2, 3631, 5, 35, 3136, 23, 43, 130, 59, 3965, 2, 1544, 874, 7, 5, 2734, 86, 163, 1, 3, 2, 3631, 11, 108, 7, 5, 1796, 1744, 134, 11, 1800, 38, 2, 510, 487, 10, 683, 29, 484, 1064, 7590, 636, 11, 95, 6, 932, 38, 2, 510, 404, 876, 882, 25, 318, 11, 173, 2, 72, 75, 3, 1066, 1026, 412, 52, 89, 28, 147, 10, 212, 60, 52, 642, 782, 558, 1140, 10, 339, 503, 188, 18, 1461, 104, 714, 601, 874, 1, 3, 117, 11, 2710, 2, 466, 339, 874, 11, 9475, 3, 96, 186, 1656, 934, 10, 1668, 2294, 4, 135, 117, 5, 1668, 2294, 790, 42, 82, 70, 12, 12, 10, 35, 4490, 1567, 4, 576, 1, 46, 7, 1746, 659, 714, 1, 7, 696, 874, 42, 3151, 784, 1, 110, 136, 2, 163, 7, 5, 191, 82, 12, 3886, 6, 47, 8, 80, 913, 356, 76, 135, 5, 131, 82, 34, 52, 25, 44, 1300, 4, 82, 70, 2, 215, 185, 700, 53, 4, 82, 316, 2, 478, 19, 13, 1460, 7, 5, 3610, 3151, 784, 42, 8, 913, 356, 52, 25, 4299, 185, 576, 53, 4, 62, 127, 271, 19, 13, 588, 4, 26, 375, 988, 1, 7, 117, 5, 2734, 86, 163, 1, 3, 2, 3631, 11, 1169, 2209, 9475, 2, 2710, 7, 5, 3610, 3151, 57, 1, 3, 2, 3631, 42, 8, 913, 356, 5, 52, 25, 7773, 79, 60]",1674.0,15297188,Synchronous primary endometrium ovary single institution review 84 cases,0,0.0
"A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer.",Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2004-08-01,"TAS-108 is a novel steroidal anti-estrogen compound that has a strong binding affinity to the estrogen receptor and, in preclinical studies, has antitumor activity against tamoxifen-resistant breast cancer cell lines. The objective of this study was to investigate the safety and the pharmacokinetics in patients with previously treated advanced breast cancer. TAS-108 was administered orally once daily starting at 40 mg/day, with dose escalations of 60, 80, 120, and 160 mg/day. A minimum of three patients were enrolled in each dose level, and, if no drug-related grade 3 or higher adverse events were seen in the first 14 days, the next cohort of patients was treated at the next level. Pharmacokinetic data were obtained on day 1, 2, 15, and 28 of the first course. A total of 16 patients were enrolled, and most had received six to seven prior therapies. Clinical toxicities included nausea, vomiting, hot flashes, headache, weakness and fatigue; all were grade 1-2. TAS-108 had no effect on endometrial thickness based on trans-vaginal ultrasound evaluation. The average duration of therapy was 17.4 weeks (range, 4-60 weeks). The mean terminal half-life ranged from 8.0 to 10.7 hour in the interval of 12 to 24 hours postdose. The mean C(max) ranged from 2.8 to 21.0 ng/mL and AUC(0-t) from 15.1 to 148.7 ng.h/mL, this showed a linear correlation with the dose. TAS-108 was well tolerated in the doses studied with no maximum tolerated dose. The drug has linear pharmacokinetics, and in this heavily treated patient population, there was evidence of biological antitumor activity. A multi-institutional phase II study is planned.",Clinical Trial,5651.0,19.0,TAS-108 novel steroidal anti-estrogen compound strong binding affinity estrogen receptor preclinical studies antitumor activity tamoxifen-resistant breast lines objective investigate safety pharmacokinetics patients previously treated advanced breast TAS-108 administered orally daily starting 40 mg/day dose escalations 60 80 120 160 mg/day minimum patients enrolled dose level drug-related grade 3 higher adverse events seen 14 days cohort patients treated level Pharmacokinetic obtained day 1 2 15 28 course total 16 patients enrolled received seven prior therapies Clinical toxicities included nausea vomiting hot flashes headache weakness fatigue grade 1-2 TAS-108 effect endometrial thickness based trans-vaginal ultrasound evaluation average duration therapy 17.4 weeks range 4-60 weeks mean terminal half-life ranged 8.0 10.7 hour interval 12 24 hours postdose mean C max ranged 2.8 21.0 ng/mL AUC 0-t 15.1 148.7 ng.h/mL showed linear correlation dose TAS-108 tolerated doses studied maximum tolerated dose drug linear pharmacokinetics heavily treated patient population evidence antitumor activity multi-institutional phase II planned,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[6141, 3590, 16, 8, 229, 7745, 312, 808, 2823, 17, 71, 8, 1082, 791, 3601, 6, 3, 808, 153, 2, 4, 693, 94, 71, 579, 128, 480, 1105, 436, 12, 31, 285, 3, 461, 1, 26, 45, 10, 6, 963, 3, 367, 2, 3, 1159, 4, 7, 5, 373, 73, 131, 12, 6141, 3590, 10, 468, 1428, 1059, 391, 1723, 28, 327, 81, 218, 5, 61, 11388, 1, 335, 493, 2031, 2, 3457, 81, 218, 8, 2499, 1, 169, 7, 11, 346, 4, 296, 61, 301, 2, 492, 77, 234, 139, 88, 27, 15, 142, 290, 281, 11, 527, 4, 3, 157, 213, 162, 3, 1305, 180, 1, 7, 10, 73, 28, 3, 1305, 301, 1456, 74, 11, 683, 23, 218, 14, 18, 167, 2, 339, 1, 3, 157, 906, 8, 181, 1, 245, 7, 11, 346, 2, 96, 42, 103, 437, 6, 648, 324, 235, 38, 385, 159, 1218, 1966, 2859, 4193, 4538, 6408, 2, 613, 62, 11, 88, 14, 18, 6141, 3590, 42, 77, 254, 23, 2903, 90, 23, 3437, 18982, 1945, 451, 3, 1011, 654, 1, 36, 10, 269, 39, 244, 184, 39, 335, 244, 3, 313, 2158, 1303, 358, 1869, 29, 66, 13, 6, 79, 67, 2583, 4, 3, 268, 1, 133, 6, 259, 1459, 18227, 3, 313, 256, 2649, 1869, 29, 18, 66, 6, 239, 13, 997, 542, 2, 1376, 13, 102, 29, 167, 14, 6, 4647, 67, 997, 555, 542, 26, 224, 8, 1646, 816, 5, 3, 61, 6141, 3590, 10, 149, 421, 4, 3, 415, 656, 5, 77, 689, 421, 61, 3, 234, 71, 1646, 1159, 2, 4, 26, 2447, 73, 69, 266, 125, 10, 241, 1, 1037, 579, 128, 8, 1414, 1115, 124, 215, 45, 16, 1465]",1571.0,15328180,phase pharmacokinetic TAS-108 postmenopausal female patients locally advanced locally recurrent inoperable progressive metastatic breast,0,0.0
p16 expression in squamous lesions of the female genital tract.,Journal of molecular histology,J. Mol. Histol.,2004-02-01,"The aim of this study was to examine the role of p16 in the pathogenesis of squamous carcinoma of the gynecologic tract. Squamous carcinoma and carcinoma in situ from the female genital tract were examined for the expression of p16 by paraffin immunohistochemistry. About 74% (40/54) of cases showed p16 expression. By primary site, 77% (23/30) of cervical, 67% (6/9) of vaginal and 85% (11/13) of vulvar primaries expressed p16, but two endometrial primary squamous carcinomas were negative (0/2). In addition, p16 was not identified in non-dysplastic tissue and low grade dysplasia. In cases where there were matched vaginal or vulvar and cervical primaries in a given patient, there was concordant positive p16 expression. It is concluded that p16 is frequently expressed in squamous carcinoma of the cervix, vagina and vulva, but not seen in cases of benign and low grade lesions. It may be a marker of transformation from a low to a high grade lesion. More cases of endometrial primaries need to be studied to see if these evolve by a p16-independent pathway.",Journal Article,5833.0,8.0,aim examine role p16 pathogenesis squamous carcinoma gynecologic tract Squamous carcinoma carcinoma situ female genital tract examined expression p16 paraffin immunohistochemistry 74 40/54 cases showed p16 expression primary site 77 23/30 cervical 67 6/9 vaginal 85 11/13 vulvar primaries expressed p16 endometrial primary squamous carcinomas negative 0/2 addition p16 identified non-dysplastic tissue low grade dysplasia cases matched vaginal vulvar cervical primaries given patient concordant positive p16 expression concluded p16 frequently expressed squamous carcinoma cervix vagina vulva seen cases benign low grade lesions marker transformation low high grade lesion cases endometrial primaries need studied evolve p16-independent pathway,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 1130, 1, 26, 45, 10, 6, 1004, 3, 200, 1, 1932, 4, 3, 1384, 1, 691, 134, 1, 3, 1512, 1696, 691, 134, 2, 134, 4, 957, 29, 3, 1061, 8226, 1696, 11, 409, 9, 3, 55, 1, 1932, 20, 2487, 888, 545, 794, 327, 667, 1, 140, 224, 1932, 55, 20, 86, 606, 849, 382, 201, 1, 598, 49, 83, 1, 2, 772, 175, 233, 1, 6183, 570, 1932, 84, 100, 86, 691, 826, 11, 199, 13, 18, 4, 352, 1932, 10, 44, 108, 4, 220, 6461, 246, 2, 154, 88, 2253, 4, 140, 1257, 125, 11, 655, 15, 2, 6183, 4, 8, 447, 69, 125, 10, 3610, 109, 1932, 55, 192, 16, 4724, 17, 1932, 16, 746, 570, 4, 691, 134, 1, 3, 3629, 7553, 2, 9263, 84, 44, 527, 4, 140, 1, 1002, 2, 154, 88, 406, 192, 68, 40, 8, 952, 1, 1392, 29, 8, 154, 6, 8, 64, 88, 1180, 80, 140, 1, 6183, 594, 6, 40, 656, 6, 3764, 492, 46, 4800, 20, 8, 1932, 306, 308]",962.0,15328914,p16 expression squamous lesions female genital tract,0,0.0
BRCAPAP: feasibility of clinical BRCA testing on liquid-based cervical cytology: implications for biomarker development.,"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology",Cancer Epidemiol. Biomarkers Prev.,2004-09-01,"The study was designed to test the feasibility that lower genital tract cytology is a compatible medium for robust germ line genetic analyses. BRCA1 and/or BRCA2 gene mutational analysis was done on DNA isolated from liquid-based cervical or vaginal cytology taken from 17 consenting women (age 29-65 years) who previously had genetic counseling followed by BRACAnalysis (Myriad Genetics, Salt Lake City, UT) blood analyses. Eleven women had known mutations in either BRCA1 or BRCA2 (cases) and six had no identified mutations (controls) on entry into the study. Anonymized cytology samples were sent to Myriad Genetics with a request for testing that was limited to the degree of genomic testing previously done on the blood samples. One cervicovaginal specimen from a test-positive woman had inadequate cellular content that precluded gene sequencing and therefore was excluded from this analysis. For the 16 women with adequate cytologic specimens, there was 100% concordance for BRCA mutation test results between blood and genital tract cytology (kappa = 1.0; 95% confidence interval, 0.51-1.0). We have shown the feasibility of using liquid-based genital tract cytology as an alternative biospecimen to blood for germ line genetic analysis using a clinical approved assay. It needs to be emphasized that any type of testing for BRCA1 or BRCA2 mutation genotype should only be done in the setting of pretest and posttest counseling.",Journal Article,5620.0,1.0,designed test feasibility lower genital tract cytology compatible medium robust germ line genetic BRCA1 and/or BRCA2 DNA isolated liquid-based cervical vaginal cytology taken 17 consenting women age 29-65 years previously genetic counseling followed BRACAnalysis Myriad Genetics Salt Lake City UT blood women known BRCA1 BRCA2 cases identified controls entry Anonymized cytology sent Myriad Genetics request testing limited degree genomic testing previously blood cervicovaginal specimen test-positive woman inadequate cellular content precluded sequencing excluded 16 women adequate cytologic specimens 100 concordance BRCA test blood genital tract cytology kappa 1.0 95 confidence interval 0.51-1.0 shown feasibility liquid-based genital tract cytology alternative biospecimen blood germ line genetic clinical approved needs emphasized type testing BRCA1 BRCA2 genotype setting pretest posttest counseling,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 45, 10, 1114, 6, 412, 3, 1437, 17, 280, 8226, 1696, 2045, 16, 8, 7293, 3759, 9, 1922, 2280, 328, 336, 318, 766, 2, 15, 1167, 145, 1619, 65, 10, 1822, 23, 261, 1355, 29, 3165, 90, 15, 2045, 1633, 29, 269, 11932, 117, 89, 462, 556, 60, 54, 373, 42, 336, 2011, 370, 20, 30650, 8390, 2894, 11818, 37757, 7235, 13609, 315, 318, 2627, 117, 42, 440, 138, 4, 361, 766, 15, 1167, 140, 2, 437, 42, 77, 108, 138, 535, 23, 3001, 237, 3, 45, 23301, 2045, 347, 11, 6325, 6, 8390, 2894, 5, 8, 11660, 9, 471, 17, 10, 383, 6, 3, 1444, 1, 572, 471, 373, 1822, 23, 3, 315, 347, 104, 43708, 2360, 29, 8, 412, 109, 2854, 42, 3358, 763, 2457, 17, 8035, 145, 615, 2, 673, 10, 1800, 29, 26, 65, 9, 3, 245, 117, 5, 1658, 4195, 623, 125, 10, 394, 1827, 9, 1555, 258, 412, 99, 59, 315, 2, 8226, 1696, 2045, 3096, 14, 13, 48, 307, 268, 13, 725, 14, 13, 21, 47, 443, 3, 1437, 1, 75, 3165, 90, 8226, 1696, 2045, 22, 35, 1091, 13603, 6, 315, 9, 2280, 328, 336, 65, 75, 8, 38, 850, 719, 192, 1891, 6, 40, 8585, 17, 500, 267, 1, 471, 9, 766, 15, 1167, 258, 1183, 257, 158, 40, 1822, 4, 3, 546, 1, 12521, 2, 19504, 2011]",1393.0,15342457,BRCAPAP feasibility clinical BRCA testing liquid-based cervical cytology implications biomarker development,0,0.0
Laparoscopic training and practice in gynecologic oncology among Society of Gynecologic Oncologists members and fellows-in-training.,Gynecologic oncology,Gynecol. Oncol.,2004-09-01,"To determine the proportion of Society of Gynecologic Oncologists (SGO) members performing laparoscopic procedures and to determine SGO members' and fellows' opinions regarding indications for and the adequacy of training in laparoscopy. Surveys were mailed to SGO members and fellows-in-training in December 2002. Anonymous responses were collected by mail or through a Web site. The survey was mailed twice and was estimated to take 5 min to complete. The data were analyzed using frequency distributions and nonparametric tests. Three hundred thirty-six SGO members (45%) and fifty-seven fellows (49%) responded. Among SGO members, 272 (84%) currently performed laparoscopic surgeries. Reasons cited for performing laparoscopy were decreased length of hospital stay (74%), improved patient quality of life (57%), patient preference (48%), improved cosmesis (46%), and better visualization (18%). Among those who did not perform laparoscopy, 50% cited increased operating time as their main reason. When asked to indicate the laparoscopic procedure most commonly performed in their practice, 69% reported diagnosis of an adnexal mass; 11%, prophylactic bilateral salpingo-oophorectomies; and 10%, laparoscopically assisted vaginal hysterectomy and lymph node staging for uterine cancer. Only 3% of SGO respondents performed more than 50% of their procedures laparoscopically, and all respondents reported converting from laparoscopy to laparotomy less than 25% of the time. Most respondents had limited laparoscopic training during their fellowships: 39% received none, and 46% received limited (less than five procedures per month) training. Nevertheless, 78% of SGO respondents rated their laparoscopic skills as either very good or good. Among fellows, only 25% believed they were receiving very good or good laparoscopic training. Eighty percent of SGO respondents believe that at least six procedures per month were necessary for adequate training, yet only 33% of fellows performed that many procedures. Most SGO respondents used laparoscopy for selective indications, and most developed their laparoscopic skills after their fellowship training. SGO respondents believed laparoscopic instruction is an important part of training, but most fellows perceived their laparoscopic training as inadequate.",Journal Article,5620.0,,determine proportion Society Gynecologic Oncologists SGO members performing laparoscopic procedures determine SGO members fellows opinions indications adequacy training laparoscopy Surveys mailed SGO members fellows-in-training December 2002 Anonymous responses collected mail Web site survey mailed twice estimated 5 min complete frequency distributions nonparametric tests thirty-six SGO members 45 fifty-seven fellows 49 responded SGO members 272 84 currently performed laparoscopic surgeries Reasons cited performing laparoscopy decreased length hospital stay 74 improved patient quality life 57 patient preference 48 improved cosmesis 46 better visualization 18 perform laparoscopy 50 cited increased operating time main reason asked indicate laparoscopic procedure commonly performed practice 69 reported diagnosis adnexal mass 11 prophylactic bilateral salpingo-oophorectomies 10 laparoscopically assisted vaginal hysterectomy lymph node staging uterine 3 SGO respondents performed 50 procedures laparoscopically respondents reported converting laparoscopy laparotomy 25 time respondents limited laparoscopic training fellowships 39 received 46 received limited procedures month training 78 SGO respondents rated laparoscopic skills good good fellows 25 believed receiving good good laparoscopic training Eighty percent SGO respondents believe procedures month necessary adequate training 33 fellows performed procedures SGO respondents laparoscopy selective indications developed laparoscopic skills fellowship training SGO respondents believed laparoscopic instruction important training fellows perceived laparoscopic training inadequate,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[6, 223, 3, 920, 1, 1174, 1, 1512, 1339, 12063, 1684, 3620, 1964, 1369, 2, 6, 223, 12063, 1684, 2, 7813, 7856, 666, 2406, 9, 2, 3, 6760, 1, 1741, 4, 3553, 3666, 11, 6703, 6, 12063, 1684, 2, 7813, 4, 1741, 4, 1397, 1544, 10609, 253, 11, 786, 20, 9650, 15, 298, 8, 3469, 606, 3, 1407, 10, 6703, 936, 2, 10, 661, 6, 3585, 33, 1538, 6, 236, 3, 74, 11, 311, 75, 675, 4477, 2, 8310, 895, 169, 1128, 977, 437, 12063, 1684, 512, 2, 1461, 648, 7813, 739, 2211, 107, 12063, 1684, 6905, 874, 694, 173, 1964, 5305, 2325, 7068, 9, 3620, 3553, 11, 340, 1318, 1, 702, 2020, 794, 231, 69, 372, 1, 358, 696, 69, 3863, 576, 231, 7119, 641, 2, 380, 6234, 203, 107, 135, 54, 205, 44, 2715, 3553, 212, 7068, 101, 2584, 98, 22, 136, 1895, 3852, 198, 3732, 6, 1008, 3, 1964, 1299, 96, 841, 173, 4, 136, 758, 790, 210, 147, 1, 35, 6462, 782, 175, 1862, 1607, 5690, 43709, 2, 79, 11472, 2927, 2622, 2, 263, 289, 632, 9, 12, 158, 27, 1, 12063, 3122, 173, 80, 76, 212, 1, 136, 1369, 11472, 2, 62, 3122, 210, 9369, 29, 3553, 6, 3274, 299, 76, 243, 1, 3, 98, 96, 3122, 42, 383, 1964, 1741, 190, 136, 30651, 587, 103, 1292, 2, 641, 103, 383, 299, 76, 365, 1369, 379, 811, 1741, 3873, 833, 1, 12063, 3122, 3982, 136, 1964, 5909, 22, 361, 923, 1178, 15, 1178, 107, 7813, 158, 243, 3979, 491, 11, 357, 923, 1178, 15, 1178, 1964, 1741, 2207, 714, 1, 12063, 3122, 4629, 17, 28, 506, 437, 1369, 379, 811, 11, 1493, 9, 1658, 1741, 1145, 158, 466, 1, 7813, 173, 17, 445, 1369, 96, 12063, 3122, 95, 3553, 9, 1094, 2406, 2, 96, 276, 136, 1964, 5909, 50, 136, 9289, 1741, 12063, 3122, 3979, 1964, 19661, 16, 35, 305, 760, 1, 1741, 84, 96, 7813, 2588, 136, 1964, 1741, 22, 3358]",2214.0,15350368,Laparoscopic training practice gynecologic oncology Society Gynecologic Oncologists members fellows-in-training,3,0.01507537688442211
Delayed hemorrhage after cervical conization unmasking severe factor XI deficiency.,Obstetrics and gynecology,Obstet Gynecol,2004-11-01,"Factor XI deficiency, a rare bleeding disorder found most commonly in patients of Ashkenazi Jewish background, may be present in patients with a history of abnormal bleeding after elective surgery. A patient of Ashkenazi Jewish descent presented 12 days after cervical conization for adenocarcinoma in situ with severe vaginal bleeding requiring multiple transfusions and uterine artery embolization. After a thorough workup, a severe factor XI deficiency was found. The patient ultimately required modified radical hysterectomy for treatment of early cervical cancer. With appropriate perioperative management, the patient underwent abdominal surgery without further bleeding complications. Factor XI deficiency can present with severe bleeding episodes after elective surgery. Adequate preoperative assessment and perioperative management are necessary to prevent bleeding complications in these patients.",Case Reports,5559.0,5.0,Factor XI deficiency rare bleeding disorder commonly patients Ashkenazi Jewish background present patients history abnormal bleeding elective surgery patient Ashkenazi Jewish descent presented 12 days cervical conization adenocarcinoma situ severe vaginal bleeding requiring multiple transfusions uterine artery embolization thorough workup severe factor XI deficiency patient ultimately required modified radical hysterectomy treatment early cervical appropriate perioperative management patient underwent abdominal surgery bleeding complications Factor XI deficiency present severe bleeding episodes elective surgery Adequate preoperative assessment perioperative management necessary prevent bleeding complications patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[161, 15996, 2299, 8, 622, 2294, 2645, 204, 96, 841, 4, 7, 1, 5939, 5476, 2426, 68, 40, 364, 4, 7, 5, 8, 532, 1, 1668, 2294, 50, 4700, 152, 8, 69, 1, 5939, 5476, 9171, 917, 133, 162, 50, 8755, 9, 449, 4, 957, 5, 905, 2294, 1888, 232, 4987, 2, 2872, 4232, 50, 8, 5506, 4755, 8, 905, 161, 15996, 2299, 10, 204, 3, 69, 2050, 616, 1230, 711, 2622, 9, 24, 1, 191, 12, 5, 870, 1547, 284, 3, 69, 208, 1467, 152, 187, 195, 2294, 521, 161, 15996, 2299, 122, 364, 5, 905, 2294, 3750, 50, 4700, 152, 1658, 498, 455, 2, 1547, 284, 32, 1493, 6, 1682, 2294, 521, 4, 46, 7]",862.0,15516448,Delayed hemorrhage cervical conization unmasking severe factor XI deficiency,0,0.0
A fertility-sparing alternative to radical hysterectomy: how many patients may be eligible?,Gynecologic oncology,Gynecol. Oncol.,2004-12-01,"To determine the percentage of patients with early-stage cervical cancer who may be eligible for fertility preservation with laparoscopic radical vaginal trachelectomy (LRVT). We retrospectively reviewed the records of patients who underwent a radical hysterectomy for invasive cervical cancer at our institution from 12/85 to 8/01, before our use of LRVT at Memorial Sloan-Kettering Cancer Center. Institutional eligibility criteria for LRVT were applied. Patients > or =40 years of age were considered ineligible. We identified 435 patients who had undergone radical hysterectomy for cervical cancer; 186 were age < 40 at surgery and constituted our study population. Eighty-nine (48%) patients may have been eligible by our pathologic criteria. In 12 patients, LRVT may have been aborted or altered because of unexpected disease spread. A significant number of patients < 40 with early-stage cervical cancer may be pathologically eligible for LRVT and should be counseled on this preoperatively.",Journal Article,5529.0,,determine percentage patients early-stage cervical eligible fertility preservation laparoscopic radical vaginal trachelectomy LRVT retrospectively reviewed records patients underwent radical hysterectomy invasive cervical institution 12/85 8/01 use LRVT Memorial Sloan-Kettering Center Institutional eligibility criteria LRVT applied Patients =40 years age considered ineligible identified 435 patients undergone radical hysterectomy cervical 186 age 40 surgery constituted population Eighty-nine 48 patients eligible pathologic criteria 12 patients LRVT aborted altered unexpected disease spread significant number patients 40 early-stage cervical pathologically eligible LRVT counseled preoperatively,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 3, 1150, 1, 7, 5, 191, 82, 12, 54, 68, 40, 625, 9, 2954, 2224, 5, 1964, 711, 5760, 30696, 21, 894, 446, 3, 1064, 1, 7, 54, 208, 8, 711, 2622, 9, 416, 12, 28, 114, 731, 29, 133, 772, 6, 66, 355, 348, 114, 119, 1, 30696, 28, 2563, 2783, 2784, 12, 574, 1115, 2317, 371, 9, 30696, 11, 1498, 7, 15, 327, 60, 1, 89, 11, 515, 3773, 21, 108, 9002, 7, 54, 42, 1989, 711, 2622, 9, 12, 5869, 11, 89, 327, 28, 152, 2, 8917, 114, 45, 266, 2207, 762, 576, 7, 68, 47, 85, 625, 20, 114, 510, 371, 4, 133, 7, 30696, 68, 47, 85, 17083, 15, 1495, 408, 1, 3792, 34, 2579, 8, 93, 207, 1, 7, 327, 5, 191, 82, 12, 68, 40, 2998, 625, 9, 30696, 2, 257, 40, 10411, 23, 26, 3888]",932.0,15581959,fertility-sparing alternative radical hysterectomy patients eligible,3,0.01507537688442211
"A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with ""high-risk"" endometrial cancer.",Gynecologic oncology,Gynecol. Oncol.,2005-01-01,"To determine the toxicity, tolerability, and feasibility of delivering combination chemotherapy with subsequent radiation therapy to women with high-risk endometrial cancer and to evaluate the long-term bowel toxicity of this regimen. The trial was approved by the Dana Farber/Partners Cancer Care (DFPCC) Institutional Review Board (IRB). Patients with stage 3 or stage 4 endometrial cancer or patients with high-risk histology and any stage disease were prospectively entered. Complete surgical staging and a normal gated blood pool scan were required prior to entry. Patients were treated with three cycles of paclitaxel (160 mg/m(2) ), doxorubicin (45 mg/m(2)) and carboplatin (AUC 5) (TAC) all on day 1 of a 21-day schedule as an outpatient with G-CSF support. At the conclusion of chemotherapy, patients received radiation therapy (4500 cGy to the whole pelvis) commencing within 35 days of the last cycle of chemotherapy. Paraaortic radiation and/or vaginal brachytherapy were allowed at the discretion of the treating radiation oncologist. Twenty patients were entered onto the trial from November 2000 through February 2003. Eighteen patients successfully completed the trial, and two patients came off trial during chemotherapy (both later completed planned radiation therapy). Patients were initially stage 1 (n = 3), stage 3 (n = 14), and stage 4 (n = 3). Papillary serous was the dominant histology with 13 patients. Chemotherapy was given on average within 32 days of surgery (range 11-63 days) and radiation was initiated on average within 14 weeks of surgery (range 10-18 weeks). Chemotherapy was well tolerated, with 57 total cycles delivered of a planned 60 cycles. Two patients required dose modification in two cycles (two patients in cycle 3 secondary to hematologic toxicity). No grade 3 or grade 4 neurotoxicity was reported. There were six episodes of grade 3 short-term toxicity with radiation therapy reported in a single patient. Late radiotherapy toxicity included bowel obstruction requiring laparotomy in two patients and grade 3 constipation in one patient. Late radiation toxicity data are still being collected as follow-up continues. The TAC chemotherapy regimen is well tolerated and three cycles were delivered successfully with G-CSF support without evidence of the neurotoxicity or cardiac toxicity reported with the cisplatin containing TAP regimen. Standard radiation was deliverable following TAC therapy without excessive toxicity. Further study of this regimen with subsequent radiation therapy is warranted in patients at risk for systemic and regional recurrence of their malignancy.",Clinical Trial,5498.0,33.0,determine toxicity tolerability feasibility delivering combination chemotherapy subsequent radiation therapy women high-risk endometrial evaluate long-term bowel toxicity regimen trial approved Dana Farber/Partners Care DFPCC Institutional Review Board IRB Patients stage 3 stage 4 endometrial patients high-risk histology stage disease prospectively entered Complete surgical staging normal gated blood pool scan required prior entry Patients treated cycles paclitaxel 160 mg/m 2 doxorubicin 45 mg/m 2 carboplatin AUC 5 TAC day 1 21-day schedule outpatient G-CSF support chemotherapy patients received radiation therapy 4500 cGy pelvis commencing 35 days cycle chemotherapy Paraaortic radiation and/or vaginal brachytherapy allowed discretion treating radiation oncologist patients entered trial November 2000 February 2003 Eighteen patients successfully completed trial patients came trial chemotherapy later completed planned radiation therapy Patients initially stage 1 n 3 stage 3 n 14 stage 4 n 3 Papillary serous dominant histology 13 patients Chemotherapy given average 32 days surgery range 11-63 days radiation initiated average 14 weeks surgery range 10-18 weeks Chemotherapy tolerated 57 total cycles delivered planned 60 cycles patients required dose modification cycles patients cycle 3 secondary hematologic toxicity grade 3 grade 4 neurotoxicity reported episodes grade 3 short-term toxicity radiation therapy reported single patient Late radiotherapy toxicity included bowel obstruction requiring laparotomy patients grade 3 constipation patient Late radiation toxicity collected follow-up continues TAC chemotherapy regimen tolerated cycles delivered successfully G-CSF support evidence neurotoxicity cardiac toxicity reported cisplatin containing TAP regimen Standard radiation deliverable following TAC therapy excessive toxicity regimen subsequent radiation therapy warranted patients risk systemic regional recurrence malignancy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,"[6, 223, 3, 155, 1543, 2, 1437, 1, 4790, 150, 56, 5, 706, 121, 36, 6, 117, 5, 64, 43, 12, 2, 6, 376, 3, 319, 337, 1659, 155, 1, 26, 477, 3, 160, 10, 850, 20, 3, 4932, 4979, 4005, 12, 165, 54526, 1115, 206, 2620, 5880, 7, 5, 82, 27, 15, 82, 39, 12, 15, 7, 5, 64, 43, 784, 2, 500, 82, 34, 11, 1143, 2836, 236, 221, 632, 2, 8, 295, 10664, 315, 6545, 1657, 11, 616, 324, 6, 3001, 7, 11, 73, 5, 169, 410, 1, 490, 3457, 81, 188, 18, 856, 512, 81, 188, 18, 2, 927, 1376, 33, 7364, 62, 23, 218, 14, 1, 8, 239, 218, 1055, 22, 35, 2379, 5, 499, 1211, 538, 28, 3, 1221, 1, 56, 7, 103, 121, 36, 21002, 3071, 6, 3, 902, 3270, 16385, 262, 465, 162, 1, 3, 1060, 417, 1, 56, 7401, 121, 2, 15, 1536, 11, 2313, 28, 3, 7772, 1, 3, 1367, 121, 2709, 737, 7, 11, 2836, 3301, 3, 160, 29, 2868, 1081, 298, 3010, 1522, 3195, 7, 1878, 781, 3, 160, 2, 100, 7, 8594, 1889, 160, 190, 56, 110, 1559, 781, 1465, 121, 36, 7, 11, 1625, 82, 14, 78, 27, 82, 27, 78, 213, 2, 82, 39, 78, 27, 1796, 1744, 10, 3, 2156, 784, 5, 233, 7, 56, 10, 447, 23, 1011, 262, 531, 162, 1, 152, 184, 175, 676, 162, 2, 121, 10, 1917, 23, 1011, 262, 213, 244, 1, 152, 184, 79, 203, 244, 56, 10, 149, 421, 5, 696, 181, 410, 1623, 1, 8, 1465, 335, 410, 100, 7, 616, 61, 2437, 4, 100, 410, 100, 7, 4, 417, 27, 568, 6, 813, 155, 77, 88, 27, 15, 88, 39, 3561, 10, 210, 125, 11, 437, 3750, 1, 88, 27, 978, 337, 155, 5, 121, 36, 210, 4, 8, 226, 69, 807, 310, 155, 159, 1659, 3191, 1888, 3274, 4, 100, 7, 2, 88, 27, 4532, 4, 104, 69, 807, 121, 155, 74, 32, 1234, 486, 786, 22, 166, 126, 2274, 3, 7364, 56, 477, 16, 149, 421, 2, 169, 410, 11, 1623, 1878, 5, 499, 1211, 538, 187, 241, 1, 3, 3561, 15, 155, 210, 5, 3, 540, 1101, 17266, 477, 260, 121, 10, 28320, 366, 7364, 36, 187, 4529, 155, 195, 45, 1, 26, 477, 5, 706, 121, 36, 16, 1197, 4, 7, 28, 43, 9, 403, 2, 951, 146, 1, 136, 710]",2522.0,15589601,pilot trial TAC paclitaxel doxorubicin carboplatin chemotherapy filgastrim r-metHuG-CSF support followed radiotherapy patients `` high-risk '' endometrial,30,0.1507537688442211
Feasibility of dose escalation using intensity-modulated radiotherapy in posthysterectomy cervical carcinoma.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2005-03-01,"To evaluate retrospectively the utility of intensity-modulated radiotherapy (IMRT) in reducing the volume of normal tissues receiving radiation at varying dose levels when the female pelvis after hysterectomy is treated to doses of 50.4 Gy and 54 Gy. Computed tomography scans from 10 patients who had previously undergone conventional postoperative RT were selected. The clinical tumor volume (vaginal apex and iliac nodes) and organs at risk were contoured. Margins were added to generate the planning tumor volume. The Pinnacle and Corvus planning systems were used to develop conventional and IMRT plans, respectively. Conventional four-field plans were prescribed to deliver 45 Gy (4F(45 Gy)) or 50.4 Gy; eight-field IMRT plans were prescribed to deliver 50.4 Gy (IMRT(50.4 Gy)) or 54 Gy (IMRT(54 Gy)) to the planning tumor volume. All plans were normalized so that > or =97% of the planning tumor volume received the prescribed dose. Student's t test was used to compare the volumes of organs at risk receiving the same doses with different plans. The mean volume of bowel receiving > or =45 Gy was lower with the IMRT(50.4 Gy) (33% lower) and IMRT(54 Gy) (18% lower) plans than with the 4F(45 Gy) plan. The mean volume of rectum receiving > or =45 Gy or > or =50 Gy was also significantly reduced with the IMRT plans despite an escalation of the prescribed dose from 45 Gy with the conventional plans to 54 Gy with IMRT. The mean volume of bladder treated to 45 Gy was the same or slightly lower with the IMRT(50.4 Gy) and IMRT(54 Gy) plans compared with the 4F(45 Gy) plan. Compared with the 4F(45 Gy) plan, the IMRT(50.4 Gy) plan resulted in a smaller volume of bowel receiving 35-45 Gy and a larger volume of bowel receiving 50-55 Gy. Compared with the 4F(45 Gy) plan, the IMRT(54 Gy) plan resulted in smaller volumes of bowel receiving 45-50 Gy; however, small volumes of bowel received 55-60 Gy with the IMRT plan. Intensity-modulated RT may permit an increase in the radiation dose that can safely be delivered to the central pelvis and pelvic lymph nodes after hysterectomy. However, dose-volume calculations using individual CT scans do not account for internal organ motion. Detailed data concerning the relationships among radiation dose, treatment volume, and treatment effects are lacking, and prospective studies of pelvic IMRT are needed to determine the safety and efficacy of this treatment.",Journal Article,5439.0,37.0,evaluate retrospectively utility intensity-modulated radiotherapy IMRT reducing volume normal tissues receiving radiation varying dose levels female pelvis hysterectomy treated doses 50.4 Gy 54 Gy Computed tomography scans 10 patients previously undergone conventional postoperative RT selected clinical volume vaginal apex iliac nodes organs risk contoured Margins added generate planning volume Pinnacle Corvus planning systems develop conventional IMRT plans respectively Conventional four-field plans prescribed deliver 45 Gy 4F 45 Gy 50.4 Gy eight-field IMRT plans prescribed deliver 50.4 Gy IMRT 50.4 Gy 54 Gy IMRT 54 Gy planning volume plans normalized =97 planning volume received prescribed dose Student 's test compare volumes organs risk receiving doses different plans mean volume bowel receiving =45 Gy lower IMRT 50.4 Gy 33 lower IMRT 54 Gy 18 lower plans 4F 45 Gy plan mean volume rectum receiving =45 Gy =50 Gy significantly reduced IMRT plans despite escalation prescribed dose 45 Gy conventional plans 54 Gy IMRT mean volume bladder treated 45 Gy slightly lower IMRT 50.4 Gy IMRT 54 Gy plans compared 4F 45 Gy plan Compared 4F 45 Gy plan IMRT 50.4 Gy plan resulted smaller volume bowel receiving 35-45 Gy larger volume bowel receiving 50-55 Gy Compared 4F 45 Gy plan IMRT 54 Gy plan resulted smaller volumes bowel receiving 45-50 Gy small volumes bowel received 55-60 Gy IMRT plan Intensity-modulated RT permit increase radiation dose safely delivered central pelvis pelvic lymph nodes hysterectomy dose-volume calculations individual CT scans account internal organ motion Detailed concerning relationships radiation dose treatment volume treatment effects lacking prospective studies pelvic IMRT needed determine safety efficacy treatment,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[6, 376, 894, 3, 1207, 1, 837, 1757, 310, 964, 4, 1818, 3, 433, 1, 295, 742, 357, 121, 28, 2990, 61, 148, 198, 3, 1061, 3270, 50, 2622, 16, 73, 6, 415, 1, 212, 39, 381, 2, 667, 381, 1220, 872, 1441, 29, 79, 7, 54, 42, 373, 1989, 809, 573, 240, 11, 715, 3, 38, 30, 433, 8670, 2, 6692, 502, 2, 2285, 28, 43, 11, 6476, 1012, 11, 1953, 6, 2562, 3, 1349, 30, 433, 3, 33839, 2, 28362, 1349, 1530, 11, 95, 6, 690, 809, 2, 964, 1853, 106, 809, 294, 1067, 1853, 11, 2746, 6, 3392, 512, 381, 20423, 512, 381, 15, 212, 39, 381, 659, 1067, 964, 1853, 11, 2746, 6, 3392, 212, 39, 381, 964, 212, 39, 381, 15, 667, 381, 964, 667, 381, 6, 3, 1349, 30, 433, 62, 1853, 11, 4207, 1743, 17, 15, 1015, 1, 3, 1349, 30, 433, 103, 3, 2746, 61, 6390, 292, 102, 412, 10, 95, 6, 932, 3, 2225, 1, 2285, 28, 43, 357, 3, 827, 415, 5, 338, 1853, 3, 313, 433, 1, 1659, 357, 15, 512, 381, 10, 280, 5, 3, 964, 212, 39, 381, 466, 280, 2, 964, 667, 381, 203, 280, 1853, 76, 5, 3, 20423, 512, 381, 2242, 3, 313, 433, 1, 3660, 357, 15, 512, 381, 15, 15, 212, 381, 10, 120, 97, 405, 5, 3, 964, 1853, 550, 35, 1125, 1, 3, 2746, 61, 29, 512, 381, 5, 3, 809, 1853, 6, 667, 381, 5, 964, 3, 313, 433, 1, 73, 6, 512, 381, 10, 3, 827, 15, 3223, 280, 5, 3, 964, 212, 39, 381, 2, 964, 667, 381, 1853, 72, 5, 3, 20423, 512, 381, 2242, 72, 5, 3, 20423, 512, 381, 2242, 3, 964, 212, 39, 381, 2242, 627, 4, 8, 2170, 433, 1, 1659, 357, 465, 512, 381, 2, 8, 1077, 433, 1, 1659, 357, 212, 614, 381, 72, 5, 3, 20423, 512, 381, 2242, 3, 964, 667, 381, 2242, 627, 4, 2170, 2225, 1, 1659, 357, 512, 212, 381, 137, 302, 2225, 1, 1659, 103, 614, 335, 381, 5, 3, 964, 2242, 837, 1757, 240, 68, 5634, 35, 344, 4, 3, 121, 61, 17, 122, 2268, 40, 1623, 6, 3, 854, 3270, 2, 1110, 263, 502, 50, 2622, 137, 61, 433, 8229, 75, 797, 425, 1441, 1022, 44, 1967, 9, 2329, 1259, 2967, 2455, 74, 4243, 3, 2467, 107, 121, 61, 24, 433, 2, 24, 176, 32, 1941, 2, 482, 94, 1, 1110, 964, 32, 575, 6, 223, 3, 367, 2, 209, 1, 26, 24]",2335.0,15752885,Feasibility dose escalation intensity-modulated radiotherapy posthysterectomy cervical carcinoma,22,0.11055276381909548
Clitoral therapy device for treatment of sexual dysfunction in irradiated cervical cancer patients.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2005-03-01,"The purpose of this pilot study was to evaluate the efficacy of the clitoral therapy device (Eros Therapy) in alleviating sexual dysfunction in irradiated cervical cancer patients. Eligible patients had a history of cervical cancer treated with radiotherapy and self-reported sexual dysfunction of sexual arousal and/or orgasmic disorders. Patients used the noninvasive, nonpharmacologic clitoral therapy device using a hand-held, battery-powered vacuum to cause clitoral engorgement four times weekly for 3 months during foreplay and self-stimulation. Study instruments included the Female Sexual Function Index, Derogatis Interview for Sexual Functioning, and Dyadic Adjustment Scale. The outcome evaluation was performed at 3 months. Between 2001 and 2002, 15 women were enrolled and 13 completed the study. The median patient age and radiotherapy-enrollment interval was 43.5 years and 2 years, respectively. At baseline, all patients reported symptoms of sexual arousal and/or orgasmic disorders, and some also had sexual desire and pain disorders. At 3 months, statistically significant improvements were seen in all domains tested, including sexual desire, arousal, lubrication, orgasm, sexual satisfaction, and reduced pain. The median Female Sexual Function Index total score increased from 17 to 29.4 (maximal score, 36; p <0.001). The median Derogatis Interview for Sexual Functioning total raw score increased from 46 to 95 (maximal score, 118; p <0.001). At baseline, the Derogatis Interview for Sexual Functioning total T-score corresponded to the bottom 10th percentile of normal sexual functioning. At 3 months, the total T-score placed the patients at the normalcy cutoff. Gynecologic examinations revealed improved mucosal color and moisture and vaginal elasticity and decreased bleeding and ulceration. Our results from this pilot study suggest that the clitoral therapy device may alleviate sexual dysfunction in irradiated cervical cancer patients. A randomized, controlled trial is warranted to assess the full benefits of this approach.",Evaluation Study,5439.0,58.0,purpose pilot evaluate efficacy clitoral therapy device Eros Therapy alleviating sexual dysfunction irradiated cervical patients Eligible patients history cervical treated radiotherapy self-reported sexual dysfunction sexual arousal and/or orgasmic disorders Patients noninvasive nonpharmacologic clitoral therapy device hand-held battery-powered vacuum cause clitoral engorgement times weekly 3 months foreplay self-stimulation instruments included Female Sexual Function Index Derogatis Interview Sexual Functioning Dyadic Adjustment Scale outcome evaluation performed 3 months 2001 2002 15 women enrolled 13 completed median patient age radiotherapy-enrollment interval 43.5 years 2 years respectively baseline patients reported symptoms sexual arousal and/or orgasmic disorders sexual desire pain disorders 3 months statistically significant improvements seen domains tested including sexual desire arousal lubrication orgasm sexual satisfaction reduced pain median Female Sexual Function Index total score increased 17 29.4 maximal score 36 p 0.001 median Derogatis Interview Sexual Functioning total raw score increased 46 95 maximal score 118 p 0.001 baseline Derogatis Interview Sexual Functioning total T-score corresponded 10th percentile normal sexual functioning 3 months total T-score placed patients normalcy cutoff Gynecologic examinations revealed improved mucosal color moisture vaginal elasticity decreased bleeding ulceration pilot suggest clitoral therapy device alleviate sexual dysfunction irradiated cervical patients randomized controlled trial warranted assess benefits approach,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 743, 1, 26, 2281, 45, 10, 6, 376, 3, 209, 1, 3, 24751, 36, 4472, 54664, 36, 4, 12956, 2232, 1527, 4, 2398, 12, 7, 625, 7, 42, 8, 532, 1, 12, 73, 5, 310, 2, 1074, 210, 2232, 1527, 1, 2232, 21313, 2, 15, 43878, 1997, 7, 95, 3, 2957, 11803, 24751, 36, 4472, 75, 8, 2833, 4033, 11665, 6855, 14519, 6, 708, 24751, 54665, 294, 1072, 709, 9, 27, 53, 190, 54666, 2, 1074, 2503, 45, 4730, 159, 3, 1061, 2232, 343, 558, 33840, 4313, 9, 2232, 2702, 2, 24799, 1852, 1124, 3, 228, 451, 10, 173, 28, 27, 53, 59, 1758, 2, 1544, 167, 117, 11, 346, 2, 233, 781, 3, 45, 3, 52, 69, 89, 2, 310, 1798, 268, 10, 601, 33, 60, 2, 18, 60, 106, 28, 330, 62, 7, 210, 507, 1, 2232, 21313, 2, 15, 43878, 1997, 2, 476, 120, 42, 2232, 5278, 2, 559, 1997, 28, 27, 53, 712, 93, 1474, 11, 527, 4, 62, 2703, 650, 141, 2232, 5278, 21313, 43879, 28363, 2232, 2885, 2, 405, 559, 3, 52, 1061, 2232, 343, 558, 181, 368, 101, 29, 269, 6, 462, 39, 2725, 368, 511, 19, 13, 144, 3, 52, 33840, 4313, 9, 2232, 2702, 181, 10170, 368, 101, 29, 641, 6, 48, 2725, 368, 4002, 19, 13, 144, 28, 330, 3, 33840, 4313, 9, 2232, 2702, 181, 102, 368, 7254, 6, 3, 9288, 14199, 6392, 1, 295, 2232, 2702, 28, 27, 53, 3, 181, 102, 368, 3295, 3, 7, 28, 3, 26124, 2779, 1512, 4209, 553, 231, 3068, 6052, 2, 54667, 2, 21314, 2, 340, 2294, 2, 5158, 114, 99, 29, 26, 2281, 45, 309, 17, 3, 24751, 36, 4472, 68, 8193, 2232, 1527, 4, 2398, 12, 7, 8, 384, 1149, 160, 16, 1197, 6, 423, 3, 1647, 1141, 1, 26, 353]",1978.0,15752887,Clitoral therapy device treatment sexual dysfunction irradiated cervical patients,0,0.0
Gynecologic cancer treatment and the impact of cancer-related infertility.,Gynecologic oncology,Gynecol. Oncol.,2005-04-01,"The objective of this study was to empirically assess the emotional and sexual impact of cancer-related infertility in women with a history of gynecologic cancer. Women with a history of gynecologic cancer were approached during their gynecologic oncology clinic appointment; they were provided a description of the study and asked to participate. All participants completed a one-time self-report survey. We present data acquired via the following methods: Center for Epidemiologic Studies-Depression Scale (CES-D), Impact of Events Scale (IES), Modified Inventory of Traumatic Grief (M-ITG), Female Sexual Function Index (FSFI), and the Menopausal Symptom Checklist. The study sample consisted of 20 women, ages 27 to 49 years (mean, approximately 40 years), who had undergone treatment for cervical (40%), ovarian (20%), or uterine (40%) cancer. Forty percent of the sample reported depressive symptoms as measured by the CES-D, with 35% of the women experiencing moderate to severe levels of distress as measured by the IES. The women in this sample experienced dissatisfaction with their overall sex lives (67%), pain during vaginal penetration (62%), and low levels of sexual desire (56%). The preliminary findings of this study indicated that feelings of depression, grief, stress, and sexual dysfunction are being experienced by women with a history of gynecologic cancer who have lost their fertility as a result of their cancer treatment.",Journal Article,5408.0,126.0,objective empirically assess emotional sexual impact cancer-related infertility women history gynecologic Women history gynecologic approached gynecologic oncology clinic appointment provided description asked participate participants completed one-time self-report survey present acquired following methods Center Epidemiologic Studies-Depression Scale CES-D Impact Events Scale IES Modified Inventory Traumatic Grief M-ITG Female Sexual Function Index FSFI Menopausal Symptom Checklist consisted 20 women ages 27 49 years mean approximately 40 years undergone treatment cervical 40 ovarian 20 uterine 40 percent reported depressive symptoms measured CES-D 35 women experiencing moderate severe levels distress measured IES women experienced dissatisfaction overall sex lives 67 pain vaginal penetration 62 low levels sexual desire 56 preliminary findings indicated feelings depression grief stress sexual dysfunction experienced women history gynecologic lost fertility treatment,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 461, 1, 26, 45, 10, 6, 9654, 423, 3, 2671, 2, 2232, 345, 1, 12, 139, 5901, 4, 117, 5, 8, 532, 1, 1512, 12, 117, 5, 8, 532, 1, 1512, 12, 11, 5738, 190, 136, 1512, 413, 1188, 9698, 491, 11, 1052, 8, 5263, 1, 3, 45, 2, 3732, 6, 3506, 62, 776, 781, 8, 104, 98, 1074, 414, 1407, 21, 364, 74, 1294, 847, 3, 366, 636, 574, 9, 3609, 94, 1774, 1124, 9979, 427, 345, 1, 281, 1124, 12331, 1230, 3818, 1, 11272, 11425, 188, 54697, 1061, 2232, 343, 558, 22278, 2, 3, 3565, 934, 9787, 3, 45, 1000, 1695, 1, 179, 117, 2165, 428, 6, 739, 60, 313, 705, 327, 60, 54, 42, 1989, 24, 9, 327, 179, 15, 327, 12, 1213, 714, 1, 3, 1000, 210, 4945, 507, 22, 644, 20, 3, 9979, 427, 5, 465, 1, 3, 117, 2985, 1163, 6, 905, 148, 1, 1462, 22, 644, 20, 3, 12331, 3, 117, 4, 26, 1000, 592, 12806, 5, 136, 63, 1035, 6407, 598, 559, 190, 4618, 744, 2, 154, 148, 1, 2232, 5278, 664, 3, 1676, 272, 1, 26, 45, 1103, 17, 12859, 1, 1774, 11425, 1531, 2, 2232, 1527, 32, 486, 592, 20, 117, 5, 8, 532, 1, 1512, 12, 54, 47, 3009, 136, 2954, 22, 8, 757, 1, 136, 12, 24]",1361.0,15790443,Gynecologic treatment impact cancer-related infertility,8,0.04020100502512563
Pediatric radical abdominal trachelectomy for cervical clear cell carcinoma: a novel surgical approach.,Gynecologic oncology,Gynecol. Oncol.,2005-04-01,"Clear cell carcinoma of the cervix and vagina is rare in the pediatric population. Many of these tumors are associated with prior intrauterine diethylstilbestrol (DES) exposure. All DES-associated tumors are believed to contain microsatellite instability (MI). Historically, the recommended treatment is radical hysterectomy and pelvic lymphadenectomy, which result in infertility in all cases. Radical abdominal or vaginal trachelectomy and pelvic lymph node dissection is a new technique utilized in adult women with early cervical cancer who wish to retain fertility. This novel approach is also pertinent to the pediatric patient and is described in this report. A molecular analysis is also performed to determine if these are DES-associated tumors. Due to the narrow vaginal anatomy in pediatric patients, a vaginal approach is not possible, and an abdominal approach is performed. The resection includes the cervix, upper vagina, parametrium, and paracolpos. Pelvic lymphadenectomy is performed in a similar manner to the adult patient. Matched pairs of normal and tumor DNA from both cases were examined for evidence of MI using a consensus panel of microsatellite markers. Two girls aged 6 and 8 years and without history of DES exposure presented with vaginal bleeding. Vaginoscopy revealed cervical polyp in both cases. Biopsies demonstrated clear cell cancer stage IB1 in both patients. They underwent radical abdominal trachelectomy and bilateral pelvic lymph node dissection along with anastomosis of uterine isthmus to upper vagina. Intraoperative frozen-section analysis confirmed negative uterine and vaginal margins. No adjuvant treatment was given and both girls remain disease free. Neither tumor showed evidence for MI, confirming that these are not DES-associated tumors. To our knowledge, this is the first report of radical abdominal trachelectomy in the pediatric age group and it is likely to include the youngest patient with clear cell carcinoma of the uterine cervix not associated with DES exposure. This novel approach is feasible and appears safe in the pediatric age group.",Case Reports,5408.0,27.0,Clear carcinoma cervix vagina rare pediatric population associated prior intrauterine diethylstilbestrol DES exposure DES-associated believed contain microsatellite instability MI Historically recommended treatment radical hysterectomy pelvic lymphadenectomy infertility cases Radical abdominal vaginal trachelectomy pelvic lymph node dissection new technique utilized adult women early cervical wish retain fertility novel approach pertinent pediatric patient described report molecular performed determine DES-associated narrow vaginal anatomy pediatric patients vaginal approach possible abdominal approach performed resection includes cervix upper vagina parametrium paracolpos Pelvic lymphadenectomy performed similar manner adult patient Matched pairs normal DNA cases examined evidence MI consensus panel microsatellite markers girls aged 6 8 years history DES exposure presented vaginal bleeding Vaginoscopy revealed cervical polyp cases Biopsies demonstrated clear stage IB1 patients underwent radical abdominal trachelectomy bilateral pelvic lymph node dissection anastomosis uterine isthmus upper vagina Intraoperative frozen-section confirmed negative uterine vaginal margins adjuvant treatment given girls remain disease free showed evidence MI confirming DES-associated knowledge report radical abdominal trachelectomy pediatric age group likely include youngest patient clear carcinoma uterine cervix associated DES exposure novel approach feasible appears safe pediatric age group,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[885, 31, 134, 1, 3, 3629, 2, 7553, 16, 622, 4, 3, 815, 266, 445, 1, 46, 57, 32, 41, 5, 324, 18242, 15522, 8683, 645, 62, 8683, 41, 57, 32, 3979, 6, 3725, 2226, 1753, 6862, 3578, 3, 793, 24, 16, 711, 2622, 2, 1110, 2048, 92, 757, 4, 5901, 4, 62, 140, 711, 1467, 15, 5760, 2, 1110, 263, 289, 1161, 16, 8, 217, 1312, 2080, 4, 780, 117, 5, 191, 12, 54, 11443, 6, 6630, 2954, 26, 229, 353, 16, 120, 5799, 6, 3, 815, 69, 2, 16, 1027, 4, 26, 414, 8, 219, 65, 16, 120, 173, 6, 223, 492, 46, 32, 8683, 41, 57, 520, 6, 3, 6958, 5081, 4, 815, 7, 8, 353, 16, 44, 899, 2, 35, 1467, 353, 16, 173, 3, 170, 1920, 3, 3629, 1726, 7553, 30751, 2, 54700, 1110, 2048, 16, 173, 4, 8, 288, 1708, 6, 3, 780, 69, 655, 2773, 1, 295, 2, 30, 261, 29, 110, 140, 11, 409, 9, 241, 1, 6862, 75, 8, 1391, 993, 1, 2226, 525, 100, 5989, 1032, 49, 2, 66, 60, 2, 187, 532, 1, 8683, 645, 917, 5, 2294, 43902, 553, 6493, 4, 110, 140, 1154, 264, 885, 31, 12, 82, 8111, 4, 110, 7, 491, 208, 711, 1467, 5760, 2, 1607, 1110, 263, 289, 1161, 1510, 5, 5519, 1, 54701, 6, 1726, 7553, 1720, 3015, 2917, 65, 557, 199, 2, 1012, 77, 249, 24, 10, 447, 2, 110, 5989, 918, 34, 115, 2174, 30, 224, 241, 9, 6862, 5030, 17, 46, 32, 44, 8683, 41, 57, 6, 114, 922, 26, 16, 3, 157, 414, 1, 711, 1467, 5760, 4, 3, 815, 89, 87, 2, 192, 16, 322, 6, 643, 3, 13042, 69, 5, 885, 31, 134, 1, 3, 3629, 44, 41, 5, 8683, 645, 26, 229, 353, 16, 1313, 2, 1233, 1165, 4, 3, 815, 89, 87]",1991.0,15790482,Pediatric radical abdominal trachelectomy cervical clear carcinoma novel surgical approach,20,0.10050251256281408
Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2005-05-01,"Despite the results of the Gynecologic Oncology Group trial No. 99 (GOG#99), some unanswered questions still remain about the role of adjuvant radiotherapy (RT) for intermediate-risk endometrial cancer. First, can intravaginal brachytherapy (IVRT) alone substitute for external beam RT but without added morbidity? Second, is the high-risk (HR) definition from GOG#99 a useful tool to predict pelvic recurrence specifically? The purpose of this study was to try to answer these questions in a group of patients with Stage IB-IIB endometrial carcinoma treated with high-dose-rate (HDR) IVRT alone. Between November 1987 and December 2002, 382 patients with Stage IB-IIB endometrial carcinoma were treated with simple hysterectomy followed by HDR-IVRT alone at our institution. Comprehensive surgical staging (CSS), defined as pelvic washings and pelvic/paraaortic lymph node sampling, was performed in 20% of patients. The mean age was 60 years (range, 29-92 years). Lymphovascular invasion (LVI) was present in 14% of patients. The median HDR-IVRT dose was 21 Gy (range, 6-21 Gy), given in three fractions. Complications were assessed in terms of late Radiation Therapy Oncology Group (Grade 3 or worse) toxicity of the GI tract, genitourinary GU tract, and vagina. With a median follow-up of 48 months, the 5-year vaginal/pelvic control rate was 95% (95% confidence interval [CI], 93-98%). On multivariate analysis, a poor vaginal/pelvic control rate correlated with age > or =60 years old (relative risk [RR], 3, 95% CI, 1-12; p = 0.01), International Federation of Gynecology and Obstetrics (FIGO) Grade 3 (RR, 9, 95% CI, 2-35; p = 0.03), and LVI (RR, 4, 95% CI, 1-13; p = 0.051). The depth of myometrial invasion and CSS, however, were not significant. With regard to pelvic control specifically, the presence of GOG#99 HR features did not affect the pelvic control rate. The 5-year rate for HR patients was 96% (95% CI, 90-100%) vs. 96% (95% CI, 94-99%) for those without HR disease (p = 0.48). Even when the CSS effect was taken into account, the influence of HR features on pelvic control was still not significant (p = 0.51). In contrast, pelvic control was significantly influenced when patients were grouped according to CSS and stage/grade substages. For those with Stage IB Grade 3-IIB and no CSS, the 5-year pelvic control rate was 86% compared with 97% for those with Stage IB Grade 3-IIB and CSS, 97% for Stage IB, Grade 1-2 without CSS, and 100% for those with Stage IB, Grade 1-2 and CSS (p = 0.027). The 5-year disease-free survival rate was 93% (95% CI, 90-96%). On multivariate analysis, poor disease-free survival correlated with age > or =60 years (RR, 5; 95% CI, 1-18; p = 0.002), FIGO Grade 3 (RR 5, 95% CI 2-17; p = 0.013), and LVI (RR 3, 95% CI 1-8; p = 0.054). Unlike pelvic control, disease-free survival was significantly affected by GOG#99 HR features, with a 5-year rate of 87% (95% CI, 76-99%) vs. 94% (95% CI, 91-97%) for those without HR features (p = 0.027). The 5-year overall and disease-specific survival rate was 93% and 97%, respectively. The overall 5-year actuarial rate of Grade 3 or worse complications was 1% (95% CI, 0-2%). Tumor grade, depth of invasion, and the use of CSS were better predictors of pelvic control than the GOG#99 HR factors. IVRT alone seemed to provide adequate tumor control with very low morbidity. Therefore, it seems prudent to consider it for intermediate-risk patients because of its superior therapeutic ratio compared with that for surgery alone or pelvic RT. Additional follow-up, however, with a larger number of patients is needed, especially for those with LVI.",Journal Article,5378.0,102.0,Despite Gynecologic Oncology Group trial 99 GOG 99 unanswered questions remain role adjuvant radiotherapy RT intermediate-risk endometrial intravaginal brachytherapy IVRT substitute external beam RT added morbidity Second high-risk HR definition GOG 99 useful tool predict pelvic recurrence specifically purpose try answer questions group patients Stage IB-IIB endometrial carcinoma treated high-dose-rate HDR IVRT November 1987 December 2002 382 patients Stage IB-IIB endometrial carcinoma treated simple hysterectomy followed HDR-IVRT institution Comprehensive surgical staging CSS defined pelvic washings pelvic/paraaortic lymph node sampling performed 20 patients mean age 60 years range 29-92 years Lymphovascular invasion LVI present 14 patients median HDR-IVRT dose 21 Gy range 6-21 Gy given fractions Complications assessed terms late Radiation Therapy Oncology Group Grade 3 worse toxicity GI tract genitourinary GU tract vagina median follow-up 48 months 5-year vaginal/pelvic control rate 95 95 confidence interval CI 93-98 multivariate poor vaginal/pelvic control rate correlated age =60 years old relative risk RR 3 95 CI 1-12 p 0.01 International Federation Gynecology Obstetrics FIGO Grade 3 RR 9 95 CI 2-35 p 0.03 LVI RR 4 95 CI 1-13 p 0.051 depth myometrial invasion CSS significant regard pelvic control specifically presence GOG 99 HR features affect pelvic control rate 5-year rate HR patients 96 95 CI 90-100 vs. 96 95 CI 94-99 HR disease p 0.48 CSS effect taken account influence HR features pelvic control significant p 0.51 contrast pelvic control significantly influenced patients grouped according CSS stage/grade substages Stage IB Grade 3-IIB CSS 5-year pelvic control rate 86 compared 97 Stage IB Grade 3-IIB CSS 97 Stage IB Grade 1-2 CSS 100 Stage IB Grade 1-2 CSS p 0.027 5-year disease-free survival rate 93 95 CI 90-96 multivariate poor disease-free survival correlated age =60 years RR 5 95 CI 1-18 p 0.002 FIGO Grade 3 RR 5 95 CI 2-17 p 0.013 LVI RR 3 95 CI 1-8 p 0.054 Unlike pelvic control disease-free survival significantly affected GOG 99 HR features 5-year rate 87 95 CI 76-99 vs. 94 95 CI 91-97 HR features p 0.027 5-year overall disease-specific survival rate 93 97 respectively overall 5-year actuarial rate Grade 3 worse complications 1 95 CI 0-2 grade depth invasion use CSS better predictors pelvic control GOG 99 HR factors IVRT provide adequate control low morbidity prudent consider intermediate-risk patients superior therapeutic ratio compared surgery pelvic RT Additional follow-up larger number patients needed especially LVI,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[550, 3, 99, 1, 3, 1512, 413, 87, 160, 77, 1058, 4760, 1058, 476, 7550, 1937, 1234, 918, 545, 3, 200, 1, 249, 310, 240, 9, 919, 43, 12, 157, 122, 16720, 1536, 12005, 279, 12577, 9, 1455, 1345, 240, 84, 187, 1953, 787, 419, 16, 3, 64, 43, 168, 2470, 29, 4760, 1058, 8, 999, 1515, 6, 678, 1110, 146, 1225, 3, 743, 1, 26, 45, 10, 6, 17665, 6, 6634, 46, 1937, 4, 8, 87, 1, 7, 5, 82, 3180, 3884, 134, 73, 5, 64, 61, 116, 5309, 12005, 279, 59, 2868, 5450, 2, 1397, 1544, 9625, 7, 5, 82, 3180, 3884, 134, 11, 73, 5, 2763, 2622, 370, 20, 5309, 12005, 279, 28, 114, 731, 949, 221, 632, 2687, 395, 22, 1110, 11161, 2, 1110, 7401, 263, 289, 2874, 10, 173, 4, 179, 1, 7, 3, 313, 89, 10, 335, 60, 184, 462, 937, 60, 2933, 578, 3327, 10, 364, 4, 213, 1, 7, 3, 52, 5309, 12005, 61, 10, 239, 381, 184, 49, 239, 381, 447, 4, 169, 1550, 521, 11, 275, 4, 1794, 1, 807, 121, 36, 413, 87, 88, 27, 15, 639, 155, 1, 3, 2104, 1696, 4109, 5581, 1696, 2, 7553, 5, 8, 52, 166, 126, 1, 576, 53, 3, 33, 111, 18982, 1110, 182, 116, 10, 48, 48, 307, 268, 58, 966, 1096, 23, 331, 65, 8, 334, 18982, 1110, 182, 116, 438, 5, 89, 15, 335, 60, 1095, 580, 43, 861, 27, 48, 58, 14, 133, 19, 13, 355, 944, 7303, 1, 6429, 2, 7407, 3837, 88, 27, 861, 83, 48, 58, 18, 465, 19, 13, 680, 2, 3327, 861, 39, 48, 58, 14, 233, 19, 13, 9891, 3, 2436, 1, 7327, 578, 2, 2687, 137, 11, 44, 93, 5, 2539, 6, 1110, 182, 1225, 3, 463, 1, 4760, 1058, 168, 404, 205, 44, 1158, 3, 1110, 182, 116, 3, 33, 111, 116, 9, 168, 7, 10, 921, 48, 58, 424, 394, 105, 921, 48, 58, 960, 1058, 9, 135, 187, 168, 34, 19, 13, 576, 871, 198, 3, 2687, 254, 10, 1633, 237, 1967, 3, 1054, 1, 168, 404, 23, 1110, 182, 10, 1234, 44, 93, 19, 13, 725, 4, 748, 1110, 182, 10, 97, 2574, 198, 7, 11, 3706, 768, 6, 2687, 2, 82, 88, 17309, 9, 135, 5, 82, 3180, 88, 27, 3884, 2, 77, 2687, 3, 33, 111, 1110, 182, 116, 10, 868, 72, 5, 1015, 9, 135, 5, 82, 3180, 88, 27, 3884, 2, 2687, 1015, 9, 82, 3180, 88, 14, 18, 187, 2687, 2, 394, 9, 135, 5, 82, 3180, 88, 14, 18, 2, 2687, 19, 13, 4523, 3, 33, 111, 34, 115, 25, 116, 10, 966, 48, 58, 424, 921, 23, 331, 65, 334, 34, 115, 25, 438, 5, 89, 15, 335, 60, 861, 33, 48, 58, 14, 203, 19, 13, 1111, 3837, 88, 27, 861, 33, 48, 58, 18, 269, 19, 13, 3612, 2, 3327, 861, 27, 48, 58, 14, 66, 19, 13, 9546, 4246, 1110, 182, 34, 115, 25, 10, 97, 1424, 20, 4760, 1058, 168, 404, 5, 8, 33, 111, 116, 1, 912, 48, 58, 846, 1058, 105, 960, 48, 58, 970, 1015, 9, 135, 187, 168, 404, 19, 13, 4523, 3, 33, 111, 63, 2, 34, 112, 25, 116, 10, 966, 2, 1015, 106, 3, 63, 33, 111, 2361, 116, 1, 88, 27, 15, 639, 521, 10, 14, 48, 58, 13, 18, 30, 88, 2436, 1, 578, 2, 3, 119, 1, 2687, 11, 380, 674, 1, 1110, 182, 76, 3, 4760, 1058, 168, 130, 12005, 279, 5025, 6, 377, 1658, 30, 182, 5, 923, 154, 787, 673, 192, 2744, 10263, 6, 2419, 192, 9, 919, 43, 7, 408, 1, 211, 1123, 189, 197, 72, 5, 17, 9, 152, 279, 15, 1110, 240, 402, 166, 126, 137, 5, 8, 1077, 207, 1, 7, 16, 575, 1093, 9, 135, 5, 3327]",3392.0,15850910,Intravaginal brachytherapy intermediate-risk endometrial,9,0.04522613065326633
Definitive radiation therapy for squamous cell carcinoma of the vagina.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2005-05-01,"To evaluate outcome and describe clinical treatment guidelines for patients with primary squamous cell carcinoma of the vagina treated with definitive radiation therapy. Between 1970 and 2000, a total of 193 patients were treated with definitive radiation therapy for squamous cell carcinoma of the vagina at The University of Texas M. D. Anderson Cancer Center. The patients' medical records were reviewed to obtain information about patient, tumor, and treatment characteristics, as well as outcome and patterns of recurrence. Surviving patients were followed for a median of 137 months. Survival rates were calculated using the Kaplan-Meier method, with differences assessed using log-rank tests. Disease-specific survival (DSS) and pelvic disease control rates correlated with International Federation of Gynecology and Obstetrics (FIGO) stage and tumor size. At 5 years, DSS rates were 85% for the 50 patients with Stage I, 78% for the 97 patients with Stage II, and 58% for the 46 patients with Stage III-IVA disease (p = 0.0013). Five-year DSS rates were 82% and 60% for patients with tumors < or =4 cm or >4 cm, respectively (p = 0.0001). At 5 years, pelvic disease control rates were 86% for Stage I, 84% for Stage II, and 71% for Stage III-IVA (p = 0.027). The predominant mode of relapse after definitive radiation therapy was local-regional (68% and 83%, respectively, for patients with stages I-II or III-IVA disease). The incidence of major complications was correlated with FIGO stage; at 5 years, the rates of major complications were 4% for Stage I, 9% for Stage II, and 21% for Stage III-IVA (p < 0.01). Excellent outcomes can be achieved with definitive radiation therapy for invasive squamous cell carcinoma of the vagina. However, to achieve these results, treatment must be individualized according to the site and size of the tumor at presentation and the response to initial external-beam radiation therapy. Brachytherapy plays an important role in the treatment of many vaginal cancers but should be carefully selected and applied to obtain optimal coverage of the target volume.",Journal Article,5378.0,108.0,evaluate outcome clinical treatment guidelines patients primary squamous carcinoma vagina treated definitive radiation therapy 1970 2000 total 193 patients treated definitive radiation therapy squamous carcinoma vagina University Texas M. D. Anderson Center patients medical records reviewed obtain information patient treatment characteristics outcome patterns recurrence Surviving patients followed median 137 months Survival rates calculated Kaplan-Meier differences assessed log-rank tests Disease-specific survival DSS pelvic disease control rates correlated International Federation Gynecology Obstetrics FIGO stage size 5 years DSS rates 85 50 patients Stage 78 97 patients Stage II 58 46 patients Stage III-IVA disease p 0.0013 Five-year DSS rates 82 60 patients =4 cm 4 cm respectively p 0.0001 5 years pelvic disease control rates 86 Stage 84 Stage II 71 Stage III-IVA p 0.027 predominant mode relapse definitive radiation therapy local-regional 68 83 respectively patients stages I-II III-IVA disease incidence major complications correlated FIGO stage 5 years rates major complications 4 Stage 9 Stage II 21 Stage III-IVA p 0.01 Excellent outcomes achieved definitive radiation therapy invasive squamous carcinoma vagina achieve treatment individualized according site size presentation response initial external-beam radiation therapy Brachytherapy plays important role treatment vaginal carefully selected applied obtain optimal coverage target volume,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 376, 228, 2, 897, 38, 24, 677, 9, 7, 5, 86, 691, 31, 134, 1, 3, 7553, 73, 5, 1057, 121, 36, 59, 4868, 2, 1081, 8, 181, 1, 5744, 7, 11, 73, 5, 1057, 121, 36, 9, 691, 31, 134, 1, 3, 7553, 28, 3, 1652, 1, 2738, 188, 427, 1929, 12, 574, 3, 7, 484, 1064, 11, 446, 6, 3140, 487, 545, 69, 30, 2, 24, 374, 22, 149, 22, 228, 2, 764, 1, 146, 3050, 7, 11, 370, 9, 8, 52, 1, 4352, 53, 25, 151, 11, 981, 75, 3, 876, 882, 596, 5, 362, 275, 75, 1066, 1026, 895, 34, 112, 25, 1788, 2, 1110, 34, 182, 151, 438, 5, 944, 7303, 1, 6429, 2, 7407, 3837, 82, 2, 30, 444, 28, 33, 60, 1788, 151, 11, 772, 9, 3, 212, 7, 5, 82, 70, 833, 9, 3, 1015, 7, 5, 82, 215, 2, 717, 9, 3, 641, 7, 5, 82, 316, 5900, 34, 19, 13, 11534, 365, 111, 1788, 151, 11, 878, 2, 335, 9, 7, 5, 57, 15, 39, 494, 15, 39, 494, 106, 19, 13, 488, 28, 33, 60, 1110, 34, 182, 151, 11, 868, 9, 82, 70, 874, 9, 82, 215, 2, 792, 9, 82, 316, 5900, 19, 13, 4523, 3, 2750, 4530, 1, 429, 50, 1057, 121, 36, 10, 293, 951, 806, 2, 852, 106, 9, 7, 5, 1153, 70, 215, 15, 316, 5900, 34, 3, 287, 1, 458, 521, 10, 438, 5, 3837, 82, 28, 33, 60, 3, 151, 1, 458, 521, 11, 39, 9, 82, 70, 83, 9, 82, 215, 2, 239, 9, 82, 316, 5900, 19, 13, 355, 1503, 123, 122, 40, 513, 5, 1057, 121, 36, 9, 416, 691, 31, 134, 1, 3, 7553, 137, 6, 1359, 46, 99, 24, 1642, 40, 2596, 768, 6, 3, 606, 2, 444, 1, 3, 30, 28, 1031, 2, 3, 51, 6, 388, 1455, 1345, 121, 36, 1536, 1698, 35, 305, 200, 4, 3, 24, 1, 445, 163, 84, 257, 40, 3900, 715, 2, 1498, 6, 3140, 665, 2139, 1, 3, 283, 433]",2023.0,15850914,Definitive radiation therapy squamous carcinoma vagina,14,0.07035175879396985
Predictors of vaginal relapse in stage I endometrial cancer.,Gynecologic oncology,Gynecol. Oncol.,2005-06-01,"To identify factors predictive of vaginal relapse in stage I endometrial cancer, thereby potentially facilitating the selection of patients who may benefit from vaginal brachytherapy. The study population included 632 patients with stage I endometrial cancer managed with hysterectomy at our institution between 1984 and 1996. Median follow-up was 73 months; 122 patients (19%) received adjuvant radiotherapy. Overall, 2.9% of the stage I cohort developed vaginal relapse at 5 years. Vaginal relapse was observed in 1.7% of patients who received radiotherapy and in 3.0% of those whose treatment did not include radiotherapy (P = 0.36). Cox regression analysis (including radiotherapy) identified only grade 3 differentiation (hazard ratio = 3.83, P = 0.007) as an independent predictor of vaginal relapse. Patients with a low-grade tumor had a 5-year vaginal relapse rate of 2%, compared with 7% for those with a grade 3 tumor. When only patients who did not receive adjuvant radiotherapy were considered, both grade 3 tumor and lymphovascular invasion were significant predictors of vaginal relapse (P < 0.05). When neither variable was present, 2% of patients experienced vaginal relapse at 5 years, compared with 11% when either 1 was present (P < 0.001). Depth of myometrial invasion was not a significant predictor of vaginal recurrence. Histologic grade 3 tumor and lymphovascular invasion were the cogent predictors of vaginal relapse in our population. The cost and morbidity of vaginal brachytherapy should be balanced against the potential risk of vaginal relapse in this group of patients.",Journal Article,5347.0,46.0,identify factors predictive vaginal relapse stage endometrial potentially facilitating selection patients benefit vaginal brachytherapy population included 632 patients stage endometrial managed hysterectomy institution 1984 1996 Median follow-up 73 months 122 patients 19 received adjuvant radiotherapy Overall 2.9 stage cohort developed vaginal relapse 5 years Vaginal relapse observed 1.7 patients received radiotherapy 3.0 treatment include radiotherapy P 0.36 Cox regression including radiotherapy identified grade 3 differentiation hazard ratio 3.83 P 0.007 independent predictor vaginal relapse Patients low-grade 5-year vaginal relapse rate 2 compared 7 grade 3 patients receive adjuvant radiotherapy considered grade 3 lymphovascular invasion significant predictors vaginal relapse P 0.05 variable present 2 patients experienced vaginal relapse 5 years compared 11 1 present P 0.001 Depth myometrial invasion significant predictor vaginal recurrence Histologic grade 3 lymphovascular invasion cogent predictors vaginal relapse population cost morbidity vaginal brachytherapy balanced potential risk vaginal relapse group patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[6, 255, 130, 464, 1, 429, 4, 82, 70, 12, 2267, 751, 5379, 3, 881, 1, 7, 54, 68, 247, 29, 1536, 3, 45, 266, 159, 14525, 7, 5, 82, 70, 12, 2231, 5, 2622, 28, 114, 731, 59, 6036, 2, 2648, 52, 166, 126, 10, 803, 53, 3285, 7, 326, 103, 249, 310, 63, 18, 83, 1, 3, 82, 70, 180, 276, 429, 28, 33, 60, 429, 10, 164, 4, 14, 67, 1, 7, 54, 103, 310, 2, 4, 27, 13, 1, 135, 1310, 24, 205, 44, 643, 310, 19, 13, 511, 418, 320, 65, 141, 310, 108, 158, 88, 27, 910, 360, 197, 27, 852, 19, 13, 1999, 22, 35, 306, 980, 1, 429, 7, 5, 8, 154, 88, 30, 42, 8, 33, 111, 429, 116, 1, 18, 72, 5, 67, 9, 135, 5, 8, 88, 27, 30, 198, 158, 7, 54, 205, 44, 560, 249, 310, 11, 515, 110, 88, 27, 30, 2, 2933, 578, 11, 93, 674, 1, 429, 19, 13, 474, 198, 2174, 1347, 10, 364, 18, 1, 7, 592, 429, 28, 33, 60, 72, 5, 175, 198, 361, 14, 10, 364, 19, 13, 144, 2436, 1, 7327, 578, 10, 44, 8, 93, 980, 1, 146, 884, 88, 27, 30, 2, 2933, 578, 11, 3, 43965, 674, 1, 429, 4, 114, 266, 3, 835, 2, 787, 1, 1536, 257, 40, 4115, 480, 3, 174, 43, 1, 429, 4, 26, 87, 1, 7]",1431.0,15894363,Predictors vaginal relapse stage endometrial,0,0.0
Effect of delivery route on natural history of cervical dysplasia.,American journal of obstetrics and gynecology,Am. J. Obstet. Gynecol.,2005-05-01,"This study was undertaken to determine the (1) impact of delivery route on the natural history of cervical dysplasia and (2) overall regression rates of cervical dysplasia in pregnant women. A retrospective analysis was performed on 705 pregnant women with abnormal Papanicolaou tests who presented for prenatal care at the Kapiolani Medical Center Women's Clinic in Honolulu, Hawaii, between 1991 and 2001. Data collection included demographics, delivery route, and cervical pathology. Two hundred one patients met the inclusion criteria. Regression rates for vaginal and cesarean section groups were as follows: atypical squamous cells (64% vs 70%, P = .32), low-grade squamous intraepithelial lesion (58% vs 42%, P = .073), and high-grade squamous intraepithelial lesion (53% vs 25%, P = .44). Of the total population, 30% of lesions persisted postpartum, 58% regressed, and 12% progressed. Mode of delivery does not influence the natural history of dysplastic lesions. Gravid and nongravid women have similar regression rates.",Journal Article,5378.0,14.0,undertaken determine 1 impact delivery route natural history cervical dysplasia 2 overall regression rates cervical dysplasia pregnant women retrospective performed 705 pregnant women abnormal Papanicolaou tests presented prenatal care Kapiolani Medical Center Women 's Clinic Honolulu Hawaii 1991 2001 collection included demographics delivery route cervical pathology patients met inclusion criteria Regression rates vaginal cesarean section groups follows atypical squamous 64 vs 70 P .32 low-grade squamous intraepithelial lesion 58 vs 42 P .073 high-grade squamous intraepithelial lesion 53 vs 25 P .44 total population 30 lesions persisted postpartum 58 regressed 12 progressed Mode delivery influence natural history dysplastic lesions Gravid nongravid women similar regression rates,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[26, 45, 10, 2789, 6, 223, 3, 14, 345, 1, 989, 5841, 23, 3, 1504, 532, 1, 2253, 2, 18, 63, 320, 151, 1, 2253, 4, 6086, 117, 8, 459, 65, 10, 173, 23, 11303, 6086, 117, 5, 1668, 10416, 895, 54, 917, 9, 15621, 165, 28, 3, 37919, 484, 574, 117, 292, 1188, 4, 30774, 18301, 59, 3372, 2, 1758, 74, 2442, 159, 2221, 989, 5841, 2, 1117, 100, 1128, 104, 7, 543, 3, 1680, 371, 320, 151, 9, 2, 28385, 2917, 271, 11, 22, 2962, 1973, 691, 37, 660, 105, 431, 19, 531, 154, 88, 691, 4153, 1180, 717, 105, 595, 19, 14571, 2, 64, 88, 691, 4153, 1180, 699, 105, 243, 19, 584, 1, 3, 181, 266, 201, 1, 406, 3760, 7830, 717, 12579, 2, 133, 1839, 4530, 1, 989, 1097, 44, 1054, 3, 1504, 532, 1, 6461, 406, 30682, 2, 54824, 117, 47, 288, 320, 151]",950.0,15902135,Effect delivery route natural history cervical dysplasia,1,0.005025125628140704
Methemoglobinemia induced by topical vaginal sulfanilamide cream in a patient with cervical cancer: a case report.,Gynecologic oncology,Gynecol. Oncol.,2005-06-01,"Methemoglobinemia is a rare disorder most commonly associated with the ingestion or topical application of an offending exogenous agent. The clinical consequences of acute methemoglobinemia can be devastating and include lethargy, headache, and dyspnea and, as methemoglobin concentrations rise, respiratory depression, confusion, seizures, and even death. Here we present a case of acute methemoglobinemia induced by exposure to topical vaginal sulfanilamide cream in a 36-year-old woman with a FIGO stage IIIB squamous cell cervical carcinoma. Although methemoglobinemia associated with topical anesthetics has been well documented, to our knowledge this is the first reported case of methemoglobinemia induced by exposure to topical sulfanilamide cream. Although patients undergoing intracavitary radiation treatment for cervical cancer are at risk for cyanosis due to the development of deep vein thromboses and pulmonary embolism, methemoglobinemia should be suspected in the setting of acute cyanosis with a normal arterial oxygen pressure.",Case Reports,5347.0,4.0,Methemoglobinemia rare disorder commonly associated ingestion topical application offending exogenous agent clinical consequences acute methemoglobinemia devastating include lethargy headache dyspnea methemoglobin concentrations rise respiratory depression confusion seizures death present case acute methemoglobinemia induced exposure topical vaginal sulfanilamide cream 36-year-old woman FIGO stage IIIB squamous cervical carcinoma methemoglobinemia associated topical anesthetics documented knowledge reported case methemoglobinemia induced exposure topical sulfanilamide cream patients undergoing intracavitary radiation treatment cervical risk cyanosis development deep vein thromboses pulmonary embolism methemoglobinemia suspected setting acute cyanosis normal arterial oxygen pressure,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[20372, 16, 8, 622, 2645, 96, 841, 41, 5, 3, 17691, 15, 5879, 1581, 1, 35, 28093, 4181, 420, 3, 38, 3255, 1, 286, 20372, 122, 40, 5778, 2, 643, 18194, 4538, 2, 2923, 2, 22, 37921, 1003, 3693, 2718, 1774, 7399, 4448, 2, 871, 273, 467, 21, 364, 8, 473, 1, 286, 20372, 277, 20, 645, 6, 5879, 43973, 14572, 4, 8, 511, 111, 1095, 2854, 5, 8, 3837, 82, 3036, 691, 31, 134, 242, 20372, 41, 5, 5879, 43974, 71, 85, 149, 1405, 6, 114, 922, 26, 16, 3, 157, 210, 473, 1, 20372, 277, 20, 645, 6, 5879, 43973, 14572, 242, 7, 479, 9122, 121, 24, 9, 12, 32, 28, 43, 9, 33895, 520, 6, 3, 193, 1, 2369, 2762, 16267, 2, 1087, 5475, 20372, 257, 40, 2768, 4, 3, 546, 1, 286, 33895, 5, 8, 295, 3127, 2848, 3738]",1006.0,15907987,Methemoglobinemia induced topical vaginal sulfanilamide cream patient cervical case report,0,0.0
Intensity-modulated radiation therapy after hysterectomy: comparison with conventional treatment and sensitivity of the normal-tissue-sparing effect to margin size.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2005-07-01,"To determine the influence of target-volume expansion on the reduction in small-bowel dose achieved with use of intensity-modulated radiation therapy (IMRT) vs. standard conformal treatment of the pelvis after hysterectomy, and to investigate the influence of patient body habitus on the normal-tissue sparing achieved with use of IMRT. A clinical target volume (CTV) was contoured on each of 10 planning computed tomography scans of patients who had been treated for cervical or endometrial cancer after a hysterectomy. Treatment planning was based on vaginal CTVs and regional nodal CTVs. To account for internal motion, margins were added to form an initial planning target volume (PTVA) as follows: 0.0 mm were added to the regional nodal CTV; 10 mm were added anteriorly to the vaginal CTV; and 5 mm were added to the vaginal CTV in all other directions. Two further PTVs (PTVB and PTVC) were produced by a 5-mm expansion of PTVA to give PTVB and a further 5-mm expansion to give PTVC. Treatment plans for all 3 PTVs were produced by use of 2 conformal fields (2FC), 4 conformal fields (4FC), or IMRT to deliver 45 Gy to more than 97% of the PTV. The primary goal of IMRT was to spare small bowel. The change in sparing that accompanied the increase in margin size was assessed by comparison of dose-volume histograms that resulted from PTVA, PTVB, and PTVC. Measured patient dimensions were correlated with bowel sparing. Significantly less small bowel was irradiated by IMRT than by 2FC (p < 0.0001) or 4FC (p < 0.0001) for doses greater than 25 Gy. Significantly less rectum was irradiated by IMRT than by 2FC (p < 0.0001) or 4FC (p < 0.0001). Significantly less bladder was irradiated by IMRT than by 2FC (p < 0.0001). However, the magnitude of the sparing achieved by use of IMRT decreased as margins increased. In particular, the volume of small bowel spared by IMRT vs. 2FC or 4FC decreased as margin size increased (p = 0.0002 and p = 0.008 for 2FC and 4FC, respectively). The amount of normal-tissue sparing achieved by use of IMRT vs. 4FC was inversely correlated with patient body mass index. Because the small-bowel sparing achieved with use of IMRT is markedly reduced by relatively small expansions of the target volume, accurate target delineation, highly reproducible patient immobilization, and a clear understanding of internal-organ motion are needed to achieve optimal advantage in the use of IMRT over conventional methods of posthysterectomy pelvic radiation therapy.",Comparative Study,5317.0,106.0,determine influence target-volume expansion reduction small-bowel dose achieved use intensity-modulated radiation therapy IMRT vs. standard conformal treatment pelvis hysterectomy investigate influence patient body habitus normal-tissue sparing achieved use IMRT clinical target volume CTV contoured 10 planning computed tomography scans patients treated cervical endometrial hysterectomy Treatment planning based vaginal CTVs regional nodal CTVs account internal motion margins added form initial planning target volume PTVA follows 0.0 mm added regional nodal CTV 10 mm added anteriorly vaginal CTV 5 mm added vaginal CTV directions PTVs PTVB PTVC produced 5-mm expansion PTVA PTVB 5-mm expansion PTVC Treatment plans 3 PTVs produced use 2 conformal fields 2FC 4 conformal fields 4FC IMRT deliver 45 Gy 97 PTV primary goal IMRT spare small bowel change sparing accompanied increase margin size assessed comparison dose-volume histograms resulted PTVA PTVB PTVC Measured patient dimensions correlated bowel sparing Significantly small bowel irradiated IMRT 2FC p 0.0001 4FC p 0.0001 doses greater 25 Gy Significantly rectum irradiated IMRT 2FC p 0.0001 4FC p 0.0001 Significantly bladder irradiated IMRT 2FC p 0.0001 magnitude sparing achieved use IMRT decreased margins increased particular volume small bowel spared IMRT vs. 2FC 4FC decreased margin size increased p 0.0002 p 0.008 2FC 4FC respectively normal-tissue sparing achieved use IMRT vs. 4FC inversely correlated patient body mass index small-bowel sparing achieved use IMRT markedly reduced relatively small expansions target volume accurate target delineation highly reproducible patient immobilization clear understanding internal-organ motion needed achieve optimal advantage use IMRT conventional methods posthysterectomy pelvic radiation therapy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,"[6, 223, 3, 1054, 1, 283, 433, 1422, 23, 3, 628, 4, 302, 1659, 61, 513, 5, 119, 1, 837, 1757, 121, 36, 964, 105, 260, 2972, 24, 1, 3, 3270, 50, 2622, 2, 6, 963, 3, 1054, 1, 69, 642, 23459, 23, 3, 295, 246, 1851, 513, 5, 119, 1, 964, 8, 38, 283, 433, 3402, 10, 6476, 23, 296, 1, 79, 1349, 1220, 872, 1441, 1, 7, 54, 42, 85, 73, 9, 15, 12, 50, 8, 2622, 24, 1349, 10, 90, 23, 14256, 2, 951, 779, 14256, 6, 1967, 9, 2329, 2967, 1012, 11, 1953, 6, 1297, 35, 388, 1349, 283, 433, 37953, 22, 2962, 13, 13, 321, 11, 1953, 6, 3, 951, 779, 3402, 79, 321, 11, 1953, 22232, 6, 3, 3402, 2, 33, 321, 11, 1953, 6, 3, 3402, 4, 62, 127, 3540, 100, 195, 13631, 37954, 2, 37955, 11, 1687, 20, 8, 33, 321, 1422, 1, 37953, 6, 4978, 37954, 2, 8, 195, 33, 321, 1422, 6, 4978, 37955, 24, 1853, 9, 62, 27, 13631, 11, 1687, 20, 119, 1, 18, 2972, 3130, 26413, 39, 2972, 3130, 28426, 15, 964, 6, 3392, 512, 381, 6, 80, 76, 1015, 1, 3, 3303, 3, 86, 1326, 1, 964, 10, 6, 8539, 302, 1659, 3, 707, 4, 1851, 17, 2756, 3, 344, 4, 959, 444, 10, 275, 20, 1155, 1, 61, 433, 8638, 17, 627, 29, 37953, 37954, 2, 37955, 644, 69, 6190, 11, 438, 5, 1659, 1851, 97, 299, 302, 1659, 10, 2398, 20, 964, 76, 20, 26413, 19, 13, 488, 15, 28426, 19, 13, 488, 9, 415, 378, 76, 243, 381, 97, 299, 3660, 10, 2398, 20, 964, 76, 20, 26413, 19, 13, 488, 15, 28426, 19, 13, 488, 97, 299, 10, 2398, 20, 964, 76, 20, 26413, 19, 13, 488, 137, 3, 3131, 1, 3, 1851, 513, 20, 119, 1, 964, 340, 22, 1012, 101, 4, 1454, 3, 433, 1, 302, 1659, 6830, 20, 964, 105, 26413, 15, 28426, 340, 22, 959, 444, 101, 19, 13, 3531, 2, 19, 13, 2155, 9, 26413, 2, 28426, 106, 3, 3108, 1, 295, 246, 1851, 513, 20, 119, 1, 964, 105, 28426, 10, 2659, 438, 5, 69, 642, 782, 558, 408, 3, 302, 1659, 1851, 513, 5, 119, 1, 964, 16, 2195, 405, 20, 1352, 302, 12384, 1, 3, 283, 433, 1481, 283, 5529, 561, 4172, 69, 10161, 2, 8, 885, 612, 1, 2329, 1259, 2967, 32, 575, 6, 1359, 665, 1874, 4, 3, 119, 1, 964, 252, 809, 636, 1, 33916, 1110, 121, 36]",2371.0,15990017,Intensity-modulated radiation therapy hysterectomy comparison conventional treatment sensitivity normal-tissue-sparing effect margin size,0,0.0
Vaginal brachytherapy alone is sufficient adjuvant treatment of surgical stage I endometrial cancer.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2005-08-01,"To determine the efficacy and complications of adjuvant vaginal high-dose-rate brachytherapy alone for patients with Stage I endometrial cancer in whom complete surgical staging had been performed. Between April 1998 and March 2004, 100 patients with Stage I endometrial cancer underwent surgical staging (total abdominal hysterectomy and bilateral salpingo-oophorectomy with pelvic +/- paraaortic nodal sampling) and postoperative vaginal high-dose-rate brachytherapy at our institution. The total dose was 2100 cGy in three fractions. With a median follow-up of 23 months (range 2-62), no pelvic or vaginal recurrences developed. All patients underwent pelvic dissection, and 42% underwent paraaortic nodal dissection. A median of 29.5 pelvic nodes (range 1-67) was removed (84% had >10 pelvic nodes removed). Most patients (73%) had endometrioid (or unspecified) adenocarcinoma, 16% had papillary serous carcinoma, and 11% had other histologic types. The International Federation of Gynecology and Obstetrics stage and grade was Stage IA, grade III in 5; Stage IB, grade I, II, or III in 6, 27, or 20, respectively; and Stage IC, grade I, II, or III in 13, 17, or 10, respectively. The Common Toxicity Criteria (version 2.0) complications were mild (Grade 1-2) and consisted primarily of vaginal mucosal changes, temporary urinary irritation, and temporary diarrhea. Adjuvant vaginal high-dose-rate brachytherapy alone may be a safe and effective alternative to pelvic external beam radiotherapy for surgical Stage I endometrial cancer.",Journal Article,5286.0,65.0,determine efficacy complications adjuvant vaginal high-dose-rate brachytherapy patients Stage endometrial complete surgical staging performed April 1998 March 2004 100 patients Stage endometrial underwent surgical staging total abdominal hysterectomy bilateral salpingo-oophorectomy pelvic +/- paraaortic nodal sampling postoperative vaginal high-dose-rate brachytherapy institution total dose 2100 cGy fractions median follow-up 23 months range 2-62 pelvic vaginal recurrences developed patients underwent pelvic dissection 42 underwent paraaortic nodal dissection median 29.5 pelvic nodes range 1-67 removed 84 10 pelvic nodes removed patients 73 endometrioid unspecified adenocarcinoma 16 papillary serous carcinoma 11 histologic types International Federation Gynecology Obstetrics stage grade Stage IA grade III 5 Stage IB grade II III 6 27 20 respectively Stage IC grade II III 13 17 10 respectively Common Toxicity Criteria version 2.0 complications mild Grade 1-2 consisted primarily vaginal mucosal changes temporary urinary irritation temporary diarrhea Adjuvant vaginal high-dose-rate brachytherapy safe effective alternative pelvic external beam radiotherapy surgical Stage endometrial,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[6, 223, 3, 209, 2, 521, 1, 249, 64, 61, 116, 1536, 279, 9, 7, 5, 82, 70, 12, 4, 953, 236, 221, 632, 42, 85, 173, 59, 2292, 1850, 2, 2363, 1131, 394, 7, 5, 82, 70, 12, 208, 221, 632, 181, 1467, 2622, 2, 1607, 5690, 3470, 5, 1110, 7401, 779, 2874, 2, 573, 64, 61, 116, 1536, 28, 114, 731, 3, 181, 61, 10, 21341, 3071, 4, 169, 1550, 5, 8, 52, 166, 126, 1, 382, 53, 184, 18, 744, 77, 1110, 15, 1593, 276, 62, 7, 208, 1110, 1161, 2, 595, 208, 7401, 779, 1161, 8, 52, 1, 462, 33, 1110, 502, 184, 14, 598, 10, 2264, 874, 42, 79, 1110, 502, 2264, 96, 7, 803, 42, 3151, 15, 12288, 449, 245, 42, 1796, 1744, 134, 2, 175, 42, 127, 884, 630, 3, 944, 7303, 1, 6429, 2, 7407, 82, 2, 88, 10, 82, 3302, 88, 316, 4, 33, 82, 3180, 88, 70, 215, 15, 316, 4, 49, 428, 15, 179, 106, 2, 82, 2340, 88, 70, 215, 15, 316, 4, 233, 269, 15, 79, 106, 3, 186, 155, 371, 2256, 18, 13, 521, 11, 1980, 88, 14, 18, 2, 1695, 1561, 1, 3068, 400, 7579, 1660, 11765, 2, 7579, 1172, 249, 64, 61, 116, 1536, 279, 68, 40, 8, 1165, 2, 323, 1091, 6, 1110, 1455, 1345, 310, 9, 221, 82, 70, 12]",1409.0,16029796,Vaginal brachytherapy sufficient adjuvant treatment surgical stage endometrial,1,0.005025125628140704
Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma?,International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists,Int. J. Gynecol. Pathol.,2006-01-01,"Low-grade endometrioid carcinomas, either of the endometrium or the ovaries, usually have an excellent prognosis. The association of this type of tumor with undifferentiated carcinoma is rare. In this study, we present the clinicopathologic features of 25 such cases. The age of the patients ranged from 30 to 82 years (median, 51 years). At presentation, the patients had either vaginal bleeding or pelvic pain. The endometrioid carcinoma involved the endometrium in 14 cases, the endometrium and 1 or both ovaries in 9 cases, and the ovaries in 2 cases. Undifferentiated carcinoma associated with low-grade endometrioid carcinoma was found at presentation in 19 grade 1 or 2 endometrioid carcinomas: 15 in the endometrium and 5 in the ovary. In one of these cases, undifferentiated carcinoma was found in the endometrium and the ovary. Undifferentiated carcinoma was found after resection of low-grade endometrioid carcinoma in six cases, involving the retroperitoneum, pelvis, vagina, or liver. The undifferentiated carcinoma was composed exclusively of diffuse sheets and solid nests of epithelial cells in l0 cases. Epithelial cells with isolated foci of keratinization were seen in nine cases and rhabdoid cells in a myxoid background in six cases. Twenty-four patients were treated with total abdominal hysterectomy and with bilateral salpingo-oophorectomy. Twenty-two patients received additional therapy as follows: chemotherapy (), radiotherapy (), and tamoxifen (). Follow-up showed that 15 patients died of disease in 1 to 60 months (median, 6 months), and 5 patients are alive with progressive disease with a follow-up between 6 and 8 months; 1 patient is alive with no evidence of disease at 104 months. In four cases, the diagnosis was made recently, with short follow-ups of 3 and 4 months. Foci of undifferentiated carcinoma may be confused with solid endometrioid adenocarcinoma erroneously leading to the diagnosis of a grade 3 or a significantly less aggressive grade 2 endometrioid carcinoma. The recognition of undifferentiated carcinoma in an otherwise low-grade endometrioid adenocarcinoma is extremely important because it indicates aggressive behavior. In asynchronous cases, being aware of this association can explain the absence of a second primary.",Journal Article,5133.0,134.0,Low-grade endometrioid carcinomas endometrium ovaries usually excellent prognosis association type undifferentiated carcinoma rare present clinicopathologic features 25 cases age patients ranged 30 82 years median 51 years presentation patients vaginal bleeding pelvic pain endometrioid carcinoma involved endometrium 14 cases endometrium 1 ovaries 9 cases ovaries 2 cases Undifferentiated carcinoma associated low-grade endometrioid carcinoma presentation 19 grade 1 2 endometrioid carcinomas 15 endometrium 5 ovary cases undifferentiated carcinoma endometrium ovary Undifferentiated carcinoma resection low-grade endometrioid carcinoma cases involving retroperitoneum pelvis vagina liver undifferentiated carcinoma composed exclusively diffuse sheets solid nests epithelial l0 cases Epithelial isolated foci keratinization seen cases rhabdoid myxoid background cases Twenty-four patients treated total abdominal hysterectomy bilateral salpingo-oophorectomy Twenty-two patients received additional therapy follows chemotherapy radiotherapy tamoxifen Follow-up showed 15 patients died disease 1 60 months median 6 months 5 patients alive progressive disease follow-up 6 8 months 1 patient alive evidence disease 104 months cases diagnosis recently short follow-ups 3 4 months Foci undifferentiated carcinoma confused solid endometrioid adenocarcinoma erroneously leading diagnosis grade 3 significantly aggressive grade 2 endometrioid carcinoma recognition undifferentiated carcinoma low-grade endometrioid adenocarcinoma extremely important indicates aggressive behavior asynchronous cases aware association explain absence second primary,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[154, 88, 3151, 826, 361, 1, 3, 15, 3, 7262, 2082, 47, 35, 1503, 356, 3, 248, 1, 26, 267, 1, 30, 5, 4480, 134, 16, 622, 4, 26, 45, 21, 364, 3, 1399, 404, 1, 243, 225, 140, 3, 89, 1, 3, 7, 1869, 29, 201, 6, 878, 60, 52, 725, 60, 28, 1031, 3, 7, 42, 361, 2294, 15, 1110, 559, 3, 3151, 134, 646, 3, 4, 213, 140, 3, 2, 14, 15, 110, 7262, 4, 83, 140, 2, 3, 7262, 4, 18, 140, 4480, 134, 41, 5, 154, 88, 3151, 134, 10, 204, 28, 1031, 4, 326, 88, 14, 15, 18, 3151, 826, 167, 4, 3, 2, 33, 4, 3, 3631, 4, 104, 1, 46, 140, 4480, 134, 10, 204, 4, 3, 2, 3, 3631, 4480, 134, 10, 204, 50, 170, 1, 154, 88, 3151, 134, 4, 437, 140, 1267, 3, 7765, 3270, 7553, 15, 3, 4480, 134, 10, 3317, 4437, 1, 1388, 13568, 2, 537, 14121, 1, 701, 37, 4, 55177, 140, 701, 37, 5, 1355, 3340, 1, 30879, 11, 527, 4, 762, 140, 2, 37, 4, 8, 5707, 2426, 4, 437, 140, 737, 294, 7, 11, 73, 5, 181, 1467, 2622, 2, 5, 1607, 5690, 3470, 737, 100, 7, 103, 402, 36, 22, 2962, 56, 310, 2, 1105, 166, 126, 224, 17, 167, 7, 1016, 1, 34, 4, 14, 6, 335, 53, 52, 49, 53, 2, 33, 7, 32, 1701, 5, 1014, 34, 5, 8, 166, 126, 59, 49, 2, 66, 53, 14, 69, 16, 1701, 5, 77, 241, 1, 34, 28, 3407, 53, 4, 294, 140, 3, 147, 10, 1229, 761, 5, 978, 166, 6106, 1, 27, 2, 39, 53, 3340, 1, 4480, 134, 68, 40, 21075, 5, 537, 3151, 449, 27829, 1049, 6, 3, 147, 1, 8, 88, 27, 15, 8, 97, 299, 571, 88, 18, 3151, 134, 3, 2335, 1, 4480, 134, 4, 35, 2632, 154, 88, 3151, 449, 16, 2938, 305, 408, 192, 2640, 571, 1710, 4, 18272, 140, 486, 4749, 1, 26, 248, 122, 2943, 3, 1127, 1, 8, 419, 86]",2142.0,16306785,Association low-grade endometrioid carcinoma uterus ovary undifferentiated carcinoma new type dedifferentiated carcinoma,3,0.01507537688442211
Successful pregnancies following fertility-preserving treatment for ovarian carcinoma.,Nature clinical practice. Oncology,Nat Clin Pract Oncol,2005-12-01,"A 30-year-old woman underwent a routine sonogram at 6 weeks of gestation during her first pregnancy and was found to have a 6 cm complex right-ovarian mass, thought to be a dermoid cyst. The pregnancy progressed to term and the patient went on to have a normal vaginal delivery. At 3 months postpartum, she underwent a laparoscopic ovarian cystectomy. Preoperative serum cancer antigen 125 was within the normal range at 23.6 U/ml. Pelvic ultrasound, evaluation of serum cancer antigen 125, abdominal and pelvic CT scans. Stage IA clear-cell epithelial carcinoma of the right ovary. Laparoscopic ovarian cystectomy, dilation and curettage, laparotomy, right salpingo-oophorectomy, infracolic omentectomy, peritoneal biopsy, peritoneal washing, appendectomy, bilateral pelvic and para-aortic lymphadenectomy, adjuvant chemotherapy with paclitaxel and carboplatin.",Case Reports,5164.0,3.0,30-year-old woman underwent routine sonogram 6 weeks gestation pregnancy 6 cm complex right-ovarian mass thought dermoid cyst pregnancy progressed term patient went normal vaginal delivery 3 months postpartum underwent laparoscopic ovarian cystectomy Preoperative serum antigen 125 normal range 23.6 U/ml Pelvic ultrasound evaluation serum antigen 125 abdominal pelvic CT scans Stage IA clear-cell epithelial carcinoma right ovary Laparoscopic ovarian cystectomy dilation curettage laparotomy right salpingo-oophorectomy infracolic omentectomy peritoneal biopsy peritoneal washing appendectomy bilateral pelvic para-aortic lymphadenectomy adjuvant chemotherapy paclitaxel carboplatin,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[8, 201, 111, 1095, 2854, 208, 8, 1311, 33567, 28, 49, 244, 1, 13250, 190, 1084, 157, 2290, 2, 10, 204, 6, 47, 8, 49, 494, 840, 1913, 6301, 782, 2739, 6, 40, 8, 28386, 3364, 3, 2290, 1839, 6, 337, 2, 3, 69, 7109, 23, 6, 47, 8, 295, 989, 28, 27, 53, 7830, 3109, 208, 8, 1964, 1750, 498, 524, 12, 448, 1731, 10, 262, 3, 295, 184, 28, 382, 49, 1767, 542, 1110, 1945, 451, 1, 524, 12, 448, 1731, 1467, 2, 1110, 425, 1441, 82, 3302, 885, 31, 701, 134, 1, 3, 1913, 3631, 1964, 1750, 8062, 2, 12529, 3274, 1913, 5690, 3470, 55195, 20196, 1639, 411, 1639, 14790, 14590, 1607, 1110, 2, 4615, 3938, 2048, 249, 56, 5, 490, 2, 927]",818.0,16341120,Successful pregnancies following fertility-preserving treatment ovarian carcinoma,46,0.23115577889447236
Screening and the prevention of gynecologic cancer: endometrial cancer.,Best practice & research. Clinical obstetrics & gynaecology,Best Pract Res Clin Obstet Gynaecol,2005-12-20,"Over the years, endometrial cancer has remained the most common gynecologic malignancy in the United States. Two categories of endometrial cancer exist: type I and type II. Type I cancers constitute the majority of cases of endometrial cancer, and the risk factors for this type have been studied in greatest detail. These cancers are driven by estrogen, and many of the risk factors are directly or indirectly linked to a state of excessive estrogen. Protective factors seem to be related to conditions that may result in decreased estrogen exposure. Cure rates for endometrial cancer remain high, mainly because of the early stage at which the majority of cases present. Warning signs of abnormal vaginal bleeding or discharge allow detection of these cancers in their early stages. Screening for these cancers is not effective and often leads to additional unnecessary tests; thus, it is not currently recommended in the general population.",Journal Article,5145.0,50.0,years endometrial remained common gynecologic malignancy United States categories endometrial exist type type II Type constitute majority cases endometrial risk factors type studied greatest driven estrogen risk factors directly indirectly linked state excessive estrogen Protective factors related conditions decreased estrogen exposure Cure rates endometrial remain high mainly early stage majority cases present Warning signs abnormal vaginal bleeding discharge allow detection early stages Screening effective leads additional unnecessary tests currently recommended general population,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[252, 3, 60, 12, 71, 958, 3, 96, 186, 1512, 710, 4, 3, 1088, 907, 100, 1996, 1, 12, 1923, 267, 70, 2, 267, 215, 267, 70, 163, 4999, 3, 686, 1, 140, 1, 12, 2, 3, 43, 130, 9, 26, 267, 47, 85, 656, 4, 2199, 5000, 46, 163, 32, 1621, 20, 808, 2, 445, 1, 3, 43, 130, 32, 1606, 15, 7792, 1199, 6, 8, 1309, 1, 4529, 808, 2864, 130, 3233, 6, 40, 139, 6, 1298, 17, 68, 757, 4, 340, 808, 645, 1722, 151, 9, 12, 918, 64, 2615, 408, 1, 3, 191, 82, 28, 92, 3, 686, 1, 140, 364, 15986, 3408, 1, 1668, 2294, 15, 2993, 1700, 638, 1, 46, 163, 4, 136, 191, 1153, 453, 9, 46, 163, 16, 44, 323, 2, 629, 1940, 6, 402, 4224, 895, 631, 192, 16, 44, 694, 793, 4, 3, 1083, 266]",872.0,16364689,Screening prevention gynecologic endometrial,0,0.0
Total laparoscopic radical hysterectomy and lymphadenectomy: the M. D. Anderson Cancer Center experience.,Gynecologic oncology,Gynecol. Oncol.,2006-02-10,"To retrospectively evaluate the feasibility and morbidity of total laparoscopic radical hysterectomy and lymphadenectomy. We performed a retrospective review of all patients who underwent a total laparoscopic radical hysterectomy at our institution between May 2004 and August 2005. Data collected included age, body mass index, stage, histopathologic subtype, tumor grade, estimated blood loss, perioperative blood transfusions, number and status of lymph nodes obtained, status of surgical margins, length of hospital stay, time to resumption of normal bladder function, intraoperative and postoperative complications, and disease-free interval. Twenty patients underwent total laparoscopic radical hysterectomy during the study period. None of the surgeries required conversion to laparotomy. The median patient age was 41.5 years (range, 25-76). Eighteen patients had cervix cancer (5 stage IA2 and 13 stage IB1), and 2 had endometrial cancer (1 stage IB and 1 stage IIIA). Among those with cervix cancer, 12 had adenocarcinoma, 4 squamous cell carcinoma, and 2 adenosquamous carcinoma. The median weight was 70 kg (range, 49-112). The median number of resected pelvic lymph nodes was 13 (range, 9-26). One patient had nodal disease. The surgical margins were free of disease in all cases. The median blood loss was 200 ml (range, 25-700 ml). Only 1 patient required an intraoperative blood transfusion (1 U packed red blood cells). The median length of hospital stay was 1 day (range, 1-5). There were 3 short-term complications--unintentional cystotomy, pulmonary embolus, and pneumomediastinum with subcutaneous emphysema. There were 2 long-term complications--vaginal eviscerations and a lymphocyst. The median time to resumption of normal bladder function was 16 days (range, 13-29). The median follow-up time was 8 months range (1-16). All patients remain free of disease at the time of this report. Total laparoscopic radical hysterectomy can be performed safely with minimal blood loss and postoperative morbidity, and patients undergoing this procedure may be discharged after an overnight stay in the hospital.",Journal Article,5093.0,125.0,retrospectively evaluate feasibility morbidity total laparoscopic radical hysterectomy lymphadenectomy performed retrospective review patients underwent total laparoscopic radical hysterectomy institution 2004 August 2005 collected included age body mass index stage histopathologic subtype grade estimated blood loss perioperative blood transfusions number status lymph nodes obtained status surgical margins length hospital stay time resumption normal bladder function intraoperative postoperative complications disease-free interval patients underwent total laparoscopic radical hysterectomy period surgeries required conversion laparotomy median patient age 41.5 years range 25-76 Eighteen patients cervix 5 stage IA2 13 stage IB1 2 endometrial 1 stage IB 1 stage IIIA cervix 12 adenocarcinoma 4 squamous carcinoma 2 adenosquamous carcinoma median weight 70 range 49-112 median number resected pelvic lymph nodes 13 range 9-26 patient nodal disease surgical margins free disease cases median blood loss 200 ml range 25-700 ml 1 patient required intraoperative blood transfusion 1 U packed red blood median length hospital stay 1 day range 1-5 3 short-term complications -- unintentional cystotomy pulmonary embolus pneumomediastinum subcutaneous emphysema 2 long-term complications -- vaginal eviscerations lymphocyst median time resumption normal bladder function 16 days range 13-29 median follow-up time 8 months range 1-16 patients remain free disease time report Total laparoscopic radical hysterectomy performed safely minimal blood loss postoperative morbidity patients undergoing procedure discharged overnight stay hospital,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,"[6, 894, 376, 3, 1437, 2, 787, 1, 181, 1964, 711, 2622, 2, 2048, 21, 173, 8, 459, 206, 1, 62, 7, 54, 208, 8, 181, 1964, 711, 2622, 28, 114, 731, 59, 68, 1131, 2, 2480, 1242, 74, 786, 159, 89, 642, 782, 558, 82, 2630, 875, 30, 88, 661, 315, 407, 1547, 315, 4987, 207, 2, 156, 1, 263, 502, 683, 156, 1, 221, 1012, 1318, 1, 702, 2020, 98, 6, 14268, 1, 295, 343, 1720, 2, 573, 521, 2, 34, 115, 268, 737, 7, 208, 181, 1964, 711, 2622, 190, 3, 45, 727, 1292, 1, 3, 5305, 616, 3111, 6, 3274, 3, 52, 69, 89, 10, 605, 33, 60, 184, 243, 846, 3195, 7, 42, 3629, 12, 33, 82, 16725, 2, 233, 82, 8111, 2, 18, 42, 12, 14, 82, 3180, 2, 14, 82, 3164, 107, 135, 5, 3629, 12, 133, 42, 449, 39, 691, 31, 134, 2, 18, 8067, 134, 3, 52, 924, 10, 431, 503, 184, 739, 3726, 3, 52, 207, 1, 1133, 1110, 263, 502, 10, 233, 184, 83, 432, 104, 69, 42, 779, 34, 3, 221, 1012, 11, 115, 1, 34, 4, 62, 140, 3, 52, 315, 407, 10, 1250, 542, 184, 243, 5692, 542, 158, 14, 69, 616, 35, 1720, 315, 2785, 14, 1767, 14203, 3422, 315, 37, 3, 52, 1318, 1, 702, 2020, 10, 14, 218, 184, 14, 33, 125, 11, 27, 978, 337, 521, 17350, 37573, 1087, 12738, 2, 28509, 5, 2529, 13124, 125, 11, 18, 319, 337, 521, 55295, 2, 8, 38114, 3, 52, 98, 6, 14268, 1, 295, 343, 10, 245, 162, 184, 233, 462, 3, 52, 166, 126, 98, 10, 66, 53, 184, 14, 245, 62, 7, 918, 115, 1, 34, 28, 3, 98, 1, 26, 414, 181, 1964, 711, 2622, 122, 40, 173, 2268, 5, 1048, 315, 407, 2, 573, 787, 2, 7, 479, 26, 1299, 68, 40, 6155, 50, 35, 18409, 2020, 4, 3, 702]",2026.0,16472844,Total laparoscopic radical hysterectomy lymphadenectomy M. D. Anderson Center experience,38,0.19095477386934673
Primary neuroendocrine carcinoma of the vagina with Merkel cell carcinoma phenotype.,The American journal of surgical pathology,Am. J. Surg. Pathol.,2006-03-01,"We describe a case of primary neuroendocrine carcinoma arising from the anterior vaginal wall of a 67-year-old woman. Primary neuroendocrine carcinoma of the vagina is a rare entity with only 25 previously reported cases in the literature. In previous reports, these tumors have not been distinguished from primary neuroendocrine carcinoma of the skin (Merkel cell carcinoma). The tumor was composed of cells that showed neuroendocrine-type nuclear features with hyperchromasia, nuclear molding, occasional small nucleoli, and a chromatin pattern that was finely granular. The tumor cells were positive for cytokeratin 20 (CK20), neuron specific enolase, pancytokeratin, epithelial membrane antigen, and chromogranin A expression. Ki-67, a marker of proliferation, was also positive in>90% of cells. The tumor cells showed intense expression of Bcl-2 oncoprotein and mild to moderate expression of c-KIT. Synaptophysin, neurofilament, CD45, CD56, CD10, S-100, HMB-45, cytokeratin 7, and thyroid transcription factor 1 were negative. This pattern of staining is consistent with a Merkel cell carcinoma. This is the first report of a primary neuroendocrine carcinoma of the vagina with a Merkel cell phenotype. Previous studies have not distinguished primary neuroendocrine carcinoma of the vagina from Merkel cell carcinoma of the skin. Positive expression of CK20 in primary small cell carcinoma of the vagina might represent a Merkel cell carcinoma subtype of this tumor.",Case Reports,5074.0,28.0,case primary neuroendocrine carcinoma arising anterior vaginal wall 67-year-old woman Primary neuroendocrine carcinoma vagina rare entity 25 previously reported cases literature previous reports distinguished primary neuroendocrine carcinoma skin Merkel carcinoma composed showed neuroendocrine-type nuclear features hyperchromasia nuclear molding occasional small nucleoli chromatin pattern finely granular positive cytokeratin 20 CK20 neuron specific enolase pancytokeratin epithelial membrane antigen chromogranin expression Ki-67 marker proliferation positive 90 showed intense expression Bcl-2 oncoprotein mild moderate expression c-KIT Synaptophysin neurofilament CD45 CD56 CD10 S-100 HMB-45 cytokeratin 7 thyroid transcription factor 1 negative pattern staining consistent Merkel carcinoma report primary neuroendocrine carcinoma vagina Merkel phenotype Previous studies distinguished primary neuroendocrine carcinoma vagina Merkel carcinoma skin Positive expression CK20 primary small carcinoma vagina represent Merkel carcinoma subtype,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,"[21, 897, 8, 473, 1, 86, 1542, 134, 2635, 29, 3, 2882, 2397, 1, 8, 598, 111, 1095, 2854, 86, 1542, 134, 1, 3, 7553, 16, 8, 622, 2983, 5, 158, 243, 373, 210, 140, 4, 3, 789, 4, 698, 1198, 46, 57, 47, 44, 85, 4735, 29, 86, 1542, 134, 1, 3, 5855, 31, 134, 3, 30, 10, 3317, 1, 37, 17, 224, 1542, 267, 928, 404, 5, 55350, 928, 38129, 9753, 302, 13282, 2, 8, 2287, 1177, 17, 10, 19734, 7694, 3, 30, 37, 11, 109, 9, 4292, 179, 10821, 13552, 112, 18262, 23508, 701, 1905, 448, 2, 8931, 8, 55, 2311, 598, 8, 952, 1, 457, 10, 120, 109, 4, 424, 1, 37, 3, 30, 37, 224, 3933, 55, 1, 1044, 18, 6159, 2, 1980, 6, 1163, 55, 1, 256, 1164, 12161, 20495, 5280, 5803, 6289, 695, 394, 16740, 512, 4292, 67, 2, 866, 161, 14, 11, 199, 26, 1177, 1, 1029, 16, 925, 5, 8, 5855, 31, 134, 26, 16, 3, 157, 414, 1, 8, 86, 1542, 134, 1, 3, 7553, 5, 8, 5855, 31, 1005, 698, 94, 47, 44, 4735, 86, 1542, 134, 1, 3, 7553, 29, 5855, 31, 134, 1, 3, 109, 55, 1, 10821, 4, 86, 302, 31, 134, 1, 3, 7553, 822, 1231, 8, 5855, 31, 134, 875, 1, 26, 30]",1411.0,16538063,Primary neuroendocrine carcinoma vagina Merkel carcinoma phenotype,0,0.0
A dosimetric analysis of intensity-modulated radiation therapy (IMRT) as an alternative to adjuvant high-dose-rate (HDR) brachytherapy in early endometrial cancer patients.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2006-05-01,"To evaluate the role of intensity-modulated radiation treatment (IMRT) as an alternative to high-dose-rate (HDR) brachytherapy in the treatment of the vagina in postoperative early endometrial cancer patients after surgery. Planning computed tomography (CT) scans of 10 patients previously treated with HDR were used in this study. In all cases, a dose of 700 cGy/fraction was prescribed at a distance of 0.5 cm from the cylinder surface. The same CT scans were then used in IMRT planning. In this paradigm, the vaginal cylinder represents a component of a hypothetical immobilization system that would be indexed to the linac treatment table. Our study showed that IMRT provided relatively lower rectal doses than HDR when treatment was prescribed at a distance of 0.5 cm away from the cylinder surface. Maximum rectal doses were lower with IMRT compared with HDR (average: 89.0% vs. 142.6%, respectively, p < 0.05). Moreover, the mean rectal dose was lower in IMRT plans compared with HDR plans with treatment prescribed either to the surface (average: 14.8% vs. 21.4%, respectively, p < 0.05) or to 0.5 cm (average: 19.6% vs. 33.5%, respectively, p < 0.05). IMRT plans had planning target volume (PTV) coverage comparable with HDR (average PTV minimum for treatment prescribed to 0.5 cm: 93.9% vs. 92.1%, p = 0.71, respectively) with less inhomogeneity (average PTV maximum: 110.8% vs. 381.6%, p < 0.05). Our dosimetric analysis suggests that when used in conjunction with a suitable immobilization system, IMRT may provide an alternative to HDR brachytherapy in women with early endometrial cancer after hysterectomy. However, more studies are needed to evaluate the clinical merit of the IMRT in these patients.",Evaluation Study,5013.0,38.0,evaluate role intensity-modulated radiation treatment IMRT alternative high-dose-rate HDR brachytherapy treatment vagina postoperative early endometrial patients surgery Planning computed tomography CT scans 10 patients previously treated HDR cases dose 700 cGy/fraction prescribed distance 0.5 cm cylinder surface CT scans IMRT planning paradigm vaginal cylinder represents component hypothetical immobilization indexed linac treatment showed IMRT provided relatively lower rectal doses HDR treatment prescribed distance 0.5 cm away cylinder surface Maximum rectal doses lower IMRT compared HDR average 89.0 vs. 142.6 respectively p 0.05 mean rectal dose lower IMRT plans compared HDR plans treatment prescribed surface average 14.8 vs. 21.4 respectively p 0.05 0.5 cm average 19.6 vs. 33.5 respectively p 0.05 IMRT plans planning target volume PTV coverage comparable HDR average PTV minimum treatment prescribed 0.5 cm 93.9 vs. 92.1 p 0.71 respectively inhomogeneity average PTV maximum 110.8 vs. 381.6 p 0.05 dosimetric suggests conjunction suitable immobilization IMRT provide alternative HDR brachytherapy women early endometrial hysterectomy studies needed evaluate clinical merit IMRT patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,"[6, 376, 3, 200, 1, 837, 1757, 121, 24, 964, 22, 35, 1091, 6, 64, 61, 116, 5309, 1536, 4, 3, 24, 1, 3, 7553, 4, 573, 191, 12, 7, 50, 152, 1349, 1220, 872, 425, 1441, 1, 79, 7, 373, 73, 5, 5309, 11, 95, 4, 26, 45, 4, 62, 140, 8, 61, 1, 5692, 3071, 1509, 10, 2746, 28, 8, 3019, 1, 13, 33, 494, 29, 3, 23326, 1255, 3, 827, 425, 1441, 11, 818, 95, 4, 964, 1349, 4, 26, 2431, 3, 23326, 1449, 8, 1249, 1, 8, 7045, 10161, 398, 17, 688, 40, 20500, 6, 3, 10734, 24, 7016, 114, 45, 224, 17, 964, 1052, 1352, 280, 415, 76, 5309, 198, 24, 10, 2746, 28, 8, 3019, 1, 13, 33, 494, 6565, 29, 3, 23326, 1255, 689, 415, 11, 280, 5, 964, 72, 5, 5309, 1011, 887, 13, 105, 4785, 49, 106, 19, 13, 474, 1393, 3, 313, 61, 10, 280, 4, 964, 1853, 72, 5, 5309, 1853, 5, 24, 2746, 361, 6, 3, 1255, 1011, 213, 66, 105, 239, 39, 106, 19, 13, 474, 15, 6, 13, 33, 494, 1011, 326, 49, 105, 466, 33, 106, 19, 13, 474, 964, 1853, 42, 1349, 283, 433, 3303, 2139, 1279, 5, 5309, 1011, 3303, 2499, 9, 24, 2746, 6, 13, 33, 494, 966, 83, 105, 937, 14, 19, 13, 792, 106, 5, 299, 15969, 1011, 3303, 689, 3129, 66, 105, 10155, 49, 19, 13, 474, 114, 3187, 65, 844, 17, 198, 95, 4, 3357, 5, 8, 2884, 10161, 398, 964, 68, 377, 35, 1091, 6, 5309, 1536, 4, 117, 5, 191, 12, 50, 2622, 137, 80, 94, 32, 575, 6, 376, 3, 38, 7062, 1, 3, 964, 4, 46, 7]",1595.0,16618581,dosimetric intensity-modulated radiation therapy IMRT alternative adjuvant high-dose-rate HDR brachytherapy early endometrial patients,0,0.0
Cystoscopic temporary ureteral catheterization during radical vaginal and abdominal trachelectomy.,Gynecologic oncology,Gynecol. Oncol.,2006-06-06,"To describe the role of temporary retrograde ureteral catheterization at the time of fertility-sparing radical vaginal or abdominal trachelectomy in women with early-stage cervical cancer. We analyzed a prospectively maintained database of all patients with cervical cancer who were explored for radical vaginal or abdominal trachelectomy at our institution. Cystourethroscopy and ureteral catheterization were performed prior to the vaginal or abdominal operation in all patients, except two pediatric ones. Temporary bilateral retrograde ureteral catheters were planned for all patients as part of our routine procedure to facilitate identification of the distal ureters. 5Fr whistle-tip or open-ended catheters were used and usually advanced to approximately 20 cm. Catheters were removed at the end of the operation in all cases. All catheters were inserted by a gynecologic oncology fellow or attending. Between 11/01 and 12/05, 40 patients were taken to the operating room for planned fertility-sparing radical vaginal or abdominal trachelectomy. We previously reported on two pediatric patients; they are excluded from this report. The median age for adult patients was 32 years (mean, 31.6; range, 23-40). International Federation of Gynecology and Obstetrics (FIGO) stage included IB1 (26), IA2 (6), and IA1 with lymphovascular invasion (6). Thirty-four patients underwent radical vaginal trachelectomy and four underwent a radical abdominal trachelectomy. Two (5%) of 38 patients required immediate completion radical hysterectomy due to extensive endocervical disease (one in the vaginal group and one in the abdominal group). Bilateral ureteral catheters were inserted successfully in 37 (97%) of 38 patients and facilitated identification of the distal ureter during the dissection. In one case, the right ureteral orifice could not be successfully catheterized, and the case was completed with unilateral catheterization. The estimated time to perform this part of the operation was approximately 15-20 min. Twenty-eight patients (74%) had 5Fr whistle-tip ureteral catheters inserted, and 10 had open-ended catheters inserted. There were no intraoperative complications. Median hospital stay was 3 days (range, 3-7). Hematuria, evident in the drainage bag attached to the Foley catheter, usually resolved in 24-48 h. Two (20%) of 10 patients who had open-ended catheters inserted developed a transient rise in postoperative creatinine (1.7 and 3.5 mg/dl, respectively) compared to 0/28 patients who had whistle-tip catheters placed (P<0.001). Both were attributed to postoperative distal ureteral edema, and only one patient required reinsertion of temporary ureteral stents. No patient developed long-term urinary complications or fistulae. Cystourethroscopy and bilateral retrograde ureteral catheterization by gynecologic oncologists is a simple and quick procedure that may facilitate identifying the distal ureter during radical vaginal or abdominal trachelectomy. We favor using 5Fr whistle-tip catheters as they may be associated with less ureteral mucosal trauma and subsequent postoperative edema. The skills needed for this procedure should be available to fellows in gynecologic oncology training.",Journal Article,4977.0,22.0,role temporary retrograde ureteral catheterization time fertility-sparing radical vaginal abdominal trachelectomy women early-stage cervical prospectively maintained database patients cervical explored radical vaginal abdominal trachelectomy institution Cystourethroscopy ureteral catheterization performed prior vaginal abdominal operation patients pediatric ones Temporary bilateral retrograde ureteral catheters planned patients routine procedure facilitate identification distal ureters 5Fr whistle-tip open-ended catheters usually advanced approximately 20 cm Catheters removed end operation cases catheters inserted gynecologic oncology fellow attending 11/01 12/05 40 patients taken operating room planned fertility-sparing radical vaginal abdominal trachelectomy previously reported pediatric patients excluded report median age adult patients 32 years mean 31.6 range 23-40 International Federation Gynecology Obstetrics FIGO stage included IB1 26 IA2 6 IA1 lymphovascular invasion 6 Thirty-four patients underwent radical vaginal trachelectomy underwent radical abdominal trachelectomy 5 38 patients required immediate completion radical hysterectomy extensive endocervical disease vaginal group abdominal group Bilateral ureteral catheters inserted successfully 37 97 38 patients facilitated identification distal ureter dissection case right ureteral orifice successfully catheterized case completed unilateral catheterization estimated time perform operation approximately 15-20 min Twenty-eight patients 74 5Fr whistle-tip ureteral catheters inserted 10 open-ended catheters inserted intraoperative complications Median hospital stay 3 days range 3-7 Hematuria evident drainage bag attached Foley catheter usually resolved 24-48 h. 20 10 patients open-ended catheters inserted developed transient rise postoperative creatinine 1.7 3.5 mg/dl respectively compared 0/28 patients whistle-tip catheters placed P 0.001 attributed postoperative distal ureteral edema patient required reinsertion temporary ureteral stents patient developed long-term urinary complications fistulae Cystourethroscopy bilateral retrograde ureteral catheterization gynecologic oncologists simple quick procedure facilitate identifying distal ureter radical vaginal abdominal trachelectomy favor 5Fr whistle-tip catheters associated ureteral mucosal trauma subsequent postoperative edema skills needed procedure available fellows gynecologic oncology training,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 897, 3, 200, 1, 7579, 10583, 7213, 15173, 28, 3, 98, 1, 2954, 1851, 711, 15, 1467, 5760, 4, 117, 5, 191, 82, 12, 21, 311, 8, 1143, 1955, 609, 1, 62, 7, 5, 12, 54, 11, 1443, 9, 711, 15, 1467, 5760, 28, 114, 731, 34100, 2, 7213, 15173, 11, 173, 324, 6, 3, 15, 1467, 2589, 4, 62, 7, 2187, 100, 815, 6737, 7579, 1607, 10583, 7213, 6722, 11, 1465, 9, 62, 7, 22, 760, 1, 114, 1311, 1299, 6, 1876, 911, 1, 3, 2107, 17796, 38188, 34101, 9372, 15, 1020, 8909, 6722, 11, 95, 2, 2082, 131, 6, 705, 179, 494, 6722, 11, 2264, 28, 3, 396, 1, 3, 2589, 4, 62, 140, 62, 6722, 11, 9882, 20, 8, 1512, 413, 10526, 15, 6895, 59, 175, 355, 2, 133, 474, 327, 7, 11, 1633, 6, 3, 2584, 4698, 9, 1465, 2954, 1851, 711, 15, 1467, 5760, 21, 373, 210, 23, 100, 815, 7, 491, 32, 1800, 29, 26, 414, 3, 52, 89, 9, 780, 7, 10, 531, 60, 313, 456, 49, 184, 382, 327, 944, 7303, 1, 6429, 2, 7407, 3837, 82, 159, 8111, 432, 16725, 49, 2, 14517, 5, 2933, 578, 49, 977, 294, 7, 208, 711, 5760, 2, 294, 208, 8, 711, 1467, 5760, 100, 33, 1, 519, 7, 616, 2181, 1438, 711, 2622, 520, 6, 1344, 10174, 34, 104, 4, 3, 87, 2, 104, 4, 3, 1467, 87, 1607, 7213, 6722, 11, 9882, 1878, 4, 567, 1015, 1, 519, 7, 2, 4667, 911, 1, 3, 2107, 9775, 190, 3, 1161, 4, 104, 473, 3, 1913, 7213, 30954, 359, 44, 40, 1878, 55546, 2, 3, 473, 10, 781, 5, 3208, 15173, 3, 661, 98, 6, 2715, 26, 760, 1, 3, 2589, 10, 705, 167, 179, 1538, 737, 659, 7, 794, 42, 38188, 34101, 9372, 7213, 6722, 9882, 2, 79, 42, 1020, 8909, 6722, 9882, 125, 11, 77, 1720, 521, 52, 702, 2020, 10, 27, 162, 184, 27, 67, 7798, 2853, 4, 3, 3528, 15260, 10409, 6, 3, 26513, 3925, 2082, 3862, 4, 259, 576, 555, 100, 179, 1, 79, 7, 54, 42, 1020, 8909, 6722, 9882, 276, 8, 2473, 3693, 4, 573, 3177, 14, 67, 2, 27, 33, 81, 1826, 106, 72, 6, 13, 339, 7, 54, 42, 34101, 9372, 6722, 3295, 19, 13, 144, 110, 11, 3073, 6, 573, 2107, 7213, 3306, 2, 158, 104, 69, 616, 44376, 1, 7579, 7213, 9910, 77, 69, 276, 319, 337, 1660, 521, 15, 17809, 34100, 2, 1607, 10583, 7213, 15173, 20, 1512, 1339, 16, 8, 2763, 2, 14431, 1299, 17, 68, 1876, 1386, 3, 2107, 9775, 190, 711, 15, 1467, 5760, 21, 4283, 75, 38188, 34101, 9372, 6722, 22, 491, 68, 40, 41, 5, 299, 7213, 3068, 11147, 2, 706, 573, 3306, 3, 5909, 575, 9, 26, 1299, 257, 40, 390, 6, 7813, 4, 1512, 413, 1741]",3077.0,16753202,Cystoscopic temporary ureteral catheterization radical vaginal abdominal trachelectomy,0,0.0
Fertility-sparing radical abdominal trachelectomy for cervical carcinoma: technique and review of the literature.,Gynecologic oncology,Gynecol. Oncol.,2006-07-11,"Radical trachelectomy has emerged as a reasonable fertility-sparing operation for selected patients with stage I cervical cancer. The purpose of this report is to describe our technique of radical abdominal trachelectomy, a fertility-sparing operation in women with cervical cancer, and review the current literature on this procedure. A review of a prospectively maintained database of all fertility-sparing radical trachelectomy procedures performed at our institution. Between 11/01 and 3/06, we performed a total of 42 fertility-preserving radical trachelectomies with pelvic lymphadenectomy for women with invasive cervical cancer. We had previously reported on 2 pediatric abdominal trachelectomies, which are excluded from this report. Five of the remaining 40 cases had undergone a radical abdominal trachelectomy, and 35 cases were performed laparoscopically with a radical vaginal approach. The characteristics of the 5 adult patients who underwent abdominal radical trachelectomy included stage IB1 disease in all cases, a mean age of 36 years (range, 33-39), and a mean estimated blood loss of 280 ml (range, 50-400); 1 patient with squamous cell carcinoma needed completion radical hysterectomy at the time of trachelectomy due to disease extending into the endometrium, and 1 patient needed postoperative chemoradiation due to a positive parametrial lymph node. The remaining 3 patients resumed normal menstruation postoperatively. All patients remain disease-free at the time of this report. The only remaining uterine blood supply in these patients are the utero-ovarian vessels. There were no postoperative complications, and transurethral Foley catheters were removed in all cases within 2 weeks. Radical abdominal trachelectomy with pelvic lymphadenectomy is a feasible operation for selected women with stage I cervical cancer who desire to preserve reproductive function. Menstruation and reproductive function may be preserved after bilateral uterine vessel ligation. The procedure expands the inclusion criteria of radical vaginal trachelectomy to patients with distorted cervicovaginal anatomy in which the vaginal approach may not be feasible.",Journal Article,4942.0,113.0,Radical trachelectomy emerged reasonable fertility-sparing operation selected patients stage cervical purpose report technique radical abdominal trachelectomy fertility-sparing operation women cervical review current literature procedure review prospectively maintained database fertility-sparing radical trachelectomy procedures performed institution 11/01 3/06 performed total 42 fertility-preserving radical trachelectomies pelvic lymphadenectomy women invasive cervical previously reported 2 pediatric abdominal trachelectomies excluded report remaining 40 cases undergone radical abdominal trachelectomy 35 cases performed laparoscopically radical vaginal approach characteristics 5 adult patients underwent abdominal radical trachelectomy included stage IB1 disease cases mean age 36 years range 33-39 mean estimated blood loss 280 ml range 50-400 1 patient squamous carcinoma needed completion radical hysterectomy time trachelectomy disease extending endometrium 1 patient needed postoperative chemoradiation positive parametrial lymph node remaining 3 patients resumed normal menstruation postoperatively patients remain disease-free time report remaining uterine blood supply patients utero-ovarian vessels postoperative complications transurethral Foley catheters removed cases 2 weeks Radical abdominal trachelectomy pelvic lymphadenectomy feasible operation selected women stage cervical desire preserve reproductive function Menstruation reproductive function preserved bilateral uterine vessel ligation procedure expands inclusion criteria radical vaginal trachelectomy patients distorted cervicovaginal anatomy vaginal approach feasible,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[711, 5760, 71, 2054, 22, 8, 3203, 2954, 1851, 2589, 9, 715, 7, 5, 82, 70, 12, 3, 743, 1, 26, 414, 16, 6, 897, 114, 1312, 1, 711, 1467, 5760, 8, 2954, 1851, 2589, 4, 117, 5, 12, 2, 206, 3, 291, 789, 23, 26, 1299, 8, 206, 1, 8, 1143, 1955, 609, 1, 62, 2954, 1851, 711, 5760, 1369, 173, 28, 114, 731, 59, 175, 355, 2, 27, 1460, 21, 173, 8, 181, 1, 595, 2954, 4972, 711, 38216, 5, 1110, 2048, 9, 117, 5, 416, 12, 21, 42, 373, 210, 23, 18, 815, 1467, 38216, 92, 32, 1800, 29, 26, 414, 365, 1, 3, 1844, 327, 140, 42, 1989, 8, 711, 1467, 5760, 2, 465, 140, 11, 173, 11472, 5, 8, 711, 353, 3, 374, 1, 3, 33, 780, 7, 54, 208, 1467, 711, 5760, 159, 82, 8111, 34, 4, 62, 140, 8, 313, 89, 1, 511, 60, 184, 466, 587, 2, 8, 313, 661, 315, 407, 1, 5775, 542, 184, 212, 1524, 14, 69, 5, 691, 31, 134, 575, 1438, 711, 2622, 28, 3, 98, 1, 5760, 520, 6, 34, 4782, 237, 3, 2, 14, 69, 575, 573, 975, 520, 6, 8, 109, 8726, 263, 289, 3, 1844, 27, 7, 11294, 295, 23264, 3541, 62, 7, 918, 34, 115, 28, 3, 98, 1, 26, 414, 3, 158, 1844, 315, 6296, 4, 46, 7, 32, 3, 13767, 6301, 3102, 125, 11, 77, 573, 521, 2, 5079, 26513, 6722, 11, 2264, 4, 62, 140, 262, 18, 244, 711, 1467, 5760, 5, 1110, 2048, 16, 8, 1313, 2589, 9, 715, 117, 5, 82, 70, 12, 54, 5278, 6, 6783, 3705, 343, 23264, 2, 3705, 343, 68, 40, 5797, 50, 1607, 3685, 5307, 3, 1299, 9365, 3, 1680, 371, 1, 711, 5760, 6, 7, 5, 23534, 43708, 5081, 4, 92, 3, 353, 68, 44, 40, 1313]",2050.0,16837027,Fertility-sparing radical abdominal trachelectomy cervical carcinoma technique review literature,0,0.0
The use of adjuvant radiation therapy in early endometrial cancer by members of the Society of Gynecologic Oncologists in 2005.,Gynecologic oncology,Gynecol. Oncol.,2006-12-20,"To determine current patterns of care for early stage endometrial cancer by the members of the Society of Gynecologic Oncologists (SGO). A survey detailing the use of adjuvant radiation in early stage endometrial cancer was conducted. Details of surgery, indications for staging, and use of adjuvant radiation for cases primarily seen by the respondent and for those cases referred postoperatively without staging information were collected and compared to a similar survey from 1999. The practice demographics of the respondents are similar to the 1999 survey. SGO members are now more likely to perform complete surgical staging during all surgeries for endometrial cancer than in 1999 (71% vs. 48%; P<0.0001). A higher percentage of respondents now describe surgery as a complete lymphadenectomy (76% vs. 44%: P<0.0001) and believe this is therapeutic (71% vs. 66%: P=0.04). Approximately half of SGO members now use laparoscopic assisted staging in the primary treatment of endometrial cancer. Since 1999, there is a significant decrease in the recommendation for postoperative RT. In almost all cases where RT is recommended, the use of vaginal RT is now more common than pelvic RT. In all situations, consult recommendations for additional intervention were more likely if complete surgical staging had not been performed, suggesting that all patients with endometrial cancer would benefit from surgery by a gynecologic oncologist. There is an increase in complete surgical staging of endometrial cancer, an increase in the use of laparoscopy, and a marked decrease in the use of pelvic RT since 1999.",Journal Article,4780.0,64.0,determine current patterns care early stage endometrial members Society Gynecologic Oncologists SGO survey detailing use adjuvant radiation early stage endometrial conducted Details surgery indications staging use adjuvant radiation cases primarily seen respondent cases referred postoperatively staging information collected compared similar survey 1999 practice demographics respondents similar 1999 survey SGO members likely perform complete surgical staging surgeries endometrial 1999 71 vs. 48 P 0.0001 higher percentage respondents surgery complete lymphadenectomy 76 vs. 44 P 0.0001 believe therapeutic 71 vs. 66 P=0.04 Approximately half SGO members use laparoscopic assisted staging primary treatment endometrial 1999 significant decrease recommendation postoperative RT cases RT recommended use vaginal RT common pelvic RT situations consult recommendations additional intervention likely complete surgical staging performed suggesting patients endometrial benefit surgery gynecologic oncologist increase complete surgical staging endometrial increase use laparoscopy marked decrease use pelvic RT 1999,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[6, 223, 291, 764, 1, 165, 9, 191, 82, 12, 20, 3, 1684, 1, 3, 1174, 1, 1512, 1339, 12063, 8, 1407, 12765, 3, 119, 1, 249, 121, 4, 191, 82, 12, 10, 426, 3791, 1, 152, 2406, 9, 632, 2, 119, 1, 249, 121, 9, 140, 1561, 527, 20, 3, 15190, 2, 9, 135, 140, 1995, 3541, 187, 632, 487, 11, 786, 2, 72, 6, 8, 288, 1407, 29, 2043, 3, 758, 2221, 1, 3, 3122, 32, 288, 6, 3, 2043, 1407, 12063, 1684, 32, 1134, 80, 322, 6, 2715, 236, 221, 632, 190, 62, 5305, 9, 12, 76, 4, 2043, 792, 105, 576, 19, 13, 488, 8, 142, 1150, 1, 3122, 1134, 897, 152, 22, 8, 236, 2048, 846, 105, 584, 19, 13, 488, 2, 4629, 26, 16, 189, 792, 105, 700, 19, 13, 755, 705, 1303, 1, 12063, 1684, 1134, 119, 1964, 2927, 632, 4, 3, 86, 24, 1, 12, 1192, 2043, 125, 16, 8, 93, 775, 4, 3, 3347, 9, 573, 240, 4, 2214, 62, 140, 1257, 240, 16, 793, 3, 119, 1, 240, 16, 1134, 80, 186, 76, 1110, 240, 4, 62, 5990, 11907, 883, 9, 402, 788, 11, 80, 322, 492, 236, 221, 632, 42, 44, 85, 173, 802, 17, 62, 7, 5, 12, 688, 247, 29, 152, 20, 8, 1512, 2709, 125, 16, 35, 344, 4, 236, 221, 632, 1, 12, 35, 344, 4, 3, 119, 1, 3553, 2, 8, 2003, 775, 4, 3, 119, 1, 1110, 240, 1192, 2043]",1491.0,17187847,use adjuvant radiation therapy early endometrial members Society Gynecologic Oncologists 2005,0,0.0
Supracervical hysterectomy in patients with advanced epithelial ovarian cancer.,Obstetrics and gynecology,Obstet Gynecol,2007-03-01,"To assess whether supracervical hysterectomy (SCH) is a reasonable alternative to total abdominal hysterectomy in patients with advanced ovarian cancer. We reviewed the records of patients with advanced ovarian cancer who underwent a SCH at one institution between 1993 and 2004 and a similar cohort who underwent total abdominal hysterectomy (TAH) at the same institution during the same period. Patients without complete surgical staging done at the institution were excluded. Independent-sample t tests, Fisher exact test, and log rank tests were used for statistical analysis. The study included 47 patients who underwent SCH (mean age, 59.6 years) and 190 who underwent TAH. There were no significant differences between the two groups in age (P=.51), preoperative CA 125 level (P=.55), or receipt of taxane-based and platinum-based chemotherapy (P=.84). Although limited by sample size, there were no significant differences between the two groups in rates of intraoperative complications (4 of 47 in the SCH group, or 8.5%, compared with 7 of 190 in the TAH group, or 3.7%; P=.24), vaginal or cervical recurrence (5 of 47 in the SCH group, or 10.6%, compared with 22 of 190 in the TAH group, or 11.6%; P=1.00), or in progression-free survival (SCH of 1.01 years compared with TAH of 1.19 years; P=.64) or overall survival (SCH of 3.28 years compared with TAH of 3.36 years; P=.12). Supracervical hysterectomy may be a reasonable alternative to TAH in patients with advanced ovarian cancer. II.",Comparative Study,4709.0,7.0,assess supracervical hysterectomy SCH reasonable alternative total abdominal hysterectomy patients advanced ovarian reviewed records patients advanced ovarian underwent SCH institution 1993 2004 similar cohort underwent total abdominal hysterectomy TAH institution period Patients complete surgical staging institution excluded Independent-sample tests Fisher exact test log rank tests statistical included 47 patients underwent SCH mean age 59.6 years 190 underwent TAH significant differences groups age P=.51 preoperative CA 125 level P=.55 receipt taxane-based platinum-based chemotherapy P=.84 limited size significant differences groups rates intraoperative complications 4 47 SCH group 8.5 compared 7 190 TAH group 3.7 P=.24 vaginal cervical recurrence 5 47 SCH group 10.6 compared 22 190 TAH group 11.6 P=1.00 progression-free survival SCH 1.01 years compared TAH 1.19 years P=.64 overall survival SCH 3.28 years compared TAH 3.36 years P=.12 Supracervical hysterectomy reasonable alternative TAH patients advanced ovarian II,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 423, 317, 44642, 2622, 11047, 16, 8, 3203, 1091, 6, 181, 1467, 2622, 4, 7, 5, 131, 12, 21, 446, 3, 1064, 1, 7, 5, 131, 12, 54, 208, 8, 11047, 28, 104, 731, 59, 3343, 2, 1131, 2, 8, 288, 180, 54, 208, 181, 1467, 2622, 16704, 28, 3, 827, 731, 190, 3, 827, 727, 7, 187, 236, 221, 632, 1822, 28, 3, 731, 11, 1800, 306, 1000, 102, 895, 3135, 2472, 412, 2, 1066, 1026, 895, 11, 95, 9, 1050, 65, 3, 45, 159, 662, 7, 54, 208, 11047, 313, 89, 728, 49, 60, 2, 5974, 54, 208, 16704, 125, 11, 77, 93, 362, 59, 3, 100, 271, 4, 89, 19, 725, 498, 1568, 1731, 301, 19, 614, 15, 1699, 1, 1715, 90, 2, 828, 90, 56, 19, 874, 242, 383, 20, 1000, 444, 125, 11, 77, 93, 362, 59, 3, 100, 271, 4, 151, 1, 1720, 521, 39, 1, 662, 4, 3, 11047, 87, 15, 66, 33, 72, 5, 67, 1, 5974, 4, 3, 16704, 87, 15, 27, 67, 19, 259, 15, 146, 33, 1, 662, 4, 3, 11047, 87, 15, 79, 49, 72, 5, 350, 1, 5974, 4, 3, 16704, 87, 15, 175, 49, 19, 14, 2038, 15, 4, 91, 115, 25, 11047, 1, 14, 355, 60, 72, 5, 16704, 1, 14, 326, 60, 19, 660, 15, 63, 25, 11047, 1, 27, 339, 60, 72, 5, 16704, 1, 27, 511, 60, 19, 133, 44642, 2622, 68, 40, 8, 3203, 1091, 6, 16704, 4, 7, 5, 131, 12, 215]",1408.0,17329515,Supracervical hysterectomy patients advanced epithelial ovarian,35,0.17587939698492464
Prognostic factors for outcomes and complications for primary squamous cell carcinoma of the vagina treated with radiation.,Gynecologic oncology,Gynecol. Oncol.,2007-03-23,"To analyze the results of treatment and identify prognostic factors for primary squamous cell carcinoma (SCCA) of the vagina managed with radiotherapy at a single institution. Seventy-eight patients were analyzed in this retrospective series. Mean characteristics: follow-up 89 months; age 65 years (range 33-99); tumor size 3.8 cm (0.3-10); treatment hemoglobin 12.4 g/dl (range 8.7-14.4); and tumor dose 72 Gy (range 6-127). In addition, 49% of our cohort had a prior hysterectomy. The FIGO stage distribution: I (42%); II (29%); III (17%); and IVA/B (11%). Sixty-two percent of patients were treated with a combination of external beam radiation (EBRT) and brachytherapy, 22% with EBRT alone and 13% with brachytherapy alone. Kaplan-Meier (KM) 5-year pelvic control, distant metastasis free survival and disease specific survival probabilities: stage I, 83%, 100%, and 92%; stage II, 76%, 95%, and 68%; stage III, 62%, 65%, and 44%; and stage IV, 30%, 18%, and 13%. On multivariate analysis: stage; treatment hemoglobin; and prior hysterectomy were prognostic for DSS (p<0.05). The KM 5-year grade 3/4 (G3/4) complication free estimate of our cohort was 84%. G3/4 complications: tumor size and tumor dose were independently predictive (p<0.05). Radiotherapy as a single modality for early stage primary vaginal SCCA produces good results. Advanced stage disease necessitates a combined modality approach and/or new methods. Treatment Hg levels appear to be clinically significant and studies on correction of anemia during treatment are warranted.",Journal Article,4687.0,41.0,treatment identify prognostic factors primary squamous carcinoma SCCA vagina managed radiotherapy single institution Seventy-eight patients retrospective series Mean characteristics follow-up 89 months age 65 years range 33-99 size 3.8 cm 0.3-10 treatment hemoglobin 12.4 g/dl range 8.7-14.4 dose 72 Gy range 6-127 addition 49 cohort prior hysterectomy FIGO stage distribution 42 II 29 III 17 IVA/B 11 Sixty-two percent patients treated combination external beam radiation EBRT brachytherapy 22 EBRT 13 brachytherapy Kaplan-Meier 5-year pelvic control distant metastasis free survival disease specific survival probabilities stage 83 100 92 stage II 76 95 68 stage III 62 65 44 stage IV 30 18 13 multivariate stage treatment hemoglobin prior hysterectomy prognostic DSS p 0.05 5-year grade 3/4 G3/4 complication free estimate cohort 84 G3/4 complications size dose independently predictive p 0.05 Radiotherapy single modality early stage primary vaginal SCCA produces good Advanced stage disease necessitates combined modality approach and/or new methods Treatment Hg levels appear clinically significant studies correction anemia treatment warranted,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 1992, 3, 99, 1, 24, 2, 255, 177, 130, 9, 86, 691, 31, 134, 6372, 1, 3, 7553, 2231, 5, 310, 28, 8, 226, 731, 2073, 659, 7, 11, 311, 4, 26, 459, 988, 313, 374, 166, 126, 887, 53, 89, 556, 60, 184, 466, 1058, 30, 444, 27, 66, 494, 13, 27, 79, 24, 2222, 133, 39, 499, 1826, 184, 66, 67, 213, 39, 2, 30, 61, 720, 381, 184, 49, 4080, 4, 352, 739, 1, 114, 180, 42, 8, 324, 2622, 3, 3837, 82, 1395, 70, 595, 215, 462, 316, 269, 2, 5900, 132, 175, 1746, 100, 714, 1, 7, 11, 73, 5, 8, 150, 1, 1455, 1345, 121, 1883, 2, 1536, 350, 5, 1883, 279, 2, 233, 5, 1536, 279, 876, 882, 12524, 33, 111, 1110, 182, 626, 278, 115, 25, 2, 34, 112, 25, 3518, 82, 70, 852, 394, 2, 937, 82, 215, 846, 48, 2, 806, 82, 316, 744, 556, 2, 584, 2, 82, 478, 201, 203, 2, 233, 23, 331, 65, 82, 24, 2222, 2, 324, 2622, 11, 177, 9, 1788, 19, 13, 474, 3, 12524, 33, 111, 88, 27, 39, 5578, 39, 1447, 115, 1191, 1, 114, 180, 10, 874, 5578, 39, 521, 30, 444, 2, 30, 61, 11, 1042, 464, 19, 13, 474, 310, 22, 8, 226, 1396, 9, 191, 82, 86, 6372, 4042, 1178, 99, 131, 82, 34, 12065, 8, 397, 1396, 353, 2, 15, 217, 636, 24, 4876, 148, 1322, 6, 40, 505, 93, 2, 94, 23, 5360, 1, 1545, 190, 24, 32, 1197]",1449.0,17363046,Prognostic factors outcomes complications primary squamous carcinoma vagina treated radiation,135,0.678391959798995
Aromatase inhibitor-associated arthralgia syndrome.,"Breast (Edinburgh, Scotland)",Breast,2007-03-21,"Aromatase inhibitors (AIs) are widely used as an adjuvant endocrine treatment in postmenopausal women with early-stage breast cancer. Clinical trials have assessed 5 years of AI therapy, either as an alternative to tamoxifen for primary adjuvant therapy of breast cancer, or after 5 years of adjuvant tamoxifen. Treatment of 2-3 years' duration after 2-3 years of tamoxifen has also been studied. AI therapy brings side effects related to estrogen deprivation, and this side effect profile differs in clinically relevant ways from that seen with tamoxifen. In particular, the selective estrogen receptor modulatory effects of tamoxifen contribute to menopausal symptoms, vaginal discharge, and the rare but worrisome risks of thromboembolism and uterine carcinoma. By contrast, the low levels of estrogen achieved with aromatase inhibition contribute to menopausal symptoms, vaginal dryness and sexual dysfunction, and accelerated bone demineralization with risk of osteoporosis and osteoporotic fracture. Clinical experience also suggests that AI therapy is associated with a novel musculoskeletal side effect consisting of an arthralgia syndrome. The actual incidence of AI-associated arthralgias or musculoskeletal symptoms is not known, though such symptoms are quite prevalent and appear more commonly with AI use than with tamoxifen. Arthralgias can be a reason for discontinuation of AI treatment. The possible mechanisms of AI-associated arthralgia are unclear. Estrogen deficiency causes bone loss, which in turn contributes to arthralgia. Less well-studied functions of estrogen include regulating immune cells and cytokines involved in bone remodeling, and modulating pain sensitivity at the level of the central nervous system. Arthralgia and arthritis have seldom been rigorously differentiated in clinical trials of AIs. Assessment of inflammatory and rheumatologic markers, as well as detailed evaluation of patient symptoms using appropriate quality-of-life instruments, may be warranted in order to understand both the symptoms and the etiology of the arthralgia syndrome. Treatment options for arthralgia (primarily non-steroidal anti-inflammatory drugs) are currently inadequate, but areas of active research include high-dose vitamin D and new-targeted therapies to inhibit bone loss.",Journal Article,4689.0,114.0,Aromatase inhibitors AIs widely adjuvant endocrine treatment postmenopausal women early-stage breast Clinical trials assessed 5 years AI therapy alternative tamoxifen primary adjuvant therapy breast 5 years adjuvant tamoxifen Treatment 2-3 years duration 2-3 years tamoxifen studied AI therapy brings effects related estrogen deprivation effect profile differs clinically relevant ways seen tamoxifen particular selective estrogen receptor modulatory effects tamoxifen contribute menopausal symptoms vaginal discharge rare worrisome risks thromboembolism uterine carcinoma contrast low levels estrogen achieved aromatase inhibition contribute menopausal symptoms vaginal dryness sexual dysfunction accelerated bone demineralization risk osteoporosis osteoporotic fracture Clinical experience suggests AI therapy associated novel musculoskeletal effect consisting arthralgia syndrome actual incidence AI-associated arthralgias musculoskeletal symptoms known symptoms prevalent appear commonly AI use tamoxifen Arthralgias reason discontinuation AI treatment possible mechanisms AI-associated arthralgia unclear Estrogen deficiency causes bone loss turn contributes arthralgia well-studied functions estrogen include regulating immune cytokines involved bone remodeling modulating pain sensitivity level central nervous Arthralgia arthritis seldom rigorously differentiated clinical trials AIs Assessment inflammatory rheumatologic markers detailed evaluation patient symptoms appropriate quality-of-life instruments warranted order understand symptoms etiology arthralgia syndrome Treatment options arthralgia primarily non-steroidal anti-inflammatory drugs currently inadequate areas active research include high-dose vitamin new-targeted therapies inhibit bone loss,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[2106, 222, 3826, 32, 1792, 95, 22, 35, 249, 1293, 24, 4, 1679, 117, 5, 191, 82, 12, 38, 143, 47, 275, 33, 60, 1, 2247, 36, 361, 22, 35, 1091, 6, 1105, 9, 86, 249, 36, 1, 12, 15, 50, 33, 60, 1, 249, 1105, 24, 1, 18, 27, 60, 654, 50, 18, 27, 60, 1, 1105, 71, 120, 85, 656, 2247, 36, 15249, 1152, 176, 139, 6, 808, 1868, 2, 26, 1152, 254, 800, 4990, 4, 505, 867, 4245, 29, 17, 527, 5, 1105, 4, 1454, 3, 1094, 808, 153, 11424, 176, 1, 1105, 1248, 6, 3565, 507, 2993, 2, 3, 622, 84, 13155, 1098, 1, 3501, 2, 134, 20, 748, 3, 154, 148, 1, 808, 513, 5, 2106, 297, 1248, 6, 3565, 507, 15822, 2, 2232, 1527, 2, 2241, 43086, 5, 43, 1, 4970, 2, 17303, 3956, 38, 730, 120, 844, 17, 2247, 36, 16, 41, 5, 8, 229, 5701, 1152, 254, 2273, 1, 35, 8451, 681, 3, 3480, 287, 1, 2247, 41, 13632, 15, 5701, 507, 16, 44, 440, 2471, 225, 507, 32, 6223, 2485, 2, 1322, 80, 841, 5, 2247, 119, 76, 5, 1105, 13632, 122, 40, 8, 3852, 9, 2007, 1, 2247, 24, 3, 899, 483, 1, 2247, 41, 8451, 32, 1200, 808, 2299, 1626, 407, 92, 4, 3854, 2444, 6, 8451, 299, 149, 656, 1681, 1, 808, 643, 2681, 250, 37, 2, 1886, 646, 4, 4429, 2, 3712, 559, 485, 28, 3, 301, 1, 3, 854, 1880, 398, 8451, 2, 8646, 47, 10805, 85, 10347, 1442, 4, 38, 143, 1, 3826, 455, 1, 1291, 2, 21444, 525, 22, 149, 22, 2455, 451, 1, 69, 507, 75, 870, 372, 1, 358, 4730, 68, 40, 1197, 4, 1732, 6, 1640, 110, 3, 507, 2, 3, 2855, 1, 3, 8451, 681, 24, 838, 9, 8451, 1561, 220, 7745, 312, 1291, 600, 32, 694, 3358, 84, 1361, 1, 544, 389, 643, 64, 61, 1610, 427, 2, 217, 238, 235, 6, 1433, 407]",2211.0,17368903,Aromatase inhibitor-associated arthralgia syndrome,0,0.0
Primary spindle cell sarcoma of the vagina treated with neoadjuvant radiation and pelvic exenteration.,Journal of lower genital tract disease,J Low Genit Tract Dis,2007-04-01,"Malignant neoplasms of the vagina are rare gynecologic tumors. Primary vaginal sarcomas are even more unusual lesions, representing fewer than 2% of malignant vaginal lesions. We present a case of a primary vaginal spindle cell sarcoma, treated with neoadjuvant radiation followed by total pelvic exenteration. The patient remains without evidence of disease 2 years after surgery. The mainstay of treatment of vaginal sarcomas is surgical. Neoadjuvant radiation treatment may decrease surgical morbidity and lead to long-term cure.",Case Reports,4678.0,3.0,Malignant neoplasms vagina rare gynecologic Primary vaginal sarcomas unusual lesions representing fewer 2 malignant vaginal lesions present case primary vaginal spindle sarcoma treated neoadjuvant radiation followed total pelvic exenteration patient remains evidence disease 2 years surgery mainstay treatment vaginal sarcomas surgical Neoadjuvant radiation treatment decrease surgical morbidity lead long-term cure,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,"[393, 1179, 1, 3, 7553, 32, 622, 1512, 57, 86, 1479, 32, 871, 80, 4015, 406, 2861, 1497, 76, 18, 1, 393, 406, 21, 364, 8, 473, 1, 8, 86, 4052, 31, 73, 5, 536, 121, 370, 20, 181, 1110, 5668, 3, 69, 469, 187, 241, 1, 34, 18, 60, 50, 152, 3, 4041, 1, 24, 1, 1479, 16, 221, 536, 121, 24, 68, 775, 221, 787, 2, 1122, 6, 319, 337, 1722]",483.0,17415115,Primary spindle sarcoma vagina treated neoadjuvant radiation pelvic exenteration,0,0.0
A prospective study of the accuracy of 18Fluorodeoxyglucose positron emission tomography (18FDG PET) in identifying sites of metastasis prior to pelvic exenteration.,Gynecologic oncology,Gynecol. Oncol.,2007-05-02,"To determine the accuracy of (18)FDG PET in identifying sites of metastatic disease prior to pelvic exenteration or radical resection in patients (pts) with recurrent cervical or vaginal cancers. Pts with recurrent cervical or vaginal cancer being evaluated for surgical resection were enrolled in a prospective study approved by the institutional human subjects review board. All patients underwent (18)FDG PET scans as well as CT and/or MRI scans and were required to have pathologic confirmation of any sites suggestive of tumor recurrence. Between 1998 and 2002 a total of 27 pts were enrolled on the study. Seven patients did not complete all study requirements and are excluded from further analysis. All pts had undergone prior pelvic radiation therapy and five patients had also received chemotherapy. CT/MRI scans identified three patients with possible metastatic disease in the following sites: (1) iliac nodes (2 pts) and (2) lungs (1 pt). After surgical and pathological evaluation, only one of these sites, the lungs, was confirmed to have metastatic disease. PET scans identified possible metastatic disease in nine patients and included the following sites: (1) pelvic nodes (4 pts), (2) para-aortic nodes (2 pts), (3) axillary node (1 pt), (4) bowel wall (1 pt) and (5) lungs (1 pt). After surgical and pathologic evaluation metastatic disease was identified in five of these pts at the following sites: iliac nodes, 2; para-aortic nodes, 1; bowel wall, 1; and lungs, 1. Of the sites identified by PET scan as areas of metastasis CT scan only identified the pulmonary metastasis. (18)FDG PET was found to have a sensitivity of 100% and a specificity of 73% in detecting sites of extra-pelvic metastasis and may be the most accurate test to determine eligibility for pelvic exenteration.",Journal Article,4647.0,60.0,determine accuracy 18 FDG PET identifying sites metastatic disease prior pelvic exenteration radical resection patients pts recurrent cervical vaginal Pts recurrent cervical vaginal evaluated surgical resection enrolled prospective approved institutional human subjects review board patients underwent 18 FDG PET scans CT and/or MRI scans required pathologic confirmation sites suggestive recurrence 1998 2002 total 27 pts enrolled Seven patients complete requirements excluded pts undergone prior pelvic radiation therapy patients received chemotherapy CT/MRI scans identified patients possible metastatic disease following sites 1 iliac nodes 2 pts 2 lungs 1 pt surgical pathological evaluation sites lungs confirmed metastatic disease PET scans identified possible metastatic disease patients included following sites 1 pelvic nodes 4 pts 2 para-aortic nodes 2 pts 3 axillary node 1 pt 4 bowel wall 1 pt 5 lungs 1 pt surgical pathologic evaluation metastatic disease identified pts following sites iliac nodes 2 para-aortic nodes 1 bowel wall 1 lungs 1 sites identified PET scan areas metastasis CT scan identified pulmonary metastasis 18 FDG PET sensitivity 100 specificity 73 detecting sites extra-pelvic metastasis accurate test determine eligibility pelvic exenteration,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 3, 1190, 1, 203, 1285, 495, 4, 1386, 633, 1, 113, 34, 324, 6, 1110, 5668, 15, 711, 170, 4, 7, 3637, 5, 387, 15, 163, 3637, 5, 387, 15, 12, 486, 194, 9, 221, 170, 11, 346, 4, 8, 482, 45, 850, 20, 3, 1115, 171, 976, 206, 2620, 62, 7, 208, 203, 1285, 495, 1441, 22, 149, 22, 425, 2, 15, 704, 1441, 2, 11, 616, 6, 47, 510, 3551, 1, 500, 633, 3832, 1, 30, 146, 59, 1850, 2, 1544, 8, 181, 1, 428, 3637, 11, 346, 23, 3, 45, 648, 7, 205, 44, 236, 62, 45, 4230, 2, 32, 1800, 29, 195, 65, 62, 3637, 42, 1989, 324, 1110, 121, 36, 2, 365, 7, 42, 120, 103, 56, 425, 704, 1441, 108, 169, 7, 5, 899, 113, 34, 4, 3, 366, 633, 14, 6692, 502, 18, 3637, 2, 18, 4465, 14, 3395, 50, 221, 2, 1301, 451, 158, 104, 1, 46, 633, 3, 4465, 10, 557, 6, 47, 113, 34, 495, 1441, 108, 899, 113, 34, 4, 762, 7, 2, 159, 3, 366, 633, 14, 1110, 502, 39, 3637, 18, 4615, 3938, 502, 18, 3637, 27, 1210, 289, 14, 3395, 39, 1659, 2397, 14, 3395, 2, 33, 4465, 14, 3395, 50, 221, 2, 510, 451, 113, 34, 10, 108, 4, 365, 1, 46, 3637, 28, 3, 366, 633, 6692, 502, 18, 4615, 3938, 502, 14, 1659, 2397, 14, 2, 4465, 14, 1, 3, 633, 108, 20, 495, 1657, 22, 1361, 1, 278, 425, 1657, 158, 108, 3, 1087, 278, 203, 1285, 495, 10, 204, 6, 47, 8, 485, 1, 394, 2, 8, 1121, 1, 803, 4, 2502, 633, 1, 3420, 1110, 278, 2, 68, 40, 3, 96, 1481, 412, 6, 223, 2317, 9, 1110, 5668]",1706.0,17477959,prospective accuracy 18Fluorodeoxyglucose positron emission tomography 18FDG PET identifying sites metastasis prior pelvic exenteration,0,0.0
Safety of aromatase inhibitors in the adjuvant setting.,Breast cancer research and treatment,Breast Cancer Res. Treat.,2007-10-03,"The third-generation aromatase inhibitors (AIs) letrozole, anastrozole, and exemestane are replacing tamoxifen as adjuvant therapy in most postmenopausal women with early breast cancer. Although AIs have demonstrated superior efficacy and better overall safety compared with tamoxifen in randomized controlled trials, they may not provide the cardioprotective effects of tamoxifen, and bone loss may be a concern with their long-term adjuvant use. Patients require regular bone mineral density monitoring, and prophylactic bisphosphonates are being evaluated to determine whether they may protect long-term bone health. AIs decrease the risks of thromboembolic and cerebrovascular events compared with tamoxifen, and the overall rate of cardiovascular events in patients treated with AIs is within the range seen in age-matched, non-breast-cancer populations. AIs are also associated with a lower incidence of endometrial cancer and fewer vaginal bleeding/discharge events than tamoxifen. Compared with tamoxifen, the incidence of hot flashes is lower with anastrozole and letrozole but may be higher with exemestane. Generally, adverse events with AIs are predictable and manageable, whereas tamoxifen may be associated with life-threatening events in a minority of patients. Overall, the benefits of AIs over tamoxifen are achieved without compromising overall quality of life.",Comparative Study,4493.0,18.0,third-generation aromatase inhibitors AIs letrozole anastrozole exemestane replacing tamoxifen adjuvant therapy postmenopausal women early breast AIs demonstrated superior efficacy better overall safety compared tamoxifen randomized controlled trials provide cardioprotective effects tamoxifen bone loss concern long-term adjuvant use Patients require regular bone mineral density monitoring prophylactic bisphosphonates evaluated determine protect long-term bone health AIs decrease risks thromboembolic cerebrovascular events compared tamoxifen overall rate cardiovascular events patients treated AIs range seen age-matched non-breast-cancer populations AIs associated lower incidence endometrial fewer vaginal bleeding/discharge events tamoxifen Compared tamoxifen incidence hot flashes lower anastrozole letrozole higher exemestane Generally adverse events AIs predictable manageable tamoxifen associated life-threatening events minority patients Overall benefits AIs tamoxifen achieved compromising overall quality life,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[3, 1282, 914, 2106, 222, 3826, 2800, 3571, 2, 3199, 32, 9574, 1105, 22, 249, 36, 4, 96, 1679, 117, 5, 191, 12, 242, 3826, 47, 264, 1123, 209, 2, 380, 63, 367, 72, 5, 1105, 4, 384, 1149, 143, 491, 68, 44, 377, 3, 17618, 176, 1, 1105, 2, 407, 68, 40, 8, 2893, 5, 136, 319, 337, 249, 119, 7, 1353, 3316, 5033, 1263, 1315, 2, 1862, 4354, 32, 486, 194, 6, 223, 317, 491, 68, 4869, 319, 337, 341, 3826, 775, 3, 1098, 1, 4703, 2, 9261, 281, 72, 5, 1105, 2, 3, 63, 116, 1, 2179, 281, 4, 7, 73, 5, 3826, 16, 262, 3, 184, 527, 4, 89, 655, 220, 1678, 12, 1184, 3826, 32, 120, 41, 5, 8, 280, 287, 1, 12, 2, 1497, 2294, 2993, 281, 76, 1105, 72, 5, 1105, 3, 287, 1, 2859, 4193, 16, 280, 5, 3571, 2, 2800, 84, 68, 40, 142, 5, 3199, 1228, 290, 281, 5, 3826, 32, 7639, 2, 2808, 547, 1105, 68, 40, 41, 5, 358, 3691, 281, 4, 8, 2652, 1, 7, 63, 3, 1141, 1, 3826, 252, 1105, 32, 513, 187, 6102, 63, 372, 1, 358]",1316.0,17912638,Safety aromatase inhibitors adjuvant setting,2,0.010050251256281407
A cost-effective analysis of adjuvant therapies for the treatment of stage I endometrial adenocarcinoma.,Gynecologic oncology,Gynecol. Oncol.,2007-10-22,"Recent surveys have indicated that four alternatives are employed for adjuvant treatment of stage I endometrial adenocarcinoma: observation (OBS), high dose rate vaginal brachytherapy (VB), whole pelvic external beam radiotherapy (EBRT), or a combination of pelvic external beam with vaginal brachytherapy (COMB). Our goal was to evaluate the cost-effectiveness of these alternatives for management of stage I endometrial adenocarcinoma. We designed a decision analysis model comparing the four possible treatments in terms of their utility and cost. We reviewed the existing literature and utilized published data to estimate complication and recurrence rates from each treatment option. We obtained cost data from a chart review of patients treated with each approach at a single institution between 1995 and 2005. OBS yielded the lowest expected cost, $437 million per 100,000 women. COMB yielded the highest cost, at $2.93 billion per 100,000 women. VB yielded the highest 5-year quality adjusted survival, 86%. In a population of 100,000 women, VB would result in an additional 8200 quality adjusted survivors compared to OBS, at a cost of $65,900 per survivor. In contrast, EBRT and COMB result in either fewer survivors and/or greater costs when compared to OBS or VB. Routine use of adjuvant EBRT or COMB in the management of surgical stage I endometrial adenocarcinoma is not cost-effective. Compared to OBS, post-operative VB improves survival at a cost of $65,900 per survivor, supporting further investigation of this adjuvant therapy.",Journal Article,4474.0,21.0,"Recent surveys indicated alternatives employed adjuvant treatment stage endometrial adenocarcinoma observation OBS high dose rate vaginal brachytherapy VB pelvic external beam radiotherapy EBRT combination pelvic external beam vaginal brachytherapy COMB goal evaluate cost-effectiveness alternatives management stage endometrial adenocarcinoma designed decision model comparing possible treatments terms utility cost reviewed existing literature utilized published estimate complication recurrence rates treatment option obtained cost chart review patients treated approach single institution 1995 2005 OBS yielded lowest expected cost 437 million 100,000 women COMB yielded highest cost 2.93 billion 100,000 women VB yielded highest 5-year quality adjusted survival 86 population 100,000 women VB additional 8200 quality adjusted survivors compared OBS cost 65,900 survivor contrast EBRT COMB fewer survivors and/or greater costs compared OBS VB Routine use adjuvant EBRT COMB management surgical stage endometrial adenocarcinoma cost-effective Compared OBS post-operative VB improves survival cost 65,900 survivor supporting investigation adjuvant therapy",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[435, 3666, 47, 1103, 17, 294, 6295, 32, 2516, 9, 249, 24, 1, 82, 70, 449, 1664, 10291, 64, 61, 116, 1536, 9464, 902, 1110, 1455, 1345, 310, 1883, 15, 8, 150, 1, 1110, 1455, 1345, 5, 1536, 22179, 114, 1326, 10, 6, 376, 3, 835, 1236, 1, 46, 6295, 9, 284, 1, 82, 70, 449, 21, 1114, 8, 948, 65, 202, 1430, 3, 294, 899, 640, 4, 1794, 1, 136, 1207, 2, 835, 21, 446, 3, 1692, 789, 2, 2080, 983, 74, 6, 1191, 1447, 2, 146, 151, 29, 296, 24, 1501, 21, 683, 835, 74, 29, 8, 2937, 206, 1, 7, 73, 5, 296, 353, 28, 8, 226, 731, 59, 2323, 2, 1242, 10291, 2178, 3, 2101, 1336, 835, 12592, 3346, 379, 394, 984, 117, 22179, 2178, 3, 1076, 835, 28, 18, 966, 10243, 379, 394, 984, 117, 9464, 2178, 3, 1076, 33, 111, 372, 586, 25, 868, 4, 8, 266, 1, 394, 984, 117, 9464, 688, 757, 4, 35, 402, 44904, 372, 586, 332, 72, 6, 10291, 28, 8, 835, 1, 556, 5310, 379, 2628, 4, 748, 1883, 2, 22179, 757, 4, 361, 1497, 332, 2, 15, 378, 1201, 198, 72, 6, 10291, 15, 9464, 1311, 119, 1, 249, 1883, 15, 22179, 4, 3, 284, 1, 221, 82, 70, 449, 16, 44, 835, 323, 72, 6, 10291, 539, 1208, 9464, 1804, 25, 28, 8, 835, 1, 556, 5310, 379, 2628, 1912, 195, 940, 1, 26, 249, 36]",1458.0,17936341,cost-effective adjuvant therapies treatment stage endometrial adenocarcinoma,0,0.0
Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates.,Gynecologic oncology,Gynecol. Oncol.,2007-11-07,"Intraperitoneal (i.p.) chemotherapy has a clear survival advantage in patients with advanced ovarian cancer, but the high rate of complications has discouraged widespread acceptance. The purpose of this study was to review the completion rate of patients receiving i.p. chemotherapy as first line treatment at a single institution and determine what factors prohibit completion of therapy. Patients receiving i.p. chemotherapy from 1993 to 2006 were identified by hospital registries for a retrospective review. Charts were abstracted for patient demographics, clinical and pathologic findings, surgical intervention, treatment modalities, and toxicity. Eighty-three patients were identified who received front line treatment with i.p. chemotherapy. All patients received a platinum and taxane agent. Port placement (single lumen, venous access device) was completed at time of cytoreductive surgery (33%, n=27) or by mini-laparotomy (67%, n=56). Fifty patients (60%) completed a minimum of 6 cycles of treatment with a mean of 5 cycles. Eleven patients (13%) discontinued treatment due to catheter-related complications including infection (n=4), access difficulties (n=3), grade 4 abdominal pain (n=1), port leaking (n=1), and development of a peritoneal-vaginal fistula (n=1). Sixteen patients (19%) did not complete i.p. treatment because of chemotherapy-related toxicity. The remaining six patients did not complete chemotherapy due to disease progression or other reasons unrelated to modality of treatment. Few catheter-related complications were encountered in a review of front-line i.p. chemotherapy administration at a single institution using a single lumen venous access device. The majority of failures were due to persistent grade 3-4 chemotherapy toxicity. i.p. chemotherapy can be safely administered by a dedicated health-care team committed to i.p. chemotherapy as a front-line treatment.",Journal Article,4458.0,38.0,Intraperitoneal i.p chemotherapy clear survival advantage patients advanced ovarian high rate complications discouraged widespread acceptance purpose review completion rate patients receiving i.p chemotherapy line treatment single institution determine factors prohibit completion therapy Patients receiving i.p chemotherapy 1993 2006 identified hospital registries retrospective review Charts abstracted patient demographics clinical pathologic findings surgical intervention treatment modalities toxicity Eighty-three patients identified received line treatment i.p chemotherapy patients received platinum taxane agent Port placement single lumen venous access device completed time cytoreductive surgery 33 n=27 mini-laparotomy 67 n=56 patients 60 completed minimum 6 cycles treatment mean 5 cycles patients 13 discontinued treatment catheter-related complications including infection n=4 access difficulties n=3 grade 4 abdominal pain n=1 port leaking n=1 development peritoneal-vaginal fistula n=1 Sixteen patients 19 complete i.p treatment chemotherapy-related toxicity remaining patients complete chemotherapy disease progression reasons unrelated modality treatment catheter-related complications encountered review front-line i.p chemotherapy administration single institution single lumen venous access device majority failures persistent grade 3-4 chemotherapy toxicity i.p chemotherapy safely administered dedicated health-care team committed i.p chemotherapy front-line treatment,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3339, 70, 19, 56, 71, 8, 885, 25, 1874, 4, 7, 5, 131, 12, 84, 3, 64, 116, 1, 521, 71, 17899, 3029, 5080, 3, 743, 1, 26, 45, 10, 6, 206, 3, 1438, 116, 1, 7, 357, 70, 19, 56, 22, 157, 328, 24, 28, 8, 226, 731, 2, 223, 2067, 130, 26643, 1438, 1, 36, 7, 357, 70, 19, 56, 29, 3343, 6, 1324, 11, 108, 20, 702, 3768, 9, 8, 459, 206, 4413, 11, 4106, 9, 69, 2221, 38, 2, 510, 272, 221, 788, 24, 1558, 2, 155, 2207, 169, 7, 11, 108, 54, 103, 3007, 328, 24, 5, 70, 19, 56, 62, 7, 103, 8, 828, 2, 1715, 420, 3083, 2613, 226, 10064, 2167, 1655, 4472, 10, 781, 28, 98, 1, 2604, 152, 466, 78, 428, 15, 20, 7313, 3274, 598, 78, 664, 1461, 7, 335, 781, 8, 2499, 1, 49, 410, 1, 24, 5, 8, 313, 1, 33, 410, 2627, 7, 233, 2402, 24, 520, 6, 3925, 139, 521, 141, 930, 78, 39, 1655, 4679, 78, 27, 88, 39, 1467, 559, 78, 14, 3083, 28732, 78, 14, 2, 193, 1, 8, 1639, 18982, 4920, 78, 14, 3228, 7, 326, 205, 44, 236, 70, 19, 24, 408, 1, 56, 139, 155, 3, 1844, 437, 7, 205, 44, 236, 56, 520, 6, 34, 91, 15, 127, 2325, 2092, 6, 1396, 1, 24, 1021, 3925, 139, 521, 11, 3903, 4, 8, 206, 1, 3007, 328, 70, 19, 56, 634, 28, 8, 226, 731, 75, 8, 226, 10064, 2167, 1655, 4472, 3, 686, 1, 3368, 11, 520, 6, 1882, 88, 27, 39, 56, 155, 70, 19, 56, 122, 40, 2268, 468, 20, 8, 4827, 341, 165, 2870, 9552, 6, 70, 19, 56, 22, 8, 3007, 328, 24]",1836.0,17988721,Intraperitoneal chemotherapy patients advanced epithelial ovarian review complications completion rates,48,0.24120603015075376
Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer.,Cancer,Cancer,2008-02-01,"Five years of adjuvant therapy with tamoxifen was considered the gold-standard treatment for postmenopausal women with estrogen receptor-positive breast cancer for many years. Data from a core group of clinical trials investigating the safety and efficacy of aromatase inhibitors (AIs) have challenged this perception. These studies were designed to evaluate the safety and efficacy of AIs in the following clinical settings: 1) as initial adjuvant therapy (the Arimidex, Tamoxifen, Alone or in Combination trial, Breast International Group Trial 1-98), 2) in a ""switched setting"" after 2 to 3 years of treatment with tamoxifen (Arimidex-Nolvadex 95, the Austrian Breast and Colorectal Cancer Study Group 8 [ABCSG 8] trial, the Italian Tamoxifen Anastrozole study, the Intergroup Exemestane Study), and 3) in extended settings (National Cancer Institute of Canada Trial MA.17, ABCSG 6a, National Surgical Adjuvant Breast and Bowel Project 33). The efficacy data from these studies suggested that AIs have added substantial benefit in terms of disease outcome. AIs were tolerated well, and patients who received them experienced fewer thrombolic events and less endometrial cancer, hot flashes, night sweats, and vaginal bleeding compared with patients who receive tamoxifen. However, patients who received tamoxifen had less skeletal events and accelerated bone resorption compared with women who received AIs. AIs should be considered when planning a patient's endocrine therapy, taking into account the differences in tolerability and end-organ effects of the classes of endocrine therapy. Outstanding issues to optimize AI therapy include identifying the optimal duration, agent, and patients for these therapies.",Journal Article,4372.0,40.0,years adjuvant therapy tamoxifen considered gold-standard treatment postmenopausal women estrogen receptor-positive breast years core group clinical trials investigating safety efficacy aromatase inhibitors AIs challenged perception studies designed evaluate safety efficacy AIs following clinical settings 1 initial adjuvant therapy Arimidex Tamoxifen Combination trial Breast International Group Trial 1-98 2 `` switched setting '' 2 3 years treatment tamoxifen Arimidex-Nolvadex 95 Austrian Breast Colorectal Group 8 ABCSG 8 trial Italian Tamoxifen Anastrozole Intergroup Exemestane 3 extended settings National Institute Canada Trial MA.17 ABCSG 6a National Surgical Adjuvant Breast Bowel Project 33 efficacy studies suggested AIs added substantial benefit terms disease outcome AIs tolerated patients received experienced fewer thrombolic events endometrial hot flashes night sweats vaginal bleeding compared patients receive tamoxifen patients received tamoxifen skeletal events accelerated bone resorption compared women received AIs AIs considered planning patient 's endocrine therapy taking account differences tolerability end-organ effects classes endocrine therapy Outstanding issues optimize AI therapy include identifying optimal duration agent patients therapies,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[365, 60, 1, 249, 36, 5, 1105, 10, 515, 3, 4159, 260, 24, 9, 1679, 117, 5, 808, 153, 109, 12, 9, 445, 60, 74, 29, 8, 1793, 87, 1, 38, 143, 3103, 3, 367, 2, 209, 1, 2106, 222, 3826, 47, 6389, 26, 4886, 46, 94, 11, 1114, 6, 376, 3, 367, 2, 209, 1, 3826, 4, 3, 366, 38, 1947, 14, 22, 388, 249, 36, 3, 17131, 1105, 279, 15, 4, 150, 160, 944, 87, 160, 14, 1096, 18, 4, 8, 7883, 546, 522, 50, 18, 6, 27, 60, 1, 24, 5, 1105, 17131, 43328, 48, 3, 22455, 2, 12, 45, 87, 66, 34390, 66, 160, 3, 10215, 1105, 3571, 45, 3, 4839, 3199, 45, 2, 27, 4, 1747, 1947, 657, 12, 1377, 1, 4740, 160, 3687, 269, 34390, 9193, 657, 221, 249, 2, 1659, 3105, 466, 3, 209, 74, 29, 46, 94, 1148, 17, 3826, 47, 1953, 1281, 247, 4, 1794, 1, 34, 228, 3826, 11, 421, 149, 2, 7, 54, 103, 1370, 592, 1497, 56748, 281, 2, 299, 12, 2859, 4193, 8955, 13298, 2, 2294, 72, 5, 7, 54, 560, 1105, 137, 7, 54, 103, 1105, 42, 299, 2621, 281, 2, 2241, 8143, 72, 5, 117, 54, 103, 3826, 3826, 257, 40, 515, 198, 1349, 8, 69, 292, 1293, 36, 2727, 237, 1967, 3, 362, 4, 1543, 2, 396, 1259, 176, 1, 3, 3211, 1, 1293, 36, 14565, 1553, 6, 2465, 2247, 36, 643, 1386, 3, 665, 654, 420, 2, 7, 9, 46, 235]",1617.0,18072256,Summary aromatase inhibitor clinical trials postmenopausal women early breast,4,0.020100502512562814
Cytologic findings after fertility-sparing radical trachelectomy.,Cancer,Cancer,2008-02-01,"Radical trachelectomy is a surgical procedure intended to preserve fertility in patients with early-stage cervical carcinoma in which the cervix is amputated in continuity with the parametrium and upper vagina, thereby sparing the uterus and adnexa. Follow-up is performed with periodic cytology specimens. The objective of the current study was to analyze the cytologic findings after this novel procedure. Isthmic and vaginal Papanicolaou-stained ThinPrep cytology specimens taken from patients after radical vaginal and abdominal trachelectomy were reviewed. The specimens were also analyzed for the presence of benign endocervical cells, lower uterine segment glandular cells, endometrial stromal cells, and endometrial cells. The findings were correlated with the original diagnosis and follow-up, which included subsequent cytology specimens and biopsies. Cytology specimens (n = 223) from 44 patients were included in this study. An endometrial component was identified in 131 of the cases (59%). Twenty-eight cases were diagnosed as abnormal in the original cytology examination. Twenty of these cases and 5 additional cases that were diagnosed cytologically as benign had subsequent biopsies. The biopsies confirmed the presence of a lesion in only 4 of 25 biopsies (3 low-grade squamous intraepithelial lesions and 1 adenosquamous carcinoma). All cases diagnosed as atypical glandular cells represented tubal metaplasia, lower uterine segment glandular cells, or endometrial stromal cells. Cytology specimens after trachelectomy frequently contain glandular cells from the lower uterine segment epithelium or endometrial stromal cells, which can lead to a misdiagnosis of atypical glandular cells of undetermined significance. Tubal metaplasia is also a potential pitfall in these specimens. Pathologists and gynecologic oncologists should be aware of the potential pitfalls in the surveillance of smears after trachelectomy.",Journal Article,4372.0,25.0,Radical trachelectomy surgical procedure intended preserve fertility patients early-stage cervical carcinoma cervix amputated continuity parametrium upper vagina sparing uterus adnexa Follow-up performed periodic cytology specimens objective current cytologic findings novel procedure Isthmic vaginal Papanicolaou-stained ThinPrep cytology specimens taken patients radical vaginal abdominal trachelectomy reviewed specimens presence benign endocervical lower uterine segment glandular endometrial stromal endometrial findings correlated original diagnosis follow-up included subsequent cytology specimens biopsies Cytology specimens n 223 44 patients included endometrial component identified 131 cases 59 Twenty-eight cases diagnosed abnormal original cytology examination cases 5 additional cases diagnosed cytologically benign subsequent biopsies biopsies confirmed presence lesion 4 25 biopsies 3 low-grade squamous intraepithelial lesions 1 adenosquamous carcinoma cases diagnosed atypical glandular represented tubal metaplasia lower uterine segment glandular endometrial stromal Cytology specimens trachelectomy frequently contain glandular lower uterine segment epithelium endometrial stromal lead misdiagnosis atypical glandular undetermined significance Tubal metaplasia potential pitfall specimens Pathologists gynecologic oncologists aware potential pitfalls surveillance smears trachelectomy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,"[711, 5760, 16, 8, 221, 1299, 4081, 6, 6783, 2954, 4, 7, 5, 191, 82, 134, 4, 92, 3, 3629, 16, 56761, 4, 12253, 5, 3, 30751, 2, 1726, 7553, 2267, 1851, 3, 2, 17778, 166, 126, 16, 173, 5, 9086, 2045, 623, 3, 461, 1, 3, 291, 45, 10, 6, 1992, 3, 4195, 272, 50, 26, 229, 1299, 44976, 2, 10416, 3386, 12772, 2045, 623, 1633, 29, 7, 50, 711, 2, 1467, 5760, 11, 446, 3, 623, 11, 120, 311, 9, 3, 463, 1, 1002, 10174, 37, 280, 4610, 6170, 37, 1126, 37, 2, 37, 3, 272, 11, 438, 5, 3, 2279, 147, 2, 166, 126, 92, 159, 706, 2045, 623, 2, 1154, 2045, 623, 78, 3907, 29, 584, 7, 11, 159, 4, 26, 45, 35, 1249, 10, 108, 4, 2229, 1, 3, 140, 728, 737, 659, 140, 11, 265, 22, 1668, 4, 3, 2279, 2045, 1385, 737, 1, 46, 140, 2, 33, 402, 140, 17, 11, 265, 8514, 22, 1002, 42, 706, 1154, 3, 1154, 557, 3, 463, 1, 8, 1180, 4, 158, 39, 1, 243, 1154, 27, 154, 88, 691, 4153, 406, 2, 14, 8067, 134, 62, 140, 265, 22, 1973, 6170, 37, 3324, 6674, 6054, 280, 4610, 6170, 37, 15, 1126, 37, 2045, 623, 50, 5760, 746, 3725, 6170, 37, 29, 3, 280, 4610, 2781, 15, 1126, 37, 92, 122, 1122, 6, 8, 13470, 1, 1973, 6170, 37, 1, 5206, 724, 6674, 6054, 16, 120, 8, 174, 28742, 4, 46, 623, 3354, 2, 1512, 1339, 257, 40, 4749, 1, 3, 174, 9631, 4, 3, 617, 1, 8916, 50, 5760]",1787.0,18085613,Cytologic findings fertility-sparing radical trachelectomy,1,0.005025125628140704
Lymphatic mapping and sentinel lymph node detection in women with vaginal cancer.,Gynecologic oncology,Gynecol. Oncol.,2008-01-10,"To determine the patterns of lymphatic drainage from primary vaginal cancers utilizing lymphoscintigraphy and to determine if this clinical information would affect treatment planning. For women with newly diagnosed vaginal cancer, pretreatment lymphatic mapping and sentinel lymph node identification were performed using lymphoscintigraphy. In patients who underwent surgery, sentinel lymph nodes were identified intraoperatively using radiocolloid and patent blue dye. The impact of pretreatment lymphoscintigraphy findings on radiation planning in women who received radiation as initial treatment was noted. Fourteen women were enrolled during the study period. At least 1 sentinel lymph node was identified on pretreatment lymphoscintigraphy in 11 patients (79%). The median number of sentinel nodes found per patient was 2, and bilateral sentinel nodes were found in 6 (55%) of the 11 patients with sentinel nodes identified. Among these 11 patients, 5 (45%) had sentinel nodes identified in the groin only, 4 (36%) had sentinel nodes identified in the pelvis only, and 2 (18%) had sentinel nodes identified in both the groin and the pelvis. No relationship was observed between sentinel lymph node location and primary tumor histologic subtype or location. Three (33%) of the 9 women treated initially with radiation therapy had their radiation field altered as a result of the lymphoscintigraphy findings. In women with vaginal cancer, lymphatic drainage from the primary lesion does not always follow the lymphatic channels that would have been predicted anatomically. The addition of lymphoscintigraphy to the pretreatment evaluation for women with vaginal cancer may significantly improve comprehensive treatment planning.",Evaluation Study,4394.0,29.0,determine patterns lymphatic drainage primary vaginal utilizing lymphoscintigraphy determine clinical information affect treatment planning women newly diagnosed vaginal pretreatment lymphatic mapping sentinel lymph node identification performed lymphoscintigraphy patients underwent surgery sentinel lymph nodes identified intraoperatively radiocolloid patent blue dye impact pretreatment lymphoscintigraphy findings radiation planning women received radiation initial treatment noted Fourteen women enrolled period 1 sentinel lymph node identified pretreatment lymphoscintigraphy 11 patients 79 median number sentinel nodes patient 2 bilateral sentinel nodes 6 55 11 patients sentinel nodes identified 11 patients 5 45 sentinel nodes identified groin 4 36 sentinel nodes identified pelvis 2 18 sentinel nodes identified groin pelvis relationship observed sentinel lymph node location primary histologic subtype location 33 9 women treated initially radiation therapy radiation field altered lymphoscintigraphy findings women vaginal lymphatic drainage primary lesion follow lymphatic channels predicted anatomically addition lymphoscintigraphy pretreatment evaluation women vaginal significantly improve comprehensive treatment planning,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 223, 3, 764, 1, 2936, 3528, 29, 86, 163, 2600, 6849, 2, 6, 223, 492, 26, 38, 487, 688, 1158, 24, 1349, 9, 117, 5, 732, 265, 12, 1194, 2936, 2568, 2, 1323, 263, 289, 911, 11, 173, 75, 6849, 4, 7, 54, 208, 152, 1323, 263, 502, 11, 108, 6595, 75, 11921, 2, 14172, 3352, 3796, 3, 345, 1, 1194, 6849, 272, 23, 121, 1349, 4, 117, 54, 103, 121, 22, 388, 24, 10, 1051, 3225, 117, 11, 346, 190, 3, 45, 727, 28, 506, 14, 1323, 263, 289, 10, 108, 23, 1194, 6849, 4, 175, 7, 842, 3, 52, 207, 1, 1323, 502, 204, 379, 69, 10, 18, 2, 1607, 1323, 502, 11, 204, 4, 49, 614, 1, 3, 175, 7, 5, 1323, 502, 108, 107, 46, 175, 7, 33, 512, 42, 1323, 502, 108, 4, 3, 9264, 158, 39, 511, 42, 1323, 502, 108, 4, 3, 3270, 158, 2, 18, 203, 42, 1323, 502, 108, 4, 110, 3, 9264, 2, 3, 3270, 77, 858, 10, 164, 59, 1323, 263, 289, 1147, 2, 86, 30, 884, 875, 15, 1147, 169, 466, 1, 3, 83, 117, 73, 1625, 5, 121, 36, 42, 136, 121, 1067, 1495, 22, 8, 757, 1, 3, 6849, 272, 4, 117, 5, 12, 2936, 3528, 29, 3, 86, 1180, 1097, 44, 3763, 166, 3, 2936, 11317, 17, 688, 47, 85, 783, 9622, 3, 352, 1, 6849, 6, 3, 1194, 451, 9, 117, 5, 12, 68, 97, 401, 949, 24, 1349]",1665.0,18190952,Lymphatic mapping sentinel lymph node detection women vaginal,0,0.0
Uterine tumors with neuroectodermal differentiation: a series of 17 cases and review of the literature.,The American journal of surgical pathology,Am. J. Surg. Pathol.,2008-02-01,"Uterine tumors with neuroectodermal differentiation, frequently referred to as primitive neuroectodermal tumors (PNETs), are uncommon. The clinicopathologic features of 17 such cases reviewed at the M.D. Anderson Cancer Center (MDACC) are presented along with a review of the literature. All of the pathology material was reviewed at MDACC, and in all cases, immunohistochemistry contributed to the diagnosis. In 12 cases, in situ hybridization techniques were used to determine whether a rearrangement of the EWSR1 gene, required for a diagnosis of peripheral PNET, was present. Clinical information was obtained from a patient chart review. Ages ranged from 31 to 81 years (median 58). Clinical presentations included vaginal bleeding (9), back pain (1), presumed fibroids (2), pelvic mass (1), incidental finding at hysterectomy (1), and unknown (3). Twelve patients had surgery or imaging to determine stage: I (2), II (0), III (6), and IV (4). Five patients had biopsy only. Ten tumors had only neuroectodermal components. In 7 tumors, the neuroectodermal component was admixed with an additional component including unclassified sarcoma (2 cases), rhabdomyosarcoma, endometrioid carcinoma, adenosarcoma and malignant mixed Mullerian tumor (2 cases). Follow-up, available for 13 patients, ranged from 2 to 41 months with 7 patients dead of disease 2 to 26 months after diagnosis. Six patients are alive with no evidence of disease after follow-up ranging from 6 to 41 months. Four patients were lost to follow-up. Results for the most commonly used immunohistochemistry studies include cytokeratin, 13/15 tumors negative (2 focally positive); synaptophysin, 15/16 tumors positive; neurofilament, 10/11 tumors positive; and CD99, 7/9 tumors positive (2 tumors had nonspecific cytoplasmic staining). None of the 12 tumors tested had a detectable rearrangement in the EWSR1 gene. Uterine tumors with neuroectodermal differentiation, similar to more common endometrial malignancies, tend to occur in postmenopausal women and frequently present with vaginal bleeding. An immunohistochemistry panel including cytokeratin, neurofilament, synaptophysin, and CD99 can highlight neuroectodermal differentiation and identify tumors for which molecular testing should be considered. Tumors without a rearrangement of the EWSR1 gene should be descriptively characterized as uterine tumors with neuroectodermal differentiation or alternatively central type PNETs rather than PNET, not otherwise specified to avoid confusion with peripheral PNET.",Journal Article,4372.0,49.0,Uterine neuroectodermal differentiation frequently referred primitive neuroectodermal PNETs uncommon clinicopathologic features 17 cases reviewed M.D Anderson Center MDACC presented review literature pathology material reviewed MDACC cases immunohistochemistry contributed diagnosis 12 cases situ hybridization techniques determine rearrangement EWSR1 required diagnosis peripheral PNET present Clinical information obtained patient chart review Ages ranged 31 81 years median 58 Clinical presentations included vaginal bleeding 9 pain 1 presumed fibroids 2 pelvic mass 1 incidental finding hysterectomy 1 unknown 3 patients surgery imaging determine stage 2 II 0 III 6 IV 4 patients biopsy neuroectodermal components 7 neuroectodermal component admixed additional component including unclassified sarcoma 2 cases rhabdomyosarcoma endometrioid carcinoma adenosarcoma malignant mixed Mullerian 2 cases Follow-up available 13 patients ranged 2 41 months 7 patients dead disease 2 26 months diagnosis patients alive evidence disease follow-up ranging 6 41 months patients lost follow-up commonly immunohistochemistry studies include cytokeratin 13/15 negative 2 focally positive synaptophysin 15/16 positive neurofilament 10/11 positive CD99 7/9 positive 2 nonspecific cytoplasmic staining 12 tested detectable rearrangement EWSR1 Uterine neuroectodermal differentiation similar common endometrial malignancies tend occur postmenopausal women frequently present vaginal bleeding immunohistochemistry panel including cytokeratin neurofilament synaptophysin CD99 highlight neuroectodermal differentiation identify molecular testing considered rearrangement EWSR1 descriptively characterized uterine neuroectodermal differentiation alternatively central type PNETs PNET specified avoid confusion peripheral PNET,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,"[57, 5, 7160, 910, 746, 1995, 6, 22, 5594, 7160, 57, 6558, 32, 2052, 3, 1399, 404, 1, 269, 225, 140, 446, 28, 3, 188, 427, 1929, 12, 574, 7412, 32, 917, 1510, 5, 8, 206, 1, 3, 789, 62, 1, 3, 1117, 3692, 10, 446, 28, 7412, 2, 4, 62, 140, 888, 3447, 6, 3, 147, 4, 133, 140, 4, 957, 1554, 1092, 11, 95, 6, 223, 317, 8, 2675, 1, 3, 6620, 145, 616, 9, 8, 147, 1, 672, 5389, 10, 364, 38, 487, 10, 683, 29, 8, 69, 2937, 206, 2165, 1869, 29, 456, 6, 865, 60, 52, 717, 38, 4261, 159, 2294, 83, 4636, 559, 14, 5472, 20404, 18, 1110, 782, 14, 4490, 1567, 28, 2622, 14, 2, 860, 27, 2544, 7, 42, 152, 15, 270, 6, 223, 82, 70, 18, 215, 13, 316, 49, 2, 478, 39, 365, 7, 42, 411, 158, 1618, 57, 42, 158, 7160, 1628, 4, 67, 57, 3, 7160, 1249, 10, 14861, 5, 35, 402, 1249, 141, 7096, 18, 140, 3151, 134, 11787, 2, 393, 1739, 18773, 30, 18, 140, 166, 126, 390, 9, 233, 7, 1869, 29, 18, 6, 605, 53, 5, 67, 7, 8311, 1, 34, 18, 6, 432, 53, 50, 147, 437, 7, 32, 1701, 5, 77, 241, 1, 34, 50, 166, 126, 2223, 29, 49, 6, 605, 53, 294, 7, 11, 3009, 6, 166, 126, 99, 9, 3, 96, 841, 95, 888, 94, 643, 4292, 233, 167, 57, 199, 18, 9772, 109, 12161, 167, 245, 57, 109, 20495, 79, 175, 57, 109, 2, 13940, 67, 83, 57, 109, 18, 57, 42, 5893, 2828, 1029, 1292, 1, 3, 133, 57, 650, 42, 8, 2083, 2675, 4, 3, 6620, 145, 57, 5, 7160, 910, 288, 6, 80, 186, 441, 5406, 6, 1271, 4, 1679, 117, 2, 746, 364, 5, 2294, 35, 888, 993, 141, 4292, 20495, 12161, 2, 13940, 122, 1817, 7160, 910, 2, 255, 57, 9, 92, 219, 471, 257, 40, 515, 57, 187, 8, 2675, 1, 3, 6620, 145, 257, 40, 16487, 765, 22, 57, 5, 7160, 910, 15, 7133, 854, 267, 6558, 1832, 76, 5389, 44, 2632, 3575, 6, 3085, 7399, 5, 672, 5389]",2370.0,18223324,Uterine neuroectodermal differentiation series 17 cases review literature,4,0.020100502512562814
Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804.,Psycho-oncology,Psychooncology,2008-11-01,"The Survivor's Health and Reaction study used a quality-of-life model adapted for cancer survivors by Dow and colleagues to identify factors related to global health-related quality of life (HRQL) and to document the prevalence of problems and health-oriented behaviors in a follow-up study of breast cancer patients who participated in CALGB 8541. A total of 245 survivors (78% of those invited) who were 9.4-16.5 years post-diagnosis completed surveys that inquired about current HRQL, economic, spiritual, physical and psychosocial concerns, and health-oriented behaviors (e.g. smoking, exercise, and supplement use). A regression model was developed to examine factors related to global HRQL across all domains. The regression model revealed that decreased energy levels (odds ratio (OR)=1.05, 95% confidence interval (CI): 1.03, 1.07), having heart disease (OR=5.01, 95% CI: 1.39, 18.1), having two or more co-morbidities (OR=2.39, 95% CI: 1.10, 5.19), and lower social support (OR=1.03, 95% CI: 1.02, 1.05) were associated with lower global HRQL. Factors related to psychological, spiritual, and economic domains were not predictive of global HRQL. Regarding lifestyle changes, some women reported engaging in health-oriented behaviors since their cancer diagnosis, such as improving eating habits (54%), increasing exercise (32%), and reducing/quitting smoking (20%). The most prevalent problems reported by women at follow-up were menopausal symptoms (64%), such as hot flashes and vaginal dryness, osteoporosis (25%), and lymphedema (23%). Suggestions are provided to target interventions, such as provider-based strategies, in order to improve HRQL in long-term breast cancer survivors.",Comparative Study,4098.0,21.0,Survivor 's Health Reaction quality-of-life model adapted survivors Dow colleagues identify factors related global health-related quality life HRQL document prevalence problems health-oriented behaviors follow-up breast patients participated CALGB 8541 total 245 survivors 78 invited 9.4-16.5 years post-diagnosis completed surveys inquired current HRQL economic spiritual physical psychosocial concerns health-oriented behaviors e.g smoking exercise supplement use regression model developed examine factors related global HRQL domains regression model revealed decreased energy levels odds ratio =1.05 95 confidence interval CI 1.03 1.07 heart disease OR=5.01 95 CI 1.39 18.1 co-morbidities OR=2.39 95 CI 1.10 5.19 lower social support OR=1.03 95 CI 1.02 1.05 associated lower global HRQL Factors related psychological spiritual economic domains predictive global HRQL lifestyle changes women reported engaging health-oriented behaviors diagnosis improving eating habits 54 increasing exercise 32 reducing/quitting smoking 20 prevalent problems reported women follow-up menopausal symptoms 64 hot flashes vaginal dryness osteoporosis 25 lymphedema 23 Suggestions provided target interventions provider-based strategies order improve HRQL long-term breast survivors,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,"[3, 2628, 292, 341, 2, 1329, 45, 95, 8, 372, 1, 358, 202, 3716, 9, 12, 332, 20, 56896, 2, 6367, 6, 255, 130, 139, 6, 1648, 341, 139, 372, 1, 358, 7332, 2, 6, 4753, 3, 1078, 1, 2408, 2, 341, 8095, 3704, 4, 8, 166, 126, 45, 1, 12, 7, 54, 3025, 4, 4077, 23076, 8, 181, 1, 7373, 332, 833, 1, 135, 7594, 54, 11, 83, 39, 245, 33, 60, 539, 147, 781, 3666, 17, 26675, 545, 291, 7332, 3875, 3573, 900, 2, 2322, 2061, 2, 341, 8095, 3704, 563, 499, 979, 2277, 2, 5836, 119, 8, 320, 202, 10, 276, 6, 1004, 130, 139, 6, 1648, 7332, 716, 62, 2703, 3, 320, 202, 553, 17, 340, 2803, 148, 610, 197, 15, 14, 474, 48, 307, 268, 58, 14, 680, 14, 1615, 1041, 34, 15, 33, 355, 48, 58, 14, 587, 203, 14, 1041, 100, 15, 80, 1269, 5655, 15, 18, 587, 48, 58, 14, 79, 33, 326, 2, 280, 2032, 538, 15, 14, 680, 48, 58, 14, 588, 14, 474, 11, 41, 5, 280, 1648, 7332, 130, 139, 6, 2624, 3573, 2, 3875, 2703, 11, 44, 464, 1, 1648, 7332, 666, 3487, 400, 476, 117, 210, 8534, 4, 341, 8095, 3704, 1192, 136, 12, 147, 225, 22, 1673, 9660, 9973, 667, 602, 2277, 531, 2, 1818, 9942, 979, 179, 3, 96, 2485, 2408, 210, 20, 117, 28, 166, 126, 11, 3565, 507, 660, 225, 22, 2859, 4193, 2, 15822, 4970, 243, 2, 3063, 382, 9796, 32, 1052, 6, 283, 1151, 225, 22, 3094, 90, 422, 4, 1732, 6, 401, 7332, 4, 319, 337, 12, 332]",1588.0,18314912,Applying conceptual model examining health-related quality life long-term breast survivors CALGB 79804,0,0.0
The spectrum and clinical sequelae of human papillomavirus infection.,Gynecologic oncology,Gynecol. Oncol.,2007-11-01,"Infection with the human papillomavirus (HPV) is the most common sexually transmitted disease afflicting approximately 80% of the population. HPV infection is an essential factor in cervical carcinogenesis and cervical carcinoma is the second most common cause of cancer among women worldwide. In addition to cervical cancer, other malignancies in both men and women such as esophageal, oropharyngeal, and anal cancer have been causally associated with this virus. Other gender-specific HPV-related cancers include penile, vulvar and vaginal cancer. HPV-16 is the most common HPV type associated with a malignant phenotype regardless of organ of origin. HPV-16 together with HPV-18 accounts for approximately 70% of cervical cancers. Other non-oncogenic HPV types including HPV types 6 and 11 are associated with over 90% of benign HPV-related lesions such as genital warts and juvenile respiratory papillomatosis.",Journal Article,4464.0,62.0,Infection human papillomavirus HPV common sexually transmitted disease afflicting approximately 80 population HPV infection essential factor cervical carcinogenesis cervical carcinoma second common cause women worldwide addition cervical malignancies men women esophageal oropharyngeal anal causally associated virus gender-specific HPV-related include penile vulvar vaginal HPV-16 common HPV type associated malignant phenotype regardless organ origin HPV-16 HPV-18 accounts approximately 70 cervical non-oncogenic HPV types including HPV types 6 11 associated 90 benign HPV-related lesions genital warts juvenile respiratory papillomatosis,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,"[930, 5, 3, 171, 3242, 933, 16, 3, 96, 186, 13588, 12959, 34, 45139, 705, 493, 1, 3, 266, 933, 930, 16, 35, 1452, 161, 4, 1719, 2, 134, 16, 3, 419, 96, 186, 708, 1, 12, 107, 117, 2358, 4, 352, 6, 12, 127, 441, 4, 110, 325, 2, 117, 225, 22, 2, 12, 47, 85, 12511, 41, 5, 26, 1450, 127, 1632, 112, 933, 139, 163, 643, 2, 12, 933, 245, 16, 3, 96, 186, 933, 267, 41, 5, 8, 393, 1005, 1583, 1, 1259, 1, 1938, 933, 245, 1162, 5, 933, 203, 4162, 9, 705, 431, 1, 163, 127, 220, 1302, 933, 630, 141, 933, 630, 49, 2, 175, 32, 41, 5, 252, 424, 1, 1002, 933, 139, 406, 225, 22, 8226, 19515, 2, 7857, 2718, 22118]",810.0,18499914,spectrum clinical sequelae human papillomavirus infection,4,0.020100502512562814
Fertility preservation in patients with early cervical cancer: radical trachelectomy.,Gynecologic oncology,Gynecol. Oncol.,2008-05-23,"The goal of this review is to summarize the latest literature on the subject of radical trachelectomy and fertility outcomes in patients with early-stage cervical cancer. We analyzed the published literature in search of all articles addressing surgical techniques, intraoperative and perioperative outcomes, and obstetrical results in patient undergoing radical trachelectomy for cervical cancer. It is estimated that 43% of all cases of cervical cancer in the United States are diagnosed in women younger than 45 years of age. As of 2007, a total of 520 patients had been reported to have undergone a radical vaginal trachelectomy. The majority of patients (60%) had a diagnosis of squamous cell carcinoma; adenocarcinoma was the second most common histologic subtype (40%). Data on outcomes after radical abdominal trachelectomy are less extensive-only approximately 50 cases have been reported worldwide. Approximately 43% of patients who undergo a radical trachelectomy subsequently attempt to become pregnant. Seventy percent of these women are successful at achieving a pregnancy. Radical trachelectomy is safe and feasible and pregnancy outcomes are very favorable. All patients interested in future fertility who are diagnosed with cervical cancer are encouraged to discuss radical trachelectomy with their physician.",Journal Article,4260.0,57.0,goal review summarize latest literature subject radical trachelectomy fertility outcomes patients early-stage cervical published literature search articles addressing surgical techniques intraoperative perioperative outcomes obstetrical patient undergoing radical trachelectomy cervical estimated 43 cases cervical United States diagnosed women younger 45 years age 2007 total 520 patients reported undergone radical vaginal trachelectomy majority patients 60 diagnosis squamous carcinoma adenocarcinoma second common histologic subtype 40 outcomes radical abdominal trachelectomy extensive-only approximately 50 cases reported worldwide Approximately 43 patients undergo radical trachelectomy subsequently attempt pregnant Seventy percent women successful achieving pregnancy Radical trachelectomy safe feasible pregnancy outcomes favorable patients interested future fertility diagnosed cervical encouraged discuss radical trachelectomy physician,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 1326, 1, 26, 206, 16, 6, 2479, 3, 5923, 789, 23, 3, 2974, 1, 711, 5760, 2, 2954, 123, 4, 7, 5, 191, 82, 12, 21, 311, 3, 983, 789, 4, 1901, 1, 62, 2384, 3432, 221, 1092, 1720, 2, 1547, 123, 2, 21031, 99, 4, 69, 479, 711, 5760, 9, 12, 192, 16, 661, 17, 601, 1, 62, 140, 1, 12, 4, 3, 1088, 907, 32, 265, 4, 117, 773, 76, 512, 60, 1, 89, 22, 1, 1307, 8, 181, 1, 9158, 7, 42, 85, 210, 6, 47, 1989, 8, 711, 5760, 3, 686, 1, 7, 335, 42, 8, 147, 1, 691, 31, 134, 449, 10, 3, 419, 96, 186, 884, 875, 327, 74, 23, 123, 50, 711, 1467, 5760, 32, 299, 1344, 158, 705, 212, 140, 47, 85, 210, 2358, 705, 601, 1, 7, 54, 1251, 8, 711, 5760, 1611, 3448, 6, 1417, 6086, 2073, 714, 1, 46, 117, 32, 1401, 28, 1785, 8, 2290, 711, 5760, 16, 1165, 2, 1313, 2, 2290, 123, 32, 923, 913, 62, 7, 7420, 4, 508, 2954, 54, 32, 265, 5, 12, 32, 5865, 6, 1139, 711, 5760, 5, 136, 1473]",1260.0,18501409,Fertility preservation patients early cervical radical trachelectomy,13,0.06532663316582915
"Lymphatic mapping and sentinel node biopsy in vulvar, vaginal, and cervical cancers.","Oncology (Williston Park, N.Y.)","Oncology (Williston Park, N.Y.)",2008-04-01,"Over the past 15 years, lymphatic mapping and sentinel lymph node biopsy in vulvar, vaginal, and cervical cancers have been explored by gynecologic oncologists around the world. Based on the results of multiple single-institution studies, most in our field are optimistic that these techniques will increase the rates of detection of lymph node metastasis while decreasing the morbidity associated with lymphadenectomy. Large validation studies are currently underway in both the United States and Europe. In this review article, we present the published data on mapping techniques and discuss future considerations for these technologies.",Journal Article,4312.0,9.0,past 15 years lymphatic mapping sentinel lymph node biopsy vulvar vaginal cervical explored gynecologic oncologists world Based multiple single-institution studies field optimistic techniques increase rates detection lymph node metastasis decreasing morbidity associated lymphadenectomy Large validation studies currently underway United States Europe review article present published mapping techniques discuss future considerations technologies,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[252, 3, 1219, 167, 60, 2936, 2568, 2, 1323, 263, 289, 411, 4, 2, 163, 47, 85, 1443, 20, 1512, 1339, 3337, 3, 1956, 90, 23, 3, 99, 1, 232, 226, 731, 94, 96, 4, 114, 1067, 32, 9566, 17, 46, 1092, 303, 344, 3, 151, 1, 638, 1, 263, 289, 278, 369, 2777, 3, 787, 41, 5, 2048, 375, 929, 94, 32, 694, 3948, 4, 110, 3, 1088, 907, 2, 3934, 4, 26, 206, 946, 21, 364, 3, 983, 74, 23, 2568, 1092, 2, 1139, 508, 3891, 9, 46, 2590]",606.0,18533402,Lymphatic mapping sentinel node biopsy vulvar vaginal cervical,0,0.0
What is the incidence of isolated paraaortic nodal recurrence in grade 1 endometrial carcinoma?,Gynecologic oncology,Gynecol. Oncol.,2008-07-26,"To describe the incidence of isolated paraaortic nodal recurrences in patients with a final diagnosis of grade 1 endometrial carcinoma initially treated with surgery. Records from a prospectively maintained endometrial carcinoma database were reviewed to identify sites of recurrence. Patients with any papillary serous or clear cell carcinoma, leiomyosarcoma, endometrial stromal sarcoma, squamous carcinoma, or adenosarcoma were excluded. Recurrence sites were classified into 4 main categories: 1) pelvic (including vaginal and other soft tissue pelvic sites); 2) abdominal (including peritoneum, omentum and liver); 3) distant (including lung, brain, supraclavicular, and groins); and 4) isolated paraaortic nodal recurrence (including any nodal recurrence between the midcommon iliac to renal vessels). Between 1/93 and 5/06, 1453 patients with endometrial carcinoma met the study inclusion criteria. Final grade distribution included: grade 1 endometrial adenocarcinoma, 310 (21%); grade 2, 578 (40%); grade 3, 481 (33%); and incomplete, 84 (5.8%). In all, 154 patients (11%) had documented recurrences. Recurrence sites for all patients/all grades included: pelvis, 52 (34%); abdomen, 51 (33%); distant, 41 (27%), and isolated paraaortic, 10 (6%). None of the isolated paraaortic recurrences occurred in patients with a final diagnosis of grade 1 carcinoma. Furthermore, 9/10 (90%) isolated paraaortic nodal recurrences were in grade 3 tumors. Only 8 (2.6%) of 310 patients with grade 1 tumors recurred. Sites of recurrence for grade 1 tumors included: abdomen, 3; pelvis, 3; and distant, 2. This large series of endometrial carcinoma patients initially treated with surgery confirms that isolated paraaortic nodal recurrence in women with a final diagnosis of grade 1 endometrial carcinoma is extremely rare. These rare isolated paraaortic nodal recurrences appear to be limited to high-grade endometrial carcinomas.",Journal Article,4196.0,26.0,incidence isolated paraaortic nodal recurrences patients final diagnosis grade 1 endometrial carcinoma initially treated surgery Records prospectively maintained endometrial carcinoma database reviewed identify sites recurrence Patients papillary serous clear carcinoma leiomyosarcoma endometrial stromal sarcoma squamous carcinoma adenosarcoma excluded Recurrence sites classified 4 main categories 1 pelvic including vaginal soft tissue pelvic sites 2 abdominal including peritoneum omentum liver 3 distant including lung brain supraclavicular groins 4 isolated paraaortic nodal recurrence including nodal recurrence midcommon iliac renal vessels 1/93 5/06 1453 patients endometrial carcinoma met inclusion criteria Final grade distribution included grade 1 endometrial adenocarcinoma 310 21 grade 2 578 40 grade 3 481 33 incomplete 84 5.8 154 patients 11 documented recurrences Recurrence sites patients/all grades included pelvis 52 34 abdomen 51 33 distant 41 27 isolated paraaortic 10 6 isolated paraaortic recurrences occurred patients final diagnosis grade 1 carcinoma Furthermore 9/10 90 isolated paraaortic nodal recurrences grade 3 8 2.6 310 patients grade 1 recurred Sites recurrence grade 1 included abdomen 3 pelvis 3 distant 2 large series endometrial carcinoma patients initially treated surgery confirms isolated paraaortic nodal recurrence women final diagnosis grade 1 endometrial carcinoma extremely rare rare isolated paraaortic nodal recurrences appear limited high-grade endometrial carcinomas,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,"[6, 897, 3, 287, 1, 1355, 7401, 779, 1593, 4, 7, 5, 8, 1457, 147, 1, 88, 14, 134, 1625, 73, 5, 152, 1064, 29, 8, 1143, 1955, 134, 609, 11, 446, 6, 255, 633, 1, 146, 7, 5, 500, 1796, 1744, 15, 885, 31, 134, 3717, 1126, 691, 134, 15, 11787, 11, 1800, 146, 633, 11, 1373, 237, 39, 1895, 1996, 14, 1110, 141, 2, 127, 1214, 246, 1110, 633, 18, 1467, 141, 6699, 12205, 2, 27, 626, 141, 342, 5804, 2, 26214, 2, 39, 1355, 7401, 779, 146, 141, 500, 779, 146, 59, 3, 57260, 6692, 6, 3102, 59, 14, 966, 2, 33, 1460, 31326, 7, 5, 134, 543, 3, 45, 1680, 371, 1457, 88, 1395, 159, 88, 14, 449, 8292, 239, 88, 18, 10431, 327, 88, 27, 12178, 466, 2, 2610, 874, 33, 66, 4, 62, 4838, 7, 175, 42, 1405, 1593, 146, 633, 9, 62, 7, 62, 2276, 159, 3270, 653, 562, 4036, 725, 466, 626, 605, 428, 2, 1355, 7401, 79, 49, 1292, 1, 3, 1355, 7401, 1593, 489, 4, 7, 5, 8, 1457, 147, 1, 88, 14, 134, 798, 83, 79, 424, 1355, 7401, 779, 1593, 11, 4, 88, 27, 57, 158, 66, 18, 49, 1, 8292, 7, 5, 88, 14, 57, 3363, 633, 1, 146, 9, 88, 14, 57, 159, 4036, 27, 3270, 27, 2, 626, 18, 26, 375, 988, 1, 134, 7, 1625, 73, 5, 152, 5120, 17, 1355, 7401, 779, 146, 4, 117, 5, 8, 1457, 147, 1, 88, 14, 134, 16, 2938, 622, 46, 622, 1355, 7401, 779, 1593, 1322, 6, 40, 383, 6, 64, 88, 826]",1699.0,18657853,incidence isolated paraaortic nodal recurrence grade 1 endometrial carcinoma,0,0.0
Radical trachelectomy for cervical cancer: postoperative physical and emotional adjustment concerns.,Gynecologic oncology,Gynecol. Oncol.,2008-07-26,"To investigate the incidence of cervical stenosis and related emotional and sexual adjustment concerns in women treated with radical trachelectomy. Prospective data of 30 stage I cervical cancer patients enrolled in an ongoing study were evaluated in combination with a medical chart review. Eight patients (27%) did not have any stenosis of the neo-cervix postoperatively; 10 (33%) had clinically notable stenosis not requiring neo-cervical dilation to allow adequate sampling; moreover, 12 (40%) had sufficient stenosis requiring a neo-cervical dilation procedure, which proved to be safe and useful. The majority of the dilation procedures (n=8) were conducted under local anesthesia in the office. At preoperative baseline survey, women reported a high rate of sexual inactivity. Fear of intercourse and dyspareunia were reported prior to surgery; however, trends of adjustment and improvement were noted over time postoperatively. Overall, fear of sexual activity tended to lessen if the degree of dyspareunia decreased over time. Postoperative dyspareunia decreased over time, which could have been associated with the mechanical stretching due to vaginal dilator use or dilating benefit of intercourse. Postoperative concerns associated with radical trachelectomy may be greater than what has been reported in the literature; however, several adjustment trends were noted with intermediate/long-term follow-up. Office cervical dilation is a simple procedure, which is helpful in the management of neo-cervical stenosis. We are currently investigating the value of a physician checklist as a clinical care model to remind medical professionals to monitor and address important survivorship issues.",Journal Article,4196.0,51.0,investigate incidence cervical stenosis related emotional sexual adjustment concerns women treated radical trachelectomy Prospective 30 stage cervical patients enrolled ongoing evaluated combination medical chart review patients 27 stenosis neo-cervix postoperatively 10 33 clinically notable stenosis requiring neo-cervical dilation allow adequate sampling 12 40 sufficient stenosis requiring neo-cervical dilation procedure proved safe useful majority dilation procedures n=8 conducted local anesthesia office preoperative baseline survey women reported high rate sexual inactivity Fear intercourse dyspareunia reported prior surgery trends adjustment improvement noted time postoperatively Overall fear sexual activity tended lessen degree dyspareunia decreased time Postoperative dyspareunia decreased time associated mechanical stretching vaginal dilator use dilating benefit intercourse Postoperative concerns associated radical trachelectomy greater reported literature adjustment trends noted intermediate/long-term follow-up Office cervical dilation simple procedure helpful management neo-cervical stenosis currently investigating value physician checklist clinical care model remind medical professionals monitor address important survivorship issues,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 963, 3, 287, 1, 6935, 2, 139, 2671, 2, 2232, 1852, 2061, 4, 117, 73, 5, 711, 5760, 482, 74, 1, 201, 82, 70, 12, 7, 346, 4, 35, 942, 45, 11, 194, 4, 150, 5, 8, 484, 2937, 206, 659, 7, 428, 205, 44, 47, 500, 6935, 1, 3, 5357, 3629, 3541, 79, 466, 42, 505, 4090, 6935, 44, 1888, 5357, 18237, 8062, 6, 1700, 1658, 2874, 1393, 133, 327, 42, 1952, 6935, 1888, 8, 5357, 18237, 8062, 1299, 92, 4328, 6, 40, 1165, 2, 999, 3, 686, 1, 3, 8062, 1369, 78, 66, 11, 426, 669, 293, 6433, 4, 3, 6489, 28, 498, 330, 1407, 117, 210, 8, 64, 116, 1, 2232, 10050, 6443, 1, 12361, 2, 22098, 11, 210, 324, 6, 152, 137, 1963, 1, 1852, 2, 767, 11, 1051, 252, 98, 3541, 63, 6443, 1, 2232, 128, 3886, 6, 13763, 492, 3, 1444, 1, 22098, 340, 252, 98, 573, 22098, 340, 252, 98, 92, 359, 47, 85, 41, 5, 3, 6065, 15369, 520, 6, 17967, 119, 15, 57263, 247, 1, 12361, 573, 2061, 41, 5, 711, 5760, 68, 40, 378, 76, 2067, 71, 85, 210, 4, 3, 789, 137, 392, 1852, 1963, 11, 1051, 5, 919, 319, 337, 166, 126, 6489, 8062, 16, 8, 2763, 1299, 92, 16, 3951, 4, 3, 284, 1, 5357, 18237, 6935, 21, 32, 694, 3103, 3, 549, 1, 8, 1473, 9787, 22, 8, 38, 165, 202, 6, 37190, 484, 3409, 6, 3334, 2, 1539, 305, 2560, 1553]",1634.0,18662827,Radical trachelectomy cervical postoperative physical emotional adjustment concerns,0,0.0
Oncologic outcome of fertility-sparing radical trachelectomy versus radical hysterectomy for stage IB1 cervical carcinoma.,Gynecologic oncology,Gynecol. Oncol.,2008-08-27,"To compare the oncologic outcomes of women who underwent a fertility-sparing radical trachelectomy (RT) to those who underwent a radical hysterectomy (RH) for stage IB1 cervical carcinoma. We performed a case-control study of all patients with stage IB1 cervical carcinoma who underwent a vaginal or abdominal RT between 11/01 and 6/07. The control group consisted of patients with stage IB1 disease who underwent an RH between 11/91 and 6/07 and who would be considered candidates for fertility-sparing surgery. Information was extracted from a prospectively acquired database. Recurrence-free and disease-specific survival (RFS and DSS) were estimated using Kaplan-Meier estimates and compared with the log-rank test where indicated. Multivariate analysis was performed using the Cox regression method. Forty stage IB1 patients underwent an RT and 110 patients underwent an RH. There were no statistical differences between the two groups for the following prognostic variables: histology, median number of lymph nodes removed, node positive rate, lymph-vascular space involvement (LVSI), or deep stromal invasion (DSI). The median follow-up for the entire group was 44 months. The 5-year RFS rate was 96% (for the RT group compared to 86% for the RH group (P=NS). On multivariate analysis in this group of stage IB1 lesions, tumor size <2 cm was not an independent predictor of outcome, but both LVSI and DSI retained independent predictive value (P=0.033 and 0.005, respectively). For selected patients with stage IB1 cervical cancer, fertility-sparing radical trachelectomy appears to have a similar oncologic outcome to radical hysterectomy. LVSI and DSI appear to be more valuable predictors of outcome than tumor diameter in this subgroup of patients.",Journal Article,4164.0,136.0,compare oncologic outcomes women underwent fertility-sparing radical trachelectomy RT underwent radical hysterectomy RH stage IB1 cervical carcinoma performed case-control patients stage IB1 cervical carcinoma underwent vaginal abdominal RT 11/01 6/07 control group consisted patients stage IB1 disease underwent RH 11/91 6/07 considered candidates fertility-sparing surgery Information extracted prospectively acquired database Recurrence-free disease-specific survival RFS DSS estimated Kaplan-Meier estimates compared log-rank test indicated Multivariate performed Cox regression stage IB1 patients underwent RT 110 patients underwent RH statistical differences groups following prognostic variables histology median number lymph nodes removed node positive rate lymph-vascular space involvement LVSI deep stromal invasion DSI median follow-up entire group 44 months 5-year RFS rate 96 RT group compared 86 RH group P=NS multivariate group stage IB1 lesions size 2 cm independent predictor outcome LVSI DSI retained independent predictive value P=0.033 0.005 respectively selected patients stage IB1 cervical fertility-sparing radical trachelectomy appears similar oncologic outcome radical hysterectomy LVSI DSI appear valuable predictors outcome diameter subgroup patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,"[6, 932, 3, 1998, 123, 1, 117, 54, 208, 8, 2954, 1851, 711, 5760, 240, 6, 135, 54, 208, 8, 711, 2622, 7240, 9, 82, 8111, 134, 21, 173, 8, 473, 182, 45, 1, 62, 7, 5, 82, 8111, 134, 54, 208, 8, 15, 1467, 240, 59, 175, 355, 2, 49, 1615, 3, 182, 87, 1695, 1, 7, 5, 82, 8111, 34, 54, 208, 35, 7240, 59, 175, 970, 2, 49, 1615, 2, 54, 688, 40, 515, 1931, 9, 2954, 1851, 152, 487, 10, 2484, 29, 8, 1143, 1294, 609, 146, 115, 2, 34, 112, 25, 1272, 2, 1788, 11, 661, 75, 876, 882, 1423, 2, 72, 5, 3, 1066, 1026, 412, 1257, 1103, 331, 65, 10, 173, 75, 3, 418, 320, 596, 1213, 82, 8111, 7, 208, 35, 240, 2, 3129, 7, 208, 35, 7240, 125, 11, 77, 1050, 362, 59, 3, 100, 271, 9, 3, 366, 177, 682, 784, 52, 207, 1, 263, 502, 2264, 289, 109, 116, 263, 756, 3865, 799, 8004, 15, 2369, 1126, 578, 38804, 3, 52, 166, 126, 9, 3, 1797, 87, 10, 584, 53, 3, 33, 111, 1272, 116, 10, 921, 9, 3, 240, 87, 72, 6, 868, 9, 3, 7240, 87, 19, 4044, 23, 331, 65, 4, 26, 87, 1, 82, 8111, 406, 30, 444, 18, 494, 10, 44, 35, 306, 980, 1, 228, 84, 110, 8004, 2, 38804, 3532, 306, 464, 549, 19, 13, 5254, 2, 13, 1614, 106, 9, 715, 7, 5, 82, 8111, 12, 2954, 1851, 711, 5760, 1233, 6, 47, 8, 288, 1998, 228, 6, 711, 2622, 8004, 2, 38804, 1322, 6, 40, 80, 2926, 674, 1, 228, 76, 30, 2549, 4, 26, 1363, 1, 7]",1684.0,18755500,Oncologic outcome fertility-sparing radical trachelectomy versus radical hysterectomy stage IB1 cervical carcinoma,0,0.0
Treatment of recurrent vaginal melanoma with external beam radiation therapy and palladium-103 brachytherapy.,Brachytherapy,Brachytherapy,2008-09-07,"Mucosal melanoma of the female genital tract that recurs locally after definitive surgery presents difficult challenges for salvage therapy. A 71-year-old female was diagnosed with a 4.5-cm x 4.1-cm x 2.8-cm vaginal recurrence of genital tract mucosal melanoma after definitive vulvectomy, distal vaginectomy, and distal urethrectomy. She refused surgery and underwent combination external beam radiation therapy (46 Gy) and an ultrasound-guided palladium-103 brachytherapy implant (100 Gy). The patient experienced complete resolution of the gross tumor and was asymptomatic with a sustained response for over a year before developing metastatic disease. Mucosal melanoma of the female genital tract is an aggressive and often fatal disease. Radical surgical excision is an option for some patients but may require pelvic exenteration and is rarely curative. In selected cases, high-dose conformal radiation therapy delivered by a combination of external beam radiation therapy and interstitial brachytherapy may be an excellent alternative, achieving local control without loss of organ function.",Case Reports,4153.0,6.0,Mucosal melanoma female genital tract recurs locally definitive surgery presents difficult challenges salvage therapy 71-year-old female diagnosed 4.5-cm x 4.1-cm x 2.8-cm vaginal recurrence genital tract mucosal melanoma definitive vulvectomy distal vaginectomy distal urethrectomy refused surgery underwent combination external beam radiation therapy 46 Gy ultrasound-guided palladium-103 brachytherapy implant 100 Gy patient experienced complete resolution gross asymptomatic sustained response year developing metastatic disease Mucosal melanoma female genital tract aggressive fatal disease Radical surgical excision option patients require pelvic exenteration rarely curative selected cases high-dose conformal radiation therapy delivered combination external beam radiation therapy interstitial brachytherapy excellent alternative achieving local control loss organ function,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3068, 1, 3, 1061, 8226, 1696, 17, 12172, 795, 50, 1057, 152, 2740, 1740, 1427, 9, 992, 36, 8, 792, 111, 1095, 1061, 10, 265, 5, 8, 39, 33, 494, 1006, 39, 14, 494, 1006, 18, 66, 494, 146, 1, 8226, 1696, 3068, 50, 1057, 22043, 2107, 33868, 2, 2107, 15180, 3109, 8237, 152, 2, 208, 150, 1455, 1345, 121, 36, 641, 381, 2, 35, 1945, 1808, 22221, 3283, 1536, 4194, 394, 381, 3, 69, 592, 236, 2125, 1, 3, 1789, 30, 2, 10, 2100, 5, 8, 2275, 51, 9, 252, 8, 111, 348, 931, 113, 34, 3068, 1, 3, 1061, 8226, 1696, 16, 35, 571, 2, 629, 3034, 34, 711, 221, 1366, 16, 35, 1501, 9, 476, 7, 84, 68, 1353, 1110, 5668, 2, 16, 2416, 1075, 4, 715, 140, 64, 61, 2972, 121, 36, 1623, 20, 8, 150, 1, 1455, 1345, 121, 36, 2, 4543, 1536, 68, 40, 35, 1503, 1091, 1785, 293, 182, 187, 407, 1, 1259, 343]",1048.0,18778972,Treatment recurrent vaginal melanoma external beam radiation therapy palladium-103 brachytherapy,23,0.11557788944723618
Radical vaginal versus abdominal trachelectomy for stage IB1 cervical cancer: a comparison of surgical and pathologic outcomes.,Gynecologic oncology,Gynecol. Oncol.,2008-10-29,"To compare the surgical and pathologic outcomes utilizing two surgical approaches for fertility-sparing radical trachelectomy in patients with stage IB1 cervical cancer. A prospectively maintained database of vaginal radical trachelectomy (VRT) and abdominal radical trachelectomy (ART) procedures was analyzed. All procedures were performed in a standardized manner by the same surgical group. Parametrial measurements were recorded from the final pathology report. Standard statistical tests were used. Between 12/2001 and 7/2007, 43 adult patients with FIGO stage IB1 cervical cancer underwent surgery with the intent to perform a fertility-sparing radical trachelectomy. VRT was attempted in 28 patients (65%) and ART in 15 patients (35%). The median measured parametrial length in the VRT group was 1.45 cm compared to 3.97 cm in the ART group, P<0.0001. None of the parametrial specimens in the VRT group contained parametrial nodes. Parametrial nodes were detected in 8 (57.3%) of the ART specimens (P=0.0002). There was no difference in histologic subtypes, lymph vascular space invasion, or median total regional lymph nodes removed in the two groups. Median blood loss was greater but not clinically significant in the ART group, and median operating time was less in the ART group. The overall complication rate was not significantly different in the two groups. Using standardized techniques, radical abdominal trachelectomy provides similar surgical and pathologic outcomes with possibly a wider parametrial resection, including contiguous parametrial nodes, as compared to the radical vaginal approach.",Comparative Study,4101.0,81.0,compare surgical pathologic outcomes utilizing surgical approaches fertility-sparing radical trachelectomy patients stage IB1 cervical prospectively maintained database vaginal radical trachelectomy VRT abdominal radical trachelectomy ART procedures procedures performed standardized manner surgical group Parametrial measurements recorded final pathology report Standard statistical tests 12/2001 7/2007 43 adult patients FIGO stage IB1 cervical underwent surgery intent perform fertility-sparing radical trachelectomy VRT attempted 28 patients 65 ART 15 patients 35 median measured parametrial length VRT group 1.45 cm compared 3.97 cm ART group P 0.0001 parametrial specimens VRT group contained parametrial nodes Parametrial nodes detected 8 57.3 ART specimens P=0.0002 difference histologic subtypes lymph vascular space invasion median total regional lymph nodes removed groups Median blood loss greater clinically significant ART group median operating time ART group overall complication rate significantly different groups standardized techniques radical abdominal trachelectomy provides similar surgical pathologic outcomes possibly wider parametrial resection including contiguous parametrial nodes compared radical vaginal approach,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 932, 3, 221, 2, 510, 123, 2600, 100, 221, 611, 9, 2954, 1851, 711, 5760, 4, 7, 5, 82, 8111, 12, 8, 1143, 1955, 609, 1, 711, 5760, 26757, 2, 1467, 711, 5760, 4363, 1369, 10, 311, 62, 1369, 11, 173, 4, 8, 1670, 1708, 20, 3, 827, 221, 87, 8726, 1685, 11, 1872, 29, 3, 1457, 1117, 414, 260, 1050, 895, 11, 95, 59, 133, 1758, 2, 67, 1307, 601, 780, 7, 5, 3837, 82, 8111, 12, 208, 152, 5, 3, 1697, 6, 2715, 8, 2954, 1851, 711, 5760, 26757, 10, 4098, 4, 339, 7, 556, 2, 4363, 4, 167, 7, 465, 3, 52, 644, 8726, 1318, 4, 3, 26757, 87, 10, 14, 512, 494, 72, 6, 27, 1015, 494, 4, 3, 4363, 87, 19, 13, 488, 1292, 1, 3, 8726, 623, 4, 3, 26757, 87, 3070, 8726, 502, 8726, 502, 11, 530, 4, 66, 696, 27, 1, 3, 4363, 623, 19, 13, 3531, 125, 10, 77, 523, 4, 884, 814, 263, 756, 3865, 578, 15, 52, 181, 951, 263, 502, 2264, 4, 3, 100, 271, 52, 315, 407, 10, 378, 84, 44, 505, 93, 4, 3, 4363, 87, 2, 52, 2584, 98, 10, 299, 4, 3, 4363, 87, 3, 63, 1447, 116, 10, 44, 97, 338, 4, 3, 100, 271, 75, 1670, 1092, 711, 1467, 5760, 777, 288, 221, 2, 510, 123, 5, 2150, 8, 7771, 8726, 170, 141, 10941, 8726, 502, 22, 72, 6, 3, 711, 353]",1545.0,18973933,Radical vaginal versus abdominal trachelectomy stage IB1 cervical comparison surgical pathologic outcomes,0,0.0
Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage I-II serous endometrial cancer.,Gynecologic oncology,Gynecol. Oncol.,2008-11-20,"To report a single institution experience in surgical stage I-II serous endometrial cancer using combined carboplatin/paclitaxel and intravaginal radiation (IVRT). Between 10/00 and 12/06, 25 stage I-II patients with serous endometrial cancer were treated at our institution with surgery, postoperative IVRT, and concurrent chemotherapy (CT). The mean age was 67 years old (range, 53-80 years). Surgery consisted of hysterectomy (TAH/BSO, 64%, LAVH/BSO, 36%), peritoneal washing, omental biopsy, and pelvic lymph-node dissection (median 14 nodes). Para-aortic node sampling was done in 88% (median, 6). IVRT median dose was 21 Gy (range, 18-21 Gy, in 3 fractions) and concurrent CT consisted of carboplatin to AUC=5 and taxol to 175 mg/m(2) given every 3 weeks for 6 cycles. CT was well tolerated with 22/25 (88%) receiving 6 cycles. Three patients received <or=5 cycles; 2 owing to physician preference (3 and 4 cycles) and 1 owing to toxicity (5 cycles). Only 1 patient (4%) had grade 3 toxicity (abscess). Grade 2 neurotoxicity was seen in 5 patients (20%). All patients finished their IVRT as scheduled, and there was no grade 3 toxicity. With a median follow-up of 30 months, the 5-year progression-free and overall survival rate was 88%. None of the patients developed vaginal recurrence. Based on this study, surgical staging followed by IVRT and carboplatin/paclitaxel is well tolerated and effective in stage I-II serous endometrial cancer. Confirmation of these results on a larger number of patients with longer follow-up is still needed.",Journal Article,4079.0,31.0,report single institution experience surgical stage I-II serous endometrial combined carboplatin/paclitaxel intravaginal radiation IVRT 10/00 12/06 25 stage I-II patients serous endometrial treated institution surgery postoperative IVRT concurrent chemotherapy CT mean age 67 years old range 53-80 years Surgery consisted hysterectomy TAH/BSO 64 LAVH/BSO 36 peritoneal washing omental biopsy pelvic lymph-node dissection median 14 nodes Para-aortic node sampling 88 median 6 IVRT median dose 21 Gy range 18-21 Gy 3 fractions concurrent CT consisted carboplatin AUC=5 taxol 175 mg/m 2 given 3 weeks 6 cycles CT tolerated 22/25 88 receiving 6 cycles patients received or=5 cycles 2 owing physician preference 3 4 cycles 1 owing toxicity 5 cycles 1 patient 4 grade 3 toxicity abscess Grade 2 neurotoxicity seen 5 patients 20 patients finished IVRT scheduled grade 3 toxicity median follow-up 30 months 5-year progression-free overall survival rate 88 patients developed vaginal recurrence Based surgical staging followed IVRT carboplatin/paclitaxel tolerated effective stage I-II serous endometrial Confirmation larger number patients longer follow-up needed,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[6, 414, 8, 226, 731, 730, 4, 221, 82, 70, 215, 1744, 12, 75, 397, 927, 490, 2, 16720, 121, 12005, 59, 79, 2038, 2, 133, 1460, 243, 82, 70, 215, 7, 5, 1744, 12, 11, 73, 28, 114, 731, 5, 152, 573, 12005, 2, 750, 56, 425, 3, 313, 89, 10, 598, 60, 1095, 184, 699, 493, 60, 152, 1695, 1, 2622, 16704, 9477, 660, 26101, 9477, 511, 1639, 14790, 11404, 411, 2, 1110, 263, 289, 1161, 52, 213, 502, 4615, 3938, 289, 2874, 10, 1822, 4, 889, 52, 49, 12005, 52, 61, 10, 239, 381, 184, 203, 239, 381, 4, 27, 1550, 2, 750, 425, 1695, 1, 927, 6, 1376, 33, 2, 7544, 6, 3300, 81, 188, 18, 447, 454, 27, 244, 9, 49, 410, 425, 10, 149, 421, 5, 350, 243, 889, 357, 49, 410, 169, 7, 103, 15, 33, 410, 18, 3421, 6, 1473, 3863, 27, 2, 39, 410, 2, 14, 3421, 6, 155, 33, 410, 158, 14, 69, 39, 42, 88, 27, 155, 7979, 88, 18, 3561, 10, 527, 4, 33, 7, 179, 62, 7, 20455, 136, 12005, 22, 4394, 2, 125, 10, 77, 88, 27, 155, 5, 8, 52, 166, 126, 1, 201, 53, 3, 33, 111, 91, 115, 2, 63, 25, 116, 10, 889, 1292, 1, 3, 7, 276, 146, 90, 23, 26, 45, 221, 632, 370, 20, 12005, 2, 927, 490, 16, 149, 421, 2, 323, 4, 82, 70, 215, 1744, 12, 3551, 1, 46, 99, 23, 8, 1077, 207, 1, 7, 5, 589, 166, 126, 16, 1234, 575]",1438.0,19019418,Concurrent carboplatin/paclitaxel intravaginal radiation surgical stage I-II serous endometrial,4,0.020100502512562814
Symptom management in premenopausal patients with breast cancer.,The Lancet. Oncology,Lancet Oncol.,2008-10-01,"Women with breast cancer have many adverse symptoms, of which some are specific to premenopausal patients. Management of these common symptoms include non-hormonal drugs, such as antidepressants and antiseizure compounds to alleviate hot flushes. Non-oestrogenic vaginal lubricants seem to moderately decrease occurrence of vaginal dryness and dyspareunia. Transdermal testosterone alone has not been shown to improve libido in these women. Options for fertility preservation include cryopreservation of embryos or oocytes before chemotherapy. Exercise is the one evidenced-based intervention shown to positively affect cancer-related fatigue. However, effective prevention and treatments for peripheral neuropathy and paclitaxel acute pain syndrome remain elusive. Weight-bearing exercise helps to maintain bone strength with adequate intake of calcium and vitamin D. Use of bisphosphonates in women taking aromatase inhibitors (combined with ovarian suppression in premenopausal women) to prevent bone fractures has not been substantiated, although it should be considered in women with osteoporosis. No specific drug has been shown to prevent radiation-induced dermatitis alone. Although some effective treatments can counteract symptoms related to cancer or treatments, research is needed to expand evidence-based care in premenopausal survivors of breast cancer.",Journal Article,4129.0,35.0,Women breast adverse symptoms specific premenopausal patients Management common symptoms include non-hormonal drugs antidepressants antiseizure compounds alleviate hot flushes Non-oestrogenic vaginal lubricants moderately decrease occurrence vaginal dryness dyspareunia Transdermal testosterone shown improve libido women Options fertility preservation include cryopreservation embryos oocytes chemotherapy Exercise evidenced-based intervention shown positively affect cancer-related fatigue effective prevention treatments peripheral neuropathy paclitaxel acute pain syndrome remain elusive Weight-bearing exercise helps maintain bone strength adequate intake calcium vitamin D. Use bisphosphonates women taking aromatase inhibitors combined ovarian suppression premenopausal women prevent bone fractures substantiated considered women osteoporosis specific drug shown prevent radiation-induced dermatitis effective treatments counteract symptoms related treatments research needed expand evidence-based care premenopausal survivors breast,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[117, 5, 12, 47, 445, 290, 507, 1, 92, 476, 32, 112, 6, 2710, 7, 284, 1, 46, 186, 507, 643, 220, 1761, 600, 225, 22, 12261, 2, 24998, 2411, 6, 8193, 2859, 18182, 220, 45358, 37673, 3233, 6, 3508, 775, 2291, 1, 15822, 2, 22098, 15101, 2660, 279, 71, 44, 85, 443, 6, 401, 16647, 4, 46, 117, 838, 9, 2954, 2224, 643, 10270, 1, 17250, 15, 19581, 348, 56, 2277, 16, 3, 104, 4728, 90, 788, 443, 6, 2375, 1158, 12, 139, 613, 137, 323, 1070, 2, 640, 9, 672, 1751, 2, 490, 286, 559, 681, 918, 5327, 924, 1894, 2277, 6484, 6, 3040, 3671, 5, 1658, 1514, 1, 3299, 2, 1610, 427, 119, 1, 4354, 4, 117, 2727, 2106, 222, 397, 5, 1332, 4, 2710, 117, 6, 1682, 3909, 71, 44, 85, 19599, 242, 192, 257, 40, 515, 4, 117, 5, 4970, 77, 112, 234, 71, 85, 443, 6, 1682, 121, 277, 5236, 279, 242, 476, 323, 640, 122, 12141, 507, 139, 6, 12, 15, 640, 389, 16, 575, 6, 4082, 241, 90, 165, 4, 2710, 332, 1, 12]",1302.0,19071256,Symptom management premenopausal patients breast,9,0.04522613065326633
Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes.,Gynecologic oncology,Gynecol. Oncol.,2009-01-01,"To determine recurrence patterns and survival outcomes of stage II uterine papillary serous carcinoma (UPSC) patients treated by various modalities with an emphasis on carboplatin/paclitaxel-based chemotherapy (CT)+/-radiotherapy (RT). A retrospective, multi-institution study of women with stage II UPSC diagnosed from 1992 to 2006 was performed. All patients underwent comprehensive surgical staging. Treatment included observation (OBS), RT (vaginal brachytherapy, whole pelvic and/or whole abdominal therapy), or >or=3 cycles carboplatin/paclitaxel alone or with RT. Recurrence and survival outcomes were determined. We identified 55 subjects: 10 treated with OBS, 26 with RT alone and 19 with CT+/-RT. After a median follow-up of 33 mos (range, 10-119), 20 recurrences (36%) were observed. There was an overall difference in recurrence based upon treatment (p=.013). Specifically, all CT+/-RT treated patients had a lower risk of recurrence (11%) compared to patients treated by RT alone (50%) or OBS (50%). No patients treated with both CT+RT (n=12) experienced a recurrence. Treatment with CT was also associated with a decreased risk of recurrence on multivariate analysis (p=.015). Most recurrences were extra-pelvic (70%), occurred within 2 years (85%) and were not salvageable (84%). Five-year progression-free survival was 86% in chemotherapy-treated patients versus 41% in those not receiving chemotherapy (p=.010); overall survival was 88% in chemotherapy-treated patients versus 64% in those not receiving chemotherapy (p=.115). Stage II UPSC patients have a significant risk for unsalvageable, extra-pelvic recurrence. However, treatment with platinum/taxane therapy+/-RT appears to reduce this risk and is associated with improved progression free survival outcomes.",Journal Article,4037.0,58.0,determine recurrence patterns survival outcomes stage II uterine papillary serous carcinoma UPSC patients treated modalities emphasis carboplatin/paclitaxel-based chemotherapy CT +/-radiotherapy RT retrospective multi-institution women stage II UPSC diagnosed 1992 2006 performed patients underwent comprehensive surgical staging Treatment included observation OBS RT vaginal brachytherapy pelvic and/or abdominal therapy or=3 cycles carboplatin/paclitaxel RT Recurrence survival outcomes determined identified 55 subjects 10 treated OBS 26 RT 19 CT+/-RT median follow-up 33 mos range 10-119 20 recurrences 36 observed overall difference recurrence based treatment p=.013 Specifically CT+/-RT treated patients lower risk recurrence 11 compared patients treated RT 50 OBS 50 patients treated CT+RT n=12 experienced recurrence Treatment CT associated decreased risk recurrence multivariate p=.015 recurrences extra-pelvic 70 occurred 2 years 85 salvageable 84 Five-year progression-free survival 86 chemotherapy-treated patients versus 41 receiving chemotherapy p=.010 overall survival 88 chemotherapy-treated patients versus 64 receiving chemotherapy p=.115 Stage II UPSC patients significant risk unsalvageable extra-pelvic recurrence treatment platinum/taxane therapy+/-RT appears reduce risk associated improved progression free survival outcomes,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[6, 223, 146, 764, 2, 25, 123, 1, 82, 215, 1796, 1744, 134, 5676, 7, 73, 20, 747, 1558, 5, 35, 3136, 23, 927, 490, 90, 56, 425, 310, 240, 8, 459, 1414, 731, 45, 1, 117, 5, 82, 215, 5676, 265, 29, 2846, 6, 1324, 10, 173, 62, 7, 208, 949, 221, 632, 24, 159, 1664, 10291, 240, 1536, 902, 1110, 2, 15, 902, 1467, 36, 15, 15, 27, 410, 927, 490, 279, 15, 5, 240, 146, 2, 25, 123, 11, 509, 21, 108, 614, 976, 79, 73, 5, 10291, 432, 5, 240, 279, 2, 326, 5, 425, 240, 50, 8, 52, 166, 126, 1, 466, 5166, 184, 79, 4299, 179, 1593, 511, 11, 164, 125, 10, 35, 63, 523, 4, 146, 90, 1548, 24, 19, 3612, 1225, 62, 425, 240, 73, 7, 42, 8, 280, 43, 1, 146, 175, 72, 6, 7, 73, 20, 240, 279, 212, 15, 10291, 212, 77, 7, 73, 5, 110, 425, 240, 78, 133, 592, 8, 146, 24, 5, 425, 10, 120, 41, 5, 8, 340, 43, 1, 146, 23, 331, 65, 19, 3433, 96, 1593, 11, 3420, 1110, 431, 489, 262, 18, 60, 772, 2, 11, 44, 28123, 874, 365, 111, 91, 115, 25, 10, 868, 4, 56, 73, 7, 185, 605, 4, 135, 44, 357, 56, 19, 4873, 63, 25, 10, 889, 4, 56, 73, 7, 185, 660, 4, 135, 44, 357, 56, 19, 3670, 82, 215, 5676, 7, 47, 8, 93, 43, 9, 34472, 3420, 1110, 146, 137, 24, 5, 828, 1715, 36, 240, 1233, 6, 969, 26, 43, 2, 16, 41, 5, 231, 91, 115, 25, 123]",1692.0,19118888,Stage II uterine papillary serous carcinoma Carboplatin/paclitaxel chemotherapy improves recurrence survival outcomes,1,0.005025125628140704
Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2009-01-12,"Vascular endothelial growth factor is a key promoter of tumor progression in cervical carcinoma. The Gynecologic Oncology Group (GOG) conducted a phase II trial to assess the efficacy and tolerability of bevacizumab, a recombinant humanized anti-vascular endothelial growth factor monoclonal antibody. Eligible patients had recurrent cervical cancer, measurable disease, and GOG performance status < or = 2. Treatment consisted of bevacizumab 15 mg/kg intravenously every 21 days until disease progression or prohibitive toxicity. Primary end points were progression-free survival (PFS) at 6 months and toxicity. Forty-six patients were enrolled (median age, 46 years); 38 patients (82.6%) received prior radiation as well as either one (n = 34, 73.9%) or two (n = 12, 26.1%) prior cytotoxic regimens for recurrent disease. Grade 3 or 4 adverse events at least possibly related to bevacizumab included hypertension (n = 7), thrombo-embolism (n = 5), GI (n = 4), anemia (n = 2), other cardiovascular (n = 2), vaginal bleeding (n = 1), neutropenia (n = 1), and fistula (n = 1). One grade 5 infection was observed. Eleven patients (23.9%; two-sided 90% CI, 14% to 37%) survived progression free for at least 6 months, and five patients (10.9%; two-sided 90% CI, 4% to 22%) had partial responses. The median response duration was 6.21 months (range, 2.83 to 8.28 months). The median PFS and overall survival times were 3.40 months (95% CI, 2.53 to 4.53 months) and 7.29 months (95% CI, 6.11 to 10.41 months), respectively. This compared favorably with historical phase II GOG trials in this setting. CONCLUSION Bevacizumab seems to be well tolerated and active in the second- and third-line treatment of patients with recurrent cervical cancer and merits phase III investigation.","Clinical Trial, Phase II",4026.0,218.0,Vascular endothelial growth factor key promoter progression cervical carcinoma Gynecologic Oncology Group GOG conducted phase II trial assess efficacy tolerability bevacizumab recombinant humanized anti-vascular endothelial growth factor monoclonal antibody Eligible patients recurrent cervical measurable disease GOG performance status 2 Treatment consisted bevacizumab 15 mg/kg intravenously 21 days disease progression prohibitive toxicity Primary end points progression-free survival PFS 6 months toxicity Forty-six patients enrolled median age 46 years 38 patients 82.6 received prior radiation n 34 73.9 n 12 26.1 prior cytotoxic regimens recurrent disease Grade 3 4 adverse events possibly related bevacizumab included hypertension n 7 thrombo-embolism n 5 GI n 4 anemia n 2 cardiovascular n 2 vaginal bleeding n 1 neutropenia n 1 fistula n 1 grade 5 infection observed patients 23.9 two-sided 90 CI 14 37 survived progression free 6 months patients 10.9 two-sided 90 CI 4 22 partial responses median response duration 6.21 months range 2.83 8.28 months median PFS overall survival times 3.40 months 95 CI 2.53 4.53 months 7.29 months 95 CI 6.11 10.41 months respectively compared favorably historical phase II GOG trials setting Bevacizumab tolerated active second- third-line treatment patients recurrent cervical merits phase III investigation,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[756, 845, 129, 161, 16, 8, 825, 973, 1, 30, 91, 4, 134, 3, 1512, 413, 87, 4760, 426, 8, 124, 215, 160, 6, 423, 3, 209, 2, 1543, 1, 599, 8, 2835, 3619, 312, 756, 845, 129, 161, 848, 548, 625, 7, 42, 387, 12, 1884, 34, 2, 4760, 528, 156, 15, 18, 24, 1695, 1, 599, 167, 81, 503, 1672, 454, 239, 162, 1100, 34, 91, 15, 10784, 155, 86, 396, 862, 11, 91, 115, 25, 300, 28, 49, 53, 2, 155, 1213, 437, 7, 11, 346, 52, 89, 641, 60, 519, 7, 878, 49, 103, 324, 121, 22, 149, 22, 361, 104, 78, 562, 803, 83, 15, 100, 78, 133, 432, 14, 324, 759, 472, 9, 387, 34, 88, 27, 15, 39, 290, 281, 28, 506, 2150, 139, 6, 599, 159, 1824, 78, 67, 23453, 5475, 78, 33, 2104, 78, 39, 1545, 78, 18, 127, 2179, 78, 18, 2294, 78, 14, 778, 78, 14, 2, 4920, 78, 14, 104, 88, 33, 930, 10, 164, 2627, 7, 382, 83, 100, 1689, 424, 58, 213, 6, 567, 2996, 91, 115, 9, 28, 506, 49, 53, 2, 365, 7, 79, 83, 100, 1689, 424, 58, 39, 6, 350, 42, 450, 253, 3, 52, 51, 654, 10, 49, 239, 53, 184, 18, 852, 6, 66, 339, 53, 3, 52, 300, 2, 63, 25, 1072, 11, 27, 327, 53, 48, 58, 18, 699, 6, 39, 699, 53, 2, 67, 462, 53, 48, 58, 49, 175, 6, 79, 605, 53, 106, 26, 72, 5001, 5, 2252, 124, 215, 4760, 143, 4, 26, 546, 1221, 599, 2744, 6, 40, 149, 421, 2, 544, 4, 3, 419, 2, 1282, 328, 24, 1, 7, 5, 387, 12, 2, 4986, 124, 316, 940]",1629.0,19139430,Phase II trial bevacizumab treatment persistent recurrent squamous carcinoma cervix gynecologic oncology group,1,0.005025125628140704
Maternal health conditions during pregnancy and acute leukemia in children with Down syndrome: A Children's Oncology Group study.,Pediatric blood & cancer,Pediatr Blood Cancer,2009-05-01,"Children with Down syndrome (DS) have about a 20-fold increased risk of developing leukemia. Early childhood infections may protect against acute lymphoid leukemia (ALL) in children with and without DS. We examined whether maternal infections and health conditions during pregnancy were associated with acute leukemia in children with DS. We conducted a case-control study of 158 children with DS and leukemia (including 97 cases with acute lymphoblastic leukemia (ALL) and 61 cases with acute myeloid leukemia (AML)) and 173 children with DS during the period 1997-2002. Maternal interview included information about 14 maternal conditions during gestation that are likely to induce an inflammatory response. We evaluated their prevalence in cases and controls. Five of these were common enough to allow analyses by leukemia subtype. Vaginal bleeding was the most frequent (18% cases, 25% controls) and was associated with a reduced risk (odds ratio (OR) = 0.57; 95% confidence interval (CI) = 0.33-0.99) for all cases combined. Other variables, while showing a potential trend toward reduced risk had effect estimates, which were imprecise and not statistically significant. In contrast, amniocentesis was marginally associated with an increased risk of AML (OR = 2.06, 95% CI = 0.90-4.69). Data from this exploratory investigation suggest that some health conditions during pregnancy may be relevant in childhood leukemogenesis. Larger epidemiological studies and other model systems (animal, clinical studies) may provide a clearer picture of the potential association and mechanisms.",Journal Article,3917.0,10.0,Children syndrome DS 20-fold increased risk developing leukemia Early childhood infections protect acute lymphoid leukemia children DS examined maternal infections health conditions pregnancy associated acute leukemia children DS conducted case-control 158 children DS leukemia including 97 cases acute lymphoblastic leukemia 61 cases acute myeloid leukemia AML 173 children DS period 1997-2002 Maternal interview included information 14 maternal conditions gestation likely induce inflammatory response evaluated prevalence cases controls common allow leukemia subtype Vaginal bleeding frequent 18 cases 25 controls associated reduced risk odds ratio 0.57 95 confidence interval CI 0.33-0.99 cases combined variables showing potential trend reduced risk effect estimates imprecise statistically significant contrast amniocentesis marginally associated increased risk AML 2.06 95 CI 0.90-4.69 exploratory investigation suggest health conditions pregnancy relevant childhood leukemogenesis Larger epidemiological studies model systems animal clinical studies provide clearer picture potential association mechanisms,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[541, 5, 1328, 681, 3602, 47, 545, 8, 179, 1116, 101, 43, 1, 931, 191, 864, 1875, 68, 4869, 480, 286, 2303, 62, 4, 541, 5, 2, 187, 3602, 21, 409, 317, 6039, 1875, 2, 341, 1298, 190, 2290, 11, 41, 5, 286, 4, 541, 5, 3602, 21, 426, 8, 473, 182, 45, 1, 5162, 541, 5, 3602, 2, 141, 1015, 140, 5, 286, 1275, 62, 2, 713, 140, 5, 286, 533, 329, 2, 5785, 541, 5, 3602, 190, 3, 727, 2341, 1544, 6039, 4313, 159, 487, 545, 213, 6039, 1298, 190, 13250, 17, 32, 322, 6, 1290, 35, 1291, 51, 21, 194, 136, 1078, 4, 140, 2, 535, 365, 1, 46, 11, 186, 5151, 6, 1700, 318, 20, 875, 2294, 10, 3, 96, 908, 203, 140, 243, 535, 2, 10, 41, 5, 8, 405, 43, 610, 197, 15, 13, 696, 48, 307, 268, 58, 13, 466, 13, 1058, 9, 62, 140, 397, 127, 682, 369, 2069, 8, 174, 853, 1317, 405, 43, 42, 254, 1423, 92, 11, 18486, 2, 44, 712, 93, 4, 748, 57628, 10, 5007, 41, 5, 35, 101, 43, 1, 329, 15, 18, 1460, 48, 58, 13, 424, 39, 790, 74, 29, 26, 2386, 940, 309, 17, 476, 341, 1298, 190, 2290, 68, 40, 867, 4, 864, 5661, 1077, 4614, 94, 2, 127, 202, 1530, 2026, 38, 94, 68, 377, 8, 15960, 8951, 1, 3, 174, 248, 2, 483]",1464.0,19148952,Maternal health conditions pregnancy acute leukemia children syndrome Children 's Oncology Group,0,0.0
Ultrasonic surgical aspiration for vaginal intraepithelial neoplasia.,International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,Int J Gynaecol Obstet,2009-01-15,"To determine the safety and efficacy of ultrasonic surgical aspiration (USA) in the treatment of vaginal intraepithelial neoplasia (VAIN). Using the ICD code for VAIN, all patients who underwent USA were evaluated. Patient demographics, clinicopathologic data, and follow-up outcomes were abstracted from the medical records. Ninety-two patients underwent USA for VAIN. No surgical complications or postoperative scarring were recorded, and all patients were followed without further therapy after the procedure. Pathologic evaluation of the degree of VAIN in the aspirate obtained at the time of USA correlated with the preoperative biopsy results in all cases. With a median follow-up period of 4.5 years, the overall recurrence rate was 19.6%. The recurrence rate for high grade VAIN was significantly greater than that for low grade VAIN (32.3% vs 13.1%, P=0.044). Ultrasonic surgical aspiration is a safe and effective surgical option for VAIN, providing a histologic sample with minimal invasiveness.",Journal Article,4023.0,12.0,determine safety efficacy ultrasonic surgical aspiration USA treatment vaginal intraepithelial neoplasia VAIN ICD code VAIN patients underwent USA evaluated Patient demographics clinicopathologic follow-up outcomes abstracted medical records Ninety-two patients underwent USA VAIN surgical complications postoperative scarring recorded patients followed therapy procedure Pathologic evaluation degree VAIN aspirate obtained time USA correlated preoperative biopsy cases median follow-up period 4.5 years overall recurrence rate 19.6 recurrence rate high grade VAIN significantly greater low grade VAIN 32.3 vs 13.1 P=0.044 Ultrasonic surgical aspiration safe effective surgical option VAIN providing histologic minimal invasiveness,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 223, 3, 367, 2, 209, 1, 19027, 221, 3256, 2706, 4, 3, 24, 1, 4153, 2298, 14802, 75, 3, 7320, 5853, 9, 14802, 62, 7, 54, 208, 2706, 11, 194, 69, 2221, 1399, 74, 2, 166, 126, 123, 11, 4106, 29, 3, 484, 1064, 2493, 100, 7, 208, 2706, 9, 14802, 77, 221, 521, 15, 573, 13542, 11, 1872, 2, 62, 7, 11, 370, 187, 195, 36, 50, 3, 1299, 510, 451, 1, 3, 1444, 1, 14802, 4, 3, 8022, 683, 28, 3, 98, 1, 2706, 438, 5, 3, 498, 411, 99, 4, 62, 140, 5, 8, 52, 166, 126, 727, 1, 39, 33, 60, 3, 63, 146, 116, 10, 326, 49, 3, 146, 116, 9, 64, 88, 14802, 10, 97, 378, 76, 17, 9, 154, 88, 14802, 531, 27, 105, 233, 14, 19, 13, 6194, 19027, 221, 3256, 16, 8, 1165, 2, 323, 221, 1501, 9, 14802, 1736, 8, 884, 1000, 5, 1048, 3807]",973.0,19150056,Ultrasonic surgical aspiration vaginal intraepithelial neoplasia,17,0.08542713567839195
Pediatric radical abdominal trachelectomy for anaplastic embryonal rhabdomyosarcoma of the uterine cervix: an alternative to radical hysterectomy.,Journal of pediatric surgery,J. Pediatr. Surg.,2009-04-01,"Rhabdomyosarcoma arising in the female genital tract carries 5-year survival in excess of 80%, but lifelong infertility may be a consequence of local control strategies. We present the technique and outcome for a fertility-sparing, radical abdominal trachelectomy in a 12-year-old girl with anaplastic, embryonal rhabdomyosarcoma involving the uterine cervix. The patient had presented to our center after the piecemeal resection of a uterine cervical mass; because of concern about microscopic residual disease, we classified her as group II-A according to the Intergroup Rhabdomyosarcoma Study system. Staging studies excluded the presence of distant disease. The patient received 4 cycles of multiagent chemotherapy and then underwent radical abdominal trachelectomy, with removal of the uterine cervix, parametria, vaginal cuff, and regional lymph nodes. Microscopically, the specimen showed treatment effect and no residual tumor. Regional nodes were negative. Radical abdominal trachelectomy, which has not been previously reported for rhabdomyosarcoma, has appeared to secure local disease control in this case while preserving the patient's future fertility potential. In properly selected cases of rhabdomyosarcoma of the uterine cervix, where involvement of the uterus proper is not present, radical abdominal trachelectomy may be an attractive fertility-sparing alternative to radical hysterectomy.",Case Reports,3947.0,17.0,Rhabdomyosarcoma arising female genital tract carries 5-year survival excess 80 lifelong infertility consequence local control strategies present technique outcome fertility-sparing radical abdominal trachelectomy 12-year-old girl anaplastic embryonal rhabdomyosarcoma involving uterine cervix patient presented center piecemeal resection uterine cervical mass concern microscopic residual disease classified group II-A according Intergroup Rhabdomyosarcoma Staging studies excluded presence distant disease patient received 4 cycles multiagent chemotherapy underwent radical abdominal trachelectomy removal uterine cervix parametria vaginal cuff regional lymph nodes Microscopically specimen showed treatment effect residual Regional nodes negative Radical abdominal trachelectomy previously reported rhabdomyosarcoma appeared secure local disease control case preserving patient 's future fertility potential properly selected cases rhabdomyosarcoma uterine cervix involvement uterus proper present radical abdominal trachelectomy attractive fertility-sparing alternative radical hysterectomy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[2635, 4, 3, 1061, 8226, 1696, 4942, 33, 111, 25, 4, 2612, 1, 493, 84, 9590, 5901, 68, 40, 8, 4177, 1, 293, 182, 422, 21, 364, 3, 1312, 2, 228, 9, 8, 2954, 1851, 711, 1467, 5760, 4, 8, 133, 111, 1095, 12079, 5, 1841, 5239, 1267, 3, 3629, 3, 69, 42, 917, 6, 114, 574, 50, 3, 28901, 170, 1, 8, 782, 408, 1, 2893, 545, 2984, 753, 34, 21, 1373, 1084, 22, 87, 215, 8, 768, 6, 3, 4839, 45, 398, 632, 94, 1800, 3, 463, 1, 626, 34, 3, 69, 103, 39, 410, 1, 7148, 56, 2, 818, 208, 711, 1467, 5760, 5, 2829, 1, 3, 3629, 19585, 11445, 2, 951, 263, 502, 7187, 3, 2360, 224, 24, 254, 2, 77, 753, 30, 951, 502, 11, 199, 711, 1467, 5760, 92, 71, 44, 85, 373, 210, 9, 71, 2121, 6, 14520, 293, 34, 182, 4, 26, 473, 369, 4972, 3, 69, 292, 508, 2954, 174, 4, 6785, 715, 140, 1, 1, 3, 3629, 1257, 799, 1, 3, 4576, 16, 44, 364, 711, 1467, 5760, 68, 40, 35, 3059, 2954, 1851, 1091, 6, 711, 2622]",1245.0,19361657,Pediatric radical abdominal trachelectomy anaplastic embryonal rhabdomyosarcoma uterine cervix alternative radical hysterectomy,0,0.0
Role of laparoscopic surgery in the management of endometrial cancer.,Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2009-05-01,"Minimum surgical treatment for endometrial cancer is removal of the uterus. The operative approach to achieve that goal ranges from vaginal hysterectomy alone to laparotomy with radical hysterectomy, bilateral salpingoophorectomy, bilateral pelvic and para-aortic lymphadenectomy with possible omentectomy, and resection of all metastatic disease. Stratifying the risk factors for predicting presence of metastatic disease has error rates exceeding tolerance for many gynecologic oncologists. Most accept routine laparoscopic surgical staging with hysterectomy, pelvic and para-aortic lymphadenectomy, and removal of adnexa as standard care for patients with endometrial cancer. Modifying the extent of surgical staging for low-risk intrauterine findings or excessive risk for postoperative morbidity is also accepted. Laparoscopic surgery has become the ideal initial surgical approach for this disease, allowing for visual inspection of common metastatic sites, biopsy of abnormal areas, and cytology from peritoneal surfaces. The extent of staging can be altered depending on frozen section findings from the uterus, adnexa, and peritoneal surfaces. Intraoperative medical decision-making can be individualized, encompassing all known risk factors for metastases and balancing comorbidities and potential adverse outcomes. This article documents how laparoscopic surgery satisfies the needs of individual patients and surgeons treating this disease.",Journal Article,3917.0,2.0,Minimum surgical treatment endometrial removal uterus operative approach achieve goal ranges vaginal hysterectomy laparotomy radical hysterectomy bilateral salpingoophorectomy bilateral pelvic para-aortic lymphadenectomy possible omentectomy resection metastatic disease Stratifying risk factors predicting presence metastatic disease error rates exceeding tolerance gynecologic oncologists accept routine laparoscopic surgical staging hysterectomy pelvic para-aortic lymphadenectomy removal adnexa standard care patients endometrial Modifying extent surgical staging low-risk intrauterine findings excessive risk postoperative morbidity accepted Laparoscopic surgery ideal initial surgical approach disease allowing visual inspection common metastatic sites biopsy abnormal areas cytology peritoneal surfaces extent staging altered depending frozen section findings uterus adnexa peritoneal surfaces Intraoperative medical decision-making individualized encompassing known risk factors metastases balancing comorbidities potential adverse outcomes article documents laparoscopic surgery satisfies needs individual patients surgeons treating disease,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[2499, 221, 24, 9, 12, 16, 2829, 1, 3, 3, 1208, 353, 6, 1359, 17, 1326, 5632, 29, 2622, 279, 6, 3274, 5, 711, 2622, 1607, 28913, 1607, 1110, 2, 4615, 3938, 2048, 5, 899, 20196, 2, 170, 1, 62, 113, 34, 5035, 3, 43, 130, 9, 1434, 463, 1, 113, 34, 71, 3444, 151, 5178, 2614, 9, 445, 1512, 1339, 96, 11485, 1311, 1964, 221, 632, 5, 2622, 1110, 2, 4615, 3938, 2048, 2, 2829, 1, 17778, 22, 260, 165, 9, 7, 5, 12, 4898, 3, 1039, 1, 221, 632, 9, 154, 43, 18242, 272, 15, 4529, 43, 9, 573, 787, 16, 120, 3058, 1964, 152, 71, 1417, 3, 3662, 388, 221, 353, 9, 26, 34, 2952, 9, 3046, 11746, 1, 186, 113, 633, 411, 1, 1668, 1361, 2, 2045, 29, 1639, 8835, 3, 1039, 1, 632, 122, 40, 1495, 3221, 23, 3015, 2917, 272, 29, 3, 17778, 2, 1639, 8835, 1720, 484, 948, 1079, 122, 40, 2596, 6853, 62, 440, 43, 130, 9, 196, 2, 13013, 1909, 2, 174, 290, 123, 26, 946, 9337, 832, 1964, 152, 43322, 3, 1891, 1, 797, 7, 2, 1613, 1367, 26, 34]",1386.0,19460281,Role laparoscopic surgery management endometrial,7,0.035175879396984924
Prediagnostic symptoms of ovarian carcinoma: a case-control study.,Gynecologic oncology,Gynecol. Oncol.,2009-05-22,"Women with ovarian carcinoma experience poor survival because symptoms are vague and diagnosis is unlikely at an early stage. The objective of this study was to identify a set of symptoms that might assist gynecologists and other clinicians in the diagnosis of localized ovarian carcinoma when treatment is most effective. This population-based case-control study included 432 women, aged 19-88 years, with invasive ovarian carcinoma and 491 controls frequency-matched to cases on age, ethnicity, and interview time. Symptoms data were collected using interviewer-administered questionnaires. Odds ratios and 95% confidence intervals for the association of symptoms with ovarian carcinoma by stage and histology were estimated using unconditional multiple polytomous logistic regression models. The predictive ability of symptoms was evaluated by comparing the area under receiver operating curves (ROC). The following self-reported symptoms were significantly predictive of localized ovarian carcinoma irrespective of histological type: abdominal pain (ROC=0.81), distended and hard abdomen (ROC=0.83), vaginal bleeding not associated with periods (ROC=0.88), and a palpable abdominal mass (ROC=0.88). Urinary symptoms had low predictive ability, and bowel symptoms and fatigue/loss of appetite were predictive only at advanced stages. The best predictive ability was observed for a 4-symptom index that included abdominal pain, distended and hard abdomen, abdominal mass, and abnormal vaginal bleeding (ROC=0.90 sensitivity=74%; specificity=71%). Greater awareness of the symptoms potentially related to ovarian cancer might lead to earlier diagnosis and might improve survival.",Journal Article,3896.0,28.0,Women ovarian carcinoma experience poor survival symptoms vague diagnosis unlikely early stage objective identify set symptoms assist gynecologists clinicians diagnosis localized ovarian carcinoma treatment effective population-based case-control included 432 women aged 19-88 years invasive ovarian carcinoma 491 controls frequency-matched cases age ethnicity interview time Symptoms collected interviewer-administered questionnaires Odds ratios 95 confidence intervals association symptoms ovarian carcinoma stage histology estimated unconditional multiple polytomous logistic regression models predictive ability symptoms evaluated comparing area receiver operating curves ROC following self-reported symptoms significantly predictive localized ovarian carcinoma irrespective histological type abdominal pain ROC=0.81 distended hard abdomen ROC=0.83 vaginal bleeding associated periods ROC=0.88 palpable abdominal mass ROC=0.88 Urinary symptoms low predictive ability bowel symptoms fatigue/loss appetite predictive advanced stages best predictive ability observed 4-symptom index included abdominal pain distended hard abdomen abdominal mass abnormal vaginal bleeding ROC=0.90 sensitivity=74 specificity=71 Greater awareness symptoms potentially related ovarian lead earlier diagnosis improve survival,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[117, 5, 134, 730, 334, 25, 408, 507, 32, 17312, 2, 147, 16, 3568, 28, 35, 191, 82, 3, 461, 1, 26, 45, 10, 6, 255, 8, 916, 1, 507, 17, 822, 3425, 14854, 2, 127, 1490, 4, 3, 147, 1, 909, 134, 198, 24, 16, 96, 323, 26, 266, 90, 473, 182, 45, 159, 11395, 117, 1032, 326, 889, 60, 5, 416, 134, 2, 10333, 535, 675, 655, 6, 140, 23, 89, 2091, 2, 4313, 98, 507, 74, 11, 786, 75, 22543, 468, 2956, 610, 1137, 2, 48, 307, 1582, 9, 3, 248, 1, 507, 5, 134, 20, 82, 2, 784, 11, 661, 75, 6438, 232, 13540, 812, 320, 274, 3, 464, 801, 1, 507, 10, 194, 20, 1430, 3, 965, 669, 3185, 2584, 2400, 3783, 3, 366, 1074, 210, 507, 11, 97, 464, 1, 909, 134, 3500, 1, 1831, 267, 1467, 559, 3783, 13, 865, 26178, 2, 9327, 4036, 3783, 13, 852, 2294, 44, 41, 5, 3338, 3783, 13, 889, 2, 8, 4880, 1467, 782, 3783, 13, 889, 1660, 507, 42, 154, 464, 801, 2, 1659, 507, 2, 613, 407, 1, 4062, 11, 464, 158, 28, 131, 1153, 3, 824, 464, 801, 10, 164, 9, 8, 39, 934, 558, 17, 159, 1467, 559, 26178, 2, 9327, 4036, 1467, 782, 2, 1668, 2294, 3783, 13, 424, 485, 794, 1121, 792, 378, 3310, 1, 3, 507, 751, 139, 6, 12, 822, 1122, 6, 1677, 147, 2, 822, 401, 25]",1578.0,19464044,Prediagnostic symptoms ovarian carcinoma case-control,1,0.005025125628140704
Patterns of regional recurrence after definitive radiotherapy for cervical cancer.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2009-07-04,"To determine the patterns of regional recurrence in patients treated with definitive radiotherapy (RT) for cervical cancer. The records of 198 patients treated with definitive RT for cervical cancer between 1980 and 2000 who experienced a regional recurrence without a central or distal vaginal recurrence were reviewed. All patients received a combination of external-beam RT and intracavitary brachytherapy. In the 180 patients with a documented location of regional recurrence, the relationship between the recurrence and the radiation fields was determined. The median time to regional recurrence was 13 months (range, 2-85 months). Of the 180 patients who had an evaluable regional recurrence, 119 (66%) had a component of marginal failure; 71 patients recurred above-the-field, 2 patients occurred in the inguinal nodes, and 2 patients recurred above-the-field and in the inguinal nodes. In addition, 105 patients (58%) had a component of in-field failure; 59 patients recurred in-field only, 39 patients recurred in-field and above-the-field, 2 patients recurred in-field, above-the-field, and in the inguinal nodes, and 5 patients recurred in-field and in the inguinal nodes. The median survival after regional recurrence was 8 months (range, 0-194 months). Most regional recurrences after definitive RT for cervical cancer include a component of marginal failure, usually immediately superior to the radiation field. These recurrences suggest a deficiency in target volume. Recurrences also occur in-field, suggesting a deficiency in dose. Developments in pretreatment staging, field delineation, dose escalation, and posttreatment surveillance may help to improve outcome in these patients.",Journal Article,3853.0,54.0,determine patterns regional recurrence patients treated definitive radiotherapy RT cervical records 198 patients treated definitive RT cervical 1980 2000 experienced regional recurrence central distal vaginal recurrence reviewed patients received combination external-beam RT intracavitary brachytherapy 180 patients documented location regional recurrence relationship recurrence radiation fields determined median time regional recurrence 13 months range 2-85 months 180 patients evaluable regional recurrence 119 66 component marginal failure 71 patients recurred above-the-field 2 patients occurred inguinal nodes 2 patients recurred above-the-field inguinal nodes addition 105 patients 58 component in-field failure 59 patients recurred in-field 39 patients recurred in-field above-the-field 2 patients recurred in-field above-the-field inguinal nodes 5 patients recurred in-field inguinal nodes median survival regional recurrence 8 months range 0-194 months regional recurrences definitive RT cervical include component marginal failure usually immediately superior radiation field recurrences suggest deficiency target volume Recurrences occur in-field suggesting deficiency dose Developments pretreatment staging field delineation dose escalation posttreatment surveillance help improve outcome patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 3, 764, 1, 951, 146, 4, 7, 73, 5, 1057, 310, 240, 9, 12, 3, 1064, 1, 6189, 7, 73, 5, 1057, 240, 9, 12, 59, 4376, 2, 1081, 54, 592, 8, 951, 146, 187, 8, 854, 15, 2107, 146, 11, 446, 62, 7, 103, 8, 150, 1, 1455, 1345, 240, 2, 9122, 1536, 4, 3, 3172, 7, 5, 8, 1405, 1147, 1, 951, 146, 3, 858, 59, 3, 146, 2, 3, 121, 3130, 10, 509, 3, 52, 98, 6, 951, 146, 10, 233, 53, 184, 18, 772, 53, 1, 3, 3172, 7, 54, 42, 35, 859, 951, 146, 4299, 700, 42, 8, 1249, 1, 3450, 496, 792, 7, 3363, 2090, 3, 1067, 18, 7, 489, 4, 3, 4907, 502, 2, 18, 7, 3363, 2090, 3, 1067, 2, 4, 3, 4907, 502, 4, 352, 3263, 7, 717, 42, 8, 1249, 1, 4, 1067, 496, 728, 7, 3363, 4, 1067, 158, 587, 7, 3363, 4, 1067, 2, 2090, 3, 1067, 18, 7, 3363, 4, 1067, 2090, 3, 1067, 2, 4, 3, 4907, 502, 2, 33, 7, 3363, 4, 1067, 2, 4, 3, 4907, 502, 3, 52, 25, 50, 951, 146, 10, 66, 53, 184, 13, 5434, 53, 96, 951, 1593, 50, 1057, 240, 9, 12, 643, 8, 1249, 1, 3450, 496, 2082, 3467, 1123, 6, 3, 121, 1067, 46, 1593, 309, 8, 2299, 4, 283, 433, 1593, 120, 1271, 4, 1067, 802, 8, 2299, 4, 61, 3703, 4, 1194, 632, 1067, 5529, 61, 1125, 2, 3149, 617, 68, 987, 6, 401, 228, 4, 46, 7]",1622.0,19581056,Patterns regional recurrence definitive radiotherapy cervical,0,0.0
Endometrial cancer in an adolescent: a possible manifestation of Cowden syndrome.,Obstetrics and gynecology,Obstet Gynecol,2009-08-01,"Cowden syndrome is an autosomal dominant disorder characterized by the development of multiple intestinal hamartomas, distinctive mucocutaneous lesions, and an increased risk of endometrial, breast, and thyroid cancer. An adolescent girl whose mother had a known germline PTEN mutation presented with abnormal vaginal bleeding and was diagnosed with a grade 2 endometrial adenocarcinoma. She underwent a robotic hysterectomy and was found to have no myometrial invasion or distant disease. Genetic testing revealed the patient to have the familial germline PTEN mutation. The strikingly young age of onset of this patient's endometrial cancer highlights the need for additional study to better understand Cowden syndrome and to determine what endometrial cancer screening and preventive strategies are needed.",Case Reports,3825.0,19.0,Cowden syndrome autosomal dominant disorder characterized development multiple intestinal hamartomas distinctive mucocutaneous lesions increased risk endometrial breast thyroid adolescent girl mother known germline PTEN presented abnormal vaginal bleeding diagnosed grade 2 endometrial adenocarcinoma underwent robotic hysterectomy myometrial invasion distant disease Genetic testing revealed patient familial germline PTEN strikingly young age onset patient 's endometrial highlights need additional better understand Cowden syndrome determine endometrial screening preventive strategies needed,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,"[5561, 681, 16, 35, 6084, 2156, 2645, 765, 20, 3, 193, 1, 232, 3077, 15473, 5049, 19418, 406, 2, 35, 101, 43, 1, 2, 12, 35, 3678, 12079, 1310, 9733, 42, 8, 440, 1009, 820, 258, 917, 5, 1668, 2294, 2, 10, 265, 5, 8, 88, 18, 449, 3109, 208, 8, 2895, 2622, 2, 10, 204, 6, 47, 77, 7327, 578, 15, 626, 34, 336, 471, 553, 3, 69, 6, 47, 3, 2200, 1009, 820, 258, 3, 6787, 1169, 89, 1, 1707, 1, 26, 69, 292, 12, 2527, 3, 594, 9, 402, 45, 6, 380, 1640, 5561, 681, 2, 6, 223, 2067, 12, 453, 2, 3494, 422, 32, 575]",730.0,19622968,Endometrial adolescent possible manifestation Cowden syndrome,2,0.010050251256281407
The expanding use of third-generation aromatase inhibitors: what the general internist needs to know.,Journal of general internal medicine,J Gen Intern Med,2009-11-01,"Breast cancer patients represent the largest group of adult cancer survivors in the US. Most breast cancers in women 50 years of age and older are hormone receptor positive. Third generation aromatase inhibitors (AIs) are the newest class of drugs used in treating hormone responsive breast cancer. It is often during start of adjuvant hormone therapy that the breast cancer patient establishes (or reestablishes) close follow-up with their general internist. Given the large numbers of breast cancer patients in the US and the increasing use of third generation AI's, general internists will need to have a clear understanding of these drugs including their benefits and potential harms. Currently there are three third generation aromatase inhibitors FDA approved for use in the US. All have been shown to be superior to tamoxifen in disease free survival (DFS) in the treatment of both metastatic and early breast cancers. While the data on side effects is limited, AI (compared to tamoxifen) may result in higher rates of osteoporosis and fractures, more arthralgias, and increased vaginal dryness and dysparuenia. Limited information on their effects on the cardiovascular system and neuro-cognitive function are also available. Patient's receiving adjuvant hormone therapy are generally considered disease free or disease stable and require less intensive monitoring by their breast cancer specialist. In situations where patients experience significant negative side effects from AI therapy, discussions to discontinue treatment (and switch to an alternative endocrine therapy) should involve the cancer specialist and take into consideration the patient's risk for breast cancer recurrence and the impact of therapy on their quality of life. In some cases, patients may choose to never initiate AI treatment. In other cases, patients may choose to prematurely discontinue therapy even if therapy is well tolerated. In both settings increased knowledge by the general internists will likely facilitate discussions of risks versus benefits of therapy and possibly improve compliance to adjuvant hormone therapy.",Journal Article,3733.0,13.0,Breast patients represent largest group adult survivors breast women 50 years age older hormone receptor positive generation aromatase inhibitors AIs newest class drugs treating hormone responsive breast start adjuvant hormone therapy breast patient establishes reestablishes close follow-up general internist Given large numbers breast patients increasing use generation AI 's general internists need clear understanding drugs including benefits potential harms Currently generation aromatase inhibitors FDA approved use shown superior tamoxifen disease free survival DFS treatment metastatic early breast effects limited AI compared tamoxifen higher rates osteoporosis fractures arthralgias increased vaginal dryness dysparuenia Limited information effects cardiovascular neuro-cognitive function available Patient 's receiving adjuvant hormone therapy generally considered disease free disease stable require intensive monitoring breast specialist situations patients experience significant negative effects AI therapy discussions discontinue treatment switch alternative endocrine therapy involve specialist consideration patient 's risk breast recurrence impact therapy quality life cases patients choose initiate AI treatment cases patients choose prematurely discontinue therapy therapy tolerated settings increased knowledge general internists likely facilitate discussions risks versus benefits therapy possibly improve compliance adjuvant hormone therapy,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[12, 7, 1231, 3, 2166, 87, 1, 780, 12, 332, 4, 3, 843, 96, 163, 4, 117, 212, 60, 1, 89, 2, 434, 32, 785, 153, 109, 1282, 914, 2106, 222, 3826, 32, 3, 16850, 1040, 1, 600, 95, 4, 1367, 785, 2443, 12, 192, 16, 629, 190, 2435, 1, 249, 785, 36, 17, 3, 12, 69, 7410, 15, 58338, 2336, 166, 126, 5, 136, 1083, 38401, 447, 3, 375, 1870, 1, 12, 7, 4, 3, 843, 2, 3, 602, 119, 1, 1282, 914, 2247, 292, 1083, 22383, 303, 594, 6, 47, 8, 885, 612, 1, 46, 600, 141, 136, 1141, 2, 174, 6753, 694, 125, 32, 169, 1282, 914, 2106, 222, 2078, 850, 9, 119, 4, 3, 843, 62, 47, 85, 443, 6, 40, 1123, 6, 1105, 4, 34, 115, 25, 1010, 4, 3, 24, 1, 110, 113, 2, 191, 163, 369, 3, 74, 23, 1152, 176, 16, 383, 2247, 72, 6, 1105, 68, 757, 4, 142, 151, 1, 4970, 2, 3909, 80, 13632, 2, 101, 15822, 2, 58339, 383, 487, 23, 136, 176, 23, 3, 2179, 398, 2, 4891, 1863, 343, 32, 120, 390, 69, 292, 357, 249, 785, 36, 32, 1228, 515, 34, 115, 15, 34, 585, 2, 1353, 299, 1686, 1315, 20, 136, 12, 6554, 4, 5990, 1257, 7, 730, 93, 199, 1152, 176, 29, 2247, 36, 3173, 6, 7934, 24, 2, 5096, 6, 35, 1091, 1293, 36, 257, 3882, 3, 12, 6554, 2, 3585, 237, 2415, 3, 69, 292, 43, 9, 12, 146, 2, 3, 345, 1, 36, 23, 136, 372, 1, 358, 4, 476, 140, 7, 68, 6009, 6, 1737, 4565, 2247, 24, 4, 127, 140, 7, 68, 6009, 6, 9771, 7934, 36, 871, 492, 36, 16, 149, 421, 4, 110, 1947, 101, 922, 20, 3, 1083, 22383, 303, 322, 1876, 3173, 1, 1098, 185, 1141, 1, 36, 2, 2150, 401, 3336, 6, 249, 785, 36]",2025.0,19838836,expanding use third-generation aromatase inhibitors general internist needs know,0,0.0
High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: a retrospective chart review.,Clinical therapeutics,Clin Ther,2009-01-01,"High-dose estrogens (HDEs) are an efficacious but widely overlooked treatment option for patients with metastatic breast cancer (MBC). This is due in part to the introduction of tamoxifen in the 1970s, which was proven to be equivalent in efficacy and associated with fewer adverse events (AEs). The aim of this study was to report our experience with the use of HDE in postmenopausal women with advanced breast cancer. Local institutional review board approval was obtained to conduct a retrospective chart review of patients with MBC treated with HDEs at the Boca Raton Comprehensive Cancer Center, Boca Raton, Florida, from 2001 through March 2009. Demographic information, response rates, and tolerability profiles were collected. Of the 426 patients with MBC identified, we found 26 patients with MBC who were prescribed HDEs as a treatment in any line of therapy for advanced breast cancer. The median age at the start of HDE therapy was 59 years (range, 42-92 years). Three of the 26 patients (11.5%) were human epidermal growth factor receptor 2-positive determined via fluorescent in situ hybridization analysis. With the exception of 1 patient who had received no prior systemic treatment for metastatic disease, all patients received multiple lines of treatment (both chemotherapy and hormonal treatments) in the advanced setting (median, 7 lines; range, 0-12) prior to the initiation of HDE. Five of 20 patients (25%) with measurable metastatic disease (visceral and/or soft tissue metastases) had objective antitumor responses defined as either a partial response (PR) or a complete response (CR). Four additional patients (20%) had prolonged stable disease (SD) for > or =6 months. Three of 6 patients (50%) with nonmeasurable metastatic disease (bone-only) had prolonged SD for > or =6 months. Clinical benefit rate (defined as CR + PR + SD > or =6 months) for all patients was 46% (12/26), with a median duration of 10 months. Overall median progression-free survival for the 26 subjects was 5 months. Median survival from the start of HDE was 17 months (range, 3-54 months). AEs included fluid retention (8 [31%]), vaginal bleeding (7 [27%]), and nausea (4 [15%]). Two patients discontinued therapy after 1 month. Three of the remaining 24 patients discontinued estrogen therapy due to AEs. This retrospective chart review details our facility's experience with the use of HDE in patients with advanced breast cancer, most of whom had received multiple prior treatments. Our data suggest that this treatment is another option for heavily-treated patients in whom further endocrine manipulation might still be appropriate.",Journal Article,4037.0,18.0,High-dose estrogens HDEs efficacious widely overlooked treatment option patients metastatic breast MBC introduction tamoxifen 1970s proven equivalent efficacy associated fewer adverse events AEs aim report experience use HDE postmenopausal women advanced breast Local institutional review board approval obtained conduct retrospective chart review patients MBC treated HDEs Boca Raton Comprehensive Center Boca Raton Florida 2001 March 2009 Demographic information response rates tolerability profiles collected 426 patients MBC identified 26 patients MBC prescribed HDEs treatment line therapy advanced breast median age start HDE therapy 59 years range 42-92 years 26 patients 11.5 human epidermal growth factor receptor 2-positive determined fluorescent situ hybridization exception 1 patient received prior systemic treatment metastatic disease patients received multiple lines treatment chemotherapy hormonal treatments advanced setting median 7 lines range 0-12 prior initiation HDE 20 patients 25 measurable metastatic disease visceral and/or soft tissue metastases objective antitumor responses defined partial response PR complete response CR additional patients 20 prolonged stable disease SD =6 months 6 patients 50 nonmeasurable metastatic disease bone-only prolonged SD =6 months Clinical benefit rate defined CR PR SD =6 months patients 46 12/26 median duration 10 months Overall median progression-free survival 26 subjects 5 months Median survival start HDE 17 months range 3-54 months AEs included fluid retention 8 31 vaginal bleeding 7 27 nausea 4 15 patients discontinued therapy 1 month remaining 24 patients discontinued estrogen therapy AEs retrospective chart review details facility 's experience use HDE patients advanced breast received multiple prior treatments suggest treatment option heavily-treated patients endocrine manipulation appropriate,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[64, 61, 6293, 39219, 32, 35, 3289, 84, 1792, 12549, 24, 1501, 9, 7, 5, 113, 12, 1864, 26, 16, 520, 4, 760, 6, 3, 2456, 1, 1105, 4, 3, 10868, 92, 10, 1930, 6, 40, 2017, 4, 209, 2, 41, 5, 1497, 290, 281, 1477, 3, 1130, 1, 26, 45, 10, 6, 414, 114, 730, 5, 3, 119, 1, 31575, 4, 1679, 117, 5, 131, 12, 293, 1115, 206, 2620, 1814, 10, 683, 6, 4073, 8, 459, 2937, 206, 1, 7, 5, 1864, 73, 5, 39219, 28, 3, 45860, 45861, 949, 12, 574, 45860, 45861, 10533, 29, 1758, 298, 2363, 1238, 1540, 487, 51, 151, 2, 1543, 1241, 11, 786, 1, 3, 12114, 7, 5, 1864, 108, 21, 204, 432, 7, 5, 1864, 54, 11, 2746, 39219, 22, 8, 24, 4, 500, 328, 1, 36, 9, 131, 12, 3, 52, 89, 28, 3, 2435, 1, 31575, 36, 10, 728, 60, 184, 595, 937, 60, 169, 1, 3, 432, 7, 175, 33, 11, 171, 829, 129, 161, 153, 18, 109, 509, 847, 2910, 4, 957, 1554, 65, 5, 3, 4188, 1, 14, 69, 54, 42, 103, 77, 324, 403, 24, 9, 113, 34, 62, 7, 103, 232, 285, 1, 24, 110, 56, 2, 1761, 640, 4, 3, 131, 546, 52, 67, 285, 184, 13, 133, 324, 6, 3, 1118, 1, 31575, 365, 1, 179, 7, 243, 5, 1884, 113, 34, 2737, 2, 15, 1214, 246, 196, 42, 461, 579, 253, 395, 22, 361, 8, 450, 51, 998, 15, 8, 236, 51, 684, 294, 402, 7, 179, 42, 1069, 585, 34, 1270, 9, 15, 49, 53, 169, 1, 49, 7, 212, 5, 18914, 113, 34, 3417, 158, 42, 1069, 1270, 9, 15, 49, 53, 38, 247, 116, 395, 22, 684, 998, 1270, 15, 49, 53, 9, 62, 7, 10, 641, 133, 432, 5, 8, 52, 654, 1, 79, 53, 63, 52, 91, 115, 25, 9, 3, 432, 976, 10, 33, 53, 52, 25, 29, 3, 2435, 1, 31575, 10, 269, 53, 184, 27, 667, 53, 1477, 159, 2357, 3947, 66, 456, 2294, 67, 428, 2, 1218, 39, 167, 100, 7, 2402, 36, 50, 14, 811, 169, 1, 3, 1844, 259, 7, 2402, 808, 36, 520, 6, 1477, 26, 459, 2937, 206, 3791, 114, 3483, 292, 730, 5, 3, 119, 1, 31575, 4, 7, 5, 131, 12, 96, 1, 953, 42, 103, 232, 324, 640, 114, 74, 309, 17, 26, 24, 16, 1809, 1501, 9, 2447, 73, 7, 4, 953, 195, 1293, 6239, 822, 1234, 40, 870]",2500.0,20110046,High-dose estrogen salvage hormonal therapy highly refractory metastatic breast retrospective chart review,9,0.04522613065326633
Symptom presentation in invasive ovarian carcinoma by tumor histological type and grade in a multiethnic population: a case analysis.,Gynecologic oncology,Gynecol. Oncol.,2010-06-29,"Although the majority of women with ovarian carcinoma report symptoms prior to diagnosis, little is known about comparative symptom presentation by histological type, stage, grade, or ethnicity. We conducted a population-based study including 622 women with invasive ovarian carcinoma diagnosed from 1993 to 2008. Epidemiological and symptom data were collected using an interviewer-administered questionnaire. Symptoms established as significant predictors of ovarian carcinoma were examined in relation to patient and tumor characteristics, using unconditional multivariate logistic regression and general linear models. Symptom presentation and duration differed significantly among women with ovarian carcinoma by stage, tumor histology, and grade, but not ethnicity. Significant differences were observed by histology in reporting a distended abdomen, abnormal vaginal bleeding, and bowel symptoms. Compared to women diagnosed with serous carcinoma, women with mucinous tumors were 2.6 times more likely to report a distended abdomen; women with endometrioid carcinoma were three times more likely to report abnormal bleeding. Women with serous tumors were significantly more likely to report bowel symptoms than were women diagnosed with other histological types. The majority of women with serous tumors were diagnosed with advanced cancer and had shorter duration of symptoms than women with early stage disease. In contrast, women with mucinous tumors were generally diagnosed at an early stage and had longer duration of symptoms (p=0.009) if diagnosed at an advanced stage. The study provides evidence that the early diagnosis of ovarian cancer is largely determined by tumor histological type.",Journal Article,3493.0,12.0,majority women ovarian carcinoma report symptoms prior diagnosis little known comparative symptom presentation histological type stage grade ethnicity conducted population-based including 622 women invasive ovarian carcinoma diagnosed 1993 2008 Epidemiological symptom collected interviewer-administered questionnaire Symptoms established significant predictors ovarian carcinoma examined relation patient characteristics unconditional multivariate logistic regression general linear models Symptom presentation duration differed significantly women ovarian carcinoma stage histology grade ethnicity Significant differences observed histology reporting distended abdomen abnormal vaginal bleeding bowel symptoms Compared women diagnosed serous carcinoma women mucinous 2.6 times likely report distended abdomen women endometrioid carcinoma times likely report abnormal bleeding Women serous significantly likely report bowel symptoms women diagnosed histological types majority women serous diagnosed advanced shorter duration symptoms women early stage disease contrast women mucinous generally diagnosed early stage longer duration symptoms p=0.009 diagnosed advanced stage provides evidence early diagnosis ovarian largely determined histological type,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[242, 3, 686, 1, 117, 5, 134, 414, 507, 324, 6, 147, 1215, 16, 440, 545, 2352, 934, 1031, 20, 1831, 267, 82, 88, 15, 2091, 21, 426, 8, 266, 90, 45, 141, 11011, 117, 5, 416, 134, 265, 29, 3343, 6, 1375, 4614, 2, 934, 74, 11, 786, 75, 35, 22543, 468, 1770, 507, 635, 22, 93, 674, 1, 134, 11, 409, 4, 2191, 6, 69, 2, 30, 374, 75, 6438, 331, 812, 320, 2, 1083, 1646, 274, 934, 1031, 2, 654, 2512, 97, 107, 117, 5, 134, 20, 82, 30, 784, 2, 88, 84, 44, 2091, 93, 362, 11, 164, 20, 784, 4, 1760, 8, 26178, 4036, 1668, 2294, 2, 1659, 507, 72, 6, 117, 265, 5, 1744, 134, 117, 5, 2391, 57, 11, 18, 49, 1072, 80, 322, 6, 414, 8, 26178, 4036, 117, 5, 3151, 134, 11, 169, 1072, 80, 322, 6, 414, 1668, 2294, 117, 5, 1744, 57, 11, 97, 80, 322, 6, 414, 1659, 507, 76, 11, 117, 265, 5, 127, 1831, 630, 3, 686, 1, 117, 5, 1744, 57, 11, 265, 5, 131, 12, 2, 42, 985, 654, 1, 507, 76, 117, 5, 191, 82, 34, 4, 748, 117, 5, 2391, 57, 11, 1228, 265, 28, 35, 191, 82, 2, 42, 589, 654, 1, 507, 19, 13, 2376, 492, 265, 28, 35, 131, 82, 3, 45, 777, 241, 17, 3, 191, 147, 1, 12, 16, 1733, 509, 20, 30, 1831, 267]",1631.0,20591474,Symptom presentation invasive ovarian carcinoma histological type grade multiethnic population case,0,0.0
Rate of vaginal cuff separation following laparoscopic or robotic hysterectomy.,Gynecologic oncology,Gynecol. Oncol.,2010-09-24,"Vaginal cuff separation is a rare but serious complication following hysterectomy. The goal of our study was to determine the rate of vaginal cuff separation and associated risk factors in patients undergoing laparoscopic or robotic hysterectomy. We retrospectively identified patients who underwent a minimally invasive simple or radical hysterectomy at one institution between January 2000 and 2009. Fisher's exact test, Wilcoxon rank sum test and multiple logistic regression were used to determine associations between variables and increased risk of separation. A total of 417 patients underwent laparoscopic (n=285) or robotic (n=132) hysterectomy during the study period. Three hundred and sixty-two underwent simple hysterectomy (249 laparoscopic, 113 robotic) and 57 underwent radical hysterectomy (36 laparoscopic, 19 robotic). Seven (1.7%) patients developed a cuff complication and all had a diagnosis of malignancy. Three (1.1%) patients in the laparoscopy group suffered a vaginal cuff evisceration (n=2) or separation (n=1). Four patients in the robotic group (3.0%) had a vaginal evisceration (n=1) or separation (n=3). There was no difference based on surgical approach (p=0.22). Vaginal cuff complications were 9.46-fold higher among patients who had a radical hysterectomy (p<0.01). Median time to presentation of vaginal cuff complication was 128 days (range, 58-175) in the laparoscopy group and 37 days (range, 32-44) in the robotic group. The overall risk of vaginal cuff complication was 1.7%. There appears to be no difference in cuff complication rates based on surgical approach. Radical hysterectomy, however, was associated with a 9-fold increase in vaginal cuff complications.",Journal Article,3406.0,43.0,Vaginal cuff separation rare complication following hysterectomy goal determine rate vaginal cuff separation associated risk factors patients undergoing laparoscopic robotic hysterectomy retrospectively identified patients underwent minimally invasive simple radical hysterectomy institution January 2000 2009 Fisher 's exact test Wilcoxon rank sum test multiple logistic regression determine associations variables increased risk separation total 417 patients underwent laparoscopic n=285 robotic n=132 hysterectomy period sixty-two underwent simple hysterectomy 249 laparoscopic 113 robotic 57 underwent radical hysterectomy 36 laparoscopic 19 robotic Seven 1.7 patients developed cuff complication diagnosis malignancy 1.1 patients laparoscopy group suffered vaginal cuff evisceration n=2 separation n=1 patients robotic group 3.0 vaginal evisceration n=1 separation n=3 difference based surgical approach p=0.22 Vaginal cuff complications 9.46-fold higher patients radical hysterectomy p 0.01 Median time presentation vaginal cuff complication 128 days range 58-175 laparoscopy group 37 days range 32-44 robotic group overall risk vaginal cuff complication 1.7 appears difference cuff complication rates based surgical approach Radical hysterectomy associated 9-fold increase vaginal cuff complications,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[11445, 5422, 16, 8, 622, 84, 1762, 1447, 366, 2622, 3, 1326, 1, 114, 45, 10, 6, 223, 3, 116, 1, 11445, 5422, 2, 41, 43, 130, 4, 7, 479, 1964, 15, 2895, 2622, 21, 894, 108, 7, 54, 208, 8, 2144, 416, 2763, 15, 711, 2622, 28, 104, 731, 59, 1024, 1081, 2, 1238, 3135, 292, 2472, 412, 3896, 1026, 3216, 412, 2, 232, 812, 320, 11, 95, 6, 223, 685, 59, 682, 2, 101, 43, 1, 5422, 8, 181, 1, 9947, 7, 208, 1964, 78, 8121, 15, 2895, 78, 4255, 2622, 190, 3, 45, 727, 169, 1128, 2, 1746, 100, 208, 2763, 2622, 7144, 1964, 4259, 2895, 2, 696, 208, 711, 2622, 511, 1964, 326, 2895, 648, 14, 67, 7, 276, 8, 11445, 1447, 2, 62, 42, 8, 147, 1, 710, 169, 14, 14, 7, 4, 3, 3553, 87, 6388, 8, 11445, 46239, 78, 18, 15, 5422, 78, 14, 294, 7, 4, 3, 2895, 87, 27, 13, 42, 8, 46239, 78, 14, 15, 5422, 78, 27, 125, 10, 77, 523, 90, 23, 221, 353, 19, 13, 350, 11445, 521, 11, 83, 641, 1116, 142, 107, 7, 54, 42, 8, 711, 2622, 19, 13, 355, 52, 98, 6, 1031, 1, 11445, 1447, 10, 3990, 162, 184, 717, 3300, 4, 3, 3553, 87, 2, 567, 162, 184, 531, 584, 4, 3, 2895, 87, 3, 63, 43, 1, 11445, 1447, 10, 14, 67, 125, 1233, 6, 40, 77, 523, 4, 11445, 1447, 151, 90, 23, 221, 353, 711, 2622, 137, 10, 41, 5, 8, 83, 1116, 344, 4, 11445, 521]",1587.0,20869763,Rate vaginal cuff separation following laparoscopic robotic hysterectomy,1,0.005025125628140704
Vaginal intraepithelial neoplasia (VAIN) after radiation therapy for gynecologic malignancies: a clinically recalcitrant entity.,Gynecologic oncology,Gynecol. Oncol.,2011-01-01,"Vaginal dysplasia is associated with prior radiation therapy (RT) for gynecologic malignancies. We reviewed our institution's experience with VAIN in patients who were treated with radiation therapy for a gynecologic malignancy. A retrospective review of patients treated for VAIN was performed. All cases of patients followed and treated for VAIN after radiation therapy were identified (n=10), along with a cohort of patients with VAIN who did not have radiation therapy (n=23). Mean follow-up after initial diagnosis of VAIN was 37.6 months (range: 12 to 72). Cytologic screening events after diagnosis of VAIN (n=105) showed that patients with prior RT were more than twice as likely to have recurrent dysplasia (OR 3.625, 95% CI=from 1.454 to 9.0376) after treatment. Of patients who recurred, the mean time to first recurrence was 12.3 months in cases and 15.3 months in controls, which was not statistically significant (p=0.31). Screening practices at our institution ranged from 3 month to 12 month intervals. 3 patients in the RT group and 1 patient in the control group developed invasive squamous cell cancer of the vagina. Vaginal dysplasia after radiation therapy is more refractory to treatment than dysplasia not associated with radiation therapy, more likely to recur after surgical and ablative therapy, and may also be more likely to progress to invasive cancer. These data support the need for further study to determine the optimal follow-up screening interval and whether aggressive surgical or ablative treatment stems disease progression in this clinical scenario.",Journal Article,3307.0,20.0,Vaginal dysplasia associated prior radiation therapy RT gynecologic malignancies reviewed institution 's experience VAIN patients treated radiation therapy gynecologic malignancy retrospective review patients treated VAIN performed cases patients followed treated VAIN radiation therapy identified n=10 cohort patients VAIN radiation therapy n=23 Mean follow-up initial diagnosis VAIN 37.6 months range 12 72 Cytologic screening events diagnosis VAIN n=105 showed patients prior RT twice likely recurrent dysplasia 3.625 95 CI=from 1.454 9.0376 treatment patients recurred mean time recurrence 12.3 months cases 15.3 months controls statistically significant p=0.31 Screening practices institution ranged 3 month 12 month intervals 3 patients RT group 1 patient control group developed invasive squamous vagina Vaginal dysplasia radiation therapy refractory treatment dysplasia associated radiation therapy likely recur surgical ablative therapy likely progress invasive support need determine optimal follow-up screening interval aggressive surgical ablative treatment stems disease progression clinical scenario,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2253, 16, 41, 5, 324, 121, 36, 240, 9, 1512, 441, 21, 446, 114, 731, 292, 730, 5, 14802, 4, 7, 54, 11, 73, 5, 121, 36, 9, 8, 1512, 710, 8, 459, 206, 1, 7, 73, 9, 14802, 10, 173, 62, 140, 1, 7, 370, 2, 73, 9, 14802, 50, 121, 36, 11, 108, 78, 79, 1510, 5, 8, 180, 1, 7, 5, 14802, 54, 205, 44, 47, 121, 36, 78, 382, 313, 166, 126, 50, 388, 147, 1, 14802, 10, 567, 49, 53, 184, 133, 6, 720, 4195, 453, 281, 50, 147, 1, 14802, 78, 3263, 224, 17, 7, 5, 324, 240, 11, 80, 76, 936, 22, 322, 6, 47, 387, 2253, 15, 27, 9629, 48, 58, 29, 14, 11026, 6, 83, 45528, 50, 24, 1, 7, 54, 3363, 3, 313, 98, 6, 157, 146, 10, 133, 27, 53, 4, 140, 2, 167, 27, 53, 4, 535, 92, 10, 44, 712, 93, 19, 13, 456, 453, 2634, 28, 114, 731, 1869, 29, 27, 811, 6, 133, 811, 1582, 27, 7, 4, 3, 240, 87, 2, 14, 69, 4, 3, 182, 87, 276, 416, 691, 31, 12, 1, 3, 7553, 2253, 50, 121, 36, 16, 80, 430, 6, 24, 76, 2253, 44, 41, 5, 121, 36, 80, 322, 6, 5609, 50, 221, 2, 4504, 36, 2, 68, 120, 40, 80, 322, 6, 1466, 6, 416, 12, 46, 74, 538, 3, 594, 9, 195, 45, 6, 223, 3, 665, 166, 126, 453, 268, 2, 317, 571, 221, 15, 4504, 24, 15651, 34, 91, 4, 26, 38, 5456]",1540.0,20937524,Vaginal intraepithelial neoplasia VAIN radiation therapy gynecologic malignancies clinically recalcitrant entity,31,0.15577889447236182
Vaginal motion and bladder and rectal volumes during pelvic intensity-modulated radiation therapy after hysterectomy.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2010-11-17,"To evaluate variations in bladder and rectal volume and the position of the vaginal vault during a 5-week course of pelvic intensity-modulated radiation therapy (IMRT) after hysterectomy. Twenty-four patients were instructed how to fill their bladders before simulation and treatment. These patients underwent computed tomography simulations with full and empty bladders and then underwent rescanning twice weekly during IMRT; patients were asked to have full bladder for treatment. Bladder and rectal volumes and the positions of vaginal fiducial markers were determined, and changes in volume and position were calculated. The mean full and empty bladder volumes at simulation were 480 cc (range, 122-1,052) and 155 cc (range, 49-371), respectively. Bladder volumes varied widely during IMRT: the median difference between the maximum and minimum volumes was 247 cc (range, 96-585). Variations in rectal volume during IMRT were less pronounced. For the 16 patients with vaginal fiducial markers in place throughout IMRT, the median maximum movement of the markers during IMRT was 0.59 cm in the right-left direction (range, 0-0.9), 1.46 cm in the anterior-posterior direction (range, 0.8-2.79), and 1.2 cm in the superior-inferior direction (range, 0.6-2.1). Large variations in rectal or bladder volume frequently correlated with significant displacement of the vaginal apex. Although treatment with a full bladder is usually preferred because of greater sparing of small bowel, our data demonstrate that even with detailed instruction, patients are unable to maintain consistent bladder filling. Variations in organ position during IMRT can result in marked changes in the position of the target volume and the volume of small bowel exposed to high doses of radiation.",Journal Article,3352.0,43.0,"evaluate variations bladder rectal volume position vaginal vault 5-week course pelvic intensity-modulated radiation therapy IMRT hysterectomy Twenty-four patients instructed bladders simulation treatment patients underwent computed tomography simulations bladders underwent rescanning twice weekly IMRT patients asked bladder treatment Bladder rectal volumes positions vaginal fiducial markers determined changes volume position calculated mean bladder volumes simulation 480 cc range 122-1,052 155 cc range 49-371 respectively Bladder volumes varied widely IMRT median difference maximum minimum volumes 247 cc range 96-585 Variations rectal volume IMRT pronounced 16 patients vaginal fiducial markers place IMRT median maximum movement markers IMRT 0.59 cm right-left direction range 0-0.9 1.46 cm anterior-posterior direction range 0.8-2.79 1.2 cm superior-inferior direction range 0.6-2.1 Large variations rectal bladder volume frequently correlated significant displacement vaginal apex treatment bladder usually preferred greater sparing small bowel demonstrate detailed instruction patients unable maintain consistent bladder filling Variations organ position IMRT marked changes position target volume volume small bowel exposed high doses radiation",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,"[6, 376, 2293, 4, 2, 433, 2, 3, 3559, 1, 3, 28115, 190, 8, 33, 647, 906, 1, 1110, 837, 1757, 121, 36, 964, 50, 2622, 737, 294, 7, 11, 17184, 832, 6, 11476, 136, 19442, 348, 4026, 2, 24, 46, 7, 208, 1220, 872, 7490, 5, 1647, 2, 9436, 19442, 2, 818, 208, 25083, 936, 709, 190, 964, 7, 11, 3732, 6, 47, 1647, 9, 24, 2, 2225, 2, 3, 7134, 1, 8416, 525, 11, 509, 2, 400, 4, 433, 2, 3559, 11, 981, 3, 313, 1647, 2, 9436, 2225, 28, 4026, 11, 9108, 1951, 184, 3285, 14, 9194, 2, 3735, 1951, 184, 739, 9196, 106, 2225, 2051, 1792, 190, 964, 3, 52, 523, 59, 3, 689, 2, 2499, 2225, 10, 7708, 1951, 184, 921, 15351, 2293, 4, 433, 190, 964, 11, 299, 3517, 9, 3, 245, 7, 5, 8416, 525, 4, 3536, 2432, 964, 3, 52, 689, 7950, 1, 3, 525, 190, 964, 10, 13, 728, 494, 4, 3, 1913, 1712, 4651, 184, 13, 13, 83, 14, 641, 494, 4, 3, 2882, 3028, 4651, 184, 13, 66, 18, 842, 2, 14, 18, 494, 4, 3, 1123, 1663, 4651, 184, 13, 49, 18, 14, 375, 2293, 4, 15, 433, 746, 438, 5, 93, 6850, 1, 3, 8670, 242, 24, 5, 8, 1647, 16, 2082, 2514, 408, 1, 378, 1851, 1, 302, 1659, 114, 74, 608, 17, 871, 5, 2455, 19661, 7, 32, 4253, 6, 3040, 925, 13930, 2293, 4, 1259, 3559, 190, 964, 122, 757, 4, 2003, 400, 4, 3, 3559, 1, 3, 283, 433, 2, 3, 433, 1, 302, 1659, 2234, 6, 64, 415, 1, 121]",1608.0,21093170,Vaginal motion bladder rectal volumes pelvic intensity-modulated radiation therapy hysterectomy,2,0.010050251256281407
Primary malignant melanoma of the vagina.,Obstetrics and gynecology,Obstet Gynecol,2010-12-01,"To describe the clinical and pathologic features of vaginal melanoma and to determine predictors of outcome in patients with this disease. Thirty-seven women with clinical and radiographic stage I vaginal melanoma treated at one institution between 1980 and 2009 were included in this retrospective study. Treatment modalities were assigned to one of three categories: pelvic exenteration, wide excision, and nonsurgical (primary radiation therapy, chemotherapy, or both). Overall survival and progression-free survival were calculated from the date of the surgical diagnosis. The median age was 60.6 years. Eighty-four percent of patients were white. Vaginal bleeding was the most common presenting symptom. Lesions were located in the distal third of the vagina in the majority (65%) of patients. Initial management included a wide local or radical excision (76% of patients); pelvic exenteration (14%); and radiotherapy, chemotherapy, or radiotherapy and chemotherapy (10%). At a median follow-up of 17.4 months, 33 women experienced disease recurrence. Recurrence was local only in seven patients (22%), distant only in 20 (63%), and both in five (15%). The most common sites of distant recurrence were lungs and liver. Median progression-free survival was 11.4 months, and median overall survival was 19 months. The 5-year progression-free and overall survival rates were 9.5% and 20.0%, respectively. Patients treated surgically had significantly longer survival than those treated nonsurgically (P=.01). Radiotherapy after wide excision reduced local recurrence risk and increased survival from 16.1 months to 29.4 months, although the increase was not significant (P=.46). Malignant vaginal melanoma, even when localized at presentation, has a very poor prognosis. Patients treated surgically have longer survival than those treated nonsurgically. Radiotherapy after wide excision reduces local but not distant recurrences.",Journal Article,3338.0,54.0,clinical pathologic features vaginal melanoma determine predictors outcome patients disease Thirty-seven women clinical radiographic stage vaginal melanoma treated institution 1980 2009 included retrospective Treatment modalities assigned categories pelvic exenteration wide excision nonsurgical primary radiation therapy chemotherapy Overall survival progression-free survival calculated date surgical diagnosis median age 60.6 years Eighty-four percent patients white Vaginal bleeding common presenting symptom Lesions located distal vagina majority 65 patients Initial management included wide local radical excision 76 patients pelvic exenteration 14 radiotherapy chemotherapy radiotherapy chemotherapy 10 median follow-up 17.4 months 33 women experienced disease recurrence Recurrence local seven patients 22 distant 20 63 15 common sites distant recurrence lungs liver Median progression-free survival 11.4 months median overall survival 19 months 5-year progression-free overall survival rates 9.5 20.0 respectively Patients treated surgically significantly longer survival treated nonsurgically P=.01 Radiotherapy wide excision reduced local recurrence risk increased survival 16.1 months 29.4 months increase significant P=.46 Malignant vaginal melanoma localized presentation poor prognosis Patients treated surgically longer survival treated nonsurgically Radiotherapy wide excision reduces local distant recurrences,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 897, 3, 38, 2, 510, 404, 1, 2, 6, 223, 674, 1, 228, 4, 7, 5, 26, 34, 977, 648, 117, 5, 38, 2, 1580, 82, 70, 73, 28, 104, 731, 59, 4376, 2, 1238, 11, 159, 4, 26, 459, 45, 24, 1558, 11, 896, 6, 104, 1, 169, 1996, 1110, 5668, 1019, 1366, 2, 5544, 86, 121, 36, 56, 15, 110, 63, 25, 2, 91, 115, 25, 11, 981, 29, 3, 1244, 1, 3, 221, 147, 3, 52, 89, 10, 335, 49, 60, 2207, 294, 714, 1, 7, 11, 886, 2294, 10, 3, 96, 186, 1656, 934, 406, 11, 2308, 4, 3, 2107, 1282, 1, 3, 7553, 4, 3, 686, 556, 1, 7, 388, 284, 159, 8, 1019, 293, 15, 711, 1366, 846, 1, 7, 1110, 5668, 213, 2, 310, 56, 15, 310, 2, 56, 79, 28, 8, 52, 166, 126, 1, 269, 39, 53, 466, 117, 592, 34, 146, 146, 10, 293, 158, 4, 648, 7, 350, 626, 158, 4, 179, 676, 2, 110, 4, 365, 167, 3, 96, 186, 633, 1, 626, 146, 11, 4465, 2, 52, 91, 115, 25, 10, 175, 39, 53, 2, 52, 63, 25, 10, 326, 53, 3, 33, 111, 91, 115, 2, 63, 25, 151, 11, 83, 33, 2, 179, 13, 106, 7, 73, 2350, 42, 97, 589, 25, 76, 135, 73, 20720, 19, 355, 310, 50, 1019, 1366, 405, 293, 146, 43, 2, 101, 25, 29, 245, 14, 53, 6, 462, 39, 53, 242, 3, 344, 10, 44, 93, 19, 641, 393, 871, 198, 909, 28, 1031, 71, 8, 923, 334, 356, 7, 73, 2350, 47, 589, 25, 76, 135, 73, 20720, 310, 50, 1019, 1366, 2389, 293, 84, 44, 626, 1593]",1801.0,21099603,Primary malignant melanoma vagina,36,0.18090452261306533
Recovery issues of fertility-preserving surgery in patients with early-stage cervical cancer and a model for survivorship: the physician checklist.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2011-01-01,"To present a qualitative data analysis of items exploring the treatment, adjustment, and recovery of 33 patients who underwent radical trachelectomy (RT), and to determine the feasibility of using a physician checklist (PCL) as a model for survivorship assessment. This prospective study was approved by the Memorial Sloan-Kettering Cancer Center's Institutional Review Board. Participants completed a survey including exploratory items focused on fertility issues and reproductive concerns, treatment, adjustment, and recovery over 2 years. All responses to the exploratory questions were transcribed verbatim; thematic analysis was used to identify, evaluate, and show patterns within the data set; and descriptive statistics were calculated for thematic categories. A limited waiver of authorization was obtained for medical chart review of these patients (who underwent RT) for 2 years before (January 2006 to December 2007) and 2 years after (January 2008 to December 2009) implementation of the checklist to evaluate its feasibility. In response to ""how successful you feel you will be at conceiving in the future?"" on a scale of 0% to 100%, scores ranged from 54% to 60%. Approximately 70% of the patients reported concerns about conceiving; however, these lessened with time-88% at 6 months to 73% at 24 months. Six percent of women were trying to conceive by 12 months; this increased to 21% by 24 months. Five primary themes emerged from the qualitative analysis that were found to be prevalent across all exploratory items inquiring about difficulties or the hardest adjustment to treatment, recovery, and problems associated with RT; these included menstrual/vaginal issues, emotional impact, life interruptions/return to normalcy, general pain, and recovery process. The PCL identified higher rates of neocervical stenosis (58%), encroachment (54%), vaginal scarring (50%), and dyspareunia (33%) than medical charts, and increased documentation of reproductive consults (54%) and assistance (21%). Global themes expressed by our patients are consistent with those of other cancer survivors. The PCL is an excellent supplement to medical charts by documenting important survivorship issues.",Journal Article,3307.0,11.0,present qualitative items exploring treatment adjustment recovery 33 patients underwent radical trachelectomy RT determine feasibility physician checklist PCL model survivorship assessment prospective approved Memorial Sloan-Kettering Center 's Institutional Review Board Participants completed survey including exploratory items focused fertility issues reproductive concerns treatment adjustment recovery 2 years responses exploratory questions transcribed verbatim thematic identify evaluate patterns set descriptive statistics calculated thematic categories limited waiver authorization obtained medical chart review patients underwent RT 2 years January 2006 December 2007 2 years January 2008 December 2009 implementation checklist evaluate feasibility response `` successful feel conceiving future '' scale 0 100 scores ranged 54 60 Approximately 70 patients reported concerns conceiving lessened time-88 6 months 73 24 months percent women trying conceive 12 months increased 21 24 months primary themes emerged qualitative prevalent exploratory items inquiring difficulties hardest adjustment treatment recovery problems associated RT included menstrual/vaginal issues emotional impact life interruptions/return normalcy general pain recovery process PCL identified higher rates neocervical stenosis 58 encroachment 54 vaginal scarring 50 dyspareunia 33 medical charts increased documentation reproductive consults 54 assistance 21 Global themes expressed patients consistent survivors PCL excellent supplement medical charts documenting important survivorship issues,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 364, 8, 3926, 74, 65, 1, 2980, 4378, 3, 24, 1852, 2, 1602, 1, 466, 7, 54, 208, 711, 5760, 240, 2, 6, 223, 3, 1437, 1, 75, 8, 1473, 9787, 9442, 22, 8, 202, 9, 2560, 455, 26, 482, 45, 10, 850, 20, 3, 2563, 2783, 2784, 12, 574, 292, 1115, 206, 2620, 776, 781, 8, 1407, 141, 2386, 2980, 1649, 23, 2954, 1553, 2, 3705, 2061, 24, 1852, 2, 1602, 252, 18, 60, 62, 253, 6, 3, 2386, 1937, 11, 10088, 28021, 12930, 65, 10, 95, 6, 255, 376, 2, 514, 764, 262, 3, 74, 916, 2, 3778, 3065, 11, 981, 9, 12930, 1996, 8, 383, 17329, 1, 19781, 10, 683, 9, 484, 2937, 206, 1, 46, 7, 54, 208, 240, 9, 18, 60, 348, 1024, 1324, 6, 1397, 1307, 2, 18, 60, 50, 1024, 1375, 6, 1397, 1238, 2393, 1, 3, 9787, 6, 376, 211, 1437, 4, 51, 6, 832, 1401, 10342, 9993, 10342, 303, 40, 28, 37789, 4, 3, 508, 522, 23, 8, 1124, 1, 13, 6, 394, 703, 1869, 29, 667, 6, 335, 705, 431, 1, 3, 7, 210, 2061, 545, 37789, 137, 46, 21933, 5, 98, 889, 28, 49, 53, 6, 803, 28, 259, 53, 437, 714, 1, 117, 11, 14453, 6, 34874, 20, 133, 53, 26, 101, 6, 239, 20, 259, 53, 365, 86, 6514, 2054, 29, 3, 3926, 65, 17, 11, 204, 6, 40, 2485, 716, 62, 2386, 2980, 34387, 545, 4679, 15, 3, 31365, 1852, 6, 24, 1602, 2, 2408, 41, 5, 240, 46, 159, 8518, 18982, 1553, 2671, 345, 358, 7406, 4656, 6, 26124, 1083, 559, 2, 1602, 1129, 3, 9442, 108, 142, 151, 1, 59676, 6935, 717, 59677, 667, 13542, 212, 2, 22098, 466, 76, 484, 4413, 2, 101, 4965, 1, 3705, 12725, 667, 2, 6050, 239, 1648, 6514, 570, 20, 114, 7, 32, 925, 5, 135, 1, 127, 12, 332, 3, 9442, 16, 35, 1503, 5836, 6, 484, 4413, 20, 9255, 305, 2560, 1553]",2125.0,21178573,Recovery issues fertility-preserving surgery patients early-stage cervical model survivorship physician checklist,8,0.04020100502512563
Local control and outcome in children with localized vaginal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma committee of the Children's Oncology Group.,Pediatric blood & cancer,Pediatr Blood Cancer,2011-02-04,"The local control approach for girls with non-resected vaginal rhabdomyosarcoma (RMS) enrolled onto Intergroup RMS Study Group (IRSG)/Children's Oncology Group (COG) studies has differed from that used at other primary sites by delaying or eliminating radiotherapy (RT) based on response achieved with chemotherapy and delayed primary resection. We reviewed locoregional treatment and outcome for patients with localized RMS of the vagina on the two most recent COG low-risk RMS studies. Forty-one patients with localized vaginal RMS were enrolled: 25 onto D9602 and 16 onto Subset 2 of ARST0331. Only four of the 39 with non-resected tumors received RT. The 5-year cumulative incidence of local recurrence was 26% on D9602, and the 2-year cumulative incidence of local recurrence was 43% on ARST0331. Increased local failure rates appeared to correlate with chemotherapy regimens that incorporated lower cumulative doses of cyclophosphamide. Estimated 5-year and 2-year failure free survival rates were 70% (95% CI: 46%, 84%) on D9602 and 42% (95% CI: 11%, 70%) on ARST0331, respectively. To prevent local recurrence, we recommend a local control approach for patients with non-resected RMS of the vagina that is similar to that used for other primary sites and includes RT. We recognize that potential long-term effects of RT are sometimes unacceptable, especially for children less than 24 months of age. However, when making the decision to eliminate RT, the risk of local recurrence must be considered especially when using a chemotherapy regimen with a total cumulative cyclophosphamide dose of  4.8 g/m.",Clinical Trial,3273.0,43.0,local control approach girls non-resected vaginal rhabdomyosarcoma RMS enrolled Intergroup RMS Group IRSG /Children 's Oncology Group COG studies differed primary sites delaying eliminating radiotherapy RT based response achieved chemotherapy delayed primary resection reviewed locoregional treatment outcome patients localized RMS vagina recent COG low-risk RMS studies Forty-one patients localized vaginal RMS enrolled 25 D9602 16 Subset 2 ARST0331 39 non-resected received RT 5-year cumulative incidence local recurrence 26 D9602 2-year cumulative incidence local recurrence 43 ARST0331 Increased local failure rates appeared correlate chemotherapy regimens incorporated lower cumulative doses cyclophosphamide Estimated 5-year 2-year failure free survival rates 70 95 CI 46 84 D9602 42 95 CI 11 70 ARST0331 respectively prevent local recurrence recommend local control approach patients non-resected RMS vagina similar primary sites includes RT recognize potential long-term effects RT unacceptable especially children 24 months age making decision eliminate RT risk local recurrence considered especially chemotherapy regimen total cumulative cyclophosphamide dose  4.8 g/m,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 293, 182, 353, 9, 5989, 5, 220, 1133, 3413, 346, 3301, 4839, 3413, 45, 87, 25047, 541, 292, 413, 87, 6377, 94, 71, 2512, 29, 17, 95, 28, 127, 86, 633, 20, 7151, 15, 6923, 310, 240, 90, 23, 51, 513, 5, 56, 2, 1612, 86, 170, 21, 446, 1325, 24, 2, 228, 9, 7, 5, 909, 3413, 1, 3, 7553, 23, 3, 100, 96, 435, 6377, 154, 43, 3413, 94, 1213, 104, 7, 5, 909, 3413, 11, 346, 243, 3301, 18613, 2, 245, 3301, 697, 18, 1, 18023, 158, 294, 1, 3, 587, 5, 220, 1133, 57, 103, 240, 3, 33, 111, 967, 287, 1, 293, 146, 10, 432, 23, 18613, 2, 3, 18, 111, 967, 287, 1, 293, 146, 10, 601, 23, 18023, 101, 293, 496, 151, 2121, 6, 1513, 5, 56, 472, 17, 2449, 280, 967, 415, 1, 1112, 661, 33, 111, 2, 18, 111, 496, 115, 25, 151, 11, 431, 48, 58, 641, 874, 23, 18613, 2, 595, 48, 58, 175, 431, 23, 18023, 106, 6, 1682, 293, 146, 21, 2237, 8, 293, 182, 353, 9, 7, 5, 220, 1133, 3413, 1, 3, 7553, 17, 16, 288, 6, 17, 95, 9, 127, 86, 633, 2, 1920, 240, 21, 4237, 17, 174, 319, 337, 176, 1, 240, 32, 5164, 3215, 1093, 9, 541, 299, 76, 259, 53, 1, 89, 137, 198, 1079, 3, 948, 6, 4964, 240, 3, 43, 1, 293, 146, 1642, 40, 515, 1093, 198, 75, 8, 56, 477, 5, 8, 181, 967, 1112, 61, 1, 1552, 39, 66, 499, 4709]",1538.0,21298768,Local control outcome children localized vaginal rhabdomyosarcoma report Soft Tissue Sarcoma committee Children 's Oncology Group,0,0.0
Disparities in treatment and survival between African American and White women with vaginal cancer.,Gynecologic oncology,Gynecol. Oncol.,2011-04-15,"The study aims to compare the difference in treatment and survival between White (W) and African American (AA) patients with vaginal cancer (VC). Patients with a diagnosis of invasive vaginal cancer were identified from Surveillance, Epidemiology, and End Results (SEER) program from 1988 to 2007 and were divided into White (W) and African American (AA) subgroups. Student's t test, Kaplan-Meier survival methods, and Cox regression proportional hazards were performed. A total of 2675 patients met the inclusion criteria, with histologic distribution of squamous cell carcinoma (SCC; 2190, 82%) and adenocarcinoma (AC; 485, 18%); 2294 (85.8%) were W, and 381 (14.2%) were AA. Median age was 69 for W and 65 for AA (p<0.001). SCC and AC were equally distributed between W and AA. Advanced stage disease (FIGO III and IV) was more prominent in AA compared with W (30.4% vs. 23.1%, p=0.019). Radiation therapy was utilized equally in both racial groups; however, surgical treatment alone or combined with radiation therapy was more frequent in W compared with AA (27.7% vs. 17.5%, p<0.001). The 5-year survival was 45% in W and 38.6% in AA (p=0.008). In multivariate analysis, AA had significantly poorer survival compared with Whites when controlling for age, histology, stage, grade and treatment modality (HR 1.2, 95% CI 1.1-1.4, p=0.007). African American women with vaginal cancer were more likely to present, at a younger age, advanced stage and less likely to receive surgical treatment. Our data suggests that AA race is an independent predictor of poor survival in vaginal cancer.",Comparative Study,3203.0,5.0,aims compare difference treatment survival White W African American AA patients vaginal VC Patients diagnosis invasive vaginal identified Surveillance Epidemiology End SEER program 1988 2007 divided White W African American AA subgroups Student 's test Kaplan-Meier survival methods Cox regression proportional hazards performed total 2675 patients met inclusion criteria histologic distribution squamous carcinoma SCC 2190 82 adenocarcinoma AC 485 18 2294 85.8 W 381 14.2 AA Median age 69 W 65 AA p 0.001 SCC AC equally distributed W AA Advanced stage disease FIGO III IV prominent AA compared W 30.4 vs. 23.1 p=0.019 Radiation therapy utilized equally racial groups surgical treatment combined radiation therapy frequent W compared AA 27.7 vs. 17.5 p 0.001 5-year survival 45 W 38.6 AA p=0.008 multivariate AA significantly poorer survival compared Whites controlling age histology stage grade treatment modality HR 1.2 95 CI 1.1-1.4 p=0.007 African American women vaginal likely present younger age advanced stage likely receive surgical treatment suggests AA race independent predictor poor survival vaginal,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 45, 2970, 6, 932, 3, 523, 4, 24, 2, 25, 59, 886, 5444, 2, 1410, 597, 1519, 7, 5, 12, 11468, 7, 5, 8, 147, 1, 416, 12, 11, 108, 29, 617, 1284, 2, 396, 99, 1605, 1243, 29, 3314, 6, 1307, 2, 11, 2176, 237, 886, 5444, 2, 1410, 597, 1519, 1453, 6390, 292, 102, 412, 876, 882, 25, 636, 2, 418, 320, 831, 1017, 11, 173, 8, 181, 1, 35098, 7, 543, 3, 1680, 371, 5, 884, 1395, 1, 691, 31, 134, 1791, 46025, 878, 2, 449, 1948, 10326, 203, 39620, 772, 66, 11, 5444, 2, 10155, 213, 18, 11, 1519, 52, 89, 10, 790, 9, 5444, 2, 556, 9, 1519, 19, 13, 144, 1791, 2, 1948, 11, 4142, 4737, 59, 5444, 2, 1519, 131, 82, 34, 3837, 316, 2, 478, 10, 80, 3689, 4, 1519, 72, 5, 5444, 201, 39, 105, 382, 14, 19, 13, 4049, 121, 36, 10, 2080, 4142, 4, 110, 2257, 271, 137, 221, 24, 279, 15, 397, 5, 121, 36, 10, 80, 908, 4, 5444, 72, 5, 1519, 428, 67, 105, 269, 33, 19, 13, 144, 3, 33, 111, 25, 10, 512, 4, 5444, 2, 519, 49, 4, 1519, 19, 13, 2155, 4, 331, 65, 1519, 42, 97, 1769, 25, 72, 5, 2556, 198, 1893, 9, 89, 784, 82, 88, 2, 24, 1396, 168, 14, 18, 48, 58, 14, 14, 14, 39, 19, 13, 1999, 1410, 597, 117, 5, 12, 11, 80, 322, 6, 364, 28, 8, 773, 89, 131, 82, 2, 299, 322, 6, 560, 221, 24, 114, 74, 844, 17, 1519, 1047, 16, 35, 306, 980, 1, 334, 25, 4, 12]",1479.0,21497383,Disparities treatment survival African American White women vaginal,0,0.0
Defining prognostic variables in recurrent endometrioid endometrial cancer: a 15-year single-institution review.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2011-08-01,"This study aimed to examine the pattern of recurrence in patients with endometrioid endometrial cancer and to identify clinically important prognostic factors in the recurrent population. With institutional review board approval, a retrospective review identified 1061 patients who underwent primary surgery and treatment of endometrioid endometrial cancer at our institution from 1994 to 2007. Of this cohort, 77 (7.2%) patients developed a recurrence. Clinical factors were recorded, and Spearman correlation coefficients and  test were used to determine associations between groups. Kaplan-Meier survival estimates and Cox proportional-hazards model were used to determine how prognostic variables affected survival after recurrence (RS) and overall survival (OS). Of 77 patients, site of recurrence was not available in 5 patients. The distribution of recurrence in the remaining 72 patients was as follows: isolated vaginal 18% (13/72), nonvaginal pelvic 12% (9/72), distant 31% (22/72), abdominal 24% (17/72), and nodal 15% (11/72). There was an overrepresentation of advanced stage (P < 0.001) and high-grade (P < 0.003) at presentation in the recurrent group. Median OS was 3.4 years and median RS was 1.3 years. Low-grade tumors, early stage, and those with less than 50% myometrial invasion were associated with a significant OS and RS advantage. Age-adjusted isolated vaginal recurrence presented with a 1.2-year RS survival advantage (P < 0.03). An age-adjusted Cox proportional hazard ratio model incorporating significant prognostic variables demonstrated that the only independent variable associated with worse OS and RS was increased histologic grade with a hazard ratio of 2.31 (95% confidence interval, 1.25-3.97) for RS and 2.44 (95% confidence interval, 1.41-4.62) for OS. Those patients with high-grade histology at the time of initial diagnosis manifest a decreased OS and RS, suggesting that the intrinsic biology of the tumor has the greatest prognostic importance.",Journal Article,3095.0,14.0,aimed examine pattern recurrence patients endometrioid endometrial identify clinically important prognostic factors recurrent population institutional review board approval retrospective review identified 1061 patients underwent primary surgery treatment endometrioid endometrial institution 1994 2007 cohort 77 7.2 patients developed recurrence Clinical factors recorded Spearman correlation coefficients  test determine associations groups Kaplan-Meier survival estimates Cox proportional-hazards model determine prognostic variables affected survival recurrence RS overall survival OS 77 patients site recurrence available 5 patients distribution recurrence remaining 72 patients follows isolated vaginal 18 13/72 nonvaginal pelvic 12 9/72 distant 31 22/72 abdominal 24 17/72 nodal 15 11/72 overrepresentation advanced stage P 0.001 high-grade P 0.003 presentation recurrent group Median OS 3.4 years median RS 1.3 years Low-grade early stage 50 myometrial invasion associated significant OS RS advantage Age-adjusted isolated vaginal recurrence presented 1.2-year RS survival advantage P 0.03 age-adjusted Cox proportional hazard ratio model incorporating significant prognostic variables demonstrated independent variable associated worse OS RS increased histologic grade hazard ratio 2.31 95 confidence interval 1.25-3.97 RS 2.44 95 confidence interval 1.41-4.62 OS patients high-grade histology time initial diagnosis manifest decreased OS RS suggesting intrinsic greatest prognostic importance,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[26, 45, 1295, 6, 1004, 3, 1177, 1, 146, 4, 7, 5, 3151, 12, 2, 6, 255, 505, 305, 177, 130, 4, 3, 387, 266, 5, 1115, 206, 2620, 1814, 8, 459, 206, 108, 22601, 7, 54, 208, 86, 152, 2, 24, 1, 3151, 12, 28, 114, 731, 29, 3023, 6, 1307, 1, 26, 180, 849, 67, 18, 7, 276, 8, 146, 38, 130, 11, 1872, 2, 5061, 816, 5161, 2, 5112, 412, 11, 95, 6, 223, 685, 59, 271, 876, 882, 25, 1423, 2, 418, 831, 1017, 202, 11, 95, 6, 223, 832, 177, 682, 1424, 25, 50, 146, 2250, 2, 63, 25, 118, 1, 849, 7, 606, 1, 146, 10, 44, 390, 4, 33, 7, 3, 1395, 1, 146, 4, 3, 1844, 720, 7, 10, 22, 2962, 1355, 203, 233, 720, 60185, 1110, 133, 83, 720, 626, 456, 350, 720, 1467, 259, 269, 720, 2, 779, 167, 175, 720, 125, 10, 35, 19547, 1, 131, 82, 19, 13, 144, 2, 64, 88, 19, 13, 1421, 28, 1031, 4, 3, 387, 87, 52, 118, 10, 27, 39, 60, 2, 52, 2250, 10, 14, 27, 60, 154, 88, 57, 191, 82, 2, 135, 5, 299, 76, 212, 7327, 578, 11, 41, 5, 8, 93, 118, 2, 2250, 1874, 89, 586, 1355, 146, 917, 5, 8, 14, 18, 111, 2250, 25, 1874, 19, 13, 680, 35, 89, 586, 418, 831, 360, 197, 202, 2570, 93, 177, 682, 264, 17, 3, 158, 306, 1347, 41, 5, 639, 118, 2, 2250, 10, 101, 884, 88, 5, 8, 360, 197, 1, 18, 456, 48, 307, 268, 14, 243, 27, 1015, 9, 2250, 2, 18, 584, 48, 307, 268, 14, 605, 39, 744, 9, 118, 135, 7, 5, 64, 88, 784, 28, 3, 98, 1, 388, 147, 7633, 8, 340, 118, 2, 2250, 802, 17, 3, 2354, 891, 1, 3, 30, 71, 3, 2199, 177, 1187]",1883.0,21633304,Defining prognostic variables recurrent endometrioid endometrial 15-year single-institution review,0,0.0
Current overview of the management of urogenital atrophy in women with breast cancer.,The breast journal,Breast J,2011-06-06,"Systemic treatments for women with breast cancer frequently induce urogenital symptoms that can negatively impact a women's quality of life. Urogenital atrophy is frequently undiagnosed and untreated, particularly in breast cancer survivors. Symptoms of urogenital atrophy can usually be relieved with vaginal estrogen preparations, but risk of recurrence and safety is undefined in women with a history of breast cancer. Treatment with nonhormonal modalities including vaginal moisturizers or lubricants and lifestyle modification are the first lines of management. Low-dose vaginal 17 -estradiol (vaginal estradiol tablets 10 g or vaginal estradiol ring) can be considered for the treatment of symptomatic urogenital atrophy in women with a history of breast cancer after appropriate disclosure to the patient. While effective in treating the urogenital symptoms, the safety of such therapy remains uncertain. The decision to offer vaginal estrogen therapy needs to be individualized and should be made jointly with the oncologist.",Journal Article,3151.0,38.0,Systemic treatments women breast frequently induce urogenital symptoms negatively impact women 's quality life Urogenital atrophy frequently undiagnosed untreated particularly breast survivors Symptoms urogenital atrophy usually relieved vaginal estrogen preparations risk recurrence safety undefined women history breast Treatment nonhormonal modalities including vaginal moisturizers lubricants lifestyle modification lines management Low-dose vaginal 17 -estradiol vaginal estradiol tablets 10 g vaginal estradiol ring considered treatment symptomatic urogenital atrophy women history breast appropriate disclosure patient effective treating urogenital symptoms safety therapy remains uncertain decision offer vaginal estrogen therapy needs individualized jointly oncologist,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[403, 640, 9, 117, 5, 12, 746, 1290, 15162, 507, 17, 122, 2723, 345, 8, 117, 292, 372, 1, 358, 15162, 7637, 16, 746, 11615, 2, 1278, 823, 4, 12, 332, 507, 1, 15162, 7637, 122, 2082, 40, 14429, 5, 808, 7791, 84, 43, 1, 146, 2, 367, 16, 5425, 4, 117, 5, 8, 532, 1, 12, 24, 5, 16196, 1558, 141, 34832, 15, 37673, 2, 3487, 2437, 32, 3, 157, 285, 1, 284, 154, 61, 269, 1458, 4507, 4507, 6675, 79, 3802, 15, 4507, 4091, 122, 40, 515, 9, 3, 24, 1, 1704, 15162, 7637, 4, 117, 5, 8, 532, 1, 12, 50, 870, 7137, 6, 3, 69, 369, 323, 4, 1367, 3, 15162, 507, 3, 367, 1, 225, 36, 469, 2717, 3, 948, 6, 1918, 808, 36, 1891, 6, 40, 2596, 2, 257, 40, 1229, 7609, 5, 3, 2709]",948.0,21645165,Current overview management urogenital atrophy women breast,0,0.0
Pagetoid adenocarcinoma in situ of the cervix with pagetoid spread into the vagina.,Obstetrics and gynecology,Obstet Gynecol,2011-08-01,"Pagetoid spread of adenocarcinoma in situ of the cervix into vaginal epithelium is a rare phenomenon, mimicking Paget's disease of the vulva. We report a case of in situ squamous cell and in situ adenocarcinoma of the cervix in a 44-year-old woman who underwent total abdominal hysterectomy, bilateral salpingo-oophorectomy, and upper vaginectomy. Pathologic evaluation showed pagetoid endocervical adenocarcinoma in situ spreading into the vagina with positive margins. Malignant cells were positive for mucin, P16, CK-7, and carcinoembryonic antigen. The asymptomatic occult finding of pagetoid changes in the vagina should raise the suspicion of vaginal extension of pagetoid genital or urothelial carcinoma in situ; however, it can be mistaken as vaginal dysplasia or primary Paget's disease. Immunohistochemical profiling may help in the differential diagnosis.",Case Reports,3095.0,8.0,Pagetoid spread adenocarcinoma situ cervix vaginal epithelium rare phenomenon mimicking Paget 's disease vulva report case situ squamous situ adenocarcinoma cervix 44-year-old woman underwent total abdominal hysterectomy bilateral salpingo-oophorectomy upper vaginectomy Pathologic evaluation showed pagetoid endocervical adenocarcinoma situ spreading vagina positive margins Malignant positive mucin P16 CK-7 carcinoembryonic antigen asymptomatic occult finding pagetoid changes vagina raise suspicion vaginal extension pagetoid genital urothelial carcinoma situ mistaken vaginal dysplasia primary Paget 's disease Immunohistochemical profiling help differential diagnosis,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[31841, 2579, 1, 449, 4, 957, 1, 3, 3629, 237, 2781, 16, 8, 622, 3936, 8191, 7497, 292, 34, 1, 3, 9263, 21, 414, 8, 473, 1, 4, 957, 691, 31, 2, 4, 957, 449, 1, 3, 3629, 4, 8, 584, 111, 1095, 2854, 54, 208, 181, 1467, 2622, 1607, 5690, 3470, 2, 1726, 33868, 510, 451, 224, 31841, 10174, 449, 4, 957, 8153, 237, 3, 7553, 5, 109, 1012, 393, 37, 11, 109, 9, 5258, 1932, 4925, 67, 2, 5139, 448, 3, 2100, 2879, 1567, 1, 31841, 400, 4, 3, 7553, 257, 5008, 3, 5782, 1, 2401, 1, 31841, 8226, 15, 1472, 134, 4, 957, 137, 192, 122, 40, 16214, 22, 2253, 15, 86, 7497, 292, 34, 1382, 1080, 68, 987, 4, 3, 1777, 147]",830.0,21768854,Pagetoid adenocarcinoma situ cervix pagetoid spread vagina,0,0.0
Recurrence patterns and surveillance for patients with early stage endometrial cancer.,Gynecologic oncology,Gynecol. Oncol.,2011-08-05,"To evaluate the recurrence patterns and the clinical and economic role of surveillance with vaginal cytology in women with low risk endometrial cancer. Patients undergoing primary surgery with final pathology consistent with a grade 1 endometrial cancer confined to the endometrium (FIGO 1988 stage IA) between 9/1997-12/2007 were retrospectively identified. Follow-up data for at least 2 years was also collected, including diagnosis of a recurrence, symptomatology at that time, and method of detection. Costs for vaginal cytology were estimated using Medicare charge-to-cost ratios adjusted to 2010 costs. One hundred fifty-four patients met study inclusion criteria. The mean age was 54.4 years and the mean follow-up was 46.9 months. Four recurrences were detected, occurring 16-73 months after the initial diagnosis. During a scheduled visit, one patient was found to have an asymptomatic vaginal cuff recurrence, detected on physical examination. The remaining three cases were diagnosed at an unscheduled visit after the presence of symptoms (vaginal bleeding, abdominal pain, shortness of breath) prompted further evaluation. In all, cytology detected no cases of recurrence and the estimated cost associated with cytology alone for all patients over the study time frame was approximately $7,760 per year. Patients with grade 1 endometrial cancer confined to the endometrium have a low risk of recurrence (2.6%) and were detected on clinical findings alone. Emphasis should be placed on counseling patients on symptoms of recurrence and performing a thorough physical examination. The elimination of vaginal cytology for this select group of patients may be appropriate and result in a significant reduction in health care costs.",Journal Article,3091.0,29.0,"evaluate recurrence patterns clinical economic role surveillance vaginal cytology women low risk endometrial Patients undergoing primary surgery final pathology consistent grade 1 endometrial confined endometrium FIGO 1988 stage IA 9/1997-12/2007 retrospectively identified Follow-up 2 years collected including diagnosis recurrence symptomatology time detection Costs vaginal cytology estimated Medicare charge-to-cost ratios adjusted 2010 costs fifty-four patients met inclusion criteria mean age 54.4 years mean follow-up 46.9 months recurrences detected occurring 16-73 months initial diagnosis scheduled visit patient asymptomatic vaginal cuff recurrence detected physical examination remaining cases diagnosed unscheduled visit presence symptoms vaginal bleeding abdominal pain shortness breath prompted evaluation cytology detected cases recurrence estimated cost associated cytology patients time frame approximately 7,760 year Patients grade 1 endometrial confined endometrium low risk recurrence 2.6 detected clinical findings Emphasis placed counseling patients symptoms recurrence performing thorough physical examination elimination vaginal cytology select group patients appropriate significant reduction health care costs",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[6, 376, 3, 146, 764, 2, 3, 38, 2, 3875, 200, 1, 617, 5, 2045, 4, 117, 5, 154, 43, 12, 7, 479, 86, 152, 5, 1457, 1117, 925, 5, 8, 88, 14, 12, 2902, 6, 3, 3837, 3314, 82, 3302, 59, 83, 2341, 133, 1307, 11, 894, 108, 166, 126, 74, 9, 28, 506, 18, 60, 10, 120, 786, 141, 147, 1, 8, 146, 12279, 28, 17, 98, 2, 596, 1, 638, 1201, 9, 2045, 11, 661, 75, 1378, 11812, 6, 835, 1137, 586, 6, 1120, 1201, 104, 1128, 1461, 294, 7, 543, 45, 1680, 371, 3, 313, 89, 10, 667, 39, 60, 2, 3, 313, 166, 126, 10, 641, 83, 53, 294, 1593, 11, 530, 1821, 245, 803, 53, 50, 3, 388, 147, 190, 8, 4394, 2807, 104, 69, 10, 204, 6, 47, 35, 2100, 11445, 146, 530, 23, 900, 1385, 3, 1844, 169, 140, 11, 265, 28, 35, 13774, 2807, 50, 3, 463, 1, 507, 2294, 1467, 559, 10977, 1, 6945, 4140, 195, 451, 4, 62, 2045, 530, 77, 140, 1, 146, 2, 3, 661, 835, 41, 5, 2045, 279, 9, 62, 7, 252, 3, 45, 98, 5331, 10, 705, 67, 13134, 379, 111, 7, 5, 88, 14, 12, 2902, 6, 3, 47, 8, 154, 43, 1, 146, 18, 49, 2, 11, 530, 23, 38, 272, 279, 3136, 257, 40, 3295, 23, 2011, 7, 23, 507, 1, 146, 2, 3620, 8, 5506, 900, 1385, 3, 3730, 1, 2045, 9, 26, 1717, 87, 1, 7, 68, 40, 870, 2, 757, 4, 8, 93, 628, 4, 341, 165, 1201]",1609.0,21820709,Recurrence patterns surveillance patients early stage endometrial,1,0.005025125628140704
Colposcopic and cytologic detection of chronic lymphocytic leukemia in the vagina: a case report.,The Journal of reproductive medicine,J Reprod Med,,"Chronic lymphocytic leukemia (CLL) is one of the chronic lymphoproliferative disorders. CLL has a wide range of physical findings at the time of initial discovery, with lymphadenopathy being the most common. We report the first case of primary presentation of CLL of the vaginal cuff in an asymptomatic patient. A 68-year-old, white woman status post-total abdominal hysterectomy and bilateral salpingo-oophorectomy for endometriosis 25 years earlier, was referred for colposcopic evaluation of low-grade squamous intraepithelial lesion of the vagina. Pathologic examination, immunohistochemical studies, and immunoglobulin gene rearrangement studies of the biopsy specimens were performed. All of these findings were supportive of a diagnosis of CLL. CLL in the vagina may present as an asymptomatic lesion. Hematologic malignancies should be considered in the differential diagnosis during workup of abnormal vaginal cytology.",Case Reports,,3.0,Chronic lymphocytic leukemia CLL chronic lymphoproliferative disorders CLL wide range physical findings time initial discovery lymphadenopathy common report case primary presentation CLL vaginal cuff asymptomatic patient 68-year-old white woman status post-total abdominal hysterectomy bilateral salpingo-oophorectomy endometriosis 25 years earlier referred colposcopic evaluation low-grade squamous intraepithelial lesion vagina Pathologic examination immunohistochemical studies immunoglobulin rearrangement studies biopsy specimens performed findings supportive diagnosis CLL CLL vagina present asymptomatic lesion Hematologic malignancies considered differential diagnosis workup abnormal vaginal cytology,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[442, 1193, 552, 16, 104, 1, 3, 442, 4192, 1997, 552, 71, 8, 1019, 184, 1, 900, 272, 28, 3, 98, 1, 388, 1574, 5, 4962, 486, 3, 96, 186, 21, 414, 3, 157, 473, 1, 86, 1031, 1, 552, 1, 3, 11445, 4, 35, 2100, 69, 8, 806, 111, 1095, 886, 2854, 156, 539, 181, 1467, 2622, 2, 1607, 5690, 3470, 9, 7915, 243, 60, 1677, 10, 1995, 9, 14131, 451, 1, 154, 88, 691, 4153, 1180, 1, 3, 7553, 510, 1385, 1382, 94, 2, 2593, 145, 2675, 94, 1, 3, 411, 623, 11, 173, 62, 1, 46, 272, 11, 1877, 1, 8, 147, 1, 552, 552, 4, 3, 7553, 68, 364, 22, 35, 2100, 1180, 813, 441, 257, 40, 515, 4, 3, 1777, 147, 190, 4755, 1, 1668, 2045]",888.0,21838166,Colposcopic cytologic detection chronic lymphocytic leukemia vagina case report,1,0.005025125628140704
Randomized clinical trial of imiquimod: an adjunct to treating cervical dysplasia.,American journal of obstetrics and gynecology,Am. J. Obstet. Gynecol.,2011-07-13,"Human papillomavirus (HPV) infection is a major risk factor for cervical cancer. Imiquimod is a topical medication that enhances the immune response to HPV-induced genital warts. This study evaluated cervical application of imiquimod as an adjunct to standard treatment for cervical dysplasia. Fifty-six patients were randomized to standard excisional/ablative treatment vs applications of imiquimod followed by standard treatment. The primary endpoint was dysplasia recurrence within 2 years. There were no differences in dysplasia recurrence between the 2 groups. Treatment was well tolerated, with side effects being mild but significantly worse in women receiving imiquimod for, chills, fatigue, fever, headache, myalgias, and vaginal discharge. This trial does not support the hypothesis that imiquimod, as used in this trial, has an impact on recurrence of cervical dysplasia, but the adequacy of findings are limited by sample size. The trial does support the feasibility and acceptability of the use of imiquimod on the cervix.",Journal Article,3114.0,,Human papillomavirus HPV infection major risk factor cervical Imiquimod topical medication enhances immune response HPV-induced genital warts evaluated cervical application imiquimod adjunct standard treatment cervical dysplasia Fifty-six patients randomized standard excisional/ablative treatment vs applications imiquimod followed standard treatment primary endpoint dysplasia recurrence 2 years differences dysplasia recurrence 2 groups Treatment tolerated effects mild significantly worse women receiving imiquimod chills fatigue fever headache myalgias vaginal discharge trial support hypothesis imiquimod trial impact recurrence cervical dysplasia adequacy findings limited size trial support feasibility acceptability use imiquimod cervix,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[171, 3242, 933, 930, 16, 8, 458, 43, 161, 9, 12, 11823, 16, 8, 5879, 3012, 17, 2519, 3, 250, 51, 6, 933, 277, 8226, 19515, 26, 45, 194, 1581, 1, 11823, 22, 35, 5471, 6, 260, 24, 9, 2253, 1461, 437, 7, 11, 384, 6, 260, 6488, 4504, 24, 105, 2911, 1, 11823, 370, 20, 260, 24, 3, 86, 1138, 10, 2253, 146, 262, 18, 60, 125, 11, 77, 362, 4, 2253, 146, 59, 3, 18, 271, 24, 10, 149, 421, 5, 1152, 176, 486, 1980, 84, 97, 639, 4, 117, 357, 11823, 9, 9730, 613, 2775, 4538, 11571, 2, 2993, 26, 160, 1097, 44, 538, 3, 1492, 17, 11823, 22, 95, 4, 26, 160, 71, 35, 345, 23, 146, 1, 2253, 84, 3, 6760, 1, 272, 32, 383, 20, 1000, 444, 3, 160, 1097, 538, 3, 1437, 2, 8065, 1, 3, 119, 1, 11823, 23, 3, 3629]",970.0,21907959,Randomized clinical trial imiquimod adjunct treating cervical dysplasia,0,0.0
Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 study.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2011-11-19,"To analyze the effect of reduced-dose radiotherapy on local control in children with low-risk rhabdomyosarcoma (RMS) treated in the Children's Oncology Group D9602 study. Patients with low-risk RMS were nonrandomly assigned to receive radiotherapy doses dependent on the completeness of surgical resection of the primary tumor (clinical group) and the presence of involved regional lymph nodes. After resection, most patients with microscopic residual and uninvolved nodes received 36 Gy, those with involved nodes received 41.4 to 50.4 Gy, and those with orbital primary tumors received 45 Gy. All patients received vincristine and dactinomycin, with cyclophosphamide added for patient subsets with a higher risk of relapse in Intergroup Rhabdomyosarcoma Study Group III and IV studies. Three hundred forty-two patients were eligible for analysis; 172 received radiotherapy as part of their treatment. The cumulative incidence of local/regional failure was 15% in patients with microscopic involved margins when cyclophosphamide was not part of the treatment regimen and 0% when cyclophosphamide was included. The cumulative incidence of local/regional failure was 14% in patients with orbital tumors. Protocol-specified omission of radiotherapy in girls with Group IIA vaginal tumors (n = 5) resulted in three failures for this group. In comparison with Intergroup Rhabdomyosarcoma Study Group III and IV results, reduced-dose radiotherapy does not compromise local control for patients with microscopic tumor after surgical resection or with orbital primary tumors when cyclophosphamide is added to the treatment program. Girls with unresected nonbladder genitourinary tumors require radiotherapy for postsurgical residual tumor for optimal local control to be achieved.",Clinical Trial,2985.0,47.0,effect reduced-dose radiotherapy local control children low-risk rhabdomyosarcoma RMS treated Children 's Oncology Group D9602 Patients low-risk RMS nonrandomly assigned receive radiotherapy doses dependent completeness surgical resection primary clinical group presence involved regional lymph nodes resection patients microscopic residual uninvolved nodes received 36 Gy involved nodes received 41.4 50.4 Gy orbital primary received 45 Gy patients received vincristine dactinomycin cyclophosphamide added patient subsets higher risk relapse Intergroup Rhabdomyosarcoma Group III IV studies forty-two patients eligible 172 received radiotherapy treatment cumulative incidence local/regional failure 15 patients microscopic involved margins cyclophosphamide treatment regimen 0 cyclophosphamide included cumulative incidence local/regional failure 14 patients orbital Protocol-specified omission radiotherapy girls Group IIA vaginal n 5 resulted failures group comparison Intergroup Rhabdomyosarcoma Group III IV reduced-dose radiotherapy compromise local control patients microscopic surgical resection orbital primary cyclophosphamide added treatment program Girls unresected nonbladder genitourinary require radiotherapy postsurgical residual optimal local control achieved,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 1992, 3, 254, 1, 405, 61, 310, 23, 293, 182, 4, 541, 5, 154, 43, 3413, 73, 4, 3, 541, 292, 413, 87, 18613, 45, 7, 5, 154, 43, 3413, 11, 24675, 896, 6, 560, 310, 415, 470, 23, 3, 7507, 1, 221, 170, 1, 3, 86, 30, 38, 87, 2, 3, 463, 1, 646, 951, 263, 502, 50, 170, 96, 7, 5, 2984, 753, 2, 7377, 502, 103, 511, 381, 135, 5, 646, 502, 103, 605, 39, 6, 212, 39, 381, 2, 135, 5, 5549, 86, 57, 103, 512, 381, 62, 7, 103, 2132, 2, 10295, 5, 1112, 1953, 9, 69, 1890, 5, 8, 142, 43, 1, 429, 4, 4839, 45, 87, 316, 2, 478, 94, 169, 1128, 1213, 100, 7, 11, 625, 9, 65, 5312, 103, 310, 22, 760, 1, 136, 24, 3, 967, 287, 1, 293, 951, 496, 10, 167, 4, 7, 5, 2984, 646, 1012, 198, 1112, 10, 44, 760, 1, 3, 24, 477, 2, 13, 198, 1112, 10, 159, 3, 967, 287, 1, 293, 951, 496, 10, 213, 4, 7, 5, 5549, 57, 1182, 3575, 5736, 1, 310, 4, 5989, 5, 87, 4088, 57, 78, 33, 627, 4, 169, 3368, 9, 26, 87, 4, 1155, 5, 4839, 45, 87, 316, 2, 478, 99, 405, 61, 310, 1097, 44, 4665, 293, 182, 9, 7, 5, 2984, 30, 50, 221, 170, 15, 5, 5549, 86, 57, 198, 1112, 16, 1953, 6, 3, 24, 1243, 5989, 5, 8096, 26026, 4109, 57, 1353, 310, 9, 6891, 753, 30, 9, 665, 293, 182, 6, 40, 513]",1688.0,22104356,Local control reduced-dose radiotherapy low-risk rhabdomyosarcoma report Children 's Oncology Group D9602,0,0.0
Modified vertical rectus abdominis myocutaneous flap vaginal reconstruction: an analysis of surgical outcomes.,Gynecologic oncology,Gynecol. Oncol.,2011-12-11,"To examine the early and late flap related morbidity and associated risk factors in patients with modified vertical rectus abdominis myocutaneous (VRAM) flap neovaginal reconstruction at the time of pelvic exenteration for gynecologic malignancy. From January 1993 to January 2011, all patients were identified who underwent anterior, posterior, or total pelvic exenteration with VRAM flap neovaginal reconstruction. Patient records were systematically reviewed and demographic, clinicopathologic, operative details, flap related complications, and risk factors for wound healing were recorded and statistical analysis performed. 46 patients were identified who underwent exenteration with VRAM flap vaginal reconstruction. A risk factor for poor healing including obesity, diabetes, smoking, prior radiation, previous abdominal surgery, or poor nutritional status was present in 38 (82.6%) patients, and 24 (52.2%) had two or more risk factors. Flap complications occurred in 9 (19.6%) patients, one with complete flap necrosis that required re-operation, two with superficial flap necrosis, and three with superficial flap separation. Three patients (6.5%) suffered from vaginal stenosis, one of which was complete. Anterior abdominal wound separation occurred in 22 (47.8%) patients and pelvic abscess occurred in 14 (30.4%) patients. No individual risk factor was significantly associated with VRAM flap related morbidity; however obesity, prior radiation, and prior abdominal incision were present in nearly all the patients with flap complications. This series confirms that modified VRAM flaps can be used successfully at the time of exenteration, even in an increasingly high risk patient population with an acceptable risk for flap complications.",Evaluation Study,2963.0,,examine early late flap related morbidity associated risk factors patients modified vertical rectus abdominis myocutaneous VRAM flap neovaginal reconstruction time pelvic exenteration gynecologic malignancy January 1993 January 2011 patients identified underwent anterior posterior total pelvic exenteration VRAM flap neovaginal reconstruction Patient records systematically reviewed demographic clinicopathologic operative details flap related complications risk factors wound healing recorded statistical performed 46 patients identified underwent exenteration VRAM flap vaginal reconstruction risk factor poor healing including obesity diabetes smoking prior radiation previous abdominal surgery poor nutritional status present 38 82.6 patients 24 52.2 risk factors Flap complications occurred 9 19.6 patients complete flap necrosis required re-operation superficial flap necrosis superficial flap separation patients 6.5 suffered vaginal stenosis complete Anterior abdominal wound separation occurred 22 47.8 patients pelvic abscess occurred 14 30.4 patients individual risk factor significantly associated VRAM flap related morbidity obesity prior radiation prior abdominal incision present nearly patients flap complications series confirms modified VRAM flaps successfully time exenteration increasingly high risk patient population acceptable risk flap complications,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 1004, 3, 191, 2, 807, 3942, 139, 787, 2, 41, 43, 130, 4, 7, 5, 1230, 11104, 15111, 18778, 17653, 22472, 3942, 46936, 1470, 28, 3, 98, 1, 1110, 5668, 9, 1512, 710, 29, 1024, 3343, 6, 1024, 1132, 62, 7, 11, 108, 54, 208, 2882, 3028, 15, 181, 1110, 5668, 5, 22472, 3942, 46936, 1470, 69, 1064, 11, 3390, 446, 2, 1540, 1399, 1208, 3791, 3942, 139, 521, 2, 43, 130, 9, 2689, 4706, 11, 1872, 2, 1050, 65, 173, 641, 7, 11, 108, 54, 208, 5668, 5, 22472, 3942, 1470, 8, 43, 161, 9, 334, 4706, 141, 1661, 1978, 979, 324, 121, 698, 1467, 152, 15, 334, 5082, 156, 10, 364, 4, 519, 878, 49, 7, 2, 259, 653, 18, 42, 100, 15, 80, 43, 130, 3942, 521, 489, 4, 83, 326, 49, 7, 104, 5, 236, 3942, 1523, 17, 616, 1491, 2589, 100, 5, 3562, 3942, 1523, 2, 169, 5, 3562, 3942, 5422, 169, 7, 49, 33, 6388, 29, 6935, 104, 1, 92, 10, 236, 2882, 1467, 2689, 5422, 489, 4, 350, 662, 66, 7, 2, 1110, 7979, 489, 4, 213, 201, 39, 7, 77, 797, 43, 161, 10, 97, 41, 5, 22472, 3942, 139, 787, 137, 1661, 324, 121, 2, 324, 1467, 7538, 11, 364, 4, 1857, 62, 3, 7, 5, 3942, 521, 26, 988, 5120, 17, 1230, 22472, 9039, 122, 40, 95, 1878, 28, 3, 98, 1, 5668, 871, 4, 35, 1635, 64, 43, 69, 266, 5, 35, 1595, 43, 9, 3942, 521]",1688.0,22166844,Modified vertical rectus abdominis myocutaneous flap vaginal reconstruction surgical outcomes,0,0.0
The effect of body mass index on surgical outcomes and survival following pelvic exenteration.,Gynecologic oncology,Gynecol. Oncol.,2012-01-16,"We sought to evaluate whether preoperative body mass index (BMI) impacts surgical outcomes, complication rates, and/or recurrence rates in women undergoing pelvic exenteration. All women who underwent pelvic exenteration for gynecologic indications at our institution from 1993 through 2010 were included. Women were stratified into 3 groups based on BMI. Baseline characteristics, surgical outcomes, early (<60 days) and late ( 60 days) postoperative complications, and recurrence/survival outcomes were collected. Multivariate logistic regression analyses were performed. Kaplan-Meier survival curves were compared using log-rank test. 161 patients were included (59 normal weight, 44 overweight, 58 obese). Median follow-up times were 22, 29, and 25 months. Most patients underwent total pelvic exenteration (68%); 64.6% had a vaginal reconstruction. On multivariate analysis, both overweight and obese patients had a higher risk of early superficial wound separation compared to normal weight patients - OR 10.74 (3.33-34.62, p<0.001) and OR 4.35 (1.40-13.52, p=0.011), respectively. Length of surgery was significantly longer for overweight (9.6h, OR 1.26, 1.02-1.55, p=0.032) and obese (10.1h, OR 1.24, 1.04-1.47, p=0.014) patients than for normal weight patients (8.7h). Late postoperative complications for patients in the normal weight, overweight, and obese groups were 47.5%, 45.5%, and 43.1% (p=0.144). There were no differences in time to recurrence (p=0.752) or overall survival (p=0.103) between groups. Although operative times were longer and risk for superficial wound separation was significantly higher, pelvic exenteration appears to be feasible and safe in overweight and obese women with overall complication rates and survival outcomes comparable to normal weight women.",Journal Article,2927.0,11.0,sought evaluate preoperative body mass index BMI impacts surgical outcomes complication rates and/or recurrence rates women undergoing pelvic exenteration women underwent pelvic exenteration gynecologic indications institution 1993 2010 included Women stratified 3 groups based BMI Baseline characteristics surgical outcomes early 60 days late  60 days postoperative complications recurrence/survival outcomes collected Multivariate logistic regression performed Kaplan-Meier survival curves compared log-rank test 161 patients included 59 normal weight 44 overweight 58 obese Median follow-up times 22 29 25 months patients underwent total pelvic exenteration 68 64.6 vaginal reconstruction multivariate overweight obese patients higher risk early superficial wound separation compared normal weight patients 10.74 3.33-34.62 p 0.001 4.35 1.40-13.52 p=0.011 respectively Length surgery significantly longer overweight 9.6h 1.26 1.02-1.55 p=0.032 obese 10.1h 1.24 1.04-1.47 p=0.014 patients normal weight patients 8.7h Late postoperative complications patients normal weight overweight obese groups 47.5 45.5 43.1 p=0.144 differences time recurrence p=0.752 overall survival p=0.103 groups operative times longer risk superficial wound separation significantly higher pelvic exenteration appears feasible safe overweight obese women overall complication rates survival outcomes comparable normal weight women,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 990, 6, 376, 317, 498, 642, 782, 558, 1140, 4719, 221, 123, 1447, 151, 2, 15, 146, 151, 4, 117, 479, 1110, 5668, 62, 117, 54, 208, 1110, 5668, 9, 1512, 2406, 28, 114, 731, 29, 3343, 298, 1120, 11, 159, 117, 11, 1173, 237, 27, 271, 90, 23, 1140, 330, 374, 221, 123, 191, 335, 162, 2, 807, 749, 335, 162, 573, 521, 2, 146, 25, 123, 11, 786, 331, 812, 320, 318, 11, 173, 876, 882, 25, 2400, 11, 72, 75, 1066, 1026, 412, 5377, 7, 11, 159, 728, 295, 924, 584, 3566, 717, 2209, 52, 166, 126, 1072, 11, 350, 462, 2, 243, 53, 96, 7, 208, 181, 1110, 5668, 806, 660, 49, 42, 8, 1470, 23, 331, 65, 110, 3566, 2, 2209, 7, 42, 8, 142, 43, 1, 191, 3562, 2689, 5422, 72, 6, 295, 924, 7, 15, 79, 794, 27, 466, 562, 744, 19, 13, 144, 2, 15, 39, 465, 14, 327, 233, 653, 19, 13, 3651, 106, 1318, 1, 152, 10, 97, 589, 9, 3566, 83, 31910, 15, 14, 432, 14, 588, 14, 614, 19, 13, 4708, 2, 2209, 79, 10147, 15, 14, 259, 14, 755, 14, 662, 19, 13, 3618, 7, 76, 9, 295, 924, 7, 66, 61018, 807, 573, 521, 9, 7, 4, 3, 295, 924, 3566, 2, 2209, 271, 11, 662, 33, 512, 33, 2, 601, 14, 19, 13, 4415, 125, 11, 77, 362, 4, 98, 6, 146, 19, 13, 11611, 15, 63, 25, 19, 13, 3283, 59, 271, 242, 1208, 1072, 11, 589, 2, 43, 9, 3562, 2689, 5422, 10, 97, 142, 1110, 5668, 1233, 6, 40, 1313, 2, 1165, 4, 3566, 2, 2209, 117, 5, 63, 1447, 151, 2, 25, 123, 1279, 6, 295, 924, 117]",1714.0,22261299,effect body mass index surgical outcomes survival following pelvic exenteration,0,0.0
A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2012-02-16,"Concurrent cisplatin-based chemoradiotherapy (CRT) is the standard treatment for locally advanced cervical cancer. RTOG 0417 was a Phase II study exploring the safety and efficacy of the addition of bevacizumab to standard CRT. Eligible patients with bulky tumors (Stage IB-IIIB) were treated with once-weekly cisplatin (40 mg/m(2)) chemotherapy and standard pelvic radiotherapy and brachytherapy. Bevacizumab was administered at 10 mg/kg intravenously every 2 weeks for three cycles. Treatment-related serious adverse event (SAE) and other adverse event (AE) rates within the first 90 days from treatment start were determined. Treatment-related SAEs were defined as any Grade  4 vaginal bleeding or thrombotic event or Grade  3 arterial event, gastrointestinal (GI) bleeding, or bowel/bladder perforation, or any Grade 5 treatment-related death. Treatment-related AEs included all SAEs and Grade 3 or 4 GI toxicity persisting for >2 weeks despite medical intervention, Grade 4 neutropenia or leukopenia persisting for >7 days, febrile neutropenia, Grade 3 or 4 other hematologic toxicity, and Grade 3 or 4 GI, renal, cardiac, pulmonary, hepatic, or neurologic AEs. All AEs were scored using the National Cancer Institute Common Terminology Criteria (CTCAE) v 3.0 (MedDRA version 6.0). A total of 60 patients from 28 institutions were enrolled between 2006 and 2009, and of these, 49 patients were evaluable. The median follow-up was 12.4 months (range, 4.6-31.4 months).The median age was 45 years (range, 22-80 years). Most patients had FIGO Stage IIB (63%) and were of Zubrod performance status of 0 (67%). 80% of cases were squamous. There were no treatment-related SAEs. There were 15 (31%) protocol-specified treatment-related AEs within 90 days of treatment start; the most common were hematologic (12/15; 80%). 18 (37%) occurred during treatment or follow-up at any time. 37 of the 49 patients (76%) had cisplatin and bevacizumab administered per protocol, and 46 of the 49 (94%) had both external beam and brachytherapy administered per protocol or with acceptable variation. Bevacizumab in addition to standard pelvic chemoradiotherapy for locally advanced cervical cancer is feasible and safe with respect to the protocol-specified treatment-related SAEs and AEs.","Clinical Trial, Phase II",2896.0,57.0,Concurrent cisplatin-based chemoradiotherapy CRT standard treatment locally advanced cervical RTOG 0417 Phase II exploring safety efficacy addition bevacizumab standard CRT Eligible patients bulky Stage IB-IIIB treated once-weekly cisplatin 40 mg/m 2 chemotherapy standard pelvic radiotherapy brachytherapy Bevacizumab administered 10 mg/kg intravenously 2 weeks cycles Treatment-related adverse event SAE adverse event AE rates 90 days treatment start determined Treatment-related SAEs defined Grade  4 vaginal bleeding thrombotic event Grade  3 arterial event gastrointestinal GI bleeding bowel/bladder perforation Grade 5 treatment-related death Treatment-related AEs included SAEs Grade 3 4 GI toxicity persisting 2 weeks despite medical intervention Grade 4 neutropenia leukopenia persisting 7 days febrile neutropenia Grade 3 4 hematologic toxicity Grade 3 4 GI renal cardiac pulmonary hepatic neurologic AEs AEs scored National Institute Common Terminology Criteria CTCAE v 3.0 MedDRA version 6.0 total 60 patients 28 institutions enrolled 2006 2009 49 patients evaluable median follow-up 12.4 months range 4.6-31.4 months .The median age 45 years range 22-80 years patients FIGO Stage IIB 63 Zubrod performance status 0 67 80 cases squamous treatment-related SAEs 15 31 protocol-specified treatment-related AEs 90 days treatment start common hematologic 12/15 80 18 37 occurred treatment follow-up time 37 49 patients 76 cisplatin bevacizumab administered protocol 46 49 94 external beam brachytherapy administered protocol acceptable variation Bevacizumab addition standard pelvic chemoradiotherapy locally advanced cervical feasible safe respect protocol-specified treatment-related SAEs AEs,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,"[750, 540, 90, 1464, 1089, 16, 3, 260, 24, 9, 795, 131, 12, 3931, 31404, 10, 8, 124, 215, 45, 4378, 3, 367, 2, 209, 1, 3, 352, 1, 599, 6, 260, 1089, 625, 7, 5, 4112, 57, 82, 3180, 3036, 11, 73, 5, 1059, 709, 540, 327, 81, 188, 18, 56, 2, 260, 1110, 310, 2, 1536, 599, 10, 468, 28, 79, 81, 503, 1672, 454, 18, 244, 9, 169, 410, 24, 139, 1762, 290, 774, 29193, 2, 127, 290, 774, 3633, 151, 262, 3, 157, 424, 162, 29, 24, 2435, 11, 509, 24, 139, 11499, 11, 395, 22, 500, 88, 749, 39, 2294, 15, 6108, 774, 15, 88, 749, 27, 3127, 774, 2104, 2294, 15, 1659, 9685, 4854, 15, 500, 88, 33, 24, 139, 273, 24, 139, 1477, 159, 62, 11499, 2, 88, 27, 15, 39, 2104, 155, 12099, 9, 18, 244, 550, 484, 788, 88, 39, 778, 15, 3904, 12099, 9, 67, 162, 2498, 778, 88, 27, 15, 39, 127, 813, 155, 2, 88, 27, 15, 39, 2104, 1087, 939, 15, 2543, 1477, 62, 1477, 11, 3179, 75, 3, 657, 12, 1377, 186, 3462, 371, 3898, 603, 27, 13, 35303, 2256, 49, 13, 8, 181, 1, 335, 7, 29, 339, 1764, 11, 346, 59, 1324, 2, 1238, 2, 1, 46, 739, 7, 11, 859, 3, 52, 166, 126, 10, 133, 39, 53, 184, 39, 49, 456, 39, 53, 3, 52, 89, 10, 512, 60, 184, 350, 493, 60, 96, 7, 42, 3837, 82, 3884, 676, 2, 11, 1, 10672, 528, 156, 1, 13, 598, 493, 1, 140, 11, 691, 125, 11, 77, 24, 139, 11499, 125, 11, 167, 456, 1182, 3575, 24, 139, 1477, 262, 424, 162, 1, 24, 2435, 3, 96, 186, 11, 813, 133, 167, 493, 203, 567, 489, 190, 24, 15, 166, 126, 28, 500, 98, 567, 1, 3, 739, 7, 846, 42, 540, 2, 599, 468, 379, 1182, 2, 641, 1, 3, 739, 960, 42, 110, 1455, 1345, 2, 1536, 468, 379, 1182, 15, 5, 1595, 1380, 599, 4, 352, 6, 260, 1110, 1464, 9, 795, 131, 12, 16, 1313, 2, 1165, 5, 2184, 6, 3, 1182, 3575, 24, 139, 11499, 2, 1477]",2140.0,22342094,phase II bevacizumab combination definitive radiotherapy cisplatin chemotherapy untreated patients locally advanced cervical carcinoma preliminary RTOG 0417,0,0.0
Sexual function after intracavitary vaginal brachytherapy for early-stage endometrial carcinoma.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2012-05-01,"To describe the effects of intracavitary brachytherapy (IVB) on sexual function and quality of life of women with early-stage endometrial cancer. Women with International Federation of Gynecology and Obstetrics stage I to stage II endometrial cancer treated surgically with or without IVB were identified and mailed questionnaires. Quality of life and sexual function were measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and the cervical cancer disease-specific module. Pertinent data from prior surgery and radiation treatments were abstracted retrospectively. Linear transformation of the survey subscale scores was conducted per European Organization for Research and Treatment of Cancer guidelines. Sixteen women in the IVB arm and 53 in the surgery-alone group completed the survey. Of the sexually active patients, 33% of the IVB patients and 42% of the surgery-alone patients felt their vagina was dry during sexual activity (P = 0.804) and 17% versus 20% felt their vagina was short (P = 0.884). Seventeen percent of patients in the IVB group felt their vagina was tight compared to 29% in the surgery-alone group (P = 0.891) and 0% versus 14% of patients reported pain during intercourse (P = 0.808). There was no statistically significant difference in sexual/vaginal functioning, sexual worry, or sexual enjoyment between the 2 groups. Although both groups report vaginal changes that may affect sexual function, the patients treated with IVB reported similar outcomes on a sexual function questionnaire compared to patients treated with surgery alone.",Journal Article,2821.0,22.0,effects intracavitary brachytherapy IVB sexual function quality life women early-stage endometrial Women International Federation Gynecology Obstetrics stage stage II endometrial treated surgically IVB identified mailed questionnaires Quality life sexual function measured European Organization Research Treatment Quality Life Questionnaire Core 30 cervical disease-specific module Pertinent prior surgery radiation treatments abstracted retrospectively Linear transformation survey subscale scores conducted European Organization Research Treatment guidelines Sixteen women IVB arm 53 surgery-alone group completed survey sexually active patients 33 IVB patients 42 surgery-alone patients felt vagina dry sexual activity P 0.804 17 versus 20 felt vagina short P 0.884 Seventeen percent patients IVB group felt vagina tight compared 29 surgery-alone group P 0.891 0 versus 14 patients reported pain intercourse P 0.808 statistically significant difference sexual/vaginal functioning sexual worry sexual enjoyment 2 groups groups report vaginal changes affect sexual function patients treated IVB reported similar outcomes sexual function questionnaire compared patients treated surgery,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 897, 3, 176, 1, 9122, 1536, 7042, 23, 2232, 343, 2, 372, 1, 358, 1, 117, 5, 191, 82, 12, 117, 5, 944, 7303, 1, 6429, 2, 7407, 82, 70, 6, 82, 215, 12, 73, 2350, 5, 15, 187, 7042, 11, 108, 2, 6703, 2956, 372, 1, 358, 2, 2232, 343, 11, 644, 75, 3, 1865, 2533, 9, 389, 2, 24, 1, 12, 372, 1, 358, 1770, 1793, 201, 2, 3, 12, 34, 112, 5980, 5799, 74, 29, 324, 152, 2, 121, 640, 11, 4106, 894, 1646, 1392, 1, 3, 1407, 5593, 703, 10, 426, 379, 1865, 2533, 9, 389, 2, 24, 1, 12, 677, 3228, 117, 4, 3, 7042, 475, 2, 699, 4, 3, 152, 279, 87, 781, 3, 1407, 1, 3, 13588, 544, 7, 466, 1, 3, 7042, 7, 2, 595, 1, 3, 152, 279, 7, 5284, 136, 7553, 10, 7922, 190, 2232, 128, 19, 13, 10853, 2, 269, 185, 179, 5284, 136, 7553, 10, 978, 19, 13, 14511, 3591, 714, 1, 7, 4, 3, 7042, 87, 5284, 136, 7553, 10, 12523, 72, 6, 462, 4, 3, 152, 279, 87, 19, 13, 14416, 2, 13, 185, 213, 1, 7, 210, 559, 190, 12361, 19, 13, 15341, 125, 10, 77, 712, 93, 523, 4, 2232, 18982, 2702, 2232, 6309, 15, 2232, 24426, 59, 3, 18, 271, 242, 110, 271, 414, 400, 17, 68, 1158, 2232, 343, 3, 7, 73, 5, 7042, 210, 288, 123, 23, 8, 2232, 343, 1770, 72, 6, 7, 73, 5, 152, 279]",1551.0,22398710,Sexual function intracavitary vaginal brachytherapy early-stage endometrial carcinoma,4,0.020100502512562814
"Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy.",Endocrinology,Endocrinology,2012-03-13,"More than 90% of ovarian cancers have been thought to arise from epithelial cells that cover the ovarian surface or, more frequently, line subserosal cysts. Recent studies suggest that histologically similar cancers can arise from the fimbriae of Fallopian tubes and from deposits of endometriosis. Different histotypes are observed that resemble epithelial cells from the normal Fallopian tube (serous), endometrium (endometrioid), cervical glands (mucinous), and vaginal rests (clear cell) and that share expression of relevant HOX genes which drive normal gynecological differentiation. Two groups of epithelial ovarian cancers have been distinguished: type I low-grade cancers that present in early stage, grow slowly, and resist conventional chemotherapy but may respond to hormonal manipulation; and type II high-grade cancers that are generally diagnosed in advanced stage and grow aggressively but respond to chemotherapy. Type I cancers have wild-type p53 and BRCA1/2, but have frequent mutations of Ras and Raf as well as expression of IGFR and activation of the phosphatidylinositol-3-kinase (PI3K) pathway. Virtually all type II cancers have mutations of p53, and almost half have mutation or dysfunction of BRCA1/2, but other mutations are rare, and oncogenesis appears to be driven by amplification of several growth-regulatory genes that activate the Ras/MAPK and PI3K pathways. Cytoreductive surgery and combination chemotherapy with platinum compounds and taxanes have improved 5-yr survival, but less than 40% of all stages can be cured. Novel therapies are being developed that target high-grade serous cancer cells with PI3Kness or BRCAness as well as the tumor vasculature. Both in silico and animal models are needed that more closely resemble type I and type II cancers to facilitate the identification of novel targets and to predict response to combinations of new agents.",Journal Article,2870.0,177.0,90 ovarian thought arise epithelial cover ovarian surface frequently line subserosal cysts Recent studies suggest histologically similar arise fimbriae Fallopian tubes deposits endometriosis Different histotypes observed resemble epithelial normal Fallopian tube serous endometrium endometrioid cervical glands mucinous vaginal rests clear share expression relevant HOX drive normal gynecological differentiation groups epithelial ovarian distinguished type low-grade present early stage grow slowly resist conventional chemotherapy respond hormonal manipulation type II high-grade generally diagnosed advanced stage grow aggressively respond chemotherapy Type wild-type p53 BRCA1/2 frequent Ras Raf expression IGFR activation phosphatidylinositol-3-kinase PI3K pathway Virtually type II p53 half dysfunction BRCA1/2 rare oncogenesis appears driven amplification growth-regulatory activate Ras/MAPK PI3K pathways Cytoreductive surgery combination chemotherapy platinum compounds taxanes improved 5-yr survival 40 stages cured Novel therapies developed target high-grade serous PI3Kness BRCAness vasculature silico animal models needed closely resemble type type II facilitate identification novel targets predict response combinations new agents,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[80, 76, 424, 1, 163, 47, 85, 2739, 6, 3043, 29, 701, 37, 17, 8308, 3, 1255, 15, 80, 746, 328, 23477, 4395, 435, 94, 309, 17, 2161, 288, 163, 122, 3043, 29, 3, 61226, 1, 6193, 2, 29, 7626, 1, 7915, 338, 13101, 32, 164, 17, 8247, 701, 37, 29, 3, 295, 2330, 1744, 3151, 3966, 2391, 2, 14405, 885, 31, 2, 17, 4349, 55, 1, 867, 14722, 214, 92, 3279, 295, 6324, 910, 100, 271, 1, 701, 163, 47, 85, 4735, 267, 70, 154, 88, 163, 17, 364, 4, 191, 82, 6265, 7681, 2, 13010, 809, 56, 84, 68, 1892, 6, 1761, 6239, 2, 267, 215, 64, 88, 163, 17, 32, 1228, 265, 4, 131, 82, 2, 6265, 8503, 84, 1892, 6, 56, 267, 70, 163, 47, 955, 267, 624, 2, 766, 18, 84, 47, 908, 138, 1, 1102, 2, 2212, 22, 149, 22, 55, 1, 35049, 2, 363, 1, 3, 3415, 27, 216, 974, 308, 5860, 62, 267, 215, 163, 47, 138, 1, 624, 2, 2214, 1303, 47, 258, 15, 1527, 1, 766, 18, 84, 127, 138, 32, 622, 2, 4503, 1233, 6, 40, 1621, 20, 1073, 1, 392, 129, 1253, 214, 17, 2977, 3, 1102, 1748, 2, 974, 460, 2604, 152, 2, 150, 56, 5, 828, 2411, 2, 2961, 47, 231, 33, 2830, 25, 84, 299, 76, 327, 1, 62, 1153, 122, 40, 3733, 229, 235, 32, 486, 276, 17, 283, 64, 88, 1744, 12, 37, 5, 47123, 15, 16971, 22, 149, 22, 3, 30, 3805, 110, 4, 6648, 2, 2026, 274, 32, 575, 17, 80, 3210, 8247, 267, 70, 2, 267, 215, 163, 6, 1876, 3, 911, 1, 229, 637, 2, 6, 678, 51, 6, 1247, 1, 217, 183]",1789.0,22416079,Minireview human ovarian current management paths personalizing therapy,157,0.7889447236180904
The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell endometrial cancer.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2012-04-28,"The optimal adjuvant therapy for International Federation of Gynecology and Obstetrics (FIGO) stage I papillary serous (UPSC) or clear cell (CC) endometrial cancer is unknown. We report on the largest single-institution experience using adjuvant high-dose-rate vaginal brachytherapy (VBT) for surgically staged women with FIGO stage I UPSC or CC endometrial cancer. From 1998-2011, 103 women with FIGO 2009 stage I UPSC (n=74), CC (n=21), or mixed UPSC/CC (n=8) endometrial cancer underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy followed by adjuvant high-dose-rate VBT. Nearly all patients (n=98, 95%) also underwent extended lymph node dissection of pelvic and paraortic lymph nodes. All VBT was performed with a vaginal cylinder, treating to a dose of 2100 cGy in 3 fractions. Thirty-five patients (34%) also received adjuvant chemotherapy. At a median follow-up time of 36 months (range, 1-146 months), 2 patients had experienced vaginal recurrence, and the 5-year Kaplan Meier estimate of vaginal recurrence was 3%. The rates of isolated pelvic recurrence, locoregional recurrence (vaginal+pelvic), and extrapelvic recurrence (including intraabdominal) were similarly low, with 5-year Kaplan-Meier estimates of 4%, 7%, and 10%, respectively. The estimated 5-year overall survival was 84%. On univariate analysis, delivery of chemotherapy did not affect recurrence or survival. VBT is effective at preventing vaginal relapse in women with surgical stage I UPSC or CC endometrial cancer. In this cohort of patients who underwent comprehensive surgical staging, the risk of isolated pelvic or extrapelvic relapse was low, implying that more extensive adjuvant radiation therapy is likely unnecessary.",Journal Article,2824.0,33.0,optimal adjuvant therapy International Federation Gynecology Obstetrics FIGO stage papillary serous UPSC clear CC endometrial unknown report largest single-institution experience adjuvant high-dose-rate vaginal brachytherapy VBT surgically staged women FIGO stage UPSC CC endometrial 1998-2011 103 women FIGO 2009 stage UPSC n=74 CC n=21 mixed UPSC/CC n=8 endometrial underwent total abdominal hysterectomy bilateral salpingo-oophorectomy followed adjuvant high-dose-rate VBT Nearly patients n=98 95 underwent extended lymph node dissection pelvic paraortic lymph nodes VBT performed vaginal cylinder treating dose 2100 cGy 3 fractions Thirty-five patients 34 received adjuvant chemotherapy median follow-up time 36 months range 1-146 months 2 patients experienced vaginal recurrence 5-year Kaplan Meier estimate vaginal recurrence 3 rates isolated pelvic recurrence locoregional recurrence vaginal+pelvic extrapelvic recurrence including intraabdominal similarly low 5-year Kaplan-Meier estimates 4 7 10 respectively estimated 5-year overall survival 84 univariate delivery chemotherapy affect recurrence survival VBT effective preventing vaginal relapse women surgical stage UPSC CC endometrial cohort patients underwent comprehensive surgical staging risk isolated pelvic extrapelvic relapse low implying extensive adjuvant radiation therapy likely unnecessary,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[3, 665, 249, 36, 9, 944, 7303, 1, 6429, 2, 7407, 3837, 82, 70, 1796, 1744, 5676, 15, 885, 31, 1951, 12, 16, 860, 21, 414, 23, 3, 2166, 226, 731, 730, 75, 249, 64, 61, 116, 1536, 15050, 9, 2350, 2930, 117, 5, 3837, 82, 70, 5676, 15, 1951, 12, 29, 1850, 1132, 3283, 117, 5, 3837, 1238, 82, 70, 5676, 78, 794, 1951, 78, 239, 15, 1739, 5676, 1951, 78, 66, 12, 208, 181, 1467, 2622, 5, 1607, 5690, 3470, 370, 20, 249, 64, 61, 116, 15050, 1857, 62, 7, 78, 1096, 48, 120, 208, 1747, 263, 289, 1161, 1, 1110, 2, 39973, 263, 502, 62, 15050, 10, 173, 5, 8, 23326, 1367, 6, 8, 61, 1, 21341, 3071, 4, 27, 1550, 977, 365, 7, 562, 120, 103, 249, 56, 28, 8, 52, 166, 126, 98, 1, 511, 53, 184, 14, 4909, 53, 18, 7, 42, 592, 146, 2, 3, 33, 111, 876, 882, 1191, 1, 146, 10, 27, 3, 151, 1, 1355, 1110, 146, 1325, 146, 18982, 1110, 2, 12070, 146, 141, 12723, 11, 1813, 154, 5, 33, 111, 876, 882, 1423, 1, 39, 67, 2, 79, 106, 3, 661, 33, 111, 63, 25, 10, 874, 23, 880, 65, 989, 1, 56, 205, 44, 1158, 146, 15, 25, 15050, 16, 323, 28, 3017, 429, 4, 117, 5, 221, 82, 70, 5676, 15, 1951, 12, 4, 26, 180, 1, 7, 54, 208, 949, 221, 632, 3, 43, 1, 1355, 1110, 15, 12070, 429, 10, 154, 7885, 17, 80, 1344, 249, 121, 36, 16, 322, 4224]",1581.0,22543202,role vaginal brachytherapy treatment surgical stage papillary serous clear endometrial,0,0.0
Orthovoltage intraoperative radiotherapy for locally advanced and recurrent colorectal cancer.,Diseases of the colon and rectum,Dis. Colon Rectum,2012-06-01,"Locally advanced and recurrent colorectal cancers pose a significant therapeutic challenge. Orthovoltage intraoperative radiotherapy provides one potential means of improving disease control at the time of surgery. This study sought to analyze outcomes and identify prognostic factors of patients treated with orthovoltage intraoperative radiotherapy for locally advanced or recurrent colorectal cancer. This study is a retrospective chart review conducted at a tertiary medical center. Between January 1990 and July 2009, 55 patients underwent intraoperative radiotherapy to a total of 61 sites for locally advanced (n = 14) or recurrent (n = 41) cancers of colon (n = 18) or rectum/rectosigmoid junction (n = 37). Median dose was 12 Gy (range, 7.5-20 Gy). Among locally advanced rectal/rectosigmoid cases, surgery included abdominoperineal resection (n = 3) or low anterior resection (n = 9). Seven treated sites had gross residual (R2) disease, 28 had pathologic or clinical microscopic residual disease (R1), and 15 were complete resections (R0). Treated sites included sacrum (n = 22), anterior pelvis/pelvic sidewall (19), sacrum and sidewall (n = 1), aortic bifurcation (n = 2), vaginal cuff (n = 2), psoas (n = 3), perivesicular region (n = 2), and other (n = 10). Outcomes measures included in-field local control, locoregional control, overall survival, and grade 3 toxicity. At a median follow-up of 27 months (range, 4-237) among living patients, 2-year Kaplan-Meier estimates of in-field local control, locoregional control, and overall survival were 69%, 51%, and 59%. Margin status predicted for improved locoregional control (p = 0.01) and overall survival (p = 0.01). Seventeen patients (31%) developed a grade 3 to 5 toxicity following surgery with intraoperative radiotherapy. This study was limited by its retrospective nature and relatively small sample size. Local control with intraoperative radiotherapy for locally advanced and recurrent colorectal cancers is good despite the high risk of residual disease. Among carefully selected patients, multimodality regimens including intraoperative radiotherapy may permit long-term survival.",Journal Article,2790.0,6.0,Locally advanced recurrent colorectal pose significant therapeutic challenge Orthovoltage intraoperative radiotherapy provides potential means improving disease control time surgery sought outcomes identify prognostic factors patients treated orthovoltage intraoperative radiotherapy locally advanced recurrent colorectal retrospective chart review conducted tertiary medical center January 1990 July 2009 55 patients underwent intraoperative radiotherapy total 61 sites locally advanced n 14 recurrent n 41 colon n 18 rectum/rectosigmoid junction n 37 Median dose 12 Gy range 7.5-20 Gy locally advanced rectal/rectosigmoid cases surgery included abdominoperineal resection n 3 low anterior resection n 9 Seven treated sites gross residual R2 disease 28 pathologic clinical microscopic residual disease R1 15 complete resections R0 Treated sites included sacrum n 22 anterior pelvis/pelvic sidewall 19 sacrum sidewall n 1 aortic bifurcation n 2 vaginal cuff n 2 psoas n 3 perivesicular region n 2 n 10 Outcomes measures included in-field local control locoregional control overall survival grade 3 toxicity median follow-up 27 months range 4-237 living patients 2-year Kaplan-Meier estimates in-field local control locoregional control overall survival 69 51 59 Margin status predicted improved locoregional control p 0.01 overall survival p 0.01 Seventeen patients 31 developed grade 3 5 toxicity following surgery intraoperative radiotherapy limited retrospective nature relatively small size Local control intraoperative radiotherapy locally advanced recurrent colorectal good despite high risk residual disease carefully selected patients multimodality regimens including intraoperative radiotherapy permit long-term survival,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,"[795, 131, 2, 387, 163, 6015, 8, 93, 189, 1745, 26691, 1720, 310, 777, 104, 174, 2263, 1, 1673, 34, 182, 28, 3, 98, 1, 152, 26, 45, 990, 6, 1992, 123, 2, 255, 177, 130, 1, 7, 73, 5, 26691, 1720, 310, 9, 795, 131, 15, 387, 12, 26, 45, 16, 8, 459, 2937, 206, 426, 28, 8, 2557, 484, 574, 59, 1024, 2289, 2, 2066, 1238, 614, 7, 208, 1720, 310, 6, 8, 181, 1, 713, 633, 9, 795, 131, 78, 213, 15, 387, 78, 605, 163, 1, 78, 203, 15, 3660, 14258, 3322, 78, 567, 52, 61, 10, 133, 381, 184, 67, 33, 179, 381, 107, 795, 131, 21092, 14258, 140, 152, 159, 8177, 170, 78, 27, 15, 154, 2882, 170, 78, 83, 648, 73, 633, 42, 1789, 753, 4332, 34, 339, 42, 510, 15, 38, 2984, 753, 34, 3239, 2, 167, 11, 236, 2185, 2328, 73, 633, 159, 11629, 78, 350, 2882, 3270, 1110, 12599, 326, 11629, 2, 12599, 78, 14, 3938, 18788, 78, 18, 11445, 78, 18, 11839, 78, 27, 39990, 1053, 78, 18, 2, 127, 78, 79, 123, 1018, 159, 4, 1067, 293, 182, 1325, 182, 63, 25, 2, 88, 2608, 155, 28, 8, 52, 166, 126, 1, 428, 53, 184, 39, 7296, 107, 2798, 7, 18, 111, 876, 882, 1423, 1, 4, 1067, 293, 182, 1325, 182, 2, 63, 25, 11, 790, 725, 2, 728, 959, 156, 783, 9, 231, 1325, 182, 19, 13, 355, 2, 63, 25, 19, 13, 355, 3591, 7, 456, 276, 8, 88, 27, 6, 33, 155, 366, 152, 5, 1720, 310, 26, 45, 10, 383, 20, 211, 459, 2202, 2, 1352, 302, 1000, 444, 293, 182, 5, 1720, 310, 9, 795, 131, 2, 387, 163, 16, 1178, 550, 3, 64, 43, 1, 753, 34, 107, 3900, 715, 7, 2425, 472, 141, 1720, 310, 68, 5634, 319, 337, 25]",1997.0,22595850,Orthovoltage intraoperative radiotherapy locally advanced recurrent colorectal,1,0.005025125628140704
Rhabdomyosarcoma of the cervix in adult women and younger patients.,Gynecologic oncology,Gynecol. Oncol.,2012-05-15,"Cervical rhabdomyosarcoma is extremely rare, and there is a paucity of literature on the subject. The purpose of this study was to describe the clinical and pathologic features of cervical rhabdomyosarcoma. We retrospectively reviewed all patients with cervical rhabdomyosarcoma who presented to our institution from 1980 to 2010. We reviewed pathologic, demographic, and clinical information. During the study period, 11 females presented with cervical rhabdomyosarcoma. The median age at presentation was 18.4 years, and 6 patients were <19 years old at diagnosis. Vaginal bleeding was the most common presenting symptom, and a vaginal mass was often a co-presenting symptom. Eight patients (73%) presented with stage IB disease, and 8 (73%) presented with the embryonal (botryoid) histologic subtype. Nine patients (82%) received multimodal therapy consisting of surgery with chemotherapy, radiation therapy, or both. All patients were without evidence of disease after completion of primary therapy, but 3 patients experienced local recurrence. At a median follow-up of 23 months, 6 patients (55%) were without evidence of disease, 1 (9%) was alive with disease, 1 (9%) had died of disease, and 3 (27%) had died of other causes. Three patients (27%) had other primary malignancies in addition to rhabdomyosarcoma-1 had a Sertoli-Leydig tumor, 1 had a Sertoli-Leydig tumor and a pinealoblastoma, and 1 had thyroid cancer and a parotid adenocarcinoma. With multimodal therapy, cervical rhabdomyosarcoma appears to be associated with a good prognosis. Favorable prognostic factors such as early stage at diagnosis and a favorable histologic subtype may contribute to the excellent observed survival.",Journal Article,2807.0,16.0,Cervical rhabdomyosarcoma extremely rare paucity literature subject purpose clinical pathologic features cervical rhabdomyosarcoma retrospectively reviewed patients cervical rhabdomyosarcoma presented institution 1980 2010 reviewed pathologic demographic clinical information period 11 females presented cervical rhabdomyosarcoma median age presentation 18.4 years 6 patients 19 years old diagnosis Vaginal bleeding common presenting symptom vaginal mass co-presenting symptom patients 73 presented stage IB disease 8 73 presented embryonal botryoid histologic subtype patients 82 received multimodal therapy consisting surgery chemotherapy radiation therapy patients evidence disease completion primary therapy 3 patients experienced local recurrence median follow-up 23 months 6 patients 55 evidence disease 1 9 alive disease 1 9 died disease 3 27 died causes patients 27 primary malignancies addition rhabdomyosarcoma-1 Sertoli-Leydig 1 Sertoli-Leydig pinealoblastoma 1 thyroid parotid adenocarcinoma multimodal therapy cervical rhabdomyosarcoma appears associated good prognosis Favorable prognostic factors early stage diagnosis favorable histologic subtype contribute excellent observed survival,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,"[16, 2938, 622, 2, 125, 16, 8, 4832, 1, 789, 23, 3, 2974, 3, 743, 1, 26, 45, 10, 6, 897, 3, 38, 2, 510, 404, 1, 21, 894, 446, 62, 7, 5, 54, 917, 6, 114, 731, 29, 4376, 6, 1120, 21, 446, 510, 1540, 2, 38, 487, 190, 3, 45, 727, 175, 2451, 917, 5, 3, 52, 89, 28, 1031, 10, 203, 39, 60, 2, 49, 7, 11, 326, 60, 1095, 28, 147, 2294, 10, 3, 96, 186, 1656, 934, 2, 8, 782, 10, 629, 8, 1269, 1656, 934, 659, 7, 803, 917, 5, 82, 3180, 34, 2, 66, 803, 917, 5, 3, 5239, 35369, 884, 875, 762, 7, 878, 103, 4122, 36, 2273, 1, 152, 5, 56, 121, 36, 15, 110, 62, 7, 11, 187, 241, 1, 34, 50, 1438, 1, 86, 36, 84, 27, 7, 592, 293, 146, 28, 8, 52, 166, 126, 1, 382, 53, 49, 7, 614, 11, 187, 241, 1, 34, 14, 83, 10, 1701, 5, 34, 14, 83, 42, 1016, 1, 34, 2, 27, 428, 42, 1016, 1, 127, 1626, 169, 7, 428, 42, 127, 86, 441, 4, 352, 6, 22050, 14, 42, 8, 31032, 23505, 30, 14, 42, 8, 31032, 23505, 30, 2, 8, 61478, 2, 14, 42, 12, 2, 8, 5838, 449, 5, 4122, 36, 1233, 6, 40, 41, 5, 8, 1178, 356, 913, 177, 130, 225, 22, 191, 82, 28, 147, 2, 8, 913, 884, 875, 68, 1248, 6, 3, 1503, 164, 25]",1488.0,22609112,Rhabdomyosarcoma cervix adult women younger patients,4,0.020100502512562814
Reproducibility and genital sparing with a vaginal dilator used for female anal cancer patients.,Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,Radiother Oncol,2012-07-26,"Acute vulvitis, acute urethritis, and permanent sexual dysfunction are common among patients treated with chemoradiation for squamous cell carcinoma of the anal canal. Avoidance of the genitalia may reduce sexual dysfunction. A vaginal dilator may help delineate and displace the vulva and lower vagina away from the primary tumor. The goal of this study was to evaluate the positional reproducibility and vaginal sparing with the use of a vaginal dilator. Ten female patients treated with IMRT for anal cancer were included in this study. A silicone vaginal dilator measuring 29 mm in diameter and 114 mm in length was inserted into the vagina before simulation and each treatment. The reproducibility of dilator placement was investigated with antero-posterior and lateral images acquired daily. Weekly cone beam CT (CBCT) imaging was used to confirm coverage of the GTV, which was typically posterior and inferior to the dilator apex. Finally, a planning study was performed to compare the vaginal doses for these 10 patients to a comparable group of 10 female patients who were treated for anal cancer with IMRT without vaginal dilators. The absolute values of the location of the dilator apex were 7.0  7.8mm in the supero-inferior direction, 7.5  5.5 mm in the antero-posterior, and 3.8  3.1mm in the lateral direction. Coverage of the GTV and CTV was confirmed from CBCT images. The mean dose to the vagina was lower by 5.5 Gy, on average, for the vaginal dilator patients, compared to patients treated without vaginal dilators. The vaginal dilator tended to be inserted more inferiorly during treatment than during simulation. For these ten patients, this did not compromise tumor coverage. Combined with IMRT treatment planning, use of a vaginal dilator could allow for maximum sparing of female genitalia for patients undergoing radiation therapy for anal cancer.",Journal Article,2735.0,10.0,Acute vulvitis acute urethritis permanent sexual dysfunction common patients treated chemoradiation squamous carcinoma anal canal Avoidance genitalia reduce sexual dysfunction vaginal dilator help delineate displace vulva lower vagina away primary goal evaluate positional reproducibility vaginal sparing use vaginal dilator female patients treated IMRT anal included silicone vaginal dilator measuring 29 mm diameter 114 mm length inserted vagina simulation treatment reproducibility dilator placement investigated antero-posterior lateral images acquired daily Weekly cone beam CT CBCT imaging confirm coverage GTV typically posterior inferior dilator apex Finally planning performed compare vaginal doses 10 patients comparable group 10 female patients treated anal IMRT vaginal dilators absolute values location dilator apex 7.0  7.8mm supero-inferior direction 7.5  5.5 mm antero-posterior 3.8  3.1mm lateral direction Coverage GTV CTV confirmed CBCT images mean dose vagina lower 5.5 Gy average vaginal dilator patients compared patients treated vaginal dilators vaginal dilator tended inserted inferiorly treatment simulation patients compromise coverage Combined IMRT treatment planning use vaginal dilator allow maximum sparing female genitalia patients undergoing radiation therapy anal,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[286, 61711, 286, 47311, 2, 4377, 2232, 1527, 32, 186, 107, 7, 73, 5, 975, 9, 691, 31, 134, 1, 3, 5614, 5863, 1, 3, 33952, 68, 969, 2232, 1527, 8, 17967, 68, 987, 5092, 2, 17651, 3, 9263, 2, 280, 7553, 6565, 29, 3, 86, 30, 3, 1326, 1, 26, 45, 10, 6, 376, 3, 16788, 4688, 2, 1851, 5, 3, 119, 1, 8, 17967, 1618, 1061, 7, 73, 5, 964, 9, 12, 11, 159, 4, 26, 45, 8, 18762, 17967, 2978, 462, 321, 4, 2549, 2, 3803, 321, 4, 1318, 10, 9882, 237, 3, 7553, 348, 4026, 2, 296, 24, 3, 4688, 1, 17967, 2613, 10, 565, 5, 35407, 3028, 2, 3855, 1572, 1294, 391, 709, 6939, 1345, 425, 5187, 270, 10, 95, 6, 1843, 2139, 1, 3, 4046, 92, 10, 1969, 3028, 2, 1663, 6, 3, 17967, 8670, 1368, 8, 1349, 45, 10, 173, 6, 932, 3, 415, 9, 46, 79, 7, 6, 8, 1279, 87, 1, 79, 1061, 7, 54, 11, 73, 9, 12, 5, 964, 187, 47312, 3, 1766, 1030, 1, 3, 1147, 1, 3, 17967, 8670, 11, 67, 13, 810, 67, 39737, 4, 3, 38987, 1663, 4651, 67, 33, 810, 33, 33, 321, 4, 3, 35407, 3028, 2, 27, 66, 810, 27, 22731, 4, 3, 3855, 4651, 2139, 1, 3, 4046, 2, 3402, 10, 557, 29, 5187, 1572, 3, 313, 61, 6, 3, 7553, 10, 280, 20, 33, 33, 381, 23, 1011, 9, 3, 17967, 7, 72, 6, 7, 73, 187, 47312, 3, 17967, 3886, 6, 40, 9882, 80, 25313, 190, 24, 76, 190, 4026, 9, 46, 1618, 7, 26, 205, 44, 4665, 30, 2139, 397, 5, 964, 24, 1349, 119, 1, 8, 17967, 359, 1700, 9, 689, 1851, 1, 1061, 33952, 9, 7, 479, 121, 36, 9, 12]",1748.0,22841019,Reproducibility genital sparing vaginal dilator female anal patients,0,0.0
Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer.,Gynecologic oncology,Gynecol. Oncol.,2012-07-28,"The purpose of this study is to report our single-institution experience with concurrent adjuvant intravaginal radiation (IVRT) and carboplatin/paclitaxel chemotherapy for early stage uterine papillary serous carcinoma (UPSC). From 10/2000 to 12/2009, 41 women with stage I-II UPSC underwent surgery followed by IVRT (median dose of 21 Gy in 3 fractions) and concurrent carboplatin (AUC=5-6) and paclitaxel (175 mg/m(2)) for six planned cycles. IVRT was administered on non-chemotherapy weeks. The Kaplan-Meier method was used to estimate survival, and the log-rank test was used for comparisons. Median patient age was 67 years (51-80 years). Surgery included hysterectomy, bilateral salpingo-oophorectomy, peritoneal washings, omental biopsy, and pelvic and paraaortic lymph node sampling. FIGO 2009 stage was IA in 73%, IB in 10%, and II in 17%. Histology was pure serous in 71% of cases. Thirty-five patients (85%) completed all planned treatment. With a median follow-up time of 58 months, the 5-year disease-free (DFS) and overall survival (OS) rates were 85% (95%CI, 73-96%) and 90% (95%CI, 80-100%). The 5-year pelvic, para-aortic, and distant recurrence rates were 9%, 5%, and 10%, respectively. There were no vaginal recurrences. Of the 4 pelvic recurrences, 2 were isolated and were successfully salvaged. Patients with stage II disease had lower DFS (71% vs. 88%; p=0.017) and OS (71% vs. 93%; p=0.001) than patients with stage I disease. Concurrent adjuvant carboplatin/paclitaxel chemotherapy and IVRT provide excellent outcomes for early stage UPSC. Whether this regimen is superior to pelvic radiation will require confirmation from the ongoing randomized trial.",Evaluation Study,2733.0,42.0,purpose report single-institution experience concurrent adjuvant intravaginal radiation IVRT carboplatin/paclitaxel chemotherapy early stage uterine papillary serous carcinoma UPSC 10/2000 12/2009 41 women stage I-II UPSC underwent surgery followed IVRT median dose 21 Gy 3 fractions concurrent carboplatin AUC=5-6 paclitaxel 175 mg/m 2 planned cycles IVRT administered non-chemotherapy weeks Kaplan-Meier estimate survival log-rank test comparisons Median patient age 67 years 51-80 years Surgery included hysterectomy bilateral salpingo-oophorectomy peritoneal washings omental biopsy pelvic paraaortic lymph node sampling FIGO 2009 stage IA 73 IB 10 II 17 Histology pure serous 71 cases Thirty-five patients 85 completed planned treatment median follow-up time 58 months 5-year disease-free DFS overall survival OS rates 85 95 CI 73-96 90 95 CI 80-100 5-year pelvic para-aortic distant recurrence rates 9 5 10 respectively vaginal recurrences 4 pelvic recurrences 2 isolated successfully salvaged Patients stage II disease lower DFS 71 vs. 88 p=0.017 OS 71 vs. 93 p=0.001 patients stage disease Concurrent adjuvant carboplatin/paclitaxel chemotherapy IVRT provide excellent outcomes early stage UPSC regimen superior pelvic radiation require confirmation ongoing randomized trial,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[3, 743, 1, 26, 45, 16, 6, 414, 114, 226, 731, 730, 5, 750, 249, 16720, 121, 12005, 2, 927, 490, 56, 9, 191, 82, 1796, 1744, 134, 5676, 29, 79, 1081, 6, 133, 1238, 605, 117, 5, 82, 70, 215, 5676, 208, 152, 370, 20, 12005, 52, 61, 1, 239, 381, 4, 27, 1550, 2, 750, 927, 1376, 33, 49, 2, 490, 3300, 81, 188, 18, 9, 437, 1465, 410, 12005, 10, 468, 23, 220, 56, 244, 3, 876, 882, 596, 10, 95, 6, 1191, 25, 2, 3, 1066, 1026, 412, 10, 95, 9, 2213, 52, 69, 89, 10, 598, 60, 725, 493, 60, 152, 159, 2622, 1607, 5690, 3470, 1639, 11161, 11404, 411, 2, 1110, 2, 7401, 263, 289, 2874, 3837, 1238, 82, 10, 3302, 4, 803, 3180, 4, 79, 2, 215, 4, 269, 784, 10, 3092, 1744, 4, 792, 1, 140, 977, 365, 7, 772, 781, 62, 1465, 24, 5, 8, 52, 166, 126, 98, 1, 717, 53, 3, 33, 111, 34, 115, 1010, 2, 63, 25, 118, 151, 11, 772, 48, 58, 803, 921, 2, 424, 48, 58, 493, 394, 3, 33, 111, 1110, 4615, 3938, 2, 626, 146, 151, 11, 83, 33, 2, 79, 106, 125, 11, 77, 1593, 1, 3, 39, 1110, 1593, 18, 11, 1355, 2, 11, 1878, 9459, 7, 5, 82, 215, 34, 42, 280, 1010, 792, 105, 889, 19, 13, 3825, 2, 118, 792, 105, 966, 19, 13, 144, 76, 7, 5, 82, 70, 34, 750, 249, 927, 490, 56, 2, 12005, 377, 1503, 123, 9, 191, 82, 5676, 317, 26, 477, 16, 1123, 6, 1110, 121, 303, 1353, 3551, 29, 3, 942, 384, 160]",1584.0,22850412,Five-year outcomes adjuvant carboplatin/paclitaxel chemotherapy intravaginal radiation stage I-II papillary serous endometrial,0,0.0
Severe late toxicities following concomitant chemoradiotherapy compared to radiotherapy alone in cervical cancer: an inter-era analysis.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2012-08-14,"To compare rates of severe late toxicities following concomitant chemoradiotherapy and radiotherapy alone for cervical cancer. Patients with cervical cancer were treated at a single institution with radiotherapy alone or concomitant chemoradiotherapy for curative intent. Severe late toxicity was defined as grade3 vaginal, urologic, or gastrointestinal toxicity or any pelvic fracture, using Common Terminology Criteria for Adverse Events version 4.0 (CTCAE), occurring 6 months from treatment completion and predating any salvage therapy. Severe late toxicity rates were compared after adjusting for pertinent covariates. At 3 years, probability of vaginal severe late toxicity was 20.2% for radiotherapy alone and 35.1% for concomitant chemoradiotherapy (P=.026). At 3 years, probability of skeletal severe late toxicity was 1.6% for radiotherapy alone and 7.5% for concomitant chemoradiotherapy (P=.010). After adjustment for case mix, concomitant chemoradiotherapy was associated with higher vaginal (hazard ratio [HR] 3.0, 95% confidence interval [CI], 1.7-5.2, P<.001), and skeletal (HR 7.0, 95% CI 1.4-34.1, P=.016) severe late toxicity. Compared to high dilator compliance, moderate (HR 3.6, 95% CI 2.0-6.5, P<.001) and poor (HR 8.5, 95% CI 4.3-16.9, P<.001) dilator compliance was associated with higher vaginal severe late toxicity. Age>50 was associated with higher vaginal (HR 1.8, 95% CI 1.1-3.0, P=.013) and skeletal (HR 5.7, 95% CI 1.2-27.0, P=.028) severe late toxicity. Concomitant chemoradiotherapy was not associated with higher gastrointestinal (P=.886) or urologic (unadjusted, P=.053; adjusted, P=.063) severe late toxicity. Compared to radiotherapy alone, concomitant chemoradiotherapy is associated with higher rates of severe vaginal and skeletal late toxicities. Other predictive factors include dilator compliance for severe vaginal late toxicity and age for severe vaginal and skeletal late toxicities.",Comparative Study,2716.0,58.0,compare rates severe late toxicities following concomitant chemoradiotherapy radiotherapy cervical Patients cervical treated single institution radiotherapy concomitant chemoradiotherapy curative intent Severe late toxicity defined grade3 vaginal urologic gastrointestinal toxicity pelvic fracture Common Terminology Criteria Adverse Events version 4.0 CTCAE occurring 6 months treatment completion predating salvage therapy Severe late toxicity rates compared adjusting pertinent covariates 3 years probability vaginal severe late toxicity 20.2 radiotherapy 35.1 concomitant chemoradiotherapy P=.026 3 years probability skeletal severe late toxicity 1.6 radiotherapy 7.5 concomitant chemoradiotherapy P=.010 adjustment case mix concomitant chemoradiotherapy associated higher vaginal hazard ratio HR 3.0 95 confidence interval CI 1.7-5.2 P .001 skeletal HR 7.0 95 CI 1.4-34.1 P=.016 severe late toxicity Compared high dilator compliance moderate HR 3.6 95 CI 2.0-6.5 P .001 poor HR 8.5 95 CI 4.3-16.9 P .001 dilator compliance associated higher vaginal severe late toxicity Age 50 associated higher vaginal HR 1.8 95 CI 1.1-3.0 P=.013 skeletal HR 5.7 95 CI 1.2-27.0 P=.028 severe late toxicity Concomitant chemoradiotherapy associated higher gastrointestinal P=.886 urologic unadjusted P=.053 adjusted P=.063 severe late toxicity Compared radiotherapy concomitant chemoradiotherapy associated higher rates severe vaginal skeletal late toxicities predictive factors include dilator compliance severe vaginal late toxicity age severe vaginal skeletal late toxicities,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 932, 151, 1, 905, 807, 385, 366, 1781, 1464, 2, 310, 279, 9, 12, 7, 5, 12, 11, 73, 28, 8, 226, 731, 5, 310, 279, 15, 1781, 1464, 9, 1075, 1697, 905, 807, 155, 10, 395, 22, 14659, 7178, 15, 155, 15, 500, 1110, 3956, 75, 186, 3462, 371, 9, 290, 281, 2256, 39, 13, 3898, 1821, 6258, 53, 29, 24, 1438, 2, 29135, 500, 992, 36, 905, 807, 155, 151, 11, 72, 50, 1358, 9, 5799, 2489, 28, 27, 60, 1320, 1, 905, 807, 155, 10, 179, 18, 9, 310, 279, 2, 465, 14, 9, 1781, 1464, 19, 4554, 28, 27, 60, 1320, 1, 2621, 905, 807, 155, 10, 14, 49, 9, 310, 279, 2, 67, 33, 9, 1781, 1464, 19, 4873, 50, 1852, 9, 473, 8842, 1781, 1464, 10, 41, 5, 142, 360, 197, 168, 27, 13, 48, 307, 268, 58, 14, 67, 33, 18, 19, 144, 2, 2621, 168, 67, 13, 48, 58, 14, 39, 562, 14, 19, 3820, 905, 807, 155, 72, 6, 64, 17967, 3336, 1163, 168, 27, 49, 48, 58, 18, 13, 49, 33, 19, 144, 2, 334, 168, 66, 33, 48, 58, 39, 27, 245, 83, 19, 144, 17967, 3336, 10, 41, 5, 142, 905, 807, 155, 89, 212, 10, 41, 5, 142, 168, 14, 66, 48, 58, 14, 14, 27, 13, 19, 3612, 2, 2621, 168, 33, 67, 48, 58, 14, 18, 428, 13, 19, 4836, 905, 807, 155, 1781, 1464, 10, 44, 41, 5, 142, 19, 14577, 15, 7178, 4487, 19, 9948, 586, 19, 10592, 905, 807, 155, 72, 6, 310, 279, 1781, 1464, 16, 41, 5, 142, 151, 1, 905, 2, 2621, 807, 385, 127, 464, 130, 643, 17967, 3336, 9, 905, 807, 155, 2, 89, 9, 905, 2, 2621, 807, 385]",1743.0,22898381,Severe late toxicities following concomitant chemoradiotherapy compared radiotherapy cervical inter-era,0,0.0
An international series on abdominal radical trachelectomy: 101 patients and 28 pregnancies.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2012-09-01,"Abdominal radical trachelectomy (ART) is a type C resection (uterine vessels ligated at origin from the hypogastric vessels). Questions arise as to whether fertility is maintained after ART, particularly when uterine vessels are sacrificed. We report an international series on ART to describe fertility and oncologic outcomes. Databases at 3 institutions were queried to identify patients planned for ART from 1999 to 2011. Clinical and demographic data were gathered. One hundred one patients underwent ART. Mean age was 31 years (range, 19-43 years). Histologic classifications were adenocarcinoma (n = 54), squamous cell carcinoma (n = 40), adenosquamous carcinoma (n = 6), and clear cell carcinoma (n = 1). Twenty patients (20%) required conversion to hysterectomy (10 margins and 10 nodes). Eight patients underwent completion hysterectomy owing to the following: positive margins on final pathology (n = 3), patient's choice (n = 4), or recurrence (n = 1). Postoperatively, 20 patients (20%) received adjuvant chemotherapy and/or radiation (4 final pathology margins and 16 nodes). Four patients (4%) had recurrence and lived 22 to 35 months after diagnosis. Of the 70 women who had neither hysterectomy nor adjuvant therapy, 38 (54%) attempted pregnancy and 28 (74%) achieved pregnancy. Thirty-one pregnancies resulted in 16 (52%) third trimester deliveries. Six patients are currently pregnant with outcomes pending. These data demonstrate that ART preserves fertility and maintains excellent oncologic outcomes. Most women (74%) attempting pregnancy after ART are able to achieve pregnancy and deliver in the third trimester (52%). Preservation of the uterine vasculature is not necessary for fertility; obstetrical outcomes are similar to those of the historical vaginal radical trachelectomy cohorts.",Journal Article,2698.0,61.0,Abdominal radical trachelectomy ART type C resection uterine vessels ligated origin hypogastric vessels Questions arise fertility maintained ART particularly uterine vessels sacrificed report international series ART fertility oncologic outcomes Databases 3 institutions queried identify patients planned ART 1999 2011 Clinical demographic gathered patients underwent ART Mean age 31 years range 19-43 years Histologic classifications adenocarcinoma n 54 squamous carcinoma n 40 adenosquamous carcinoma n 6 clear carcinoma n 1 patients 20 required conversion hysterectomy 10 margins 10 nodes patients underwent completion hysterectomy owing following positive margins final pathology n 3 patient 's choice n 4 recurrence n 1 Postoperatively 20 patients 20 received adjuvant chemotherapy and/or radiation 4 final pathology margins 16 nodes patients 4 recurrence lived 22 35 months diagnosis 70 women hysterectomy adjuvant therapy 38 54 attempted pregnancy 28 74 achieved pregnancy Thirty-one pregnancies resulted 16 52 trimester deliveries patients currently pregnant outcomes pending demonstrate ART preserves fertility maintains excellent oncologic outcomes women 74 attempting pregnancy ART able achieve pregnancy deliver trimester 52 Preservation uterine vasculature necessary fertility obstetrical outcomes similar historical vaginal radical trachelectomy cohorts,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[1467, 711, 5760, 4363, 16, 8, 267, 256, 170, 3102, 18971, 28, 1938, 29, 3, 21449, 3102, 1937, 3043, 22, 6, 317, 2954, 16, 1955, 50, 4363, 823, 198, 3102, 32, 15470, 21, 414, 35, 944, 988, 23, 4363, 6, 897, 2954, 2, 1998, 123, 2348, 28, 27, 1764, 11, 3547, 6, 255, 7, 1465, 9, 4363, 29, 2043, 6, 1132, 38, 2, 1540, 74, 11, 7546, 104, 1128, 104, 7, 208, 4363, 313, 89, 10, 456, 60, 184, 326, 601, 60, 884, 5787, 11, 449, 78, 667, 691, 31, 134, 78, 327, 8067, 134, 78, 49, 2, 885, 31, 134, 78, 14, 737, 7, 179, 616, 3111, 6, 2622, 79, 1012, 2, 79, 502, 659, 7, 208, 1438, 2622, 3421, 6, 3, 366, 109, 1012, 23, 1457, 1117, 78, 27, 69, 292, 1866, 78, 39, 15, 146, 78, 14, 3541, 179, 7, 179, 103, 249, 56, 2, 15, 121, 39, 1457, 1117, 1012, 2, 245, 502, 294, 7, 39, 42, 146, 2, 4813, 350, 6, 465, 53, 50, 147, 1, 3, 431, 117, 54, 42, 2174, 2622, 2110, 249, 36, 519, 667, 4098, 2290, 2, 339, 794, 513, 2290, 977, 104, 8746, 627, 4, 245, 653, 1282, 12693, 26092, 437, 7, 32, 694, 6086, 5, 123, 9453, 46, 74, 608, 17, 4363, 16221, 2954, 2, 8107, 1503, 1998, 123, 96, 117, 794, 9632, 2290, 50, 4363, 32, 1665, 6, 1359, 2290, 2, 3392, 4, 3, 1282, 12693, 653, 2224, 1, 3, 3805, 16, 44, 1493, 9, 2954, 21031, 123, 32, 288, 6, 135, 1, 3, 2252, 711, 5760, 736]",1690.0,22914213,international series abdominal radical trachelectomy 101 patients 28 pregnancies,1,0.005025125628140704
Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate- and high-risk cervical cancer.,Gynecologic oncology,Gynecol. Oncol.,2012-11-15,"According to national surveys, the use of intensity-modulated radiation therapy (IMRT) in gynecologic cancers is on the rise, yet there is still some reluctance to adopt adjuvant IMRT as standard practice. The purpose of this study is to report a single-institution experience using postoperative pelvic IMRT with concurrent chemotherapy in intermediate- and high-risk early stage cervical cancer. From 1/2004 to 12/2009, 34 patients underwent radical hysterectomy and pelvic lymph node dissection (28 median nodes were removed) for early stage cervical cancer. Median dose of postoperative pelvic IMRT was 50.4 Gy (range, 45-50.4). All patients received concurrent cisplatin. With a median follow-up of 44 months, 3 patients have recurred; 1 vaginal recurrence, 1 regional and distant, and 1 distant. The 3- and 5-year disease-free survival (DFS) was 91.2% (95% CI, 81.4-100%) and overall survival (OS) was 91.1% (95% CI, 81.3-100%). All failures and all deaths were in the high-risk group (n=3/26). There was 32.3% G3-4 hematologic toxicity, 2.9% acute G3 gastrointestinal toxicity, and no acute G3 or higher genitourinary toxicity. There were no chronic G3 or higher toxicities. Oncologic outcomes with postoperative IMRT were very good, with DFS and OS rates of >90% at median follow-up of 44 months, despite a preponderance (76.5%) of high-risk features. Toxicity was minimal even in the setting of an aggressive trimodality approach. Data from this study and emerging data from the Phase II RTOG study (0418) demonstrate the advantages of postoperative IMRT in early stage cervical cancer.",Journal Article,2623.0,46.0,According national surveys use intensity-modulated radiation therapy IMRT gynecologic rise reluctance adopt adjuvant IMRT standard practice purpose report single-institution experience postoperative pelvic IMRT concurrent chemotherapy intermediate- high-risk early stage cervical 1/2004 12/2009 34 patients underwent radical hysterectomy pelvic lymph node dissection 28 median nodes removed early stage cervical Median dose postoperative pelvic IMRT 50.4 Gy range 45-50.4 patients received concurrent cisplatin median follow-up 44 months 3 patients recurred 1 vaginal recurrence 1 regional distant 1 distant 3- 5-year disease-free survival DFS 91.2 95 CI 81.4-100 overall survival OS 91.1 95 CI 81.3-100 failures deaths high-risk group n=3/26 32.3 G3-4 hematologic toxicity 2.9 acute G3 gastrointestinal toxicity acute G3 higher genitourinary toxicity chronic G3 higher toxicities Oncologic outcomes postoperative IMRT good DFS OS rates 90 median follow-up 44 months despite preponderance 76.5 high-risk features Toxicity minimal setting aggressive trimodality approach emerging Phase II RTOG 0418 demonstrate advantages postoperative IMRT early stage cervical,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[768, 6, 657, 3666, 3, 119, 1, 837, 1757, 121, 36, 964, 4, 1512, 163, 16, 23, 3, 3693, 1145, 125, 16, 1234, 476, 13872, 6, 11462, 249, 964, 22, 260, 758, 3, 743, 1, 26, 45, 16, 6, 414, 8, 226, 731, 730, 75, 573, 1110, 964, 5, 750, 56, 4, 919, 2, 64, 43, 191, 82, 12, 29, 14, 1131, 6, 133, 1238, 562, 7, 208, 711, 2622, 2, 1110, 263, 289, 1161, 339, 52, 502, 11, 2264, 9, 191, 82, 12, 52, 61, 1, 573, 1110, 964, 10, 212, 39, 381, 184, 512, 212, 39, 62, 7, 103, 750, 540, 5, 8, 52, 166, 126, 1, 584, 53, 27, 7, 47, 3363, 14, 146, 14, 951, 2, 626, 2, 14, 626, 3, 27, 2, 33, 111, 34, 115, 25, 1010, 10, 970, 18, 48, 58, 865, 39, 394, 2, 63, 25, 118, 10, 970, 14, 48, 58, 865, 27, 394, 62, 3368, 2, 62, 1043, 11, 4, 3, 64, 43, 87, 78, 27, 432, 125, 10, 531, 27, 5578, 39, 813, 155, 18, 83, 286, 5578, 155, 2, 77, 286, 5578, 15, 142, 4109, 155, 125, 11, 77, 442, 5578, 15, 142, 385, 1998, 123, 5, 573, 964, 11, 923, 1178, 5, 1010, 2, 118, 151, 1, 424, 28, 52, 166, 126, 1, 584, 53, 550, 8, 12531, 846, 33, 1, 64, 43, 404, 155, 10, 1048, 871, 4, 3, 546, 1, 35, 571, 4625, 353, 74, 29, 26, 45, 2, 1478, 74, 29, 3, 124, 215, 3931, 45, 31487, 608, 3, 3126, 1, 573, 964, 4, 191, 82, 12]",1485.0,23159818,Postoperative pelvic intensity-modulated radiotherapy concurrent chemotherapy intermediate- high-risk cervical,2,0.010050251256281407
Postoperative pelvic intensity-modulated radiotherapy in high risk endometrial cancer.,Gynecologic oncology,Gynecol. Oncol.,2012-11-20,"According to national surveys, the use of intensity-modulated radiation therapy (IMRT) in gynecologic cancers is on the rise, yet there is still some reluctance to adopt adjuvant IMRT as standard practice. The purpose of this study is to report a single-institution experience using postoperative pelvic IMRT with or without chemotherapy in high-risk endometrial cancer. From 11/2004 to 12/2009, 46 patients underwent hysterectomy/bilateral salpingo-oophorectomy for stage I-III (22% stage I/II and 78% stage III) endometrial cancer. Median IMRT dose was 50.4Gy. Adjuvant chemotherapy was given to 30 (65%) patients. With a median follow-up of 52months, 4 patients recurred: 1 vaginal plus lung metastasis, 2 isolated para-aortic recurrences, and 1 lungs and liver metastasis. Five-year relapse rate was 9% (95% CI, 0-13.6%). Five-year disease-free survival (DFS) was 88% (95% CI, 77-98%) and overall survival (OS) was 97% (95% CI, 90-100%). There were 2 patients with non-hematological grade 3 toxicity: 1 (2%) acute and 1 (2%) chronic gastrointestinal toxicity. In patients treated with IMRT and chemotherapy (n=30), 5 had grade 3 leukopenia, 8 grade 2 anemia, and 2 grade 2 thrombocytopenia. Oncologic outcomes with postoperative IMRT were very good, with DFS and OS rates of >88% at median follow-up of 52months, despite a preponderance (78%) of stage III disease. Toxicity was minimal even in the setting of an aggressive trimodality (65% of patients) approach. Data from this study and emerging data from RTOG trial 0418 demonstrate the advantages of IMRT in high-risk endometrial cancer.",Journal Article,2618.0,32.0,According national surveys use intensity-modulated radiation therapy IMRT gynecologic rise reluctance adopt adjuvant IMRT standard practice purpose report single-institution experience postoperative pelvic IMRT chemotherapy high-risk endometrial 11/2004 12/2009 46 patients underwent hysterectomy/bilateral salpingo-oophorectomy stage I-III 22 stage I/II 78 stage III endometrial Median IMRT dose 50.4Gy Adjuvant chemotherapy given 30 65 patients median follow-up 52months 4 patients recurred 1 vaginal plus lung metastasis 2 isolated para-aortic recurrences 1 lungs liver metastasis Five-year relapse rate 9 95 CI 0-13.6 Five-year disease-free survival DFS 88 95 CI 77-98 overall survival OS 97 95 CI 90-100 2 patients non-hematological grade 3 toxicity 1 2 acute 1 2 chronic gastrointestinal toxicity patients treated IMRT chemotherapy n=30 5 grade 3 leukopenia 8 grade 2 anemia 2 grade 2 thrombocytopenia Oncologic outcomes postoperative IMRT good DFS OS rates 88 median follow-up 52months despite preponderance 78 stage III disease Toxicity minimal setting aggressive trimodality 65 patients approach emerging RTOG trial 0418 demonstrate advantages IMRT high-risk endometrial,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[768, 6, 657, 3666, 3, 119, 1, 837, 1757, 121, 36, 964, 4, 1512, 163, 16, 23, 3, 3693, 1145, 125, 16, 1234, 476, 13872, 6, 11462, 249, 964, 22, 260, 758, 3, 743, 1, 26, 45, 16, 6, 414, 8, 226, 731, 730, 75, 573, 1110, 964, 5, 15, 187, 56, 4, 64, 43, 12, 29, 175, 1131, 6, 133, 1238, 641, 7, 208, 2622, 1607, 5690, 3470, 9, 82, 70, 316, 350, 82, 70, 215, 2, 833, 82, 316, 12, 52, 964, 61, 10, 212, 17384, 249, 56, 10, 447, 6, 201, 556, 7, 5, 8, 52, 166, 126, 1, 35475, 39, 7, 3363, 14, 349, 278, 18, 1355, 4615, 3938, 1593, 2, 14, 4465, 2, 278, 365, 111, 429, 116, 10, 83, 48, 58, 13, 233, 49, 365, 111, 34, 115, 25, 1010, 10, 889, 48, 58, 849, 1096, 2, 63, 25, 118, 10, 1015, 48, 58, 424, 394, 125, 11, 18, 7, 5, 220, 2890, 88, 27, 155, 14, 18, 286, 2, 14, 18, 442, 155, 4, 7, 73, 5, 964, 2, 56, 78, 201, 33, 42, 88, 27, 3904, 66, 88, 18, 1545, 2, 18, 88, 18, 1340, 1998, 123, 5, 573, 964, 11, 923, 1178, 5, 1010, 2, 118, 151, 1, 889, 28, 52, 166, 126, 1, 35475, 550, 8, 12531, 833, 1, 82, 316, 34, 155, 10, 1048, 871, 4, 3, 546, 1, 35, 571, 4625, 556, 1, 7, 353, 74, 29, 26, 45, 2, 1478, 74, 29, 3931, 160, 31487, 608, 3, 3126, 1, 964, 4, 64, 43, 12]",1449.0,23174538,Postoperative pelvic intensity-modulated radiotherapy high risk endometrial,8,0.04020100502512563
Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.,Gynecologic oncology,Gynecol. Oncol.,2012-12-20,"This two-stage phase II study was designed to assess the activity of the combination of temsirolimus and bevacizumab in patients with recurrent or persistent endometrial carcinoma (EMC). Eligible patients had persistent or recurrent EMC after receiving 1-2 prior cytotoxic regimens, measurable disease, and Gynecologic Oncology Group performance status  2. Treatment consisted of bevacizumab 10 mg/kg every other week and temsirolimus 25 mg IV weekly until disease progression or prohibitory toxicity. Primary end points were progression-free survival (PFS) at six months and overall response rate using RECIST criteria. Fifty-three patients were enrolled. Forty-nine patients were eligible and evaluable. Median age was 63 years, and prior treatment consisted of one or two regimens in 40 (82%) and 9 (18%), respectively. Twenty (41%) received prior radiation. Adverse events were consistent with those expected with bevacizumab and temsirolimus treatment. Two gastrointestinal-vaginal fistulas, one grade 3 epistaxis, two intestinal perforations and 1 grade 4 thrombosis/embolism were seen. Three patient deaths were possibly treatment related. Twelve patients (24.5%) experienced clinical responses (one complete and 11 partial responses), and 23 patients (46.9%) survived progression free for at least six months. Median progression-free survival (PFS) and overall survival (OS) were 5.6 and 16.9 months, respectively. Combination of temsirolimus and bevacizumab is deemed active based on both objective tumor response and PFS at six months in recurrent or persistent EMC. However, this treatment regimen was associated with significant toxicity in this pretreated group. Future study will be guided by strategies to decrease toxicity and increase response rates.","Clinical Trial, Phase II",2588.0,87.0,two-stage phase II designed assess activity combination temsirolimus bevacizumab patients recurrent persistent endometrial carcinoma EMC Eligible patients persistent recurrent EMC receiving 1-2 prior cytotoxic regimens measurable disease Gynecologic Oncology Group performance status  2 Treatment consisted bevacizumab 10 mg/kg week temsirolimus 25 mg IV weekly disease progression prohibitory toxicity Primary end points progression-free survival PFS months overall response rate RECIST criteria Fifty-three patients enrolled Forty-nine patients eligible evaluable Median age 63 years prior treatment consisted regimens 40 82 9 18 respectively 41 received prior radiation Adverse events consistent expected bevacizumab temsirolimus treatment gastrointestinal-vaginal fistulas grade 3 epistaxis intestinal perforations 1 grade 4 thrombosis/embolism seen patient deaths possibly treatment related patients 24.5 experienced clinical responses complete 11 partial responses 23 patients 46.9 survived progression free months Median progression-free survival PFS overall survival OS 5.6 16.9 months respectively Combination temsirolimus bevacizumab deemed active based objective response PFS months recurrent persistent EMC treatment regimen associated significant toxicity pretreated group Future guided strategies decrease toxicity increase response rates,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[26, 100, 82, 124, 215, 45, 10, 1114, 6, 423, 3, 128, 1, 3, 150, 1, 2831, 2, 599, 4, 7, 5, 387, 15, 1882, 134, 13650, 625, 7, 42, 1882, 15, 387, 13650, 50, 357, 14, 18, 324, 759, 472, 1884, 34, 2, 1512, 413, 87, 528, 156, 1552, 18, 24, 1695, 1, 599, 79, 81, 503, 454, 127, 647, 2, 2831, 243, 81, 478, 709, 1100, 34, 91, 15, 47544, 155, 86, 396, 862, 11, 91, 115, 25, 300, 28, 437, 53, 2, 63, 51, 116, 75, 1834, 371, 1461, 169, 7, 11, 346, 1213, 762, 7, 11, 625, 2, 859, 52, 89, 10, 676, 60, 2, 324, 24, 1695, 1, 104, 15, 100, 472, 4, 327, 878, 2, 83, 203, 106, 737, 605, 103, 324, 121, 290, 281, 11, 925, 5, 135, 1336, 5, 599, 2, 2831, 24, 100, 16055, 18982, 13244, 104, 88, 27, 12575, 100, 3077, 13041, 2, 14, 88, 39, 2839, 5475, 11, 527, 169, 69, 1043, 11, 2150, 24, 139, 2544, 7, 259, 33, 592, 38, 253, 104, 236, 2, 175, 450, 253, 2, 382, 7, 641, 83, 2996, 91, 115, 9, 28, 506, 437, 53, 52, 91, 115, 25, 300, 2, 63, 25, 118, 11, 33, 49, 2, 245, 83, 53, 106, 150, 1, 2831, 2, 599, 16, 3779, 544, 90, 23, 110, 461, 30, 51, 2, 300, 28, 437, 53, 4, 387, 15, 1882, 13650, 137, 26, 24, 477, 10, 41, 5, 93, 155, 4, 26, 2193, 87, 508, 45, 303, 40, 1808, 20, 422, 6, 775, 155, 2, 344, 51, 151]",1706.0,23262204,Phase II trial combination bevacizumab temsirolimus treatment recurrent persistent endometrial carcinoma Gynecologic Oncology Group,0,0.0
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2013-01-28,"In patients with hormone-dependent postmenopausal breast cancer, standard adjuvant therapy involves 5 years of the nonsteroidal aromatase inhibitors anastrozole and letrozole. The steroidal inhibitor exemestane is partially non-cross-resistant with nonsteroidal aromatase inhibitors and is a mild androgen and could prove superior to anastrozole regarding efficacy and toxicity, specifically with less bone loss. We designed an open-label, randomized, phase III trial of 5 years of exemestane versus anastrozole with a two-sided test of superiority to detect a 2.4% improvement with exemestane in 5-year event-free survival (EFS). Secondary objectives included assessment of overall survival, distant disease-free survival, incidence of contralateral new primary breast cancer, and safety. In the study, 7,576 women (median age, 64.1 years) were enrolled. At median follow-up of 4.1 years, 4-year EFS was 91% for exemestane and 91.2% for anastrozole (stratified hazard ratio, 1.02; 95% CI, 0.87 to 1.18; P = .85). Overall, distant disease-free survival and disease-specific survival were also similar. In all, 31.6% of patients discontinued treatment as a result of adverse effects, concomitant disease, or study refusal. Osteoporosis/osteopenia, hypertriglyceridemia, vaginal bleeding, and hypercholesterolemia were less frequent on exemestane, whereas mild liver function abnormalities and rare episodes of atrial fibrillation were less frequent on anastrozole. Vasomotor and musculoskeletal symptoms were similar between arms. This first comparison of steroidal and nonsteroidal classes of aromatase inhibitors showed neither to be superior in terms of breast cancer outcomes as 5-year initial adjuvant therapy for postmenopausal breast cancer by two-way test. Less toxicity on bone is compatible with one hypothesis behind MA.27 but requires confirmation. Exemestane should be considered another option as up-front adjuvant therapy for postmenopausal hormone receptor-positive breast cancer.","Clinical Trial, Phase III",2549.0,141.0,"patients hormone-dependent postmenopausal breast standard adjuvant therapy involves 5 years nonsteroidal aromatase inhibitors anastrozole letrozole steroidal inhibitor exemestane partially non-cross-resistant nonsteroidal aromatase inhibitors mild androgen prove superior anastrozole efficacy toxicity specifically bone loss designed open-label randomized phase III trial 5 years exemestane versus anastrozole two-sided test superiority detect 2.4 improvement exemestane 5-year event-free survival EFS Secondary objectives included assessment overall survival distant disease-free survival incidence contralateral new primary breast safety 7,576 women median age 64.1 years enrolled median follow-up 4.1 years 4-year EFS 91 exemestane 91.2 anastrozole stratified hazard ratio 1.02 95 CI 0.87 1.18 P .85 Overall distant disease-free survival disease-specific survival similar 31.6 patients discontinued treatment adverse effects concomitant disease refusal Osteoporosis/osteopenia hypertriglyceridemia vaginal bleeding hypercholesterolemia frequent exemestane mild liver function abnormalities rare episodes atrial fibrillation frequent anastrozole Vasomotor musculoskeletal symptoms similar arms comparison steroidal nonsteroidal classes aromatase inhibitors showed superior terms breast outcomes 5-year initial adjuvant therapy postmenopausal breast two-way test toxicity bone compatible hypothesis MA.27 requires confirmation Exemestane considered option up-front adjuvant therapy postmenopausal hormone receptor-positive breast",1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4, 7, 5, 785, 470, 1679, 12, 260, 249, 36, 2921, 33, 60, 1, 3, 4960, 2106, 222, 3571, 2, 2800, 3, 7745, 230, 3199, 16, 2995, 220, 1383, 436, 5, 4960, 2106, 222, 2, 16, 8, 1980, 687, 2, 359, 4361, 1123, 6, 3571, 666, 209, 2, 155, 1225, 5, 299, 407, 21, 1114, 35, 1020, 1756, 384, 124, 316, 160, 1, 33, 60, 1, 3199, 185, 3571, 5, 8, 100, 1689, 412, 1, 5233, 6, 1426, 8, 18, 39, 767, 5, 3199, 4, 33, 111, 774, 115, 25, 1683, 568, 2409, 159, 455, 1, 63, 25, 626, 34, 115, 25, 287, 1, 2138, 217, 86, 12, 2, 367, 4, 3, 45, 67, 14552, 117, 52, 89, 660, 14, 60, 11, 346, 28, 52, 166, 126, 1, 39, 14, 60, 39, 111, 1683, 10, 970, 9, 3199, 2, 970, 18, 9, 3571, 1173, 360, 197, 14, 588, 48, 58, 13, 912, 6, 14, 203, 19, 772, 63, 626, 34, 115, 25, 2, 34, 112, 25, 11, 120, 288, 4, 62, 456, 49, 1, 7, 2402, 24, 22, 8, 757, 1, 290, 176, 1781, 34, 15, 45, 8104, 4970, 10434, 10427, 2294, 2, 12932, 11, 299, 908, 23, 3199, 547, 1980, 343, 1171, 2, 622, 3750, 1, 7658, 9380, 11, 299, 908, 23, 3571, 12157, 2, 5701, 507, 11, 288, 59, 1335, 26, 157, 1155, 1, 7745, 2, 4960, 3211, 1, 2106, 222, 224, 2174, 6, 40, 1123, 4, 1794, 1, 12, 123, 22, 33, 111, 388, 249, 36, 9, 1679, 12, 20, 100, 2255, 412, 299, 155, 23, 16, 7293, 5, 104, 1492, 5219, 3687, 428, 84, 1706, 3551, 3199, 257, 40, 515, 1809, 1501, 22, 126, 3007, 249, 36, 9, 1679, 785, 153, 109, 12]",1888.0,23358971,Exemestane versus anastrozole postmenopausal women early breast NCIC CTG MA.27 -- randomized controlled phase III trial,8,0.04020100502512563
A contemporary analysis of epidemiology and management of vaginal intraepithelial neoplasia.,American journal of obstetrics and gynecology,Am. J. Obstet. Gynecol.,2013-02-01,"The purpose of this study was to review a large cohort of patients with vaginal intraepithelial neoplasia (VAIN) and to analyze the epidemiology and outcomes with various treatment modalities. A retrospective chart review was performed that encompassed patients who were treated for VAIN at a single center from 1990-2007. Demographics, disease characteristics, referring cytology, and histologic information were recorded. Primary outcome was recurrence or progression to carcinoma. Statistical analyses were performed with statistical software. One hundred sixty-three women were included in the study: median age, 50 years (range, 21-84 years); white, 87%; current or previous smokers, 35%. At the time of diagnosis, 23% of the women had VAIN1; 37% of the women had VAIN2, and 35% of the women had VAIN3. Referral Papanicolaou smear results of high-grade squamous intraepithelial lesion or atypical glandular cells revealed VAIN2 or VAIN3 in 89% of cases (P = .0019) vs 53% of cases with low-grade squamous intraepithelial lesion. The median follow-up period was 18 months (range, 1-194 months). VAIN1 was observed in 70% of cases; 71% of patients who were treated for VAIN1 had recurrence or progression. VAIN2 was treated in 77% of patients; 53% of those who were treated had recurrence or progression. VAIN3 was treated in 94% of cases; 31% of them had recurrence or progression. Risk of recurrence was not correlated to VAIN type (P = .3). Six carcinomas were discovered in patients with VAIN2 and VAIN3. Median time to progression was 17 months for VAIN1, 11 months for VAIN2, and 11 months for VAIN3 (P = .036). Despite the subtype, VAIN often recurs but does so more quickly with higher grade dysplasia.",Evaluation Study,2545.0,,purpose review large cohort patients vaginal intraepithelial neoplasia VAIN epidemiology outcomes treatment modalities retrospective chart review performed encompassed patients treated VAIN single center 1990-2007 Demographics disease characteristics referring cytology histologic information recorded Primary outcome recurrence progression carcinoma Statistical performed statistical software sixty-three women included median age 50 years range 21-84 years white 87 current previous smokers 35 time diagnosis 23 women VAIN1 37 women VAIN2 35 women VAIN3 Referral Papanicolaou smear high-grade squamous intraepithelial lesion atypical glandular revealed VAIN2 VAIN3 89 cases P .0019 vs 53 cases low-grade squamous intraepithelial lesion median follow-up period 18 months range 1-194 months VAIN1 observed 70 cases 71 patients treated VAIN1 recurrence progression VAIN2 treated 77 patients 53 treated recurrence progression VAIN3 treated 94 cases 31 recurrence progression Risk recurrence correlated VAIN type P .3 carcinomas discovered patients VAIN2 VAIN3 Median time progression 17 months VAIN1 11 months VAIN2 11 months VAIN3 P .036 Despite subtype VAIN recurs quickly higher grade dysplasia,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 743, 1, 26, 45, 10, 6, 206, 8, 375, 180, 1, 7, 5, 4153, 2298, 14802, 2, 6, 1992, 3, 1284, 2, 123, 5, 747, 24, 1558, 8, 459, 2937, 206, 10, 173, 17, 9226, 7, 54, 11, 73, 9, 14802, 28, 8, 226, 574, 29, 2289, 1307, 2221, 34, 374, 8636, 2045, 2, 884, 487, 11, 1872, 86, 228, 10, 146, 15, 91, 6, 134, 1050, 318, 11, 173, 5, 1050, 3639, 104, 1128, 1746, 169, 117, 11, 159, 4, 3, 45, 52, 89, 212, 60, 184, 239, 874, 60, 886, 912, 291, 15, 698, 1485, 465, 28, 3, 98, 1, 147, 382, 1, 3, 117, 42, 35523, 567, 1, 3, 117, 42, 32087, 2, 465, 1, 3, 117, 42, 32088, 2096, 10416, 8379, 99, 1, 64, 88, 691, 4153, 1180, 15, 1973, 6170, 37, 553, 32087, 15, 32088, 4, 887, 1, 140, 19, 12960, 105, 699, 1, 140, 5, 154, 88, 691, 4153, 1180, 3, 52, 166, 126, 727, 10, 203, 53, 184, 14, 5434, 53, 35523, 10, 164, 4, 431, 1, 140, 792, 1, 7, 54, 11, 73, 9, 35523, 42, 146, 15, 91, 32087, 10, 73, 4, 849, 1, 7, 699, 1, 135, 54, 11, 73, 42, 146, 15, 91, 32088, 10, 73, 4, 960, 1, 140, 456, 1, 1370, 42, 146, 15, 91, 43, 1, 146, 10, 44, 438, 6, 14802, 267, 19, 27, 437, 826, 11, 2747, 4, 7, 5, 32087, 2, 32088, 52, 98, 6, 91, 10, 269, 53, 9, 35523, 175, 53, 9, 32087, 2, 175, 53, 9, 32088, 19, 5395, 550, 3, 875, 14802, 629, 12172, 84, 1097, 1743, 80, 7325, 5, 142, 88, 2253]",1638.0,23380265,contemporary epidemiology management vaginal intraepithelial neoplasia,1,0.005025125628140704
A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium.,Gynecologic oncology,Gynecol. Oncol.,2013-02-04,"To prospectively evaluate tumor control, survival, and toxic effects in patients with International Federation of Gynecology and Obstetrics (1988) stage I-IIIA papillary serous carcinoma of the endometrium treated with concurrent chemoradiation and adjuvant chemotherapy. Thirty-two patients were enrolled from October 2001 through July 2009. Patients underwent full surgical disease staging and postoperative concurrent weekly paclitaxel (50 mg/m2) and pelvic RT to 45 Gy plus a vaginal cuff boost followed by 4 cycles of adjuvant paclitaxel (135 mg/m2). Thirty patients (94%) were evaluable (3 with stage IA disease, 11 IB, 3 IC, 1 IIB, and 12 IIIA). Eighteen patients (60%) received all 5 planned courses of concurrent chemotherapy, 10 (33%) received 4 courses, and 2 (7%) received 3 courses. All 30 patients received RT; 27 (90%) received the full dose, 2 received 43.2 Gy, and 1 received 39.6 Gy owing to toxic effects. Twenty-three patients (77%) completed all 4 cycles of adjuvant paclitaxel, 3 (10%) completed 3 cycles, 2 (7%) completed 2 cycles, and 2 received no adjuvant therapy. Overall survival (OS), progression-free survival (PFS), and local control rates for all patients were 93%, 87%, and 87%, respectively, at 2 years and 85%, 83%, and 87%, respectively, at 5years. Six patients developed (20%) grade 3/4 toxicities from the treatment. Four patients (13%) had grade 3 or more severe bowel complications and two patients developed symptomatic pelvic fractures. Treatment with concurrent paclitaxel and pelvic RT followed by 4 courses of systemic paclitaxel produced favorable results in patients with surgically staged I-III UPSC.","Clinical Trial, Phase II",2542.0,20.0,prospectively evaluate control survival toxic effects patients International Federation Gynecology Obstetrics 1988 stage I-IIIA papillary serous carcinoma endometrium treated concurrent chemoradiation adjuvant chemotherapy Thirty-two patients enrolled October 2001 July 2009 Patients underwent surgical disease staging postoperative concurrent weekly paclitaxel 50 mg/m2 pelvic RT 45 Gy plus vaginal cuff boost followed 4 cycles adjuvant paclitaxel 135 mg/m2 Thirty patients 94 evaluable 3 stage IA disease 11 IB 3 IC 1 IIB 12 IIIA Eighteen patients 60 received 5 planned courses concurrent chemotherapy 10 33 received 4 courses 2 7 received 3 courses 30 patients received RT 27 90 received dose 2 received 43.2 Gy 1 received 39.6 Gy owing toxic effects Twenty-three patients 77 completed 4 cycles adjuvant paclitaxel 3 10 completed 3 cycles 2 7 completed 2 cycles 2 received adjuvant therapy Overall survival OS progression-free survival PFS local control rates patients 93 87 87 respectively 2 years 85 83 87 respectively 5years patients developed 20 grade 3/4 toxicities treatment patients 13 grade 3 severe bowel complications patients developed symptomatic pelvic fractures Treatment concurrent paclitaxel pelvic RT followed 4 courses systemic paclitaxel produced favorable patients surgically staged I-III UPSC,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[6, 1143, 376, 30, 182, 25, 2, 1812, 176, 4, 7, 5, 944, 7303, 1, 6429, 2, 7407, 3314, 82, 70, 3164, 1796, 1744, 134, 1, 3, 73, 5, 750, 975, 2, 249, 56, 977, 100, 7, 11, 346, 29, 2551, 1758, 298, 2066, 1238, 7, 208, 1647, 221, 34, 632, 2, 573, 750, 709, 490, 212, 81, 821, 2, 1110, 240, 6, 512, 381, 349, 8, 11445, 2569, 370, 20, 39, 410, 1, 249, 490, 3978, 81, 821, 977, 7, 960, 11, 859, 27, 5, 82, 3302, 34, 175, 3180, 27, 2340, 14, 3884, 2, 133, 3164, 3195, 7, 335, 103, 62, 33, 1465, 1993, 1, 750, 56, 79, 466, 103, 39, 1993, 2, 18, 67, 103, 27, 1993, 62, 201, 7, 103, 240, 428, 424, 103, 3, 1647, 61, 18, 103, 601, 18, 381, 2, 14, 103, 587, 49, 381, 3421, 6, 1812, 176, 737, 169, 7, 849, 781, 62, 39, 410, 1, 249, 490, 27, 79, 781, 27, 410, 18, 67, 781, 18, 410, 2, 18, 103, 77, 249, 36, 63, 25, 118, 91, 115, 25, 300, 2, 293, 182, 151, 9, 62, 7, 11, 966, 912, 2, 912, 106, 28, 18, 60, 2, 772, 852, 2, 912, 106, 28, 18577, 437, 7, 276, 179, 88, 27, 39, 385, 29, 3, 24, 294, 7, 233, 42, 88, 27, 15, 80, 905, 1659, 521, 2, 100, 7, 276, 1704, 1110, 3909, 24, 5, 750, 490, 2, 1110, 240, 370, 20, 39, 1993, 1, 403, 490, 1687, 913, 99, 4, 7, 5, 2350, 2930, 70, 316, 5676]",1545.0,23385150,prospective phase II chemoradiation followed adjuvant chemotherapy FIGO stage I-IIIA 1988 uterine papillary serous carcinoma endometrium,0,0.0
"The physical consequences of gynecologic cancer surgery and their impact on sexual, emotional, and quality of life issues.",The journal of sexual medicine,J Sex Med,2013-02-01,"Surgical management of gynecologic cancer can cause short- and long-term effects on sexuality, reproductive function, and overall quality of life (QOL) (e.g., sexual dysfunction, infertility, lymphedema). However, innovative approaches developed over the past several decades have improved oncologic outcomes and reduced treatment sequelae. To provide an overview of the standards of care and major advancements in gynecologic cancer surgery, with a focus on their direct physical impact, as well as emotional, sexual, and QOL issues. This overview will aid researchers and clinicians in the conceptualization of future clinical care strategies and interventions to improve sexual/vaginal/reproductive health and QOL in gynecologic cancer patients. Comprehensive overview of the literature on gynecologic oncology surgery. Conceptual framework for this overview follows the current standards of care and recent surgical approaches to treat gynecologic cancer, with a brief overview describing primary management objectives and the physical, sexual, and emotional impact on patients. Extensive literature support is provided. The type and radicality of surgical treatment for gynecologic cancer can influence sexual function and play a significant role in QOL. Psychological, sexual, and QOL outcomes improve as surgical procedures continue to evolve. Procedures for fertility preservation, laparoscopy, sentinel lymph node mapping, and robotic and risk-reducing surgery have advanced the field while reducing treatment sequelae. Nevertheless, interventions that address sexual and vaginal health issues are limited. It is imperative to consider QOL and sexuality during the treatment decision-making process. New advances in detection and treatment exist; however, psycho-educational interventions and greater patient-physician communication to address sexual and vaginal health concerns are warranted. Large, prospective clinical trials including patient-reported outcomes are needed in gynecologic oncology populations to identify subgroups at risk. Future study designs need clearly defined samples to gain insight about sexual morbidity and foster the development of targeted interventions.",Journal Article,2545.0,,Surgical management gynecologic cause short- long-term effects sexuality reproductive function overall quality life QOL e.g. sexual dysfunction infertility lymphedema innovative approaches developed past decades improved oncologic outcomes reduced treatment sequelae provide overview standards care major advancements gynecologic surgery focus direct physical impact emotional sexual QOL issues overview aid researchers clinicians conceptualization future clinical care strategies interventions improve sexual/vaginal/reproductive health QOL gynecologic patients Comprehensive overview literature gynecologic oncology surgery Conceptual framework overview follows current standards care recent surgical approaches treat gynecologic brief overview describing primary management objectives physical sexual emotional impact patients Extensive literature support provided type radicality surgical treatment gynecologic influence sexual function play significant role QOL Psychological sexual QOL outcomes improve surgical procedures continue evolve Procedures fertility preservation laparoscopy sentinel lymph node mapping robotic risk-reducing surgery advanced field reducing treatment sequelae interventions address sexual vaginal health issues limited imperative consider QOL sexuality treatment decision-making process New advances detection treatment exist psycho-educational interventions greater patient-physician communication address sexual vaginal health concerns warranted Large prospective clinical trials including patient-reported outcomes needed gynecologic oncology populations identify subgroups risk Future designs need clearly defined gain insight sexual morbidity foster development targeted interventions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[221, 284, 1, 1512, 12, 122, 708, 978, 2, 319, 337, 176, 23, 18923, 3705, 343, 2, 63, 372, 1, 358, 1001, 563, 499, 2232, 1527, 5901, 3063, 137, 4019, 611, 276, 252, 3, 1219, 392, 1968, 47, 231, 1998, 123, 2, 405, 24, 4156, 6, 377, 35, 2901, 1, 3, 3371, 1, 165, 2, 458, 6217, 4, 1512, 12, 152, 5, 8, 1222, 23, 136, 1196, 900, 345, 22, 149, 22, 2671, 2232, 2, 1001, 1553, 26, 2901, 303, 2427, 4211, 2, 1490, 4, 3, 35526, 1, 508, 38, 165, 422, 2, 1151, 6, 401, 2232, 18982, 3705, 341, 2, 1001, 4, 1512, 12, 7, 949, 2901, 1, 3, 789, 23, 1512, 413, 152, 8329, 2586, 9, 26, 2901, 2962, 3, 291, 3371, 1, 165, 2, 435, 221, 611, 6, 943, 1512, 12, 5, 8, 3190, 2901, 4950, 86, 284, 2409, 2, 3, 900, 2232, 2, 2671, 345, 23, 7, 1344, 789, 538, 16, 1052, 3, 267, 2, 33241, 1, 221, 24, 9, 1512, 12, 122, 1054, 2232, 343, 2, 1343, 8, 93, 200, 4, 1001, 2624, 2232, 2, 1001, 123, 401, 22, 221, 1369, 1906, 6, 4800, 1369, 9, 2954, 2224, 3553, 1323, 263, 289, 2568, 2, 2895, 2, 43, 1818, 152, 47, 131, 3, 1067, 369, 1818, 24, 4156, 3873, 1151, 17, 1539, 2232, 2, 341, 1553, 32, 383, 192, 16, 6305, 6, 2419, 1001, 2, 18923, 190, 3, 24, 948, 1079, 1129, 217, 954, 4, 638, 2, 24, 1923, 137, 18464, 3624, 1151, 2, 378, 69, 1473, 2063, 6, 1539, 2232, 2, 341, 2061, 32, 1197, 375, 482, 38, 143, 141, 69, 210, 123, 32, 575, 4, 1512, 413, 1184, 6, 255, 1453, 28, 43, 508, 45, 4120, 594, 2536, 395, 347, 6, 1803, 2670, 545, 2232, 787, 2, 9899, 3, 193, 1, 238, 1151]",2137.0,23387909,physical consequences gynecologic surgery impact sexual emotional quality life issues,0,0.0
Anastrozole-associated joint pain and other symptoms in patients with breast cancer.,The journal of pain : official journal of the American Pain Society,J Pain,2013-03-01,"More than a third of breast cancer patients undergoing aromatase inhibitor (AI) treatment report joint pain. We conducted a longitudinal study to characterize the course of AI-induced joint pain and other symptoms and to identify potential predictors for developing these symptoms. Patients were recruited before AI initiation. The Brief Pain Inventory, M. D. Anderson Symptom Inventory, and a joint-pain questionnaire were administered at baseline and then biweekly for 1 year. Analysis included logistic regression, Cox models, and mixed-effects models. Of 47 patients assessed, 16 (34%) reported joint pain at least once. Median time to first report of joint pain was 7 weeks (range, 1-38). Baseline pain was the only predictor for both incidence of joint pain and time to first event. In the first 6 weeks, emergence of joint pain was associated with increase in general pain, fatigue, disturbed sleep, hot flashes, vaginal dryness, and decreased sexual activity. After week 6, having joint pain was associated with increase in general pain and with persistently high fatigue. Having AI-associated joint pain correlated with increase in or persistence of other symptoms likely related to AI therapy. Further research is needed to validate predictors of AI-associated symptoms. We demonstrate for the first time that AI-induced joint pain associates with development of other symptoms and that pretreatment pain level is a potential, measurable predictor of symptom development during treatment. Because baseline pain is easily assessed with a brief questionnaire, it can be applied clinically with minimal patient burden.",Journal Article,2517.0,14.0,breast patients undergoing aromatase inhibitor AI treatment report joint pain conducted longitudinal characterize course AI-induced joint pain symptoms identify potential predictors developing symptoms Patients recruited AI initiation Brief Pain Inventory M. D. Anderson Symptom Inventory joint-pain questionnaire administered baseline biweekly 1 year included logistic regression Cox models mixed-effects models 47 patients assessed 16 34 reported joint pain Median time report joint pain 7 weeks range 1-38 Baseline pain predictor incidence joint pain time event 6 weeks emergence joint pain associated increase general pain fatigue disturbed sleep hot flashes vaginal dryness decreased sexual activity week 6 joint pain associated increase general pain persistently high fatigue AI-associated joint pain correlated increase persistence symptoms likely related AI therapy research needed validate predictors AI-associated symptoms demonstrate time AI-induced joint pain associates development symptoms pretreatment pain level potential measurable predictor symptom development treatment baseline pain easily assessed brief questionnaire applied clinically minimal patient burden,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[80, 76, 8, 1282, 1, 12, 7, 479, 2106, 230, 2247, 24, 414, 2093, 559, 21, 426, 8, 2380, 45, 6, 1507, 3, 906, 1, 2247, 277, 2093, 559, 2, 127, 507, 2, 6, 255, 174, 674, 9, 931, 46, 507, 7, 11, 2619, 348, 2247, 1118, 3, 3190, 559, 3818, 188, 427, 1929, 934, 3818, 2, 8, 2093, 559, 1770, 11, 468, 28, 330, 2, 818, 7551, 9, 14, 111, 65, 159, 812, 320, 418, 274, 2, 1739, 176, 274, 1, 662, 7, 275, 245, 562, 210, 2093, 559, 28, 506, 1059, 52, 98, 6, 157, 414, 1, 2093, 559, 10, 67, 244, 184, 14, 519, 330, 559, 10, 3, 158, 980, 9, 110, 287, 1, 2093, 559, 2, 98, 6, 157, 774, 4, 3, 157, 49, 244, 3397, 1, 2093, 559, 10, 41, 5, 344, 4, 1083, 559, 613, 15672, 2494, 2859, 4193, 15822, 2, 340, 2232, 128, 50, 647, 49, 1041, 2093, 559, 10, 41, 5, 344, 4, 1083, 559, 2, 5, 8684, 64, 613, 1041, 2247, 41, 2093, 559, 438, 5, 344, 4, 15, 4108, 1, 127, 507, 322, 139, 6, 2247, 36, 195, 389, 16, 575, 6, 2183, 674, 1, 2247, 41, 507, 21, 608, 9, 3, 157, 98, 17, 2247, 277, 2093, 559, 7326, 5, 193, 1, 127, 507, 2, 17, 1194, 559, 301, 16, 8, 174, 1884, 980, 1, 934, 193, 190, 24, 408, 330, 559, 16, 4697, 275, 5, 8, 3190, 1770, 192, 122, 40, 1498, 505, 5, 1048, 69, 892]",1574.0,23452648,Anastrozole-associated joint pain symptoms patients breast,1,0.005025125628140704
Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity.,American journal of clinical oncology,Am. J. Clin. Oncol.,2014-10-01,"To evaluate toxicity, local control, and survival in anal cancer patients treated with intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy. Sixty-five patients were treated at a single institution with IMRT and concurrent chemotherapy for localized squamous cell carcinoma of the anal canal. Radiotherapy was delivered with a simultaneous integrated boost technique, with dose based on the T stage. The median dose to the primary tumor and pelvis were 54 Gy (range, 50 to 58.8 Gy) and 45 Gy (range, 40.5 to 50.4 Gy), respectively. The most common concurrent chemotherapy regimens were 5-fluorouracil and cisplatin (75%), capecitabine and oxaliplatin (11%), and 5-fluorouracil and mitomycin C (5%). The percentage of patients with Tx, T1, T2, T3, and T4 disease were 8%, 17%, 49%, 15%, and 11%, respectively. The percentage of patients with N0, N1, N2, and N3 disease were 46%, 17%, 9%, and 28%, respectively. Ninety-one percent of patients completed treatment without a break. Grade 3 gastrointestinal toxicity occurred in 9%, and moist desquamation beyond the perianal area occurred in 17%. The use of a vaginal dilator during simulation and treatment seemed to lower the rates of acute skin and late sexual toxicity. With a median follow-up of 19 months, the 2-year local and distant control rates were both 93%. The 2-year overall and disease-free survival rates were 96% and 86%, respectively. Concurrent chemotherapy and IMRT was well tolerated, and was associated with low rates of acute and late toxicity and excellent local control, disease-free survival, and overall survival.",Journal Article,1938.0,45.0,evaluate toxicity local control survival anal patients treated intensity-modulated radiation therapy IMRT concurrent chemotherapy Sixty-five patients treated single institution IMRT concurrent chemotherapy localized squamous carcinoma anal canal Radiotherapy delivered simultaneous integrated boost technique dose based stage median dose primary pelvis 54 Gy range 50 58.8 Gy 45 Gy range 40.5 50.4 Gy respectively common concurrent chemotherapy regimens 5-fluorouracil cisplatin 75 capecitabine oxaliplatin 11 5-fluorouracil mitomycin C 5 percentage patients Tx T1 T2 T3 T4 disease 8 17 49 15 11 respectively percentage patients N0 N1 N2 N3 disease 46 17 9 28 respectively Ninety-one percent patients completed treatment break Grade 3 gastrointestinal toxicity occurred 9 moist desquamation perianal area occurred 17 use vaginal dilator simulation treatment lower rates acute skin late sexual toxicity median follow-up 19 months 2-year local distant control rates 93 2-year overall disease-free survival rates 96 86 respectively Concurrent chemotherapy IMRT tolerated associated low rates acute late toxicity excellent local control disease-free survival overall survival,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,"[6, 376, 155, 293, 182, 2, 25, 4, 12, 7, 73, 5, 837, 1757, 121, 36, 964, 2, 750, 56, 1746, 365, 7, 11, 73, 28, 8, 226, 731, 5, 964, 2, 750, 56, 9, 909, 691, 31, 134, 1, 3, 5614, 310, 10, 1623, 5, 8, 2824, 2102, 2569, 1312, 5, 61, 90, 23, 3, 102, 82, 3, 52, 61, 6, 3, 86, 30, 2, 3270, 11, 667, 381, 184, 212, 6, 717, 66, 381, 2, 512, 381, 184, 327, 33, 6, 212, 39, 381, 106, 3, 96, 186, 750, 56, 472, 11, 33, 1404, 2, 540, 481, 1629, 2, 1476, 175, 2, 33, 1404, 2, 5837, 256, 33, 3, 1150, 1, 7, 5, 6614, 1534, 1786, 2065, 2, 2463, 34, 11, 66, 269, 739, 167, 2, 175, 106, 3, 1150, 1, 7, 5, 3394, 3192, 3473, 2, 5749, 34, 11, 641, 269, 83, 2, 339, 106, 2493, 104, 714, 1, 7, 781, 24, 187, 8, 4338, 88, 27, 155, 489, 4, 83, 2, 16368, 11320, 1654, 3, 10855, 965, 489, 4, 269, 3, 119, 1, 8, 17967, 190, 4026, 2, 24, 5025, 6, 280, 3, 151, 1, 286, 2, 807, 2232, 155, 5, 8, 52, 166, 126, 1, 326, 53, 3, 18, 111, 293, 2, 626, 182, 151, 11, 110, 966, 3, 18, 111, 63, 2, 34, 115, 25, 151, 11, 921, 2, 868, 106, 750, 56, 2, 964, 10, 149, 421, 2, 10, 41, 5, 154, 151, 1, 286, 2, 807, 155, 2, 1503, 293, 182, 34, 115, 25, 2, 63, 25]",1494.0,23466576,Intensity-modulated radiation therapy concurrent chemotherapy anal outcomes toxicity,0,0.0
"Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers.",Gynecologic oncology,Gynecol. Oncol.,2013-04-18,"Cervical and vaginal cancers have virally-mediated or mutated defects in DNA damage repair responses, making these cancers sensible targets for ribonucleotide reductase inhibition during radiochemotherapy. We conducted a phase II study evaluating 3 weekly 2-hour intravenous 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, 25 mg/m(2)) co-administered with 1 weekly intravenous cisplatin (40 mg/m(2)) and daily pelvic radiation (45 Gy) in women with stage I(B2)-IV(B) cervical (n=22) or stage II-IV vaginal (n=3) cancers. Brachytherapy followed (40 Gy). Toxicity was monitored by common terminology criteria for adverse events (version 3.0). The primary end point of response was assessed by 3-month posttherapy 2-[(18)F] fluoro-2-deoxy-d-glucose positron emission tomography (PET/CT) and clinical examination. 3-AP radiochemotherapy achieved clinical responses in 24 (96% [95% confidence interval: 80-99%]) of 25 patients (median follow-up 20 months, range 2-35 months). 23 (96% [95% confidence interval: 80-99%]) of 24 patients had 3-month posttherapy PET/CT scans that recorded metabolic activity in the cervix or vagina equal or less than that of the cardiac blood pool, suggesting complete metabolic responses. The most frequent 3-AP radiochemotherapy-related adverse events included fatigue, nausea, diarrhea, and reversible hematological and electrolyte abnormalities. The addition of 3-AP to cisplatin radiochemotherapy was tolerable and produced high rates of clinical and metabolic responses in women with cervical and vaginal cancers. Future randomized phase II and III clinical trials of 3-AP radiochemotherapy are warranted.","Clinical Trial, Phase II",2469.0,54.0,Cervical vaginal virally-mediated defects DNA damage repair responses making sensible targets ribonucleotide reductase inhibition radiochemotherapy conducted phase II evaluating 3 weekly 2-hour intravenous 3-aminopyridine-2-carboxaldehyde thiosemicarbazone 3-AP 25 mg/m 2 co-administered 1 weekly intravenous cisplatin 40 mg/m 2 daily pelvic radiation 45 Gy women stage B2 -IV B cervical n=22 stage II-IV vaginal n=3 Brachytherapy followed 40 Gy Toxicity monitored common terminology criteria adverse events version 3.0 primary end point response assessed 3-month posttherapy 2- 18 F fluoro-2-deoxy-d-glucose positron emission tomography PET/CT clinical examination 3-AP radiochemotherapy achieved clinical responses 24 96 95 confidence interval 80-99 25 patients median follow-up 20 months range 2-35 months 23 96 95 confidence interval 80-99 24 patients 3-month posttherapy PET/CT scans recorded metabolic activity cervix vagina equal cardiac blood pool suggesting complete metabolic responses frequent 3-AP radiochemotherapy-related adverse events included fatigue nausea diarrhea reversible hematological electrolyte abnormalities addition 3-AP cisplatin radiochemotherapy tolerable produced high rates clinical metabolic responses women cervical vaginal Future randomized phase II III clinical trials 3-AP radiochemotherapy warranted,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,"[2, 163, 47, 18811, 517, 15, 1185, 2945, 4, 261, 1350, 972, 253, 1079, 46, 163, 22365, 637, 9, 7050, 4027, 297, 190, 6836, 21, 426, 8, 124, 215, 45, 1435, 22635, 709, 18, 2583, 1262, 27, 23330, 18, 23331, 24704, 27, 2517, 243, 81, 188, 18, 1269, 468, 5, 40336, 709, 1262, 540, 327, 81, 188, 18, 2, 391, 1110, 121, 512, 381, 4, 117, 5, 82, 70, 6617, 478, 132, 78, 350, 15, 82, 215, 478, 78, 27, 163, 1536, 370, 327, 381, 155, 10, 2909, 20, 186, 3462, 371, 9, 290, 281, 2256, 27, 13, 3, 86, 396, 741, 1, 51, 10, 275, 20, 27, 811, 8163, 18, 203, 1068, 6231, 18, 6149, 427, 2522, 1900, 1799, 872, 495, 425, 2, 38, 1385, 27, 2517, 6836, 513, 38, 253, 4, 259, 921, 48, 307, 268, 493, 1058, 1, 243, 7, 52, 166, 126, 179, 53, 184, 18, 465, 53, 382, 921, 48, 307, 268, 493, 1058, 1, 259, 7, 42, 27, 811, 8163, 495, 425, 1441, 17, 1872, 1436, 128, 4, 3, 3629, 15, 7553, 2997, 15, 299, 76, 17, 1, 3, 315, 6545, 802, 236, 1436, 253, 3, 96, 908, 27, 2517, 6836, 139, 290, 281, 159, 613, 1218, 1172, 2, 2786, 2890, 2, 10834, 1171, 3, 352, 1, 27, 2517, 6, 540, 6836, 10, 2668, 2, 1687, 64, 151, 1, 38, 2, 1436, 253, 4, 117, 5, 2, 163, 508, 384, 124, 215, 2, 316, 38, 143, 1, 27, 2517, 6836, 32, 1197]",1533.0,23603372,Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone 3-AP NSC 663249 advanced-stage cervical vaginal,0,0.0
Vaginal cancer: the experience from 2 large academic centers during a 15-year period.,Journal of lower genital tract disease,J Low Genit Tract Dis,2013-10-01,"Limited data regarding the natural history, management, and prognosis of vaginal cancer exist owing to the relative disease rarity. A retrospective chart review was performed at 2 institutions to identify women receiving treatment for vaginal cancer between 1990 and 2004. Demographics, risk factors, histology, International Federation of Gynecology and Obstetrics stage, treatment, and treatment-related complications were recorded. Statistical Analysis Software (SAS) version 9.2 was used. A total of 110 patients were identified in the 2 university databases. Median age was 63 years (range = 36-93 years), and 84% were white; 73% had squamous cell carcinoma, 40% were ever users of tobacco, and 64% had no abnormal Pap smear results. Of the patients, 83% had early-stage (I or II) disease. Treatment varied by stage with increasing use of radiation with advancing stage. Recurrence was 24%, 32%, and 53% for stage I, II, and III/IV disease, respectively. After a median follow-up of 21 months, progression-free survival was 59, 35, and 23 months for stage I, II, and III/IV disease, respectively. Overall survival was 106, 58, and 34 months for stage I, II, and III/IV disease, respectively. Age greater than 60 years (p = .0339; hazard ratio [HR] = 2.162), advanced stage (p = .0004; HR = 2.475), and tobacco use (p = .0004; HR = 1.02) were negatively associated with survival. Thirty percent developed a significant complication (fistula, stricture, cystitis, or proctitis), and 21% developed a vesicovaginal and/or rectovaginal fistula. There was no association of fistula development with age, stage, tobacco use, histological finding, or treatment history (including radiation therapy). Age, stage, and tobacco abuse seem to be negatively associated with survival in vaginal cancer. However, no risk factors were associated with fistula development.",Journal Article,2303.0,9.0,Limited natural history management prognosis vaginal exist owing relative disease rarity retrospective chart review performed 2 institutions identify women receiving treatment vaginal 1990 2004 Demographics risk factors histology International Federation Gynecology Obstetrics stage treatment treatment-related complications recorded Statistical Software SAS version 9.2 total 110 patients identified 2 university databases Median age 63 years range 36-93 years 84 white 73 squamous carcinoma 40 users tobacco 64 abnormal Pap smear patients 83 early-stage II disease Treatment varied stage increasing use radiation advancing stage Recurrence 24 32 53 stage II III/IV disease respectively median follow-up 21 months progression-free survival 59 35 23 months stage II III/IV disease respectively Overall survival 106 58 34 months stage II III/IV disease respectively Age greater 60 years p .0339 hazard ratio HR 2.162 advanced stage p .0004 HR 2.475 tobacco use p .0004 HR 1.02 negatively associated survival Thirty percent developed significant complication fistula stricture cystitis proctitis 21 developed vesicovaginal and/or rectovaginal fistula association fistula development age stage tobacco use histological finding treatment history including radiation therapy Age stage tobacco abuse negatively associated survival vaginal risk factors associated fistula development,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[383, 74, 666, 3, 1504, 532, 284, 2, 356, 1, 12, 1923, 3421, 6, 3, 580, 34, 4989, 8, 459, 2937, 206, 10, 173, 28, 18, 1764, 6, 255, 117, 357, 24, 9, 12, 59, 2289, 2, 1131, 2221, 43, 130, 784, 944, 7303, 1, 6429, 2, 7407, 82, 24, 2, 24, 139, 521, 11, 1872, 1050, 65, 3639, 8265, 2256, 83, 18, 10, 95, 8, 181, 1, 3129, 7, 11, 108, 4, 3, 18, 1652, 2348, 52, 89, 10, 676, 60, 184, 511, 966, 60, 2, 874, 11, 886, 803, 42, 691, 31, 134, 327, 11, 3353, 2735, 1, 2607, 2, 660, 42, 77, 1668, 4290, 8379, 99, 1, 3, 7, 852, 42, 191, 82, 70, 15, 215, 34, 24, 2051, 20, 82, 5, 602, 119, 1, 121, 5, 5155, 82, 146, 10, 259, 531, 2, 699, 9, 82, 70, 215, 2, 316, 478, 34, 106, 50, 8, 52, 166, 126, 1, 239, 53, 91, 115, 25, 10, 728, 465, 2, 382, 53, 9, 82, 70, 215, 2, 316, 478, 34, 106, 63, 25, 10, 3251, 717, 2, 562, 53, 9, 82, 70, 215, 2, 316, 478, 34, 106, 89, 378, 76, 335, 60, 19, 47713, 360, 197, 168, 18, 5441, 131, 82, 19, 5295, 168, 18, 9201, 2, 2607, 119, 19, 5295, 168, 14, 588, 11, 2723, 41, 5, 25, 977, 714, 276, 8, 93, 1447, 4920, 6673, 13032, 15, 17612, 2, 239, 276, 8, 25979, 2, 15, 22569, 4920, 125, 10, 77, 248, 1, 4920, 193, 5, 89, 82, 2607, 119, 1831, 1567, 15, 24, 532, 141, 121, 36, 89, 82, 2, 2607, 10847, 3233, 6, 40, 2723, 41, 5, 25, 4, 12, 137, 77, 43, 130, 11, 41, 5, 4920, 193]",1734.0,23609592,Vaginal experience 2 large academic centers 15-year period,1,0.005025125628140704
Postoperative pain medication requirements in patients undergoing computer-assisted (Robotic) and standard laparoscopic procedures for newly diagnosed endometrial cancer.,Annals of surgical oncology,Ann. Surg. Oncol.,2013-10-01,"Laparoscopy (LSC) offers superior patient outcomes compared to laparotomy. Small retrospective/prospective series have suggested robotics offers further reduction in postoperative pain and pain medication use compared to standard LSC. Our objective was to compare postoperative pain in patients undergoing robotically assisted (RBT) versus standard LSC for newly diagnosed endometrial cancer. All preoperative endometrial cancer cases scheduled for RBT and LSC from May 1, 2007 to June 9, 2010 were identified. For this analysis, we only included cases not requiring conversion to laparotomy. All patients were offered intravenous (IV) patient-controlled analgesia (PCA) postoperatively. Intraoperative equivalent fentanyl doses (IEFDs) and pain scores in the postanesthesia care unit (PACU) were assessed. IV PCA was used in 206 RBTs (86 %) and 208 LSCs (88 %). Median IEFD was 425 g for LSCs and 500 g for RBTs (P = 0.03). Median pain scores on PACU arrival were similar in both groups. Median highest pain score was 5 for LSCs and 4 for RBTs (P = 0.007). Linear regression demonstrated that the IEFD was not correlated with the highest pain score (R = 0.09; P = 0.07). Fentanyl was used postoperatively in 196 of 206 RBTs (95 %) and 187 of 208 LSCs (90 %). The total fentanyl doses were 242.5 (range 0-2705) g and 380 (range 0-2625) g, respectively (P < 0.001). The median hourly fentanyl doses were 16.7 (range 0-122.5) g and 23.5 (range 0-132.4) g, respectively (P = 0.005). Simultaneous multiple regression analysis further demonstrated RBT was independently associated with a lower total fentanyl dose compared to LSC (P = 0.02). RBT is independently associated with significantly lower postoperative pain and pain medication requirements compared to LSC. The amount of intraoperative fentanyl analgesia does not appear to correlate with postoperative pain.Endometrial cancer is the most common gynecologic malignancy in the United States, with an estimated 47,130 new cases in 2012.1 An estimated 287,100 women were diagnosed with endometrial cancer worldwide in 2008.2 Surgery is the primary treatment of choice for the majority of these women.3 The standard surgical approach has been total abdominal hysterectomy, bilateral salpingo-oophorectomy, and staging via laparotomy. Multiple retrospective series have shown that a less invasive surgical approach via laparoscopy (LSC) is feasible and safe, and also associated with improved perioperative outcomes compared to laparotomy in these patients.4 The Gynecologic Oncology Group (GOG) published results of the largest randomized trial (LAP2) comparing LSC to laparotomy in patients with newly diagnosed endometrial carcinoma in 2009.5,6 This landmark study essentially changed the accepted standard surgical approach in this group. Postoperative complications, median blood loss, and median length of stay (LOS), despite increased operative time, were significantly lower in LSC patients despite 25 % requiring conversion to laparotomy.5 The first 802 eligible patients randomized in LAP2 also participated in a quality-of-life (QOL) study. Within 6 weeks of surgery, patients assigned to LSC reported significantly better QOL on all scales other than fear of recurrence.6 Overall, during this 6-week postoperative period, patients assigned to LSC had superior QOL, fewer physical symptoms, less pain and pain-related interference with functioning, better physical functioning and emotional state, earlier resumption of normal activities, earlier return to work, and better body image compared to those assigned to laparotomy.6 Recurrence-free and overall survivals were the same in both groups.7 Multiple published retrospective series have shown possible benefits, such as reduced postoperative pain, using the robotic (RBT) platform compared to LSC or laparotomy in patients with endometrial cancer.8-11 In a randomized trial, LSC was found to be associated with less postoperative pain compared to vaginal approaches in patients undergoing hysterectomy for benign gynecologic disease.12 A small retrospective series reported further reductions in postoperative pain in patients who had undergone an RBT hysterectomy compared to a standard total LSC hysterectomy for benign indications.13 A recent cost analysis suggested that patients experienced less pain and required less pain medication use after RBT procedures compared to LSC for endometrial cancer.14 Based on these reports, we sought to analyze postoperative pain and the use of pain medication in patients undergoing RBT compared to standard transperitoneal LSC procedures for newly diagnosed endometrial cancer during a concurrent time period. Of note, current RBT surgery is not truly robotic in that it is not autonomous. A more appropriate term is computer-assisted surgery, but to satisfy current convention, we refer to it as robotic surgery in this manuscript.",Comparative Study,2303.0,36.0,"Laparoscopy LSC offers superior patient outcomes compared laparotomy Small retrospective/prospective series suggested robotics offers reduction postoperative pain pain medication use compared standard LSC objective compare postoperative pain patients undergoing robotically assisted RBT versus standard LSC newly diagnosed endometrial preoperative endometrial cases scheduled RBT LSC 1 2007 June 9 2010 identified included cases requiring conversion laparotomy patients offered intravenous IV patient-controlled analgesia PCA postoperatively Intraoperative equivalent fentanyl doses IEFDs pain scores postanesthesia care unit PACU assessed IV PCA 206 RBTs 86 208 LSCs 88 Median IEFD 425 g LSCs 500 g RBTs P 0.03 Median pain scores PACU arrival similar groups Median highest pain score 5 LSCs 4 RBTs P 0.007 Linear regression demonstrated IEFD correlated highest pain score R 0.09 P 0.07 Fentanyl postoperatively 196 206 RBTs 95 187 208 LSCs 90 total fentanyl doses 242.5 range 0-2705 g 380 range 0-2625 g respectively P 0.001 median hourly fentanyl doses 16.7 range 0-122.5 g 23.5 range 0-132.4 g respectively P 0.005 Simultaneous multiple regression demonstrated RBT independently associated lower total fentanyl dose compared LSC P 0.02 RBT independently associated significantly lower postoperative pain pain medication requirements compared LSC intraoperative fentanyl analgesia appear correlate postoperative pain.Endometrial common gynecologic malignancy United States estimated 47,130 new cases 2012.1 estimated 287,100 women diagnosed endometrial worldwide 2008.2 Surgery primary treatment choice majority women.3 standard surgical approach total abdominal hysterectomy bilateral salpingo-oophorectomy staging laparotomy Multiple retrospective series shown invasive surgical approach laparoscopy LSC feasible safe associated improved perioperative outcomes compared laparotomy patients.4 Gynecologic Oncology Group GOG published largest randomized trial LAP2 comparing LSC laparotomy patients newly diagnosed endometrial carcinoma 2009.5,6 landmark essentially changed accepted standard surgical approach group Postoperative complications median blood loss median length stay LOS despite increased operative time significantly lower LSC patients despite 25 requiring conversion laparotomy.5 802 eligible patients randomized LAP2 participated quality-of-life QOL 6 weeks surgery patients assigned LSC reported significantly better QOL scales fear recurrence.6 Overall 6-week postoperative period patients assigned LSC superior QOL fewer physical symptoms pain pain-related interference functioning better physical functioning emotional state earlier resumption normal activities earlier return work better body image compared assigned laparotomy.6 Recurrence-free overall survivals groups.7 Multiple published retrospective series shown possible benefits reduced postoperative pain robotic RBT platform compared LSC laparotomy patients endometrial cancer.8-11 randomized trial LSC associated postoperative pain compared vaginal approaches patients undergoing hysterectomy benign gynecologic disease.12 small retrospective series reported reductions postoperative pain patients undergone RBT hysterectomy compared standard total LSC hysterectomy benign indications.13 recent cost suggested patients experienced pain required pain medication use RBT procedures compared LSC endometrial cancer.14 Based reports sought postoperative pain use pain medication patients undergoing RBT compared standard transperitoneal LSC procedures newly diagnosed endometrial concurrent time period note current RBT surgery truly robotic autonomous appropriate term computer-assisted surgery satisfy current convention refer robotic surgery manuscript",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[3553, 6643, 2339, 1123, 69, 123, 72, 6, 3274, 302, 459, 482, 988, 47, 1148, 23681, 2339, 195, 628, 4, 573, 559, 2, 559, 3012, 119, 72, 6, 260, 6643, 114, 461, 10, 6, 932, 573, 559, 4, 7, 479, 15573, 2927, 12048, 185, 260, 6643, 9, 732, 265, 12, 62, 498, 12, 140, 4394, 9, 12048, 2, 6643, 29, 68, 14, 1307, 6, 1924, 83, 1120, 11, 108, 9, 26, 65, 21, 158, 159, 140, 44, 1888, 3111, 6, 3274, 62, 7, 11, 2216, 1262, 478, 69, 1149, 7737, 1265, 3541, 1720, 2017, 11053, 415, 62981, 2, 559, 703, 4, 3, 33549, 165, 2712, 29448, 11, 275, 478, 1265, 10, 95, 4, 5956, 35607, 868, 2, 5920, 7033, 889, 52, 47817, 10, 8544, 3802, 9, 7033, 2, 1666, 3802, 9, 35607, 19, 13, 680, 52, 559, 703, 23, 29448, 13286, 11, 288, 4, 110, 271, 52, 1076, 559, 368, 10, 33, 9, 7033, 2, 39, 9, 35607, 19, 13, 1999, 1646, 320, 264, 17, 3, 47817, 10, 44, 438, 5, 3, 1076, 559, 368, 668, 13, 1730, 19, 13, 1615, 11053, 10, 95, 3541, 4, 6369, 1, 5956, 35607, 48, 2, 5568, 1, 5920, 7033, 424, 3, 181, 11053, 415, 11, 7722, 33, 184, 13, 38561, 3802, 2, 8389, 184, 13, 62982, 3802, 106, 19, 13, 144, 3, 52, 39094, 11053, 415, 11, 245, 67, 184, 13, 3285, 33, 3802, 2, 382, 33, 184, 13, 4255, 39, 3802, 106, 19, 13, 1614, 2824, 232, 320, 65, 195, 264, 12048, 10, 1042, 41, 5, 8, 280, 181, 11053, 61, 72, 6, 6643, 19, 13, 588, 12048, 16, 1042, 41, 5, 97, 280, 573, 559, 2, 559, 3012, 4230, 72, 6, 6643, 3, 3108, 1, 1720, 11053, 7737, 1097, 44, 1322, 6, 1513, 5, 573, 559, 18442, 12, 16, 3, 96, 186, 1512, 710, 4, 3, 1088, 907, 5, 35, 661, 662, 3431, 217, 140, 4, 1195, 14, 35, 661, 8488, 394, 117, 11, 265, 5, 12, 2358, 4, 1375, 18, 152, 16, 3, 86, 24, 1, 1866, 9, 3, 686, 1, 46, 117, 27, 3, 260, 221, 353, 71, 85, 181, 1467, 2622, 1607, 5690, 3470, 2, 632, 847, 3274, 232, 459, 988, 47, 443, 17, 8, 299, 416, 221, 353, 847, 3553, 6643, 16, 1313, 2, 1165, 2, 120, 41, 5, 231, 1547, 123, 72, 6, 3274, 4, 46, 7, 39, 3, 1512, 413, 87, 4760, 983, 99, 1, 3, 2166, 384, 160, 20800, 1430, 6643, 6, 3274, 4, 7, 5, 732, 265, 134, 4, 1238, 33, 49, 26, 3829, 45, 7257, 2368, 3, 3058, 260, 221, 353, 4, 26, 87, 573, 521, 52, 315, 407, 2, 52, 1318, 1, 2020, 3649, 550, 101, 1208, 98, 11, 97, 280, 4, 6643, 7, 550, 243, 1888, 3111, 6, 3274, 33, 3, 157, 15135, 625, 7, 384, 4, 20800, 120, 3025, 4, 8, 372, 1, 358, 1001, 45, 262, 49, 244, 1, 152, 7, 896, 6, 6643, 210, 97, 380, 1001, 23, 62, 5083, 127, 76, 6443, 1, 146, 49, 63, 190, 26, 49, 647, 573, 727, 7, 896, 6, 6643, 42, 1123, 1001, 1497, 900, 507, 299, 559, 2, 559, 139, 3182, 5, 2702, 380, 900, 2702, 2, 2671, 1309, 1677, 14268, 1, 295, 2042, 1677, 4656, 6, 1357, 2, 380, 642, 1482, 72, 6, 135, 896, 6, 3274, 49, 146, 115, 2, 63, 3794, 11, 3, 827, 4, 110, 271, 67, 232, 983, 459, 988, 47, 443, 899, 1141, 225, 22, 405, 573, 559, 75, 3, 2895, 12048, 2243, 72, 6, 6643, 15, 3274, 4, 7, 5, 12, 66, 175, 4, 8, 384, 160, 6643, 10, 204, 6, 40, 41, 5, 299, 573, 559, 72, 6, 611, 4, 7, 479, 2622, 9, 1002, 1512, 34, 133, 8, 302, 459, 988, 210, 195, 2153, 4, 573, 559, 4, 7, 54, 42, 1989, 35, 12048, 2622, 72, 6, 8, 260, 181, 6643, 2622, 9, 1002, 2406, 233, 8, 435, 835, 65, 1148, 17, 7, 592, 299, 559, 2, 616, 299, 559, 3012, 119, 50, 12048, 1369, 72, 6, 6643, 9, 12, 213, 90, 23, 46, 1198, 21, 990, 6, 1992, 573, 559, 2, 3, 119, 1, 559, 3012, 4, 7, 479, 12048, 72, 6, 260, 12145, 6643, 1369, 9, 732, 265, 12, 190, 8, 750, 98, 727, 1, 5739, 291, 12048, 152, 16, 44, 7260, 2895, 4, 17, 192, 16, 44, 12369, 8, 80, 870, 337, 16, 4236, 2927, 152, 84, 6, 18807, 291, 24634, 21, 7851, 6, 192, 22, 2895, 152, 4, 26, 5825]",4677.0,23797751,Postoperative pain medication requirements patients undergoing computer-assisted Robotic standard laparoscopic procedures newly diagnosed endometrial,0,0.0
Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancer.,Gynecologic oncology,Gynecol. Oncol.,2013-06-22,"The optimal adjuvant therapy in advanced endometrial cancer is controversial. One regimen is concurrent external beam pelvic irradiation (RT) and cisplatin, then carboplatin/paclitaxel. This study reports an institutional experience using this approach in stage III (FIGO 2009) endometrial cancer. Patients with stage III (FIGO 2009) endometrial cancer who underwent total hysterectomy and bilateral salpingo-oophorectomy at a single institution from 01/2004 to 12/2009 were identified retrospectively. Those treated with adjuvant RT/cisplatin, followed by carboplatin/paclitaxel comprised the study population. Of the 40 eligible patients, 7 (18%) were stage IIIA and 33 (82%) IIIC. Nineteen patients (48%) were  60 years of age. Twenty-three (58%) had  50% myometrial invasion, 30 (75%) lymphovascular invasion, 11 (28%) cervical stromal invasion, and 5 (12%) positive peritoneal cytology. Histology was endometrioid in 32 (80%), serous in 6 (15%), and clear cell in 2 (5%). At a median follow-up of 49 months, the 5-year freedom from relapse was 79% and overall survival 85%. The 5-year rate of vaginal recurrence was 3%, non-vaginal pelvic recurrence 3%, para-aortic recurrence 11%, peritoneal recurrence 5%, and other distant recurrence 11%. Thirty-one patients (78%) were able to complete the planned RT/cisplatin and 4 cycles of carboplatin/paclitaxel. Acute grade 3 toxicity occurred in 10 patients (4 neutropenia, 2 anemia, 1 fatigue, 2 diarrhea). No late toxicity was grade  3. These favorable outcomes corroborate those of RTOG 9708. Until prospective data that compare adjuvant therapy regimens mature, concurrent chemoradiation should be strongly considered in stage III endometrial cancer.",Journal Article,2404.0,23.0,optimal adjuvant therapy advanced endometrial controversial regimen concurrent external beam pelvic irradiation RT cisplatin carboplatin/paclitaxel reports institutional experience approach stage III FIGO 2009 endometrial Patients stage III FIGO 2009 endometrial underwent total hysterectomy bilateral salpingo-oophorectomy single institution 01/2004 12/2009 identified retrospectively treated adjuvant RT/cisplatin followed carboplatin/paclitaxel comprised population 40 eligible patients 7 18 stage IIIA 33 82 IIIC Nineteen patients 48  60 years age Twenty-three 58  50 myometrial invasion 30 75 lymphovascular invasion 11 28 cervical stromal invasion 5 12 positive peritoneal cytology Histology endometrioid 32 80 serous 6 15 clear 2 5 median follow-up 49 months 5-year freedom relapse 79 overall survival 85 5-year rate vaginal recurrence 3 non-vaginal pelvic recurrence 3 para-aortic recurrence 11 peritoneal recurrence 5 distant recurrence 11 Thirty-one patients 78 able complete planned RT/cisplatin 4 cycles carboplatin/paclitaxel Acute grade 3 toxicity occurred 10 patients 4 neutropenia 2 anemia 1 fatigue 2 diarrhea late toxicity grade  3 favorable outcomes corroborate RTOG 9708 prospective compare adjuvant therapy regimens mature concurrent chemoradiation strongly considered stage III endometrial,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,"[3, 665, 249, 36, 4, 131, 12, 16, 2010, 104, 477, 16, 750, 1455, 1345, 1110, 1104, 240, 2, 540, 818, 927, 490, 26, 45, 1198, 35, 1115, 730, 75, 26, 353, 4, 82, 316, 3837, 1238, 12, 7, 5, 82, 316, 3837, 1238, 12, 54, 208, 181, 2622, 2, 1607, 5690, 3470, 28, 8, 226, 731, 29, 355, 1131, 6, 133, 1238, 11, 108, 894, 135, 73, 5, 249, 240, 540, 370, 20, 927, 490, 2603, 3, 45, 266, 1, 3, 327, 625, 7, 67, 203, 11, 82, 3164, 2, 466, 878, 3842, 3498, 7, 576, 11, 749, 335, 60, 1, 89, 737, 169, 717, 42, 749, 212, 7327, 578, 201, 481, 2933, 578, 175, 339, 1126, 578, 2, 33, 133, 109, 1639, 2045, 784, 10, 3151, 4, 531, 493, 1744, 4, 49, 167, 2, 885, 31, 4, 18, 33, 28, 8, 52, 166, 126, 1, 739, 53, 3, 33, 111, 3060, 29, 429, 10, 842, 2, 63, 25, 772, 3, 33, 111, 116, 1, 146, 10, 27, 220, 18982, 1110, 146, 27, 4615, 3938, 146, 175, 1639, 146, 33, 2, 127, 626, 146, 175, 977, 104, 7, 833, 11, 1665, 6, 236, 3, 1465, 240, 540, 2, 39, 410, 1, 927, 490, 286, 88, 27, 155, 489, 4, 79, 7, 39, 778, 18, 1545, 14, 613, 18, 1172, 77, 807, 155, 10, 88, 749, 27, 46, 913, 123, 14855, 135, 1, 3931, 62988, 1100, 482, 74, 17, 932, 249, 36, 472, 2908, 750, 975, 257, 40, 1327, 515, 4, 82, 316, 12]",1559.0,23800696,Postoperative external beam radiation therapy concurrent cisplatin followed carboplatin/paclitaxel stage III FIGO 2009 endometrial,0,0.0
"Primary squamous cell carcinoma of the vagina: prognostic factors, treatment patterns, and outcomes.",Gynecologic oncology,Gynecol. Oncol.,2013-08-15,"Primary squamous cell carcinoma (SCCA) of the vagina is a rare malignancy with limited data to guide treatment. We evaluated prognostic factors and outcomes for patients with primary vaginal SCCA treated with definitive radiation therapy at a single institution. A retrospective analysis was performed on patients treated for primary vaginal SCCA from 1959 to 2011. Ninety-one patients with primary vaginal SCCA were treated with definitive radiation therapy. Thirty-eight patients had FIGO stage I, 28 stage II, 13 stage III, and 12 stage IV disease. The mean total dose was 70.1 Gy. Two-year overall survival (OS), locoregional control rate (LRC), and distant metastasis-free survival by stage were, respectively: stage I: 96.2%, 80.6%, 87.5%; stage II: 92.3%, 64.7%, 84.6%; stage III: 66.6%, 44.4%, 50.0%; and stage IV: 25.0%, 14.3%, 25.0%. Treatment with total dose over 70 Gy was associated with improved OS (p=0.0956) and LRC (p=0.055). There was a significant difference in median dose received by patients who developed grade 3/4 toxicity compared to those who did not (82.9 Gy versus 70.0 Gy, p=0.0019). None of the 10 patients treated with IMRT experienced locoregional recurrence or grade 3/4 toxicity. Tumor size larger than 4 cm was associated with worse OS (p=0.0034) and LRC (p=0.006). Our analysis suggests that the optimal dose for definitive treatment of SCCA of the vagina lies between 70 and 80 Gy. Treatment with IMRT may allow for dose escalation with reduced toxicity and excellent LRC. Tumor size over 4 cm is associated with inferior outcomes and may require additional treatment modalities.",Journal Article,2350.0,28.0,Primary squamous carcinoma SCCA vagina rare malignancy limited guide treatment evaluated prognostic factors outcomes patients primary vaginal SCCA treated definitive radiation therapy single institution retrospective performed patients treated primary vaginal SCCA 1959 2011 Ninety-one patients primary vaginal SCCA treated definitive radiation therapy Thirty-eight patients FIGO stage 28 stage II 13 stage III 12 stage IV disease mean total dose 70.1 Gy Two-year overall survival OS locoregional control rate LRC distant metastasis-free survival stage respectively stage 96.2 80.6 87.5 stage II 92.3 64.7 84.6 stage III 66.6 44.4 50.0 stage IV 25.0 14.3 25.0 Treatment total dose 70 Gy associated improved OS p=0.0956 LRC p=0.055 significant difference median dose received patients developed grade 3/4 toxicity compared 82.9 Gy versus 70.0 Gy p=0.0019 10 patients treated IMRT experienced locoregional recurrence grade 3/4 toxicity size larger 4 cm associated worse OS p=0.0034 LRC p=0.006 suggests optimal dose definitive treatment SCCA vagina lies 70 80 Gy Treatment IMRT allow dose escalation reduced toxicity excellent LRC size 4 cm associated inferior outcomes require additional treatment modalities,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[86, 691, 31, 134, 6372, 1, 3, 7553, 16, 8, 622, 710, 5, 383, 74, 6, 1597, 24, 21, 194, 177, 130, 2, 123, 9, 7, 5, 86, 6372, 73, 5, 1057, 121, 36, 28, 8, 226, 731, 8, 459, 65, 10, 173, 23, 7, 73, 9, 86, 6372, 29, 22247, 6, 1132, 2493, 104, 7, 5, 86, 6372, 11, 73, 5, 1057, 121, 36, 977, 659, 7, 42, 3837, 82, 70, 339, 82, 215, 233, 82, 316, 2, 133, 82, 478, 34, 3, 313, 181, 61, 10, 431, 14, 381, 100, 111, 63, 25, 118, 1325, 182, 116, 4000, 2, 626, 278, 115, 25, 20, 82, 11, 106, 82, 70, 921, 18, 493, 49, 912, 33, 82, 215, 937, 27, 660, 67, 874, 49, 82, 316, 700, 49, 584, 39, 212, 13, 2, 82, 478, 243, 13, 213, 27, 243, 13, 24, 5, 181, 61, 252, 431, 381, 10, 41, 5, 231, 118, 19, 13, 63242, 2, 4000, 19, 13, 9186, 125, 10, 8, 93, 523, 4, 52, 61, 103, 20, 7, 54, 276, 88, 27, 39, 155, 72, 6, 135, 54, 205, 44, 878, 83, 381, 185, 431, 13, 381, 19, 13, 12960, 1292, 1, 3, 79, 7, 73, 5, 964, 592, 1325, 146, 15, 88, 27, 39, 155, 30, 444, 1077, 76, 39, 494, 10, 41, 5, 639, 118, 19, 13, 19746, 2, 4000, 19, 13, 1861, 114, 65, 844, 17, 3, 665, 61, 9, 1057, 24, 1, 6372, 1, 3, 7553, 9247, 59, 431, 2, 493, 381, 24, 5, 964, 68, 1700, 9, 61, 1125, 5, 405, 155, 2, 1503, 4000, 30, 444, 252, 39, 494, 16, 41, 5, 1663, 123, 2, 68, 1353, 402, 24, 1558]",1527.0,23954572,Primary squamous carcinoma vagina prognostic factors treatment patterns outcomes,0,0.0
Patterns of relapse in stage I-II uterine papillary serous carcinoma treated with adjuvant intravaginal radiation (IVRT) with or without chemotherapy.,Gynecologic oncology,Gynecol. Oncol.,2013-09-20,"To evaluate patterns of relapse in early stage uterine papillary carcinoma (UPSC) patients receiving adjuvant intravaginal radiotherapy (IVRT) with or without chemotherapy. From 1/1996 to 12/2010, 77 women with stage I-II UPSC underwent surgery followed by IVRT (median 21Gy). Stage IA patients without residual disease at surgery were excluded. IVRT and chemotherapy (carboplatin/taxane) was given to 61 (79%) patients and IVRT alone to 16 (21%). The median follow-up was 62 months for surviving patients. Of the 77 patients, 11 (14%) relapsed as follows: vaginal 2 (3%), pelvic 5 (6%), para-aortic 5 (6%), peritoneal 6 (8%), and other distant sites 8 (10%). Of the 5 pelvic relapses, 2 were isolated and were salvaged. In those treated without chemotherapy, only 1/16 developed recurrence (mediastinal). The 5-year vaginal, pelvic, para-aortic, peritoneal, and distant recurrence rates were 2.7% (C.I. 0-6.2%), 5.8% (C.I. 0.6-11.0%), 5.4% (C.I. 0.6-10.1%), 5.3% (C.I. 0.5-10.1%) and 6.6% (C.I. 1.4-11.8%), respectively. The 5-year disease-free survival (DFS), and overall survival (OS) were 88% (C.I. 81-95%), and 91% (C.I. 84-97%), respectively. The only predictor of worse 5-year pelvic control was stage (96.2% stage IA vs 87.7% for stage IB-II, p=0.043). In stage I-II UPSC patients who predominantly receive adjuvant chemotherapy, IVRT as the sole form of adjuvant RT provides excellent locoregional control. The risk of isolated pelvic recurrence is too low to warrant routine use of external pelvic RT.",Journal Article,2314.0,19.0,evaluate patterns relapse early stage uterine papillary carcinoma UPSC patients receiving adjuvant intravaginal radiotherapy IVRT chemotherapy 1/1996 12/2010 77 women stage I-II UPSC underwent surgery followed IVRT median 21Gy Stage IA patients residual disease surgery excluded IVRT chemotherapy carboplatin/taxane given 61 79 patients IVRT 16 21 median follow-up 62 months surviving patients 77 patients 11 14 relapsed follows vaginal 2 3 pelvic 5 6 para-aortic 5 6 peritoneal 6 8 distant sites 8 10 5 pelvic relapses 2 isolated salvaged treated chemotherapy 1/16 developed recurrence mediastinal 5-year vaginal pelvic para-aortic peritoneal distant recurrence rates 2.7 C.I 0-6.2 5.8 C.I 0.6-11.0 5.4 C.I 0.6-10.1 5.3 C.I 0.5-10.1 6.6 C.I 1.4-11.8 respectively 5-year disease-free survival DFS overall survival OS 88 C.I 81-95 91 C.I 84-97 respectively predictor worse 5-year pelvic control stage 96.2 stage IA vs 87.7 stage IB-II p=0.043 stage I-II UPSC patients predominantly receive adjuvant chemotherapy IVRT sole form adjuvant RT provides excellent locoregional control risk isolated pelvic recurrence low warrant routine use external pelvic RT,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[6, 376, 764, 1, 429, 4, 191, 82, 1796, 134, 5676, 7, 357, 249, 16720, 310, 12005, 5, 15, 187, 56, 29, 14, 2648, 6, 133, 1120, 849, 117, 5, 82, 70, 215, 5676, 208, 152, 370, 20, 12005, 52, 63406, 82, 3302, 7, 187, 753, 34, 28, 152, 11, 1800, 12005, 2, 56, 927, 1715, 10, 447, 6, 713, 842, 7, 2, 12005, 279, 6, 245, 239, 3, 52, 166, 126, 10, 744, 53, 9, 3050, 7, 1, 3, 849, 7, 175, 213, 591, 22, 2962, 18, 27, 1110, 33, 49, 4615, 3938, 33, 49, 1639, 49, 66, 2, 127, 626, 633, 66, 79, 1, 3, 33, 1110, 3713, 18, 11, 1355, 2, 11, 9459, 4, 135, 73, 187, 56, 158, 14, 245, 276, 146, 2626, 3, 33, 111, 1110, 4615, 3938, 1639, 2, 626, 146, 151, 11, 18, 67, 256, 70, 13, 49, 18, 33, 66, 256, 70, 13, 49, 175, 13, 33, 39, 256, 70, 13, 49, 79, 14, 33, 27, 256, 70, 13, 33, 79, 14, 2, 49, 49, 256, 70, 14, 39, 175, 66, 106, 3, 33, 111, 34, 115, 25, 1010, 2, 63, 25, 118, 11, 889, 256, 70, 865, 48, 2, 970, 256, 70, 874, 1015, 106, 3, 158, 980, 1, 639, 33, 111, 1110, 182, 10, 82, 921, 18, 82, 3302, 105, 912, 67, 9, 82, 3180, 215, 19, 13, 5653, 4, 82, 70, 215, 5676, 7, 54, 2117, 560, 249, 56, 12005, 22, 3, 4991, 1297, 1, 249, 240, 777, 1503, 1325, 182, 3, 43, 1, 1355, 1110, 146, 16, 5044, 154, 6, 2946, 1311, 119, 1, 1455, 1110, 240]",1375.0,24055615,Patterns relapse stage I-II uterine papillary serous carcinoma treated adjuvant intravaginal radiation IVRT chemotherapy,0,0.0
Reducing readmissions after robotic surgical management of endometrial cancer: a potential for improved quality care.,Gynecologic oncology,Gynecol. Oncol.,2013-10-04,"To describe readmission patterns after robotic surgery for endometrial cancer and identify risk factors for readmission within 90 days of discharge. Patients with endometrial cancer who underwent robotic surgical management at an academic institution from 2006 to 2010 were identified. Patient characteristics, intraoperative data, and postoperative complications were analyzed. Student's t-test and Fisher's exact test were used to compare patients readmitted within 90 days to those who were not. Three hundred ninety-five patients were included. Thirty (7.6%) were readmitted within 90 days of surgical discharge. Length of stay greater than one day (40.0% vs. 23.0%, p=0.04) and postoperative complication (63.3% vs. 13.4%, p<0.01) were associated with readmission. The median interval to readmission was 9.5 days and median duration of subsequent hospitalization was 2.5 days. Fever (31.3%) and workup for vaginal drainage (25.0%) were the most common reasons for readmission. Only 2 of the 10 patients readmitted with fever had culture-proven infection, and no patients readmitted for vaginal drainage had a confirmed urinary tract injury. Of the 30 patients readmitted, 5 required a second operation - 3 for vaginal cuff dehiscence and 2 for port site hernia. Robotic surgery for endometrial cancer was associated with a 7.6% readmission rate. The most common reasons for readmission, fever and evaluation for urinary tract injury, were frequently not associated with severe illness. This supports additional education to consider raising the threshold for readmission by using more widespread outpatient evaluation for the potential complications of robotic endometrial cancer surgery.",Journal Article,2300.0,16.0,readmission patterns robotic surgery endometrial identify risk factors readmission 90 days discharge Patients endometrial underwent robotic surgical management academic institution 2006 2010 identified Patient characteristics intraoperative postoperative complications Student 's t-test Fisher 's exact test compare patients readmitted 90 days ninety-five patients included Thirty 7.6 readmitted 90 days surgical discharge Length stay greater day 40.0 vs. 23.0 p=0.04 postoperative complication 63.3 vs. 13.4 p 0.01 associated readmission median interval readmission 9.5 days median duration subsequent hospitalization 2.5 days Fever 31.3 workup vaginal drainage 25.0 common reasons readmission 2 10 patients readmitted fever culture-proven infection patients readmitted vaginal drainage confirmed urinary tract injury 30 patients readmitted 5 required second operation 3 vaginal cuff dehiscence 2 port site hernia Robotic surgery endometrial associated 7.6 readmission rate common reasons readmission fever evaluation urinary tract injury frequently associated severe illness supports additional education consider raising threshold readmission widespread outpatient evaluation potential complications robotic endometrial surgery,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[6, 897, 3146, 764, 50, 2895, 152, 9, 12, 2, 255, 43, 130, 9, 3146, 262, 424, 162, 1, 2993, 7, 5, 12, 54, 208, 2895, 221, 284, 28, 35, 1916, 731, 29, 1324, 6, 1120, 11, 108, 69, 374, 1720, 74, 2, 573, 521, 11, 311, 6390, 292, 102, 412, 2, 3135, 292, 2472, 412, 11, 95, 6, 932, 7, 8351, 262, 424, 162, 6, 135, 54, 11, 44, 169, 1128, 2493, 365, 7, 11, 159, 977, 67, 49, 11, 8351, 262, 424, 162, 1, 221, 2993, 1318, 1, 2020, 378, 76, 104, 218, 327, 13, 105, 382, 13, 19, 13, 755, 2, 573, 1447, 676, 27, 105, 233, 39, 19, 13, 355, 11, 41, 5, 3146, 3, 52, 268, 6, 3146, 10, 83, 33, 162, 2, 52, 654, 1, 706, 2826, 10, 18, 33, 162, 2775, 456, 27, 2, 4755, 9, 3528, 243, 13, 11, 3, 96, 186, 2325, 9, 3146, 158, 18, 1, 3, 79, 7, 8351, 5, 2775, 42, 2099, 1930, 930, 2, 77, 7, 8351, 9, 3528, 42, 8, 557, 1660, 1696, 2730, 1, 3, 201, 7, 8351, 33, 616, 8, 419, 2589, 27, 9, 11445, 11811, 2, 18, 9, 3083, 606, 10236, 2895, 152, 9, 12, 10, 41, 5, 8, 67, 49, 3146, 116, 3, 96, 186, 2325, 9, 3146, 2775, 2, 451, 9, 1660, 1696, 2730, 11, 746, 44, 41, 5, 905, 2973, 26, 2304, 402, 1848, 6, 2419, 6627, 3, 2390, 9, 3146, 20, 75, 80, 3029, 2379, 451, 9, 3, 174, 521, 1, 2895, 12, 152]",1581.0,24096114,Reducing readmissions robotic surgical management endometrial potential improved quality care,53,0.2663316582914573
Outcomes in patients with mucosal melanomas.,Journal of surgical oncology,J Surg Oncol,2013-10-16,"Our goal was to evaluate the different subtypes of mucosal melanoma and describe specific variables that predict outcomes. Prospective review of two tertiary care center databases identified 76 mucosal melanoma patients; 73 with complete records were included. Demographic and clinical data were analyzed. Cox regression determined variables impacting recurrence and survival. In the 73 patients, the mean age was 64 years, and 74% were female. Sixty-seven percent presented with lymph node involvement, and 73% had ulcerated tumors. Major sites affected were nasal/palate/oral (36%), vulvar/vaginal/cervical (48%), and anorectal (15%). Mean overall and disease-free survival were 56.9 and 27.2 months. Variables associated with decreased survival included: lymphovascular invasion (HR17.70, P=0.0093), Caucasian race (HR3.02, P=0.0362), nasal/palate/oral sub-group (HR1.85, P=0.026), Breslow thickness (HR1.23, P=0.00004), T stage (HR1.34, P=0.0075), M stage (HR3.03, P=0.0039), and chemotherapy (HR3.13, P=0.0002). The worst prognosis was seen in the nasal/palate/oral sub-group, with a median overall survival of 9.7 months and recurrence-free time of 4.5 months. This subtype also demonstrated high lymph node positivity, ulceration, and larger tumor size. The nasal, palate, oral subtype has the worst prognosis compared to other mucosal melanoma locations. Studies are ongoing to evaluate pathologic and genomic variables that may predict outcomes.",Journal Article,2288.0,23.0,goal evaluate different subtypes mucosal melanoma specific variables predict outcomes Prospective review tertiary care center databases identified 76 mucosal melanoma patients 73 complete records included Demographic clinical Cox regression determined variables impacting recurrence survival 73 patients mean age 64 years 74 female Sixty-seven percent presented lymph node involvement 73 ulcerated Major sites affected nasal/palate/oral 36 vulvar/vaginal/cervical 48 anorectal 15 Mean overall disease-free survival 56.9 27.2 months Variables associated decreased survival included lymphovascular invasion HR17.70 P 0.0093 Caucasian race HR3.02 P 0.0362 nasal/palate/oral sub-group HR1.85 P 0.026 Breslow thickness HR1.23 P 0.00004 stage HR1.34 P 0.0075 stage HR3.03 P 0.0039 chemotherapy HR3.13 P 0.0002 worst prognosis seen nasal/palate/oral sub-group median overall survival 9.7 months recurrence-free time 4.5 months subtype demonstrated high lymph node positivity ulceration larger size nasal palate oral subtype worst prognosis compared mucosal melanoma locations Studies ongoing evaluate pathologic genomic variables predict outcomes,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[114, 1326, 10, 6, 376, 3, 338, 814, 1, 3068, 2, 897, 112, 682, 17, 678, 123, 482, 206, 1, 100, 2557, 165, 574, 2348, 108, 846, 3068, 7, 803, 5, 236, 1064, 11, 159, 1540, 2, 38, 74, 11, 311, 418, 320, 509, 682, 8661, 146, 2, 25, 4, 3, 803, 7, 3, 313, 89, 10, 660, 60, 2, 794, 11, 1061, 1746, 648, 714, 917, 5, 263, 289, 799, 2, 803, 42, 13571, 57, 458, 633, 1424, 11, 6743, 10988, 518, 511, 48010, 18982, 18237, 576, 2, 9778, 167, 313, 63, 2, 34, 115, 25, 11, 664, 83, 2, 428, 18, 53, 682, 41, 5, 340, 25, 159, 2933, 578, 63528, 431, 19, 13, 26813, 3229, 1047, 40512, 588, 19, 13, 40227, 6743, 10988, 518, 551, 87, 25099, 772, 19, 13, 4554, 6931, 2903, 25099, 382, 19, 13, 30815, 102, 82, 25099, 562, 19, 13, 23345, 188, 82, 40512, 680, 19, 13, 20518, 2, 56, 40512, 233, 19, 13, 3531, 3, 4066, 356, 10, 527, 4, 3, 6743, 10988, 518, 551, 87, 5, 8, 52, 63, 25, 1, 83, 67, 53, 2, 146, 115, 98, 1, 39, 33, 53, 26, 875, 120, 264, 64, 263, 289, 1887, 5158, 2, 1077, 30, 444, 3, 6743, 10988, 518, 875, 71, 3, 4066, 356, 72, 6, 127, 3068, 4069, 94, 32, 942, 6, 376, 510, 2, 572, 682, 17, 68, 678, 123]",1364.0,24132665,Outcomes patients mucosal melanomas,4,0.020100502512562814
Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors.,Gynecologic oncology,Gynecol. Oncol.,2013-11-09,"To determine the progression free survival (PFS), toxicity, and patterns of failure for early stage, high-intermediate risk (H-IR) patients in a phase II trial with adjuvant vaginal cuff brachytherapy (VCB) and three cycles of carboplatin and paclitaxel. Surgically staged patients with stage I-IIb endometrial cancer with H-IR factors were treated with VCB (2100cGy) followed by three cycles of carboplatin (AUC 6) and paclitaxel (175 mg/m(2)). The primary endpoint was PFS at 2 years, with toxicity and sites of failure as secondary endpoints. Toxicity was assessed by patient report (CTCAE v. 3) as well as by delays or dose modifications in treatment. All patients completed VCB and 19/23 (83%) completed both VCB and 3 cycles of chemotherapy. Mean time to complete VCB was 14.5 days with minimal acute toxicity noted. At 6 months, all toxicity related to VCB had resolved. In total 60 cycles of chemotherapy were given, with one dose reduction (1.6%) for grade 2 neuropathy and seven delays (11.6%) in treatment due to hematologic toxicity. At a median follow-up of 44.5 months, 91% of patients remained progression free at 2 years. Four patients experienced a recurrence; they recurred both locally and distant. Adjuvant therapy with VCB and chemotherapy is well tolerated in a population of patients with H-IR endometrial carcinoma and provides 2 year PFS of 91%. A randomized trial is currently underway to assess whether combined VCB and chemotherapy reduces the rate of recurrence compared to external beam radiation therapy (EBRT) in this patient population.","Clinical Trial, Phase II",2264.0,20.0,determine progression free survival PFS toxicity patterns failure early stage high-intermediate risk H-IR patients phase II trial adjuvant vaginal cuff brachytherapy VCB cycles carboplatin paclitaxel Surgically staged patients stage I-IIb endometrial H-IR factors treated VCB 2100cGy followed cycles carboplatin AUC 6 paclitaxel 175 mg/m 2 primary endpoint PFS 2 years toxicity sites failure secondary endpoints Toxicity assessed patient report CTCAE v. 3 delays dose modifications treatment patients completed VCB 19/23 83 completed VCB 3 cycles chemotherapy Mean time complete VCB 14.5 days minimal acute toxicity noted 6 months toxicity related VCB resolved total 60 cycles chemotherapy given dose reduction 1.6 grade 2 neuropathy seven delays 11.6 treatment hematologic toxicity median follow-up 44.5 months 91 patients remained progression free 2 years patients experienced recurrence recurred locally distant Adjuvant therapy VCB chemotherapy tolerated population patients H-IR endometrial carcinoma provides 2 year PFS 91 randomized trial currently underway assess combined VCB chemotherapy reduces rate recurrence compared external beam radiation therapy EBRT patient population,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[6, 223, 3, 91, 115, 25, 300, 155, 2, 764, 1, 496, 9, 191, 82, 64, 919, 43, 555, 2123, 7, 4, 8, 124, 215, 160, 5, 249, 11445, 1536, 25573, 2, 169, 410, 1, 927, 2, 490, 2350, 2930, 7, 5, 82, 70, 3884, 12, 5, 555, 2123, 130, 11, 73, 5, 25573, 63608, 370, 20, 169, 410, 1, 927, 1376, 49, 2, 490, 3300, 81, 188, 18, 3, 86, 1138, 10, 300, 28, 18, 60, 5, 155, 2, 633, 1, 496, 22, 568, 1387, 155, 10, 275, 20, 69, 414, 3898, 603, 27, 22, 149, 22, 20, 3257, 15, 61, 2916, 4, 24, 62, 7, 781, 25573, 2, 326, 382, 852, 781, 110, 25573, 2, 27, 410, 1, 56, 313, 98, 6, 236, 25573, 10, 213, 33, 162, 5, 1048, 286, 155, 1051, 28, 49, 53, 62, 155, 139, 6, 25573, 42, 3862, 4, 181, 335, 410, 1, 56, 11, 447, 5, 104, 61, 628, 14, 49, 9, 88, 18, 1751, 2, 648, 3257, 175, 49, 4, 24, 520, 6, 813, 155, 28, 8, 52, 166, 126, 1, 584, 33, 53, 970, 1, 7, 958, 91, 115, 28, 18, 60, 294, 7, 592, 8, 146, 491, 3363, 110, 795, 2, 626, 249, 36, 5, 25573, 2, 56, 16, 149, 421, 4, 8, 266, 1, 7, 5, 555, 2123, 134, 2, 777, 18, 111, 300, 1, 970, 8, 384, 160, 16, 694, 3948, 6, 423, 317, 397, 25573, 2, 56, 2389, 3, 116, 1, 146, 72, 6, 1455, 1345, 121, 36, 1883, 4, 26, 69, 266]",1489.0,24219982,Phase II trial vaginal cuff brachytherapy followed chemotherapy early stage endometrial patients high-intermediate risk factors,3,0.01507537688442211
Pelvic exenteration: impact of age on surgical and oncologic outcomes.,Gynecologic oncology,Gynecol. Oncol.,2013-11-18,"To evaluate whether preoperative age impacts surgical outcomes, complication rates, and/or recurrence in women undergoing pelvic exenteration. All women who underwent a pelvic exenteration for any gynecologic indication at our institution from 1993 to 2010 were included. Women were stratified into groups based on age in years (young:  50, middle: 51-64, and senior:  65). Baseline characteristics, surgical outcomes, early (<60 days) and late ( 60 days) postoperative complications, and recurrence/survival outcomes were ascertained. Fisher's exact test or Kruskal-Wallis test was performed. Kaplan-Meier survival curves were compared. 161 patients were included (58 young, 62 in the middle, and 41 senior). Women in the young group predominately had a diagnosis of cervical cancer (82.8%) while women in the senior group primarily had a diagnosis of vulvar or vaginal cancer (70.7%). Senior women were also more likely to have hypertension (p < 0.0001) and pulmonary disease (p = 0.040). Operative time was significantly shorter for women in the senior group (8.5h) compared with the middle (9.5h) and young group (10.1h) (p = 0.0089). There were no significant differences in early or late complications when stratified by age. The overall survival did not differ between age groups (p = 0.3760). Although hypertension and pulmonary disease were more frequent in the senior age group, duration of surgery, blood loss, length of hospital stay and complication rates did not increase with age. Advanced chronological age should not be considered a contraindication to a potentially curative surgical procedure.",Journal Article,2255.0,16.0,evaluate preoperative age impacts surgical outcomes complication rates and/or recurrence women undergoing pelvic exenteration women underwent pelvic exenteration gynecologic indication institution 1993 2010 included Women stratified groups based age years young  50 middle 51-64 senior  65 Baseline characteristics surgical outcomes early 60 days late  60 days postoperative complications recurrence/survival outcomes ascertained Fisher 's exact test Kruskal-Wallis test performed Kaplan-Meier survival curves compared 161 patients included 58 young 62 middle 41 senior Women young group predominately diagnosis cervical 82.8 women senior group primarily diagnosis vulvar vaginal 70.7 Senior women likely hypertension p 0.0001 pulmonary disease p 0.040 Operative time significantly shorter women senior group 8.5h compared middle 9.5h young group 10.1h p 0.0089 significant differences early late complications stratified age overall survival differ age groups p 0.3760 hypertension pulmonary disease frequent senior age group duration surgery blood loss length hospital stay complication rates increase age Advanced chronological age considered contraindication potentially curative surgical procedure,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 376, 317, 498, 89, 4719, 221, 123, 1447, 151, 2, 15, 146, 4, 117, 479, 1110, 5668, 62, 117, 54, 208, 8, 1110, 5668, 9, 500, 1512, 3607, 28, 114, 731, 29, 3343, 6, 1120, 11, 159, 117, 11, 1173, 237, 271, 90, 23, 89, 4, 60, 1169, 1552, 212, 3897, 725, 660, 2, 10898, 749, 556, 330, 374, 221, 123, 191, 335, 162, 2, 807, 749, 335, 162, 573, 521, 2, 146, 25, 123, 11, 5240, 3135, 292, 2472, 412, 15, 8800, 8875, 412, 10, 173, 876, 882, 25, 2400, 11, 72, 5377, 7, 11, 159, 717, 1169, 744, 4, 3, 3897, 2, 605, 10898, 117, 4, 3, 1169, 87, 11583, 42, 8, 147, 1, 12, 878, 66, 369, 117, 4, 3, 10898, 87, 1561, 42, 8, 147, 1, 15, 12, 431, 67, 10898, 117, 11, 120, 80, 322, 6, 47, 1824, 19, 13, 488, 2, 1087, 34, 19, 13, 6824, 1208, 98, 10, 97, 985, 9, 117, 4, 3, 10898, 87, 66, 38494, 72, 5, 3, 3897, 83, 38494, 2, 1169, 87, 79, 10147, 19, 13, 21191, 125, 11, 77, 93, 362, 4, 191, 15, 807, 521, 198, 1173, 20, 89, 3, 63, 25, 205, 44, 1505, 59, 89, 271, 19, 13, 40545, 242, 1824, 2, 1087, 34, 11, 80, 908, 4, 3, 10898, 89, 87, 654, 1, 152, 315, 407, 1318, 1, 702, 2020, 2, 1447, 151, 205, 44, 344, 5, 89, 131, 14921, 89, 257, 44, 40, 515, 8, 8363, 6, 8, 751, 1075, 221, 1299]",1526.0,24262877,Pelvic exenteration impact age surgical oncologic outcomes,0,0.0
Causes and palliation of transfusion-associated vaginal bleeding in patients with metastatic cancer.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2014-01-01,"The current study was undertaken (1) to capture a clinically relevant, systematically collected series of patients with metastatic cancer and transfusion-associated vaginal bleeding and (2) to provide insight into how best to palliate this bleeding. As part of a single-institution review, 46 patients with metastatic cancer and transfusion-associated vaginal bleeding were identified. In a minority, 14 (30%), the cancer itself was directly responsible for the bleeding, and under these circumstances, gynecological cancer was the most frequent cause. In 13 patients (28%), more than 1 palliative intervention was attempted. Of all the interventions, a hysterectomy was performed most frequently and was successful in 11 patients. The use of ablation or embolization procedures was rarely tried but successful in 4 patients. However, 2 patients died of vaginal bleeding, despite multiple palliative procedures to control bleeding, including tumor embolization in one. Transfusion-associated vaginal bleeding in patients with metastatic cancer can arise from nonmalignant causes and often assumes an uneventful course but can, at times, be serious and difficult to control.",Journal Article,2211.0,0.0,current undertaken 1 capture clinically relevant systematically collected series patients metastatic transfusion-associated vaginal bleeding 2 provide insight best palliate bleeding single-institution review 46 patients metastatic transfusion-associated vaginal bleeding identified minority 14 30 directly responsible bleeding circumstances gynecological frequent cause 13 patients 28 1 palliative intervention attempted interventions hysterectomy performed frequently successful 11 patients use ablation embolization procedures rarely tried successful 4 patients 2 patients died vaginal bleeding despite multiple palliative procedures control bleeding including embolization Transfusion-associated vaginal bleeding patients metastatic arise nonmalignant causes assumes uneventful course times difficult control,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 291, 45, 10, 2789, 14, 6, 2891, 8, 505, 867, 3390, 786, 988, 1, 7, 5, 113, 12, 2, 2785, 41, 2294, 2, 18, 6, 377, 2670, 237, 832, 824, 6, 10982, 26, 2294, 22, 760, 1, 8, 226, 731, 206, 641, 7, 5, 113, 12, 2, 2785, 41, 2294, 11, 108, 4, 8, 2652, 213, 201, 3, 12, 4045, 10, 1606, 2327, 9, 3, 2294, 2, 669, 46, 7684, 6324, 12, 10, 3, 96, 908, 708, 4, 233, 7, 339, 80, 76, 14, 994, 788, 10, 4098, 1, 62, 3, 1151, 8, 2622, 10, 173, 96, 746, 2, 10, 1401, 4, 175, 7, 3, 119, 1, 1650, 15, 4232, 1369, 10, 2416, 13780, 84, 1401, 4, 39, 7, 137, 18, 7, 1016, 1, 2294, 550, 232, 994, 1369, 6, 182, 2294, 141, 30, 4232, 4, 104, 2785, 41, 2294, 4, 7, 5, 113, 12, 122, 3043, 29, 5967, 1626, 2, 629, 19029, 35, 16742, 906, 84, 122, 28, 1072, 40, 1762, 2, 1740, 6, 182]",1110.0,24270998,Causes palliation transfusion-associated vaginal bleeding patients metastatic,0,0.0
Metastatic mucosal melanoma: imaging patterns of metastasis and recurrence.,Cancer imaging : the official publication of the International Cancer Imaging Society,Cancer Imaging,2013-12-30,"Mucosal melanoma is a rare but aggressive subtype of melanoma with unique clinicopathologic features. We hypothesize that mucosal melanoma shows predilection for separate and unique metastatic pathways. This was a retrospective analysis of 19 patients (5 men and 14 women; median age 60 years, range 38-76 years) with metastatic mucosal melanoma presenting to a tertiary oncology center between 2005 and 2010. We performed a review of medical records and histologic and imaging studies to evaluate the natural history, metastatic patterns and the role of imaging in the management of patients with advanced mucosal melanoma. At presentation, disease was confined to the primary site (58%, n = 11) or to the regional lymph nodes (32%, n = 6) in most patients. The most common site of metastasis was the lungs (89%, n = 16), followed by the liver (67%, n = 12) and peritoneum (44%, n = 8). Sinonasal melanoma preferentially spread to the liver (100%, n = 4), vaginal melanoma to the lungs (100%, n = 7) and anal melanoma to the inguinal lymph nodes (100%, n = 4). Pathways of metastatic spread in mucosal melanoma may differ from other forms of melanoma and between different primary sites of mucosal origin.",Journal Article,2213.0,11.0,Mucosal melanoma rare aggressive subtype melanoma unique clinicopathologic features hypothesize mucosal melanoma shows predilection separate unique metastatic pathways retrospective 19 patients 5 men 14 women median age 60 years range 38-76 years metastatic mucosal melanoma presenting tertiary oncology center 2005 2010 performed review medical records histologic imaging studies evaluate natural history metastatic patterns role imaging management patients advanced mucosal melanoma presentation disease confined primary site 58 n 11 regional lymph nodes 32 n 6 patients common site metastasis lungs 89 n 16 followed liver 67 n 12 peritoneum 44 n 8 Sinonasal melanoma preferentially spread liver 100 n 4 vaginal melanoma lungs 100 n 7 anal melanoma inguinal lymph nodes 100 n 4 Pathways metastatic spread mucosal melanoma differ forms melanoma different primary sites mucosal origin,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3068, 16, 8, 622, 84, 571, 875, 1, 5, 991, 1399, 404, 21, 4919, 17, 3068, 1949, 8904, 9, 2282, 2, 991, 113, 460, 26, 10, 8, 459, 65, 1, 326, 7, 33, 325, 2, 213, 117, 52, 89, 335, 60, 184, 519, 846, 60, 5, 113, 3068, 1656, 6, 8, 2557, 413, 574, 59, 1242, 2, 1120, 21, 173, 8, 206, 1, 484, 1064, 2, 884, 2, 270, 94, 6, 376, 3, 1504, 532, 113, 764, 2, 3, 200, 1, 270, 4, 3, 284, 1, 7, 5, 131, 3068, 28, 1031, 34, 10, 2902, 6, 3, 86, 606, 717, 78, 175, 15, 6, 3, 951, 263, 502, 531, 78, 49, 4, 96, 7, 3, 96, 186, 606, 1, 278, 10, 3, 4465, 887, 78, 245, 370, 20, 3, 598, 78, 133, 2, 6699, 584, 78, 66, 7605, 3509, 2579, 6, 3, 394, 78, 39, 6, 3, 4465, 394, 78, 67, 2, 6, 3, 4907, 263, 502, 394, 78, 39, 460, 1, 113, 2579, 4, 3068, 68, 1505, 29, 127, 2377, 1, 2, 59, 338, 86, 633, 1, 3068, 1938]",1027.0,24434078,Metastatic mucosal melanoma imaging patterns metastasis recurrence,0,0.0
Effect of age and race on quality of life in young breast cancer survivors.,Clinical breast cancer,Clin. Breast Cancer,2013-10-25,"Given their early age at diagnosis, young breast cancer survivors (YBCSs) face issues that differ widely from their older counterparts. We mailed a survey to 2209 patients who were  45 years at the time of breast cancer (BC) diagnosis. Each survey was composed of the Quality of Life in Adult Cancer Survivors instrument, Menopause Symptom Scale, and questions aimed at obtaining pertinent background information. One thousand ninety patients completed the survey. Mean age at time of diagnosis was 39.5 years; median years from diagnosis was 6.6 years. Distress related to vaginal dryness (P = .0002) and pain from intercourse (P = .0014) was significantly higher in patients who were < 5 years from diagnosis compared with those > 10 years from diagnosis. In the area of financial problems, black women had greater distress than did white women (P = .0010). Compared with white women, Hispanic women had worse family distress scores (P = .0028) and summary cancer-specific scores (P = .0076). Patients > 10 years from diagnosis had less sexual interest (P = .003) than did women who were closer to diagnosis. Women  40 years at diagnosis had significantly lower sexual interest (P = .0016) than did women < 40 years. Stage and neoadjuvant chemotherapy did not have a significant effect on quality of life (QOL). Even in comparison to stage and neoadjuvant chemotherapy, race, age at diagnosis, and time from diagnosis have significant long-term effects on QOL after treatment for BC.",Journal Article,2279.0,24.0,Given early age diagnosis young breast survivors YBCSs face issues differ widely older counterparts mailed survey 2209 patients  45 years time breast BC diagnosis survey composed Quality Life Adult Survivors instrument Menopause Symptom Scale questions aimed obtaining pertinent background information thousand ninety patients completed survey Mean age time diagnosis 39.5 years median years diagnosis 6.6 years Distress related vaginal dryness P .0002 pain intercourse P .0014 significantly higher patients 5 years diagnosis compared 10 years diagnosis area financial problems black women greater distress white women P .0010 Compared white women Hispanic women worse family distress scores P .0028 summary cancer-specific scores P .0076 Patients 10 years diagnosis sexual P .003 women closer diagnosis Women  40 years diagnosis significantly lower sexual P .0016 women 40 years Stage neoadjuvant chemotherapy significant effect quality life QOL comparison stage neoadjuvant chemotherapy race age diagnosis time diagnosis significant long-term effects QOL treatment BC,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[447, 136, 191, 89, 28, 147, 1169, 12, 332, 63867, 3376, 1553, 17, 1505, 1792, 29, 136, 434, 3953, 21, 6703, 8, 1407, 6, 46022, 7, 54, 11, 1552, 512, 60, 28, 3, 98, 1, 12, 1402, 147, 296, 1407, 10, 3317, 1, 3, 372, 1, 358, 4, 780, 12, 332, 3877, 5034, 934, 1124, 2, 1937, 1295, 28, 5244, 5799, 2426, 487, 104, 6161, 2493, 7, 781, 3, 1407, 313, 89, 28, 98, 1, 147, 10, 587, 33, 60, 52, 60, 29, 147, 10, 49, 49, 60, 1462, 139, 6, 15822, 19, 3531, 2, 559, 29, 12361, 19, 11408, 10, 97, 142, 4, 7, 54, 11, 33, 60, 29, 147, 72, 5, 135, 79, 60, 29, 147, 4, 3, 965, 1, 3021, 2408, 1445, 117, 42, 378, 1462, 76, 205, 886, 117, 19, 22712, 72, 5, 886, 117, 1776, 117, 42, 639, 607, 1462, 703, 19, 16735, 2, 1962, 12, 112, 703, 19, 26779, 7, 79, 60, 29, 147, 42, 299, 2232, 1333, 19, 1421, 76, 205, 117, 54, 11, 6576, 6, 147, 117, 749, 327, 60, 28, 147, 42, 97, 280, 2232, 1333, 19, 13230, 76, 205, 117, 327, 60, 82, 2, 536, 56, 205, 44, 47, 8, 93, 254, 23, 372, 1, 358, 1001, 871, 4, 1155, 6, 82, 2, 536, 56, 1047, 89, 28, 147, 2, 98, 29, 147, 47, 93, 319, 337, 176, 23, 1001, 50, 24, 9, 1402]",1402.0,24461458,Effect age race quality life young breast survivors,3,0.01507537688442211
The role of postoperative radiation therapy for endometrial cancer: Executive summary of an American Society for Radiation Oncology evidence-based guideline.,Practical radiation oncology,Pract Radiat Oncol,2014-03-31,"To present evidence-based guidelines for adjuvant radiation in the treatment of endometrial cancer. Key clinical questions to be addressed in this evidence-based guideline on endometrial cancer were identified. A comprehensive literature review was performed to identify studies that included no adjuvant therapy, or pelvic radiation or vaginal brachytherapy with or without systemic chemotherapy. Outcomes included local control, survival rates, and overall assessment of quality of life. Patients with grade 1 or 2 cancers with either no invasion or <50% myometrial invasion (MI), especially when no other high risk features are present, can be safely observed after hysterectomy. Vaginal cuff brachytherapy is as effective as pelvic radiation therapy at preventing vaginal recurrence for patients with grade 1 or 2 cancers with 50% MI or grade 3 tumors with <50% MI. Patients with grade 3 cancer with 50% MI or cervical stroma invasion may benefit from pelvic radiation to reduce the risk of pelvic recurrence. There is limited evidence for a benefit to vaginal cuff brachytherapy following pelvic radiation. Multimodality treatment is recommended for patients with positive nodes or involved uterine serosa, ovaries or fallopian tubes, vagina, bladder, or rectum. External beam and vaginal brachytherapy remain integral aspects of adjuvant therapy for endometrial cancer.",Journal Article,2122.0,95.0,present evidence-based guidelines adjuvant radiation treatment endometrial Key clinical questions addressed evidence-based guideline endometrial identified comprehensive literature review performed identify studies included adjuvant therapy pelvic radiation vaginal brachytherapy systemic chemotherapy Outcomes included local control survival rates overall assessment quality life Patients grade 1 2 invasion 50 myometrial invasion MI especially high risk features present safely observed hysterectomy Vaginal cuff brachytherapy effective pelvic radiation therapy preventing vaginal recurrence patients grade 1 2 50 MI grade 3 50 MI Patients grade 3 50 MI cervical stroma invasion benefit pelvic radiation reduce risk pelvic recurrence limited evidence benefit vaginal cuff brachytherapy following pelvic radiation Multimodality treatment recommended patients positive nodes involved uterine serosa ovaries fallopian tubes vagina bladder rectum External beam vaginal brachytherapy remain integral aspects adjuvant therapy endometrial,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,"[6, 364, 241, 90, 677, 9, 249, 121, 4, 3, 24, 1, 12, 825, 38, 1937, 6, 40, 2814, 4, 26, 241, 90, 2009, 23, 12, 11, 108, 8, 949, 789, 206, 10, 173, 6, 255, 94, 17, 159, 77, 249, 36, 15, 1110, 121, 15, 1536, 5, 15, 187, 403, 56, 123, 159, 293, 182, 25, 151, 2, 63, 455, 1, 372, 1, 358, 7, 5, 88, 14, 15, 18, 163, 5, 361, 77, 578, 15, 212, 7327, 578, 6862, 1093, 198, 77, 127, 64, 43, 404, 32, 364, 122, 40, 2268, 164, 50, 2622, 11445, 1536, 16, 22, 323, 22, 1110, 121, 36, 28, 3017, 146, 9, 7, 5, 88, 14, 15, 18, 163, 5, 5660, 6862, 15, 88, 27, 57, 5, 212, 6862, 7, 5, 88, 27, 12, 5, 5660, 6862, 15, 2477, 578, 68, 247, 29, 1110, 121, 6, 969, 3, 43, 1, 1110, 146, 125, 16, 383, 241, 9, 8, 247, 6, 11445, 1536, 366, 1110, 121, 2425, 24, 16, 793, 9, 7, 5, 109, 502, 15, 646, 23561, 7262, 15, 6193, 7553, 15, 3660, 1455, 1345, 2, 1536, 918, 4450, 2695, 1, 249, 36, 9, 12]",1239.0,24766678,role postoperative radiation therapy endometrial Executive summary American Society Radiation Oncology evidence-based guideline,2,0.010050251256281407
Management of vulvar and vaginal melanomas: current and future strategies.,American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting,Am Soc Clin Oncol Educ Book,2014-01-01,"Melanomas arising in the vulva and vagina are rare and therefore there is minimal data specific to these malignancies. Data are often extrapolated from other cutaneous melanomas, which may or may not be appropriate. Surgery remains the primary treatment modality at initial diagnosis and in select recurrent cases. Wide local excision of the primary lesion not requiring an exenteration, along with sentinel lymph node (SLN) mapping, should be routinely considered in vulvar melanomas. Local excision and SLN mapping is difficult and often not considered for vaginal melanomas. Primary exenterative procedures should not be routinely offered. In locally advanced cases potentially requiring an exenterative procedure, radiation therapy with or without concurrent immunotherapy is a consideration. The role of adjuvant therapy remains unclear. Surgery or radiation therapy can be considered in recurrent cases. Systemic chemotherapy agents have a modest response rate with associated poor survival outcomes. Novel immunotherapeutic and targeted agents have been reported to improve survival in melanoma and should be considered in cases of vulvovaginal melanoma. All cases should be tested for at least c-KIT and BRAF V600E mutations. Patients with vulvovaginal melanomas should be strongly encouraged to participate in clinical trials. ",Journal Article,2211.0,20.0,Melanomas arising vulva vagina rare minimal specific malignancies extrapolated cutaneous melanomas appropriate Surgery remains primary treatment modality initial diagnosis select recurrent cases Wide local excision primary lesion requiring exenteration sentinel lymph node SLN mapping routinely considered vulvar melanomas Local excision SLN mapping difficult considered vaginal melanomas Primary exenterative procedures routinely offered locally advanced cases potentially requiring exenterative procedure radiation therapy concurrent immunotherapy consideration role adjuvant therapy remains unclear Surgery radiation therapy considered recurrent cases Systemic chemotherapy agents modest response rate associated poor survival outcomes Novel immunotherapeutic targeted agents reported improve survival melanoma considered cases vulvovaginal melanoma cases tested c-KIT BRAF V600E Patients vulvovaginal melanomas strongly encouraged participate clinical trials,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1965, 2635, 4, 3, 9263, 2, 7553, 32, 622, 2, 673, 125, 16, 1048, 74, 112, 6, 46, 441, 74, 32, 629, 10727, 29, 127, 1486, 1965, 92, 68, 15, 68, 44, 40, 870, 152, 469, 3, 86, 24, 1396, 28, 388, 147, 2, 4, 1717, 387, 140, 1019, 293, 1366, 1, 3, 86, 1180, 44, 1888, 35, 5668, 1510, 5, 1323, 263, 289, 1099, 2568, 257, 40, 3066, 515, 4, 1965, 293, 1366, 2, 1099, 2568, 16, 1740, 2, 629, 44, 515, 9, 1965, 86, 23501, 1369, 257, 44, 40, 3066, 2216, 4, 795, 131, 140, 751, 1888, 35, 23501, 1299, 121, 36, 5, 15, 187, 750, 726, 16, 8, 2415, 3, 200, 1, 249, 36, 469, 1200, 152, 15, 121, 36, 122, 40, 515, 4, 387, 140, 403, 56, 183, 47, 8, 1721, 51, 116, 5, 41, 334, 25, 123, 229, 3222, 2, 238, 183, 47, 85, 210, 6, 401, 25, 4, 2, 257, 40, 515, 4, 140, 1, 18998, 62, 140, 257, 40, 650, 9, 28, 506, 256, 1164, 2, 566, 2047, 138, 7, 5, 18998, 1965, 257, 40, 1327, 5865, 6, 3506, 4, 38, 143]",1283.0,24857113,Management vulvar vaginal melanomas current future strategies,0,0.0
Treatment-related amenorrhea and sexual functioning in young breast cancer survivors.,Cancer,Cancer,2014-05-28,"Sexual dysfunction is a known complication of adjuvant therapy for breast cancer and an important determinant of quality of life. However, few studies have explored how treatment and other factors affect sexual functioning in young breast cancer survivors. Four hundred sixty-one premenopausal women with stage 0 through III breast cancer were surveyed an average of 1 year after diagnosis as part of a prospective cohort study of women who were aged 40 years at diagnosis. Sexual interest and dysfunction were assessed using the Cancer Rehabilitation Evaluation System (CARES). Mean CARES scores were compared and multiple regression models were fit to assess treatment and a range of menopausal and somatic symptoms in relation to sexual functioning. Mean CARES sexual interest and dysfunction scores were both highest (indicating poorer functioning) among women who received chemotherapy and were amenorrheic from treatment. After accounting for menopausal and somatic symptoms, treatment-associated amenorrhea remained associated with decreased interest but was no longer an independent predictor of dysfunction. In the multivariable analysis, independent predictors of dysfunction included vaginal pain symptoms, poorer body image, and fatigue. Sexual interest was associated with vaginal pain symptoms, body image, and weight problems. Factors associated with decreased sexual functioning in young breast cancer survivors can often be ameliorated. The current findings have implications for premenopausal women with other types of cancer who might be experiencing amenorrhea because of chemotherapy or surgery. Increased awareness and early intervention is essential to help improve sexual functioning and associated quality of life for all young cancer survivors.",Journal Article,2064.0,45.0,Sexual dysfunction known complication adjuvant therapy breast important determinant quality life studies explored treatment factors affect sexual functioning young breast survivors sixty-one premenopausal women stage 0 III breast surveyed average 1 year diagnosis prospective cohort women aged 40 years diagnosis Sexual dysfunction assessed Rehabilitation Evaluation CARES Mean CARES scores compared multiple regression models fit assess treatment range menopausal somatic symptoms relation sexual functioning Mean CARES sexual dysfunction scores highest indicating poorer functioning women received chemotherapy amenorrheic treatment accounting menopausal somatic symptoms treatment-associated amenorrhea remained associated decreased longer independent predictor dysfunction multivariable independent predictors dysfunction included vaginal pain symptoms poorer body image fatigue Sexual associated vaginal pain symptoms body image weight problems Factors associated decreased sexual functioning young breast survivors ameliorated current findings implications premenopausal women types experiencing amenorrhea chemotherapy surgery Increased awareness early intervention essential help improve sexual functioning associated quality life young survivors,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2232, 1527, 16, 8, 440, 1447, 1, 249, 36, 9, 12, 2, 35, 305, 4372, 1, 372, 1, 358, 137, 1021, 94, 47, 1443, 832, 24, 2, 127, 130, 1158, 2232, 2702, 4, 1169, 12, 332, 294, 1128, 1746, 104, 2710, 117, 5, 82, 13, 298, 316, 12, 11, 3696, 35, 1011, 1, 14, 111, 50, 147, 22, 760, 1, 8, 482, 180, 45, 1, 117, 54, 11, 1032, 12437, 60, 28, 147, 2232, 1333, 2, 1527, 11, 275, 75, 3, 12, 4182, 451, 398, 22355, 313, 22355, 703, 11, 72, 2, 232, 320, 274, 11, 2975, 6, 423, 24, 2, 8, 184, 1, 3565, 2, 1119, 507, 4, 2191, 6, 2232, 2702, 313, 22355, 2232, 1333, 2, 1527, 703, 11, 110, 1076, 1716, 1769, 2702, 107, 117, 54, 103, 56, 2, 11, 31561, 29, 24, 50, 3116, 9, 3565, 2, 1119, 507, 24, 41, 9373, 958, 41, 5, 340, 1333, 84, 10, 77, 589, 35, 306, 980, 1, 1527, 4, 3, 658, 65, 306, 674, 1, 1527, 159, 559, 507, 1769, 642, 1482, 2, 613, 2232, 1333, 10, 41, 5, 559, 507, 642, 1482, 2, 924, 2408, 130, 41, 5, 340, 2232, 2702, 4, 1169, 12, 332, 122, 629, 40, 13841, 3, 291, 272, 47, 1268, 9, 2710, 117, 5, 127, 630, 1, 12, 54, 822, 40, 2985, 9373, 408, 1, 56, 15, 152, 101, 3310, 2, 191, 788, 16, 1452, 6, 987, 401, 2232, 2702, 2, 41, 372, 1, 358, 9, 62, 1169, 12, 332]",1704.0,24891236,Treatment-related amenorrhea sexual functioning young breast survivors,0,0.0
Patient preferences for side effects associated with cervical cancer treatment.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2014-07-01,"The aim of this study was to assess patient preferences regarding side effects associated with cervical cancer treatment. The visual analog scale (VAS) and modified standard gamble (SG) were used to elicit preferences of women with no evidence of disease after primary treatment of cervical cancer. Higher scores on VAS and SG indicated more favorable ratings for a given health state. Health states (HS) included vaginal shortening, diarrhea, dietary changes, menopause, moderate nausea/vomiting, rectal bleeding, sexual dysfunction, and urinary self-catheterization. Descriptive statistics, Kruskal-Wallis, Mann-Whitney U, and Wilcoxon signed-ranks tests and correlation coefficients were used for statistical analysis. Seventy-eight patients participated in the study. Median age was 44.1 years (range, 24.9-67.8 years). Median time since treatment completion was 31.2 months (range, 1.0-113.3 months). The HSs rated as most favorable by VAS were also rated as most favorable by SG. Increasing age was associated with higher VAS scores for menopause and vaginal shortening (P = 0.04 and 0.036). African Americans had higher VAS scores for dietary changes (P = 0.05), sexual dysfunction (P = 0.028), and diarrhea (P = 0.05) when compared with Hispanic and non-Hispanic white patients. Women receiving radiation had more favorable VAS scores for menopause compared with women undergoing radical hysterectomy (P = 0.05). Women receiving chemotherapy rated urinary self-catheterization less favorably by VAS score compared with those not receiving chemotherapy (P = 0.045). Multiple demographic and clinical factors influence the severity of treatment-related adverse effects perceived by women surviving cervical cancer. A better understanding of factors influencing patient preferences regarding treatment side effects will allow providers to formulate care better tailored to the individual desires of each patient.",Journal Article,2030.0,5.0,aim assess patient preferences effects associated cervical treatment visual analog scale VAS modified standard gamble SG elicit preferences women evidence disease primary treatment cervical Higher scores VAS SG indicated favorable ratings given health state Health states HS included vaginal shortening diarrhea dietary changes menopause moderate nausea/vomiting rectal bleeding sexual dysfunction urinary self-catheterization Descriptive statistics Kruskal-Wallis Mann-Whitney U Wilcoxon signed-ranks tests correlation coefficients statistical Seventy-eight patients participated Median age 44.1 years range 24.9-67.8 years Median time treatment completion 31.2 months range 1.0-113.3 months HSs rated favorable VAS rated favorable SG Increasing age associated higher VAS scores menopause vaginal shortening P 0.04 0.036 African Americans higher VAS scores dietary changes P 0.05 sexual dysfunction P 0.028 diarrhea P 0.05 compared Hispanic non-Hispanic white patients Women receiving radiation favorable VAS scores menopause compared women undergoing radical hysterectomy P 0.05 Women receiving chemotherapy rated urinary self-catheterization favorably VAS score compared receiving chemotherapy P 0.045 Multiple demographic clinical factors influence severity treatment-related adverse effects perceived women surviving cervical better understanding factors influencing patient preferences treatment effects allow providers formulate care better tailored individual desires patient,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,"[3, 1130, 1, 26, 45, 10, 6, 423, 69, 2875, 666, 1152, 176, 41, 5, 12, 24, 3, 3046, 3497, 1124, 8458, 2, 1230, 260, 19561, 7995, 11, 95, 6, 5487, 2875, 1, 117, 5, 77, 241, 1, 34, 50, 86, 24, 1, 12, 142, 703, 23, 8458, 2, 7995, 1103, 80, 913, 5548, 9, 8, 447, 341, 1309, 341, 907, 5871, 159, 9245, 1172, 2013, 400, 5034, 1163, 1218, 1966, 2294, 2232, 1527, 2, 1660, 1074, 15173, 3778, 3065, 8800, 8875, 7470, 7471, 1767, 2, 3896, 7717, 14740, 895, 2, 816, 5161, 11, 95, 9, 1050, 65, 2073, 659, 7, 3025, 4, 3, 45, 52, 89, 10, 584, 14, 60, 184, 259, 83, 598, 66, 60, 52, 98, 1192, 24, 1438, 10, 456, 18, 53, 184, 14, 13, 4259, 27, 53, 3, 64475, 3982, 22, 96, 913, 20, 8458, 11, 120, 3982, 22, 96, 913, 20, 7995, 602, 89, 10, 41, 5, 142, 8458, 703, 9, 5034, 2, 9245, 19, 13, 755, 2, 13, 5395, 1410, 2731, 42, 142, 8458, 703, 9, 2013, 400, 19, 13, 474, 2232, 1527, 19, 13, 4836, 2, 1172, 19, 13, 474, 198, 72, 5, 1776, 2, 220, 1776, 886, 7, 117, 357, 121, 42, 80, 913, 8458, 703, 9, 5034, 72, 5, 117, 479, 711, 2622, 19, 13, 474, 117, 357, 56, 3982, 1660, 1074, 15173, 299, 5001, 20, 8458, 368, 72, 5, 135, 44, 357, 56, 19, 13, 4918, 232, 1540, 2, 38, 130, 1054, 3, 1702, 1, 24, 139, 290, 176, 2588, 20, 117, 3050, 12, 8, 380, 612, 1, 130, 4743, 69, 2875, 666, 24, 1152, 176, 303, 1700, 1994, 6, 10992, 165, 380, 3632, 6, 3, 797, 27248, 1, 296, 69]",1804.0,24905618,Patient preferences effects associated cervical treatment,0,0.0
Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen.,Clinical breast cancer,Clin. Breast Cancer,2014-06-02,"In premenopausal women with breast cancer, standard adjuvant endocrine therapy has been 5 years of tamoxifen. This study sought to investigate the safety and feasibility of treating patients who remain premenopausal after adjuvant tamoxifen with gonadotropin-releasing hormone agonist (GnRH-a) concurrent with an aromatase inhibitor, mimicking the strategy that has proven effective in postmenopausal patients. This phase II single-arm clinical trial aimed to enroll 50 premenopausal women who had completed > 4.5 years of adjuvant tamoxifen for a 2-year course of leuprolide (7.5 mg intramuscularly monthly or 22.5 mg intramuscularly every 3months) and letrozole (2.5 mg orally daily). Zoledronic acid (4 mg intravenously every 6 months) was offered optionally to help prevent bone loss. Despite aggressive recruitment strategies at the 3 participating sites (including Dana-Farber Cancer Institute), poor accrual over 3.5 years ultimately led to early study closure after only 16patients began therapy. Of the 16, 4 stopped treatment before 1 year, owing to toxicity; 5 completed 2 years of protocol-directed therapy; and 7 remained on treatment as of September 1, 2013, for an average of 53.5 weeks (SD,17.2 weeks). Hot flashes, vaginal dryness, and pain were common toxicities. Extended therapy with GnRH-a and an aromatase inhibitor (plus optional bisphosphonate) is associated with substantial side effects in premenopausal women who have already completed > 4.5 years of adjuvant tamoxifen. This study's poor accrual suggests that young women may not be highly motivated to pursue lengthier courses of endocrine therapy and that future studies of this approach may be challenging.","Clinical Trial, Phase II",2059.0,8.0,premenopausal women breast standard adjuvant endocrine therapy 5 years tamoxifen sought investigate safety feasibility treating patients remain premenopausal adjuvant tamoxifen gonadotropin-releasing hormone agonist GnRH-a concurrent aromatase inhibitor mimicking strategy proven effective postmenopausal patients phase II single-arm clinical trial aimed enroll 50 premenopausal women completed 4.5 years adjuvant tamoxifen 2-year course leuprolide 7.5 mg intramuscularly monthly 22.5 mg intramuscularly 3 months letrozole 2.5 mg orally daily Zoledronic acid 4 mg intravenously 6 months offered optionally help prevent bone loss Despite aggressive recruitment strategies 3 participating sites including Dana-Farber Institute poor accrual 3.5 years ultimately led early closure 16 patients began therapy 16 4 stopped treatment 1 year owing toxicity 5 completed 2 years protocol-directed therapy 7 remained treatment September 1 2013 average 53.5 weeks SD 17.2 weeks Hot flashes vaginal dryness pain common toxicities Extended therapy GnRH-a aromatase inhibitor plus optional bisphosphonate associated substantial effects premenopausal women completed 4.5 years adjuvant tamoxifen 's poor accrual suggests young women highly motivated pursue lengthier courses endocrine therapy future studies approach challenging,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4, 2710, 117, 5, 12, 260, 249, 1293, 36, 71, 85, 33, 60, 1, 1105, 26, 45, 990, 6, 963, 3, 367, 2, 1437, 1, 1367, 7, 54, 918, 2710, 50, 249, 1105, 5, 6501, 5586, 785, 3821, 7926, 8, 750, 5, 35, 2106, 230, 8191, 3, 692, 17, 71, 1930, 323, 4, 1679, 7, 26, 124, 215, 226, 475, 38, 160, 1295, 6, 6559, 212, 2710, 117, 54, 42, 781, 39, 33, 60, 1, 249, 1105, 9, 8, 18, 111, 906, 1, 13106, 67, 33, 81, 12800, 3889, 15, 350, 33, 81, 12800, 454, 27, 53, 2, 2800, 18, 33, 81, 1428, 391, 4055, 971, 39, 81, 1672, 454, 49, 53, 10, 2216, 40486, 6, 987, 1682, 407, 550, 571, 3202, 422, 28, 3, 27, 3052, 633, 141, 4932, 4979, 12, 1377, 334, 2262, 252, 27, 33, 60, 2050, 836, 6, 191, 45, 4830, 50, 158, 245, 7, 4603, 36, 1, 3, 245, 39, 4403, 24, 348, 14, 111, 3421, 6, 155, 33, 781, 18, 60, 1, 1182, 1166, 36, 2, 67, 958, 23, 24, 22, 1, 2636, 14, 1346, 9, 35, 1011, 1, 699, 33, 244, 1270, 269, 18, 244, 2859, 4193, 15822, 2, 559, 11, 186, 385, 1747, 36, 5, 7926, 8, 2, 35, 2106, 230, 349, 9281, 7110, 16, 41, 5, 1281, 1152, 176, 4, 2710, 117, 54, 47, 3298, 781, 39, 33, 60, 1, 249, 1105, 26, 45, 292, 334, 2262, 844, 17, 1169, 117, 68, 44, 40, 561, 9252, 6, 7874, 64553, 1993, 1, 1293, 36, 2, 17, 508, 94, 1, 26, 353, 68, 40, 1950]",1632.0,24970714,Extended therapy letrozole ovarian suppression premenopausal patients breast tamoxifen,0,0.0
"Does intra-operative radiation at the time of pelvic exenteration improve survival for patients with recurrent, previously irradiated cervical, vaginal, or vulvar cancer?",Gynecologic oncology,Gynecol. Oncol.,2014-07-30,"To determine whether intra-operative radiation therapy (IORT) at the time of pelvic exenteration (PE) or laterally extended endopelvic resection (LEER) improves progression-free survival (PFS) in patients with recurrent, previously irradiated gynecologic cancers. We conducted a single institution retrospective review of patients who had undergone a complete PE for locally recurrent gynecologic cancer. Demographic and clinicopathologic data were collected. 32 patients were identified (2000-2012); 21 (66%) cervical cancer, 8 (25%) vaginal, and 3 (9%) vulvar cancer. All patients were previously irradiated. Twenty-one (66%) received IORT. Mean age was 51. Eight patients had a LEER, all with IORT. Median PFS and OS, respectively, for those with PE alone was 33 and 41 vs. 10 and 10 months for PE+IORT compared to 9 and 17 months for LEER+IORT (P=.04). Increasing tumor size negatively impacted PFS (hazard ratio 1.3; 95%CI 1.12-1.52). Margin status was not associated with survival. No patients undergoing LEER+IORT recurred only locally whereas 62% recurred with a distant component (+/- local). Patients with PE alone had mainly local (36%) and few (9%) distant recurrences compared to 31% local and 38% distant (+/- local) recurrences for those with PE+IORT. We failed to demonstrate that IORT changes survival and recurrence outcomes. However, patients with clinical indications for IORT at the time of PE have worse prognosis compared to those who do not require IORT. If the need for IORT is anticipated, the surgeon may consider performing a LEER to decrease local recurrence if cure is the goal or consider palliative treatment options.",Journal Article,2001.0,15.0,determine intra-operative radiation therapy IORT time pelvic exenteration PE laterally extended endopelvic resection LEER improves progression-free survival PFS patients recurrent previously irradiated gynecologic conducted single institution retrospective review patients undergone complete PE locally recurrent gynecologic Demographic clinicopathologic collected 32 patients identified 2000-2012 21 66 cervical 8 25 vaginal 3 9 vulvar patients previously irradiated Twenty-one 66 received IORT Mean age 51 patients LEER IORT Median PFS OS respectively PE 33 41 vs. 10 10 months PE+IORT compared 9 17 months LEER+IORT P=.04 Increasing size negatively impacted PFS hazard ratio 1.3 95 CI 1.12-1.52 Margin status associated survival patients undergoing LEER+IORT recurred locally 62 recurred distant component +/- local Patients PE mainly local 36 9 distant recurrences compared 31 local 38 distant +/- local recurrences PE+IORT failed demonstrate IORT changes survival recurrence outcomes patients clinical indications IORT time PE worse prognosis compared require IORT need IORT anticipated surgeon consider performing LEER decrease local recurrence cure goal consider palliative treatment options,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 317, 2392, 1208, 121, 36, 4158, 28, 3, 98, 1, 1110, 5668, 4878, 15, 17800, 1747, 64703, 170, 32313, 1804, 91, 115, 25, 300, 4, 7, 5, 387, 373, 2398, 1512, 163, 21, 426, 8, 226, 731, 459, 206, 1, 7, 54, 42, 1989, 8, 236, 4878, 9, 795, 387, 1512, 12, 1540, 2, 1399, 74, 11, 786, 531, 7, 11, 108, 1081, 1195, 239, 700, 12, 66, 243, 2, 27, 83, 12, 62, 7, 11, 373, 2398, 737, 104, 700, 103, 4158, 313, 89, 10, 725, 659, 7, 42, 8, 32313, 62, 5, 4158, 52, 300, 2, 118, 106, 9, 135, 5, 4878, 279, 10, 466, 2, 605, 105, 79, 2, 79, 53, 9, 4878, 4158, 72, 6, 83, 2, 269, 53, 9, 32313, 4158, 19, 755, 602, 30, 444, 2723, 4619, 300, 360, 197, 14, 27, 48, 58, 14, 133, 14, 653, 959, 156, 10, 44, 41, 5, 25, 77, 7, 479, 32313, 4158, 3363, 158, 795, 547, 744, 3363, 5, 8, 626, 1249, 293, 7, 5, 4878, 279, 42, 2615, 293, 511, 2, 1021, 83, 626, 1593, 72, 6, 456, 293, 2, 519, 626, 293, 1593, 9, 135, 5, 4878, 4158, 21, 1551, 6, 608, 17, 4158, 400, 25, 2, 146, 123, 137, 7, 5, 38, 2406, 9, 4158, 28, 3, 98, 1, 4878, 47, 639, 356, 72, 6, 135, 54, 1022, 44, 1353, 4158, 492, 3, 594, 9, 4158, 16, 4078, 3, 1897, 68, 2419, 3620, 8, 32313, 6, 775, 293, 146, 492, 1722, 16, 3, 1326, 15, 2419, 994, 24, 838]",1560.0,25084510,intra-operative radiation time pelvic exenteration improve survival patients recurrent previously irradiated cervical vaginal vulvar,2,0.010050251256281407
Definitive salvage for vaginal recurrence of endometrial cancer: the impact of modern intensity-modulated-radiotherapy with image-based HDR brachytherapy and the interplay of the PORTEC 1 risk stratification.,Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,Radiother Oncol,2014-09-18,"Data for salvage radiotherapy for recurrent endometrial cancer are limited especially in the era of modern radiotherapy including IMRT and 3-dimensional image-based HDR brachytherapy. Theoretically, modern radiotherapy reduces the dose to critical organs-at-risk and maximizes dose to the target volume, possibly decreasing morbidity and increasing tumor control. Forty-one patients completing definitive salvage radiotherapy for vaginal recurrence of endometrial cancer from June 2004 to December 2013 were retrospectively reviewed. HDR Brachytherapy was completed using image-based planning with contouring/optimization with each fraction to a median dose of 23.75 Gy in 5 fractions. HDR brachytherapy was preceded by external beam radiotherapy predominately using an IMRT technique (90%) to a median dose of 45 Gy in 25 fractions. Toxicity was reported according to CTCAEv4. At a median follow-up of 18 months (range: 3-78), the clinical complete response rate was 95%. The 3-year local control, distant control, recurrence free survival, and overall survival were 95%, 61%, 68%, and 67%. Significant predictors of both distant failure and overall survival were primary prognostic factors of depth of myometrial invasion, FIGO stage, and FIGO grade. There was no grade 3+ acute toxicity; the 3-year rate of grade 3+ late toxicity was 8%. Salvage IMRT plus 3-dimensional image-based HDR brachytherapy shows excellent tumor control and minimal morbidity for vaginal recurrence of endometrial cancer. Anticipated salvage rates must be taken in the context of primary risk factors including depth of myometrial invasion, FIGO stage, and FIGO grade.",Journal Article,1951.0,21.0,salvage radiotherapy recurrent endometrial limited especially era modern radiotherapy including IMRT 3-dimensional image-based HDR brachytherapy Theoretically modern radiotherapy reduces dose critical organs-at-risk maximizes dose target volume possibly decreasing morbidity increasing control Forty-one patients completing definitive salvage radiotherapy vaginal recurrence endometrial June 2004 December 2013 retrospectively reviewed HDR Brachytherapy completed image-based planning contouring/optimization fraction median dose 23.75 Gy 5 fractions HDR brachytherapy preceded external beam radiotherapy predominately IMRT technique 90 median dose 45 Gy 25 fractions Toxicity reported according CTCAEv4 median follow-up 18 months range 3-78 clinical complete response rate 95 3-year local control distant control recurrence free survival overall survival 95 61 68 67 Significant predictors distant failure overall survival primary prognostic factors depth myometrial invasion FIGO stage FIGO grade grade 3+ acute toxicity 3-year rate grade 3+ late toxicity 8 Salvage IMRT plus 3-dimensional image-based HDR brachytherapy shows excellent control minimal morbidity vaginal recurrence endometrial Anticipated salvage rates taken context primary risk factors including depth myometrial invasion FIGO stage FIGO grade,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[74, 9, 992, 310, 9, 387, 12, 32, 383, 1093, 4, 3, 1713, 1, 2366, 310, 141, 964, 2, 27, 2201, 1482, 90, 5309, 1536, 9662, 2366, 310, 2389, 3, 61, 6, 740, 2285, 28, 43, 2, 15939, 61, 6, 3, 283, 433, 2150, 2777, 787, 2, 602, 30, 182, 1213, 104, 7, 4144, 1057, 992, 310, 9, 146, 1, 12, 29, 1924, 1131, 6, 1397, 1346, 11, 894, 446, 5309, 1536, 10, 781, 75, 1482, 90, 1349, 5, 7997, 3980, 5, 296, 1509, 6, 8, 52, 61, 1, 382, 481, 381, 4, 33, 1550, 5309, 1536, 10, 6083, 20, 1455, 1345, 310, 11583, 75, 35, 964, 1312, 424, 6, 8, 52, 61, 1, 512, 381, 4, 243, 1550, 155, 10, 210, 768, 6, 48024, 28, 8, 52, 166, 126, 1, 203, 53, 184, 27, 833, 3, 38, 236, 51, 116, 10, 48, 3, 27, 111, 293, 182, 626, 182, 146, 115, 25, 2, 63, 25, 11, 48, 713, 806, 2, 598, 93, 674, 1, 110, 626, 496, 2, 63, 25, 11, 86, 177, 130, 1, 2436, 1, 7327, 578, 3837, 82, 2, 3837, 88, 125, 10, 77, 88, 27, 286, 155, 3, 27, 111, 116, 1, 88, 27, 807, 155, 10, 66, 992, 964, 349, 27, 2201, 1482, 90, 5309, 1536, 1949, 1503, 30, 182, 2, 1048, 787, 9, 146, 1, 12, 4078, 992, 151, 1642, 40, 1633, 4, 3, 1533, 1, 86, 43, 130, 141, 2436, 1, 7327, 578, 3837, 82, 2, 3837, 88]",1557.0,25241996,Definitive salvage vaginal recurrence endometrial impact modern intensity-modulated-radiotherapy image-based HDR brachytherapy interplay PORTEC 1 risk stratification,0,0.0
Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2014-11-01,"Carcinosarcomas (also known as malignant mixed mllerian tumors) are rare and highly aggressive epithelial malignancies that contain both malignant sarcomatous and carcinomatous elements. Uterine carcinosarcomas (UCs) are uncommon with approximately more than 35% presenting with extra uterine disease at diagnosis. Up to 90% ovarian carcinosarcomas (OCs) will have disease that has spread beyond the ovary. Prognosis for localized stage disease is poor with a high risk of recurrences, both local and distant, occurring within 1 year. The survival of women with advanced UC or OC is worse than survival of endometrioid or high-grade serous histologies. No improvement in survival rates has been observed in the past few decades with an overall median survival of less than 2 years. Currently, there is no clear evidence to establish consensus guidelines for therapeutic management of carcinosarcomas. Until recently, gynecological carcinosarcomas were considered as a subtype of sarcoma and treated as such. However, carcinosarcomas are now known to be metaplastic carcinomas and so should be treated as endometrial or ovarian high-risk carcinomas, despite the lack of specific data. For UCs, a comprehensive approach to management is recommended with complete surgical staging followed by systemic chemotherapy in patients with both early and advanced stage disease. Active agents include paraplatin, cisplatin, ifosfamide, and paclitaxel. The combination of carboplatin-paclitaxel is the most commonly used regimen in the adjuvant and advanced setting. Adjuvant radiotherapy (external beam irradiation and/or vaginal brachytherapy) has not shown any overall survival benefit but has been reported to decrease local recurrences. For OCs and for other ovarian epithelial cancer, the mainstay of treatment remains cytoreductive surgical effort followed, even in early stage, by platinum-based chemotherapy, usually carboplatin-paclitaxel. ",Journal Article,1907.0,43.0,Carcinosarcomas known malignant mixed mllerian rare highly aggressive epithelial malignancies contain malignant sarcomatous carcinomatous elements Uterine carcinosarcomas UCs uncommon approximately 35 presenting extra uterine disease diagnosis 90 ovarian carcinosarcomas OCs disease spread ovary Prognosis localized stage disease poor high risk recurrences local distant occurring 1 year survival women advanced UC OC worse survival endometrioid high-grade serous histologies improvement survival rates observed past decades overall median survival 2 years Currently clear evidence establish consensus guidelines therapeutic management carcinosarcomas recently gynecological carcinosarcomas considered subtype sarcoma treated carcinosarcomas known metaplastic carcinomas treated endometrial ovarian high-risk carcinomas despite lack specific UCs comprehensive approach management recommended complete surgical staging followed systemic chemotherapy patients early advanced stage disease Active agents include paraplatin cisplatin ifosfamide paclitaxel combination carboplatin-paclitaxel commonly regimen adjuvant advanced setting Adjuvant radiotherapy external beam irradiation and/or vaginal brachytherapy shown overall survival benefit reported decrease local recurrences OCs ovarian epithelial mainstay treatment remains cytoreductive surgical effort followed early stage platinum-based chemotherapy usually carboplatin-paclitaxel,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,"[12885, 120, 440, 22, 393, 1739, 9751, 57, 32, 622, 2, 561, 571, 701, 441, 17, 3725, 110, 393, 10445, 2, 14085, 2531, 12885, 10933, 32, 2052, 5, 705, 80, 76, 465, 1656, 5, 3420, 34, 28, 147, 126, 6, 424, 12885, 8002, 303, 47, 34, 17, 71, 2579, 1654, 3, 3631, 356, 9, 909, 82, 34, 16, 334, 5, 8, 64, 43, 1, 1593, 110, 293, 2, 626, 1821, 262, 14, 111, 3, 25, 1, 117, 5, 131, 2417, 15, 2950, 16, 639, 76, 25, 1, 3151, 15, 64, 88, 1744, 3489, 77, 767, 4, 25, 151, 71, 85, 164, 4, 3, 1219, 1021, 1968, 5, 35, 63, 52, 25, 1, 299, 76, 18, 60, 694, 125, 16, 77, 885, 241, 6, 1811, 1391, 677, 9, 189, 284, 1, 12885, 1100, 761, 6324, 12885, 11, 515, 22, 8, 875, 1, 2, 73, 22, 225, 137, 12885, 32, 1134, 440, 6, 40, 7779, 826, 2, 1743, 257, 40, 73, 22, 15, 64, 43, 826, 550, 3, 926, 1, 112, 74, 9, 10933, 8, 949, 353, 6, 284, 16, 793, 5, 236, 221, 632, 370, 20, 403, 56, 4, 7, 5, 110, 191, 2, 131, 82, 34, 544, 183, 643, 27971, 540, 3157, 2, 490, 3, 150, 1, 927, 490, 16, 3, 96, 841, 95, 477, 4, 3, 249, 2, 131, 546, 249, 310, 1455, 1345, 1104, 2, 15, 1536, 71, 44, 443, 500, 63, 25, 247, 84, 71, 85, 210, 6, 775, 293, 1593, 9, 8002, 2, 9, 127, 701, 12, 3, 4041, 1, 24, 469, 2604, 221, 2919, 370, 871, 4, 191, 82, 20, 828, 90, 56, 2082, 927, 490]",1832.0,25341582,Gynecologic InterGroup GCIG consensus review uterine ovarian carcinosarcoma,51,0.2562814070351759
Clinical and treatment factors associated with vaginal stenosis after definitive chemoradiation for anal canal cancer.,Practical radiation oncology,Pract Radiat Oncol,2014-10-30,"We sought to evaluate the incidence of vaginal stenosis (VS) and identify clinical and treatment factors that predict for VS in female patients with anal cancer treated with definitive chemoradiation. The cohort included 95 consecutive women receiving definitive chemoradiation between 2003 and 2012. All but 1 received intensity modulated radiation therapy; median primary tumor dose 50.4 Gy (range, 41.4-60). A modified National Cancer Institute Common Terminology Criteria for Adverse Events version 4 was used to score VS based on the medical record description of dyspareunia, pain with dilator use, vaginal dryness, or difficult pelvic examination. Ordered logistic regression was performed to assess VS predictors. Median age was 60.4 years (range, 19-97). With median follow-up of 2.5 years, 70 women (74%) had adequate information to assess VS. Of these, VS grade distribution was 21.4% grade 0, 14.3% grade 1, 27.1% grade 2, and 37.1% grade 3. By multivariable ordered logistic regression, younger age (P = .02), higher tumor dose (P = .06), and earlier treatment year (P = .04) were associated with higher grade of VS. VS is a common late complication in women treated definitively with chemoradiation for anal canal cancer. Younger age, higher tumor dose, and earlier year of treatment were associated with a higher grade of stenosis. Prospective investigation into patient reported outcomes is warranted, including sexual function and VS prevention strategies to better understand its effect on long-term survivorship.",Clinical Study,1909.0,15.0,sought evaluate incidence vaginal stenosis VS identify clinical treatment factors predict VS female patients anal treated definitive chemoradiation cohort included 95 consecutive women receiving definitive chemoradiation 2003 2012 1 received intensity modulated radiation therapy median primary dose 50.4 Gy range 41.4-60 modified National Institute Common Terminology Criteria Adverse Events version 4 score VS based medical record description dyspareunia pain dilator use vaginal dryness difficult pelvic examination Ordered logistic regression performed assess VS predictors Median age 60.4 years range 19-97 median follow-up 2.5 years 70 women 74 adequate information assess VS. VS grade distribution 21.4 grade 0 14.3 grade 1 27.1 grade 2 37.1 grade 3 multivariable ordered logistic regression younger age P .02 higher dose P .06 earlier treatment year P .04 associated higher grade VS. VS common late complication women treated definitively chemoradiation anal canal Younger age higher dose earlier year treatment associated higher grade stenosis Prospective investigation patient reported outcomes warranted including sexual function VS prevention strategies better understand effect long-term survivorship,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 990, 6, 376, 3, 287, 1, 6935, 105, 2, 255, 38, 2, 24, 130, 17, 678, 9, 105, 4, 1061, 7, 5, 12, 73, 5, 1057, 975, 3, 180, 159, 48, 935, 117, 357, 1057, 975, 59, 1522, 2, 1195, 62, 84, 14, 103, 837, 1757, 121, 36, 52, 86, 30, 61, 212, 39, 381, 184, 605, 39, 335, 8, 1230, 657, 12, 1377, 186, 3462, 371, 9, 290, 281, 2256, 39, 10, 95, 6, 368, 105, 90, 23, 3, 484, 3237, 5263, 1, 22098, 559, 5, 17967, 119, 15822, 15, 1740, 1110, 1385, 7591, 812, 320, 10, 173, 6, 423, 105, 674, 52, 89, 10, 335, 39, 60, 184, 326, 1015, 5, 52, 166, 126, 1, 18, 33, 60, 431, 117, 794, 42, 1658, 487, 6, 423, 105, 1, 46, 105, 88, 1395, 10, 239, 39, 88, 13, 213, 27, 88, 14, 428, 14, 88, 18, 2, 567, 14, 88, 27, 20, 658, 7591, 812, 320, 773, 89, 19, 588, 142, 30, 61, 19, 1460, 2, 1677, 24, 111, 19, 755, 11, 41, 5, 142, 88, 1, 105, 105, 16, 8, 186, 807, 1447, 4, 117, 73, 6008, 5, 975, 9, 5614, 12, 773, 89, 142, 30, 61, 2, 1677, 111, 1, 24, 11, 41, 5, 8, 142, 88, 1, 6935, 482, 940, 237, 69, 210, 123, 16, 1197, 141, 2232, 343, 2, 105, 1070, 422, 6, 380, 1640, 211, 254, 23, 319, 337, 2560]",1453.0,25424587,Clinical treatment factors associated vaginal stenosis definitive chemoradiation anal canal,5,0.02512562814070352
Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer.,Obstetrics and gynecology,Obstet Gynecol,2014-11-01,"To investigate whether tumor cells could be detected in the vagina of women with serous ovarian cancer through TP53 analysis of DNA samples collected by placement of a vaginal tampon. Women undergoing surgery for a pelvic mass were identified in the gynecologic oncology clinic. They placed a vaginal tampon before surgery, which was removed in the operating room. Cells were isolated and DNA was extracted from both the cells trapped within the tampon and the primary tumor. In patients with serous carcinoma, the DNA was interrogated for the presence of TP53 mutations using a method capable of detecting rare mutant alleles in a mixture of mutant and wild-type DNA. Thirty-three patients were enrolled. Eight patients with advanced serous ovarian cancer were included for analysis. Three had a prior tubal ligation. TP53 mutations were identified in all eight tumor samples. Analysis of the DNA from the tampons revealed mutations in three of the five patients with intact tubes (sensitivity 60%) and in none of the three patients with tubal ligation. In all three participants with mutation detected in the tampon specimen, the tumor and the vaginal DNA harbored the exact same TP53 mutation. The fraction of DNA derived from exfoliated tumor cells ranged from 0.01% to 0.07%. In this pilot study, DNA derived from tumor was detected in the vaginas of 60% of patients with ovarian cancer with intact fallopian tubes. With further development, this approach may hold promise for the early detection of this deadly disease.",Clinical Trial,1907.0,16.0,investigate detected vagina women serous ovarian TP53 DNA collected placement vaginal tampon Women undergoing surgery pelvic mass identified gynecologic oncology clinic placed vaginal tampon surgery removed operating room isolated DNA extracted trapped tampon primary patients serous carcinoma DNA interrogated presence TP53 capable detecting rare alleles mixture wild-type DNA Thirty-three patients enrolled patients advanced serous ovarian included prior tubal ligation TP53 identified DNA tampons revealed patients intact tubes sensitivity 60 patients tubal ligation participants detected tampon specimen vaginal DNA harbored exact TP53 fraction DNA derived exfoliated ranged 0.01 0.07 pilot DNA derived detected vaginas 60 patients ovarian intact fallopian tubes development approach hold promise early detection deadly disease,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 963, 317, 30, 37, 359, 40, 530, 4, 3, 7553, 1, 117, 5, 1744, 12, 298, 1206, 65, 1, 261, 347, 786, 20, 2613, 1, 8, 25657, 117, 479, 152, 9, 8, 1110, 782, 11, 108, 4, 3, 1512, 413, 1188, 491, 3295, 8, 25657, 348, 152, 92, 10, 2264, 4, 3, 2584, 4698, 37, 11, 1355, 2, 261, 10, 2484, 29, 110, 3, 37, 23885, 262, 3, 25657, 2, 3, 86, 30, 4, 7, 5, 1744, 134, 3, 261, 10, 7227, 9, 3, 463, 1, 1206, 138, 75, 8, 596, 2787, 1, 2502, 622, 620, 2558, 4, 8, 6972, 1, 620, 2, 955, 267, 261, 977, 169, 7, 11, 346, 659, 7, 5, 131, 1744, 12, 11, 159, 9, 65, 169, 42, 8, 324, 6674, 5307, 1206, 138, 11, 108, 4, 62, 659, 30, 347, 65, 1, 3, 261, 29, 3, 48703, 553, 138, 4, 169, 1, 3, 365, 7, 5, 2964, 6193, 485, 335, 2, 4, 1292, 1, 3, 169, 7, 5, 6674, 5307, 4, 62, 169, 776, 5, 258, 530, 4, 3, 25657, 2360, 3, 30, 2, 3, 261, 3253, 3, 2472, 827, 1206, 258, 3, 1509, 1, 261, 526, 29, 24604, 30, 37, 1869, 29, 13, 355, 6, 13, 1615, 4, 26, 2281, 45, 261, 526, 29, 30, 10, 530, 4, 3, 65226, 1, 335, 1, 7, 5, 12, 5, 2964, 6193, 5, 195, 193, 26, 353, 68, 4164, 1783, 9, 3, 191, 638, 1, 26, 6610, 34]",1442.0,25437714,Detection somatic TP53 tampons patients high-grade serous ovarian,0,0.0
Image-based multichannel vaginal cylinder brachytherapy for vaginal cancer.,Brachytherapy,Brachytherapy,2014-11-12,"To investigate the clinical feasibility and treatment outcomes of image-based high-dose-rate (HDR) brachytherapy using an intracavitary multichannel vaginal cylinder for the definitive treatment of vaginal cancers. A total of 41 patients with vaginal cancer (24% primary vaginal and 76% recurrence from other gynecologic primaries) treated with definitive radiotherapy  chemotherapy including image-based HDR brachytherapy with a multichannel vaginal cylinder were included in the study. Image-based brachytherapy was completed using either CT- (41%) or MR-based planning (59%) with each fraction. The high-risk clinical target volume was defined based on the pre- and postexternal beam radiotherapy gross tumor volume. Doses were converted to equivalent dose of 2Gy per fraction. Endpoints examined were dose-volume parameters and early clinical outcomes. The median high-risk clinical target volume was 24.2 cc (interquartile range [IQR], 12.6), with a median dose to 90% (D90) of 77.1 Gy (IQR, 3.4). The median dose to 2 cc (D(2 cc)) for the bladder, rectum, and sigmoid were 59.4 Gy (IQR, 5.6), 58.2 Gy (IQR, 4.1), and 52.3 Gy (IQR, 5.5), respectively. After a median followup of 16 months (range, 3-35), complete clinical response was documented in 98% of the patients. The 2-year local, regional, and distant control; and disease-free and overall survival were 93%, 100%, 81%, 78%, and 88%, respectively. The 2-year actuarial rate of late Grade 3 or higher toxicity was 4% overall with 0%, 0%, 0%, and 4% for vaginal, bladder, urethral, and gastrointestinal, respectively. Image-based HDR brachytherapy using an intracavitary multichannel cylinder seems feasible in definitive vaginal cancer treatment. The described clinical implementation shows promising early clinical outcomes with high rates of local control and little toxicity, which should be validated with extended followup.",Evaluation Study,1896.0,10.0,investigate clinical feasibility treatment outcomes image-based high-dose-rate HDR brachytherapy intracavitary multichannel vaginal cylinder definitive treatment vaginal total 41 patients vaginal 24 primary vaginal 76 recurrence gynecologic primaries treated definitive radiotherapy  chemotherapy including image-based HDR brachytherapy multichannel vaginal cylinder included Image-based brachytherapy completed CT- 41 MR-based planning 59 fraction high-risk clinical target volume defined based pre- postexternal beam radiotherapy gross volume Doses converted equivalent dose 2Gy fraction Endpoints examined dose-volume parameters early clinical outcomes median high-risk clinical target volume 24.2 cc interquartile range IQR 12.6 median dose 90 D90 77.1 Gy IQR 3.4 median dose 2 cc 2 cc bladder rectum sigmoid 59.4 Gy IQR 5.6 58.2 Gy IQR 4.1 52.3 Gy IQR 5.5 respectively median followup 16 months range 3-35 complete clinical response documented 98 patients 2-year local regional distant control disease-free overall survival 93 100 81 78 88 respectively 2-year actuarial rate late Grade 3 higher toxicity 4 overall 0 0 0 4 vaginal bladder urethral gastrointestinal respectively Image-based HDR brachytherapy intracavitary multichannel cylinder feasible definitive vaginal treatment described clinical implementation shows promising early clinical outcomes high rates local control little toxicity validated extended followup,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[6, 963, 3, 38, 1437, 2, 24, 123, 1, 1482, 90, 64, 61, 116, 5309, 1536, 75, 35, 9122, 19778, 23326, 9, 3, 1057, 24, 1, 163, 8, 181, 1, 605, 7, 5, 12, 259, 86, 2, 846, 146, 29, 127, 1512, 6183, 73, 5, 1057, 310, 810, 56, 141, 1482, 90, 5309, 1536, 5, 8, 19778, 23326, 11, 159, 4, 3, 45, 1482, 90, 1536, 10, 781, 75, 361, 425, 605, 15, 1638, 90, 1349, 728, 5, 296, 1509, 3, 64, 43, 38, 283, 433, 10, 395, 90, 23, 3, 671, 2, 65273, 1345, 310, 1789, 30, 433, 415, 11, 4764, 6, 2017, 61, 1, 23823, 379, 1509, 1387, 409, 11, 61, 433, 1038, 2, 191, 38, 123, 3, 52, 64, 43, 38, 283, 433, 10, 259, 18, 1951, 2899, 184, 2245, 133, 49, 5, 8, 52, 61, 6, 424, 13040, 1, 849, 14, 381, 2245, 27, 39, 3, 52, 61, 6, 18, 1951, 427, 18, 1951, 9, 3, 3660, 2, 9356, 11, 728, 39, 381, 2245, 33, 49, 717, 18, 381, 2245, 39, 14, 2, 653, 27, 381, 2245, 33, 33, 106, 50, 8, 52, 3569, 1, 245, 53, 184, 27, 465, 236, 38, 51, 10, 1405, 4, 1096, 1, 3, 7, 3, 18, 111, 293, 951, 2, 626, 182, 2, 34, 115, 2, 63, 25, 11, 966, 394, 865, 833, 2, 889, 106, 3, 18, 111, 2361, 116, 1, 807, 88, 27, 15, 142, 155, 10, 39, 63, 5, 13, 13, 13, 2, 39, 9, 2, 106, 1482, 90, 5309, 1536, 75, 35, 9122, 19778, 23326, 2744, 1313, 4, 1057, 12, 24, 3, 1027, 38, 2393, 1949, 721, 191, 38, 123, 5, 64, 151, 1, 293, 182, 2, 1215, 155, 92, 257, 40, 938, 5, 1747, 3569]",1708.0,25456026,Image-based multichannel vaginal cylinder brachytherapy vaginal,0,0.0
Recurrence patterns and survival endpoints in women with stage II uterine endometrioid carcinoma: a multi-institution study.,Gynecologic oncology,Gynecol. Oncol.,2014-12-12,"There is paucity of data in regard to prognostic factors and outcome of women with 2009 FIGO stage II disease. The objective of this study was to investigate prognostic factors, recurrence patterns and survival endpoints in this group of patients. Data from four academic institutions were analyzed. 130 women were identified with 2009 FIGO stage II. All patients underwent hysterectomy, oophorectomy and lymph node evaluation with or without pelvic and paraaortic lymph node dissections and peritoneal cytology. The Kaplan-Meier approach and Cox regression analysis were used to estimate recurrence-free (RFS), disease-specific (DSS) and overall survival (OS). Median follow-up was 44months. 120 patients (92%) underwent simple hysterectomy, 78% had lymph node dissection and 95% had peritoneal cytology examination. 99 patients (76%) received adjuvant radiation treatment (RT). 5-year RFS, DSS and OS were 77%, 90%, and 72%, respectively. On multivariate analysis of RFS, adjuvant RT, the presence of lymphovascular space invasion (LVSI) and high tumor grades were significant predictors. For DSS, LVSI and high tumor grades were significant predictors while older age and high tumor grade were the only predictors of OS. In this multi-institutional study, disease-specific survival for women with FIGO stage II uterine endometrioid carcinoma is excellent. High tumor grade, lymphovascular space invasion, adjuvant radiation treatment and old age are important prognostic factors. There was no significant difference in the outcome between patients who received vaginal cuff brachytherapy compared to those who received pelvic external beam radiation treatment.",Journal Article,1866.0,20.0,paucity regard prognostic factors outcome women 2009 FIGO stage II disease objective investigate prognostic factors recurrence patterns survival endpoints group patients academic institutions 130 women identified 2009 FIGO stage II patients underwent hysterectomy oophorectomy lymph node evaluation pelvic paraaortic lymph node dissections peritoneal cytology Kaplan-Meier approach Cox regression estimate recurrence-free RFS disease-specific DSS overall survival OS Median follow-up 44months 120 patients 92 underwent simple hysterectomy 78 lymph node dissection 95 peritoneal cytology examination 99 patients 76 received adjuvant radiation treatment RT 5-year RFS DSS OS 77 90 72 respectively multivariate RFS adjuvant RT presence lymphovascular space invasion LVSI high grades significant predictors DSS LVSI high grades significant predictors older age high grade predictors OS multi-institutional disease-specific survival women FIGO stage II uterine endometrioid carcinoma excellent High grade lymphovascular space invasion adjuvant radiation treatment old age important prognostic factors significant difference outcome patients received vaginal cuff brachytherapy compared received pelvic external beam radiation treatment,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[125, 16, 4832, 1, 74, 4, 2539, 6, 177, 130, 2, 228, 1, 117, 5, 1238, 3837, 82, 215, 34, 3, 461, 1, 26, 45, 10, 6, 963, 177, 130, 146, 764, 2, 25, 1387, 4, 26, 87, 1, 7, 74, 29, 294, 1916, 1764, 11, 311, 3431, 117, 11, 108, 5, 1238, 3837, 82, 215, 62, 7, 208, 2622, 3470, 2, 263, 289, 451, 5, 15, 187, 1110, 2, 7401, 263, 289, 6894, 2, 1639, 2045, 3, 876, 882, 353, 2, 418, 320, 65, 11, 95, 6, 1191, 146, 115, 1272, 34, 112, 1788, 2, 63, 25, 118, 52, 166, 126, 10, 65337, 2031, 7, 937, 208, 2763, 2622, 833, 42, 263, 289, 1161, 2, 48, 42, 1639, 2045, 1385, 1058, 7, 846, 103, 249, 121, 24, 240, 33, 111, 1272, 1788, 2, 118, 11, 849, 424, 2, 720, 106, 23, 331, 65, 1, 1272, 249, 240, 3, 463, 1, 2933, 3865, 578, 8004, 2, 64, 30, 2276, 11, 93, 674, 9, 1788, 8004, 2, 64, 30, 2276, 11, 93, 674, 369, 434, 89, 2, 64, 30, 88, 11, 3, 158, 674, 1, 118, 4, 26, 1414, 1115, 45, 34, 112, 25, 9, 117, 5, 3837, 82, 215, 3151, 134, 16, 1503, 64, 30, 88, 2933, 3865, 578, 249, 121, 24, 2, 1095, 89, 32, 305, 177, 130, 125, 10, 77, 93, 523, 4, 3, 228, 59, 7, 54, 103, 11445, 1536, 72, 6, 135, 54, 103, 1110, 1455, 1345, 121, 24]",1597.0,25511158,Recurrence patterns survival endpoints women stage II uterine endometrioid carcinoma multi-institution,13,0.06532663316582915
Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma. A multi-institutional study.,Gynecologic oncology,Gynecol. Oncol.,2015-01-07,"To investigate the impact of adjuvant vaginal brachytherapy on vaginal recurrence in stage I non-invasive uterine papillary serous carcinoma (UPSC). This is a retrospective multi-institutional study from 2000-2012. 103 patients who underwent surgical treatment with non-invasive stage IA UPSC were included. 85% and 55% underwent staging lymphadenectomy and omentectomy respectively. 28.2% (29/103) developed recurrence. Vaginal, pelvic and extra-pelvic recurrences developed in 7.8% (8/103), 3.9% (4/103) and 16.5% (17/103) respectively. Among patients who were observed or received only chemotherapy, the rate of vaginal recurrence was 10.9% (7/64) compared to 2.6% (1/39) among those who received vaginal brachytherapy +/- chemotherapy (p=0.035). The rate of vaginal recurrence was not different between those who were observed and those who received only chemotherapy (9.3% vs. 14.3%, p=0.27). The 5-year progression free survival (PFS) and overall survival (OS) for the entire cohort were 88.3% and 90.6%. Patients who underwent surgical staging had longer PFS (p=0.001) and OS (p=0.0005) compared to those who did not. In multivariable analysis controlling for age, histology, chemotherapy, brachytherapy, and staging lymphadenectomy, only lymphadenectomy was an independent predictor of PFS (HR 0.28, 95% CI 0.11-0.71, p=0.0037) and OS (HR 0.27, 95% CI 0.10-0.71, p=0.0035). Neither chemotherapy nor brachytherapy were predictors of PFS or OS. This is the largest study reported in stage I non-invasive UPSC. The majority of recurrences were extra-pelvic. Vaginal brachytherapy has a significant role in reducing the risk of vaginal recurrence and surgical staging was the only predictor of outcome. Therefore, both should be considered in these patients.",Comparative Study,1840.0,9.0,investigate impact adjuvant vaginal brachytherapy vaginal recurrence stage non-invasive uterine papillary serous carcinoma UPSC retrospective multi-institutional 2000-2012 103 patients underwent surgical treatment non-invasive stage IA UPSC included 85 55 underwent staging lymphadenectomy omentectomy respectively 28.2 29/103 developed recurrence Vaginal pelvic extra-pelvic recurrences developed 7.8 8/103 3.9 4/103 16.5 17/103 respectively patients observed received chemotherapy rate vaginal recurrence 10.9 7/64 compared 2.6 1/39 received vaginal brachytherapy +/- chemotherapy p=0.035 rate vaginal recurrence different observed received chemotherapy 9.3 vs. 14.3 p=0.27 5-year progression free survival PFS overall survival OS entire cohort 88.3 90.6 Patients underwent surgical staging longer PFS p=0.001 OS p=0.0005 compared multivariable controlling age histology chemotherapy brachytherapy staging lymphadenectomy lymphadenectomy independent predictor PFS HR 0.28 95 CI 0.11-0.71 p=0.0037 OS HR 0.27 95 CI 0.10-0.71 p=0.0035 chemotherapy brachytherapy predictors PFS OS largest reported stage non-invasive UPSC majority recurrences extra-pelvic Vaginal brachytherapy significant role reducing risk vaginal recurrence surgical staging predictor outcome considered patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[6, 963, 3, 345, 1, 249, 1536, 23, 146, 4, 82, 70, 220, 416, 1796, 1744, 134, 5676, 26, 16, 8, 459, 1414, 1115, 45, 29, 1081, 1195, 3283, 7, 54, 208, 221, 24, 5, 220, 416, 82, 3302, 5676, 11, 159, 772, 2, 614, 208, 632, 2048, 2, 20196, 106, 339, 18, 462, 3283, 276, 146, 1110, 2, 3420, 1110, 1593, 276, 4, 67, 66, 66, 3283, 27, 83, 39, 3283, 2, 245, 33, 269, 3283, 106, 107, 7, 54, 11, 164, 15, 103, 158, 56, 3, 116, 1, 146, 10, 79, 83, 67, 660, 72, 6, 18, 49, 14, 587, 107, 135, 54, 103, 1536, 56, 19, 13, 4514, 3, 116, 1, 146, 10, 44, 338, 59, 135, 54, 11, 164, 2, 135, 54, 103, 158, 56, 83, 27, 105, 213, 27, 19, 13, 428, 3, 33, 111, 91, 115, 25, 300, 2, 63, 25, 118, 9, 3, 1797, 180, 11, 889, 27, 2, 424, 49, 7, 54, 208, 221, 632, 42, 589, 300, 19, 13, 144, 2, 118, 19, 13, 4252, 72, 6, 135, 54, 205, 44, 4, 658, 65, 1893, 9, 89, 784, 56, 1536, 2, 632, 2048, 158, 2048, 10, 35, 306, 980, 1, 300, 168, 13, 339, 48, 58, 13, 175, 13, 792, 19, 13, 15987, 2, 118, 168, 13, 428, 48, 58, 13, 79, 13, 792, 19, 13, 15569, 2174, 56, 2110, 1536, 11, 674, 1, 300, 15, 118, 26, 16, 3, 2166, 45, 210, 4, 82, 70, 220, 416, 5676, 3, 686, 1, 1593, 11, 3420, 1110, 1536, 71, 8, 93, 200, 4, 1818, 3, 43, 1, 146, 2, 221, 632, 10, 3, 158, 980, 1, 228, 673, 110, 257, 40, 515, 4, 46, 7]",1616.0,25575483,Adjuvant vaginal brachytherapy decreases risk vaginal recurrence patients stage non-invasive uterine papillary serous carcinoma multi-institutional,2,0.010050251256281407
Optimizing packing contrast for MRI-based intracavitary brachytherapy planning for cervical cancer.,Brachytherapy,Brachytherapy,2015-01-22,"We prospectively tested five variations in vaginal gauze packing in an effort to improve contrast between the packing, cervix, and applicator for MRI-based intracavitary brachytherapy planning. Five patients enrolled on a prospective study from May 2013 to October 2013 received MRI-based intracavitary brachytherapy for cervical cancer with variations of impregnated gauze packing. Substances tested included antibiotic cream alone, antibiotic cream mixed with ultrasound gel, conjugated estrogens cream mixed with ultrasound gel, ultrasound gel alone, and gadolinium. Images from the T2-weighted pelvic MRI were used to obtain signal intensity measurements at points within the packing, cervix, and applicator. Signal intensity values were normalized using the signal-to-noise ratio and compared using an unpaired t-test. Ultrasound gel-impregnated gauze allowed for the greatest contrast between the packing and the cervix with a difference in mean normalized signal intensity of 38.2 (p < 0.01). Conjugated estrogens cream mixed with ultrasound gel and gadolinium also provided contrast when compared with cervix, with differences in mean normalized signal intensity of 25.3 and -16.2, respectively (p < 0.01 for both). For all variations but gadolinium, the normalized mean signal intensity of the packing was found to be significantly different from the applicator, with the ultrasound gel again demonstrating the greatest contrast with a difference of 42.5 (p < 0.01). Gauze impregnated with ultrasound gel, conjugated estrogens cream mixed with ultrasound gel, and gadolinium allowed for a significant difference in MRI signal intensity between the packing and the cervix. With respect to both the cervix and the applicator, ultrasoundgel-impregnated gauze provided the best contrast overall.",Journal Article,1825.0,1.0,prospectively tested variations vaginal gauze packing effort improve contrast packing cervix applicator MRI-based intracavitary brachytherapy planning patients enrolled prospective 2013 October 2013 received MRI-based intracavitary brachytherapy cervical variations impregnated gauze packing Substances tested included antibiotic cream antibiotic cream mixed ultrasound gel conjugated estrogens cream mixed ultrasound gel ultrasound gel gadolinium Images T2-weighted pelvic MRI obtain signal intensity measurements points packing cervix applicator Signal intensity values normalized signal-to-noise ratio compared unpaired t-test Ultrasound gel-impregnated gauze allowed greatest contrast packing cervix difference mean normalized signal intensity 38.2 p 0.01 Conjugated estrogens cream mixed ultrasound gel gadolinium provided contrast compared cervix differences mean normalized signal intensity 25.3 -16.2 respectively p 0.01 variations gadolinium normalized mean signal intensity packing significantly different applicator ultrasound gel demonstrating greatest contrast difference 42.5 p 0.01 Gauze impregnated ultrasound gel conjugated estrogens cream mixed ultrasound gel gadolinium allowed significant difference MRI signal intensity packing cervix respect cervix applicator ultrasoundgel-impregnated gauze provided best contrast overall,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[21, 1143, 650, 365, 2293, 4, 28291, 18479, 4, 35, 2919, 6, 401, 748, 59, 3, 18479, 3629, 2, 8789, 9, 704, 90, 9122, 1536, 1349, 365, 7, 346, 23, 8, 482, 45, 29, 68, 1346, 6, 2551, 1346, 103, 704, 90, 9122, 1536, 9, 12, 5, 2293, 1, 23215, 28291, 18479, 17124, 650, 159, 5210, 14572, 279, 5210, 14572, 1739, 5, 1945, 5916, 3868, 6293, 14572, 1739, 5, 1945, 5916, 1945, 5916, 279, 2, 7295, 1572, 29, 3, 1786, 2337, 1110, 704, 11, 95, 6, 3140, 1235, 837, 1685, 28, 862, 262, 3, 18479, 3629, 2, 8789, 1235, 837, 1030, 11, 4207, 75, 3, 1235, 6, 7556, 197, 2, 72, 75, 35, 16248, 102, 412, 1945, 5916, 23215, 28291, 2313, 9, 3, 2199, 748, 59, 3, 18479, 2, 3, 3629, 5, 8, 523, 4, 313, 4207, 1235, 837, 1, 519, 18, 19, 13, 355, 3868, 6293, 14572, 1739, 5, 1945, 5916, 2, 7295, 120, 1052, 748, 198, 72, 5, 3629, 5, 362, 4, 313, 4207, 1235, 837, 1, 243, 27, 2, 245, 18, 106, 19, 13, 355, 9, 110, 9, 62, 2293, 84, 7295, 3, 4207, 313, 1235, 837, 1, 3, 18479, 10, 204, 6, 40, 97, 338, 29, 3, 8789, 5, 3, 1945, 5916, 5089, 2219, 3, 2199, 748, 5, 8, 523, 1, 595, 33, 19, 13, 355, 28291, 23215, 5, 1945, 5916, 3868, 6293, 14572, 1739, 5, 1945, 5916, 2, 7295, 2313, 9, 8, 93, 523, 4, 704, 1235, 837, 59, 3, 18479, 2, 3, 3629, 5, 2184, 6, 110, 3, 3629, 2, 3, 8789, 65537, 23215, 28291, 1052, 3, 824, 748, 63]",1746.0,25620163,Optimizing packing contrast MRI-based intracavitary brachytherapy planning cervical,3,0.01507537688442211
"Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics.",International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2015-03-01,"The aim of this study was to evaluate outcomes of patients with stage III endometrial adenocarcinoma treated with surgery followed by adjuvant chemotherapy and vaginal cuff brachytherapy. We retrospectively identified 83 patients treated for 1988 International Federation of Gynecology and Obstetrics (FIGO) stage III endometrial adenocarcinoma at our institution between 2003 and 2010. All patients underwent comprehensive surgical staging. Adjuvant therapy was carboplatin and paclitaxel for 6 cycles and vaginal cuff brachytherapy. For analysis, patients were grouped into type I (FIGO grade 1-2 endometrioid histology, n = 41) or type II (FIGO grade 3, clear cell or papillary serous histology, n = 42) disease. Forty-three patients (52%) had node-positive disease, with similar node-positive rates for type I (n = 21, 51.2%) and type II (n = 22, 52.4%). The median follow-up was 38.6 months. There were no isolated vaginal failures. The estimated 3-year disease-free survival (DFS) and overall survival (OS) for type I versus type II were 92.4% versus 58.0% (P = 0.001) and 97.2% versus 65.8% (P = 0.002), respectively. The 3-year DFS and OS for node negative versus node positive were 85.0% versus 63.6% (P = 0.02) and 84.2% versus 78.0% (P = 0.02), respectively. Associations between type I histology and node-negative disease with improved DFS and OS persisted on multivariate analysis. Our institutional approach of adjuvant chemotherapy and vaginal cuff brachytherapy for stage III endometrial cancer seemed acceptable for patients with low-risk histology or node-negative disease. In contrast, higher rates of failure among those with high-risk histology and/or node-positive disease support intensification of therapy in these subsets.",Journal Article,1787.0,9.0,aim evaluate outcomes patients stage III endometrial adenocarcinoma treated surgery followed adjuvant chemotherapy vaginal cuff brachytherapy retrospectively identified 83 patients treated 1988 International Federation Gynecology Obstetrics FIGO stage III endometrial adenocarcinoma institution 2003 2010 patients underwent comprehensive surgical staging Adjuvant therapy carboplatin paclitaxel 6 cycles vaginal cuff brachytherapy patients grouped type FIGO grade 1-2 endometrioid histology n 41 type II FIGO grade 3 clear papillary serous histology n 42 disease Forty-three patients 52 node-positive disease similar node-positive rates type n 21 51.2 type II n 22 52.4 median follow-up 38.6 months isolated vaginal failures estimated 3-year disease-free survival DFS overall survival OS type versus type II 92.4 versus 58.0 P 0.001 97.2 versus 65.8 P 0.002 respectively 3-year DFS OS node negative versus node positive 85.0 versus 63.6 P 0.02 84.2 versus 78.0 P 0.02 respectively Associations type histology node-negative disease improved DFS OS persisted multivariate institutional approach adjuvant chemotherapy vaginal cuff brachytherapy stage III endometrial acceptable patients low-risk histology node-negative disease contrast higher rates failure high-risk histology and/or node-positive disease support intensification therapy subsets,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[3, 1130, 1, 26, 45, 10, 6, 376, 123, 1, 7, 5, 82, 316, 449, 73, 5, 152, 370, 20, 249, 56, 2, 11445, 1536, 21, 894, 108, 852, 7, 73, 9, 3314, 944, 7303, 1, 6429, 2, 7407, 3837, 82, 316, 449, 28, 114, 731, 59, 1522, 2, 1120, 62, 7, 208, 949, 221, 632, 249, 36, 10, 927, 2, 490, 9, 49, 410, 2, 11445, 1536, 9, 65, 7, 11, 3706, 237, 267, 70, 3837, 88, 14, 18, 3151, 784, 78, 605, 15, 267, 215, 3837, 88, 27, 885, 31, 15, 1796, 1744, 784, 78, 595, 34, 1213, 169, 7, 653, 42, 289, 109, 34, 5, 288, 289, 109, 151, 9, 267, 70, 78, 239, 725, 18, 2, 267, 215, 78, 350, 653, 39, 3, 52, 166, 126, 10, 519, 49, 53, 125, 11, 77, 1355, 3368, 3, 661, 27, 111, 34, 115, 25, 1010, 2, 63, 25, 118, 9, 267, 70, 185, 267, 215, 11, 937, 39, 185, 717, 13, 19, 13, 144, 2, 1015, 18, 185, 556, 66, 19, 13, 1111, 106, 3, 27, 111, 1010, 2, 118, 9, 289, 199, 185, 289, 109, 11, 772, 13, 185, 676, 49, 19, 13, 588, 2, 874, 18, 185, 833, 13, 19, 13, 588, 106, 685, 59, 267, 70, 784, 2, 289, 199, 34, 5, 231, 1010, 2, 118, 3760, 23, 331, 65, 114, 1115, 353, 1, 249, 56, 2, 11445, 1536, 9, 82, 316, 12, 5025, 1595, 9, 7, 5, 154, 43, 784, 15, 289, 199, 34, 4, 748, 142, 151, 1, 496, 107, 135, 5, 64, 43, 784, 2, 15, 289, 109, 34, 538, 5091, 1, 36, 4, 46, 1890]",1605.0,25621409,Adjuvant carboplatin paclitaxel vaginal cuff brachytherapy stage III endometrial outcomes patterns recurrence based pathologic characteristics,0,0.0
Impact of adjuvant chemotherapy and pelvic radiation on pattern of recurrence and outcome in stage I non-invasive uterine papillary serous carcinoma. A multi-institution study.,Gynecologic oncology,Gynecol. Oncol.,2015-01-29,"To determine the impact of adjuvant chemotherapy or pelvic radiation on risk of recurrence and outcome in stage IA non-invasive uterine papillary serous carcinoma (UPSC). This is a multi-institutional retrospective study for 115 patients with stage IA non-invasive UPSC (confined to endometrium) treated between 2000 and 2012. Kaplan-Meier and multivariable Cox proportional hazards regression modeling were used. Staging lymphadenectomy and omentectomy were performed in 84% and 57% respectively. Recurrence was seen in 26% (30/115). Sites of recurrences were vaginal in 7.8% (9/115), pelvic in 3.5% (4/115) and extra-pelvic in 14.7% (17/115). Adjuvant chemotherapy did not impact risk of recurrence (25.5% vs. 26.9%, p=0.85) even in subset of patients who underwent lymphadenectomy (20% vs. 23.5%, p=0.80). These findings were consistent for pattern of recurrence. Among those who underwent lymphadenectomy, adjuvant chemotherapy did not impact progression-free survival (p=0.34) and overall survival (p=0.12). However among patients who did not have lymphadenectomy, adjuvant chemotherapy or pelvic radiation was associated with longer progression-free survival (p=0.04) and overall survival (p=0.025). In multivariable analysis, only staging lymphadenectomy was associated with improved progression-free survival (HR 0.34, 95% CI 0.12-0.95, p=0.04) and overall survival (HR 0.35, 95% CI 0.12-1.0, p=0.05). Neither adjuvant chemotherapy nor pelvic radiation were predictors of progression-free or overall survivals. In stage IA non-invasive UPSC, staging lymphadenectomy was significantly associated with recurrence and outcome and therefore, should be performed in all patients. Adjuvant chemotherapy or pelvic radiation had no impact on outcome in surgically staged patients but was associated with improved outcome in unstaged patients.",Journal Article,1818.0,11.0,determine impact adjuvant chemotherapy pelvic radiation risk recurrence outcome stage IA non-invasive uterine papillary serous carcinoma UPSC multi-institutional retrospective 115 patients stage IA non-invasive UPSC confined endometrium treated 2000 2012 Kaplan-Meier multivariable Cox proportional hazards regression modeling Staging lymphadenectomy omentectomy performed 84 57 respectively Recurrence seen 26 30/115 Sites recurrences vaginal 7.8 9/115 pelvic 3.5 4/115 extra-pelvic 14.7 17/115 Adjuvant chemotherapy impact risk recurrence 25.5 vs. 26.9 p=0.85 subset patients underwent lymphadenectomy 20 vs. 23.5 p=0.80 findings consistent pattern recurrence underwent lymphadenectomy adjuvant chemotherapy impact progression-free survival p=0.34 overall survival p=0.12 patients lymphadenectomy adjuvant chemotherapy pelvic radiation associated longer progression-free survival p=0.04 overall survival p=0.025 multivariable staging lymphadenectomy associated improved progression-free survival HR 0.34 95 CI 0.12-0.95 p=0.04 overall survival HR 0.35 95 CI 0.12-1.0 p=0.05 adjuvant chemotherapy pelvic radiation predictors progression-free overall survivals stage IA non-invasive UPSC staging lymphadenectomy significantly associated recurrence outcome performed patients Adjuvant chemotherapy pelvic radiation impact outcome surgically staged patients associated improved outcome unstaged patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[6, 223, 3, 345, 1, 249, 56, 15, 1110, 121, 23, 43, 1, 146, 2, 228, 4, 82, 3302, 220, 416, 1796, 1744, 134, 5676, 26, 16, 8, 1414, 1115, 459, 45, 9, 3670, 7, 5, 82, 3302, 220, 416, 5676, 2902, 6, 73, 59, 1081, 2, 1195, 876, 882, 2, 658, 418, 831, 1017, 320, 2057, 11, 95, 632, 2048, 2, 20196, 11, 173, 4, 874, 2, 696, 106, 146, 10, 527, 4, 432, 201, 3670, 633, 1, 1593, 11, 4, 67, 66, 83, 3670, 1110, 4, 27, 33, 39, 3670, 2, 3420, 1110, 4, 213, 67, 269, 3670, 249, 56, 205, 44, 345, 43, 1, 146, 243, 33, 105, 432, 83, 19, 13, 772, 871, 4, 697, 1, 7, 54, 208, 2048, 179, 105, 382, 33, 19, 13, 493, 46, 272, 11, 925, 9, 1177, 1, 146, 107, 135, 54, 208, 2048, 249, 56, 205, 44, 345, 91, 115, 25, 19, 13, 562, 2, 63, 25, 19, 13, 133, 137, 107, 7, 54, 205, 44, 47, 2048, 249, 56, 15, 1110, 121, 10, 41, 5, 589, 91, 115, 25, 19, 13, 755, 2, 63, 25, 19, 13, 4067, 4, 658, 65, 158, 632, 2048, 10, 41, 5, 231, 91, 115, 25, 168, 13, 562, 48, 58, 13, 133, 13, 48, 19, 13, 755, 2, 63, 25, 168, 13, 465, 48, 58, 13, 133, 14, 13, 19, 13, 474, 2174, 249, 56, 2110, 1110, 121, 11, 674, 1, 91, 115, 15, 63, 3794, 4, 82, 3302, 220, 416, 5676, 632, 2048, 10, 97, 41, 5, 146, 2, 228, 2, 673, 257, 40, 173, 4, 62, 7, 249, 56, 15, 1110, 121, 42, 77, 345, 23, 228, 4, 2350, 2930, 7, 84, 10, 41, 5, 231, 228, 4, 23261, 7]",1748.0,25641568,Impact adjuvant chemotherapy pelvic radiation pattern recurrence outcome stage non-invasive uterine papillary serous carcinoma multi-institution,0,0.0
Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons.,Gynecologic oncology,Gynecol. Oncol.,2015-02-10,"We demonstrate the feasibility of detecting EC by combining minimally-invasive specimen collection techniques with sensitive molecular testing. Prior to hysterectomy for EC or benign indications, women collected vaginal pool samples with intravaginal tampons and underwent endometrial brushing. Specimens underwent pyrosequencing for DNA methylation of genes reported to be hypermethylated in gynecologic cancers and recently identified markers discovered by profiling over 200 ECs. Methylation was evaluated individually across CpGs and averaged across genes. Differences between EC and benign endometrium (BE) were assessed using two-sample t-tests and area under the curve (AUC). Thirty-eight ECs and 28 BEs were included. We evaluated 97 CpGs within 12 genes, including previously reported markers (RASSF1, HSP2A, HOXA9, CDH13, HAAO, and GTF2A1) and those identified in discovery work (ASCL2, HTR1B, NPY, HS3ST2, MME, ADCYAP1, and additional CDH13 CpG sites). Mean methylation was higher in tampon specimens from EC v. BE for 9 of 12 genes (ADCYAP1, ASCL2, CDH13, HS3ST2, HTR1B, MME, HAAO, HOXA9, and RASSF1) (all p<0.05). Among these genes, relative hypermethylation was observed in EC v. BE across CpGs. Endometrial brush and tampon results were similar. Within tampon specimens, AUC was highest for HTR1B (0.82), RASSF1 (0.75), and HOXA9 (0.74). This is the first report of HOXA9 hypermethylation in EC. DNA hypermethylation in EC tissues can also be identified in vaginal pool DNA collected via intravaginal tampon. Identification of additional EC biomarkers and refined collection methods are needed to develop an early detection tool for EC.",Journal Article,1806.0,28.0,demonstrate feasibility detecting EC combining minimally-invasive specimen collection techniques sensitive molecular testing Prior hysterectomy EC benign indications women collected vaginal pool intravaginal tampons underwent endometrial brushing Specimens underwent pyrosequencing DNA methylation reported hypermethylated gynecologic recently identified markers discovered profiling 200 ECs Methylation evaluated individually CpGs averaged Differences EC benign endometrium assessed two-sample t-tests area curve AUC Thirty-eight ECs 28 BEs included evaluated 97 CpGs 12 including previously reported markers RASSF1 HSP2A HOXA9 CDH13 HAAO GTF2A1 identified discovery work ASCL2 HTR1B NPY HS3ST2 MME ADCYAP1 additional CDH13 CpG sites Mean methylation higher tampon specimens EC v. 9 12 ADCYAP1 ASCL2 CDH13 HS3ST2 HTR1B MME HAAO HOXA9 RASSF1 p 0.05 relative hypermethylation observed EC v. CpGs Endometrial brush tampon similar tampon specimens AUC highest HTR1B 0.82 RASSF1 0.75 HOXA9 0.74 report HOXA9 hypermethylation EC DNA hypermethylation EC tissues identified vaginal pool DNA collected intravaginal tampon Identification additional EC biomarkers refined collection methods needed develop early detection tool EC,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[21, 608, 3, 1437, 1, 2502, 2180, 20, 1525, 2144, 416, 2360, 2442, 1092, 5, 745, 219, 471, 324, 6, 2622, 9, 2180, 15, 1002, 2406, 117, 786, 6545, 347, 5, 16720, 48703, 2, 208, 13607, 623, 208, 6031, 9, 261, 569, 1, 214, 210, 6, 40, 6936, 4, 1512, 163, 2, 761, 108, 525, 2747, 20, 1080, 252, 1250, 5861, 569, 10, 194, 4257, 716, 11432, 2, 6893, 716, 214, 362, 59, 2180, 2, 1002, 40, 11, 275, 75, 100, 1000, 102, 895, 2, 965, 669, 3, 1496, 1376, 977, 659, 5861, 2, 339, 65624, 11, 159, 21, 194, 1015, 11432, 262, 133, 214, 141, 373, 210, 525, 17629, 65625, 11453, 14143, 48856, 2, 65626, 2, 135, 108, 4, 1574, 1357, 48857, 40993, 40994, 32393, 35623, 48858, 2, 402, 14143, 2075, 633, 313, 569, 10, 142, 4, 25657, 623, 29, 2180, 603, 40, 9, 83, 1, 133, 214, 48858, 48857, 14143, 32393, 40993, 35623, 48856, 11453, 2, 17629, 62, 19, 13, 474, 107, 46, 214, 580, 2575, 10, 164, 4, 2180, 603, 40, 716, 11432, 12556, 2, 25657, 99, 11, 288, 262, 25657, 623, 1376, 10, 1076, 9, 40993, 13, 878, 17629, 13, 481, 2, 11453, 13, 794, 26, 16, 3, 157, 414, 1, 11453, 2575, 4, 2180, 261, 2575, 4, 2180, 742, 122, 120, 40, 108, 4, 6545, 261, 786, 847, 16720, 25657, 911, 1, 402, 2180, 582, 2, 5332, 2442, 636, 32, 575, 6, 690, 35, 191, 638, 1515, 9, 2180]",1542.0,25677060,Detection endometrial molecular DNA collected vaginal tampons,1,0.005025125628140704
Vaginal brachytherapy for early-stage carcinosarcoma of the uterus.,Brachytherapy,Brachytherapy,2015-04-15,"Uterine carcinosarcoma (CS) is an aggressive malignancy and the optimal adjuvant treatment is not well-established. We report outcomes with vaginal brachytherapy (VB) for women with early-stage CS. A multi-institutional retrospective study of Stage I-II CS treated with hysterectomy, surgical staging, and adjuvant high-dose-rate VB without external-beam pelvic radiotherapy was performed. Rates of vaginal control, pelvic control, locoregional control, disease-free survival, and overall survival were determined using the Kaplan-Meier method. 33 patients were identified. Prescribed VB dose was 21 Gy in three fractions (n = 15 [45%]) or 24 Gy in six fractions (n = 18 [55%]). Eighteen patients (55%) received chemotherapy. Median followup was 2.0 years. Twenty-seven patients (82%) underwent pelvic lymphadenectomy, 5 (15%) had nodal sampling, and 1 (3%) had no lymph node assessment. Relapse occurred in 11 patients (33%), all of whom had lymph node evaluation. Locoregional relapse was a component of failure in 6 patients (18%), of whom 3 (9%) failed in the pelvis alone. Three patients (9%) had simultaneous distant and locoregional relapse (two vaginal, one pelvic). Five additional patients (15%) had distant relapse. Six of the 11 patients (55%) with disease recurrence received chemotherapy. Two-year vaginal control and pelvic control were 94% and 87%. Two-year locoregional control, disease-free survival, and overall survival were 81%, 66%, and 79%. Despite having early-stage disease and treatment with VB, patients in this series had relatively high rates of local and distant relapse. Patients who undergo lymphadenectomy and VB remain at risk for relapse. Novel treatment strategies are needed.",Evaluation Study,1742.0,7.0,Uterine carcinosarcoma CS aggressive malignancy optimal adjuvant treatment well-established report outcomes vaginal brachytherapy VB women early-stage CS multi-institutional retrospective Stage I-II CS treated hysterectomy surgical staging adjuvant high-dose-rate VB external-beam pelvic radiotherapy performed Rates vaginal control pelvic control locoregional control disease-free survival overall survival determined Kaplan-Meier 33 patients identified Prescribed VB dose 21 Gy fractions n 15 45 24 Gy fractions n 18 55 Eighteen patients 55 received chemotherapy Median followup 2.0 years Twenty-seven patients 82 underwent pelvic lymphadenectomy 5 15 nodal sampling 1 3 lymph node assessment Relapse occurred 11 patients 33 lymph node evaluation Locoregional relapse component failure 6 patients 18 3 9 failed pelvis patients 9 simultaneous distant locoregional relapse vaginal pelvic additional patients 15 distant relapse 11 patients 55 disease recurrence received chemotherapy Two-year vaginal control pelvic control 94 87 Two-year locoregional control disease-free survival overall survival 81 66 79 Despite early-stage disease treatment VB patients series relatively high rates local distant relapse Patients undergo lymphadenectomy VB remain risk relapse Novel treatment strategies needed,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[5623, 2188, 16, 35, 571, 710, 2, 3, 665, 249, 24, 16, 44, 149, 635, 21, 414, 123, 5, 1536, 9464, 9, 117, 5, 191, 82, 2188, 8, 1414, 1115, 459, 45, 1, 82, 70, 215, 2188, 73, 5, 2622, 221, 632, 2, 249, 64, 61, 116, 9464, 187, 1455, 1345, 1110, 310, 10, 173, 151, 1, 182, 1110, 182, 1325, 182, 34, 115, 25, 2, 63, 25, 11, 509, 75, 3, 876, 882, 596, 466, 7, 11, 108, 2746, 9464, 61, 10, 239, 381, 4, 169, 1550, 78, 167, 512, 15, 259, 381, 4, 437, 1550, 78, 203, 614, 3195, 7, 614, 103, 56, 52, 3569, 10, 18, 13, 60, 737, 648, 7, 878, 208, 1110, 2048, 33, 167, 42, 779, 2874, 2, 14, 27, 42, 77, 263, 289, 455, 429, 489, 4, 175, 7, 466, 62, 1, 953, 42, 263, 289, 451, 1325, 429, 10, 8, 1249, 1, 496, 4, 49, 7, 203, 1, 953, 27, 83, 1551, 4, 3, 3270, 279, 169, 7, 83, 42, 2824, 626, 2, 1325, 429, 100, 104, 1110, 365, 402, 7, 167, 42, 626, 429, 437, 1, 3, 175, 7, 614, 5, 34, 146, 103, 56, 100, 111, 182, 2, 1110, 182, 11, 960, 2, 912, 100, 111, 1325, 182, 34, 115, 25, 2, 63, 25, 11, 865, 700, 2, 842, 550, 1041, 191, 82, 34, 2, 24, 5, 9464, 7, 4, 26, 988, 42, 1352, 64, 151, 1, 293, 2, 626, 429, 7, 54, 1251, 2048, 2, 9464, 918, 28, 43, 9, 429, 229, 24, 422, 32, 575]",1582.0,25890795,Vaginal brachytherapy early-stage carcinosarcoma uterus,0,0.0
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.,The Lancet. Oncology,Lancet Oncol.,2015-06-16,"The combined efficacy analysis of the TEXT and SOFT trials showed a significant disease-free survival benefit with exemestane plus ovarian function suppression (OFS) compared with tamoxifen plus OFS. We present patient-reported outcomes from these trials. Between Nov 7, 2003, and April 7, 2011, 4717 premenopausal women with hormone-receptor positive breast cancer were enrolled in TEXT or SOFT to receive unmasked adjuvant treatment with 5 years of exemestane plus OFS or tamoxifen plus OFS. Gonadotropin-releasing hormone analogue triptorelin, bilateral oophorectomy, or bilateral ovarian irradiation were used to achieve OFS. Chemotherapy use was optional. Randomisation with permuted blocks was done with the International Breast Cancer Study Group's internet-based system and was stratified by chemotherapy use and status of lymph nodes. Patients completed a quality of life (QoL) form comprising several global and symptom indicators at baseline, every 6 months for 24 months, and then every year during years 3 to 6. Differences in the change of QoL from baseline between the two treatments were tested at 6 months, 24 months, and 60 months with mixed-models for repeated measures for each trial with and without chemotherapy and overall. The analysis was by intention to treat. At the time of analysis, the median follow-up was 57 years (IQR 37-69); treatment and follow-up of patients continue. The trials are registered with ClinicalTrials.gov, as NCT00066703 (TEXT) and NCT00066690 (SOFT). Patients on tamoxifen plus OFS were more affected by hot flushes and sweats over 5 years than were those on exemestane plus OFS, although these symptoms improved. Patients on exemestane plus OFS reported more vaginal dryness, greater loss of sexual interest, and difficulties becoming aroused than did patients on tamoxifen plus OFS; these differences persisted over time. An increase in bone or joint pain was more pronounced, particularly in the short term, in patients on exemestane plus OFS than patients on tamoxifen plus OFS. Changes in global QoL indicators from baseline were small and similar between treatments over the 5 years. Overall, from a QoL perspective, there is no strong indication to favour either exemestane plus OFS or tamoxifen plus OFS. The distinct effects of the two treatments on the burden of endocrine symptoms need to be addressed with patients individually. Pfizer, International Breast Cancer Study Group, and US National Cancer Institute.","Clinical Trial, Phase III",1680.0,74.0,combined efficacy TEXT SOFT trials showed significant disease-free survival benefit exemestane plus ovarian function suppression OFS compared tamoxifen plus OFS present patient-reported outcomes trials Nov 7 2003 April 7 2011 4717 premenopausal women hormone-receptor positive breast enrolled TEXT SOFT receive unmasked adjuvant treatment 5 years exemestane plus OFS tamoxifen plus OFS Gonadotropin-releasing hormone analogue triptorelin bilateral oophorectomy bilateral ovarian irradiation achieve OFS Chemotherapy use optional Randomisation permuted blocks International Breast Group 's internet-based stratified chemotherapy use status lymph nodes Patients completed quality life QoL form comprising global symptom indicators baseline 6 months 24 months year years 3 6 Differences change QoL baseline treatments tested 6 months 24 months 60 months mixed-models repeated measures trial chemotherapy overall intention treat time median follow-up 57 years IQR 37-69 treatment follow-up patients continue trials registered ClinicalTrials.gov NCT00066703 TEXT NCT00066690 SOFT Patients tamoxifen plus OFS affected hot flushes sweats 5 years exemestane plus OFS symptoms improved Patients exemestane plus OFS reported vaginal dryness greater loss sexual difficulties aroused patients tamoxifen plus OFS differences persisted time increase bone joint pain pronounced particularly short term patients exemestane plus OFS patients tamoxifen plus OFS Changes global QoL indicators baseline small similar treatments 5 years Overall QoL perspective strong indication favour exemestane plus OFS tamoxifen plus OFS distinct effects treatments burden endocrine symptoms need addressed patients individually Pfizer International Breast Group National Institute,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 397, 209, 65, 1, 3, 6153, 2, 1214, 143, 224, 8, 93, 34, 115, 25, 247, 5, 3199, 349, 343, 1332, 8354, 72, 5, 1105, 349, 8354, 21, 364, 69, 210, 123, 29, 46, 143, 59, 10369, 67, 1522, 2, 2292, 67, 1132, 47984, 2710, 117, 5, 785, 153, 109, 12, 11, 346, 4, 6153, 15, 1214, 6, 560, 27141, 249, 24, 5, 33, 60, 1, 3199, 349, 8354, 15, 1105, 349, 8354, 6501, 5586, 785, 4696, 16564, 1607, 3470, 15, 1607, 1104, 11, 95, 6, 1359, 8354, 56, 119, 10, 9281, 5204, 5, 10496, 2860, 10, 1822, 5, 3, 944, 12, 45, 87, 292, 5912, 90, 398, 2, 10, 1173, 20, 56, 119, 2, 156, 1, 263, 502, 7, 781, 8, 372, 1, 358, 1001, 1297, 3538, 392, 1648, 2, 934, 3539, 28, 330, 454, 49, 53, 9, 259, 53, 2, 818, 454, 111, 190, 60, 27, 6, 49, 362, 4, 3, 707, 1, 1001, 29, 330, 59, 3, 100, 640, 11, 650, 28, 49, 53, 259, 53, 2, 335, 53, 5, 1739, 274, 9, 2113, 1018, 9, 296, 160, 5, 2, 187, 56, 2, 63, 3, 65, 10, 20, 3205, 6, 943, 28, 3, 98, 1, 65, 3, 52, 166, 126, 10, 17502, 60, 2245, 15777, 18024, 24, 2, 166, 126, 1, 7, 1906, 3, 143, 32, 1653, 5, 1252, 1239, 22, 40744, 6153, 2, 35822, 1214, 7, 23, 1105, 349, 8354, 11, 80, 1424, 20, 2859, 18182, 2, 13298, 252, 33, 60, 76, 11, 135, 23, 3199, 349, 8354, 242, 46, 507, 231, 7, 23, 3199, 349, 8354, 210, 80, 15822, 378, 407, 1, 2232, 1333, 2, 4679, 4009, 38768, 76, 205, 7, 23, 1105, 349, 8354, 46, 362, 3760, 252, 98, 35, 344, 4, 15, 2093, 559, 10, 80, 3517, 823, 4, 3, 978, 337, 4, 7, 23, 3199, 349, 8354, 76, 7, 23, 1105, 349, 8354, 400, 4, 1648, 1001, 3539, 29, 330, 11, 302, 2, 288, 59, 640, 252, 3, 33, 60, 63, 29, 8, 1001, 3727, 125, 16, 77, 1082, 3607, 6, 17486, 361, 3199, 349, 8354, 15, 1105, 349, 8354, 3, 834, 176, 1, 3, 100, 640, 23, 3, 892, 1, 1293, 507, 594, 6, 40, 2814, 5, 7, 4257, 8982, 944, 12, 45, 87, 2, 843, 657, 12, 1377]",2377.0,26092816,Patient-reported outcomes adjuvant exemestane versus tamoxifen premenopausal women early breast undergoing ovarian suppression TEXT SOFT combined phase 3 randomised trials,2,0.010050251256281407
Postoperative Radiation Therapy for Endometrial Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2015-07-06,"To provide guidance on the role of adjuvant radiation therapy in the treatment of endometrial cancer. ""The Role of Postoperative Radiation Therapy for Endometrial Cancer: An ASTRO Evidence-Based Guideline"" by Klopp et al, published in 2014 in Practical Radiation Oncology, was reviewed for developmental rigor by methodologists. The American Society for Radiation Oncology (ASTRO) guideline content and recommendations were further reviewed by the American Society of Clinical Oncology (ASCO) Endorsement Panel. The ASCO Endorsement Panel determined that the recommendations from the ASTRO guideline are clear, thorough, and based on the most relevant scientific evidence. ASCO endorsed the ASTRO guideline with several qualifying statements. Surveillance without adjuvant radiation therapy is a reasonable option for women without residual disease in the hysterectomy specimen and for women with grade 1 or 2 cancer and < 50% myometrial invasion, especially when no other high-risk features are present. For women with grade 1 or 2 cancer and  50% myometrial invasion or grade 3 cancer and < 50% myometrial invasion, vaginal brachytherapy is as effective as pelvic radiation therapy at preventing vaginal recurrence and is preferred. Patients with grade 3 cancer and  50% myometrial invasion or cervical stroma invasion may benefit from pelvic radiation to prevent pelvic recurrence. For women with high-risk early-stage disease and advanced disease, the ASCO Endorsement Panel added qualifying statements to the ASTRO recommendations to provide stronger statements in favor of chemotherapy (with or without radiation therapy).",Journal Article,1660.0,45.0,provide guidance role adjuvant radiation therapy treatment endometrial `` Role Postoperative Radiation Therapy Endometrial ASTRO Evidence-Based Guideline '' Klopp published 2014 Practical Radiation Oncology reviewed developmental rigor methodologists American Society Radiation Oncology ASTRO guideline content recommendations reviewed American Society Clinical Oncology ASCO Endorsement Panel ASCO Endorsement Panel determined recommendations ASTRO guideline clear thorough based relevant scientific evidence ASCO endorsed ASTRO guideline qualifying statements Surveillance adjuvant radiation therapy reasonable option women residual disease hysterectomy specimen women grade 1 2 50 myometrial invasion especially high-risk features present women grade 1 2  50 myometrial invasion grade 3 50 myometrial invasion vaginal brachytherapy effective pelvic radiation therapy preventing vaginal recurrence preferred Patients grade 3  50 myometrial invasion cervical stroma invasion benefit pelvic radiation prevent pelvic recurrence women high-risk early-stage disease advanced disease ASCO Endorsement Panel added qualifying statements ASTRO recommendations provide stronger statements favor chemotherapy radiation therapy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 377, 2753, 23, 3, 200, 1, 249, 121, 36, 4, 3, 24, 1, 12, 3, 200, 1, 573, 121, 36, 9, 12, 35, 7709, 241, 90, 2009, 522, 20, 66420, 2022, 2171, 983, 4, 1409, 4, 3320, 121, 413, 10, 446, 9, 4566, 13117, 20, 19827, 3, 597, 1174, 9, 121, 413, 7709, 2009, 2457, 2, 883, 11, 195, 446, 20, 3, 597, 1174, 1, 38, 413, 2697, 11049, 993, 3, 2697, 11049, 993, 509, 17, 3, 883, 29, 3, 7709, 2009, 32, 885, 5506, 2, 90, 23, 3, 96, 867, 3138, 241, 2697, 6864, 3, 7709, 2009, 5, 392, 14646, 7072, 617, 187, 249, 121, 36, 16, 8, 3203, 1501, 9, 117, 187, 753, 34, 4, 3, 2622, 2360, 2, 9, 117, 5, 88, 14, 15, 18, 12, 2, 212, 7327, 578, 1093, 198, 77, 127, 64, 43, 404, 32, 364, 9, 117, 5, 88, 14, 15, 18, 12, 2, 749, 212, 7327, 578, 15, 88, 27, 12, 2, 212, 7327, 578, 1536, 16, 22, 323, 22, 1110, 121, 36, 28, 3017, 146, 2, 16, 2514, 7, 5, 88, 27, 12, 2, 749, 212, 7327, 578, 15, 2477, 578, 68, 247, 29, 1110, 121, 6, 1682, 1110, 146, 9, 117, 5, 64, 43, 191, 82, 34, 2, 131, 34, 3, 2697, 11049, 993, 1953, 14646, 7072, 6, 3, 7709, 883, 6, 377, 3355, 7072, 4, 4283, 1, 56, 5, 15, 187, 121, 36]",1554.0,26150442,Postoperative Radiation Therapy Endometrial American Society Clinical Oncology Clinical Practice Guideline Endorsement American Society Radiation Oncology Evidence-Based Guideline,0,0.0
Survivors of gynecologic malignancies: impact of treatment on health and well-being.,Journal of cancer survivorship : research and practice,J Cancer Surviv,2015-08-06,"While overall survival from gynecologic malignancies has greatly improved over the last three decades, required treatments can lead to multiple health issues for survivors. Our objective was to identify health concerns that gynecologic cancer survivors face. A systematic, stratified sample of women with gynecologic malignancies was surveyed for 18 health issues occurring before, during, or after treatment. The impact of clinical features and treatment modality on health issues was assessed through multivariate logistic regression models. Of 2,546 surveys mailed, 622 were not received by eligible subjects secondary to invalid address, incorrect diagnosis, or death. Thus, 1924 survivors potentially received surveys. Of the 1,029 surveys (53.5%) completed, median age was 59 years; diagnoses included 29% cervical, 26% endometrial, 26% ovarian/primary peritoneal/fallopian tube, 12.1% vulvar, and 5.4% vaginal cancers. The most frequently reported health issues included fatigue (60.6%), sleep disturbance (54.9%), urinary difficulties (50.9%), sexual dysfunction (48.4%), neurologic issues (45.4%), bowel complaints (42.0%), depression (41.3%), and memory problems (41.2%). These rankings were consistent with patients' self-reported rankings of ""highest impact"" personal issues. After controlling for demographic and clinical variables, multivariate analyses revealed that treatment modality impacted the odds of experiencing a given health issue. Our study demonstrates that gynecologic cancer survivors experience a high frequency of health conditions and highlights the association between treatment modality and specific health concerns. The study findings highlight the multiple health concerns experienced by gynecologic cancer survivors and suggest the potential for developing interventions to mitigate these concerns in survivorship.",Journal Article,1629.0,17.0,"overall survival gynecologic malignancies greatly improved decades required treatments lead multiple health issues survivors objective identify health concerns gynecologic survivors face systematic stratified women gynecologic malignancies surveyed 18 health issues occurring treatment impact clinical features treatment modality health issues assessed multivariate logistic regression models 2,546 surveys mailed 622 received eligible subjects secondary invalid address incorrect diagnosis death 1924 survivors potentially received surveys 1,029 surveys 53.5 completed median age 59 years diagnoses included 29 cervical 26 endometrial 26 ovarian/primary peritoneal/fallopian tube 12.1 vulvar 5.4 vaginal frequently reported health issues included fatigue 60.6 sleep disturbance 54.9 urinary difficulties 50.9 sexual dysfunction 48.4 neurologic issues 45.4 bowel complaints 42.0 depression 41.3 memory problems 41.2 rankings consistent patients self-reported rankings `` highest impact '' personal issues controlling demographic clinical variables multivariate revealed treatment modality impacted odds experiencing given health issue demonstrates gynecologic survivors experience high frequency health conditions highlights association treatment modality specific health concerns findings highlight multiple health concerns experienced gynecologic survivors suggest potential developing interventions mitigate concerns survivorship",0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[369, 63, 25, 29, 1512, 441, 71, 3510, 231, 252, 3, 1060, 169, 1968, 616, 640, 122, 1122, 6, 232, 341, 1553, 9, 332, 114, 461, 10, 6, 255, 341, 2061, 17, 1512, 12, 332, 3376, 8, 1556, 1173, 1000, 1, 117, 5, 1512, 441, 10, 3696, 9, 203, 341, 1553, 1821, 348, 190, 15, 50, 24, 3, 345, 1, 38, 404, 2, 24, 1396, 23, 341, 1553, 10, 275, 298, 331, 812, 320, 274, 1, 18, 11912, 3666, 6703, 11011, 11, 44, 103, 20, 625, 976, 568, 6, 25008, 1539, 11774, 147, 15, 273, 631, 36079, 332, 751, 103, 3666, 1, 3, 14, 4770, 3666, 699, 33, 781, 52, 89, 10, 728, 60, 2403, 159, 462, 432, 432, 6301, 86, 1639, 25234, 2330, 133, 14, 2, 33, 39, 163, 3, 96, 746, 210, 341, 1553, 159, 613, 335, 49, 2494, 6663, 667, 83, 1660, 4679, 212, 83, 2232, 1527, 576, 39, 2543, 1553, 512, 39, 1659, 6938, 595, 13, 1774, 605, 27, 2, 2407, 2408, 605, 18, 46, 17820, 11, 925, 5, 7, 1074, 210, 17820, 1, 1076, 345, 522, 3008, 1553, 50, 1893, 9, 1540, 2, 38, 682, 331, 318, 553, 17, 24, 1396, 4619, 3, 610, 1, 2985, 8, 447, 341, 2537, 114, 45, 1902, 17, 1512, 12, 332, 730, 8, 64, 675, 1, 341, 1298, 2, 2527, 3, 248, 59, 24, 1396, 2, 112, 341, 2061, 3, 45, 272, 1817, 3, 232, 341, 2061, 592, 20, 1512, 12, 332, 2, 309, 3, 174, 9, 931, 1151, 6, 5626, 46, 2061, 4, 2560]",1752.0,26245979,Survivors gynecologic malignancies impact treatment health well-being,0,0.0
Pros and cons of vaginal brachytherapy after external beam radiation therapy in endometrial cancer.,Gynecologic oncology,Gynecol. Oncol.,2015-09-30,"A large number of studies have looked at the role of radiation therapy in the treatment of endometrial cancer. One particular radiation strategy in common practice is the use of adjuvant external beam (EB) radiotherapy followed by vaginal brachytherapy (VB). While the addition of VB to EB provides a theoretical benefit of a localized boost with higher focused dose to an area of potentially high recurrence risk, a randomized clinical trial to compare outcomes and toxicities of EB+VB vs. EB alone is lacking. The goal of this review is to present the current data for and against the use of this combined radiation modality and to provide some preliminary evidence regarding which patient populations may be most likely to benefit. ",Journal Article,1574.0,10.0,large number studies looked role radiation therapy treatment endometrial particular radiation strategy common practice use adjuvant external beam EB radiotherapy followed vaginal brachytherapy VB addition VB EB provides theoretical benefit localized boost higher focused dose area potentially high recurrence risk randomized clinical trial compare outcomes toxicities EB+VB vs. EB lacking goal review present current use combined radiation modality provide preliminary evidence patient populations likely benefit,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[8, 375, 207, 1, 94, 47, 13058, 28, 3, 200, 1, 121, 36, 4, 3, 24, 1, 12, 104, 1454, 121, 692, 4, 186, 758, 16, 3, 119, 1, 249, 1455, 1345, 13794, 310, 370, 20, 1536, 9464, 369, 3, 352, 1, 9464, 6, 13794, 777, 8, 7060, 247, 1, 8, 909, 2569, 5, 142, 1649, 61, 6, 35, 965, 1, 751, 64, 146, 43, 8, 384, 38, 160, 6, 932, 123, 2, 385, 1, 13794, 9464, 105, 13794, 279, 16, 1941, 3, 1326, 1, 26, 206, 16, 6, 364, 3, 291, 74, 9, 2, 480, 3, 119, 1, 26, 397, 121, 1396, 2, 6, 377, 476, 1676, 241, 666, 92, 69, 1184, 68, 40, 96, 322, 6, 247]",705.0,26432041,Pros cons vaginal brachytherapy external beam radiation therapy endometrial,9,0.04522613065326633
The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2016-01-01,"The aim of the study was to characterize the impact of adjuvant therapy on survival in women with stage I/II uterine carcinosarcoma after primary surgery. We reviewed records of 118 consecutively treated women with 2009 International Federation of Gynecology and Obstetrics stage I/II uterine carcinosarcoma who underwent hysterectomy between 1990 and 2014 at 4 academic institutions. Patients were categorized by adjuvant treatment group into observation, chemotherapy only, radiation only, and combined chemotherapy and radiation. Survival analyses were conducted using Kaplan-Meier and Cox proportional hazards models. Median follow-up was 28 months (range, 1-244 months). Lymphadenectomy was performed in 94 patients (80%). Postoperative management included observation (n = 37 [31%]), chemotherapy alone (n = 19 [16%]), radiation therapy (RT) alone (n = 24 [20%]), and combined RT and chemotherapy (n = 38 [32%]). Radiation therapy modality included vaginal brachytherapy in 22 patients, pelvic external beam RT in 21 patients, and combination in 19 patients. In 58% of women, chemotherapy consisted of carboplatin/paclitaxel. Median overall survival for all women was 97 months. On univariate analysis, adjuvant treatment group was associated with improved overall survival (hazard ratio [HR], 0.74; confidence interval [CI], 0.58-0.96; p = 0.02), freedom from vaginal recurrence (HR, 0.55; CI, 0.37-0.82]; p = 0.004), and freedom from any recurrence (HR, 0.70; CI, 0.54-0.92; p = 0.01). Pairwise comparisons demonstrated a significant benefit to chemoradiation over other adjuvant treatments. Adjuvant treatment group remained a significant covariate for all 3 end points on multivariate analysis as well. In addition, lymphadenectomy improved overall survival on multivariate analysis (HR, 0.24; CI, 0.09-0.61; p = 0.003). Of patients under observation only who had a recurrence, 8 (44%) of 18 had a recurrence in the vagina as the sole site of recurrence. By contrast, of women who received vaginal brachytherapy, significantly fewer had a recurrence in the vagina (1/42 [2.3%]; p < 0.003, log-rank test). In women with early-stage uterine carcinosarcoma, our data suggest superior survival end points with combined RT and chemotherapy. The frequency of vaginal recurrence suggests a role for incorporating vaginal brachytherapy in the adjuvant management of this disease.",Journal Article,1481.0,10.0,aim characterize impact adjuvant therapy survival women stage I/II uterine carcinosarcoma primary surgery reviewed records 118 consecutively treated women 2009 International Federation Gynecology Obstetrics stage I/II uterine carcinosarcoma underwent hysterectomy 1990 2014 4 academic institutions Patients categorized adjuvant treatment group observation chemotherapy radiation combined chemotherapy radiation Survival conducted Kaplan-Meier Cox proportional hazards models Median follow-up 28 months range 1-244 months Lymphadenectomy performed 94 patients 80 Postoperative management included observation n 37 31 chemotherapy n 19 16 radiation therapy RT n 24 20 combined RT chemotherapy n 38 32 Radiation therapy modality included vaginal brachytherapy 22 patients pelvic external beam RT 21 patients combination 19 patients 58 women chemotherapy consisted carboplatin/paclitaxel Median overall survival women 97 months univariate adjuvant treatment group associated improved overall survival hazard ratio HR 0.74 confidence interval CI 0.58-0.96 p 0.02 freedom vaginal recurrence HR 0.55 CI 0.37-0.82 p 0.004 freedom recurrence HR 0.70 CI 0.54-0.92 p 0.01 Pairwise comparisons demonstrated significant benefit chemoradiation adjuvant treatments Adjuvant treatment group remained significant covariate 3 end points multivariate addition lymphadenectomy improved overall survival multivariate HR 0.24 CI 0.09-0.61 p 0.003 patients observation recurrence 8 44 18 recurrence vagina sole site recurrence contrast women received vaginal brachytherapy significantly fewer recurrence vagina 1/42 2.3 p 0.003 log-rank test women early-stage uterine carcinosarcoma suggest superior survival end points combined RT chemotherapy frequency vaginal recurrence suggests role incorporating vaginal brachytherapy adjuvant management disease,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[3, 1130, 1, 3, 45, 10, 6, 1507, 3, 345, 1, 249, 36, 23, 25, 4, 117, 5, 82, 70, 215, 5623, 50, 86, 152, 21, 446, 1064, 1, 4002, 7380, 73, 117, 5, 1238, 944, 7303, 1, 6429, 2, 7407, 82, 70, 215, 5623, 54, 208, 2622, 59, 2289, 2, 1409, 28, 39, 1916, 1764, 7, 11, 2320, 20, 249, 24, 87, 237, 1664, 56, 158, 121, 158, 2, 397, 56, 2, 121, 25, 318, 11, 426, 75, 876, 882, 2, 418, 831, 1017, 274, 52, 166, 126, 10, 339, 53, 184, 14, 6567, 53, 2048, 10, 173, 4, 960, 7, 493, 573, 284, 159, 1664, 78, 567, 456, 56, 279, 78, 326, 245, 121, 36, 240, 279, 78, 259, 179, 2, 397, 240, 2, 56, 78, 519, 531, 121, 36, 1396, 159, 1536, 4, 350, 7, 1110, 1455, 1345, 240, 4, 239, 7, 2, 150, 4, 326, 7, 4, 717, 1, 117, 56, 1695, 1, 927, 490, 52, 63, 25, 9, 62, 117, 10, 1015, 53, 23, 880, 65, 249, 24, 87, 10, 41, 5, 231, 63, 25, 360, 197, 168, 13, 794, 307, 268, 58, 13, 717, 13, 921, 19, 13, 588, 3060, 29, 146, 168, 13, 614, 58, 13, 567, 13, 878, 19, 13, 1520, 2, 3060, 29, 500, 146, 168, 13, 431, 58, 13, 667, 13, 937, 19, 13, 355, 8716, 2213, 264, 8, 93, 247, 6, 975, 252, 127, 249, 640, 249, 24, 87, 958, 8, 93, 6322, 9, 62, 27, 396, 862, 23, 331, 65, 22, 149, 4, 352, 2048, 231, 63, 25, 23, 331, 65, 168, 13, 259, 58, 13, 1730, 13, 713, 19, 13, 1421, 1, 7, 669, 1664, 158, 54, 42, 8, 146, 66, 584, 1, 203, 42, 8, 146, 4, 3, 7553, 22, 3, 4991, 606, 1, 146, 20, 748, 1, 117, 54, 103, 1536, 97, 1497, 42, 8, 146, 4, 3, 7553, 14, 595, 18, 27, 19, 13, 1421, 1066, 1026, 412, 4, 117, 5, 191, 82, 5623, 114, 74, 309, 1123, 25, 396, 862, 5, 397, 240, 2, 56, 3, 675, 1, 146, 844, 8, 200, 9, 2570, 1536, 4, 3, 249, 284, 1, 26, 34]",2196.0,26509850,Impact Adjuvant Therapy Survival Recurrence Patterns Women Early-Stage Uterine Carcinosarcoma Multi-institutional,2,0.010050251256281407
"Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.","Lancet (London, England)",Lancet,2015-12-11,"The NSABP B-35 trial compared 5 years of treatment with anastrozole versus tamoxifen for reducing subsequent occurrence of breast cancer in postmenopausal patients with ductal carcinoma in situ. This report assesses the effect of these drugs on quality of life and symptoms. The study was done at 333 hospitals in North America. Postmenopausal women with hormone-positive ductal carcinoma in situ treated by lumpectomy with clear resection margins and whole breast irradiation were randomly assigned to receive either tamoxifen (20 mg/day) or anastrazole (1 mg/day) for 5 years, stratified by age (<60 years vs 60 years). Patients and investigators were masked to treatment allocation. Patients completed questionnaires at baseline and every 6 months thereafter for 6 years. The primary outcomes were SF-12 physical and mental health component scale scores, and vasomotor symptoms (as per the BCPT symptom scale). Secondary outcomes were vaginal symptoms and sexual functioning. Exploratory outcomes were musculoskeletal pain, bladder symptoms, gynaecological symptoms, cognitive symptoms, weight problems, vitality, and depression. We did the analyses by intention to treat, including patients who completed questionnaires at baseline and at least once during follow-up. This study is registered with ClinicalTrials.gov, NCT00053898. Between Jan 6, 2003, and June 15, 2006, 3104 patients were enrolled in the study, of whom 1193 were included in the quality-of-life substudy: 601 assigned to tamoxifen and 592 assigned to anastrozole. We detected no significant difference between treatment groups for: physical health scores (mean severity score 4672 for tamoxifen vs 4585 for anastrozole; p=020), mental health scores (5238 vs 5148; p=038), energy and fatigue (5834 vs 5754; p=086), or symptoms of depression (619 vs 639; p=046) over 5 years. Vasomotor symptoms (133 vs 117; p=0011), difficulty with bladder control (096 vs 080; p=00002), and gynaecological symptoms (029 vs 018; p<00001) were significantly more severe in the tamoxifen group than in the anastrozole group. Musculoskeletal pain (150 vs 172; p=00006) and vaginal symptoms (076 vs 086; p=0035) were significantly worse in the anastrozole group than in the tamoxifen group. Sexual functioning did not differ significantly between the two treatments (4365 vs 4529; p=056). Younger age was significantly associated with more severe vasomotor symptoms (mean severity score 145 for age <60 years vs 065 for age 60 years; p=00006), vaginal symptoms (098 vs 065; p<00001), weight problems (132 vs 102; p<00001), and gynaecological symptoms (026 vs 022; p=0014). Given the similar efficacy of tamoxifen and anastrozole for women older than age 60 years, decisions about treatment should be informed by the risk for serious adverse health effects and the symptoms associated with each drug. For women younger than 60 years old, treatment decisions might be driven by efficacy (favouring anastrozole); however, if the side-effects of anastrozole are intolerable, then switching to tamoxifen is a good alternative. US National Cancer Institute, AstraZeneca Pharmaceuticals.","Clinical Trial, Phase III",1502.0,30.0,NSABP B-35 trial compared 5 years treatment anastrozole versus tamoxifen reducing subsequent occurrence breast postmenopausal patients ductal carcinoma situ report assesses effect drugs quality life symptoms 333 hospitals North America Postmenopausal women hormone-positive ductal carcinoma situ treated lumpectomy clear resection margins breast irradiation randomly assigned receive tamoxifen 20 mg/day anastrazole 1 mg/day 5 years stratified age 60 years vs 60 years Patients investigators masked treatment allocation Patients completed questionnaires baseline 6 months 6 years primary outcomes SF-12 physical mental health component scale scores vasomotor symptoms BCPT symptom scale Secondary outcomes vaginal symptoms sexual functioning Exploratory outcomes musculoskeletal pain bladder symptoms gynaecological symptoms cognitive symptoms weight problems vitality depression intention treat including patients completed questionnaires baseline follow-up registered ClinicalTrials.gov NCT00053898 Jan 6 2003 June 15 2006 3104 patients enrolled 1193 included quality-of-life substudy 601 assigned tamoxifen 592 assigned anastrozole detected significant difference treatment groups physical health scores mean severity score 4672 tamoxifen vs 4585 anastrozole p=020 mental health scores 5238 vs 5148 p=038 energy fatigue 5834 vs 5754 p=086 symptoms depression 619 vs 639 p=046 5 years Vasomotor symptoms 133 vs 117 p=0011 difficulty bladder control 096 vs 080 p=00002 gynaecological symptoms 029 vs 018 p 00001 significantly severe tamoxifen group anastrozole group Musculoskeletal pain 150 vs 172 p=00006 vaginal symptoms 076 vs 086 p=0035 significantly worse anastrozole group tamoxifen group Sexual functioning differ significantly treatments 4365 vs 4529 p=056 Younger age significantly associated severe vasomotor symptoms mean severity score 145 age 60 years vs 065 age 60 years p=00006 vaginal symptoms 098 vs 065 p 00001 weight problems 132 vs 102 p 00001 gynaecological symptoms 026 vs 022 p=0014 Given similar efficacy tamoxifen anastrozole women older age 60 years decisions treatment informed risk adverse health effects symptoms associated drug women younger 60 years old treatment decisions driven efficacy favouring anastrozole side-effects anastrozole intolerable switching tamoxifen good alternative National Institute AstraZeneca Pharmaceuticals,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[3, 8449, 132, 465, 160, 72, 33, 60, 1, 24, 5, 3571, 185, 1105, 9, 1818, 706, 2291, 1, 12, 4, 1679, 7, 5, 1258, 134, 4, 957, 26, 414, 7777, 3, 254, 1, 46, 600, 23, 372, 1, 358, 2, 507, 3, 45, 10, 1822, 28, 9616, 1987, 4, 2669, 4010, 1679, 117, 5, 785, 109, 1258, 134, 4, 957, 73, 20, 3524, 5, 885, 170, 1012, 2, 902, 1104, 11, 1108, 896, 6, 560, 361, 1105, 179, 81, 218, 15, 30509, 14, 81, 218, 9, 33, 60, 1173, 20, 89, 335, 60, 105, 6690, 60, 7, 2, 2394, 11, 7415, 6, 24, 6834, 7, 781, 2956, 28, 330, 2, 454, 49, 53, 3972, 9, 49, 60, 3, 86, 123, 11, 4086, 133, 900, 2, 3031, 341, 1249, 1124, 703, 2, 12157, 507, 22, 379, 3, 40236, 934, 1124, 568, 123, 11, 507, 2, 2232, 2702, 2386, 123, 11, 5701, 559, 507, 18832, 507, 1863, 507, 924, 2408, 15721, 2, 1774, 21, 205, 3, 318, 20, 3205, 6, 943, 141, 7, 54, 781, 2956, 28, 330, 2, 28, 506, 1059, 190, 166, 126, 26, 45, 16, 1653, 5, 1252, 1239, 49471, 59, 7555, 49, 1522, 2, 1924, 167, 1324, 49472, 7, 11, 346, 4, 3, 45, 1, 953, 35462, 11, 159, 4, 3, 372, 1, 358, 13843, 10488, 896, 6, 1105, 2, 12646, 896, 6, 3571, 21, 530, 77, 93, 523, 59, 24, 271, 9, 900, 341, 703, 313, 1702, 368, 67337, 9, 1105, 105, 67338, 9, 3571, 19, 26984, 3031, 341, 703, 67339, 105, 67340, 19, 27269, 2803, 2, 613, 67341, 105, 67342, 19, 18056, 15, 507, 1, 1774, 67343, 105, 67344, 19, 21627, 252, 33, 60, 12157, 507, 48390, 105, 26985, 19, 27134, 4035, 5, 182, 20798, 105, 17002, 19, 23933, 2, 18832, 507, 29519, 105, 31991, 19, 4599, 11, 97, 80, 905, 4, 3, 1105, 87, 76, 4, 3, 3571, 87, 5701, 559, 35308, 105, 27493, 19, 32147, 2, 507, 18664, 105, 18056, 19, 67345, 11, 97, 639, 4, 3, 3571, 87, 76, 4, 3, 1105, 87, 2232, 2702, 205, 44, 1505, 97, 59, 3, 100, 640, 67346, 105, 67347, 19, 20803, 773, 89, 10, 97, 41, 5, 80, 905, 12157, 507, 313, 1702, 368, 25390, 9, 89, 335, 60, 105, 17025, 9, 89, 6690, 60, 19, 32147, 507, 18075, 105, 17025, 19, 4599, 924, 2408, 29261, 105, 18650, 19, 4599, 2, 18832, 507, 24114, 105, 27300, 19, 29113, 447, 3, 288, 209, 1, 1105, 2, 3571, 9, 117, 434, 76, 89, 335, 60, 1526, 545, 24, 257, 40, 2767, 20, 3, 43, 9, 1762, 290, 341, 176, 2, 3, 507, 41, 5, 296, 234, 9, 117, 773, 76, 335, 60, 1095, 24, 1526, 822, 40, 1621, 20, 209, 19888, 3571, 137, 492, 3, 1152, 176, 1, 3571, 32, 7130, 818, 7718, 6, 1105, 16, 8, 1178, 1091, 843, 657, 12, 1377, 11073, 5888]",3015.0,26686960,Patient-reported outcomes anastrozole versus tamoxifen postmenopausal patients ductal carcinoma situ treated lumpectomy plus radiotherapy NSABP B-35 randomised double-blind phase 3 clinical trial,0,0.0
Dying well: How equal is end of life care among gynecologic oncology patients?,Gynecologic oncology,Gynecol. Oncol.,2015-12-17,"To identify disparities in utilization of end of life (EoL) resources by gynecologic oncology (GO) patients. This retrospective analysis of the medical records of GO patients treated 1/2007-12/2011 and deceased 1/2012-8/2014 evaluated patient demographics, disease characteristics, and utilization of EoL resources. Chi-square, Fisher's exact test, Mann Whitney and Kruskal-Wallis tests were used for statistical analysis. Of 189 patients analyzed, 113 (60%) were white, 38 (20%) Hispanic, 31 (16%) black, and seven (4%) Asian. Ninety-five (48%) had ovarian cancer, 51 (26%) uterine, 47 (23%) cervical, seven (3%) vulvar/vaginal. In the last 30days of life (DoL), 18 (10%) had multiple hospital admissions, 10 (5%) admitted to the Intensive Care Unit (ICU), 30 (16%) multiple Emergency Room (ER) visits, 45 (24%) received aggressive medical care and eight (4%) received chemotherapy in the final 14 DoL. Furthermore, 54 (29%) had no Supportive Care referral and 29 (15%) no hospice referral. Only 46 (24%) had a Medical Power of Attorney (PoA) or Living Will (LW) on file. Non-white race was associated with increased odds of dying without hospice (OR 3.07; 95%CI [1.27, 2.46], p=0.013). However, non-white patients who enrolled in hospice did so earlier than white patients (42 v. 27days before death, p=0.054). Non-white patients were also significantly less likely to have PoA/LW documentation (24% v. 76%, p=0.009) even if enrolled in hospice (12% v. 31%, p=0.007). Significant racial disparities in hospice enrollment and PoA/LW documentation were seen in GO patients. This warrants further study to identify barriers to use of EoL resources.",Journal Article,1496.0,9.0,identify disparities utilization end life EoL resources gynecologic oncology patients retrospective medical records patients treated 1/2007-12/2011 deceased 1/2012-8/2014 evaluated patient demographics disease characteristics utilization EoL resources Chi-square Fisher 's exact test Mann Whitney Kruskal-Wallis tests statistical 189 patients 113 60 white 38 20 Hispanic 31 16 black seven 4 Asian Ninety-five 48 ovarian 51 26 uterine 47 23 cervical seven 3 vulvar/vaginal 30days life DoL 18 10 multiple hospital admissions 10 5 admitted Intensive Care Unit ICU 30 16 multiple Emergency Room ER visits 45 24 received aggressive medical care 4 received chemotherapy final 14 DoL Furthermore 54 29 Supportive Care referral 29 15 hospice referral 46 24 Medical Power Attorney PoA Living LW file Non-white race associated increased odds dying hospice 3.07 95 CI 1.27 2.46 p=0.013 non-white patients enrolled hospice earlier white patients 42 v. 27days death p=0.054 Non-white patients significantly likely PoA/LW documentation 24 v. 76 p=0.009 enrolled hospice 12 v. 31 p=0.007 Significant racial disparities hospice enrollment PoA/LW documentation seen patients warrants identify barriers use EoL resources,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 255, 2227, 4, 1961, 1, 396, 1, 358, 3946, 2892, 20, 1512, 413, 3537, 7, 26, 459, 65, 1, 3, 484, 1064, 1, 3537, 7, 73, 14, 1307, 133, 1132, 2, 11956, 14, 1195, 66, 1409, 194, 69, 2221, 34, 374, 2, 1961, 1, 3946, 2892, 3163, 3219, 3135, 292, 2472, 412, 7470, 7471, 2, 8800, 8875, 895, 11, 95, 9, 1050, 65, 1, 5899, 7, 311, 4259, 335, 11, 886, 519, 179, 1776, 456, 245, 1445, 2, 648, 39, 2399, 2493, 365, 576, 42, 12, 725, 432, 662, 382, 648, 27, 48010, 18982, 4, 3, 1060, 20849, 1, 358, 49483, 203, 79, 42, 232, 702, 5565, 79, 33, 4319, 6, 3, 1686, 165, 2712, 6195, 201, 245, 232, 4605, 4698, 516, 2690, 512, 259, 103, 571, 484, 165, 2, 659, 39, 103, 56, 4, 3, 1457, 213, 49483, 798, 667, 462, 42, 77, 1877, 165, 2096, 2, 462, 167, 77, 2490, 2096, 158, 641, 259, 42, 8, 484, 2349, 1, 21034, 20078, 15, 2798, 303, 36164, 23, 12339, 220, 886, 1047, 10, 41, 5, 101, 610, 1, 4536, 187, 2490, 15, 27, 1615, 48, 58, 14, 428, 18, 641, 19, 13, 3612, 137, 220, 886, 7, 54, 346, 4, 2490, 205, 1743, 1677, 76, 886, 7, 595, 603, 49085, 348, 273, 19, 13, 9546, 220, 886, 7, 11, 120, 97, 299, 322, 6, 47, 20078, 36164, 4965, 259, 603, 846, 19, 13, 2376, 871, 492, 346, 4, 2490, 133, 603, 456, 19, 13, 1999, 93, 2257, 2227, 4, 2490, 1798, 2, 20078, 36164, 4965, 11, 527, 4, 3537, 7, 26, 2782, 195, 45, 6, 255, 2160, 6, 119, 1, 3946, 2892]",1511.0,26706661,Dying equal end life care gynecologic oncology patients,30,0.1507537688442211
Impact of Robotic Platforms on Surgical Approach and Costs in the Management of Morbidly Obese Patients with Newly Diagnosed Uterine Cancer.,Annals of surgical oncology,Ann. Surg. Oncol.,2016-01-07,"Minimally invasive surgery (MIS) is associated with decreased complication rates, length of hospital stay, and cost compared with laparotomy. Robotic-assisted surgery-a method of laparoscopy-addresses many of the limitations of standard laparoscopic instrumentation, thus leading to increased rates of MIS. We sought to assess the impact of robotics on the rates and costs of surgical approaches in morbidly obese patients with uterine cancer. Patients who underwent primary surgery at our institution for uterine cancer from 1993 to 2012 with a BMI 40mg/m(2) were identified. Surgical approaches were categorized as laparotomy (planned or converted), laparoscopic, robotic, or vaginal. We identified two time periods based on the evolving use of MIS at our institution: laparoscopic (1993-2007) and robotic (2008-2012). Direct costs were analyzed for cases performed from 2009 to 2012. We identified 426 eligible cases; 299 performed via laparotomy, 125 via MIS, and 2 via a vaginal approach. The rates of MIS for the laparoscopic and robotic time periods were 6% and 57%, respectively. The rate of MIS was 78% in this morbidly obese cohort in 2012; 69% were completed robotically. The median length of hospital stay was 5days (range 2-37) for laparotomy cases and 1day (range 0-7) for MIS cases (P<0.001). The complication rate was 36 and 15%, respectively (P<0.001). The rate of wound-related complications was 27 and 6%, respectively (P<0.001). Laparotomy was associated with the highest cost. The robotic platform provides significant health and cost benefits by increasing MIS rates in this patient population.",Journal Article,1475.0,13.0,Minimally invasive surgery MIS associated decreased complication rates length hospital stay cost compared laparotomy Robotic-assisted surgery-a laparoscopy-addresses limitations standard laparoscopic instrumentation leading increased rates MIS sought assess impact robotics rates costs surgical approaches morbidly obese patients uterine Patients underwent primary surgery institution uterine 1993 2012 BMI 40 mg/m 2 identified Surgical approaches categorized laparotomy planned converted laparoscopic robotic vaginal identified time periods based evolving use MIS institution laparoscopic 1993-2007 robotic 2008-2012 Direct costs cases performed 2009 2012 identified 426 eligible cases 299 performed laparotomy 125 MIS 2 vaginal approach rates MIS laparoscopic robotic time periods 6 57 respectively rate MIS 78 morbidly obese cohort 2012 69 completed robotically median length hospital stay 5 days range 2-37 laparotomy cases 1 day range 0-7 MIS cases P 0.001 complication rate 36 15 respectively P 0.001 rate wound-related complications 27 6 respectively P 0.001 Laparotomy associated highest cost robotic platform provides significant health cost benefits increasing MIS rates patient population,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[2144, 416, 152, 4386, 16, 41, 5, 340, 1447, 151, 1318, 1, 702, 2020, 2, 835, 72, 5, 3274, 2895, 2927, 152, 8, 596, 1, 3553, 5437, 445, 1, 3, 1939, 1, 260, 1964, 9166, 631, 1049, 6, 101, 151, 1, 4386, 21, 990, 6, 423, 3, 345, 1, 23681, 23, 3, 151, 2, 1201, 1, 221, 611, 4, 9920, 2209, 7, 5, 12, 7, 54, 208, 86, 152, 28, 114, 731, 9, 12, 29, 3343, 6, 1195, 5, 8, 1140, 8483, 81, 188, 18, 11, 108, 221, 611, 11, 2320, 22, 3274, 1465, 15, 4764, 1964, 2895, 15, 21, 108, 100, 98, 3338, 90, 23, 3, 3276, 119, 1, 4386, 28, 114, 731, 1964, 3343, 1307, 2, 2895, 1375, 1195, 1196, 1201, 11, 311, 9, 140, 173, 29, 1238, 6, 1195, 21, 108, 12114, 625, 140, 8769, 173, 847, 3274, 1731, 847, 4386, 2, 18, 847, 8, 353, 3, 151, 1, 4386, 9, 3, 1964, 2, 2895, 98, 3338, 11, 49, 2, 696, 106, 3, 116, 1, 4386, 10, 833, 4, 26, 9920, 2209, 180, 4, 1195, 790, 11, 781, 15573, 3, 52, 1318, 1, 702, 2020, 10, 33, 162, 184, 18, 567, 9, 3274, 140, 2, 14, 218, 184, 13, 67, 9, 4386, 140, 19, 13, 144, 3, 1447, 116, 10, 511, 2, 167, 106, 19, 13, 144, 3, 116, 1, 2689, 139, 521, 10, 428, 2, 49, 106, 19, 13, 144, 3274, 10, 41, 5, 3, 1076, 835, 3, 2895, 2243, 777, 93, 341, 2, 835, 1141, 20, 602, 4386, 151, 4, 26, 69, 266]",1534.0,26744108,Impact Robotic Platforms Surgical Approach Costs Management Morbidly Obese Patients Newly Diagnosed Uterine,0,0.0
Surgical Outcomes of Patients Undergoing Extrafascial Hysterectomy After Neoadjuvant Radiotherapy With or Without Chemotherapy for Locally Advanced Endometrial Cancer Clinically Extending to the Cervix or Parametria.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2017-07-01,"Recent data have shown high rates of clinical and pathologic responses to neoadjuvant radiation therapy for locally advanced endometrial cancer. There are limited data on the surgical outcomes of these patients in the era of modern radiation and surgical techniques. We sought to characterize surgical outcomes after extrafascial hysterectomy in this population. Patients with endometrial cancer of all histologies clinically involving the cervix or parametria treated with neoadjuvant brachytherapy followed by extrafascial hysterectomy from 1999 to 2014 were identified. Patient charts were reviewed for data regarding treatment characteristics and postoperative outcomes. Pearson  and logistic regression analyses were used to assess correlations between surgical complications and treatment-related variables. Twenty-nine patients met inclusion criteria. Mean operating time for the cohort was 115 minutes. Mean estimated blood loss was 100 mL. No visceral injuries occurred. Mean length of hospital stay was 1 and 4 days for the minimally invasive and laparotomy groups, respectively. Rates of postoperative ileus, blood transfusion, wound infection, and readmission were 3%, 3%, 6%, and 3%, respectively. No case of prolonged urodynamic dysfunction was noted. The rate of vaginal complications was significantly higher in the group of patients who underwent minimally invasive surgery as compared with laparotomy (33% vs 5%, P < 0.041). These data support adjuvant extrafascial hysterectomy after neoadjuvant radiotherapy for endometrial cancer with cervical or parametrial involvement as a safe and viable procedure, with low rates of postoperative complications. Extra care should be taken when closing the vaginal cuff to reduce the risk of vaginal cuff complications.",Journal Article,934.0,3.0,Recent shown high rates clinical pathologic responses neoadjuvant radiation therapy locally advanced endometrial limited surgical outcomes patients era modern radiation surgical techniques sought characterize surgical outcomes extrafascial hysterectomy population Patients endometrial histologies clinically involving cervix parametria treated neoadjuvant brachytherapy followed extrafascial hysterectomy 1999 2014 identified Patient charts reviewed treatment characteristics postoperative outcomes Pearson  logistic regression assess correlations surgical complications treatment-related variables Twenty-nine patients met inclusion criteria Mean operating time cohort 115 minutes Mean estimated blood loss 100 mL visceral injuries occurred Mean length hospital stay 1 4 days minimally invasive laparotomy groups respectively Rates postoperative ileus blood transfusion wound infection readmission 3 3 6 3 respectively case prolonged urodynamic dysfunction noted rate vaginal complications significantly higher group patients underwent minimally invasive surgery compared laparotomy 33 vs 5 P 0.041 support adjuvant extrafascial hysterectomy neoadjuvant radiotherapy endometrial cervical parametrial involvement safe viable procedure low rates postoperative complications Extra care taken closing vaginal cuff reduce risk vaginal cuff complications,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[435, 74, 47, 443, 64, 151, 1, 38, 2, 510, 253, 6, 536, 121, 36, 9, 795, 131, 12, 125, 32, 383, 74, 23, 3, 221, 123, 1, 46, 7, 4, 3, 1713, 1, 2366, 121, 2, 221, 1092, 21, 990, 6, 1507, 221, 123, 50, 25094, 2622, 4, 26, 266, 7, 5, 12, 1, 62, 3489, 505, 1267, 3, 3629, 15, 19585, 73, 5, 536, 1536, 370, 20, 25094, 2622, 29, 2043, 6, 1409, 11, 108, 69, 4413, 11, 446, 9, 74, 666, 24, 374, 2, 573, 123, 4720, 5112, 2, 812, 320, 318, 11, 95, 6, 423, 2553, 59, 221, 521, 2, 24, 139, 682, 737, 762, 7, 543, 1680, 371, 313, 2584, 98, 9, 3, 180, 10, 3670, 2511, 313, 661, 315, 407, 10, 394, 542, 77, 2737, 13063, 489, 313, 1318, 1, 702, 2020, 10, 14, 2, 39, 162, 9, 3, 2144, 416, 2, 3274, 271, 106, 151, 1, 573, 9843, 315, 2785, 2689, 930, 2, 3146, 11, 27, 27, 49, 2, 27, 106, 77, 473, 1, 1069, 39950, 1527, 10, 1051, 3, 116, 1, 521, 10, 97, 142, 4, 3, 87, 1, 7, 54, 208, 2144, 416, 152, 22, 72, 5, 3274, 466, 105, 33, 19, 13, 5937, 46, 74, 538, 249, 25094, 2622, 50, 536, 310, 9, 12, 5, 15, 8726, 799, 22, 8, 1165, 2, 2663, 1299, 5, 154, 151, 1, 573, 521, 3420, 165, 257, 40, 1633, 198, 21257, 3, 11445, 6, 969, 3, 43, 1, 11445, 521]",1673.0,26825835,Surgical Outcomes Patients Undergoing Extrafascial Hysterectomy Neoadjuvant Radiotherapy Chemotherapy Locally Advanced Endometrial Clinically Extending Cervix Parametria,1,0.005025125628140704
Stage I and II Endometrial Adenocarcinoma: Analysis of 2009 FIGO Staging Revision and Impact on Survival by Adjuvant Therapy.,American journal of clinical oncology,Am. J. Clin. Oncol.,2018-03-01,"In 2009, the International Federation of Gynecology and Obstetrics revised the staging classification for endometrial cancer. Mucosal cervical involvement was eliminated from the criteria and only those with stromal cervical involvement were considered stage II. We examined the implications of the staging changes and the survival impact of adjuvant therapy in stage I to II endometrial adenocarcinoma. Data were obtained from the National Oncology Data Alliance. Stage I to II endometrial adenocarcinoma patients diagnosed between 1988 and 2008 were identified and grouped according to the 1988 International Federation of Gynecology and Obstetrics staging. Multivariate analysis (MVA) was performed using proportional hazards model; comparison of Kaplan-Meier survival curves was based on the log-rank statistic. A total of 14,158 patients with stage I to II endometrial adenocarcinoma were identified with a median follow-up of 41 months. Adjuvant external-beam radiation therapy (EBRT) and adjuvant vaginal brachytherapy (VB) were positive predictors for overall survival (OS) only in IC, IIA, and IIB. On MVA, stages IA and IB OS did not differ (P=0.17), IIA had worse OS compared with IC (P<0.05), and IIA OS did not differ from IIB (P=0.57). Neither IA nor IB benefited from adjuvant radiotherapy on MVA. However, both IC and IIA had OS improvements with VBEBRT (P<0.05) with the greatest impact from the VB. Mucosal cervical involvement represents a risk factor and should be considered when determining adjuvant therapy. Adjuvant therapy provided no survival benefit in 1988 stage IA or IB; however, adjuvant radiotherapy is recommended in the management of IC, IIA, and IIB.",Journal Article,691.0,2.0,"2009 International Federation Gynecology Obstetrics revised staging classification endometrial Mucosal cervical involvement eliminated criteria stromal cervical involvement considered stage II examined implications staging changes survival impact adjuvant therapy stage II endometrial adenocarcinoma obtained National Oncology Alliance Stage II endometrial adenocarcinoma patients diagnosed 1988 2008 identified grouped according 1988 International Federation Gynecology Obstetrics staging Multivariate MVA performed proportional hazards model comparison Kaplan-Meier survival curves based log-rank statistic total 14,158 patients stage II endometrial adenocarcinoma identified median follow-up 41 months Adjuvant external-beam radiation therapy EBRT adjuvant vaginal brachytherapy VB positive predictors overall survival OS IC IIA IIB MVA stages IA IB OS differ P=0.17 IIA worse OS compared IC P 0.05 IIA OS differ IIB P=0.57 IA IB benefited adjuvant radiotherapy MVA IC IIA OS improvements VBEBRT P 0.05 greatest impact VB Mucosal cervical involvement represents risk factor considered determining adjuvant therapy Adjuvant therapy provided survival benefit 1988 stage IA IB adjuvant radiotherapy recommended management IC IIA IIB",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,"[4, 1238, 3, 944, 7303, 1, 6429, 2, 7407, 4218, 3, 632, 947, 9, 12, 3068, 799, 10, 6173, 29, 3, 371, 2, 158, 135, 5, 1126, 799, 11, 515, 82, 215, 21, 409, 3, 1268, 1, 3, 632, 400, 2, 3, 25, 345, 1, 249, 36, 4, 82, 70, 6, 215, 449, 74, 11, 683, 29, 3, 657, 413, 74, 7127, 82, 70, 6, 215, 449, 7, 265, 59, 3314, 2, 1375, 11, 108, 2, 3706, 768, 6, 3, 3314, 944, 7303, 1, 6429, 2, 7407, 632, 331, 65, 5320, 10, 173, 75, 831, 1017, 202, 1155, 1, 876, 882, 25, 2400, 10, 90, 23, 3, 1066, 1026, 4502, 8, 181, 1, 213, 5162, 7, 5, 82, 70, 6, 215, 449, 11, 108, 5, 8, 52, 166, 126, 1, 605, 53, 249, 1455, 1345, 121, 36, 1883, 2, 249, 1536, 9464, 11, 109, 674, 9, 63, 25, 118, 158, 4, 2340, 4088, 2, 3884, 23, 5320, 1153, 3302, 2, 3180, 118, 205, 44, 1505, 19, 13, 269, 4088, 42, 639, 118, 72, 5, 2340, 19, 13, 474, 2, 4088, 118, 205, 44, 1505, 29, 3884, 19, 13, 696, 2174, 3302, 2110, 3180, 7067, 29, 249, 310, 23, 5320, 137, 110, 2340, 2, 4088, 42, 118, 1474, 5, 67654, 19, 13, 474, 5, 3, 2199, 345, 29, 3, 9464, 3068, 799, 1449, 8, 43, 161, 2, 257, 40, 515, 198, 2196, 249, 36, 249, 36, 1052, 77, 25, 247, 4, 3314, 82, 3302, 15, 3180, 137, 249, 310, 16, 793, 4, 3, 284, 1, 2340, 4088, 2, 3884]",1562.0,26886945,Stage II Endometrial Adenocarcinoma 2009 FIGO Staging Revision Impact Survival Adjuvant Therapy,0,0.0
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2016-03-28,"The Suppression of Ovarian Function trial showed improved disease control for tamoxifen plus ovarian function suppression (OFS) compared with tamoxifen alone for the cohort of premenopausal patients who received prior chemotherapy. We present the patient-reported outcomes. The quality-of-life (QoL) analysis includes 1,722 of 2,045 premenopausal patients with hormone receptor-positive breast cancer randomly assigned to receive adjuvant treatment with 5 years of tamoxifen plus OFS or tamoxifen alone. Chemotherapy use before enrollment was optional. Patients completed a QoL form consisting of global and symptom indicators at baseline, every 6 months for 24 months, and annually during years 3 to 6. Differences in the change of QoL from baseline between the two treatments were tested at 6, 24, and 60 months with mixed models for repeated measures with and without chemotherapy and overall. Patients on tamoxifen plus OFS were more affected than patients on tamoxifen alone by hot flushes at 6 and 24 months, by loss of sexual interest and sleep disturbance at 6 months, and by vaginal dryness up to 60 months. Without prior chemotherapy, patients on tamoxifen alone reported more vaginal discharge over the 5 years than patients on tamoxifen plus OFS. Symptom-specific treatment differences at 6 months were less pronounced in patients with prior chemotherapy. Changes in global QoL indicators from baseline were small and similar between treatments over the whole treatment period. Overall, OFS added to tamoxifen resulted in worse endocrine symptoms and sexual functioning during the first 2 years of treatment, with variable magnitudes of treatment differences. Short-term differences in symptom-specific QoL, treatment burden, and coping effort between treatment groups were less pronounced for patients with prior chemotherapy, the cohort that benefited most from OFS in terms of disease control.",Journal Article,1394.0,36.0,"Suppression Ovarian Function trial showed improved disease control tamoxifen plus ovarian function suppression OFS compared tamoxifen cohort premenopausal patients received prior chemotherapy present patient-reported outcomes quality-of-life QoL includes 1,722 2,045 premenopausal patients hormone receptor-positive breast randomly assigned receive adjuvant treatment 5 years tamoxifen plus OFS tamoxifen Chemotherapy use enrollment optional Patients completed QoL form consisting global symptom indicators baseline 6 months 24 months annually years 3 6 Differences change QoL baseline treatments tested 6 24 60 months mixed models repeated measures chemotherapy overall Patients tamoxifen plus OFS affected patients tamoxifen hot flushes 6 24 months loss sexual sleep disturbance 6 months vaginal dryness 60 months prior chemotherapy patients tamoxifen reported vaginal discharge 5 years patients tamoxifen plus OFS Symptom-specific treatment differences 6 months pronounced patients prior chemotherapy Changes global QoL indicators baseline small similar treatments treatment period Overall OFS added tamoxifen resulted worse endocrine symptoms sexual functioning 2 years treatment variable magnitudes treatment differences Short-term differences symptom-specific QoL treatment burden coping effort treatment groups pronounced patients prior chemotherapy cohort benefited OFS terms disease control",1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 1332, 1, 343, 160, 224, 231, 34, 182, 9, 1105, 349, 343, 1332, 8354, 72, 5, 1105, 279, 9, 3, 180, 1, 2710, 7, 54, 103, 324, 56, 21, 364, 3, 69, 210, 123, 3, 372, 1, 358, 1001, 65, 1920, 14, 13968, 1, 18, 4918, 2710, 7, 5, 785, 153, 109, 12, 1108, 896, 6, 560, 249, 24, 5, 33, 60, 1, 1105, 349, 8354, 15, 1105, 279, 56, 119, 348, 1798, 10, 9281, 7, 781, 8, 1001, 1297, 2273, 1, 1648, 2, 934, 3539, 28, 330, 454, 49, 53, 9, 259, 53, 2, 4226, 190, 60, 27, 6, 49, 362, 4, 3, 707, 1, 1001, 29, 330, 59, 3, 100, 640, 11, 650, 28, 49, 259, 2, 335, 53, 5, 1739, 274, 9, 2113, 1018, 5, 2, 187, 56, 2, 63, 7, 23, 1105, 349, 8354, 11, 80, 1424, 76, 7, 23, 1105, 279, 20, 2859, 18182, 28, 49, 2, 259, 53, 20, 407, 1, 2232, 1333, 2, 2494, 6663, 28, 49, 53, 2, 20, 15822, 126, 6, 335, 53, 187, 324, 56, 7, 23, 1105, 279, 210, 80, 2993, 252, 3, 33, 60, 76, 7, 23, 1105, 349, 8354, 934, 112, 24, 362, 28, 49, 53, 11, 299, 3517, 4, 7, 5, 324, 56, 400, 4, 1648, 1001, 3539, 29, 330, 11, 302, 2, 288, 59, 640, 252, 3, 902, 24, 727, 63, 8354, 1953, 6, 1105, 627, 4, 639, 1293, 507, 2, 2232, 2702, 190, 3, 157, 18, 60, 1, 24, 5, 1347, 17801, 1, 24, 362, 978, 337, 362, 4, 934, 112, 1001, 24, 892, 2, 4276, 2919, 59, 24, 271, 11, 299, 3517, 9, 7, 5, 324, 56, 3, 180, 17, 7067, 96, 29, 8354, 4, 1794, 1, 34, 182]",1841.0,27022111,Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Premenopausal Women Early Breast Patient-Reported Outcomes Suppression Ovarian Function Trial,0,0.0
Endometrial Cancer Associated Symptoms: A Case-Control Study.,Journal of women's health (2002),J Womens Health (Larchmt),2016-06-02,"The majority of women with endometrial cancer (EC) present at an early stage with an associated 5-year survival rate of >90%. High rates of early detection are attributed to warning symptoms; however, the prevalence of such symptoms has not been well defined. A case-control study was conducted assessing the prevalence of symptoms in EC patients at a large cancer center compared with healthy controls. Controls included patients seen for an annual gynecologic care visit (AV) or for a gynecological problem-based visit (PV). A self-administered questionnaire was given to all participants addressing EC-associated symptoms, at the time of initial clinic visit. Odds ratios (ORs) were used to compare prevalence of symptoms between EC cases and controls. Logistic regression was used to determine the impact of menopausal status and obesity on symptom prevalence. The cases (n=75) were significantly older than the AV (n=203) and PV (n=151) controls (59.7 vs. 49.8 vs. 51.0 years, p<0.01), had a higher body mass index (35.5 vs. 29.4 vs. 30.9kg/m<sup>2</sup>, p<0.01), and were more likely to be postmenopausal (76% vs. 53.7% vs. 52.0%, p<0.01). The cases were more likely to report postmenopausal bleeding (OR=32.99 and 5.83, p<0.01) and abnormal vaginal discharge (OR=8.8 and 3.3, p<0.01) compared with the AV and PV groups. Overall, 55.4% of cases reported abnormal vaginal discharge. Symptoms of both postmenopausal bleeding and abnormal vaginal discharge were significantly higher in EC compared with controls. The presence of such symptoms should raise concern for malignant disease and prompt immediate gynecological evaluation.",Journal Article,1328.0,4.0,majority women endometrial EC present early stage associated 5-year survival rate 90 High rates early detection attributed warning symptoms prevalence symptoms defined case-control conducted assessing prevalence symptoms EC patients large center compared healthy controls Controls included patients seen annual gynecologic care visit AV gynecological problem-based visit PV self-administered questionnaire given participants addressing EC-associated symptoms time initial clinic visit Odds ratios ORs compare prevalence symptoms EC cases controls Logistic regression determine impact menopausal status obesity symptom prevalence cases n 75 significantly older AV n 203 PV n 151 controls 59.7 vs. 49.8 vs. 51.0 years p 0.01 higher body mass index 35.5 vs. 29.4 vs. 30.9 kg/m sup 2 /sup p 0.01 likely postmenopausal 76 vs. 53.7 vs. 52.0 p 0.01 cases likely report postmenopausal bleeding 32.99 5.83 p 0.01 abnormal vaginal discharge 8.8 3.3 p 0.01 compared AV PV groups Overall 55.4 cases reported abnormal vaginal discharge Symptoms postmenopausal bleeding abnormal vaginal discharge significantly higher EC compared controls presence symptoms raise concern malignant disease prompt immediate gynecological evaluation,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[3, 686, 1, 117, 5, 12, 2180, 364, 28, 35, 191, 82, 5, 35, 41, 33, 111, 25, 116, 1, 424, 64, 151, 1, 191, 638, 32, 3073, 6, 15986, 507, 137, 3, 1078, 1, 225, 507, 71, 44, 85, 149, 395, 8, 473, 182, 45, 10, 426, 1977, 3, 1078, 1, 507, 4, 2180, 7, 28, 8, 375, 12, 574, 72, 5, 1331, 535, 535, 159, 7, 527, 9, 35, 2114, 1512, 165, 2807, 19679, 15, 9, 8, 6324, 2497, 90, 2807, 3328, 8, 1074, 468, 1770, 10, 447, 6, 62, 776, 3432, 2180, 41, 507, 28, 3, 98, 1, 388, 1188, 2807, 610, 1137, 3694, 11, 95, 6, 932, 1078, 1, 507, 59, 2180, 140, 2, 535, 812, 320, 10, 95, 6, 223, 3, 345, 1, 3565, 156, 2, 1661, 23, 934, 1078, 3, 140, 78, 481, 11, 97, 434, 76, 3, 19679, 78, 5426, 2, 3328, 78, 5075, 535, 728, 67, 105, 739, 66, 105, 725, 13, 60, 19, 13, 355, 42, 8, 142, 642, 782, 558, 465, 33, 105, 462, 39, 105, 201, 83, 503, 188, 172, 18, 172, 19, 13, 355, 2, 11, 80, 322, 6, 40, 1679, 846, 105, 699, 67, 105, 653, 13, 19, 13, 355, 3, 140, 11, 80, 322, 6, 414, 1679, 2294, 15, 531, 1058, 2, 33, 852, 19, 13, 355, 2, 1668, 2993, 15, 66, 66, 2, 27, 27, 19, 13, 355, 72, 5, 3, 19679, 2, 3328, 271, 63, 614, 39, 1, 140, 210, 1668, 2993, 507, 1, 110, 1679, 2294, 2, 1668, 2993, 11, 97, 142, 4, 2180, 72, 5, 535, 3, 463, 1, 225, 507, 257, 5008, 2893, 9, 393, 34, 2, 4776, 2181, 6324, 451]",1547.0,27254529,Endometrial Associated Symptoms Case-Control,1,0.005025125628140704
American Brachytherapy Task Group Report: Adjuvant vaginal brachytherapy for early-stage endometrial cancer: A comprehensive review.,Brachytherapy,Brachytherapy,2016-05-31,"This article aims to review the risk stratification of endometrial cancer, treatment rationale, outcomes, treatment planning, and treatment recommendations of vaginal brachytherapy (VBT) in the postoperative management of endometrial cancer patients. The authors performed a thorough review of the literature and reference pertinent articles pertaining to the aims of this review. Adjuvant VBT for early-stage endometrial cancer patients results in very low rates of vaginal recurrence (0-3.1%) with low rates of late toxicity which are primarily vaginal in nature. Post-Operative Radiation Therapy in Endometrial Cancer 2 (PORTEC-2) supports that VBT results in noninferior rates ofvaginal recurrence compared to external beam radiotherapy for the treatment of high-intermediate risk patients. VBT as a boost after external beam radiotherapy, in combination with chemotherapy, and for high-risk histologies have shown excellent results as well though randomized data do not exist supporting VBT boost. There are many different applicators, dose-fractionation schedules, and treatment planning techniques which all result in favorable clinical outcomes and low rates of toxicity. Recommendations have been published by the American Brachytherapy Society and the American Society of Radiation Oncology to help guide practitioners in the use of VBT. Data support that patients and physicians prefer joint decision making regarding the use of VBT, and patients often desire additional treatment for a marginal benefit inrisk of recurrence. Discussions regarding adjuvant therapy for endometrial cancer are best performed in a multidisciplinary setting, and patients should be counseled properly regarding the risks and benefits of adjuvant therapy.",Journal Article,1330.0,22.0,article aims review risk stratification endometrial treatment rationale outcomes treatment planning treatment recommendations vaginal brachytherapy VBT postoperative management endometrial patients authors performed thorough review literature reference pertinent articles pertaining aims review Adjuvant VBT early-stage endometrial patients low rates vaginal recurrence 0-3.1 low rates late toxicity primarily vaginal nature Post-Operative Radiation Therapy Endometrial 2 PORTEC-2 supports VBT noninferior rates vaginal recurrence compared external beam radiotherapy treatment high-intermediate risk patients VBT boost external beam radiotherapy combination chemotherapy high-risk histologies shown excellent randomized exist supporting VBT boost different applicators dose-fractionation schedules treatment planning techniques favorable clinical outcomes low rates toxicity Recommendations published American Brachytherapy Society American Society Radiation Oncology help guide practitioners use VBT support patients physicians prefer joint decision making use VBT patients desire additional treatment marginal benefit risk recurrence Discussions adjuvant therapy endometrial best performed multidisciplinary setting patients counseled properly risks benefits adjuvant therapy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[26, 946, 2970, 6, 206, 3, 43, 1541, 1, 12, 24, 1728, 123, 24, 1349, 2, 24, 883, 1, 1536, 15050, 4, 3, 573, 284, 1, 12, 7, 3, 738, 173, 8, 5506, 206, 1, 3, 789, 2, 2482, 5799, 2384, 6553, 6, 3, 2970, 1, 26, 206, 249, 15050, 9, 191, 82, 12, 7, 99, 4, 923, 154, 151, 1, 146, 13, 27, 14, 5, 154, 151, 1, 807, 155, 92, 32, 1561, 4, 2202, 539, 1208, 121, 36, 4, 12, 18, 32606, 18, 2304, 17, 15050, 99, 4, 12427, 151, 1, 146, 72, 6, 1455, 1345, 310, 9, 3, 24, 1, 64, 919, 43, 7, 15050, 22, 8, 2569, 50, 1455, 1345, 310, 4, 150, 5, 56, 2, 9, 64, 43, 3489, 47, 443, 1503, 99, 22, 149, 2471, 384, 74, 1022, 44, 1923, 1912, 15050, 2569, 125, 32, 445, 338, 11800, 61, 3519, 2314, 2, 24, 1349, 1092, 92, 62, 757, 4, 913, 38, 123, 2, 154, 151, 1, 155, 883, 47, 85, 983, 20, 3, 597, 1536, 1174, 2, 3, 597, 1174, 1, 121, 413, 6, 987, 1597, 6323, 4, 3, 119, 1, 15050, 74, 538, 17, 7, 2, 1261, 11279, 2093, 948, 1079, 666, 3, 119, 1, 15050, 2, 7, 629, 5278, 402, 24, 9, 8, 3450, 247, 4, 43, 1, 146, 3173, 666, 249, 36, 9, 12, 32, 824, 173, 4, 8, 1643, 546, 2, 7, 257, 40, 10411, 6785, 666, 3, 1098, 2, 1141, 1, 249, 36]",1629.0,27260082,American Brachytherapy Task Group Report Adjuvant vaginal brachytherapy early-stage endometrial comprehensive review,7,0.035175879396984924
Management of Hormone Deprivation Symptoms After Cancer.,Mayo Clinic proceedings,Mayo Clin. Proc.,2016-08-01,"Cancer survivors often experience symptoms related to hormone deprivation, including vasomotor symptoms, genitourinary symptoms, and sexual health concerns. These symptoms can occur due to natural menopause in midlife women, or they can be brought on by oncologic therapies in younger women or men. We searched PubMed for English-language studies from January 1990 through January 2016 to identify relevant articles on the management of hormone deprivation symptoms, including vasomotor, genitourinary, and sexual symptoms in patients with cancer. The search terms used included hormone deprivation, vasomotor symptoms, hot flash, vaginal dryness, sexual dysfunction, and breast cancer. This manuscript provides a comprehensive description of data supporting the treatment of symptoms associated with hormone deprivation.",Journal Article,1268.0,4.0,survivors experience symptoms related hormone deprivation including vasomotor symptoms genitourinary symptoms sexual health concerns symptoms occur natural menopause midlife women brought oncologic therapies younger women men searched PubMed English-language studies January 1990 January 2016 identify relevant articles management hormone deprivation symptoms including vasomotor genitourinary sexual symptoms patients search terms included hormone deprivation vasomotor symptoms hot flash vaginal dryness sexual dysfunction breast manuscript provides comprehensive description supporting treatment symptoms associated hormone deprivation,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[12, 332, 629, 730, 507, 139, 6, 785, 1868, 141, 12157, 507, 4109, 507, 2, 2232, 341, 2061, 46, 507, 122, 1271, 520, 6, 1504, 5034, 4, 38302, 117, 15, 491, 122, 40, 6681, 23, 20, 1998, 235, 4, 773, 117, 15, 325, 21, 3080, 3161, 9, 4201, 4794, 94, 29, 1024, 2289, 298, 1024, 1390, 6, 255, 867, 2384, 23, 3, 284, 1, 785, 1868, 507, 141, 12157, 4109, 2, 2232, 507, 4, 7, 5, 12, 3, 1901, 1794, 95, 159, 785, 1868, 12157, 507, 2859, 6568, 15822, 2232, 1527, 2, 12, 26, 5825, 777, 8, 949, 5263, 1, 74, 1912, 3, 24, 1, 507, 41, 5, 785, 1868]",789.0,27492917,Management Hormone Deprivation Symptoms,4,0.020100502512562814
Perioperative Outcomes for Laparotomy Compared to Robotic Surgical Staging of Endometrial Cancer in the Elderly: A Retrospective Cohort.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2016-11-01,"This study aimed to compare outcomes of endometrial cancer (EMCA) staging in elderly patients performed either robotically or via laparotomy. A retrospective, multi-institutional chart review was conducted of all robotic and laparotomy staging surgeries for EMCA between 2003 and 2009. Charts were reviewed for intraoperative and postoperative complications and morbidities. Seven hundred forty-six women were identified who had undergone EMCA staging either robotically or via laparotomy; 89 and 93 patients 70 years or older underwent staging for EMCA via robotic and laparotomy, respectively. Both groups had similar age and body mass index. Among elderly patients being staged robotically, a higher incidence of pelvic lymphadenectomy, and decreased blood loss, incidence of blood transfusion, and overall complications were seen compared to laparotomy. Postoperatively, elderly patients staged robotically had a shorter median hospital stay (1 vs 4 days, P < 0.001), with no increase in readmission or return to the operating theater. No vessel, bowel, or genitourinary injuries occurred. Vaginal cuff dehiscence after robotic surgery was not significantly different, but wound and fascial complications were significantly increased in patients undergoing laparotomy. Thromboembolism rates were similar between both groups. Elderly patients can safely undergo robotic EMCA staging with improved outcomes compared to laparotomy. The benefits of robotic staging include higher incidence of completion of lymphadenectomy, decreased hospital stay (without an increase in readmissions or reoperations), decreased transfusions, and decreased wound and fascial complications.",Comparative Study,1176.0,8.0,aimed compare outcomes endometrial EMCA staging elderly patients performed robotically laparotomy retrospective multi-institutional chart review conducted robotic laparotomy staging surgeries EMCA 2003 2009 Charts reviewed intraoperative postoperative complications morbidities Seven forty-six women identified undergone EMCA staging robotically laparotomy 89 93 patients 70 years older underwent staging EMCA robotic laparotomy respectively groups similar age body mass index elderly patients staged robotically higher incidence pelvic lymphadenectomy decreased blood loss incidence blood transfusion overall complications seen compared laparotomy Postoperatively elderly patients staged robotically shorter median hospital stay 1 vs 4 days P 0.001 increase readmission return operating theater vessel bowel genitourinary injuries occurred Vaginal cuff dehiscence robotic surgery significantly different wound fascial complications significantly increased patients undergoing laparotomy Thromboembolism rates similar groups Elderly patients safely undergo robotic EMCA staging improved outcomes compared laparotomy benefits robotic staging include higher incidence completion lymphadenectomy decreased hospital stay increase readmissions reoperations decreased transfusions decreased wound fascial complications,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[26, 45, 1295, 6, 932, 123, 1, 12, 32645, 632, 4, 1216, 7, 173, 361, 15573, 15, 847, 3274, 8, 459, 1414, 1115, 2937, 206, 10, 426, 1, 62, 2895, 2, 3274, 632, 5305, 9, 32645, 59, 1522, 2, 1238, 4413, 11, 446, 9, 1720, 2, 573, 521, 2, 5655, 648, 1128, 1213, 437, 117, 11, 108, 54, 42, 1989, 32645, 632, 361, 15573, 15, 847, 3274, 887, 2, 966, 7, 431, 60, 15, 434, 208, 632, 9, 32645, 847, 2895, 2, 3274, 106, 110, 271, 42, 288, 89, 2, 642, 782, 558, 107, 1216, 7, 486, 2930, 15573, 8, 142, 287, 1, 1110, 2048, 2, 340, 315, 407, 287, 1, 315, 2785, 2, 63, 521, 11, 527, 72, 6, 3274, 3541, 1216, 7, 2930, 15573, 42, 8, 985, 52, 702, 2020, 14, 105, 39, 162, 19, 13, 144, 5, 77, 344, 4, 3146, 15, 4656, 6, 3, 2584, 68895, 77, 3685, 1659, 15, 4109, 13063, 489, 11445, 11811, 50, 2895, 152, 10, 44, 97, 338, 84, 2689, 2, 15027, 521, 11, 97, 101, 4, 7, 479, 3274, 3501, 151, 11, 288, 59, 110, 271, 1216, 7, 122, 2268, 1251, 2895, 32645, 632, 5, 231, 123, 72, 6, 3274, 3, 1141, 1, 2895, 632, 643, 142, 287, 1, 1438, 1, 2048, 340, 702, 2020, 187, 35, 344, 4, 5319, 15, 10691, 340, 4987, 2, 340, 2689, 2, 15027, 521]",1617.0,27575633,Perioperative Outcomes Laparotomy Compared Robotic Surgical Staging Endometrial Elderly Retrospective Cohort,0,0.0
Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up.,Gynecologic oncology,Gynecol. Oncol.,2016-09-09,"The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial originally reported no mortality benefit of ovarian cancer screening after a median of 12.4years of follow-up. The UKCTOCS screening trial failed to show a statistically significant mortality reduction in the primary analysis but reported an apparent increased mortality benefit in trial years 7-14 compared to 0-7. Here we report an updated analysis of PLCO with extended mortality follow-up. Participants were randomized from 1993 to 2001 at ten U.S. centers to an intervention or usual care arm. Intervention arm women were screened for ovarian cancer with annual trans-vaginal ultrasound (TVU) (4years) and CA-125 (6years), with a fixed cutoff at 35U/mL for CA-125. The original follow-up period was for up to 13years (median follow-up 12.4years); in this analysis follow-up for mortality was extended by up to 6years. 39,105 (intervention) and 39,111 (usual care) women were randomized, of which 34,253 and 34,304, respectively, had at least one ovary at baseline. Median follow-up was 14.7years in each arm and maximum follow-up 19.2years in each arm. A total of 187 (intervention) and 176 (usual care) deaths from ovarian cancer were observed, for a risk-ratio of 1.06 (95% CI: 0.87-1.30). Risk-ratios were similar for study years 0-7 (RR=1.04), 7-14 (RR=1.06) and 14+ (RR=1.09). The risk ratio for all-cause mortality was 1.01 (95% CI: 0.97-1.05). Ovarian cancer specific survival was not significantly different across trial arms (p=0.16). Extended follow-up of PLCO indicated no mortality benefit from screening for ovarian cancer with CA-125 and TVU.",Journal Article,1229.0,35.0,"Prostate Lung Colorectal Ovarian PLCO Screening Trial originally reported mortality benefit ovarian screening median 12.4years follow-up UKCTOCS screening trial failed statistically significant mortality reduction primary reported apparent increased mortality benefit trial years 7-14 compared 0-7 report updated PLCO extended mortality follow-up Participants randomized 1993 2001 U.S. centers intervention usual care arm Intervention arm women screened ovarian annual trans-vaginal ultrasound TVU 4years CA-125 6years fixed cutoff 35U/mL CA-125 original follow-up period 13years median follow-up 12.4years follow-up mortality extended 6years 39,105 intervention 39,111 usual care women randomized 34,253 34,304 respectively ovary baseline Median follow-up 14.7years arm maximum follow-up 19.2years arm total 187 intervention 176 usual care deaths ovarian observed risk-ratio 1.06 95 CI 0.87-1.30 Risk-ratios similar years 0-7 RR=1.04 7-14 RR=1.06 14+ RR=1.09 risk ratio all-cause mortality 1.01 95 CI 0.97-1.05 Ovarian specific survival significantly different trial arms p=0.16 Extended follow-up PLCO indicated mortality benefit screening ovarian CA-125 TVU",0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 2, 9299, 12, 453, 160, 5045, 210, 77, 282, 247, 1, 12, 453, 50, 8, 52, 1, 133, 23939, 1, 166, 126, 3, 26462, 453, 160, 1551, 6, 514, 8, 712, 93, 282, 628, 4, 3, 86, 65, 84, 210, 35, 2235, 101, 282, 247, 4, 160, 60, 67, 213, 72, 6, 13, 67, 467, 21, 414, 35, 2939, 65, 1, 9299, 5, 1747, 282, 166, 126, 776, 11, 384, 29, 3343, 6, 1758, 28, 1618, 1767, 695, 1168, 6, 35, 788, 15, 3521, 165, 475, 788, 475, 117, 11, 2261, 9, 12, 5, 2114, 3437, 18982, 1945, 12814, 23939, 2, 1568, 1731, 27052, 5, 8, 1959, 2779, 28, 31861, 542, 9, 1568, 1731, 3, 2279, 166, 126, 727, 10, 9, 126, 6, 68964, 52, 166, 126, 133, 23939, 4, 26, 65, 166, 126, 9, 282, 10, 1747, 20, 126, 6, 27052, 587, 3263, 788, 2, 587, 3167, 3521, 165, 117, 11, 384, 1, 92, 562, 8105, 2, 562, 8940, 106, 42, 28, 506, 104, 3631, 28, 330, 52, 166, 126, 10, 213, 41552, 4, 296, 475, 2, 689, 166, 126, 326, 15766, 4, 296, 475, 8, 181, 1, 5568, 788, 2, 5800, 3521, 165, 1043, 29, 12, 11, 164, 9, 8, 43, 197, 1, 14, 1460, 48, 58, 13, 912, 14, 201, 43, 1137, 11, 288, 9, 45, 60, 13, 67, 861, 14, 755, 67, 213, 861, 14, 1460, 2, 213, 861, 14, 1730, 3, 43, 197, 9, 62, 708, 282, 10, 14, 355, 48, 58, 13, 1015, 14, 474, 12, 112, 25, 10, 44, 97, 338, 716, 160, 1335, 19, 13, 245, 1747, 166, 126, 1, 9299, 1103, 77, 282, 247, 29, 453, 9, 12, 5, 1568, 1731, 2, 12814]",1505.0,27615399,Extended mortality ovarian screening PLCO trial median 15years follow-up,0,0.0
Menopausal hormone therapy in cancer survivors: A narrative review of the literature.,Maturitas,Maturitas,2016-07-27,"Decision making regarding the use of menopausal hormone therapy (MHT) for the treatment of bothersome menopausal symptoms in a cancer survivor can be complex, and includes assessment of its impact on disease-free or overall survival. Estrogen receptors are present in several cancer types, but this does not always result in estrogen-mediated tumor proliferation and adverse cancer-related outcomes. Estrogen may even be protective against certain cancers. Menopausal hormone therapy is associated with an increased risk of recurrence and mortality after diagnosis of some cancer types, but not others. We provide a narrative review of the medical literature regarding the risk of cancer recurrence and associated mortality with initiation of MHT after the diagnosis of breast, gynecologic, lung, colorectal, hematologic cancers, and melanoma. Menopausal hormone therapy may be considered for management of bothersome menopausal symptoms in women with some cancer types (e.g., colorectal and hematologic cancer, localized melanoma, and most cervical, vulvar and vaginal cancers), while nonhormonal treatment options may be preferred for others (e.g., breast cancer). In women with other cancer types, recommendations are less straightforward, and the use of MHT must be individualized. ",Journal Article,1273.0,12.0,Decision making use menopausal hormone therapy MHT treatment bothersome menopausal symptoms survivor complex includes assessment impact disease-free overall survival Estrogen receptors present types estrogen-mediated proliferation adverse cancer-related outcomes Estrogen protective certain Menopausal hormone therapy associated increased risk recurrence mortality diagnosis types provide narrative review medical literature risk recurrence associated mortality initiation MHT diagnosis breast gynecologic lung colorectal hematologic melanoma Menopausal hormone therapy considered management bothersome menopausal symptoms women types e.g. colorectal hematologic localized melanoma cervical vulvar vaginal nonhormonal treatment options preferred e.g. breast women types recommendations straightforward use MHT individualized,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[948, 1079, 666, 3, 119, 1, 3565, 785, 36, 10381, 9, 3, 24, 1, 14768, 3565, 507, 4, 8, 12, 2628, 122, 40, 840, 2, 1920, 455, 1, 211, 345, 23, 34, 115, 15, 63, 25, 808, 1186, 32, 364, 4, 392, 12, 630, 84, 26, 1097, 44, 3763, 757, 4, 808, 517, 30, 457, 2, 290, 12, 139, 123, 808, 68, 871, 40, 2864, 480, 1840, 163, 3565, 785, 36, 16, 41, 5, 35, 101, 43, 1, 146, 2, 282, 50, 147, 1, 476, 12, 630, 84, 44, 1749, 21, 377, 8, 8963, 206, 1, 3, 484, 789, 666, 3, 43, 1, 12, 146, 2, 41, 282, 5, 1118, 1, 10381, 50, 3, 147, 1, 1512, 813, 163, 2, 3565, 785, 36, 68, 40, 515, 9, 284, 1, 14768, 3565, 507, 4, 117, 5, 476, 12, 630, 563, 499, 2, 813, 12, 909, 2, 96, 2, 163, 369, 16196, 24, 838, 68, 40, 2514, 9, 1749, 563, 499, 12, 4, 117, 5, 127, 12, 630, 883, 32, 299, 12753, 2, 3, 119, 1, 10381, 1642, 40, 2596]",1173.0,27621244,Menopausal hormone therapy survivors narrative review literature,0,0.0
Primary Gastric Choriocarcinoma Presenting as a Pregnancy of Unknown Location.,Obstetrics and gynecology,Obstet Gynecol,2017-02-01,"Pregnancy of unknown location presents a diagnostic challenge, in rare occasions leading to the diagnosis of malignancy. We describe a case of -hCG-secreting nongestational primary gastric choriocarcinoma presenting as a pregnancy of unknown location. A 37-year-old woman, gravida 4 para 3013, presented with several days of vaginal bleeding and rising -hCG level without ultrasound localization of pregnancy. The diagnosis of pregnancy of unknown location was made and methotrexate administered at a -hCG level of 7,779 milli-international units/mL. A 40% decrease in -hCG level was noted between days 4 and 7. One week later, an inappropriate -hCG level rise to 10,937 milli-international units/mL was noted, prompting a second dose of methotrexate and computed tomography imaging, leading to the discovery of gastric and liver lesions. Pathology from gastric biopsies revealed nongestational choriocarcinoma. The patient was treated with chemotherapy, with death from cardiac arrest 7 months after diagnosis. Malignancies that can secrete -hCG include gestational trophoblastic disease, gonadal and extragonadal germ cell tumors, and malignancies with choriocarcinoma differentiation. Although ectopic pregnancy compromises approximately 2% of first-trimester pregnancy, gestational trophoblastic neoplasia and gestational choriocarcinoma can be seen in 1 of 1,500 and 1 of 20,000 pregnancies, respectively. When -hCG levels do not fall appropriately in women undergoing medical management for pregnancy of unknown location, ectopic -hCG secretion by a malignancy must be considered.",Case Reports,1084.0,3.0,"Pregnancy unknown location presents diagnostic challenge rare occasions leading diagnosis malignancy case -hCG-secreting nongestational primary gastric choriocarcinoma presenting pregnancy unknown location 37-year-old woman gravida 4 para 3013 presented days vaginal bleeding rising -hCG level ultrasound localization pregnancy diagnosis pregnancy unknown location methotrexate administered -hCG level 7,779 milli-international units/mL 40 decrease -hCG level noted days 4 7 week later inappropriate -hCG level rise 10,937 milli-international units/mL noted prompting second dose methotrexate computed tomography imaging leading discovery gastric liver lesions Pathology gastric biopsies revealed nongestational choriocarcinoma patient treated chemotherapy death cardiac arrest 7 months diagnosis Malignancies secrete -hCG include gestational trophoblastic disease gonadal extragonadal germ malignancies choriocarcinoma differentiation ectopic pregnancy compromises approximately 2 first-trimester pregnancy gestational trophoblastic neoplasia gestational choriocarcinoma seen 1 1,500 1 20,000 pregnancies respectively -hCG levels fall appropriately women undergoing medical management pregnancy unknown location ectopic -hCG secretion malignancy considered",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,"[2290, 1, 860, 1147, 2740, 8, 752, 1745, 4, 622, 19704, 1049, 6, 3, 147, 1, 710, 21, 897, 8, 473, 1, 1458, 6920, 5052, 50178, 86, 13081, 1656, 22, 8, 2290, 1, 860, 1147, 8, 567, 111, 1095, 2854, 50179, 39, 4615, 69645, 917, 5, 392, 162, 1, 2294, 2, 3699, 1458, 6920, 301, 187, 1945, 2145, 1, 2290, 3, 147, 1, 2290, 1, 860, 1147, 10, 1229, 2, 2116, 468, 28, 8, 1458, 6920, 301, 1, 67, 7173, 36360, 944, 2960, 542, 8, 327, 775, 4, 1458, 6920, 301, 10, 1051, 59, 162, 39, 2, 67, 104, 647, 1559, 35, 5148, 1458, 6920, 301, 3693, 6, 79, 15361, 36360, 944, 2960, 542, 10, 1051, 8499, 8, 419, 61, 1, 2116, 2, 1220, 872, 270, 1049, 6, 3, 1574, 1, 2, 406, 1117, 29, 1154, 553, 50178, 13081, 3, 69, 10, 73, 5, 56, 5, 273, 29, 1854, 67, 53, 50, 147, 441, 17, 122, 6401, 1458, 6920, 643, 9383, 11355, 34, 7999, 2, 12368, 2280, 31, 57, 2, 441, 5, 13081, 910, 242, 3647, 2290, 17336, 705, 18, 1, 157, 12693, 2290, 9383, 11355, 2298, 2, 9383, 13081, 122, 40, 527, 4, 14, 1, 14, 1666, 2, 14, 1, 179, 984, 8746, 106, 198, 1458, 6920, 148, 1022, 44, 6712, 4544, 4, 117, 479, 484, 284, 9, 2290, 1, 860, 1147, 3647, 1458, 6920, 2935, 20, 8, 710, 1642, 40, 515]",1523.0,28079767,Primary Gastric Choriocarcinoma Presenting Pregnancy Unknown Location,0,0.0
Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.,Cancer,Cancer,2017-02-17,"Failure-free survival (FFS) and overall survival (OS) rates were found to improve on Intergroup Rhabdomyosarcoma Study (IRS) IV (IRS-IV) compared with IRS-III for patients with subset 2 (IRS stage 1, group III nonorbit or stage 3, group I/II) low-risk embryonal rhabdomyosarcoma with the addition of cyclophosphamide (total cumulative cyclophosphamide dose of 26.4g/m<sup>2</sup> ) to the combination of vincristine and dactinomycin (VAC). The goal of Children's Oncology Group ARST0331 for subset 2 low-risk patients was to reduce the total cumulative cyclophosphamide dose without compromising FFS. Therapy included 4 cycles of VAC (total cumulative cyclophosphamide dose of 4.8g/m<sup>2</sup> ) followed by 12 cycles of vincristine and dactinomycin over 46 weeks. Patients with group II or III tumors received radiotherapy, except for girls with group III vaginal tumors who enrolled before September 2009 and achieved a complete response with chemotherapy with or without delayed surgical resection. Among 66 eligible patients who were followed for a median of 3.5 years, there were 20 failures versus 10.53 expected failures. The estimated 3-year FFS and OS rates were 70% (95% confidence interval [95% CI], 57%-80%) and 92% (95% CI, 83%-97%), respectively. The estimated 3-year FFS rate was 57% (95% CI, 33%-75%) for girls with subset 2 genital tract embryonal rhabdomyosarcoma (21 patients) and 77% (95% CI, 61%-87%) for all other subset 2 patients (45 patients) (P=.02). The authors observed suboptimal FFS among patients with subset 2 low-risk rhabdomyosarcoma using reduced total cyclophosphamide. Eliminating radiotherapy for girls with group III vaginal tumors in combination with reduced total cyclophosphamide appeared to contribute to the suboptimal outcome. Cancer 2017;123:2368-2375.  2017 American Cancer Society.",Journal Article,1068.0,23.0,Failure-free survival FFS overall survival OS rates improve Intergroup Rhabdomyosarcoma IRS IV IRS-IV compared IRS-III patients subset 2 IRS stage 1 group III nonorbit stage 3 group I/II low-risk embryonal rhabdomyosarcoma addition cyclophosphamide total cumulative cyclophosphamide dose 26.4 g/m sup 2 /sup combination vincristine dactinomycin VAC goal Children 's Oncology Group ARST0331 subset 2 low-risk patients reduce total cumulative cyclophosphamide dose compromising FFS Therapy included 4 cycles VAC total cumulative cyclophosphamide dose 4.8 g/m sup 2 /sup followed 12 cycles vincristine dactinomycin 46 weeks Patients group II III received radiotherapy girls group III vaginal enrolled September 2009 achieved complete response chemotherapy delayed surgical resection 66 eligible patients followed median 3.5 years 20 failures versus 10.53 expected failures estimated 3-year FFS OS rates 70 95 confidence interval 95 CI 57 -80 92 95 CI 83 -97 respectively estimated 3-year FFS rate 57 95 CI 33 -75 girls subset 2 genital tract embryonal rhabdomyosarcoma 21 patients 77 95 CI 61 -87 subset 2 patients 45 patients P .02 authors observed suboptimal FFS patients subset 2 low-risk rhabdomyosarcoma reduced total cyclophosphamide Eliminating radiotherapy girls group III vaginal combination reduced total cyclophosphamide appeared contribute suboptimal outcome 2017 123:2368-2375  2017 American Society,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[496, 115, 25, 5058, 2, 63, 25, 118, 151, 11, 204, 6, 401, 23, 4839, 45, 5056, 478, 5056, 478, 72, 5, 5056, 316, 9, 7, 5, 697, 18, 5056, 82, 14, 87, 316, 38234, 15, 82, 27, 87, 70, 215, 154, 43, 5239, 5, 3, 352, 1, 1112, 181, 967, 1112, 61, 1, 432, 39, 499, 188, 172, 18, 172, 6, 3, 150, 1, 2132, 2, 10295, 7278, 3, 1326, 1, 541, 292, 413, 87, 18023, 9, 697, 18, 154, 43, 7, 10, 6, 969, 3, 181, 967, 1112, 61, 187, 6102, 5058, 36, 159, 39, 410, 1, 7278, 181, 967, 1112, 61, 1, 39, 66, 499, 188, 172, 18, 172, 370, 20, 133, 410, 1, 2132, 2, 10295, 252, 641, 244, 7, 5, 87, 215, 15, 316, 57, 103, 310, 2187, 9, 5989, 5, 87, 316, 57, 54, 346, 348, 2636, 1238, 2, 513, 8, 236, 51, 5, 56, 5, 15, 187, 1612, 221, 170, 107, 700, 625, 7, 54, 11, 370, 9, 8, 52, 1, 27, 33, 60, 125, 11, 179, 3368, 185, 79, 699, 1336, 3368, 3, 661, 27, 111, 5058, 2, 118, 151, 11, 431, 48, 307, 268, 48, 58, 696, 493, 2, 937, 48, 58, 852, 1015, 106, 3, 661, 27, 111, 5058, 116, 10, 696, 48, 58, 466, 481, 9, 5989, 5, 697, 18, 8226, 1696, 5239, 239, 7, 2, 849, 48, 58, 713, 912, 9, 62, 127, 697, 18, 7, 512, 7, 19, 588, 3, 738, 164, 3291, 5058, 107, 7, 5, 697, 18, 154, 43, 75, 405, 181, 1112, 6923, 310, 9, 5989, 5, 87, 316, 57, 4, 150, 5, 405, 181, 1112, 2121, 6, 1248, 6, 3, 3291, 228, 12, 1759, 2698, 40206, 50244, 2206, 1759, 597, 12, 1174]",1682.0,28211936,Reduction cyclophosphamide dose patients subset 2 low-risk rhabdomyosarcoma associated increased risk recurrence report Soft Tissue Sarcoma Committee Children 's Oncology Group,15,0.07537688442211055
A pilot randomized trial to prevent sexual dysfunction in postmenopausal breast cancer survivors starting adjuvant aromatase inhibitor therapy.,Journal of cancer survivorship : research and practice,J Cancer Surviv,2017-02-22,"A randomized pilot trial evaluated the hypothesis that early intervention lessens sexual dysfunction in the first year on aromatase inhibitors. A secondary aim was comparing the efficacy of two vaginal moisturizers. Fifty-seven postmenopausal women with early stage breast cancer starting aromatase inhibitors were randomized to three treatment groups. All received a handout on managing sexual and other side effects. The Usual Care group received no additional therapy. The Active Treatment groups received a 6-month supply of a vaginal moisturizer (hyaluronic acid-based in Active Group-H and prebiotic in Active Group-P) and a vaginal lubricant and dilator, plus access to an educational website and phone coaching. Questionnaires completed at baseline, 6, and 12months included the Female Sexual Function Index (FSFI), Menopausal Sexual Interest Questionnaire (MSIQ), Female Sexual Distress Scale-Revised (FSDS-R), and a menopausal symptom scale. Forty-nine women (86%) provided follow-up data. Mean age was 59 and 77% were non-Hispanic Caucasian. Sexual function was impaired at baseline, but remained stable over 12months for all groups. The combined active treatment group had less dyspareunia (P=0.07) and sexual distress (P=0.02) at 6months than the Usual Care group. At 6months, the Active-H group improved significantly more than the Active-P group on FSFI total score (P=0.04). Sexual counseling helped women maintain stable sexual function on aromatase inhibitors. Active intervention resulted in better outcomes at 6months. This promising pilot trial suggests a need for more research on preventive counseling to maintain sexual function during aromatase inhibitor treatment.",Journal Article,1063.0,8.0,randomized pilot trial evaluated hypothesis early intervention lessens sexual dysfunction year aromatase inhibitors secondary aim comparing efficacy vaginal moisturizers Fifty-seven postmenopausal women early stage breast starting aromatase inhibitors randomized treatment groups received handout managing sexual effects Usual Care group received additional therapy Active Treatment groups received 6-month supply vaginal moisturizer hyaluronic acid-based Active Group-H prebiotic Active Group-P vaginal lubricant dilator plus access educational website phone coaching Questionnaires completed baseline 6 12 months included Female Sexual Function Index FSFI Menopausal Sexual Questionnaire MSIQ Female Sexual Distress Scale-Revised FSDS-R menopausal symptom scale Forty-nine women 86 provided follow-up Mean age 59 77 non-Hispanic Caucasian Sexual function impaired baseline remained stable 12 months groups combined active treatment group dyspareunia P 0.07 sexual distress P 0.02 6 months Usual Care group 6 months Active-H group improved significantly Active-P group FSFI total score P 0.04 Sexual counseling helped women maintain stable sexual function aromatase inhibitors Active intervention resulted better outcomes 6 months promising pilot trial suggests need research preventive counseling maintain sexual function aromatase inhibitor treatment,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[8, 384, 2281, 160, 194, 3, 1492, 17, 191, 788, 40911, 2232, 1527, 4, 3, 157, 111, 23, 2106, 222, 8, 568, 1130, 10, 1430, 3, 209, 1, 100, 34832, 1461, 648, 1679, 117, 5, 191, 82, 12, 1723, 2106, 222, 11, 384, 6, 169, 24, 271, 62, 103, 8, 35474, 23, 3969, 2232, 2, 127, 1152, 176, 3, 3521, 165, 87, 103, 77, 402, 36, 3, 544, 24, 271, 103, 8, 49, 811, 6296, 1, 8, 34860, 13651, 971, 90, 4, 544, 87, 555, 2, 69945, 4, 544, 87, 19, 2, 8, 69946, 2, 17967, 349, 1655, 6, 35, 3624, 8262, 2, 8772, 16681, 2956, 781, 28, 330, 49, 2, 133, 53, 159, 3, 1061, 2232, 343, 558, 22278, 3565, 2232, 1333, 1770, 69947, 1061, 2232, 1462, 1124, 4218, 69948, 668, 2, 8, 3565, 934, 1124, 1213, 762, 117, 868, 1052, 166, 126, 74, 313, 89, 10, 728, 2, 849, 11, 220, 1776, 3229, 2232, 343, 10, 2364, 28, 330, 84, 958, 585, 252, 133, 53, 9, 62, 271, 3, 397, 544, 24, 87, 42, 299, 22098, 19, 13, 1615, 2, 2232, 1462, 19, 13, 588, 28, 49, 53, 76, 3, 3521, 165, 87, 28, 49, 53, 3, 544, 555, 87, 231, 97, 80, 76, 3, 544, 19, 87, 23, 22278, 181, 368, 19, 13, 755, 2232, 2011, 6156, 117, 3040, 585, 2232, 343, 23, 2106, 222, 544, 788, 627, 4, 380, 123, 28, 49, 53, 26, 721, 2281, 160, 844, 8, 594, 9, 80, 389, 23, 3494, 2011, 6, 3040, 2232, 343, 190, 2106, 230, 24]",1623.0,28229275,pilot randomized trial prevent sexual dysfunction postmenopausal breast survivors starting adjuvant aromatase inhibitor therapy,7,0.035175879396984924
Impact of Chemotherapy and Radiotherapy on Management of Early Stage Clear Cell and Papillary Serous Carcinoma of the Uterus.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2017-05-01,"The aim of the study was to assess interaction of lymph node dissection (LND), adjuvant chemotherapy (CT), and radiotherapy (RT) in stage I uterine papillary serous carcinoma (UPSC) and uterine clear cell carcinoma (UCC). The National Cancer Data Base was queried for women diagnosed with International Federation of Gynecology and Obstetrics stage I UPSC and UCC from 1998 to 2012. Overall survival (OS) was estimated for combinations of RT and CT by the Kaplan-Meier method stratified by histology and LND. Multivariate Cox proportional hazard models were generated. Uterine papillary serous carcinoma: 5432 women with UPSC were identified. Uterine papillary serous carcinoma had the highest 5-year OS with CT + RT with (83%) or without LND (76%). On multivariate analyses, CT [hazard ratio (HR), 0.77; P = 0.01] and vaginal cuff brachytherapy (HR, 0.68; P = 0.003) with LND were independently associated with OS. Without LND, vaginal cuff brachytherapy (HR, 0.53; P = 0.03), but not CT (HR, 1.21; P = 0.92), was associated with OS. Uterine clear cell carcinoma: 2516 women with UCC were identified. Uterine clear cell carcinoma with and without LND had comparable 5-year OS for all combinations of CT and RT on univariate and multivariate analyses. In stage I papillary serous uterine cancer, brachytherapy and CT were associated with increased survival; however, the benefit of chemotherapy was limited to those with surgical staging. In contrast, no adjuvant therapy was associated with survival in stage I uterine clear cell carcinoma, and further investigation to identify more effective therapies is warranted.",Journal Article,995.0,5.0,aim assess interaction lymph node dissection LND adjuvant chemotherapy CT radiotherapy RT stage uterine papillary serous carcinoma UPSC uterine clear carcinoma UCC National Base queried women diagnosed International Federation Gynecology Obstetrics stage UPSC UCC 1998 2012 Overall survival OS estimated combinations RT CT Kaplan-Meier stratified histology LND Multivariate Cox proportional hazard models generated Uterine papillary serous carcinoma 5432 women UPSC identified Uterine papillary serous carcinoma highest 5-year OS CT RT 83 LND 76 multivariate CT hazard ratio HR 0.77 P 0.01 vaginal cuff brachytherapy HR 0.68 P 0.003 LND independently associated OS LND vaginal cuff brachytherapy HR 0.53 P 0.03 CT HR 1.21 P 0.92 associated OS Uterine clear carcinoma 2516 women UCC identified Uterine clear carcinoma LND comparable 5-year OS combinations CT RT univariate multivariate stage papillary serous uterine brachytherapy CT associated increased survival benefit chemotherapy limited surgical staging contrast adjuvant therapy associated survival stage uterine clear carcinoma investigation identify effective therapies warranted,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[3, 1130, 1, 3, 45, 10, 6, 423, 915, 1, 263, 289, 1161, 3400, 249, 56, 425, 2, 310, 240, 4, 82, 70, 1796, 1744, 134, 5676, 2, 885, 31, 134, 15424, 3, 657, 12, 74, 1782, 10, 3547, 9, 117, 265, 5, 944, 7303, 1, 6429, 2, 7407, 82, 70, 5676, 2, 15424, 29, 1850, 6, 1195, 63, 25, 118, 10, 661, 9, 1247, 1, 240, 2, 425, 20, 3, 876, 882, 596, 1173, 20, 784, 2, 3400, 331, 418, 831, 360, 274, 11, 1419, 1796, 1744, 134, 50305, 117, 5, 5676, 11, 108, 1796, 1744, 134, 42, 3, 1076, 33, 111, 118, 5, 425, 240, 5, 852, 15, 187, 3400, 846, 23, 331, 318, 425, 360, 197, 168, 13, 849, 19, 13, 355, 2, 11445, 1536, 168, 13, 806, 19, 13, 1421, 5, 3400, 11, 1042, 41, 5, 118, 187, 3400, 11445, 1536, 168, 13, 699, 19, 13, 680, 84, 44, 425, 168, 14, 239, 19, 13, 937, 10, 41, 5, 118, 885, 31, 134, 50306, 117, 5, 15424, 11, 108, 885, 31, 134, 5, 2, 187, 3400, 42, 1279, 33, 111, 118, 9, 62, 1247, 1, 425, 2, 240, 23, 880, 2, 331, 318, 4, 82, 70, 1796, 1744, 12, 1536, 2, 425, 11, 41, 5, 101, 25, 137, 3, 247, 1, 56, 10, 383, 6, 135, 5, 221, 632, 4, 748, 77, 249, 36, 10, 41, 5, 25, 4, 82, 70, 885, 31, 134, 2, 195, 940, 6, 255, 80, 323, 235, 16, 1197]",1467.0,28375927,Impact Chemotherapy Radiotherapy Management Early Stage Clear Papillary Serous Carcinoma Uterus,1,0.005025125628140704
Urinary incontinence and other pelvic floor disorders after radiation therapy in endometrial cancer survivors.,Maturitas,Maturitas,2017-03-18,"To investigate radiation therapy as a risk factor for urinary or fecal incontinence, pelvic organ prolapse, and sexual dysfunction in endometrial cancer survivors. We performed a retrospective cohort study of endometrial cancer survivors. Data were collected using a mailed survey and the medical record. Validated questionnaires were used to generate rates of urinary incontinence and other pelvic floor disorders. The incidence rates of pelvic floor disorders were compared across groups with different exposures to radiation. Of the 149 endometrial cancer survivors, 41% received radiation therapy. Fifty-one percent of women reported urine leakage. The rates of urinary incontinence in women exposed and not exposed to vaginal brachytherapy (VBT) or whole-pelvis radiation were 48% and 58%, respectively (p=0.47). The incidence of fecal incontinence did not differ between groups, but the score for overall sexual function was significantly higher in women who did not undergo radiation therapy. On multivariable analysis, significant risk factors for urinary incontinence were age (AOR 1.06 95% CI 1.02, 1.10) and BMI (AOR 1.07 95% CI 1.02, 1.11), but treatment with radiation was not significantly associated with urinary incontinence, or fecal incontinence (p>0.05). Age, BMI, and radiation exposure were independent predictors of decreased sexual function score (p<0.01). Local or regional radiation is not associated with urinary or fecal incontinence, but may contribute to sexual dysfunction in endometrial cancer survivors.",Journal Article,1039.0,3.0,investigate radiation therapy risk factor urinary fecal incontinence pelvic organ prolapse sexual dysfunction endometrial survivors performed retrospective cohort endometrial survivors collected mailed survey medical record Validated questionnaires generate rates urinary incontinence pelvic floor disorders incidence rates pelvic floor disorders compared groups different exposures radiation 149 endometrial survivors 41 received radiation therapy Fifty-one percent women reported urine leakage rates urinary incontinence women exposed exposed vaginal brachytherapy VBT whole-pelvis radiation 48 58 respectively p=0.47 incidence fecal incontinence differ groups score overall sexual function significantly higher women undergo radiation therapy multivariable significant risk factors urinary incontinence age AOR 1.06 95 CI 1.02 1.10 BMI AOR 1.07 95 CI 1.02 1.11 treatment radiation significantly associated urinary incontinence fecal incontinence p 0.05 Age BMI radiation exposure independent predictors decreased sexual function score p 0.01 Local regional radiation associated urinary fecal incontinence contribute sexual dysfunction endometrial survivors,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[6, 963, 121, 36, 22, 8, 43, 161, 9, 1660, 15, 6784, 6152, 1110, 1259, 38025, 2, 2232, 1527, 4, 12, 332, 21, 173, 8, 459, 180, 45, 1, 12, 332, 74, 11, 786, 75, 8, 6703, 1407, 2, 3, 484, 3237, 938, 2956, 11, 95, 6, 2562, 151, 1, 1660, 6152, 2, 127, 1110, 12557, 1997, 3, 287, 151, 1, 1110, 12557, 1997, 11, 72, 716, 271, 5, 338, 3401, 6, 121, 1, 3, 4928, 12, 332, 605, 103, 121, 36, 1461, 104, 714, 1, 117, 210, 2646, 9256, 3, 151, 1, 1660, 6152, 4, 117, 2234, 2, 44, 2234, 6, 1536, 15050, 15, 902, 3270, 121, 11, 576, 2, 717, 106, 19, 13, 662, 3, 287, 1, 6784, 6152, 205, 44, 1505, 59, 271, 84, 3, 368, 9, 63, 2232, 343, 10, 97, 142, 4, 117, 54, 205, 44, 1251, 121, 36, 23, 658, 65, 93, 43, 130, 9, 1660, 6152, 11, 89, 3366, 14, 1460, 48, 58, 14, 588, 14, 79, 2, 1140, 3366, 14, 1615, 48, 58, 14, 588, 14, 175, 84, 24, 5, 121, 10, 44, 97, 41, 5, 1660, 6152, 15, 6784, 6152, 19, 13, 474, 89, 1140, 2, 121, 645, 11, 306, 674, 1, 340, 2232, 343, 368, 19, 13, 355, 293, 15, 951, 121, 16, 44, 41, 5, 1660, 15, 6784, 6152, 84, 68, 1248, 6, 2232, 1527, 4, 12, 332]",1437.0,28396018,Urinary incontinence pelvic floor disorders radiation therapy endometrial survivors,0,0.0
Missing documentation in breast cancer survivors: genitourinary syndrome of menopause.,"Menopause (New York, N.Y.)",Menopause,2017-12-01,"Breast cancer survivors often take hormonal treatments to prevent the recurrence of breast cancer, particularly aromatase inhibitors that can worsen the symptoms of genitourinary syndrome of menopause (GSM) such as dyspareunia, dysuria, and urinary incontinence, all of which may adversely affect survivors' quality of life. Few breast cancer survivors experiencing GSM receive adequate assessment or treatment. In this descriptive study, we reviewed medical records for documented GSM and any treatments administered or referrals for treatment in 800 female patients who visited the Breast Cancer Survivorship Clinic at a comprehensive cancer center between July 1, 2010 and June 30, 2011, either at least 5 years after completion of treatment for invasive breast cancer or at least 6 months after completion of treatment for ductal carcinoma in situ. Of the 279 patients with documented symptoms of vaginal atrophy, only 111 (39.8%) had documentation of having received any form of treatment or referral. Of the 71 patients with documented symptoms of urinary tract atrophy, only 33.8% had documentation of having received treatment or referral for treatment. Breast cancer survivors often experience GSM due to lack of estrogen. The worrisome lack of documentation of assessment or treatment for GSM in a large breast cancer survivorship practice reveals missed opportunities to improve quality of life. Dissemination of recent progress in the development of GSM assessment tools, patient handouts, and new treatments to providers who care for breast cancer survivors is needed to improve this process.",Journal Article,781.0,6.0,Breast survivors hormonal treatments prevent recurrence breast particularly aromatase inhibitors worsen symptoms genitourinary syndrome menopause GSM dyspareunia dysuria urinary incontinence adversely affect survivors quality life breast survivors experiencing GSM receive adequate assessment treatment descriptive reviewed medical records documented GSM treatments administered referrals treatment 800 female patients visited Breast Survivorship Clinic comprehensive center July 1 2010 June 30 2011 5 years completion treatment invasive breast 6 months completion treatment ductal carcinoma situ 279 patients documented symptoms vaginal atrophy 111 39.8 documentation received form treatment referral 71 patients documented symptoms urinary tract atrophy 33.8 documentation received treatment referral treatment Breast survivors experience GSM lack estrogen worrisome lack documentation assessment treatment GSM large breast survivorship practice reveals missed opportunities improve quality life Dissemination recent progress development GSM assessment tools patient handouts new treatments providers care breast survivors needed improve process,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[12, 332, 629, 3585, 1761, 640, 6, 1682, 3, 146, 1, 12, 823, 2106, 222, 17, 122, 12500, 3, 507, 1, 4109, 681, 1, 5034, 19392, 225, 22, 22098, 18282, 2, 1660, 6152, 62, 1, 92, 68, 4311, 1158, 332, 372, 1, 358, 1021, 12, 332, 2985, 19392, 560, 1658, 455, 15, 24, 4, 26, 3778, 45, 21, 446, 484, 1064, 9, 1405, 19392, 2, 500, 640, 468, 15, 6902, 9, 24, 4, 2796, 1061, 7, 54, 13082, 3, 12, 2560, 1188, 28, 8, 949, 12, 574, 59, 2066, 14, 1120, 2, 1924, 201, 1132, 361, 28, 506, 33, 60, 50, 1438, 1, 24, 9, 416, 12, 15, 28, 506, 49, 53, 50, 1438, 1, 24, 9, 1258, 134, 4, 957, 1, 3, 8562, 7, 5, 1405, 507, 1, 7637, 158, 3167, 587, 66, 42, 4965, 1, 1041, 103, 500, 1297, 1, 24, 15, 2096, 1, 3, 792, 7, 5, 1405, 507, 1, 1660, 1696, 7637, 158, 466, 66, 42, 4965, 1, 1041, 103, 24, 15, 2096, 9, 24, 12, 332, 629, 730, 19392, 520, 6, 926, 1, 808, 3, 13155, 926, 1, 4965, 1, 455, 15, 24, 9, 19392, 4, 8, 375, 12, 2560, 758, 4054, 5149, 2605, 6, 401, 372, 1, 358, 3430, 1, 435, 1466, 4, 3, 193, 1, 19392, 455, 1896, 69, 49912, 2, 217, 640, 6, 1994, 54, 165, 9, 12, 332, 16, 575, 6, 401, 26, 1129]",1514.0,28640166,Missing documentation breast survivors genitourinary syndrome menopause,0,0.0
Prospective screening with the validated Opioid Risk Tool demonstrates gynecologic oncology patients are at low risk for opioid misuse.,Gynecologic oncology,Gynecol. Oncol.,2017-08-12,"To characterize risk for opioid misuse among gynecologic oncology patients. The Opioid Risk Tool (ORT), a validated screen for opioid misuse risk, was administered to a convenience sample of patients with gynecologic cancer receiving opioid prescriptions in gynecologic oncology or palliative care clinics from January 2012-June 2016. Demographic and clinical information was abstracted on chart review. The primary outcome was ORT risk level (low vs. moderate or high). Chi-square tests were performed for categorical variables. A total of 118 women were screened. Most women were Caucasian (79%) with a median age of 57years. Ovarian cancer patients comprised 46% of the cohort with fewer endometrial (25%), cervical (23%), vulvar (4%), and vaginal (2%) cancer patients. The median ORT score was 1.0 (range, 0-10) out of a possible 26. Overall, 87% of patients were categorized as low-risk for opioid misuse, 7% as moderate-risk, and 6% as high-risk. Patients who were at moderate or high-risk of opioid misuse were significantly younger (47 vs. 58years, p=0.02), more likely to have cervical cancer (p=0.02), be smokers (p=0.01) and be uninsured or on Medicare (p=0.03). Most gynecologic oncology patients in our cohort were low-risk for opioid misuse (87%). Cervical cancer patients were more likely to be moderate to high-risk for misuse. Future screening efforts for opioid misuse may have the highest utility in this subset of patients.",Journal Article,892.0,5.0,characterize risk opioid misuse gynecologic oncology patients Opioid Risk Tool ORT validated screen opioid misuse risk administered convenience patients gynecologic receiving opioid prescriptions gynecologic oncology palliative care clinics January 2012-June 2016 Demographic clinical information abstracted chart review primary outcome ORT risk level low vs. moderate high Chi-square tests performed categorical variables total 118 women screened women Caucasian 79 median age 57years Ovarian patients comprised 46 cohort fewer endometrial 25 cervical 23 vulvar 4 vaginal 2 patients median ORT score 1.0 range 0-10 possible 26 Overall 87 patients categorized low-risk opioid misuse 7 moderate-risk 6 high-risk Patients moderate high-risk opioid misuse significantly younger 47 vs. 58years p=0.02 likely cervical p=0.02 smokers p=0.01 uninsured Medicare p=0.03 gynecologic oncology patients cohort low-risk opioid misuse 87 Cervical patients likely moderate high-risk misuse Future screening efforts opioid misuse highest utility subset patients,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 1507, 43, 9, 2742, 13739, 107, 1512, 413, 7, 3, 2742, 43, 1515, 19957, 8, 938, 2413, 9, 2742, 13739, 43, 10, 468, 6, 8, 8184, 1000, 1, 7, 5, 1512, 12, 357, 2742, 7654, 4, 1512, 413, 15, 994, 165, 4736, 29, 1024, 1195, 1924, 1390, 1540, 2, 38, 487, 10, 4106, 23, 2937, 206, 3, 86, 228, 10, 19957, 43, 301, 154, 105, 1163, 15, 64, 3163, 3219, 895, 11, 173, 9, 5982, 682, 8, 181, 1, 4002, 117, 11, 2261, 96, 117, 11, 3229, 842, 5, 8, 52, 89, 1, 32414, 12, 7, 2603, 641, 1, 3, 180, 5, 1497, 243, 382, 39, 2, 18, 12, 7, 3, 52, 19957, 368, 10, 14, 13, 184, 13, 79, 1205, 1, 8, 899, 432, 63, 912, 1, 7, 11, 2320, 22, 154, 43, 9, 2742, 13739, 67, 22, 1163, 43, 2, 49, 22, 64, 43, 7, 54, 11, 28, 1163, 15, 64, 43, 1, 2742, 13739, 11, 97, 773, 662, 105, 71018, 19, 13, 588, 80, 322, 6, 47, 12, 19, 13, 588, 40, 1485, 19, 13, 355, 2, 40, 4955, 15, 23, 1378, 19, 13, 680, 96, 1512, 413, 7, 4, 114, 180, 11, 154, 43, 9, 2742, 13739, 912, 12, 7, 11, 80, 322, 6, 40, 1163, 6, 64, 43, 9, 13739, 508, 453, 1413, 9, 2742, 13739, 68, 47, 3, 1076, 1207, 4, 26, 697, 1, 7]",1319.0,28807366,Prospective screening validated Opioid Risk Tool demonstrates gynecologic oncology patients low risk opioid misuse,0,0.0
American Brachytherapy Society recurrent carcinoma of the endometrium task force patterns of care and review of the literature.,Brachytherapy,Brachytherapy,2017-09-06,"The purpose of this American Brachytherapy Society task force is to present a literature review and patterns of care by a panel of experts for the management of vaginal recurrence of endometrial cancer. In 2016, the American Brachytherapy Society Board selected a panel of experts in gynecologic brachytherapy to update our current state of knowledge for managing vaginal recurrence of endometrial cancer. Practice patterns were evaluated via an online survey and clinical updates occurred through a combination of literature review and clinical experience and/or expertise. There are various retrospective series of patients treated with radiation for vaginal recurrence of endometrial cancer, which include a varied group of patients, multiple treatment techniques, and a range of total doses and demonstrate a wide scope of local control and overall survival outcomes. In the era of image-guided brachytherapy, high local control rates with low significant late-term morbidities can be achieved. Lower rates of local control and higher late-term toxicity are reported in the retreatment setting. In patients with no previous history of radiation treatment, external beam radiation therapy followed by brachytherapy boost should be used. There are varying practices with regard to the definition and appropriate doses of both the high-risk clinical target volume and the intermediate-risk clinical target volume in the setting of vaginal recurrence of endometrial cancer. There are limited data to provide appropriate dose constraints for some organs at risk with the majority of guidance taken from the definitive cervical cancer literature. A summary of literature and expert practice patterns for patient selection, dose recommendations, and constraints are provided as guidance for practitioners.",Consensus Development Conference,867.0,6.0,purpose American Brachytherapy Society task force present literature review patterns care panel experts management vaginal recurrence endometrial 2016 American Brachytherapy Society Board selected panel experts gynecologic brachytherapy update current state knowledge managing vaginal recurrence endometrial Practice patterns evaluated online survey clinical updates occurred combination literature review clinical experience and/or expertise retrospective series patients treated radiation vaginal recurrence endometrial include varied group patients multiple treatment techniques range total doses demonstrate wide scope local control overall survival outcomes era image-guided brachytherapy high local control rates low significant late-term morbidities achieved Lower rates local control higher late-term toxicity reported retreatment setting patients previous history radiation treatment external beam radiation therapy followed brachytherapy boost varying practices regard definition appropriate doses high-risk clinical target volume intermediate-risk clinical target volume setting vaginal recurrence endometrial limited provide appropriate dose constraints organs risk majority guidance taken definitive cervical literature summary literature expert practice patterns patient selection dose recommendations constraints provided guidance practitioners,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 743, 1, 26, 597, 1536, 1174, 3488, 4380, 16, 6, 364, 8, 789, 206, 2, 764, 1, 165, 20, 8, 993, 1, 3186, 9, 3, 284, 1, 146, 1, 12, 4, 1390, 3, 597, 1536, 1174, 2620, 715, 8, 993, 1, 3186, 4, 1512, 1536, 6, 2991, 114, 291, 1309, 1, 922, 9, 3969, 146, 1, 12, 758, 764, 11, 194, 847, 35, 4123, 1407, 2, 38, 5454, 489, 298, 8, 150, 1, 789, 206, 2, 38, 730, 2, 15, 4935, 125, 32, 747, 459, 988, 1, 7, 73, 5, 121, 9, 146, 1, 12, 92, 643, 8, 2051, 87, 1, 7, 232, 24, 1092, 2, 8, 184, 1, 181, 415, 2, 608, 8, 1019, 7924, 1, 293, 182, 2, 63, 25, 123, 4, 3, 1713, 1, 1482, 1808, 1536, 64, 293, 182, 151, 5, 154, 93, 807, 337, 5655, 122, 40, 513, 280, 151, 1, 293, 182, 2, 142, 807, 337, 155, 32, 210, 4, 3, 6291, 546, 4, 7, 5, 77, 698, 532, 1, 121, 24, 1455, 1345, 121, 36, 370, 20, 1536, 2569, 257, 40, 95, 125, 32, 2990, 2634, 5, 2539, 6, 3, 2470, 2, 870, 415, 1, 110, 3, 64, 43, 38, 283, 433, 2, 3, 919, 43, 38, 283, 433, 4, 3, 546, 1, 146, 1, 12, 125, 32, 383, 74, 6, 377, 870, 61, 4879, 9, 476, 2285, 28, 43, 5, 3, 686, 1, 2753, 1633, 29, 3, 1057, 12, 789, 8, 1962, 1, 789, 2, 2005, 758, 764, 9, 69, 881, 61, 883, 2, 4879, 32, 1052, 22, 2753, 9, 6323]",1695.0,28888417,American Brachytherapy Society recurrent carcinoma endometrium task force patterns care review literature,3,0.01507537688442211
Role of Radiation Therapy in the Multidisciplinary Management of Uterine Carcinosarcoma.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2018-01-01,"This study aimed to evaluate the impact of radiation therapy on outcomes for patients with uterine carcinosarcoma (UC). We retrospectively reviewed the records of 155 women with stage I (98), II (11), or III (46) UC who underwent total abdominal hysterectomy/bilateral salpingo-oophorectomy at our institution between 1990 and 2011. Survival rates were assessed using the Kaplan-Meier method and log-rank test. Univariate and multivariate Cox regression analyses were performed. Seventy-six patients (49%) received radiation therapy: 38 (50%) had vaginal cuff brachytherapy (VBT) alone and 38 had external beam radiation therapy (EBRT)  VBT. Seventy patients (45%) received chemotherapy (12 concurrent, 49 adjuvant, 9 both). The 5-year overall survival rate was 48.6% (stage I, 53.8%; II, 30.0%; and III, 42.5%). The disease-specific survival (DSS) rate was 57.2% (stage I, 60.9%; II, 44.4%; and III, 51.8%). Patients treated with EBRT had a higher 5-year pelvic disease control rate (88.3%) than did patients treated with VBT only (67.4%) or no radiation (71.2%; P = 0.04). In stage III patients, EBRT was associated with higher 5-year pelvic disease control (90.0% vs 55.5%, P = 0.046), DSS (64.6% vs 46.4%, P = 0.13), and overall survival (64.6% vs 34.0%, P = 0.04) rates. For all 155 patients, age at least 65 years, cervical involvement, and lymph vascular space invasion were correlated with lower DSS on univariate and multivariate analyses. In addition, treatment with concurrent chemoradiation therapy was independently associated with a higher DSS rate on multivariate analysis. Patients with UC have a high rate of relapse in the regional nodes and distant sites. External beam radiation therapy improves locoregional control in all stages and may improve survival in stage III patients who are at the highest risk of pelvic relapse.",Journal Article,750.0,2.0,aimed evaluate impact radiation therapy outcomes patients uterine carcinosarcoma UC retrospectively reviewed records 155 women stage 98 II 11 III 46 UC underwent total abdominal hysterectomy/bilateral salpingo-oophorectomy institution 1990 2011 Survival rates assessed Kaplan-Meier log-rank test Univariate multivariate Cox regression performed Seventy-six patients 49 received radiation therapy 38 50 vaginal cuff brachytherapy VBT 38 external beam radiation therapy EBRT  VBT Seventy patients 45 received chemotherapy 12 concurrent 49 adjuvant 9 5-year overall survival rate 48.6 stage 53.8 II 30.0 III 42.5 disease-specific survival DSS rate 57.2 stage 60.9 II 44.4 III 51.8 Patients treated EBRT higher 5-year pelvic disease control rate 88.3 patients treated VBT 67.4 radiation 71.2 P 0.04 stage III patients EBRT associated higher 5-year pelvic disease control 90.0 vs 55.5 P 0.046 DSS 64.6 vs 46.4 P 0.13 overall survival 64.6 vs 34.0 P 0.04 rates 155 patients age 65 years cervical involvement lymph vascular space invasion correlated lower DSS univariate multivariate addition treatment concurrent chemoradiation therapy independently associated higher DSS rate multivariate Patients UC high rate relapse regional nodes distant sites External beam radiation therapy improves locoregional control stages improve survival stage III patients highest risk pelvic relapse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[26, 45, 1295, 6, 376, 3, 345, 1, 121, 36, 23, 123, 9, 7, 5, 5623, 2417, 21, 894, 446, 3, 1064, 1, 3735, 117, 5, 82, 70, 1096, 215, 175, 15, 316, 641, 2417, 54, 208, 181, 1467, 2622, 1607, 5690, 3470, 28, 114, 731, 59, 2289, 2, 1132, 25, 151, 11, 275, 75, 3, 876, 882, 596, 2, 1066, 1026, 412, 880, 2, 331, 418, 320, 318, 11, 173, 2073, 437, 7, 739, 103, 121, 36, 519, 212, 42, 11445, 1536, 15050, 279, 2, 519, 42, 1455, 1345, 121, 36, 1883, 810, 15050, 2073, 7, 512, 103, 56, 133, 750, 739, 249, 83, 110, 3, 33, 111, 63, 25, 116, 10, 576, 49, 82, 70, 699, 66, 215, 201, 13, 2, 316, 595, 33, 3, 34, 112, 25, 1788, 116, 10, 696, 18, 82, 70, 335, 83, 215, 584, 39, 2, 316, 725, 66, 7, 73, 5, 1883, 42, 8, 142, 33, 111, 1110, 34, 182, 116, 889, 27, 76, 205, 7, 73, 5, 15050, 158, 598, 39, 15, 77, 121, 792, 18, 19, 13, 755, 4, 82, 316, 7, 1883, 10, 41, 5, 142, 33, 111, 1110, 34, 182, 424, 13, 105, 614, 33, 19, 13, 4902, 1788, 660, 49, 105, 641, 39, 19, 13, 233, 2, 63, 25, 660, 49, 105, 562, 13, 19, 13, 755, 151, 9, 62, 3735, 7, 89, 28, 506, 556, 60, 799, 2, 263, 756, 3865, 578, 11, 438, 5, 280, 1788, 23, 880, 2, 331, 318, 4, 352, 24, 5, 750, 975, 36, 10, 1042, 41, 5, 8, 142, 1788, 116, 23, 331, 65, 7, 5, 2417, 47, 8, 64, 116, 1, 429, 4, 3, 951, 502, 2, 626, 633, 1455, 1345, 121, 36, 1804, 1325, 182, 4, 62, 1153, 2, 68, 401, 25, 4, 82, 316, 7, 54, 32, 28, 3, 1076, 43, 1, 1110, 429]",1714.0,28930812,Role Radiation Therapy Multidisciplinary Management Uterine Carcinosarcoma,49,0.24623115577889448
Life after endometrial cancer: A systematic review of patient-reported outcomes.,Gynecologic oncology,Gynecol. Oncol.,2017-11-14,"Women with endometrial cancer (EC) are the second largest population of female cancer survivors in the United States. However, the outcomes of EC survivors, from the patient perspective, are not well-understood. Therefore, we conducted a systematic review of patient-reported outcomes (PROs) following an EC diagnosis. We searched MEDLINE, EMBASE, Scopus, CINAHL, and reference lists to identify published observational studies that examined PROs among women with EC. Reviewers independently reviewed eligible full-text study articles and conducted data extraction. We qualitatively summarized included articles according to exposures [e.g. body mass index (BMI), treatment, etc.] or specific PROs (e.g. sexual function). Of 1722 unique studies, 102 full-text articles were reviewed, of which a total of 27 studies fulfilled the inclusion criteria. The most commonly used PRO questionnaires were the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) (n=9), Short Form 36 Questionnaire (SF-36, n=8), the Functional Assessment of Cancer Therapy-General (FACT-G, n=5), and the Female Sexual Function Index (FSFI, n=4). Obesity was associated with lower quality of life (QOL) and physical functioning. Treatment type affected several outcomes. Laparoscopy generally resulted in better QOL outcomes than laparotomy. Likewise, vaginal brachytherapy was associated with better outcomes compared to external beam radiation. Sexual function outcomes were dependent on age, time since diagnosis, and having consulted a physician before engaging in sexual activities. In addition, a physical activity intervention was associated with improved sexual interest but not sexual function. Our review provides insight into the experience of EC survivors from the patient perspective. Factors that contribute to QOL, such as pain, fatigue, emotional and social functioning, should be monitored following an EC diagnosis.",Journal Article,798.0,9.0,Women endometrial EC second largest population female survivors United States outcomes EC survivors patient perspective well-understood conducted systematic review patient-reported outcomes PROs following EC diagnosis searched MEDLINE EMBASE Scopus CINAHL reference lists identify published observational studies examined PROs women EC Reviewers independently reviewed eligible full-text articles conducted extraction qualitatively summarized included articles according exposures e.g body mass index BMI treatment specific PROs e.g sexual function 1722 unique studies 102 full-text articles reviewed total 27 studies fulfilled inclusion criteria commonly PRO questionnaires European Organization Research Treatment Quality Life Questionnaire-Core 30 EORTC QLQ-C30 n=9 Short Form 36 Questionnaire SF-36 n=8 Functional Assessment Therapy-General FACT-G n=5 Female Sexual Function Index FSFI n=4 Obesity associated lower quality life QOL physical functioning Treatment type affected outcomes Laparoscopy generally resulted better QOL outcomes laparotomy Likewise vaginal brachytherapy associated better outcomes compared external beam radiation Sexual function outcomes dependent age time diagnosis consulted physician engaging sexual activities addition physical activity intervention associated improved sexual sexual function review provides insight experience EC survivors patient perspective Factors contribute QOL pain fatigue emotional social functioning monitored following EC diagnosis,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[117, 5, 12, 2180, 32, 3, 419, 2166, 266, 1, 1061, 12, 332, 4, 3, 1088, 907, 137, 3, 123, 1, 2180, 332, 29, 3, 69, 3727, 32, 44, 149, 1784, 673, 21, 426, 8, 1556, 206, 1, 69, 210, 123, 4660, 366, 35, 2180, 147, 21, 3080, 3388, 4995, 11347, 14657, 2, 2482, 11471, 6, 255, 983, 2495, 94, 17, 409, 4660, 107, 117, 5, 2180, 7171, 1042, 446, 625, 1647, 6153, 45, 2384, 2, 426, 74, 5763, 21, 8040, 3989, 159, 2384, 768, 6, 3401, 563, 499, 642, 782, 558, 1140, 24, 9188, 15, 112, 4660, 563, 499, 2232, 343, 1, 26081, 991, 94, 2867, 1647, 6153, 2384, 11, 446, 1, 92, 8, 181, 1, 428, 94, 9091, 3, 1680, 371, 3, 96, 841, 95, 1805, 2956, 11, 3, 1865, 2533, 9, 389, 2, 24, 1, 12, 372, 1, 358, 1770, 1793, 201, 4359, 5144, 6273, 78, 83, 978, 1297, 511, 1770, 4086, 511, 78, 66, 3, 583, 455, 1, 12, 36, 1083, 1991, 499, 78, 33, 2, 3, 1061, 2232, 343, 558, 22278, 78, 39, 1661, 10, 41, 5, 280, 372, 1, 358, 1001, 2, 900, 2702, 24, 267, 1424, 392, 123, 3553, 1228, 627, 4, 380, 1001, 123, 76, 3274, 6269, 1536, 10, 41, 5, 380, 123, 72, 6, 1455, 1345, 121, 2232, 343, 123, 11, 470, 23, 89, 98, 1192, 147, 2, 1041, 12824, 8, 1473, 348, 8534, 4, 2232, 2042, 4, 352, 8, 900, 128, 788, 10, 41, 5, 231, 2232, 1333, 84, 44, 2232, 343, 114, 206, 777, 2670, 237, 3, 730, 1, 2180, 332, 29, 3, 69, 3727, 130, 17, 1248, 6, 1001, 225, 22, 559, 613, 2671, 2, 2032, 2702, 257, 40, 2909, 366, 35, 2180, 147]",1878.0,29150143,Life endometrial systematic review patient-reported outcomes,5,0.02512562814070352
Development of a goat model for evaluation of withaferin A: Cervical implants for the treatment of cervical intraepithelial neoplasia.,Experimental and molecular pathology,Exp. Mol. Pathol.,2017-11-21,"Cervical cancer is caused by human papillomavirus (HPV). The disease develops over many years through a series of precancerous lesions. Cervical cancer can be prevented by HPV-vaccination, screening and treatment of precancer before development of cervical cancer. The treatment of high-grade cervical dysplasia (CIN <sup>2+</sup>) has traditionally been by cervical conization. Surgical procedures are associated with increased risk of undesirable side effects including bleeding, infection, scarring (stenosis), infertility and complications in later pregnancies. An inexpensive, non-invasive method of delivering therapeutics locally will be favorable to treat precancerous cervical lesions without damaging healthy tissue. The feasibility and safety of a sustained, continuous drug-releasing cervical polymeric implant for use in clinical trials was studied using a large animal model. The goat (Capra hircus), non-pregnant adult female Boer goats, was chosen due to similarities in cervical dimensions to the human. Estrus was induced with progesterone CIDR vaginal implants for 14days followed by the administration of chorionic gonadotropins 48h prior to removal of the progesterone implants to relax the cervix to allow for the placement of the cervical implant. Cervical implants, containing 2% and 4% withaferin A (WFA), with 8 coats of blank polymer, provided sustained release for a long duration and were used for the animal study. The 'mushroom'-shaped cervical polymeric implant, originally designed for women required redesigning to be accommodated within the goat cervix. The cervical implants were well tolerated by the animals with no obvious evidence of discomfort, systemic or local inflammation or toxicity. In addition, we developed a new method to analyze tissue WFA levels by solvent extractions and LS/MS-MS. WFA was found to be localized to the target and adjacent tissues with 12-16ng WFA/g tissue, with essentially no detectable WFA in distant tissues. This study suggests that the goat is a good large animal model for the future development and evaluation of therapeutic efficacy of continuous local drug delivery by cervical polymeric implants to treat precancerous cervical lesions.",Journal Article,791.0,1.0,Cervical caused human papillomavirus HPV disease develops years series precancerous lesions Cervical prevented HPV-vaccination screening treatment precancer development cervical treatment high-grade cervical dysplasia CIN sup 2+ /sup traditionally cervical conization Surgical procedures associated increased risk undesirable effects including bleeding infection scarring stenosis infertility complications later pregnancies inexpensive non-invasive delivering therapeutics locally favorable treat precancerous cervical lesions damaging healthy tissue feasibility safety sustained continuous drug-releasing cervical polymeric implant use clinical trials studied large animal model goat Capra hircus non-pregnant adult female Boer goats chosen similarities cervical dimensions human Estrus induced progesterone CIDR vaginal implants 14days followed administration chorionic gonadotropins 48h prior removal progesterone implants relax cervix allow placement cervical implant Cervical implants containing 2 4 withaferin WFA 8 coats blank polymer provided sustained release long duration animal 'mushroom'-shaped cervical polymeric implant originally designed women required redesigning accommodated goat cervix cervical implants tolerated animals obvious evidence discomfort systemic local inflammation toxicity addition developed new tissue WFA levels solvent extractions LS/MS-MS. WFA localized target adjacent tissues 12-16ng WFA/g tissue essentially detectable WFA distant tissues suggests goat good large animal model future development evaluation therapeutic efficacy continuous local drug delivery cervical polymeric implants treat precancerous cervical lesions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12, 16, 1546, 20, 171, 3242, 933, 3, 34, 4734, 252, 445, 60, 298, 8, 988, 1, 6605, 406, 12, 122, 40, 3902, 20, 933, 1915, 453, 2, 24, 1, 12380, 348, 193, 1, 12, 3, 24, 1, 64, 88, 2253, 4652, 172, 18, 172, 71, 4206, 85, 20, 8755, 221, 1369, 32, 41, 5, 101, 43, 1, 13572, 1152, 176, 141, 2294, 930, 13542, 6935, 5901, 2, 521, 4, 1559, 8746, 35, 8168, 220, 416, 596, 1, 4790, 1943, 795, 303, 40, 913, 6, 943, 6605, 406, 187, 4904, 1331, 246, 3, 1437, 2, 367, 1, 8, 2275, 1314, 234, 5586, 9770, 4194, 9, 119, 4, 38, 143, 10, 656, 75, 8, 375, 2026, 202, 3, 29075, 29617, 71604, 220, 6086, 780, 1061, 71605, 27348, 10, 4695, 520, 6, 6089, 4, 6190, 6, 3, 171, 71606, 10, 277, 5, 2143, 71607, 5966, 9, 50088, 370, 20, 3, 634, 1, 10420, 34749, 41659, 324, 6, 2829, 1, 3, 2143, 5966, 6, 34731, 3, 3629, 6, 1700, 9, 3, 2613, 1, 3, 4194, 5966, 1101, 18, 2, 39, 21604, 8, 14381, 5, 66, 49907, 1, 16024, 5570, 1052, 2275, 2008, 9, 8, 319, 654, 2, 11, 95, 9, 3, 2026, 45, 3, 71608, 8902, 9770, 4194, 5045, 1114, 9, 117, 616, 41909, 6, 40, 50705, 262, 3, 29075, 3629, 3, 5966, 11, 149, 421, 20, 3, 2258, 5, 77, 6228, 241, 1, 7381, 403, 15, 293, 1815, 15, 155, 4, 352, 21, 276, 8, 217, 596, 6, 1992, 246, 14381, 148, 20, 10614, 20462, 2, 3153, 2307, 2307, 14381, 10, 204, 6, 40, 909, 6, 3, 283, 2, 2086, 742, 5, 133, 71609, 14381, 499, 246, 5, 7257, 77, 2083, 14381, 4, 626, 742, 26, 45, 844, 17, 3, 29075, 16, 8, 1178, 375, 2026, 202, 9, 3, 508, 193, 2, 451, 1, 189, 209, 1, 1314, 293, 234, 989, 20, 9770, 5966, 6, 943, 6605, 406]",2039.0,29157955,Development goat model evaluation withaferin Cervical implants treatment cervical intraepithelial neoplasia,7,0.035175879396984924
Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance).,Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,Support Care Cancer,2017-11-21,"Dehydroepiandrosterone (DHEA) is helpful for treating vaginal symptoms. This secondary analysis evaluated the impact of vaginal DHEA on hormone concentrations, bone turnover, and vaginal cytology in women with a cancer history. Postmenopausal women, diagnosed with breast or gynecologic cancer, were eligible if they reported at least moderate vaginal symptoms. Participants could be on tamoxifen or aromatase inhibitors (AIs). Women were randomized to 3.25 versus 6.5mg/day of DHEA versus a plain moisturizer (PM) control. Sex steroid hormone levels, biomarkers of bone formation, vaginal pH, and maturation index were collected at baseline and 12weeks. Analysis included independent t tests and Wilcoxon rank tests, comparing each DHEA arm with the control. Three hundred forty-five women contributed evaluable blood and 46 contributed evaluable cytology and pH values. Circulating DHEA-S and testosterone levels were significantly increased in those on vaginal DHEA in a dose-dependent manner compared to PM. Estradiol was significantly increased in those on 6.5mg/day DHEA but not in those on 3.25mg/day DHEA (p<0.05 and p=0.05, respectively), and not in those on AIs. Biomarkers of bone formation were unchanged in all arms. Maturation of vaginal cells was 100% (3.25mg/day), 86% (6.5mg/day), and 64% (PM); pH decreased more in DHEA arms. DHEA resulted in increased hormone concentrations, though still in the lowest half or quartile of the postmenopausal range, and provided more favorable effects on vaginal cytology, compared to PM. Estrogen concentrations in women on AIs were not changed. Further research on the benefit of vaginal DHEA is warranted in hormone-dependent cancers.","Clinical Trial, Phase III",791.0,5.0,Dehydroepiandrosterone DHEA helpful treating vaginal symptoms secondary evaluated impact vaginal DHEA hormone concentrations bone turnover vaginal cytology women history Postmenopausal women diagnosed breast gynecologic eligible reported moderate vaginal symptoms Participants tamoxifen aromatase inhibitors AIs Women randomized 3.25 versus 6.5 mg/day DHEA versus plain moisturizer PM control Sex steroid hormone levels biomarkers bone formation vaginal pH maturation index collected baseline 12 weeks included independent tests Wilcoxon rank tests comparing DHEA arm control forty-five women contributed evaluable blood 46 contributed evaluable cytology pH values Circulating DHEA-S testosterone levels significantly increased vaginal DHEA dose-dependent manner compared PM Estradiol significantly increased 6.5 mg/day DHEA 3.25 mg/day DHEA p 0.05 p 0.05 respectively AIs Biomarkers bone formation unchanged arms Maturation vaginal 100 3.25 mg/day 86 6.5 mg/day 64 PM pH decreased DHEA arms DHEA resulted increased hormone concentrations lowest half quartile postmenopausal range provided favorable effects vaginal cytology compared PM Estrogen concentrations women AIs changed research benefit vaginal DHEA warranted hormone-dependent,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[12317, 10850, 16, 3951, 9, 1367, 507, 26, 568, 65, 194, 3, 345, 1, 10850, 23, 785, 1003, 5445, 2, 2045, 4, 117, 5, 8, 12, 532, 1679, 117, 265, 5, 15, 1512, 12, 11, 625, 492, 491, 210, 28, 506, 1163, 507, 776, 359, 40, 23, 1105, 15, 2106, 222, 3826, 117, 11, 384, 6, 27, 243, 185, 49, 33, 81, 218, 1, 10850, 185, 8, 15858, 34860, 3377, 182, 1035, 3853, 785, 148, 582, 1, 1264, 2058, 2, 4537, 558, 11, 786, 28, 330, 2, 133, 244, 65, 159, 306, 102, 895, 2, 3896, 1026, 895, 1430, 296, 10850, 475, 5, 3, 182, 169, 1128, 1213, 365, 117, 3447, 859, 315, 2, 641, 3447, 859, 2045, 2, 2058, 1030, 1033, 10850, 695, 2, 2660, 148, 11, 97, 101, 4, 135, 23, 10850, 4, 8, 61, 470, 1708, 72, 6, 3377, 4507, 10, 97, 101, 4, 135, 23, 49, 33, 81, 218, 10850, 84, 44, 4, 135, 23, 27, 243, 81, 218, 10850, 19, 13, 474, 2, 19, 13, 474, 106, 2, 44, 4, 135, 23, 3826, 582, 1, 1264, 11, 4639, 4, 62, 1335, 4537, 1, 37, 10, 394, 27, 243, 81, 218, 868, 49, 33, 81, 218, 2, 660, 3377, 2058, 340, 80, 4, 10850, 1335, 10850, 627, 4, 101, 785, 1003, 2471, 1234, 4, 3, 2101, 1303, 15, 3708, 1, 3, 1679, 184, 2, 1052, 80, 913, 176, 23, 2045, 72, 6, 3377, 808, 1003, 4, 117, 23, 3826, 11, 44, 2368, 195, 389, 23, 3, 247, 1, 10850, 16, 1197, 4, 785, 470, 163]",1553.0,29164377,Systemic local effects vaginal dehydroepiandrosterone DHEA NCCTG N10C1 Alliance,0,0.0
"Local control for vaginal botryoid rhabdomyosarcoma with pre-rectal transperineal surgical resection and autologous buccal graft vaginal replacement: A novel, minimally invasive, radiation-sparing approach.",Journal of pediatric surgery,J. Pediatr. Surg.,2017-11-21,"Localized vaginal rhabdomyosarcoma (RMS) is associated with a favorable prognosis, but strategies for local control remain controversial. The use of radiotherapy (RT) can have important long-term sequelae, while traditional resection involves major reconstructive surgery. We describe a new surgical approach employing a minimally-invasive resection and immediate reconstruction. Records from 4 consecutive patients with localized vaginal RMS managed in 4 major pediatric referral centers were reviewed. All cases were performed with a standardized technique. Patients were diagnosed at a median age of 24months. Each underwent a total/subtotal vaginectomy with autologous buccal graft vaginal replacement. Final margins were focally positive in one patient and negative in three. None received radiotherapy. To date, all patients have patent buccal neovaginas, enjoy a favorable aesthetic result, and remain disease-free at a median follow-up of 35months. We report 4 cases of localized vaginal RMS successfully treated with a minimally invasive surgical approach. All patients have avoided radiation and remain disease-free. Our initial data suggest that surgical local control and immediate reconstruction are feasible and can spare these patients the long-term complications of RT. Longer follow-up is critical to ensure disease-free survival with a functional, successfully reconstructed neovagina. Case series. Level IV.",Journal Article,791.0,1.0,Localized vaginal rhabdomyosarcoma RMS associated favorable prognosis strategies local control remain controversial use radiotherapy RT important long-term sequelae traditional resection involves major reconstructive surgery new surgical approach employing minimally-invasive resection immediate reconstruction Records 4 consecutive patients localized vaginal RMS managed 4 major pediatric referral centers reviewed cases performed standardized technique Patients diagnosed median age 24months underwent total/subtotal vaginectomy autologous buccal graft vaginal replacement Final margins focally positive patient negative received radiotherapy date patients patent buccal neovaginas enjoy favorable aesthetic remain disease-free median follow-up 35months report 4 cases localized vaginal RMS successfully treated minimally invasive surgical approach patients avoided radiation remain disease-free initial suggest surgical local control immediate reconstruction feasible spare patients long-term complications RT Longer follow-up critical ensure disease-free survival functional successfully reconstructed neovagina Case series Level IV,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[909, 3413, 16, 41, 5, 8, 913, 356, 84, 422, 9, 293, 182, 918, 2010, 3, 119, 1, 310, 240, 122, 47, 305, 319, 337, 4156, 369, 1847, 170, 2921, 458, 8060, 152, 21, 897, 8, 217, 221, 353, 6898, 8, 2144, 416, 170, 2, 2181, 1470, 1064, 29, 39, 935, 7, 5, 909, 3413, 2231, 4, 39, 458, 815, 2096, 1168, 11, 446, 62, 140, 11, 173, 5, 8, 1670, 1312, 7, 11, 265, 28, 8, 52, 89, 1, 41924, 296, 208, 8, 181, 5503, 33868, 5, 1028, 9883, 1599, 3892, 1457, 1012, 11, 9772, 109, 4, 104, 69, 2, 199, 4, 169, 1292, 103, 310, 6, 1244, 62, 7, 47, 14172, 9883, 71831, 16381, 8, 913, 15975, 757, 2, 918, 34, 115, 28, 8, 52, 166, 126, 1, 36372, 21, 414, 39, 140, 1, 909, 3413, 1878, 73, 5, 8, 2144, 416, 221, 353, 62, 7, 47, 5617, 121, 2, 918, 34, 115, 114, 388, 74, 309, 17, 221, 293, 182, 2, 2181, 1470, 32, 1313, 2, 122, 8539, 46, 7, 3, 319, 337, 521, 1, 240, 589, 166, 126, 16, 740, 6, 3478, 34, 115, 25, 5, 8, 583, 1878, 7267, 71832, 473, 988, 301, 478]",1351.0,29258699,Local control vaginal botryoid rhabdomyosarcoma pre-rectal transperineal surgical resection autologous buccal graft vaginal replacement novel minimally invasive radiation-sparing approach,26,0.1306532663316583
Cost-effectiveness of adjuvant intravaginal brachytherapy in high-intermediate risk endometrial carcinoma.,Brachytherapy,Brachytherapy,2017-12-21,"We assessed the cost-effectiveness of adjuvant intravaginal brachytherapy (IVBT) vs. observation after total hysterectomy and bilateral salpingo-oophorectomy (TH/BSO) for high-intermediate risk (HIR) endometrial carcinoma. A Markov model was used to assess the cost-effectiveness of IVBT by comparing average cumulative costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) between patients allocated to (1) 'observation' or (2) 'IVBT' after TH/BSO. We used a prototype Post-Operative Radiation Therapy in Endometrial Carcinoma (PORTEC)-defined HIR patient in the base case analysis. We calibrated the model to match the outcomes reported in the PORTEC-1 and PORTEC-2 trials. Utilities were obtained from published estimates, and costs were calculated based on Medicare reimbursement ($5445 for IVBT). The societal willingness-to-pay threshold was set at $100,000 per QALY. The time horizon was 5years. IVBT was associated with a net increase of 0.094 QALYs (4.512 vs. 4.418) as well as an increase in mean cost ($17,453 vs. $15,620) relative to observation. The ICER for IVBT was $19,500 per QALY. On one-way sensitivity analysis, IVBT remained cost-effective when its cost was less than $12,937. If the probability of vaginal recurrence in the observation arm was increased or decreased by 25%, the ICER became $1335 per QALY and $87,925 per QALY, respectively. Probabilistic sensitivity analysis revealed that IVBT was the preferred management option in 86% of simulations. IVBT is cost-effective compared with observation after TH/BSO for HIR endometrial carcinoma by commonly accepted willingness-to-pay thresholds.",Journal Article,761.0,3.0,"assessed cost-effectiveness adjuvant intravaginal brachytherapy IVBT vs. observation total hysterectomy bilateral salpingo-oophorectomy TH/BSO high-intermediate risk HIR endometrial carcinoma Markov model assess cost-effectiveness IVBT comparing average cumulative costs quality-adjusted life years QALYs incremental cost-effectiveness ratios ICERs patients allocated 1 'observation 2 'IVBT TH/BSO prototype Post-Operative Radiation Therapy Endometrial Carcinoma PORTEC -defined HIR patient base case calibrated model match outcomes reported PORTEC-1 PORTEC-2 trials Utilities obtained published estimates costs calculated based Medicare reimbursement 5445 IVBT societal willingness-to-pay threshold set 100,000 QALY time horizon 5 years IVBT associated net increase 0.094 QALYs 4.512 vs. 4.418 increase mean cost 17,453 vs. 15,620 relative observation ICER IVBT 19,500 QALY one-way sensitivity IVBT remained cost-effective cost 12,937 probability vaginal recurrence observation arm increased decreased 25 ICER 1335 QALY 87,925 QALY respectively Probabilistic sensitivity revealed IVBT preferred management option 86 simulations IVBT cost-effective compared observation TH/BSO HIR endometrial carcinoma commonly accepted willingness-to-pay thresholds",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[21, 275, 3, 835, 1236, 1, 249, 16720, 1536, 25841, 105, 1664, 50, 181, 2622, 2, 1607, 5690, 3470, 4517, 9477, 9, 64, 919, 43, 19814, 134, 8, 6516, 202, 10, 95, 6, 423, 3, 835, 1236, 1, 25841, 20, 1430, 1011, 967, 1201, 372, 586, 358, 60, 6764, 2, 3648, 835, 1236, 1137, 10393, 59, 7, 6682, 6, 14, 71864, 15, 18, 71865, 50, 4517, 9477, 21, 95, 8, 8743, 539, 1208, 121, 36, 4, 134, 32606, 395, 19814, 69, 4, 3, 1782, 473, 65, 21, 10570, 3, 202, 6, 5364, 3, 123, 210, 4, 3, 32606, 14, 2, 32606, 18, 143, 7114, 11, 683, 29, 983, 1423, 2, 1201, 11, 981, 90, 23, 1378, 6642, 39795, 9, 25841, 3, 9378, 5268, 6, 6974, 2390, 10, 916, 28, 394, 984, 379, 4124, 3, 98, 8704, 10, 33, 60, 25841, 10, 41, 5, 8, 2587, 344, 1, 13, 13877, 6764, 39, 12287, 105, 39, 10387, 22, 149, 22, 35, 344, 4, 313, 835, 269, 9861, 105, 167, 10811, 580, 6, 1664, 3, 6463, 9, 25841, 10, 326, 1666, 379, 4124, 23, 104, 2255, 485, 65, 25841, 958, 835, 323, 198, 211, 835, 10, 299, 76, 133, 15361, 492, 3, 1320, 1, 146, 4, 3, 1664, 475, 10, 101, 15, 340, 20, 243, 3, 6463, 3451, 31923, 379, 4124, 2, 912, 14838, 379, 4124, 106, 7889, 485, 65, 553, 17, 25841, 10, 3, 2514, 284, 1501, 4, 868, 1, 7490, 25841, 16, 835, 323, 72, 5, 1664, 50, 4517, 9477, 9, 19814, 134, 20, 841, 3058, 5268, 6, 6974, 4634]",1565.0,29275078,Cost-effectiveness adjuvant intravaginal brachytherapy high-intermediate risk endometrial carcinoma,6,0.03015075376884422
Uterine rhabdomyosarcoma in adults.,Human pathology,Hum. Pathol.,2018-01-07,"Rhabdomyosarcoma (RMS) is an aggressive mesenchymal tumor most commonly diagnosed in the pediatric population, and when occurring in adults, tends to develop in the deep soft tissue of the limbs. Primary uterine RMS comprises an even more restricted subset, with little known or reported when compared to most other gynecologic sarcomas. Our goal with this study was to retrospectively evaluate cases from two academic institutions and describe the main histopathologic findings of this rare gynecologic malignancy. A total of 8 cases were identified, consisting of 4 pleomorphic rhabdomyosarcomas (PRMS), 2 alveolar rhabdomyosarcomas (ARMS), and 2 embryonal rhabdomyosarcomas (ERMS). They occurred in patients ranging from 22 to 70 years old, and the most common presenting symptom was vaginal bleeding. Most patients presented with advanced stage at diagnosis, including metastatic disease to lymph nodes and to distant sites. The masses were mostly (6/8) centered in the myometrium, while two cases arose in the cervix (2/8). Histologic characteristics of the tumors were dependent on the RMS subtype, although all cases demonstrated a similar immunohistochemical profile regardless of their subclassification. RMS of the uterus has a very poor prognosis, and data regarding treatment of this rare malignancy is limited, and usually extrapolated from non-uterine sites.",Journal Article,744.0,3.0,Rhabdomyosarcoma RMS aggressive mesenchymal commonly diagnosed pediatric population occurring adults tends develop deep soft tissue limbs Primary uterine RMS comprises restricted subset little known reported compared gynecologic sarcomas goal retrospectively evaluate cases academic institutions main histopathologic findings rare gynecologic malignancy total 8 cases identified consisting 4 pleomorphic rhabdomyosarcomas PRMS 2 alveolar rhabdomyosarcomas ARMS 2 embryonal rhabdomyosarcomas ERMS occurred patients ranging 22 70 years old common presenting symptom vaginal bleeding patients presented advanced stage diagnosis including metastatic disease lymph nodes distant sites masses 6/8 centered myometrium cases arose cervix 2/8 Histologic characteristics dependent RMS subtype cases demonstrated similar immunohistochemical profile regardless subclassification RMS uterus poor prognosis treatment rare malignancy limited usually extrapolated non-uterine sites,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,"[3413, 16, 35, 571, 1569, 30, 96, 841, 265, 4, 3, 815, 266, 2, 198, 1821, 4, 857, 11488, 6, 690, 4, 3, 2369, 1214, 246, 1, 3, 17075, 86, 3413, 6704, 35, 871, 80, 2016, 697, 5, 1215, 440, 15, 210, 198, 72, 6, 96, 127, 1512, 1479, 114, 1326, 5, 26, 45, 10, 6, 894, 376, 140, 29, 100, 1916, 1764, 2, 897, 3, 1895, 2630, 272, 1, 26, 622, 1512, 710, 8, 181, 1, 66, 140, 11, 108, 2273, 1, 39, 4581, 15480, 36531, 18, 5641, 15480, 1335, 2, 18, 5239, 15480, 9302, 491, 489, 4, 7, 2223, 29, 350, 6, 431, 60, 1095, 2, 3, 96, 186, 1656, 934, 10, 2294, 96, 7, 917, 5, 131, 82, 28, 147, 141, 113, 34, 6, 263, 502, 2, 6, 626, 633, 3, 2692, 11, 2754, 49, 66, 4846, 4, 3, 41014, 369, 100, 140, 7268, 4, 3, 3629, 18, 66, 884, 374, 1, 3, 57, 11, 470, 23, 3, 3413, 875, 242, 62, 140, 264, 8, 288, 1382, 800, 1583, 1, 136, 9341, 3413, 1, 3, 71, 8, 923, 334, 356, 2, 74, 666, 24, 1, 26, 622, 710, 16, 383, 2, 2082, 10727, 29, 220, 16369, 633]",1299.0,29320751,Uterine rhabdomyosarcoma adults,1,0.005025125628140704
Minimally invasive hysterectomy surgery rates for endometrial cancer performed at National Comprehensive Cancer Network (NCCN) Centers.,Gynecologic oncology,Gynecol. Oncol.,2018-01-12,"Minimally invasive surgery (MIS) is a quality measure for endometrial cancer (EC) established by the Society of Gynecologic Oncology and the American College of Surgeons. Our study objective was to assess the proportion of EC cases performed by MIS at National Comprehensive Cancer Network (NCCN) centers and evaluate perioperative outcomes. A retrospective cohort study of women who underwent surgical treatment for EC from 2013 to 2014 was conducted at four NCCN centers. Multivariable mixed logistic regression models analyzed factors associated with failure to perform MIS and perioperative complications. In total 1621 patients were evaluated; 86.5% underwent MIS (robotic-assisted 72.5%, laparoscopic 20.9%, vaginal 6.6%). On multivariable analysis, factors associated with failure to undergo MIS were uterine size >12cm (Odds Ratio [OR]: 0.17, 95% CI 0.03-0.9), stage III (OR: 0.16, 95% CI 0.05-0.49) and IV disease (OR: 0.07, 95% CI 0.02-0.22). For stage I/II disease, complications occurred in 5.1% of MIS and 21.7% of laparotomy cases (p<0.01). Laparotomy was associated with increases in any complication (OR: 6.0, 95% CI 3.3-10.8), gastrointestinal (OR: 7.2, 95% CI 2.6-19.5), wound (OR: 3.7, 95% CI 1.5-9.2), respiratory (OR 37.5, 95% CI 3.9-358.0), VTE (OR 10.5, 95% CI 1.3-82.8) and 30-day readmission (OR: 2.6, 95% CI 1.4-4.9) compared to MIS. At NCCN-designated centers, the MIS hysterectomy rate in EC is higher than the published national average, with low perioperative complications. Previously identified disparities of age, race, and BMI were not observed. A proposed MIS hysterectomy benchmark of >80% in EC care is feasible when performed at high volume centers.",Journal Article,739.0,18.0,Minimally invasive surgery MIS quality measure endometrial EC established Society Gynecologic Oncology American College Surgeons objective assess proportion EC cases performed MIS National Comprehensive Network NCCN centers evaluate perioperative outcomes retrospective cohort women underwent surgical treatment EC 2013 2014 conducted NCCN centers Multivariable mixed logistic regression models factors associated failure perform MIS perioperative complications total 1621 patients evaluated 86.5 underwent MIS robotic-assisted 72.5 laparoscopic 20.9 vaginal 6.6 multivariable factors associated failure undergo MIS uterine size 12cm Odds Ratio 0.17 95 CI 0.03-0.9 stage III 0.16 95 CI 0.05-0.49 IV disease 0.07 95 CI 0.02-0.22 stage I/II disease complications occurred 5.1 MIS 21.7 laparotomy cases p 0.01 Laparotomy associated increases complication 6.0 95 CI 3.3-10.8 gastrointestinal 7.2 95 CI 2.6-19.5 wound 3.7 95 CI 1.5-9.2 respiratory 37.5 95 CI 3.9-358.0 VTE 10.5 95 CI 1.3-82.8 30-day readmission 2.6 95 CI 1.4-4.9 compared MIS NCCN-designated centers MIS hysterectomy rate EC higher published national average low perioperative complications Previously identified disparities age race BMI observed proposed MIS hysterectomy benchmark 80 EC care feasible performed high volume centers,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[2144, 416, 152, 4386, 16, 8, 372, 1463, 9, 12, 2180, 635, 20, 3, 1174, 1, 1512, 413, 2, 3, 597, 2979, 1, 1613, 114, 45, 461, 10, 6, 423, 3, 920, 1, 2180, 140, 173, 20, 4386, 28, 657, 949, 12, 1801, 1944, 1168, 2, 376, 1547, 123, 8, 459, 180, 45, 1, 117, 54, 208, 221, 24, 9, 2180, 29, 1346, 6, 1409, 10, 426, 28, 294, 1944, 1168, 658, 1739, 812, 320, 274, 311, 130, 41, 5, 496, 6, 2715, 4386, 2, 1547, 521, 4, 181, 45098, 7, 11, 194, 868, 33, 208, 4386, 2895, 2927, 720, 33, 1964, 179, 83, 49, 49, 23, 658, 65, 130, 41, 5, 496, 6, 1251, 4386, 11, 444, 71959, 610, 197, 15, 13, 269, 48, 58, 13, 680, 13, 83, 82, 316, 15, 13, 245, 48, 58, 13, 474, 13, 739, 2, 478, 34, 15, 13, 1615, 48, 58, 13, 588, 13, 350, 9, 82, 70, 215, 34, 521, 489, 4, 33, 14, 1, 4386, 2, 239, 67, 1, 3274, 140, 19, 13, 355, 3274, 10, 41, 5, 1106, 4, 500, 1447, 15, 49, 13, 48, 58, 27, 27, 79, 66, 15, 67, 18, 48, 58, 18, 49, 326, 33, 2689, 15, 27, 67, 48, 58, 14, 33, 83, 18, 2718, 15, 567, 33, 48, 58, 27, 83, 8396, 13, 1779, 15, 79, 33, 48, 58, 14, 27, 878, 66, 2, 201, 218, 3146, 15, 18, 49, 48, 58, 14, 39, 39, 83, 72, 6, 4386, 28, 1944, 4107, 1168, 3, 4386, 2622, 116, 4, 2180, 16, 142, 76, 3, 983, 657, 1011, 5, 154, 1547, 521, 373, 108, 2227, 1, 89, 1047, 2, 1140, 11, 44, 164, 8, 1587, 4386, 2622, 7330, 1, 493, 4, 2180, 165, 16, 1313, 198, 173, 28, 64, 433, 1168]",1553.0,29338923,Minimally invasive hysterectomy surgery rates endometrial performed National Comprehensive Network NCCN Centers,0,0.0
"Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2018-02-12,"Purpose We compared the efficacy and toxicity of neoadjuvant chemotherapy followed by radical surgery versus standard cisplatin-based chemoradiation in patients with locally advanced squamous cervical cancer. Patients and Methods This was a single-center, phase III, randomized controlled trial ( ClinicalTrials.gov identifier: NCT00193739). Eligible patients were between 18 and 65 years old and had stage IB2, IIA, or IIB squamous cervical cancer. They were randomly assigned, after stratification by stage, to receive either three cycles of neoadjuvant chemotherapy using paclitaxel and carboplatin once every 3 weeks followed by radical hysterectomy or standard radiotherapy with concomitant cisplatin once every week for 5 weeks. Patients in the neoadjuvant group received postoperative adjuvant radiation or concomitant chemotherapy and radiotherapy, if indicated. The primary end point was disease-free survival (DFS), defined as survival without relapse or death related to cancer, and secondary end points included overall survival and toxicity. Results Between September 2003 and February 2015, 635 patients were randomly assigned, of whom 633 (316 patients in the neoadjuvant chemotherapy plus surgery group and 317 patients in the concomitant chemoradiation group) were included in the final analysis, with a median follow-up time of 58.5 months. The 5-year DFS in the neoadjuvant chemotherapy plus surgery group was 69.3% compared with 76.7% in the concomitant chemoradiation group (hazard ratio, 1.38; 95% CI, 1.02 to 1.87; P = .038), whereas the corresponding 5-year OS rates were 75.4% and 74.7%, respectively (hazard ratio, 1.025; 95% CI, 0.752 to 1.398; P = .87). The delayed toxicities at 24 months or later after treatment completion in the neoadjuvant chemotherapy plus surgery group versus the concomitant chemoradiation group were rectal (2.2% v 3.5%, respectively), bladder (1.6% v 3.5%, respectively), and vaginal (12.0% v 25.6%, respectively). Conclusion Cisplatin-based concomitant chemoradiation resulted in superior DFS compared with neoadjuvant chemotherapy followed by radical surgery in locally advanced cervical cancer.","Clinical Trial, Phase III",708.0,61.0,Purpose compared efficacy toxicity neoadjuvant chemotherapy followed radical surgery versus standard cisplatin-based chemoradiation patients locally advanced squamous cervical Patients Methods single-center phase III randomized controlled trial ClinicalTrials.gov identifier NCT00193739 Eligible patients 18 65 years old stage IB2 IIA IIB squamous cervical randomly assigned stratification stage receive cycles neoadjuvant chemotherapy paclitaxel carboplatin 3 weeks followed radical hysterectomy standard radiotherapy concomitant cisplatin week 5 weeks Patients neoadjuvant group received postoperative adjuvant radiation concomitant chemotherapy radiotherapy indicated primary end point disease-free survival DFS defined survival relapse death related secondary end points included overall survival toxicity September 2003 February 2015 635 patients randomly assigned 633 316 patients neoadjuvant chemotherapy plus surgery group 317 patients concomitant chemoradiation group included final median follow-up time 58.5 months 5-year DFS neoadjuvant chemotherapy plus surgery group 69.3 compared 76.7 concomitant chemoradiation group hazard ratio 1.38 95 CI 1.02 1.87 P .038 corresponding 5-year OS rates 75.4 74.7 respectively hazard ratio 1.025 95 CI 0.752 1.398 P .87 delayed toxicities 24 months later treatment completion neoadjuvant chemotherapy plus surgery group versus concomitant chemoradiation group rectal 2.2 v 3.5 respectively bladder 1.6 v 3.5 respectively vaginal 12.0 v 25.6 respectively Cisplatin-based concomitant chemoradiation resulted superior DFS compared neoadjuvant chemotherapy followed radical surgery locally advanced cervical,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,"[743, 21, 72, 3, 209, 2, 155, 1, 536, 56, 370, 20, 711, 152, 185, 260, 540, 90, 975, 4, 7, 5, 795, 131, 691, 12, 7, 2, 636, 26, 10, 8, 226, 574, 124, 316, 384, 1149, 160, 1252, 1239, 3719, 72140, 625, 7, 11, 59, 203, 2, 556, 60, 1095, 2, 42, 82, 9537, 4088, 15, 3884, 691, 12, 491, 11, 1108, 896, 50, 1541, 20, 82, 6, 560, 361, 169, 410, 1, 536, 56, 75, 490, 2, 927, 1059, 454, 27, 244, 370, 20, 711, 2622, 15, 260, 310, 5, 1781, 540, 1059, 454, 647, 9, 33, 244, 7, 4, 3, 536, 87, 103, 573, 249, 121, 15, 1781, 56, 2, 310, 492, 1103, 3, 86, 396, 741, 10, 34, 115, 25, 1010, 395, 22, 25, 187, 429, 15, 273, 139, 6, 12, 2, 568, 396, 862, 159, 63, 25, 2, 155, 99, 59, 2636, 1522, 2, 3010, 1483, 12254, 7, 11, 1108, 896, 1, 953, 11967, 8500, 7, 4, 3, 536, 56, 349, 152, 87, 2, 7869, 7, 4, 3, 1781, 975, 87, 11, 159, 4, 3, 1457, 65, 5, 8, 52, 166, 126, 98, 1, 717, 33, 53, 3, 33, 111, 1010, 4, 3, 536, 56, 349, 152, 87, 10, 790, 27, 72, 5, 846, 67, 4, 3, 1781, 975, 87, 360, 197, 14, 519, 48, 58, 14, 588, 6, 14, 912, 19, 5215, 547, 3, 1734, 33, 111, 118, 151, 11, 481, 39, 2, 794, 67, 106, 360, 197, 14, 4067, 48, 58, 13, 11611, 6, 14, 8336, 19, 912, 3, 1612, 385, 28, 259, 53, 15, 1559, 50, 24, 1438, 4, 3, 536, 56, 349, 152, 87, 185, 3, 1781, 975, 87, 11, 18, 18, 603, 27, 33, 106, 14, 49, 603, 27, 33, 106, 2, 133, 13, 603, 243, 49, 106, 1221, 540, 90, 1781, 975, 627, 4, 1123, 1010, 72, 5, 536, 56, 370, 20, 711, 152, 4, 795, 131, 12]",2031.0,29432076,Neoadjuvant Chemotherapy Followed Radical Surgery Versus Concomitant Chemotherapy Radiotherapy Patients Stage IB2 IIA IIB Squamous Cervical Randomized Controlled Trial,2,0.010050251256281407
Factors Predictive of Receiving Adjuvant Radiotherapy in High-Intermediate-Risk Stage I Endometrial Cancer.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2018-06-01,"Randomized trials have shown a local control benefit with adjuvant radiotherapy (RT) in high-intermediate-risk endometrial cancer patients, although not all such patients receive RT. We reviewed the National Cancer Data Base to investigate which patient/tumor-related factors are associated with delivery of adjuvant RT. The National Cancer Data Base was queried for patients diagnosed with International Federation of Gynecology and Obstetrics 2009 stage I endometrioid adenocarcinoma from 1998 to 2012 who underwent surgery +/- adjuvant RT. Exclusion criteria were unknown stage/grade, nonsurgical primary therapy, less than 30 days' follow-up, RT of more than 6 months after surgery, or palliative treatment. High-intermediate risk was defined based on Post Operative Radiation Therapy in Endometrial Carcinoma 2 criteria: older than 60 years with stage IA grade 3 or stage IB grade 1-2. Seventeen thousand five hundred twenty-four met inclusion criteria, and the 13,651 patients with complete data were subjected to a multiple logistic regression analysis; 7814 (57.2%) received surgery alone, and 5837 (42.8%) received surgery + RT. Receipt of adjuvant RT was more likely among black women and women with higher income, Northeastern residence, diagnosis after 2010, greater than 50% myometrial invasion, and receipt of adjuvant chemotherapy (P < 0.05). Patients older than 80 years or those undergoing lymph node dissection were less likely to receive adjuvant RT (P < 0.05). Of those treated with RT, 44.0% received external beam therapy, 54.8% received vaginal cuff brachytherapy, and 0.6% received both. Among irradiated women, patients older than 80 years and those with Northeastern residence, treatment at academic facilities, diagnosis after 2004, and lymph node dissection were more likely to undergo brachytherapy over external beam radiation therapy (P < 0.05). Overall use of adjuvant RT was 28.8% between 1998 and 2004, 42.0% between 2005 and 2010, and 43.4% between 2011 and 2012; the difference between 1998-2004 and 2005-2010 was not statistically significant. Fewer than half of patients with high-intermediate-risk endometrial cancer by Post Operative Radiation Therapy in Endometrial Carcinoma 2 criteria received adjuvant RT despite evidence demonstrating improved local control. Both patient- and tumor-related factors are associated with delivery of adjuvant RT and the modality selected.",Journal Article,599.0,0.0,"Randomized trials shown local control benefit adjuvant radiotherapy RT high-intermediate-risk endometrial patients patients receive RT reviewed National Base investigate patient/tumor-related factors associated delivery adjuvant RT National Base queried patients diagnosed International Federation Gynecology Obstetrics 2009 stage endometrioid adenocarcinoma 1998 2012 underwent surgery +/- adjuvant RT Exclusion criteria unknown stage/grade nonsurgical primary therapy 30 days follow-up RT 6 months surgery palliative treatment High-intermediate risk defined based Post Operative Radiation Therapy Endometrial Carcinoma 2 criteria older 60 years stage IA grade 3 stage IB grade 1-2 Seventeen thousand twenty-four met inclusion criteria 13,651 patients complete subjected multiple logistic regression 7814 57.2 received surgery 5837 42.8 received surgery RT Receipt adjuvant RT likely black women women higher income Northeastern residence diagnosis 2010 greater 50 myometrial invasion receipt adjuvant chemotherapy P 0.05 Patients older 80 years undergoing lymph node dissection likely receive adjuvant RT P 0.05 treated RT 44.0 received external beam therapy 54.8 received vaginal cuff brachytherapy 0.6 received irradiated women patients older 80 years Northeastern residence treatment academic facilities diagnosis 2004 lymph node dissection likely undergo brachytherapy external beam radiation therapy P 0.05 Overall use adjuvant RT 28.8 1998 2004 42.0 2005 2010 43.4 2011 2012 difference 1998-2004 2005-2010 statistically significant Fewer half patients high-intermediate-risk endometrial Post Operative Radiation Therapy Endometrial Carcinoma 2 criteria received adjuvant RT despite evidence demonstrating improved local control patient- tumor-related factors associated delivery adjuvant RT modality selected",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[384, 143, 47, 443, 8, 293, 182, 247, 5, 249, 310, 240, 4, 64, 919, 43, 12, 7, 242, 44, 62, 225, 7, 560, 240, 21, 446, 3, 657, 12, 74, 1782, 6, 963, 92, 69, 30, 139, 130, 32, 41, 5, 989, 1, 249, 240, 3, 657, 12, 74, 1782, 10, 3547, 9, 7, 265, 5, 944, 7303, 1, 6429, 2, 7407, 1238, 82, 70, 3151, 449, 29, 1850, 6, 1195, 54, 208, 152, 249, 240, 4721, 371, 11, 860, 82, 88, 5544, 86, 36, 299, 76, 201, 162, 166, 126, 240, 1, 80, 76, 49, 53, 50, 152, 15, 994, 24, 64, 919, 43, 10, 395, 90, 23, 539, 1208, 121, 36, 4, 134, 18, 371, 434, 76, 335, 60, 5, 82, 3302, 88, 27, 15, 82, 3180, 88, 14, 18, 3591, 6161, 365, 1128, 737, 294, 543, 1680, 371, 2, 3, 233, 13114, 7, 5, 236, 74, 11, 4325, 6, 8, 232, 812, 320, 65, 72369, 696, 18, 103, 152, 279, 2, 39500, 595, 66, 103, 152, 240, 1699, 1, 249, 240, 10, 80, 322, 107, 1445, 117, 2, 117, 5, 142, 2306, 22567, 5562, 147, 50, 1120, 378, 76, 212, 7327, 578, 2, 1699, 1, 249, 56, 19, 13, 474, 7, 434, 76, 493, 60, 15, 135, 479, 263, 289, 1161, 11, 299, 322, 6, 560, 249, 240, 19, 13, 474, 1, 135, 73, 5, 240, 584, 13, 103, 1455, 1345, 36, 667, 66, 103, 11445, 1536, 2, 13, 49, 103, 110, 107, 2398, 117, 7, 434, 76, 493, 60, 2, 135, 5, 22567, 5562, 24, 28, 1916, 4351, 147, 50, 1131, 2, 263, 289, 1161, 11, 80, 322, 6, 1251, 1536, 252, 1455, 1345, 121, 36, 19, 13, 474, 63, 119, 1, 249, 240, 10, 339, 66, 59, 1850, 2, 1131, 595, 13, 59, 1242, 2, 1120, 2, 601, 39, 59, 1132, 2, 1195, 3, 523, 59, 1850, 1131, 2, 1242, 1120, 10, 44, 712, 93, 1497, 76, 1303, 1, 7, 5, 64, 919, 43, 12, 20, 539, 1208, 121, 36, 4, 134, 18, 371, 103, 249, 240, 550, 241, 2219, 231, 293, 182, 110, 69, 2, 30, 139, 130, 32, 41, 5, 989, 1, 249, 240, 2, 3, 1396, 715]",2292.0,29538253,Factors Predictive Receiving Adjuvant Radiotherapy High-Intermediate-Risk Stage Endometrial,0,0.0
Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health.,"Menopause (New York, N.Y.)",Menopause,2018-06-01,"The objective of The North American Menopause Society (NAMS) and The International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel was to create a point of care algorithm for treating genitourinary syndrome of menopause (GSM) in women with or at high risk for breast cancer. The consensus recommendations will assist healthcare providers in managing GSM with a goal of improving the care and quality of life for these women. The Expert Consensus Panel is comprised of a diverse group of 16 multidisciplinary experts well respected in their fields. The panelists individually conducted an evidence-based review of the literature in their respective areas of expertise. They then met to discuss the latest treatment options for genitourinary syndrome of menopause (GSM) in survivors of breast cancer and review management strategies for GSM in women with or at high risk for breast cancer, using a modified Delphi method. This iterative process involved presentations summarizing the current literature, debate, and discussion of divergent opinions concerning GSM assessment and management, leading to the development of consensus recommendations for the clinician.Genitourinary syndrome of menopause is more prevalent in survivors of breast cancer, is commonly undiagnosed and untreated, and may have early onset because of cancer treatments or risk-reducing strategies. The paucity of evidence regarding the safety of vaginal hormone therapies in women with or at high risk for breast cancer has resulted in avoidance of treatment, potentially adversely affecting quality of life and intimate relationships. Factors influencing decision-making regarding treatment for GSM include breast cancer recurrence risk, severity of symptoms, response to prior therapies, and personal preference.We review current evidence for various pharmacologic and nonpharmacologic therapeutic modalities in women with a history of or at high risk for breast cancer and highlight the substantial gaps in the evidence for safe and effective therapies and the need for future research. Treatment of GSM is individualized, with nonhormone treatments generally being first line in this population. The use of local hormone therapies may be an option for some women who fail nonpharmacologic and nonhormone treatments after a discussion of risks and benefits and review with a woman's oncologist. We provide consensus recommendations for an approach to the management of GSM in specific patient populations, including women at high risk for breast cancer, women with estrogen-receptor positive breast cancers, women with triple-negative breast cancers, and women with metastatic disease.",Consensus Development Conference,599.0,26.0,objective North American Menopause Society NAMS International Society Women 's Sexual Health ISSWSH Expert Consensus Panel create point care algorithm treating genitourinary syndrome menopause GSM women high risk breast consensus recommendations assist healthcare providers managing GSM goal improving care quality life women Expert Consensus Panel comprised diverse group 16 multidisciplinary experts respected fields panelists individually conducted evidence-based review literature respective areas expertise met discuss latest treatment options genitourinary syndrome menopause GSM survivors breast review management strategies GSM women high risk breast modified Delphi iterative process involved presentations summarizing current literature debate discussion divergent opinions concerning GSM assessment management leading development consensus recommendations clinician.Genitourinary syndrome menopause prevalent survivors breast commonly undiagnosed untreated early onset treatments risk-reducing strategies paucity evidence safety vaginal hormone therapies women high risk breast resulted avoidance treatment potentially adversely affecting quality life intimate relationships Factors influencing decision-making treatment GSM include breast recurrence risk severity symptoms response prior therapies personal preference.We review current evidence pharmacologic nonpharmacologic therapeutic modalities women history high risk breast highlight substantial gaps evidence safe effective therapies need future research Treatment GSM individualized nonhormone treatments generally line population use local hormone therapies option women fail nonpharmacologic nonhormone treatments discussion risks benefits review woman 's oncologist provide consensus recommendations approach management GSM specific patient populations including women high risk breast women estrogen-receptor positive breast women triple-negative breast women metastatic disease,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 461, 1, 3, 2669, 597, 5034, 1174, 29861, 2, 3, 944, 1174, 9, 3, 45, 1, 117, 292, 2232, 341, 72769, 2005, 1391, 993, 10, 6, 3736, 8, 741, 1, 165, 2124, 9, 1367, 4109, 681, 1, 5034, 19392, 4, 117, 5, 15, 28, 64, 43, 9, 12, 3, 1391, 883, 303, 3425, 2819, 1994, 4, 3969, 19392, 5, 8, 1326, 1, 1673, 3, 165, 2, 372, 1, 358, 9, 46, 117, 3, 2005, 1391, 993, 16, 2603, 1, 8, 1867, 87, 1, 245, 1643, 3186, 149, 30870, 4, 136, 3130, 3, 12036, 4257, 426, 35, 241, 90, 206, 1, 3, 789, 4, 136, 3847, 1361, 1, 4935, 491, 818, 543, 6, 1139, 3, 5923, 24, 838, 9, 4109, 681, 1, 5034, 19392, 4, 332, 1, 12, 2, 206, 284, 422, 9, 19392, 4, 117, 5, 15, 28, 64, 43, 9, 12, 75, 8, 1230, 6803, 596, 26, 10718, 1129, 646, 4261, 15693, 3, 291, 789, 5220, 2, 2488, 1, 8332, 7856, 4243, 19392, 455, 2, 284, 1049, 6, 3, 193, 1, 1391, 883, 9, 3, 3744, 4109, 681, 1, 5034, 16, 80, 2485, 4, 332, 1, 12, 16, 841, 11615, 2, 1278, 2, 68, 47, 191, 1707, 408, 1, 12, 640, 15, 43, 1818, 422, 3, 4832, 1, 241, 666, 3, 367, 1, 785, 235, 4, 117, 5, 15, 28, 64, 43, 9, 12, 71, 627, 4, 5863, 1, 24, 751, 4311, 2319, 372, 1, 358, 2, 14894, 2467, 130, 4743, 948, 1079, 666, 24, 9, 19392, 643, 12, 146, 43, 1702, 1, 507, 51, 6, 324, 235, 2, 3008, 3863, 21, 206, 291, 241, 9, 747, 2788, 2, 11803, 189, 1558, 4, 117, 5, 8, 532, 1, 15, 28, 64, 43, 9, 12, 2, 1817, 3, 1281, 5287, 4, 3, 241, 9, 1165, 2, 323, 235, 2, 3, 594, 9, 508, 389, 24, 1, 19392, 16, 2596, 5, 51064, 640, 1228, 486, 157, 328, 4, 26, 266, 3, 119, 1, 293, 785, 235, 68, 40, 35, 1501, 9, 476, 117, 54, 4373, 11803, 2, 51064, 640, 50, 8, 2488, 1, 1098, 2, 1141, 2, 206, 5, 8, 2854, 292, 2709, 21, 377, 1391, 883, 9, 35, 353, 6, 3, 284, 1, 19392, 4, 112, 69, 1184, 141, 117, 28, 64, 43, 9, 12, 117, 5, 808, 153, 109, 163, 117, 5, 1500, 199, 163, 2, 117, 5, 113, 34]",2581.0,29762200,Management genitourinary syndrome menopause women high risk breast consensus recommendations North American Menopause Society International Society Women 's Sexual Health,0,0.0
Localized vaginal/uterine rhabdomyosarcoma-results of a pooled analysis from four international cooperative groups.,Pediatric blood & cancer,Pediatr Blood Cancer,2018-05-21,"Vaginal/uterine rhabdomyosarcoma (VU RMS) is one of the most favorable RMS sites. To determine the optimal therapy, the experience of four cooperative groups (Children's Oncology Group [COG], International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Group [MMT], Italian Cooperative Soft Tissue Sarcoma Group [ICG], and European pediatric Soft tissue sarcoma Study Group [EpSSG]) was analyzed. From 1981 to 2009, 237 patients were identified. Median age (years) at diagnosis differed by tumor location; it was 1.9 for vagina (n=160), 2.7 for uterus corpus (n=26), and 13.5 for uterus cervix (n=51). Twenty-eight percent of patients received radiation therapy (RT) as part of primary therapy (23% COG, 27% MMT, 46% ICG, and 42% EpSSG), with significant differences in the use of brachytherapy between the cooperative groups (23% COG, 76% MMT, 64% ICG, and 88% EpSSG). Ten-year event-free (EFS) and overall survival (OS) were 74% (95% CI, 67-79%) and 92% (95% CI, 88-96%), respectively. In univariate analysis, OS was inferior for patients with uterine RMS and for those with regional lymph node involvement. Although EFS was slightly lower in patients without initial RT (71% without RT vs. 81% with RT; P=0.08), there was no difference in OS (94% without RT vs. 89% with RT; P=0.18). Local control using brachytherapy was excellent (93%). Fifty-one (51.5%) of the 99 survivors with known primary therapy and treatment for relapse were cured with chemotherapy with or without conservative surgery. About half of all patients with VU RMS can be cured without systematic RT or radical surgery. When RT is indicated, modalities that limit sequelae should be considered, such as brachytherapy.",Journal Article,610.0,1.0,Vaginal/uterine rhabdomyosarcoma VU RMS favorable RMS sites determine optimal therapy experience cooperative groups Children 's Oncology Group COG International Society Pediatric Oncology SIOP Malignant Mesenchymal Group MMT Italian Cooperative Soft Tissue Sarcoma Group ICG European pediatric Soft tissue sarcoma Group EpSSG 1981 2009 237 patients identified Median age years diagnosis differed location 1.9 vagina n 160 2.7 uterus corpus n 26 13.5 uterus cervix n 51 Twenty-eight percent patients received radiation therapy RT primary therapy 23 COG 27 MMT 46 ICG 42 EpSSG significant differences use brachytherapy cooperative groups 23 COG 76 MMT 64 ICG 88 EpSSG Ten-year event-free EFS overall survival OS 74 95 CI 67-79 92 95 CI 88-96 respectively univariate OS inferior patients uterine RMS regional lymph node involvement EFS slightly lower patients initial RT 71 RT vs. 81 RT P 0.08 difference OS 94 RT vs. 89 RT P 0.18 Local control brachytherapy excellent 93 Fifty-one 51.5 99 survivors known primary therapy treatment relapse cured chemotherapy conservative surgery half patients VU RMS cured systematic RT radical surgery RT indicated modalities limit sequelae considered brachytherapy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,"[18982, 16369, 51072, 3413, 16, 104, 1, 3, 96, 913, 3413, 633, 6, 223, 3, 665, 36, 3, 730, 1, 294, 1690, 271, 541, 292, 413, 87, 6377, 944, 1174, 1, 815, 413, 28737, 393, 1569, 30, 87, 17947, 10215, 1690, 1214, 246, 87, 9118, 2, 1865, 815, 1214, 246, 45, 87, 42067, 10, 311, 29, 10264, 6, 1238, 7296, 7, 11, 108, 52, 89, 60, 28, 147, 2512, 20, 30, 1147, 192, 10, 14, 83, 9, 7553, 78, 3457, 18, 67, 9, 7758, 78, 432, 2, 233, 33, 9, 3629, 78, 725, 737, 659, 714, 1, 7, 103, 121, 36, 240, 22, 760, 1, 86, 36, 382, 6377, 428, 17947, 641, 9118, 2, 595, 42067, 5, 93, 362, 4, 3, 119, 1, 1536, 59, 3, 1690, 271, 382, 6377, 846, 17947, 660, 9118, 2, 889, 42067, 1618, 111, 774, 115, 1683, 2, 63, 25, 118, 11, 794, 48, 58, 598, 842, 2, 937, 48, 58, 889, 921, 106, 4, 880, 65, 118, 10, 1663, 9, 7, 5, 3413, 2, 9, 135, 5, 951, 263, 289, 799, 242, 1683, 10, 3223, 280, 4, 7, 187, 388, 240, 792, 187, 240, 105, 865, 5, 240, 19, 13, 1592, 125, 10, 77, 523, 4, 118, 960, 187, 240, 105, 887, 5, 240, 19, 13, 203, 293, 182, 75, 1536, 10, 1503, 966, 1461, 104, 725, 33, 1, 3, 1058, 332, 5, 440, 86, 36, 2, 24, 9, 429, 11, 3733, 5, 56, 5, 15, 187, 4476, 152, 545, 1303, 1, 62, 7, 5, 51072, 3413, 122, 40, 3733, 187, 1556, 240, 15, 711, 152, 198, 240, 16, 1103, 1558, 17, 2385, 4156, 257, 40, 515, 225, 22, 1536]",1555.0,29781567,Localized vaginal/uterine rhabdomyosarcoma-results pooled international cooperative groups,1,0.005025125628140704
The influence of surgeon volume on outcomes after pelvic exenteration for a gynecologic cancer.,Journal of gynecologic oncology,J Gynecol Oncol,2018-05-04,"To determine the effect of surgeon experience on intraoperative, postoperative and long-term outcomes among patients undergoing pelvic exenteration for gynecologic cancer. This was a retrospective analysis of all women who underwent exenteration for a gynecologic malignancy at MD Anderson Cancer Center, between January 1993 and June 2013. A logistic regression was used to model the relationship between surgeon experience (measured as the number of exenteration cases performed by the surgeon prior to a given exenteration) and operative outcomes and postoperative complications. Cox proportional hazards regression was used to model survival outcomes. A total of 167 exenterations were performed by 19 surgeons for cervix (78, 46.7%), vaginal (43, 25.8%), uterine (24, 14.4%), vulvar (14, 8.4%) and other cancer (8, 4.7%). The most common procedure was total pelvic exenteration (69.4%), incontinent urinary diversion (63.5%) and vertical rectus abdominis musculocutaneous reconstruction (42.5%). Surgical experience was associated with decreased estimated blood loss (p<0.001), intraoperative transfusion (p=0.009) and a shorter length of stay (p=0.03). No difference was noted in the postoperative complication rate (p=0.12-0.95). More surgeon experience was not associated with overall or disease specific survival: OS (hazard ratio [HR]=1.02; 95% confidence interval [CI]=0.97-1.06; p=0.46) and DSS (HR=1.01; 95% CI=0.97-1.04; p=0.66), respectively. Patients undergoing exenteration by more experienced surgeons had improvement in intraoperative factors such as estimated blood loss, transfusion rates and length of stay. No difference was seen in postoperative complication rates, overall or disease specific survival.",Journal Article,627.0,3.0,determine effect surgeon experience intraoperative postoperative long-term outcomes patients undergoing pelvic exenteration gynecologic retrospective women underwent exenteration gynecologic malignancy MD Anderson Center January 1993 June 2013 logistic regression model relationship surgeon experience measured number exenteration cases performed surgeon prior given exenteration operative outcomes postoperative complications Cox proportional hazards regression model survival outcomes total 167 exenterations performed 19 surgeons cervix 78 46.7 vaginal 43 25.8 uterine 24 14.4 vulvar 14 8.4 8 4.7 common procedure total pelvic exenteration 69.4 incontinent urinary diversion 63.5 vertical rectus abdominis musculocutaneous reconstruction 42.5 Surgical experience associated decreased estimated blood loss p 0.001 intraoperative transfusion p=0.009 shorter length stay p=0.03 difference noted postoperative complication rate p=0.12-0.95 surgeon experience associated overall disease specific survival OS hazard ratio HR =1.02 95 confidence interval CI =0.97-1.06 p=0.46 DSS HR=1.01 95 CI=0.97-1.04 p=0.66 respectively Patients undergoing exenteration experienced surgeons improvement intraoperative factors estimated blood loss transfusion rates length stay difference seen postoperative complication rates overall disease specific survival,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[6, 223, 3, 254, 1, 1897, 730, 23, 1720, 573, 2, 319, 337, 123, 107, 7, 479, 1110, 5668, 9, 1512, 12, 26, 10, 8, 459, 65, 1, 62, 117, 54, 208, 5668, 9, 8, 1512, 710, 28, 2244, 1929, 12, 574, 59, 1024, 3343, 2, 1924, 1346, 8, 812, 320, 10, 95, 6, 202, 3, 858, 59, 1897, 730, 644, 22, 3, 207, 1, 5668, 140, 173, 20, 3, 1897, 324, 6, 8, 447, 5668, 2, 1208, 123, 2, 573, 521, 418, 831, 1017, 320, 10, 95, 6, 202, 25, 123, 8, 181, 1, 5431, 44747, 11, 173, 20, 326, 1613, 9, 3629, 833, 641, 67, 601, 243, 66, 259, 213, 39, 213, 66, 39, 2, 127, 12, 66, 39, 67, 3, 96, 186, 1299, 10, 181, 1110, 5668, 790, 39, 20445, 1660, 6067, 676, 33, 2, 11104, 15111, 18778, 33230, 1470, 595, 33, 221, 730, 10, 41, 5, 340, 661, 315, 407, 19, 13, 144, 1720, 2785, 19, 13, 2376, 2, 8, 985, 1318, 1, 2020, 19, 13, 680, 77, 523, 10, 1051, 4, 3, 573, 1447, 116, 19, 13, 133, 13, 48, 80, 1897, 730, 10, 44, 41, 5, 63, 15, 34, 112, 25, 118, 360, 197, 168, 14, 588, 48, 307, 268, 58, 13, 1015, 14, 1460, 19, 13, 641, 2, 1788, 168, 14, 355, 48, 58, 13, 1015, 14, 755, 19, 13, 700, 106, 7, 479, 5668, 20, 80, 592, 1613, 42, 767, 4, 1720, 130, 225, 22, 661, 315, 407, 2785, 151, 2, 1318, 1, 2020, 77, 523, 10, 527, 4, 573, 1447, 151, 63, 15, 34, 112, 25]",1631.0,30022632,influence surgeon volume outcomes pelvic exenteration gynecologic,0,0.0
Extensive trophoblastic differentiation in case of an endometrial carcinoma.,Indian journal of pathology & microbiology,Indian J Pathol Microbiol,,"Trophoblastic differentiation of endometrial carcinoma is extremely rare, till date 18 cases reports are there in the literature. A 68-year-old postmenopausal female presented with abnormal vaginal bleeding. Histopathologically, there were areas of serous carcinoma with trophoblastic differentiation (~90%). On immunohistochemistry, the trophoblastic component was positive for -human chorionic gonadotropin (hCG), HPL and EMA. IHC confirmed the diagnosis of serous carcinoma with trophoblastic differentiation. The clinicopathological features of 18 previously reported cases of trophoblastic differentiation in the uterine tumor were analyzed in addition to the present case.",Case Reports,,0.0,Trophoblastic differentiation endometrial carcinoma extremely rare till date 18 cases reports literature 68-year-old postmenopausal female presented abnormal vaginal bleeding Histopathologically areas serous carcinoma trophoblastic differentiation ~90 immunohistochemistry trophoblastic component positive -human chorionic gonadotropin hCG HPL EMA IHC confirmed diagnosis serous carcinoma trophoblastic differentiation clinicopathological features 18 previously reported cases trophoblastic differentiation uterine addition present case,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[11355, 910, 1, 134, 16, 2938, 622, 20528, 1244, 203, 140, 1198, 32, 125, 4, 3, 789, 8, 806, 111, 1095, 1679, 1061, 917, 5, 1668, 2294, 8631, 125, 11, 1361, 1, 1744, 134, 5, 11355, 910, 424, 23, 888, 3, 11355, 1249, 10, 109, 9, 1458, 171, 10420, 6501, 6920, 73760, 2, 13135, 1289, 557, 3, 147, 1, 1744, 134, 5, 11355, 910, 3, 2721, 404, 1, 203, 373, 210, 140, 1, 11355, 910, 4, 3, 30, 11, 311, 4, 352, 6, 3, 364, 473]",636.0,30303166,Extensive trophoblastic differentiation case endometrial carcinoma,0,0.0
Laparoscopic Radical Trachelectomy for Embryonal Rhabdomyosarcoma of the Cervix in a 2-Year-Old Girl.,Obstetrics and gynecology,Obstet Gynecol,2018-12-01,"Embryonal rhabdomyosarcoma of the cervix is a rare and aggressive malignancy that usually affects children and young adults. We describe a 2-year-old patient who presented with a mass protruding through the vaginal introitus. Preoperative investigations including vaginoscopy, hysteroscopy, magnetic resonance imaging, and biopsies confirmed embryonal rhabdomyosarcoma, botryoid subtype, arising from the cervix. She was successfully treated with neoadjuvant chemotherapy and interval laparoscopic radical trachelectomy to achieve remission. Collaboration between the pediatric and adult surgical and medical oncology teams was critical to implement this fertility-sparing treatment strategy in such a young girl having this rare tumor.",Case Reports,416.0,0.0,Embryonal rhabdomyosarcoma cervix rare aggressive malignancy usually affects children young adults 2-year-old patient presented mass protruding vaginal introitus Preoperative investigations including vaginoscopy hysteroscopy magnetic resonance imaging biopsies confirmed embryonal rhabdomyosarcoma botryoid subtype arising cervix successfully treated neoadjuvant chemotherapy interval laparoscopic radical trachelectomy achieve remission Collaboration pediatric adult surgical medical oncology teams critical implement fertility-sparing treatment strategy young girl rare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[5239, 1, 3, 3629, 16, 8, 622, 2, 571, 710, 17, 2082, 2561, 541, 2, 1169, 857, 21, 897, 8, 18, 111, 1095, 69, 54, 917, 5, 8, 782, 45384, 298, 3, 73927, 498, 2492, 141, 43902, 33896, 1484, 1535, 270, 2, 1154, 557, 5239, 35369, 875, 2635, 29, 3, 3629, 3109, 10, 1878, 73, 5, 536, 56, 2, 268, 1964, 711, 5760, 6, 1359, 734, 4119, 59, 3, 815, 2, 780, 221, 2, 484, 413, 6127, 10, 740, 6, 6207, 26, 2954, 1851, 24, 692, 4, 225, 8, 1169, 12079, 1041, 26, 622, 30]",684.0,30399094,Laparoscopic Radical Trachelectomy Embryonal Rhabdomyosarcoma Cervix 2-Year-Old Girl,1,0.005025125628140704
Prognostic factors impacting survival in early stage uterine carcinosarcoma.,Gynecologic oncology,Gynecol. Oncol.,2018-11-08,"Evaluate the impact of clinicopathologic characteristics and adjuvant treatment on survival outcomes in early stage uterine carcinosarcoma patients. We performed a retrospective cohort study of women with stage I or II uterine carcinosarcoma at our institution between March 1990 and June 2016. All pathology had been reviewed and confirmed by gynecologic pathologists. Data were extracted from the electronic medical record. Descriptive and comparative statistics were used to compare clinicopathologic characteristics. Univariable and multivariable analyses were performed for survival outcomes. 140 patients were identified. Median age was 67years (range: 36-91). Median follow-up was 39.1months (2.9-297.4). The majority of patients had stage IA (67%) versus stage IB (21%) or stage II (11%) disease. The majority of patients (63%) received adjuvant treatment: vaginal brachytherapy only (14%); whole pelvic radiation therapy only (16%); chemotherapy only (n=13, 9%); combination chemotherapy and vaginal brachytherapy (15%); combination chemotherapy and whole pelvic radiation (9%). 52 patients (37%) received no adjuvant therapy. Median overall survival (OS) was 48.0months (95% CI 32.7-80.9). On multivariable analysis for OS, advancing age (HR 1.05, 95% CI 1.03-1.08, p<0.001), higher stage (stage IB: HR 1.64, 95% CI 0.91-2.95, p=0.10; stage II: HR 3.04, 95% CI 1.51-6.13, p=0.002), and the presence of a rhabdomyosarcoma component (HR 1.66, 95% CI 1.02-2.70, p=0.04) were significantly associated with worse OS. Advancing age, stage, and the presence of a rhabdomyosarcoma component were all associated with worse OS in patients with early stage uterine carcinosarcoma. New treatment algorithms should incorporate factors aside from stage alone.",Journal Article,439.0,3.0,Evaluate impact clinicopathologic characteristics adjuvant treatment survival outcomes early stage uterine carcinosarcoma patients performed retrospective cohort women stage II uterine carcinosarcoma institution March 1990 June 2016 pathology reviewed confirmed gynecologic pathologists extracted electronic medical record Descriptive comparative statistics compare clinicopathologic characteristics Univariable multivariable performed survival outcomes 140 patients identified Median age 67 years range 36-91 Median follow-up 39.1 months 2.9-297.4 majority patients stage IA 67 versus stage IB 21 stage II 11 disease majority patients 63 received adjuvant treatment vaginal brachytherapy 14 pelvic radiation therapy 16 chemotherapy n 13 9 combination chemotherapy vaginal brachytherapy 15 combination chemotherapy pelvic radiation 9 52 patients 37 received adjuvant therapy Median overall survival OS 48.0 months 95 CI 32.7-80.9 multivariable OS advancing age HR 1.05 95 CI 1.03-1.08 p 0.001 higher stage stage IB HR 1.64 95 CI 0.91-2.95 p 0.10 stage II HR 3.04 95 CI 1.51-6.13 p 0.002 presence rhabdomyosarcoma component HR 1.66 95 CI 1.02-2.70 p 0.04 significantly associated worse OS Advancing age stage presence rhabdomyosarcoma component associated worse OS patients early stage uterine carcinosarcoma New treatment algorithms incorporate factors aside stage,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[376, 3, 345, 1, 1399, 374, 2, 249, 24, 23, 25, 123, 4, 191, 82, 5623, 7, 21, 173, 8, 459, 180, 45, 1, 117, 5, 82, 70, 15, 215, 5623, 28, 114, 731, 59, 2363, 2289, 2, 1924, 1390, 62, 1117, 42, 85, 446, 2, 557, 20, 1512, 3354, 74, 11, 2484, 29, 3, 3098, 484, 3237, 3778, 2, 2352, 3065, 11, 95, 6, 932, 1399, 374, 4084, 2, 658, 318, 11, 173, 9, 25, 123, 3304, 7, 11, 108, 52, 89, 10, 598, 60, 184, 511, 970, 52, 166, 126, 10, 587, 14, 53, 18, 83, 8526, 39, 3, 686, 1, 7, 42, 82, 3302, 598, 185, 82, 3180, 239, 15, 82, 215, 175, 34, 3, 686, 1, 7, 676, 103, 249, 24, 1536, 158, 213, 902, 1110, 121, 36, 158, 245, 56, 158, 78, 233, 83, 150, 56, 2, 1536, 167, 150, 56, 2, 902, 1110, 121, 83, 653, 7, 567, 103, 77, 249, 36, 52, 63, 25, 118, 10, 576, 13, 53, 48, 58, 531, 67, 493, 83, 23, 658, 65, 9, 118, 5155, 89, 168, 14, 474, 48, 58, 14, 680, 14, 1592, 19, 13, 144, 142, 82, 82, 3180, 168, 14, 660, 48, 58, 13, 970, 18, 48, 19, 13, 79, 82, 215, 168, 27, 755, 48, 58, 14, 725, 49, 233, 19, 13, 1111, 2, 3, 463, 1, 8, 1249, 168, 14, 700, 48, 58, 14, 588, 18, 431, 19, 13, 755, 11, 97, 41, 5, 639, 118, 5155, 89, 82, 2, 3, 463, 1, 8, 1249, 11, 62, 41, 5, 639, 118, 4, 7, 5, 191, 82, 5623, 217, 24, 3529, 257, 3360, 130, 11731, 29, 82, 279]",1596.0,30414738,Prognostic factors impacting survival early stage uterine carcinosarcoma,4,0.020100502512562814
Stage IV Gestational Choriocarcinoma Diagnosed in the Third Trimester.,Obstetrics and gynecology,Obstet Gynecol,2019-01-01,"Gestational trophoblastic neoplasia rarely occurs in term pregnancies. Stage IV choriocarcinoma treated with conventional chemotherapy can result in death as a result of hemorrhagic sequelae at tumor sites. A 30-year-old woman at 34 weeks of gestation presented with a persistent cough, worsening dyspnea, and vaginal bleeding. Chest radiograph demonstrated innumerable lung nodules, and quantitative -hcg concentration exceeded 1.3 million milli-international units/mL. Cesarean delivery was performed for presumed abruption. Placental pathology demonstrated choriocarcinoma, and imaging confirmed stage IV disease with a World Health Organization score of 14. Remission was achieved after two courses of low-dose induction chemotherapy followed by 10 cycles of combination chemotherapy. Gestational trophoblastic neoplasia should be considered in a pregnant or postpartum woman presenting with atypical vaginal bleeding. Coexistent pulmonary or neurologic findings may suggest advanced disease.",Case Reports,385.0,0.0,Gestational trophoblastic neoplasia rarely occurs term pregnancies Stage IV choriocarcinoma treated conventional chemotherapy death hemorrhagic sequelae sites 30-year-old woman 34 weeks gestation presented persistent cough worsening dyspnea vaginal bleeding Chest radiograph demonstrated innumerable lung nodules quantitative -hcg concentration exceeded 1.3 million milli-international units/mL Cesarean delivery performed presumed abruption Placental pathology demonstrated choriocarcinoma imaging confirmed stage IV disease World Health Organization score 14 Remission achieved courses low-dose induction chemotherapy followed 10 cycles combination chemotherapy Gestational trophoblastic neoplasia considered pregnant postpartum woman presenting atypical vaginal bleeding Coexistent pulmonary neurologic findings suggest advanced disease,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[9383, 11355, 2298, 2416, 1780, 4, 337, 8746, 82, 478, 13081, 73, 5, 809, 56, 122, 757, 4, 273, 22, 8, 757, 1, 6998, 4156, 28, 30, 633, 8, 201, 111, 1095, 2854, 28, 562, 244, 1, 13250, 917, 5, 8, 1882, 6546, 4323, 2923, 2, 2294, 1662, 12295, 264, 18293, 2597, 2, 1156, 1458, 6920, 1227, 4726, 14, 27, 3346, 36360, 944, 2960, 542, 28385, 989, 10, 173, 9, 5472, 74152, 9690, 1117, 264, 13081, 2, 270, 557, 82, 478, 34, 5, 8, 1956, 341, 2533, 368, 1, 213, 734, 10, 513, 50, 100, 1993, 1, 154, 61, 504, 56, 370, 20, 79, 410, 1, 150, 56, 9383, 11355, 2298, 257, 40, 515, 4, 8, 6086, 15, 7830, 2854, 1656, 5, 1973, 2294, 12779, 1087, 15, 2543, 272, 68, 309, 131, 34]",963.0,30531566,Stage IV Gestational Choriocarcinoma Diagnosed Trimester,1,0.005025125628140704
Trends in Risks for Second Primary Cancers Associated With Index Human Papillomavirus-Associated Cancers.,JAMA network open,JAMA Netw Open,2018-09-07,"In the last 4 decades, survival among patients with human papillomavirus (HPV)-associated cancers has improved, while the incidence of these cancers has increased among younger cohorts. Among survivors of HPV-associated cancers, persistent HPV infection may remain a risk factor for preventable HPV-associated second primary cancers (HPV-SPCs). To investigate the risk of HPV-SPCs among survivors of HPV-associated index cancers and to test the hypothesis that the HPV-SPC risk among these persons has increased over the last 4 decades. A retrospective cohort study of 9 cancer registries of the Surveillance, Epidemiology, and End Results (SEER) database was conducted to identify patients with HPV-associated (cervical, vaginal, vulvar, oropharyngeal, anal, and penile) cancers diagnosed from January 1, 1973, through December 31, 2014. The dates of analysis were July 1, 2017, to January 31, 2018. The HPV-SPC risk was quantified by calculating standard incidence ratios (SIRs) and excess absolute risks (EARs) per 10 000 person-years at risk (PYR). The HPV-SPC risk by time was estimated using Poisson regression. From 113 272 (73 085 female and 40 187 male) survivors of HPV-associated cancers, 1397 women and 1098 men developed HPV-SPCs. The SIRs for HPV-SPCs were 6.2 (95% CI, 5.9-6.6) among women and 15.8 (95% CI, 14.9-16.8) among men. The EARs were 18.2 per 10000 PYR for women and 53.5 per 10000 PYR for men. Among both women and men, those who had index oropharyngeal cancers had the highest HPV-SPC risk (SIR, 19.8 [95% CI, 18.4-21.4] and EAR, 80.6 per 10000 PYR among women; SIR, 18.0 [95% CI, 16.9-19.1] and EAR, 61.5 per 10000 PYR among men). Women who had index cervical cancers and men who had index anal cancers had the lowest HPV-SPC risk (SIR, 2.4 [95% CI, 2.2-2.7] and EAR, 4.5 per 10000 PYR among women; SIR, 6.5 [95% CI, 4.7-8.8] and EAR, 18.5 per 10000 PYR among men). Both women and men who had index HPV-associated cancers of any kind had a significantly higher risk of oropharyngeal HPV-SPCs. Over the last 4 decades, the risk of developing most types of HPV-SPCs after index cervical, vaginal, and vulvar cancers increased. According to this study, the HPV-SPC risk among survivors of HPV-associated cancers is significant, implying that persistent HPV infection at multiple sites may be associated with HPV-SPCs. These findings have the potential to inform surveillance recommendations for survivors of HPV-associated cancers.",Journal Article,501.0,4.0,4 decades survival patients human papillomavirus HPV -associated improved incidence increased younger cohorts survivors HPV-associated persistent HPV infection remain risk factor preventable HPV-associated second primary HPV-SPCs investigate risk HPV-SPCs survivors HPV-associated index test hypothesis HPV-SPC risk persons increased 4 decades retrospective cohort 9 registries Surveillance Epidemiology End SEER database conducted identify patients HPV-associated cervical vaginal vulvar oropharyngeal anal penile diagnosed January 1 1973 December 31 2014 dates July 1 2017 January 31 2018 HPV-SPC risk quantified calculating standard incidence ratios SIRs excess absolute risks EARs 10 000 person-years risk PYR HPV-SPC risk time estimated Poisson regression 113 272 73 085 female 40 187 male survivors HPV-associated 1397 women 1098 men developed HPV-SPCs SIRs HPV-SPCs 6.2 95 CI 5.9-6.6 women 15.8 95 CI 14.9-16.8 men EARs 18.2 10 000 PYR women 53.5 10 000 PYR men women men index oropharyngeal highest HPV-SPC risk SIR 19.8 95 CI 18.4-21.4 EAR 80.6 10 000 PYR women SIR 18.0 95 CI 16.9-19.1 EAR 61.5 10 000 PYR men Women index cervical men index anal lowest HPV-SPC risk SIR 2.4 95 CI 2.2-2.7 EAR 4.5 10 000 PYR women SIR 6.5 95 CI 4.7-8.8 EAR 18.5 10 000 PYR men women men index HPV-associated kind significantly higher risk oropharyngeal HPV-SPCs 4 decades risk developing types HPV-SPCs index cervical vaginal vulvar increased According HPV-SPC risk survivors HPV-associated significant implying persistent HPV infection multiple sites associated HPV-SPCs findings potential inform surveillance recommendations survivors HPV-associated,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[4, 3, 1060, 39, 1968, 25, 107, 7, 5, 171, 3242, 933, 41, 163, 71, 231, 369, 3, 287, 1, 46, 163, 71, 101, 107, 773, 736, 107, 332, 1, 933, 41, 163, 1882, 933, 930, 68, 918, 8, 43, 161, 9, 7936, 933, 41, 419, 86, 163, 933, 25885, 6, 963, 3, 43, 1, 933, 25885, 107, 332, 1, 933, 41, 558, 163, 2, 6, 412, 3, 1492, 17, 3, 933, 13490, 43, 107, 46, 4327, 71, 101, 252, 3, 1060, 39, 1968, 8, 459, 180, 45, 1, 83, 12, 3768, 1, 3, 617, 1284, 2, 396, 99, 1605, 609, 10, 426, 6, 255, 7, 5, 933, 41, 2, 163, 265, 29, 1024, 14, 4756, 298, 1397, 456, 1409, 3, 9561, 1, 65, 11, 2066, 14, 1759, 6, 1024, 456, 2982, 3, 933, 13490, 43, 10, 2790, 20, 8408, 260, 287, 1137, 7120, 2, 2612, 1766, 1098, 19743, 379, 79, 984, 2719, 60, 28, 43, 17475, 3, 933, 13490, 43, 20, 98, 10, 661, 75, 7668, 320, 29, 4259, 6905, 803, 13639, 1061, 2, 327, 5568, 1045, 332, 1, 933, 41, 163, 30993, 117, 2, 39715, 325, 276, 933, 25885, 3, 7120, 9, 933, 25885, 11, 49, 18, 48, 58, 33, 83, 49, 49, 107, 117, 2, 167, 66, 48, 58, 213, 83, 245, 66, 107, 325, 3, 19743, 11, 203, 18, 379, 79, 984, 17475, 9, 117, 2, 699, 33, 379, 79, 984, 17475, 9, 325, 107, 110, 117, 2, 325, 135, 54, 42, 558, 163, 42, 3, 1076, 933, 13490, 43, 3636, 326, 66, 48, 58, 203, 39, 239, 39, 2, 7815, 493, 49, 379, 79, 984, 17475, 107, 117, 3636, 203, 13, 48, 58, 245, 83, 326, 14, 2, 7815, 713, 33, 379, 79, 984, 17475, 107, 325, 117, 54, 42, 558, 163, 2, 325, 54, 42, 558, 163, 42, 3, 2101, 933, 13490, 43, 3636, 18, 39, 48, 58, 18, 18, 18, 67, 2, 7815, 39, 33, 379, 79, 984, 17475, 107, 117, 3636, 49, 33, 48, 58, 39, 67, 66, 66, 2, 7815, 203, 33, 379, 79, 984, 17475, 107, 325, 110, 117, 2, 325, 54, 42, 558, 933, 41, 163, 1, 500, 11968, 42, 8, 97, 142, 43, 1, 933, 25885, 252, 3, 1060, 39, 1968, 3, 43, 1, 931, 96, 630, 1, 933, 25885, 50, 558, 2, 163, 101, 768, 6, 26, 45, 3, 933, 13490, 43, 107, 332, 1, 933, 41, 163, 16, 93, 7885, 17, 1882, 933, 930, 28, 232, 633, 68, 40, 41, 5, 933, 25885, 46, 272, 47, 3, 174, 6, 2295, 617, 883, 9, 332, 1, 933, 41, 163]",2254.0,30646145,Trends Risks Second Primary Associated Index Human Papillomavirus-Associated,0,0.0
Bidirectional Text Messaging to Monitor Endocrine Therapy Adherence and Patient-Reported Outcomes in Breast Cancer.,JCO clinical cancer informatics,JCO Clin Cancer Inform,2017-11-01,"Up to 40% of patients with breast cancer may not adhere to adjuvant endocrine therapy. Therapy-related adverse effects (AEs) are important contributors to nonadherence. We developed a bidirectional text-message application, BETA-Text, that simultaneously tracks adherence, records symptoms, and alerts the clinical team. We piloted our intervention in 100 patients. The intervention consisted of text messages to which patients responded for 3 months: daily, evaluating adherence; weekly, evaluating medication-related AEs; and monthly, regarding barriers to adherence. Concerning responses prompted a telephone call from a clinic nurse. The primary objective was to assess patient acceptance of this intervention using self-reported surveys. To compare participants with the general population at our institution, we assessed 100 consecutively treated patients as historical controls using medical record review. We approached 141 consecutive patients, 100 (71%) of whom agreed to participate and 89 of whom completed the intervention. A majority of patients reported that the intervention was easy to use (98%) and helpful in taking their medication (96%). Four patients discontinued therapy before 3 months, and 93% of patients who continued therapy took  80% of their medication. The frequency of AEs reported by participants via text was higher than that reported in clinical trials: hot flashes (72%), arthralgias (53%), and vaginal symptoms (35%). Approximately 39% of patients reported one or more severe AE that prompted an alert to the provider team to call the patient. A daily bidirectional text-messaging system can monitor adherence and identify AEs and other barriers to adherence in real time without inconveniencing patients. AEs of endocrine therapy, as detected using this texting approach, are more prevalent than reported in clinical trials.",Journal Article,811.0,4.0,40 patients breast adhere adjuvant endocrine therapy Therapy-related adverse effects AEs important contributors nonadherence developed bidirectional text-message application BETA-Text simultaneously tracks adherence records symptoms alerts clinical team piloted intervention 100 patients intervention consisted text messages patients responded 3 months daily evaluating adherence weekly evaluating medication-related AEs monthly barriers adherence Concerning responses prompted telephone clinic nurse primary objective assess patient acceptance intervention self-reported surveys compare participants general population institution assessed 100 consecutively treated patients historical controls medical record review approached 141 consecutive patients 100 71 agreed participate 89 completed intervention majority patients reported intervention easy use 98 helpful taking medication 96 patients discontinued therapy 3 months 93 patients continued therapy took  80 medication frequency AEs reported participants text higher reported clinical trials hot flashes 72 arthralgias 53 vaginal symptoms 35 Approximately 39 patients reported severe AE prompted alert provider team patient daily bidirectional text-messaging monitor adherence identify AEs barriers adherence real time inconveniencing patients AEs endocrine therapy detected texting approach prevalent reported clinical trials,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[126, 6, 327, 1, 7, 5, 12, 68, 44, 11898, 6, 249, 1293, 36, 36, 139, 290, 176, 1477, 32, 305, 9680, 6, 9271, 21, 276, 8, 10953, 6153, 10035, 1581, 1090, 6153, 17, 3074, 14481, 2149, 1064, 507, 2, 21757, 3, 38, 2870, 21, 22292, 114, 788, 4, 394, 7, 3, 788, 1695, 1, 6153, 12610, 6, 92, 7, 2211, 9, 27, 53, 391, 1435, 2149, 709, 1435, 3012, 139, 1477, 2, 3889, 666, 2160, 6, 2149, 4243, 253, 4140, 8, 4258, 7715, 29, 8, 1188, 6756, 3, 86, 461, 10, 6, 423, 69, 5080, 1, 26, 788, 75, 1074, 210, 3666, 6, 932, 776, 5, 3, 1083, 266, 28, 114, 731, 21, 275, 394, 7380, 73, 7, 22, 2252, 535, 75, 484, 3237, 206, 21, 5738, 4379, 935, 7, 394, 792, 1, 953, 4681, 6, 3506, 2, 887, 1, 953, 781, 3, 788, 8, 686, 1, 7, 210, 17, 3, 788, 10, 6261, 6, 119, 1096, 2, 3951, 4, 2727, 136, 3012, 921, 294, 7, 2402, 36, 348, 27, 53, 2, 966, 1, 7, 54, 1351, 36, 5060, 749, 493, 1, 136, 3012, 3, 675, 1, 1477, 210, 20, 776, 847, 6153, 10, 142, 76, 17, 210, 4, 38, 143, 2859, 4193, 720, 13632, 699, 2, 507, 465, 705, 587, 1, 7, 210, 104, 15, 80, 905, 3633, 17, 4140, 35, 12781, 6, 3, 3094, 2870, 6, 7715, 3, 69, 8, 391, 10953, 6153, 27199, 398, 122, 3334, 2149, 2, 255, 1477, 2, 127, 2160, 6, 2149, 4, 1589, 98, 187, 74326, 7, 1477, 1, 1293, 36, 22, 530, 75, 26, 74327, 353, 32, 80, 2485, 76, 210, 4, 38, 143]",1791.0,30657377,Bidirectional Text Messaging Monitor Endocrine Therapy Adherence Patient-Reported Outcomes Breast,0,0.0
Prevalence of high-grade anal dysplasia among women with high-grade lower genital tract dysplasia or cancer: Results of a pilot study.,Gynecologic oncology,Gynecol. Oncol.,2019-03-01,"To estimate the prevalence of high-grade anal dysplasia in women with high-grade dysplasia or carcinoma of the cervix, vagina or vulva. In this cross-sectional study, participants underwent anal cytology, anal HPV testing with Cervista HPV16/18 and high-resolution anoscopy (HRA). Patients with HSIL (high-grade squamous cell intraepithelial lesion) or greater on anal cytology or anal biopsy were referred to a colorectal surgery specialist for further evaluation. Seventy-five women were enrolled in the study, including 47 with cervical (cervix group), 10 with vaginal (vagina group), 15 with vulvar (vulva group), 1 with cervical and vaginal, and 2 with vulvar and vaginal disease. The median age in the cervix group (40years (range 26-69)) was substantially younger than in the vagina (60years (38-69)) and the vulva (59years (36-75)) groups. Anal HSIL based on composite endpoints of the most severe cytology or histology result was diagnosed in 6 patients (8.0%). Anal cytology revealed HSIL in 2 (2.7%), atypical squamous cells of undetermined significance (ASCUS) in 12 (16.0%), low-grade squamous cell intraepithelial lesion (LSIL) in 2 (2.7%), and was normal in 59 (78.7%) patients. Anal HPV16/18 test was positive in 15 (20.0%), negative in 48 (64.0%) and insufficient in 12 (16.0%) patients. Of the 6 women with high-grade anal dysplasia, three (50%) had a positive anal HPV16/18 test. No case of anal cancer was observed. Our results suggest that the prevalence of anal HSIL is elevated among women with HPV-related lower genital tract dysplasia or cancer. To further support the inclusion of this high-risk group into screening guidelines for anal dysplasia, further studies are necessary to determine what screening strategy is suited to this population.",Journal Article,326.0,2.0,estimate prevalence high-grade anal dysplasia women high-grade dysplasia carcinoma cervix vagina vulva cross-sectional participants underwent anal cytology anal HPV testing Cervista HPV16/18 high-resolution anoscopy HRA Patients HSIL high-grade squamous intraepithelial lesion greater anal cytology anal biopsy referred colorectal surgery specialist evaluation Seventy-five women enrolled including 47 cervical cervix group 10 vaginal vagina group 15 vulvar vulva group 1 cervical vaginal 2 vulvar vaginal disease median age cervix group 40 years range 26-69 substantially younger vagina 60 years 38-69 vulva 59 years 36-75 groups Anal HSIL based composite endpoints severe cytology histology diagnosed 6 patients 8.0 Anal cytology revealed HSIL 2 2.7 atypical squamous undetermined significance ASCUS 12 16.0 low-grade squamous intraepithelial lesion LSIL 2 2.7 normal 59 78.7 patients Anal HPV16/18 test positive 15 20.0 negative 48 64.0 insufficient 12 16.0 patients 6 women high-grade anal dysplasia 50 positive anal HPV16/18 test case anal observed suggest prevalence anal HSIL elevated women HPV-related lower genital tract dysplasia support inclusion high-risk group screening guidelines anal dysplasia studies necessary determine screening strategy suited population,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 1191, 3, 1078, 1, 64, 88, 2253, 4, 117, 5, 64, 88, 2253, 15, 134, 1, 3, 3629, 7553, 15, 9263, 4, 26, 1383, 2832, 45, 776, 208, 2045, 933, 471, 5, 74507, 4048, 203, 2, 64, 2125, 21979, 20959, 7, 5, 16067, 64, 88, 691, 31, 4153, 1180, 15, 378, 23, 2045, 15, 411, 11, 1995, 6, 8, 152, 6554, 9, 195, 451, 2073, 365, 117, 11, 346, 4, 3, 45, 141, 662, 5, 3629, 87, 79, 5, 7553, 87, 167, 5, 9263, 87, 14, 5, 2, 2, 18, 5, 2, 34, 3, 52, 89, 4, 3, 3629, 87, 327, 60, 184, 432, 790, 10, 2109, 773, 76, 4, 3, 7553, 335, 60, 519, 790, 2, 3, 9263, 728, 60, 511, 481, 271, 16067, 90, 23, 3308, 1387, 1, 3, 96, 905, 2045, 15, 784, 757, 10, 265, 4, 49, 7, 66, 13, 2045, 553, 16067, 4, 18, 18, 67, 1973, 691, 37, 1, 5206, 724, 21337, 4, 133, 245, 13, 154, 88, 691, 31, 4153, 1180, 17849, 4, 18, 18, 67, 2, 10, 295, 4, 728, 833, 67, 7, 4048, 203, 412, 10, 109, 4, 167, 179, 13, 199, 4, 576, 660, 13, 2, 3027, 4, 133, 245, 13, 7, 1, 3, 49, 117, 5, 64, 88, 2253, 169, 212, 42, 8, 109, 4048, 203, 412, 77, 473, 1, 12, 10, 164, 114, 99, 309, 17, 3, 1078, 1, 16067, 16, 804, 107, 117, 5, 933, 139, 280, 8226, 1696, 2253, 15, 12, 6, 195, 538, 3, 1680, 1, 26, 64, 43, 87, 237, 453, 677, 9, 2253, 195, 94, 32, 1493, 6, 223, 2067, 453, 692, 16, 7247, 6, 26, 266]",1562.0,30827725,Prevalence high-grade anal dysplasia women high-grade lower genital tract dysplasia pilot,0,0.0
"National trends, outcomes, and costs of radiation therapy in the management of low- and high-intermediate risk endometrial cancer.",Gynecologic oncology,Gynecol. Oncol.,2019-03-01,"To assess treatment patterns, outcomes, and costs for women with low-(LIR) and high-intermediate risk endometrial cancer (HIR) who are treated with and without adjuvant radiotherapy. All patients with stage I endometrioid endometrial cancer who underwent surgery from 2000 to 2011 were identified from the SEER-Medicare database. LIR was defined as G1-2 tumors with <50% myometrial invasion or G3 with no invasion. HIR was defined as G1-2 tumors with 50% or G3 with <50% invasion. Patients were categorized according to whether they received adjuvant radiotherapy (vaginal brachytherapy [VBT], external beam radiotherapy [EBRT], or both) or no radiotherapy. Outcomes were analyzed and compared (primary outcome was overall survival). 10,842 patients met inclusion criteria. In the LIR group (n=7609), there was no difference in 10-year overall survival between patients who received radiotherapy and those who did not (67% vs 65%, adjusted HR 0.95, 95% CI 0.81-1.11). In the HIR group (n=3233), patients who underwent radiotherapy had a significant increase in survival (60% vs 47%, aHR 0.75, 95% CI 0.67-0.85). Radiotherapy was associated with increased costs compared to surgery alone ($26,585 vs $16,712, p<.001). Costs for patients receiving VBT, EBRT, and concurrent VBT/EBRT were $24,044, $27,512, and $31,564, respectively (p<.001). Radiotherapy was associated with an increased risk of gastrointestinal (7 vs 4%), genitourinary (2 vs 1%), and hematologic (16 vs 12%) complications (p<.001). Radiotherapy was associated with improved survival in women with HIR, but not in LIR. It also had increased costs and a higher morbidity risk. Consideration of observation without radiotherapy in LIR may be reasonable.",Journal Article,326.0,2.0,"assess treatment patterns outcomes costs women low- LIR high-intermediate risk endometrial HIR treated adjuvant radiotherapy patients stage endometrioid endometrial underwent surgery 2000 2011 identified SEER-Medicare database LIR defined G1-2 50 myometrial invasion G3 invasion HIR defined G1-2 50 G3 50 invasion Patients categorized according received adjuvant radiotherapy vaginal brachytherapy VBT external beam radiotherapy EBRT radiotherapy Outcomes compared primary outcome overall survival 10,842 patients met inclusion criteria LIR group n 7609 difference 10-year overall survival patients received radiotherapy 67 vs 65 adjusted HR 0.95 95 CI 0.81-1.11 HIR group n 3233 patients underwent radiotherapy significant increase survival 60 vs 47 aHR 0.75 95 CI 0.67-0.85 Radiotherapy associated increased costs compared surgery 26,585 vs 16,712 p .001 Costs patients receiving VBT EBRT concurrent VBT/EBRT 24,044 27,512 31,564 respectively p .001 Radiotherapy associated increased risk gastrointestinal 7 vs 4 genitourinary 2 vs 1 hematologic 16 vs 12 complications p .001 Radiotherapy associated improved survival women HIR LIR increased costs higher morbidity risk Consideration observation radiotherapy LIR reasonable",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[6, 423, 24, 764, 123, 2, 1201, 9, 117, 5, 154, 32955, 2, 64, 919, 43, 12, 19814, 54, 32, 73, 5, 2, 187, 249, 310, 62, 7, 5, 82, 70, 3151, 12, 54, 208, 152, 29, 1081, 6, 1132, 11, 108, 29, 3, 1605, 1378, 609, 32955, 10, 395, 22, 3344, 18, 57, 5, 212, 7327, 578, 15, 5578, 5, 77, 578, 19814, 10, 395, 22, 3344, 18, 57, 5, 5660, 15, 5578, 5, 212, 578, 7, 11, 2320, 768, 6, 317, 491, 103, 249, 310, 1536, 15050, 1455, 1345, 310, 1883, 15, 110, 15, 77, 310, 123, 11, 311, 2, 72, 86, 228, 10, 63, 25, 79, 19883, 7, 543, 1680, 371, 4, 3, 32955, 87, 78, 74567, 125, 10, 77, 523, 4, 79, 111, 63, 25, 59, 7, 54, 103, 310, 2, 135, 54, 205, 44, 598, 105, 556, 586, 168, 13, 48, 48, 58, 13, 865, 14, 175, 4, 3, 19814, 87, 78, 51006, 7, 54, 208, 310, 42, 8, 93, 344, 4, 25, 335, 105, 662, 3657, 13, 481, 48, 58, 13, 598, 13, 772, 310, 10, 41, 5, 101, 1201, 72, 6, 152, 279, 432, 15351, 105, 245, 13251, 19, 144, 1201, 9, 7, 357, 15050, 1883, 2, 750, 15050, 1883, 11, 259, 6194, 428, 12287, 2, 456, 11090, 106, 19, 144, 310, 10, 41, 5, 35, 101, 43, 1, 67, 105, 39, 4109, 18, 105, 14, 2, 813, 245, 105, 133, 521, 19, 144, 310, 10, 41, 5, 231, 25, 4, 117, 5, 19814, 84, 44, 4, 32955, 192, 120, 42, 101, 1201, 2, 8, 142, 787, 43, 2415, 1, 1664, 187, 310, 4, 32955, 68, 40, 3203]",1585.0,30876486,National trends outcomes costs radiation therapy management low- high-intermediate risk endometrial,0,0.0
Evolving trends in the management of high-intermediate risk endometrial cancer in the United States.,Gynecologic oncology,Gynecol. Oncol.,2019-03-01,"Gynecologic oncology group protocol 249 (GOG 249) is the contemporary US study that aimed to define the standard of care adjuvant therapy for patients with high-intermediate risk (HIR) endometrial cancer; patients were randomized to pelvic radiation therapy (RT) or vaginal brachytherapy (VBT) with chemotherapy (VBT-C). The preliminary results of GOG 249 were recently presented, yet the management of patients represented in this trial remains controversial. We set out to review US patterns of care for patients meeting eligibility criteria for GOG 249. The National Cancer Database (NCDB) was used to identify patients meeting GOG 249 eligibility criteria between 2010 and 2015. The Man-Kendall trend test was used to assess for significant trends over time. We identified 23,015 patients that met study inclusion criteria. Between 2010 and 2015, there was a decline in the use of pelvic RT from 9.8% to 7.5%, although not meeting statistical significance (p=0.136), and an increase in the use of VBT-C from 4.6% to 7.7% (p=0.017). Most patients did not receive treatment per either arm of GOG 249, with observation being the most common approach throughout this era, although the percentage of patients observed decreased from 58.1% to 45.8% between 2010 and 2015 (p=0.003). Further, 21.5% of patients received VBT alone in 2010, increasing to 30.3% by 2015 (p=0.003). National practice trends in HIR endometrial cancer reveal that a large number of patients are observed in lieu of receiving adjuvant therapy. Further, the utilization of pelvic RT has declined below utilization of VBT-C, despite a lack of data supporting either improved disease outcomes or toxicity with this experimental regimen on GOG 249.",Journal Article,326.0,0.0,"Gynecologic oncology group protocol 249 GOG 249 contemporary aimed define standard care adjuvant therapy patients high-intermediate risk HIR endometrial patients randomized pelvic radiation therapy RT vaginal brachytherapy VBT chemotherapy VBT-C preliminary GOG 249 recently presented management patients represented trial remains controversial set review patterns care patients meeting eligibility criteria GOG 249 National Database NCDB identify patients meeting GOG 249 eligibility criteria 2010 2015 Man-Kendall trend test assess significant trends time identified 23,015 patients met inclusion criteria 2010 2015 decline use pelvic RT 9.8 7.5 meeting statistical significance p 0.136 increase use VBT-C 4.6 7.7 p 0.017 patients receive treatment arm GOG 249 observation common approach era percentage patients observed decreased 58.1 45.8 2010 2015 p 0.003 21.5 patients received VBT 2010 increasing 30.3 2015 p 0.003 National practice trends HIR endometrial reveal large number patients observed lieu receiving adjuvant therapy utilization pelvic RT declined utilization VBT-C despite lack supporting improved disease outcomes toxicity experimental regimen GOG 249",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[1512, 413, 87, 1182, 7144, 4760, 7144, 16, 3, 2667, 843, 45, 17, 1295, 6, 1107, 3, 260, 1, 165, 249, 36, 9, 7, 5, 64, 919, 43, 19814, 12, 7, 11, 384, 6, 1110, 121, 36, 240, 15, 1536, 15050, 5, 56, 15050, 256, 3, 1676, 99, 1, 4760, 7144, 11, 761, 917, 1145, 3, 284, 1, 7, 3324, 4, 26, 160, 469, 2010, 21, 916, 1205, 6, 206, 843, 764, 1, 165, 9, 7, 2238, 2317, 371, 9, 4760, 7144, 3, 657, 12, 609, 4315, 10, 95, 6, 255, 7, 2238, 4760, 7144, 2317, 371, 59, 1120, 2, 1483, 3, 3628, 11657, 853, 412, 10, 95, 6, 423, 9, 93, 1963, 252, 98, 21, 108, 382, 3433, 7, 17, 543, 45, 1680, 371, 59, 1120, 2, 1483, 125, 10, 8, 1858, 4, 3, 119, 1, 1110, 240, 29, 83, 66, 6, 67, 33, 242, 44, 2238, 1050, 724, 19, 13, 4829, 2, 35, 344, 4, 3, 119, 1, 15050, 256, 29, 39, 49, 6, 67, 67, 19, 13, 3825, 96, 7, 205, 44, 560, 24, 379, 361, 475, 1, 4760, 7144, 5, 1664, 486, 3, 96, 186, 353, 2432, 26, 1713, 242, 3, 1150, 1, 7, 164, 340, 29, 717, 14, 6, 512, 66, 59, 1120, 2, 1483, 19, 13, 1421, 195, 239, 33, 1, 7, 103, 15050, 279, 4, 1120, 602, 6, 201, 27, 20, 1483, 19, 13, 1421, 657, 758, 1963, 4, 19814, 12, 2396, 17, 8, 375, 207, 1, 7, 32, 164, 4, 14575, 1, 357, 249, 36, 195, 3, 1961, 1, 1110, 240, 71, 3054, 2736, 1961, 1, 15050, 256, 550, 8, 926, 1, 74, 1912, 361, 231, 34, 123, 15, 155, 5, 26, 1560, 477, 23, 4760, 7144]",1634.0,30876498,Evolving trends management high-intermediate risk endometrial United States,19,0.09547738693467336
"Cervical, Vaginal, and Vulvar Cancer Costs Incurred by the Medicaid Program in Publicly Insured Patients in Texas.",Journal of lower genital tract disease,J Low Genit Tract Dis,2019-04-01,"To determine from the perspective of the State of Texas, the direct medical care costs associated with cervical, vaginal, and vulvar cancers in Texas Medicaid enrollees. We conducted a case-control study and searched Texas Medicaid databases between 2008 and 2012 for eligible cancer patients. A comparison group was selected for each cancer site using a 2-step 1:1 propensity score matching method. Patients were followed for 2 years after cancer diagnosis to estimate monthly and yearly direct medical costs. For each cancer site, the differential cost between patients and the matched comparison individuals was the estimated cost associated with cancer. The study included 583 cervical, 62 vaginal, and 137 vulvar cancer patients and equal numbers of cancer-free comparison individuals. Among the cases, 322 cervical cancer patients, 46 vaginal cancer patients, and 102 vulvar cancer patients were Medicaid-Medicare dual eligible enrollees. For Medicaid-only enrollees, the adjusted first- and second-year mean total differential costs were US $19,859 and $3,110 for cervical cancer, US $19,627 and $4,582 for vaginal cancer, and US $7,631 and $777 for vulvar cancer patients, respectively. For Medicaid-Medicare dual eligible enrollees, adjusted first- and second-year mean total differential costs incurred by Medicaid were US $2,565 and $792 for cervical cancer, US $1,293 and $181 for vaginal cancer, and US $1,774 and $1,049 for vulvar cancer patients, respectively. The direct medical costs associated with cervical, vaginal, and vulvar cancers in Texas Medicaid were substantial in the first 2 years after cancer diagnosis, but dual eligibility for Medicare coverage attenuated Medicaid costs.",Journal Article,295.0,0.0,"determine perspective State Texas direct medical care costs associated cervical vaginal vulvar Texas Medicaid enrollees conducted case-control searched Texas Medicaid databases 2008 2012 eligible patients comparison group selected site 2-step 1:1 propensity score matching Patients followed 2 years diagnosis estimate monthly yearly direct medical costs site differential cost patients matched comparison individuals estimated cost associated included 583 cervical 62 vaginal 137 vulvar patients equal numbers cancer-free comparison individuals cases 322 cervical patients 46 vaginal patients 102 vulvar patients Medicaid-Medicare dual eligible enrollees Medicaid-only enrollees adjusted first- second-year mean total differential costs 19,859 3,110 cervical 19,627 4,582 vaginal 7,631 777 vulvar patients respectively Medicaid-Medicare dual eligible enrollees adjusted first- second-year mean total differential costs incurred Medicaid 2,565 792 cervical 1,293 181 vaginal 1,774 1,049 vulvar patients respectively direct medical costs associated cervical vaginal vulvar Texas Medicaid substantial 2 years diagnosis dual eligibility Medicare coverage attenuated Medicaid costs",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 29, 3, 3727, 1, 3, 1309, 1, 2738, 3, 1196, 484, 165, 1201, 41, 5, 2, 163, 4, 2738, 2843, 9888, 21, 426, 8, 473, 182, 45, 2, 3080, 2738, 2843, 2348, 59, 1375, 2, 1195, 9, 625, 12, 7, 8, 1155, 87, 10, 715, 9, 296, 12, 606, 75, 8, 18, 2458, 14, 14, 1925, 368, 2616, 596, 7, 11, 370, 9, 18, 60, 50, 12, 147, 6, 1191, 3889, 2, 9460, 1196, 484, 1201, 9, 296, 12, 606, 3, 1777, 835, 59, 7, 2, 3, 655, 1155, 869, 10, 3, 661, 835, 41, 5, 12, 3, 45, 159, 12876, 744, 2, 4352, 12, 7, 2, 2997, 1870, 1, 12, 115, 1155, 869, 107, 3, 140, 8024, 12, 7, 641, 12, 7, 2, 2867, 12, 7, 11, 2843, 1378, 1828, 625, 9888, 9, 2843, 158, 9888, 3, 586, 157, 2, 419, 111, 313, 181, 1777, 1201, 11, 843, 326, 20149, 2, 27, 3129, 9, 12, 843, 326, 13598, 2, 39, 13909, 9, 12, 2, 843, 67, 14576, 2, 12021, 9, 12, 7, 106, 9, 2843, 1378, 1828, 625, 9888, 586, 157, 2, 419, 111, 313, 181, 1777, 1201, 11172, 20, 2843, 11, 843, 18, 10852, 2, 13760, 9, 12, 843, 14, 7541, 2, 5540, 9, 12, 2, 843, 14, 11927, 2, 14, 5121, 9, 12, 7, 106, 3, 1196, 484, 1201, 41, 5, 2, 163, 4, 2738, 2843, 11, 1281, 4, 3, 157, 18, 60, 50, 12, 147, 84, 1828, 2317, 9, 1378, 2139, 2656, 2843, 1201]",1518.0,30907776,Cervical Vaginal Vulvar Costs Incurred Medicaid Program Publicly Insured Patients Texas,0,0.0
Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer.,The New England journal of medicine,N. Engl. J. Med.,2019-06-01,"Stage III or IVA endometrial cancer carries a significant risk of systemic and locoregional recurrence. In this randomized phase 3 trial, we tested whether 6 months of platinum-based chemotherapy plus radiation therapy (chemoradiotherapy) is associated with longer relapse-free survival (primary end point) than six cycles of combination chemotherapy alone in patients with stage III or IVA endometrial carcinoma. Secondary end points included overall survival, acute and chronic toxic effects, and quality of life. Of the 813 patients enrolled, 736 were eligible and were included in the analysis of relapse-free survival; of those patients, 707 received the randomly assigned intervention (346 received chemoradiotherapy and 361 received chemotherapy only). The median follow-up period was 47 months. At 60 months, the Kaplan-Meier estimate of the percentage of patients alive and relapse-free was 59% (95% confidence interval [CI], 53 to 65) in the chemoradiotherapy group and 58% (95% CI, 53 to 64) in the chemotherapy-only group (hazard ratio, 0.90; 90% CI, 0.74 to 1.10). Chemoradiotherapy was associated with a lower 5-year incidence of vaginal recurrence (2% vs. 7%; hazard ratio, 0.36; 95% CI, 0.16 to 0.82) and pelvic and paraaortic lymph-node recurrence (11% vs. 20%; hazard ratio, 0.43; 95% CI, 0.28 to 0.66) than chemotherapy alone, but distant recurrence was more common in association with chemoradiotherapy (27% vs. 21%; hazard ratio, 1.36; 95% CI, 1.00 to 1.86). Grade 3, 4, or 5 adverse events were reported in 202 patients (58%) in the chemoradiotherapy group and 227 patients (63%) in the chemotherapy-only group. Chemotherapy plus radiation was not associated with longer relapse-free survival than chemotherapy alone in patients with stage III or IVA endometrial carcinoma. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00942357.).","Clinical Trial, Phase III",234.0,20.0,Stage III IVA endometrial carries significant risk systemic locoregional recurrence randomized phase 3 trial tested 6 months platinum-based chemotherapy plus radiation therapy chemoradiotherapy associated longer relapse-free survival primary end point cycles combination chemotherapy patients stage III IVA endometrial carcinoma Secondary end points included overall survival acute chronic toxic effects quality life 813 patients enrolled 736 eligible included relapse-free survival patients 707 received randomly assigned intervention 346 received chemoradiotherapy 361 received chemotherapy median follow-up period 47 months 60 months Kaplan-Meier estimate percentage patients alive relapse-free 59 95 confidence interval CI 53 65 chemoradiotherapy group 58 95 CI 53 64 chemotherapy-only group hazard ratio 0.90 90 CI 0.74 1.10 Chemoradiotherapy associated lower 5-year incidence vaginal recurrence 2 vs. 7 hazard ratio 0.36 95 CI 0.16 0.82 pelvic paraaortic lymph-node recurrence 11 vs. 20 hazard ratio 0.43 95 CI 0.28 0.66 chemotherapy distant recurrence common association chemoradiotherapy 27 vs. 21 hazard ratio 1.36 95 CI 1.00 1.86 Grade 3 4 5 adverse events reported 202 patients 58 chemoradiotherapy group 227 patients 63 chemotherapy-only group Chemotherapy plus radiation associated longer relapse-free survival chemotherapy patients stage III IVA endometrial carcinoma Funded National Institute ClinicalTrials.gov number NCT00942357,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[82, 316, 15, 5900, 12, 4942, 8, 93, 43, 1, 403, 2, 1325, 146, 4, 26, 384, 124, 27, 160, 21, 650, 317, 49, 53, 1, 828, 90, 56, 349, 121, 36, 1464, 16, 41, 5, 589, 429, 115, 25, 86, 396, 741, 76, 437, 410, 1, 150, 56, 279, 4, 7, 5, 82, 316, 15, 5900, 134, 568, 396, 862, 159, 63, 25, 286, 2, 442, 1812, 176, 2, 372, 1, 358, 1, 3, 15980, 7, 346, 13953, 11, 625, 2, 11, 159, 4, 3, 65, 1, 429, 115, 25, 1, 135, 7, 13939, 103, 3, 1108, 896, 788, 9184, 103, 1464, 2, 9234, 103, 56, 158, 3, 52, 166, 126, 727, 10, 662, 53, 28, 335, 53, 3, 876, 882, 1191, 1, 3, 1150, 1, 7, 1701, 2, 429, 115, 10, 728, 48, 307, 268, 58, 699, 6, 556, 4, 3, 1464, 87, 2, 717, 48, 58, 699, 6, 660, 4, 3, 56, 158, 87, 360, 197, 13, 424, 424, 58, 13, 794, 6, 14, 79, 1464, 10, 41, 5, 8, 280, 33, 111, 287, 1, 146, 18, 105, 67, 360, 197, 13, 511, 48, 58, 13, 245, 6, 13, 878, 2, 1110, 2, 7401, 263, 289, 146, 175, 105, 179, 360, 197, 13, 601, 48, 58, 13, 339, 6, 13, 700, 76, 56, 279, 84, 626, 146, 10, 80, 186, 4, 248, 5, 1464, 428, 105, 239, 360, 197, 14, 511, 48, 58, 14, 2038, 6, 14, 868, 88, 27, 39, 15, 33, 290, 281, 11, 210, 4, 5918, 7, 717, 4, 3, 1464, 87, 2, 7132, 7, 676, 4, 3, 56, 158, 87, 56, 349, 121, 10, 44, 41, 5, 589, 429, 115, 25, 76, 56, 279, 4, 7, 5, 82, 316, 15, 5900, 134, 3827, 20, 3, 657, 12, 1377, 1252, 1239, 207, 74881]",1753.0,31189035,Adjuvant Chemotherapy plus Radiation Locally Advanced Endometrial,3,0.01507537688442211
